<SEC-DOCUMENT>0001638833-22-000096.txt : 20220503
<SEC-HEADER>0001638833-22-000096.hdr.sgml : 20220503
<ACCEPTANCE-DATETIME>20220503171638
ACCESSION NUMBER:		0001638833-22-000096
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		72
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220503
DATE AS OF CHANGE:		20220503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Surgery Partners, Inc.
		CENTRAL INDEX KEY:			0001638833
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062]
		IRS NUMBER:				473620923
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37576
		FILM NUMBER:		22888309

	BUSINESS ADDRESS:	
		STREET 1:		310 SEVEN SPRINGS WAY
		STREET 2:		SUITE 500
		CITY:			BRENTWOOD
		STATE:			TN
		ZIP:			37027
		BUSINESS PHONE:		615-234-5900

	MAIL ADDRESS:	
		STREET 1:		310 SEVEN SPRINGS WAY
		STREET 2:		SUITE 500
		CITY:			BRENTWOOD
		STATE:			TN
		ZIP:			37027
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sgry-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:b4dabe6f-88db-4fc2-b66b-139c1a2f1a72,g:e82a3438-fa59-433e-866a-e64d4d57702b,d:8d24edc59a384ef08748223de247b6a7--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:sgry="http://www.surgerypartners.com/20220331" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sgry-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180L2ZyYWc6ZDZiOGQzMjQ4NTlkNDMyZmFkMGQwMzUyNzBiOTRiMWEvdGFibGU6ODhjNTZkM2E4YjA1NGRjYzhiMDNiOTFhZmNmOWE0YmYvdGFibGVyYW5nZTo4OGM1NmQzYThiMDU0ZGNjOGIwM2I5MWFmY2Y5YTRiZl80LTEtMS0xLTM5OTM2_ea5404c5-5e3c-4553-aa2c-8553d7335f06">0001638833</ix:nonNumeric><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180L2ZyYWc6ZDZiOGQzMjQ4NTlkNDMyZmFkMGQwMzUyNzBiOTRiMWEvdGFibGU6ODhjNTZkM2E4YjA1NGRjYzhiMDNiOTFhZmNmOWE0YmYvdGFibGVyYW5nZTo4OGM1NmQzYThiMDU0ZGNjOGIwM2I5MWFmY2Y5YTRiZl81LTEtMS0xLTM5OTM2_206b70ea-2ed7-4a14-a1fa-21bc93354d25">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180L2ZyYWc6ZDZiOGQzMjQ4NTlkNDMyZmFkMGQwMzUyNzBiOTRiMWEvdGFibGU6ODhjNTZkM2E4YjA1NGRjYzhiMDNiOTFhZmNmOWE0YmYvdGFibGVyYW5nZTo4OGM1NmQzYThiMDU0ZGNjOGIwM2I5MWFmY2Y5YTRiZl85LTEtMS0xLTM5OTM2_e663c5f0-d96e-4f1e-8691-6a09e9162262">2022</ix:nonNumeric><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180L2ZyYWc6ZDZiOGQzMjQ4NTlkNDMyZmFkMGQwMzUyNzBiOTRiMWEvdGFibGU6ODhjNTZkM2E4YjA1NGRjYzhiMDNiOTFhZmNmOWE0YmYvdGFibGVyYW5nZTo4OGM1NmQzYThiMDU0ZGNjOGIwM2I5MWFmY2Y5YTRiZl8xMC0xLTEtMS0zOTkzNg_95b052af-51de-48ee-a71a-c2da7861d98e">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180L2ZyYWc6ZDZiOGQzMjQ4NTlkNDMyZmFkMGQwMzUyNzBiOTRiMWEvdGFibGU6ODhjNTZkM2E4YjA1NGRjYzhiMDNiOTFhZmNmOWE0YmYvdGFibGVyYW5nZTo4OGM1NmQzYThiMDU0ZGNjOGIwM2I5MWFmY2Y5YTRiZl8xMS0xLTEtMS0zOTkzNg_52bac0e9-743b-4dfc-a8da-2421da67c2ab">false</ix:nonNumeric><ix:nonNumeric contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNC0yLTEtMS00NjQ2Ng_0f2dda77-9e14-4a9d-bd4c-1fca9c544334">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNC0yLTEtMS00NjQ2Ng_32523eef-34e6-4b2a-913b-0c4967f1b23d">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfOS0yLTEtMS00NjQ2OA_4491f22a-c2d0-4ffb-9a7d-8129b50d1a26">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfOS0yLTEtMS00NjQ2OA_e2b110e3-da5b-424a-8c7d-d3e258e86a47">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTMtMi0xLTEtNDY0NzI_4d4afb66-9139-4863-9c1e-c7148377256b">http://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligationsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTMtMi0xLTEtNDY0NzI_822c6ee1-f967-42b7-8426-35b31d91efae">http://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligationsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTQtMi0xLTEtNDY0Nzc_9fb4ebe5-aa6a-445d-86cd-135374660488">http://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonNumeric contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTQtMi0xLTEtNDY0Nzc_f854c062-dd64-4d2b-a477-9bd1f49a42d6">http://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sgry-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i650656e76ffc4d5eaefdd127e9d68ab3_I20220426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i46ce349a7375461fa1b7f757dc08d081_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65d685057ae641c3b746cf6377dd430f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48d044e479254b2f8935070ff1a00ac4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02439221d0d244d9bcd5569225a9eceb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61d245da91744ed8b196945289f8015a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2faf06f152e04dfaac19ae85d0f6df18_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64de719b0ad14503b4dba6762866534b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a8fc7979812433d8763ce3c5642dc80_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a837d715cbc4966875dc62f6e78cbd7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf10b9430f6847b490ed2cf648c93e32_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aeda0f667e349c086a29bab4acce588_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0cfdca28efe4489bed9689a67756a3c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i253dec092e2d41f28b85f643ccdd68cd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44d8b197c09347a5bfe50b624fa0d5b3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a8cdfe2cc68416e866d30dbf21372d9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1114172ce5094c68bedb86e8b7d44cb7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib49a1cb0982e43ec901c64053a39f745_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia510a69b8e64403eb11f83898b8a08ec_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic00c0198779b477e9adb83fad573131e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5cf9408c2ea45248462023da0418e49_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07efbfabca9b4e33acccafb2fe2d7c82_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8070a501ab2c40589c94526f6bda6ebe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25ae47e0aa9a4921a427c583c4ff6645_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2930feb3f5944505ad4c3d63f26d5f4f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i635f7b61fc044f528748645b77893543_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifeb7edc101bf4e3ca14bd0a2df3bec5f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacb41fa48e0c4c0280b70a8b8b967a6c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib052d4f8c5ef41118d1450786f139047_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if23681243e73450cb3fa31d9cffac2b7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58b12b437d5442cbbfda520a3f432240_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2e53044aa4142028b8b7d9863d3accb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4c0aada0e14421286ede0517722bf59_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10d1f1007efc4b109adc6675a736352c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="surgical_facility"><xbrli:measure>sgry:surgical_facility</xbrli:measure></xbrli:unit><xbrli:context id="i01ae3c8148ba4c25b35336360e5e7dc2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:FacilitiesAmbulatorySurgeryCentersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0b5bb8fa6d646029f554028ebaa467d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:FacilitiesSurgicalHospitalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="state"><xbrli:measure>sgry:state</xbrli:measure></xbrli:unit><xbrli:context id="i88ed6b4d58e5453984121369f4f11efc_D20200327-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-27</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6defdbda29a4879a3bd483aed3cec04_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="physician_practice"><xbrli:measure>sgry:physician_practice</xbrli:measure></xbrli:unit><xbrli:context id="i637e4d2ab4e8411490e75163721ebd0f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf52a3e1a85b4de2af6a8274e5c65a76_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i506df12890674df3996c010a349ca7c0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2db8fa84c09d480799b76b68681936d9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ad5676bd3f84e0d8244dd53d99a6a10_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ed8c6b6471245ee8d17d81941bd3725_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcfcf6c0b474488abf86dd8a19ab641d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ib8e675c069904c2e8d2f8233b2f7c50c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfcab3d9997245d19b06ae33b0d19589_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13642547953b42fdb47054b1218975af_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i966e8ae61ccd4f959e269cc4f8b50a26_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4c64a5508684384921c71fc65d53263_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc4246d5efcb4678b5c651d7a3105ea2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia76476dcbd9b4daa8c5d611fe63a4b6f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdeef4374f4d4416b5733b872ca3567b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccee81bad7154b409425f6d227df3575_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc7c7055d90440d89c4a9125446ce784_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4d0a1269abf4dceb2f3b53070b65c94_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa35c00cc5c94cc98aa5fc428cac0a9a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60c5087599d24a0695f4e51d9b7328cd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fdee6a1e69f430b9fc7afc764249da1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c305d408ef046519c734c40b5368141_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib886d75d98b64a8ba3306ec5ed447ea9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69bd64deadca4e6987ccdd1fe1a5acd1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i959b5b49ffbc4125a8ae719a2e147008_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a4abce686244862adef8618f10a35ed_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2581fac27134361aaf1f3ca3c3db4de_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32fa0d6361714af289d98b250659260a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib355fe300c3849b69133727cc10b4d92_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27472f8f1c174b2aa18b1c47df6601f6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b35f441d1234c148a0c51b5feb19edd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic27723e5b1494789a14c6e03c6cef1d1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia93d7f09a5db46538ab762616820eb2b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i319afcfd65824c03b4113efb64fc3b29_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6669ea6cc07c457ab9a998a810a31b86_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccb4e1634f8c4cbf9f988a392008a061_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a3ac13dcce1497ea3da4a85c473c3c3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ad6e3e1169d4e76ac6ee8f514dd661a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8520c7f7026a4db4b18532d86207d82e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47646e2fdd1a4fe7a52ba359cf577a71_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2c5800e21be4fe29d33c18b7bcf1f2a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0024968fe06e453fbbb57a1a738a5ea7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i094886c1cfb34257a319635071262fdd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc8bc1d058e74796a84a897fcabea948_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccfe7b6d79b74feb8e7a7078913f412a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bffa160d95c4aa38530da4f45398c33_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23a8281e1b3a4519bcf1d6d34c3cddf9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13eb2c0495f34e2bbb3d47dd7920135f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie823b906c9164e118eff58dafb9c18ce_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6de0b52340d4ee0be44beb83074a915_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesExistingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc9abc5f15644909ae180fa28f65f13e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib803580ff3fd404097fe48426bec1d0b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97af3ba9bf154ce48824c269e037ff4f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:DisposalGroupOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64cc0a22695c41e39895df392aa6ef14_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:DisposalGroupOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23157d624d184f359c7bfa4ba8b5e305_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="business_entity"><xbrli:measure>sgry:business_entity</xbrli:measure></xbrli:unit><xbrli:context id="iabc81fe53c8740a5835ce19d18a21d80_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c6502e60a4b4f40b2ab3906a1e7320a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6f81ce56efe4167827c87bda7c7d7ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic09d86ac1f06413595ed16720d86db9a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6efe1dcecbea4bcbbe13edfdc24585b8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sgry:NotesPayableAndSecuredLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d53ad311174404c83910a5b4a784afd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sgry:NotesPayableAndSecuredLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d81a2e35ef544709f6c3c5a6ec09d33_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib597d64d1a7b476fa1d8e9c70fa2d9c6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ed7fc212be442dab6bdeb5bf9fc9902_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6f105cec2c74bac8f0818b041444a8f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83e7577cfc3e485fa204871cd2bebed9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="interest_rate_swap"><xbrli:measure>sgry:interest_rate_swap</xbrli:measure></xbrli:unit><xbrli:context id="ia5195b743fe34283b9ca5fca00063c24_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia71c20142f984a65b73126b2fc598e6b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfefa22461da4d3d8abc5576226480fb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae1b34f8d424499badf3a4c4c1482bff_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ThreePayFixedInterestRateSwapsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0cd5769098e47f6a43dac3d7b1801fc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ThreePayFixedInterestRateSwapsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35f44859d11f47c1b1e53d1b04378a95_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ThreeReceiveFixedInterestRateSwapsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i612b998bf6814f52b34921481a7fed42_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6feaa769eee6494280e04ca4428e2d1e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id325fcdc0f7c47528506f54fa3611300_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8b44c0e1c7740bd90f41c1945029459_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia15782f2cb274cddb56795539491873a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9d8edabf0d9426fb79d750950a72128_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i110b4a998ba9459cb22bd9c1786eb35f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:InterestRateCapOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36389bf37a7143988be57524833186e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:InterestRateCapOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if939f474cbd9448a890aaa8ad9497a6c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:InterestRateCapTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i470b3213c5384e66a7ea1d5fe3c19aec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:InterestRateCapTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i482b7170e0e44958a6bccac3fb8b4bb1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc2a066e204b487d9b869bbac4264ca0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b59666e5a6445af800a6e82b2247fa6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72dbce711df14aa19565cfda8712ae96_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i279c0b5c9ef6400db373978fe16df294_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8205810c50914fc8b2ee5716cdd1e3ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5179e2adfc75478a8bceb8a842e8343d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06b61d1351f642c39e07376db16278bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c751ca3945547ff89766e783b1692c2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifec07c218a224559988b65a85dca34bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75a4d54131d04ec7a9ad66d50af16a7e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i746cdb6a8857465b8789529fa778ae72_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i052e333e8fbc4c8d828f8652b2a87288_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie234fc584e43432db473ff2d1b925b9b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5395316d4cc4c4cb5531fc9710de0ef_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ed5590de58f45ffa296c26e82b8cb5d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dd7a0c476e3425a9cd8fdf81d246d59_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i290ced8dda3d48ff99a0576554a33576_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86d66d0402e1453c9f1b3777c6d974bd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ff93bdfad7b424a8bf0ec3d14822809_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i774a5b342a17415398ee546db06a900e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i393e1260928244db91312ff5bdb20b39_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i187ebd1016734402ac3d28311bd88d06_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1b3debb3c6a4868aa2e70b6925bc311_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6066679117046deaa28e14ca575fd6b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79f21a0125dd44b3a07effa007c432cf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d0118a56e5349658c4a7dc1533913ce_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67c06ab0cc1645feb07263a0b462f478_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06587c3ef400423ab6d0e0c77f4b8182_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17ca4d1cea4549488f03f41d62feb261_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39d94629b8b54e53a9a62a201b44250b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49e70dcd4ab4442e93dc776b77191c75_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf580ac915f4455f888d4bffc00ceccd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62d2751322cd45d690eae0422a55f102_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">sgry:MateriallyMoreRestrictiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ae955700f5a407192e0f30ca8c9cef7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">sgry:NotMateriallyMoreRestrictiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>sgry:segment</xbrli:measure></xbrli:unit><xbrli:context id="i06f4c1e12ebf42428954114c64170b8b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95c194ebfbd94fa8a271308daec9afbb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id484bee12a474b8bbcedacad3a0e452e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia230717bfdb149e5b55ed8b1922373c3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37cfe03bc9ed4713b3b1e61e87a612c2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id144f2f56936461e8128c2d94933dc55_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2df432d764946c98419eddd4b217200_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30d11e9517014207867a3d78c850cb1c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i241a5e9cb633484a83e8b37dd0d53c59_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i405edebb54534016a7214669c2bd5d18_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67f8f1225fb34764b0261414fc217735_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a3f22cbbd5f47d4955fd2c0473366ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95727e44b2eb479d8bbcd65296068f83_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="non-controlling_interest"><xbrli:measure>sgry:non-controlling_interest</xbrli:measure></xbrli:unit><xbrli:context id="iea161d59c161497f8a5bb07b4bdb04b9_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzQtMi0xLTEtMzk5MzY_f316c610-a8bf-4296-81dd-e5befb731d9e id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzQtNC0xLTEtMzk5MzY_5b797168-8f73-4ca9-8faa-caa680e32762 id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzctNC0xLTEtMzk5MzY_e0983b0a-cd91-4e3f-af96-ff0084a35973 id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzctMi0xLTEtMzk5MzY_3aaf1ab2-cdc3-4241-9f41-41b592762a11" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RleHRyZWdpb246ODQ3MGZiMGI3NjY4NDQ4MGFhNGEyM2Q5ODVlNGUyNzNfMzky_e44d5c8e-2e66-4df1-a1e1-4d01aa20ae69" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i8d24edc59a384ef08748223de247b6a7_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">_____________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzM3_12a76239-81db-4f5e-96b4-e272f4bae61c">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">_____________________________________</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:9pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzQx_da939a36-8510-4488-9b1f-84710acd95c2">&#9746;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yOTg_6be44b66-2886-4b1a-a3c6-4ee7dfa7d7e3">March&#160;31, 2022</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzUy_fd65bf6f-bfc9-4e22-8c33-54d26ae7dc2e">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number:&#160; <ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzM4_24a7b917-a5ea-458f-b576-2c2f4c37855d">001-37576</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">_____________________________________</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzQ3_f104a784-081b-4949-b955-0b050a30978c">Surgery Partners, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">_____________________________________</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.583%"><tr><td style="width:1.0%"></td><td style="width:47.064%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.065%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGFibGU6NTZhNDg4MGJjNjM2NGUwOTgyYjRkMjI0Y2M3MThkZmMvdGFibGVyYW5nZTo1NmE0ODgwYmM2MzY0ZTA5ODJiNGQyMjRjYzcxOGRmY18wLTAtMS0xLTM5OTM2_f7894b43-d092-42ed-8e31-09e84aef5f85">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGFibGU6NTZhNDg4MGJjNjM2NGUwOTgyYjRkMjI0Y2M3MThkZmMvdGFibGVyYW5nZTo1NmE0ODgwYmM2MzY0ZTA5ODJiNGQyMjRjYzcxOGRmY18wLTItMS0xLTM5OTM2_3f674c14-fc68-4bf6-90b9-3ea8e9141498">47-3620923</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzUz_2705d7f5-9808-4bca-8577-aadbb3e316f5">310 Seven Springs Way, Suite&#160;500</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzQ5_f86982b4-7430-402e-bb76-0c9d074a55e7">Brentwood</ix:nonNumeric>, <ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzQz_2bd5a531-924a-46ea-9df3-48fbf7866b37">Tennessee</ix:nonNumeric> <ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzQw_cb5ab6e8-f87a-47f6-99dd-c09e01706044">37027</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzQ0_0a927710-4df0-462d-b7a1-e808675abcbb">615</ix:nonNumeric>) <ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzQ1_36d53f02-673d-4ee0-ba99-49775b0b3993">234-5900</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">_____________________________________</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:33.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.167%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGFibGU6YTE3NjljMzI4ZjA4NDZiNWIxOTgwNmEzNzBmZWFjNjgvdGFibGVyYW5nZTphMTc2OWMzMjhmMDg0NmI1YjE5ODA2YTM3MGZlYWM2OF8xLTAtMS0xLTM5OTM2_b4b088cf-b18f-4400-a8a1-f7a72b218234">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGFibGU6YTE3NjljMzI4ZjA4NDZiNWIxOTgwNmEzNzBmZWFjNjgvdGFibGVyYW5nZTphMTc2OWMzMjhmMDg0NmI1YjE5ODA2YTM3MGZlYWM2OF8xLTItMS0xLTM5OTM2_ba375e4a-e093-4bda-8b15-5ce8671f5393">SGRY</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGFibGU6YTE3NjljMzI4ZjA4NDZiNWIxOTgwNmEzNzBmZWFjNjgvdGFibGVyYW5nZTphMTc2OWMzMjhmMDg0NmI1YjE5ODA2YTM3MGZlYWM2OF8xLTQtMS0xLTM5OTM2_6535126d-7d3e-474a-8bbb-1a80105a20e7">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;<ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzU0_c64a9d94-9690-4dab-98a0-1791e97661b8">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160; <ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzUw_bef0f763-5c81-4227-8299-ff4a5385b5c4">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.&#160;</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.250%"><tr><td style="width:1.0%"></td><td style="width:46.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGFibGU6MzdlOTgwM2YwZTI4NDdmNzlmMmVmMDQ4NzMyNWU2YTQvdGFibGVyYW5nZTozN2U5ODAzZjBlMjg0N2Y3OWYyZWYwNDg3MzI1ZTZhNF8wLTAtMS0xLTQxNDY4L3RleHRyZWdpb246YzM1N2YzYmZkYTk5NDllNGExNjY4ZmZiZmQyYTBkNWZfMTA5OTUxMTYyNzgyOQ_483ddcb6-6e0b-4cae-8442-2973e16d4c0c">Large accelerated filer</ix:nonNumeric>&#160;&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer&#160;&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer&#160;&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company&#160;<ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGFibGU6MzdlOTgwM2YwZTI4NDdmNzlmMmVmMDQ4NzMyNWU2YTQvdGFibGVyYW5nZTozN2U5ODAzZjBlMjg0N2Y3OWYyZWYwNDg3MzI1ZTZhNF8xLTItMS0xLTM5OTM2L3RleHRyZWdpb246M2U1YzBkNDUwYmM1NDE2NDgxMTIzY2U4MDNhNTlhZDRfMzA_f789d5fb-1519-45f2-aa30-e201aabbace7">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company&#160;<ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGFibGU6MzdlOTgwM2YwZTI4NDdmNzlmMmVmMDQ4NzMyNWU2YTQvdGFibGVyYW5nZTozN2U5ODAzZjBlMjg0N2Y3OWYyZWYwNDg3MzI1ZTZhNF8yLTItMS0xLTM5OTM2L3RleHRyZWdpb246YTJjNDFiYmE5MzY0NDE1MGFhYTJlN2FmZDlmMWM4NDlfMjg_b3bed20c-7488-4889-8ad5-8480155c6d22">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzUx_38aaff93-6a42-4043-9fba-2049215e5c1c">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of April&#160;26, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i650656e76ffc4d5eaefdd127e9d68ab3_I20220426" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMjgx_05910138-5342-49eb-b149-5ad56c1f22e4">89,904,299</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">shares of the registrant&#8217;s common stock outstanding.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i8d24edc59a384ef08748223de247b6a7_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:11.567%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_10">PART I - FINANCIAL INFORMATION</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_10">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_10">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_13">Condensed Consolidated Balance Sheets (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_16">Condensed Consolidated Statements of Operations (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_16">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_19">Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_22">Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_25">Condensed Consolidated Statements of Cash Flows (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_28">Notes to Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_28">6</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_64">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_64">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_64">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_94">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_94">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_94">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_97">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_97">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_97">27</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_100">PART II - OTHER INFORMATION</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_103">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_103">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_103">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_106">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_106">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_106">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_109">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_109">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_109">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_112">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_112">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_112">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_115">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_115">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_115">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_118">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_118">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_118">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_121">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_121">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_121">29</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_124">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_124">30</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i8d24edc59a384ef08748223de247b6a7_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div style="margin-bottom:4pt;text-align:center"><span><br/></span></div><div id="i8d24edc59a384ef08748223de247b6a7_13"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Dollars in millions, except per share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNC0yLTEtMS0zOTkzNg_ee43879a-75bd-49de-bf25-f4a2f3c01c3e">378.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNC00LTEtMS0zOTkzNg_d0da05c9-7a01-4227-82fd-70d91090561b">389.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNS0yLTEtMS0zOTkzNg_4cce10aa-f0fa-499b-b5a1-c498dd3f216a">412.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNS00LTEtMS0zOTkzNg_9be79f8b-0dae-4bf9-ba71-1711ac490a3f">430.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNi0yLTEtMS0zOTkzNg_75cd2f04-651c-4195-b36e-71f7c8ce0782">62.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNi00LTEtMS0zOTkzNg_a1180807-09ef-45fc-adc3-6c088709e3b2">61.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:PrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNy0yLTEtMS0zOTkzNg_11f0c24b-c5f5-4170-9412-64e26ef66b7d">32.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:PrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNy00LTEtMS0zOTkzNg_1b4a0c7a-8eb0-4261-b42f-d6f66abd93ee">25.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfOC0yLTEtMS0zOTkzNg_04fac9aa-07e6-47e3-b298-f9994d678c99">50.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfOC00LTEtMS0zOTkzNg_7132435c-0995-457a-8470-1b781c4f5f11">39.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfOS0yLTEtMS0zOTkzNg_e934d6a4-d514-496e-8b59-9c6c9459d090">937.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfOS00LTEtMS0zOTkzNg_89947f46-5b2c-41d0-9407-790dcdfc47a6">946.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTAtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjphYmE3YzI5NDYwMjI0YTg2YjdiZjE3MzA1OTVjZTI2YV82Mw_9c39f2fe-0bed-4166-87d7-c41b7d99f85f">294.6</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTAtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjphYmE3YzI5NDYwMjI0YTg2YjdiZjE3MzA1OTVjZTI2YV83MA_0ee34bce-1836-4d11-8488-a9aae0c0697e">272.3</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTAtMi0xLTEtMzk5MzY_020dff01-ccfa-4056-8c92-e5624700f940">778.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTAtNC0xLTEtMzk5MzY_b30bdc30-3a64-4223-b271-c30505097576">629.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill and other intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTEtMi0xLTEtMzk5MzY_fc09bed6-fe22-4325-9bd9-f9119293d849">3,967.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTEtNC0xLTEtMzk5MzY_64308782-3a3b-4b1b-b771-0c218a6eb986">3,955.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in and advances to affiliates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTItMi0xLTEtMzk5MzY_eb1b3c9e-be53-4848-9dfe-451bdb691fee">94.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTItNC0xLTEtMzk5MzY_4e345461-8ee2-4a12-9dba-3a9e2f78400f">88.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTMtMi0xLTEtMzk5MzY_5b607240-8a12-41ed-bea5-0aa04ae905d9">277.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTMtNC0xLTEtMzk5MzY_78518414-ae32-4876-bcd1-18463ba223a8">324.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTQtMi0xLTEtMzk5MzY_3937a5d6-1c91-4e79-991b-1c44bdbb3a4c">113.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTQtNC0xLTEtMzk5MzY_1fbfb0e8-285f-49af-8247-2d3c53f6f041">114.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTUtMi0xLTEtMzk5MzY_541d4bf4-1abb-47b6-b125-e5a1676244f0">120.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTUtNC0xLTEtMzk5MzY_8bbea040-9e0e-4117-b7de-16de7262194d">59.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTYtMi0xLTEtMzk5MzY_a91e7878-1769-49ef-a182-2c2bc9cb8c06">6,289.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTYtNC0xLTEtMzk5MzY_ca224ff3-15b7-45cb-860b-120b9e0a2318">6,117.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjAtMi0xLTEtMzk5MzY_cab37492-67f8-4122-8810-7032bc1add53">122.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjAtNC0xLTEtMzk5MzY_f40dcdf9-21b5-41bf-b19d-53e056234495">124.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjEtMi0xLTEtMzk5MzY_9f04466c-2189-4faa-a777-8c13c9ff400b">83.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjEtNC0xLTEtMzk5MzY_72161e07-2e5f-4607-9a99-acafcb1ec6bd">77.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare accelerated payments and deferred governmental grants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="sgry:MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjItMi0xLTEtMzk5MzY_f134591f-3154-42d0-b08f-256e3f7ad2c4">46.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="sgry:MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjItNC0xLTEtMzk5MzY_c23acc3e-f5d8-4c1d-93b6-8268ce2d8414">64.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjMtMi0xLTEtMzk5MzY_2fd247db-9bdf-4a74-9c95-11f741e188de">221.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjMtNC0xLTEtMzk5MzY_b29bd614-1f12-4fe0-87da-c9640c6bb53e">210.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current maturities of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjQtMi0xLTEtMzk5MzY_533e7844-c41d-4269-afb7-d1ecffbe43a5">68.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjQtNC0xLTEtMzk5MzY_d6f6e91b-084a-40e1-af95-3bde3f3461ae">60.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjUtMi0xLTEtMzk5MzY_564d93ae-a5eb-44a2-9aae-38477761dc33">542.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjUtNC0xLTEtMzk5MzY_87ad4a4b-ea52-418d-aac5-d26e93162cf1">536.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, less current maturities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjYtMi0xLTEtMzk5MzY_6a396544-6861-4e6b-a7b8-e789fec5b92c">3,025.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjYtNC0xLTEtMzk5MzY_1afb652f-1fb0-4444-a6be-1e9e8dae9363">2,878.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjctMi0xLTEtMzk5MzY_29d32512-14e8-49d0-ae81-6abd67c6b618">272.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjctNC0xLTEtMzk5MzY_36614f0a-c8dc-471f-a31a-842df71f10d0">315.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjgtMi0xLTEtMzk5MzY_6a546438-edc7-4103-9a81-cdc6b59687e0">95.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjgtNC0xLTEtMzk5MzY_e2c81be7-46fe-415d-8e30-66cc2baa3002">87.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-controlling interests&#8212;redeemable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzAtMi0xLTEtMzk5MzY_d61b21d7-a77c-46ff-924f-dd99d285a59a">341.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzAtNC0xLTEtMzk5MzY_2df9367e-5bf0-469e-b6b6-7bea28b6cfb9">330.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzQtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjoxYzY3MTRiZWQ0ZmU0OTgwYjM3ZDcyNTc0ODU1MTg5Nl8yMQ_97fbe686-42ed-440b-a7cc-8236733fcf92"><ix:nonFraction unitRef="usdPerShare" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzQtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjoxYzY3MTRiZWQ0ZmU0OTgwYjM3ZDcyNTc0ODU1MTg5Nl8yMQ_d0c3e131-a179-4135-a764-e9447cf519cb">0.01</ix:nonFraction></ix:nonFraction> par value; shares authorized - <ix:nonFraction unitRef="shares" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzQtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjoxYzY3MTRiZWQ0ZmU0OTgwYjM3ZDcyNTc0ODU1MTg5Nl81NQ_37f7f87c-49cf-44de-aed1-561443dea855"><ix:nonFraction unitRef="shares" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzQtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjoxYzY3MTRiZWQ0ZmU0OTgwYjM3ZDcyNTc0ODU1MTg5Nl81NQ_64bfd1c6-6545-4973-97c6-68bf143547ce">20,310,000</ix:nonFraction></ix:nonFraction>; shares issued or outstanding - <ix:nonFraction unitRef="shares" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzQtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjoxYzY3MTRiZWQ0ZmU0OTgwYjM3ZDcyNTc0ODU1MTg5Nl85MA_22d7c400-77d1-47f8-8a5b-be5db7f13ecb"><ix:nonFraction unitRef="shares" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzQtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjoxYzY3MTRiZWQ0ZmU0OTgwYjM3ZDcyNTc0ODU1MTg5Nl85MA_790972b5-ba16-44d7-8cf8-ea20b7b26668"><ix:nonFraction unitRef="shares" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzQtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjoxYzY3MTRiZWQ0ZmU0OTgwYjM3ZDcyNTc0ODU1MTg5Nl85MA_b6ac732b-8d29-490a-97d1-4600b3ce3e04"><ix:nonFraction unitRef="shares" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzQtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjoxYzY3MTRiZWQ0ZmU0OTgwYjM3ZDcyNTc0ODU1MTg5Nl85MA_c6e5f5c6-6c79-48a6-b155-3e4cb32f786a">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzQtMi0xLTEtMzk5MzY_7a9708a7-8891-4683-b4ca-ed0db75c34d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzQtNC0xLTEtMzk5MzY_d0206a27-8938-4060-8068-57f5f25f99b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzUtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjo5MWQ2ZjBjNTc4Njc0MDBmYjQ3NTM2ZDY5MGIyNDdjZl8xOA_1fb8236e-9ec5-41a3-912f-8635aea23694"><ix:nonFraction unitRef="usdPerShare" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzUtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjo5MWQ2ZjBjNTc4Njc0MDBmYjQ3NTM2ZDY5MGIyNDdjZl8xOA_e9ec46b7-0644-4676-b750-229535b4a83e">0.01</ix:nonFraction></ix:nonFraction> par value; shares authorized - <ix:nonFraction unitRef="shares" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzUtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjo5MWQ2ZjBjNTc4Njc0MDBmYjQ3NTM2ZDY5MGIyNDdjZl81Mg_89502ce1-df92-4c39-8ab1-b8f517405d8b"><ix:nonFraction unitRef="shares" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzUtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjo5MWQ2ZjBjNTc4Njc0MDBmYjQ3NTM2ZDY5MGIyNDdjZl81Mg_fd766783-9082-41ce-996f-d2d9ad7d69ee">300,000,000</ix:nonFraction></ix:nonFraction>; shares issued and outstanding - <ix:nonFraction unitRef="shares" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzUtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjo5MWQ2ZjBjNTc4Njc0MDBmYjQ3NTM2ZDY5MGIyNDdjZl84OA_1bba6c7f-dd20-4383-85f2-266602f3abd2"><ix:nonFraction unitRef="shares" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzUtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjo5MWQ2ZjBjNTc4Njc0MDBmYjQ3NTM2ZDY5MGIyNDdjZl84OA_7a4dd198-e940-41a9-a046-563828eaaedb">89,904,913</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzUtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjo5MWQ2ZjBjNTc4Njc0MDBmYjQ3NTM2ZDY5MGIyNDdjZl85NQ_573fba06-cf88-43e8-8a8a-7481ea534822"><ix:nonFraction unitRef="shares" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzUtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjo5MWQ2ZjBjNTc4Njc0MDBmYjQ3NTM2ZDY5MGIyNDdjZl85NQ_6c3c7ed0-352c-4ce0-82f4-bc8e63776af4">89,332,557</ix:nonFraction></ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:CommonStockValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzUtMi0xLTEtMzk5MzY_0456cd0e-ec13-484a-8b00-2add76b4dc27">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:CommonStockValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzUtNC0xLTEtMzk5MzY_b72591ff-4de9-4b15-85ab-b412919beda8">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzYtMi0xLTEtMzk5MzY_6383324b-73ba-470c-8b5e-87fd0e0d03ce">1,625.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzYtNC0xLTEtMzk5MzY_968c9c1b-3e8b-440a-8f9b-13eb88125c2d">1,622.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzctMi0xLTEtMzk5MzY_addb573e-7c9a-43da-9d14-203aac414c2a">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzctNC0xLTEtMzk5MzY_a1b34ee2-5ad8-4275-802f-b62131354258">31.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzgtMi0xLTEtMzk5MzY_28b99a02-f06f-463d-830c-783b66a30716">490.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzgtNC0xLTEtMzk5MzY_54172555-9f28-463a-b314-13376669c85a">502.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Surgery Partners, Inc. stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzktMi0xLTEtMzk5MzY_3e6b087f-b4f0-4542-948a-7dd99739acb1">1,160.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzktNC0xLTEtMzk5MzY_c59d65c2-f653-40ad-8b0e-89e53075c4b2">1,089.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-controlling interests&#8212;non-redeemable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNDAtMi0xLTEtMzk5MzY_ab1e7d57-f5f7-46f5-83e1-bba9a9816211">851.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNDAtNC0xLTEtMzk5MzY_ff5960f1-0446-4bd1-bf93-7cbe557c50f5">880.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNDEtMi0xLTEtMzk5MzY_1e3ccd80-1d10-4917-80ae-cc54b4b45d3d">2,012.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNDEtNC0xLTEtMzk5MzY_35ea28e5-1748-44de-94f6-6bedc0e75e76">1,969.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNDItMi0xLTEtMzk5MzY_e0a88f01-6fbe-4c2c-9a0f-eb82799a98b3">6,289.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNDItNC0xLTEtMzk5MzY_68c34d70-b431-4683-9dc7-e4ae1257e01f">6,117.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See notes to unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i8d24edc59a384ef08748223de247b6a7_16"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited, dollars in millions, except per share amounts, shares in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.612%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.968%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMy0yLTEtMS0zOTkzNg_3d40a682-fc54-4c3c-bade-5962f09eef0b">596.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMy00LTEtMS0zOTkzNg_9bccfd8d-c814-4191-a303-d69474e0d145">512.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:LaborAndRelatedExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfNS0yLTEtMS0zOTkzNg_a3cdf6b0-940d-44c9-8de2-342f9de9e6e0">178.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:LaborAndRelatedExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfNS00LTEtMS0zOTkzNg_1af48e6a-5f56-4b0a-a637-0a6d17d5d2af">151.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfNi0yLTEtMS0zOTkzNg_f5f0ef51-64ea-429e-a181-e29ceef4dbb2">171.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfNi00LTEtMS0zOTkzNg_a72ab08a-b410-4f59-b392-ed96b3852e66">147.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional and medical fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:ProfessionalFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfNy0yLTEtMS0zOTkzNg_575592e9-9f89-44f8-ae68-18bf036d330c">63.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:ProfessionalFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfNy00LTEtMS0zOTkzNg_44252d69-3460-4443-8a6f-b7d50f00c05b">55.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="sgry:OperatingAndFinanceLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfOC0yLTEtMS0zOTkzNg_fee238f0-df84-4d95-8fce-e89e01145905">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="sgry:OperatingAndFinanceLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfOC00LTEtMS0zOTkzNg_4a3a1abc-e0ee-4f7b-8c9d-20e527154e98">22.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfOS0yLTEtMS0zOTkzNg_6e46291a-56a8-4bb9-8538-c78ec57b7025">37.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfOS00LTEtMS0zOTkzNg_0d3d633e-3358-494c-a955-025009ba33aa">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTAtMi0xLTEtMzk5MzY_5be87a48-5a46-4e07-93da-085cc9fd5bbd">471.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTAtNC0xLTEtMzk5MzY_dd87dfbc-cf79-443c-a861-609a90d82648">408.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTEtMi0xLTEtMzk5MzY_7383a8ef-8ec8-4165-be55-2dbefae6a9ac">29.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTEtNC0xLTEtMzk5MzY_2b6aa91e-ecb0-4ca5-b5be-74084b291e30">26.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTItMi0xLTEtMzk5MzY_ffd327f2-bd5b-4802-ae36-d9d3f9590e30">27.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTItNC0xLTEtMzk5MzY_f7c36219-1805-4efd-8043-d7680d57018e">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction and integration costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTMtMi0xLTEtNDU5NDI_52ac4cd4-1979-4620-886d-a06ebef56133">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTMtNC0xLTEtNDU5NDI_268af92e-c3f4-480b-870c-ec3f226f598b">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="sgry:GrantRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTMtMi0xLTEtMzk5MzY_78a06e46-ea8d-489d-8eb0-dce36bc8a439">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="sgry:GrantRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTMtNC0xLTEtMzk5MzY_820462a0-9010-4a23-9758-8e39ba9f4819">15.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on disposals and deconsolidations, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="sgry:GainLossOnDispositionOfAssetsAndDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTQtMi0xLTEtMzk5MzY_96ec6285-1c17-482f-9047-7c1b4dcda0fb">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="sgry:GainLossOnDispositionOfAssetsAndDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTQtNC0xLTEtMzk5MzY_60c8f1bf-b64f-4025-9f17-eff928d0f49d">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of unconsolidated affiliates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTUtMi0xLTEtMzk5MzY_96ff62f1-aa8e-490a-a346-aa99f120028f">3.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTUtNC0xLTEtMzk5MzY_662786bb-17ba-499d-93db-08ded00fc725">2.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Litigation settlement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTktMi0xLTEtMzk5MzY_29f12a66-c5d5-495e-bae9-cc72eae83022">32.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTktNC0xLTEtMzk5MzY_10c0ffea-175b-4e8a-a460-800a19d0b5ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherNonrecurringIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjAtMi0xLTEtMzk5MzY_f4a2d72a-b13d-4238-84d0-4f7c4c6f3fbd">2.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:OtherNonrecurringIncomeExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjAtNC0xLTEtMzk5MzY_983dbb5e-04d1-4542-bf61-fb2727651a3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 25.75pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjEtMi0xLTEtMzk5MzY_b6b1c966-84c3-43f3-a21e-2e168a205e50">495.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjEtNC0xLTEtMzk5MzY_7fbd6484-9069-4729-abee-95e17fbfb535">448.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjItMi0xLTEtMzk5MzY_a9ef279b-5b6b-45e4-a826-96b1bde9bef0">100.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjItNC0xLTEtMzk5MzY_9dcd0272-d83b-4db3-b3c7-d3e580f73b7a">64.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjMtMi0xLTEtMzk5MzY_5d202a14-6c9c-493f-ad98-b28d884a1605">56.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjMtNC0xLTEtMzk5MzY_d0e29818-5068-4950-badd-7c1404a5e825">53.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjQtMi0xLTEtMzk5MzY_049d1494-e8b1-4af0-8760-9659e626bb52">44.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjQtNC0xLTEtMzk5MzY_b4937285-ab0c-4ed6-9390-989cb21419a9">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjUtMi0xLTEtMzk5MzY_0baa17cc-1059-4c14-a52f-27fb1fbb90cf">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjUtNC0xLTEtMzk5MzY_b7ca889d-d8fd-45c6-94d6-74f5cfb0700a">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjYtMi0xLTEtMzk5MzY_df555325-d808-46a3-a506-df7eea36e675">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjYtNC0xLTEtMzk5MzY_c0d055a6-d538-4fec-ac51-ddf6db2c0932">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjctMi0xLTEtMzk5MzY_6685bfaf-1f58-4c28-9626-d50aee385fa7">30.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjctNC0xLTEtMzk5MzY_1207415d-2588-41ad-9758-e72bddc49a5c">31.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) attributable to Surgery Partners, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjgtMi0xLTEtMzk5MzY_021d40ac-326a-4613-9348-957adbe20857">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjgtNC0xLTEtMzk5MzY_f564e7f8-459e-4b47-a968-80f0d162def9">21.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Amounts attributable to participating securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjktMi0xLTEtMzk5MzY_7db3f465-ab87-461d-b2ce-8afbfaa3227e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjktNC0xLTEtMzk5MzY_8d8c1d79-f95d-4599-9afc-e07f501d5f7f">10.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzAtMi0xLTEtMzk5MzY_8262f76b-0891-4af7-8ab5-b9d516a1e4f8">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzAtNC0xLTEtMzk5MzY_971af0c0-9dcb-4cbf-995d-a6222446414c">31.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzMtMi0xLTEtMzk5MzY_a5dc84c9-7ed4-4db3-86c4-3bad89c0b62a">0.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzMtNC0xLTEtMzk5MzY_217963fe-d3ee-4e63-ad6c-65d6503d56ba">0.57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzQtMi0xLTEtMzk5MzY_f316c610-a8bf-4296-81dd-e5befb731d9e">0.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzQtNC0xLTEtMzk5MzY_5b797168-8f73-4ca9-8faa-caa680e32762">0.57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzYtMi0xLTEtMzk5MzY_eb7a87c7-0dde-4a2e-9a13-6d22507a886e">87,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzYtNC0xLTEtMzk5MzY_8fee75fc-a378-4f03-9b06-2717fa85ee0b">54,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzctMi0xLTEtMzk5MzY_3aaf1ab2-cdc3-4241-9f41-41b592762a11">90,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzctNC0xLTEtMzk5MzY_e0983b0a-cd91-4e3f-af96-ff0084a35973">54,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RleHRyZWdpb246ODQ3MGZiMGI3NjY4NDQ4MGFhNGEyM2Q5ODVlNGUyNzNfMzky_e44d5c8e-2e66-4df1-a1e1-4d01aa20ae69" footnoteRole="http://www.xbrl.org/2003/role/footnote">The impact of potentially dilutive securities for the three months ended March 31, 2021 was not considered because the effect would be anti-dilutive.</ix:footnote></span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See notes to unaudited condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i8d24edc59a384ef08748223de247b6a7_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited, dollars in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xOS9mcmFnOjhhNDY5ZDVmMzExOTQ3YWE5MjM5ZTQ2YmZiOWM3ODg5L3RhYmxlOmE4YTQwZTU1ZTgxMzRiNmViYmQ3OWY1NDhjMmM1ZjE1L3RhYmxlcmFuZ2U6YThhNDBlNTVlODEzNGI2ZWJiZDc5ZjU0OGMyYzVmMTVfMy0yLTEtMS0zOTkzNg_df555325-d808-46a3-a506-df7eea36e675">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xOS9mcmFnOjhhNDY5ZDVmMzExOTQ3YWE5MjM5ZTQ2YmZiOWM3ODg5L3RhYmxlOmE4YTQwZTU1ZTgxMzRiNmViYmQ3OWY1NDhjMmM1ZjE1L3RhYmxlcmFuZ2U6YThhNDBlNTVlODEzNGI2ZWJiZDc5ZjU0OGMyYzVmMTVfMy00LTEtMS0zOTkzNg_c0d055a6-d538-4fec-ac51-ddf6db2c0932">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xOS9mcmFnOjhhNDY5ZDVmMzExOTQ3YWE5MjM5ZTQ2YmZiOWM3ODg5L3RhYmxlOmE4YTQwZTU1ZTgxMzRiNmViYmQ3OWY1NDhjMmM1ZjE1L3RhYmxlcmFuZ2U6YThhNDBlNTVlODEzNGI2ZWJiZDc5ZjU0OGMyYzVmMTVfNS0yLTEtMS0zOTkzNg_e0273c9b-dc90-465c-ba21-23491268c0b3">56.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xOS9mcmFnOjhhNDY5ZDVmMzExOTQ3YWE5MjM5ZTQ2YmZiOWM3ODg5L3RhYmxlOmE4YTQwZTU1ZTgxMzRiNmViYmQ3OWY1NDhjMmM1ZjE1L3RhYmxlcmFuZ2U6YThhNDBlNTVlODEzNGI2ZWJiZDc5ZjU0OGMyYzVmMTVfNS00LTEtMS0zOTkzNg_3a872617-fdb2-46f9-9032-db2ace817f37">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xOS9mcmFnOjhhNDY5ZDVmMzExOTQ3YWE5MjM5ZTQ2YmZiOWM3ODg5L3RhYmxlOmE4YTQwZTU1ZTgxMzRiNmViYmQ3OWY1NDhjMmM1ZjE1L3RhYmxlcmFuZ2U6YThhNDBlNTVlODEzNGI2ZWJiZDc5ZjU0OGMyYzVmMTVfNi0yLTEtMS0zOTkzNg_9b8699a6-fb64-49eb-aac7-d2d7397df577">99.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xOS9mcmFnOjhhNDY5ZDVmMzExOTQ3YWE5MjM5ZTQ2YmZiOWM3ODg5L3RhYmxlOmE4YTQwZTU1ZTgxMzRiNmViYmQ3OWY1NDhjMmM1ZjE1L3RhYmxlcmFuZ2U6YThhNDBlNTVlODEzNGI2ZWJiZDc5ZjU0OGMyYzVmMTVfNi00LTEtMS0zOTkzNg_3fc465df-7ca9-4ef4-95c9-0aac003240ea">17.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Comprehensive income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xOS9mcmFnOjhhNDY5ZDVmMzExOTQ3YWE5MjM5ZTQ2YmZiOWM3ODg5L3RhYmxlOmE4YTQwZTU1ZTgxMzRiNmViYmQ3OWY1NDhjMmM1ZjE1L3RhYmxlcmFuZ2U6YThhNDBlNTVlODEzNGI2ZWJiZDc5ZjU0OGMyYzVmMTVfNy0yLTEtMS0zOTkzNg_5c9f24b9-69aa-4ade-8e32-5ea61a6e424d">30.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xOS9mcmFnOjhhNDY5ZDVmMzExOTQ3YWE5MjM5ZTQ2YmZiOWM3ODg5L3RhYmxlOmE4YTQwZTU1ZTgxMzRiNmViYmQ3OWY1NDhjMmM1ZjE1L3RhYmxlcmFuZ2U6YThhNDBlNTVlODEzNGI2ZWJiZDc5ZjU0OGMyYzVmMTVfNy00LTEtMS0zOTkzNg_04e5e458-9b9f-4a64-b8c1-23c4e5025a77">31.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to Surgery Partners, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xOS9mcmFnOjhhNDY5ZDVmMzExOTQ3YWE5MjM5ZTQ2YmZiOWM3ODg5L3RhYmxlOmE4YTQwZTU1ZTgxMzRiNmViYmQ3OWY1NDhjMmM1ZjE1L3RhYmxlcmFuZ2U6YThhNDBlNTVlODEzNGI2ZWJiZDc5ZjU0OGMyYzVmMTVfOC0yLTEtMS0zOTkzNg_eb022e9a-7e26-4220-ab9b-95e66f6c2a89">69.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xOS9mcmFnOjhhNDY5ZDVmMzExOTQ3YWE5MjM5ZTQ2YmZiOWM3ODg5L3RhYmxlOmE4YTQwZTU1ZTgxMzRiNmViYmQ3OWY1NDhjMmM1ZjE1L3RhYmxlcmFuZ2U6YThhNDBlNTVlODEzNGI2ZWJiZDc5ZjU0OGMyYzVmMTVfOC00LTEtMS0zOTkzNg_27fc56ef-0b69-4261-85d3-52fb18ebab3d">14.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See notes to unaudited condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i8d24edc59a384ef08748223de247b6a7_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited, dollars in millions, shares in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.797%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional <br/>Paid-in Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-Controlling Interests&#8212;  <br/>Non-Redeemable</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65d685057ae641c3b746cf6377dd430f_I20201231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMy0xLTEtMS0zOTkzNg_c873e142-ebf2-4542-b923-f5574659b65f">50,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65d685057ae641c3b746cf6377dd430f_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMy0zLTEtMS0zOTkzNg_944730b2-78fc-48d7-98b2-707c0b312957">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48d044e479254b2f8935070ff1a00ac4_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMy01LTEtMS0zOTkzNg_5724e23a-f03c-40bb-9f6c-807e4b2852a8">607.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02439221d0d244d9bcd5569225a9eceb_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMy03LTEtMS0zOTkzNg_ef34228d-8209-43b4-8145-7becabb3bce6">61.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61d245da91744ed8b196945289f8015a_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMy05LTEtMS0zOTkzNg_c96a9fad-84f1-4ce5-aa11-2f9600077790">431.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2faf06f152e04dfaac19ae85d0f6df18_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMy0xMS0xLTEtMzk5MzY_a13331a5-d295-4e00-9068-03ad6632ffaf">766.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64de719b0ad14503b4dba6762866534b_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMy0xMy0xLTEtMzk5MzY_7207f622-dee0-454e-acc1-a9758b642751">882.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a8fc7979812433d8763ce3c5642dc80_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNC05LTEtMS0zOTkzNg_de5fc144-cd1e-4362-83eb-5fc09d911dde">21.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a837d715cbc4966875dc62f6e78cbd7_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNC0xMS0xLTEtMzk5MzY_38231e11-81cb-4ef7-a265-694cb3cf9c95">21.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNC0xMy0xLTEtMzk5MzY_63fd0910-53f8-4ab4-94f6-b3274c16f44e">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf10b9430f6847b490ed2cf648c93e32_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNS0xLTEtMS0zOTkzNg_c7fe206e-4f65-4673-84c6-da2b4dd67446">812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1aeda0f667e349c086a29bab4acce588_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNS01LTEtMS0zOTkzNg_d5386f91-85e9-4e8d-9900-47f8b258d322">2.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNS0xMy0xLTEtMzk5MzY_3625771e-2eae-4b86-91c5-e4cdbfbc58df">2.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1aeda0f667e349c086a29bab4acce588_D20210101-20210331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNi01LTEtMS0zOTkzNg_c6483415-f04b-4f2d-9135-0fb0b4b071fb">10.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNi0xMy0xLTEtMzk5MzY_5edd0c0e-6a80-471c-9086-1e0c55768db3">10.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf10b9430f6847b490ed2cf648c93e32_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNy0xLTEtMS0zOTkzNg_8f4148fb-41f2-4985-98d1-6ac99e33af57">8,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf10b9430f6847b490ed2cf648c93e32_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNy0zLTEtMS0zOTkzNg_781507fd-bcb2-464a-87f1-e2cb3083f17c">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1aeda0f667e349c086a29bab4acce588_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNy01LTEtMS0zOTkzNg_72d59c02-c186-4b7a-8b54-f201d24d0b69">248.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNy0xMy0xLTEtMzk5MzY_8a60cd17-dfba-4667-b88d-ce990026d7bf">248.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0cfdca28efe4489bed9689a67756a3c_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfOC03LTEtMS0zOTkzNg_04f17634-edd7-49c0-a885-87d7b0a95e96">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfOC0xMy0xLTEtMzk5MzY_5866a825-cdd3-4a98-b747-9ae113ed62d1">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition and disposal of shares of non-controlling interests, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1aeda0f667e349c086a29bab4acce588_D20210101-20210331" decimals="-5" name="sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfOS01LTEtMS0zOTkzNg_08a4d030-da0a-4638-ae8b-e27270d83bfa">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a837d715cbc4966875dc62f6e78cbd7_D20210101-20210331" decimals="-5" name="sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfOS0xMS0xLTEtMzk5MzY_69971cba-32fc-4599-8cfa-aafb39d1a2fb">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfOS0xMy0xLTEtMzk5MzY_60f9ffba-ca15-46c2-9d99-667340f05336">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions to non-controlling interests&#8212;non-redeemable holders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a837d715cbc4966875dc62f6e78cbd7_D20210101-20210331" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMTAtMTEtMS0xLTM5OTM2_ff7f5307-bd7f-4344-b44f-e8ce7c32348d">20.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMTAtMTMtMS0xLTM5OTM2_c86dd2ee-2bef-4bbc-ae76-9ae3ddecc272">20.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i253dec092e2d41f28b85f643ccdd68cd_I20210331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMTEtMS0xLTEtMzk5MzY_fc1e9419-be73-45d5-b35d-3bb0c1febf51">59,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i253dec092e2d41f28b85f643ccdd68cd_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMTEtMy0xLTEtMzk5MzY_6906331b-6ae2-4789-a510-7400dfebc1c4">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44d8b197c09347a5bfe50b624fa0d5b3_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMTEtNS0xLTEtMzk5MzY_1b15e8ae-fdd7-4f12-9aad-812e60807581">843.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a8cdfe2cc68416e866d30dbf21372d9_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMTEtNy0xLTEtMzk5MzY_c74cefe9-349e-420b-84f3-aca6e786afb5">54.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1114172ce5094c68bedb86e8b7d44cb7_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMTEtOS0xLTEtMzk5MzY_9f1bd171-d099-4a8f-ba2d-1f63e05b8b7a">452.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib49a1cb0982e43ec901c64053a39f745_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMTEtMTEtMS0xLTM5OTM2_b78583c4-9e4c-4a57-9a13-7a5375f4ded6">768.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia510a69b8e64403eb11f83898b8a08ec_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMTEtMTMtMS0xLTM5OTM2_16aaa2d0-3048-460c-975c-fd578ddbc6b0">1,105.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt;text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic00c0198779b477e9adb83fad573131e_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMC0xLTEtMS00MTU2NQ_24801cb4-7e91-4d3b-bf15-cef3daa66364">89,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic00c0198779b477e9adb83fad573131e_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMC0zLTEtMS00MTU3MQ_a67d080a-3184-46c7-a052-d7846e93c532">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cf9408c2ea45248462023da0418e49_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMC01LTEtMS00MTU3Nw_85650362-6fa6-4793-b87f-029c228ac225">1,622.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07efbfabca9b4e33acccafb2fe2d7c82_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMC03LTEtMS00MTU4Mw_8a9e9a4d-a574-4166-b5cf-af1a00e39733">31.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8070a501ab2c40589c94526f6bda6ebe_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMC05LTEtMS00MTU4OQ_f16591e3-f1f1-483e-bb08-c300a4962f31">502.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ae47e0aa9a4921a427c583c4ff6645_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMC0xMS0xLTEtNDE1OTU_ce9bfc81-b037-4556-b653-835761d33e1b">880.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMC0xMy0xLTEtNDI0ODE_41b4e581-90ff-4be3-b9e3-49fcba397a95">1,969.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2930feb3f5944505ad4c3d63f26d5f4f_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMS05LTEtMS00MTU4OQ_ab4d7157-72be-4fe7-b4ca-212dff528b93">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i635f7b61fc044f528748645b77893543_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMS0xMS0xLTEtNDE1OTU_0c09cd46-4297-4406-9445-eecbc11e9a69">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMS0xMy0xLTEtNDI0ODk_a240044f-61c1-4f94-9157-508f446e4584">32.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifeb7edc101bf4e3ca14bd0a2df3bec5f_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMi0xLTEtMS00MTU2NQ_0307388e-d13b-4080-ba4e-c49d341e046b">572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacb41fa48e0c4c0280b70a8b8b967a6c_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMi01LTEtMS00MTU3Nw_f6b6eb06-de0f-4dc5-ba9d-d34f13e08310">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMi0xMy0xLTEtNDI0ODk_1a37c89e-3280-4444-b86c-5bf3f0164dfa">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib052d4f8c5ef41118d1450786f139047_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMy03LTEtMS00MTU4Mw_fb9e265e-8335-4ec4-9b4d-f867fb195e93">56.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMy0xMy0xLTEtNDI0ODc_6abb5ade-90f9-470f-8709-1a56b5d6a8d7">56.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition and disposal of shares of non-controlling interests, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacb41fa48e0c4c0280b70a8b8b967a6c_D20220101-20220331" decimals="-5" sign="-" name="sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNC01LTEtMS00MTU3Nw_563520b5-be38-4a38-ad8f-451d8dc854f0">4.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i635f7b61fc044f528748645b77893543_D20220101-20220331" decimals="-5" sign="-" name="sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNC0xMS0xLTEtNDE1OTU_a269a8d4-122c-43f1-b09b-ebf03abbdb73">24.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" sign="-" name="sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNC0xMy0xLTEtNDI0ODc_9b4585a2-b83d-49de-aca2-de2d27cb8b86">29.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions to non-controlling interests&#8212;non-redeemable holders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i635f7b61fc044f528748645b77893543_D20220101-20220331" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNS0xMS0xLTEtNDE1OTU_61b85dc2-a716-43bd-9511-d3c70ec292aa">24.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNS0xMy0xLTEtNDI0ODc_6ad9599f-ec09-4dfc-9d6f-12028380139e">24.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if23681243e73450cb3fa31d9cffac2b7_I20220331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNi0xLTEtMS00MjQ4NQ_6d9f5417-a880-4a91-a7aa-abe47a80c1d9">89,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if23681243e73450cb3fa31d9cffac2b7_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNi0zLTEtMS00MjQ4NQ_11b105a3-8c5e-438f-9b29-fe5d7a4a8f73">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b12b437d5442cbbfda520a3f432240_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNi01LTEtMS00MjQ4NQ_f8f22fe1-6d71-41bc-92f0-8b17d70a2649">1,625.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e53044aa4142028b8b7d9863d3accb_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNi03LTEtMS00MjQ4NQ_c6a3db2b-ef5b-440a-a3d1-0ba6d19a6cc1">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4c0aada0e14421286ede0517722bf59_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNi05LTEtMS00MjQ4NQ_b926f863-3ce6-4fbf-9f08-ee1a04fe039a">490.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10d1f1007efc4b109adc6675a736352c_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNi0xMS0xLTEtNDI0ODU_94cbf63a-df5c-4acb-8427-c818ed411791">851.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNi0xMy0xLTEtNDI0ODU_963f9db6-cf77-4264-befe-a40a35b1fccf">2,012.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See notes to unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i8d24edc59a384ef08748223de247b6a7_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited, dollars in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:73.266%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.973%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMy0yLTEtMS0zOTkzNg_72b6cf0c-dcd5-4e65-9075-9f267c932a01">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMy00LTEtMS0zOTkzNg_a5e6d5df-c8cc-414f-abff-7f38c2842372">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfNS0yLTEtMS0zOTkzNg_08a69bfe-a757-404e-bd96-326d48b4963f">27.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfNS00LTEtMS0zOTkzNg_3fd10c8c-b872-4183-9042-97632c20bb03">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" sign="-" name="sgry:NoncashInterestIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfNi0yLTEtMS0zOTkzNg_9f7a6ad7-4107-4c6d-8ed0-6ef97a4edf44">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" sign="-" name="sgry:NoncashInterestIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfNi00LTEtMS0zOTkzNg_bd881e9d-142b-4f0c-83ca-6ecea2cfdbec">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfNy0yLTEtMS0zOTkzNg_7f026ed2-96f4-43b6-b462-1c657187f98f">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfNy00LTEtMS0zOTkzNg_54ba043e-6db8-4dee-8eee-10459e142d19">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on disposals and deconsolidations, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="sgry:GainLossOnDispositionOfAssetsAndDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfOC0yLTEtMS0zOTkzNg_f45a0f4d-0cdd-405c-9188-d3bf653276ac">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="sgry:GainLossOnDispositionOfAssetsAndDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfOC00LTEtMS0zOTkzNg_e4073728-42d1-4424-85d8-fd8d4c6154a6">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTEtMi0xLTEtMzk5MzY_634a5982-8168-4ef0-bc94-c9ba28eab594">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTEtNC0xLTEtMzk5MzY_032c1825-8545-4d4d-9820-d6b2cc4c6086">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of unconsolidated affiliates, net of distributions received</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTItMi0xLTEtMzk5MzY_d5c6bce3-c243-4af5-958f-5450a8d22324">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTItNC0xLTEtMzk5MzY_8fb548c6-99ca-472f-9c1b-0da62255e24e">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTMtMi0xLTEtMzk5MzY_16c42b82-f628-4f9a-a157-e90d78573c40">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTMtNC0xLTEtMzk5MzY_4b9af0fd-d8ed-4d61-a8f4-e320794ca44c">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTUtMi0xLTEtMzk5MzY_72ea8f9e-6477-4e58-80ba-052dd159d04a">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTUtNC0xLTEtMzk5MzY_08d97622-60f1-4239-b2a7-e7d7ca5ee5af">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare accelerated payments and deferred governmental grants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" sign="-" name="sgry:IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTYtMi0xLTEtMzk5MzY_2db65d67-b5fe-4ee5-aeb9-f480f5a90db2">18.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" sign="-" name="sgry:IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTYtNC0xLTEtMzk5MzY_20296328-1112-45af-8341-258526ef5a01">7.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other operating assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTgtMi0xLTEtMzk5MzY_8818806d-74d3-42b8-bd41-2276956fef7f">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTgtNC0xLTEtMzk5MzY_674461f3-3485-4a34-b2c3-02767f18bc83">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTktMi0xLTEtMzk5MzY_236da617-568d-466b-9b49-8a46d80c1b56">79.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTktNC0xLTEtMzk5MzY_324a23bb-1e2a-4958-a7e7-f6749a7fcfa6">50.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjItMi0xLTEtMzk5MzY_e04c6dbc-5a2a-4b27-8331-564a80755655">18.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjItNC0xLTEtMzk5MzY_7706b541-9d1b-420a-ac34-e7c99544f3c5">14.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for acquisitions, net of cash acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjMtMi0xLTEtMzk5MzY_89b87a8c-bd54-4a48-969c-5a6b338bc6ef">31.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjMtNC0xLTEtMzk5MzY_5207fdb2-2bf0-475b-b03f-91d61115a7a8">2.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from disposals of facilities and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjQtMi0xLTEtMzk5MzY_90e6e611-54cf-4fbd-a2c2-f88a27c43106">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjQtNC0xLTEtMzk5MzY_cbb68f0c-983b-4c54-ae35-a26df75c43fa">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales of equity investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjUtMi0xLTEtNDQ2NjI_002466a2-2bc8-4859-8d62-0a8c1ef44edf">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjUtNC0xLTEtNDQ2NjI_7bc1f003-ae04-4d39-a393-2e9582acfa06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjUtMi0xLTEtMzk5MzY_e2ca5b0f-56f8-4d2a-8b54-6b1236675948">9.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjUtNC0xLTEtMzk5MzY_896e41ca-863c-4f6e-9c66-757615573ef6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjYtMi0xLTEtMzk5MzY_28efdb5e-20f9-48a0-a936-75893e6f6596">47.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjYtNC0xLTEtMzk5MzY_f2d4bcf7-f9d8-4643-8c5c-591200fdeb2c">14.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal payments on long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjktMi0xLTEtMzk5MzY_bf9f8444-5582-4055-ba90-abf27285cbae">17.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjktNC0xLTEtMzk5MzY_390f2cf4-4348-404a-8862-2cad0068e3c1">16.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Borrowings of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzAtMi0xLTEtMzk5MzY_f0f7972b-63a3-490f-936c-4c865b0c9514">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzAtNC0xLTEtMzk5MzY_9d447cbe-6c7e-4711-9975-269fe22daa09">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzEtMi0xLTEtMzk5MzY_495c4559-ad7e-4c2b-b51c-ccfc261ed4d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzEtNC0xLTEtMzk5MzY_5e73a3c6-9032-4abb-a1a0-941c1589941f">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from equity offering</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzItMi0xLTEtMzk5MzY_4a15fd6d-9aaf-42ba-bb39-d48edb34f539">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzItNC0xLTEtMzk5MzY_d2221f47-23be-46a7-83e9-f5880e5cc144">260.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of equity offering costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzMtMi0xLTEtMzk5MzY_c34b3ca0-add9-4ceb-82c1-fcb13bd22c6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzMtNC0xLTEtMzk5MzY_799d2480-da9b-42de-a7af-8ef52c0c848a">12.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of preferred dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzQtMi0xLTEtMzk5MzY_9b98f44e-a50d-481f-a897-3604bd9152eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzQtNC0xLTEtMzk5MzY_b7c9fe0c-cceb-4b53-90c1-a44b80ae86fd">5.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to non-controlling interest holders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsOfDividendsMinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzUtMi0xLTEtMzk5MzY_61201db4-e50b-400e-8b11-7be7c0107052">36.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsOfDividendsMinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzUtNC0xLTEtMzk5MzY_02ed5d6b-0b81-401d-a56b-01d4a5d5614e">31.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Payments) receipts related to ownership transactions with non-controlling interest holders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzYtMi0xLTEtMzk5MzY_3933f4a8-420d-49ad-a989-32e24ea9f437">3.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzYtNC0xLTEtMzk5MzY_2961f516-f53e-463a-804f-48cec675dc66">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzctMi0xLTEtMzk5MzY_3527f158-2977-4107-ab56-1e7d632d25ed">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzctNC0xLTEtMzk5MzY_0fd57005-b08c-47eb-952f-fb112b33fbb3">8.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzgtMi0xLTEtMzk5MzY_6c4c11c1-65b6-406a-a0f6-93c2656b37b4">43.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzgtNC0xLTEtMzk5MzY_2019150a-6a26-4eba-8b1d-7d03d1a4624e">187.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzktMi0xLTEtMzk5MzY_71b737d5-2d71-4de1-b48c-c220f821e1ae">11.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzktNC0xLTEtMzk5MzY_52c600d4-c7fc-447d-9fa2-cd64c2f10777">223.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfNDAtMi0xLTEtMzk5MzY_f22bd252-b8ae-45d4-b581-4e8a0484e969">389.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64de719b0ad14503b4dba6762866534b_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfNDAtNC0xLTEtMzk5MzY_811d4048-223e-4ea3-a46f-dfdd3266b89b">318.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfNDEtMi0xLTEtMzk5MzY_d10afdd1-0e45-4ef9-905e-26c829b4cd8a">378.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia510a69b8e64403eb11f83898b8a08ec_I20210331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfNDEtNC0xLTEtMzk5MzY_9fdfc806-73d7-4ac8-b65b-3ae25f0d49ea">541.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See notes to unaudited condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i8d24edc59a384ef08748223de247b6a7_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-align:center"><span><br/></span></div><div id="i8d24edc59a384ef08748223de247b6a7_31"></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1.  <ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgzMTc_59ece22b-8b17-496f-ba65-18145e260dc7" continuedAt="i7d396cc89b134aefab0aef73ad2354e4" escape="true">Organization and Summary of Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i7d396cc89b134aefab0aef73ad2354e4" continuedAt="id168c29f436149949842c2edec4e47b8"><div style="margin-bottom:6pt;margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Surgery Partners, Inc., a Delaware corporation, acting through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. The surgical facilities, which include ambulatory surgery centers ("ASCs") and surgical hospitals, primarily provide non-emergency surgical procedures across many specialties, including, among others, gastroenterology, general surgery, ophthalmology, orthopedics and pain management. The Company's surgical hospitals also provide services such as diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy and wound care. Ancillary services are comprised of multi-specialty physician practices, urgent care facilities and anesthesia services. Unless the context otherwise indicates, Surgery Partners, Inc. and its subsidiaries are referred to herein as "Surgery Partners," "we," "us," "our" or the "Company."</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company owned or operated a portfolio of <ix:nonFraction unitRef="surgical_facility" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="INF" name="sgry:NumberOfSurgicalFacilitiesOwned" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTAyMQ_7ddbb0cc-47c0-4ac9-aeba-b7d98fdd06f3">127</ix:nonFraction> surgical facilities, comprised of <ix:nonFraction unitRef="surgical_facility" contextRef="i01ae3c8148ba4c25b35336360e5e7dc2_I20220331" decimals="INF" name="sgry:NumberOfSurgicalFacilitiesOwned" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA1OA_ca9b4aee-0a90-4e06-ad3b-41487632313f">109</ix:nonFraction> ASCs and <ix:nonFraction unitRef="surgical_facility" contextRef="ib0b5bb8fa6d646029f554028ebaa467d_I20220331" decimals="INF" name="sgry:NumberOfSurgicalFacilitiesOwned" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA3MA_7e1850cf-305b-4ba8-b81a-004874320e42">18</ix:nonFraction> surgical hospitals in <ix:nonFraction unitRef="state" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5NQ_10710396-841e-4ed2-ab84-817a6df7651c">31</ix:nonFraction> states. The Company owns these facilities in partnership with physicians and, in some cases, health care systems in the markets and communities it serves.&#160;The Company owned a majority interest in <ix:nonFraction unitRef="surgical_facility" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="INF" name="sgry:NumberOfSurgicalFacilitiesOwnedMajorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTI5NA_814dfafe-c57a-4564-a030-8574bdee552d">85</ix:nonFraction> of the surgical facilities and consolidated <ix:nonFraction unitRef="surgical_facility" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="INF" name="sgry:NumberOfSurgicalFacilitiesOwnedConsolidated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTM0MQ_692f36d7-50d6-44da-90e8-0957f07de14d">108</ix:nonFraction> of the facilities for financial reporting purposes.</span></div><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyNzY_ea1f9972-b381-463a-a285-9c54b27ccbd0" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation of the Company's financial position and results of operations have been included. The Company&#8217;s fiscal year ends on December&#160;31 and interim results are not necessarily indicative of results for a full year or any other interim period. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company&#8217;s consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021 (the "2021 Annual Report on Form 10-K").</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyMjI_4d6549fd-40ca-4081-bfa9-80e708cce523" escape="true">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyNTQ_10fafa56-2b64-4106-98b3-8c010d4107cd" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. Actual results could differ from those estimates.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The COVID-19 pandemic has significantly affected the Company's facilities, employees, patients, communities, business operations and financial performance, as well as the United States economy and financial markets. The impact of the COVID-19 pandemic on the Company's surgical facilities varies based on the market in which the facility operates, the type of surgical facility and the procedures that are typically performed. The Company cannot provide any certainty regarding the length and severity of the impact of the COVID-19 pandemic on its business operations and financial performance. As a result of the COVID-19 pandemic, the Company has implemented new clinical safety measures to provide a safe environment for its patients, surgeons and employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CARES Act </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the &#8220;CARES Act&#8221;) was signed into law to provide stimulus funding for the United States economy. As part of the CARES Act, the United States government announced that it would offer relief to eligible health care providers, including distribution of direct grants to hospitals, ASCs and other health care providers based on how much they bill Medicare. Payments received from these grants are not required to be repaid provided the recipients attest to and comply with certain terms and conditions, including limitations on balance billing and not using funds received from the grants to reimburse expenses or losses that other sources are obligated to reimburse. The Company has received approximately $<ix:nonFraction unitRef="usd" contextRef="i88ed6b4d58e5453984121369f4f11efc_D20200327-20220331" decimals="-6" name="sgry:ProceedsFromGovernmentAssistance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY4NDE1Mw_399ea590-987d-4039-ab1b-ac8ec41f8285">87</ix:nonFraction>&#160;million of the grant funds distributed under the CARES Act and other governmental assistance programs, including approximately $<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-6" name="sgry:ProceedsFromGovernmentAssistance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY4NDg0Nw_9981516b-c3a1-4f79-a4d6-09e3e6f923a3">1</ix:nonFraction>&#160;million during the three months ended March&#160;31, 2022. The recognition of amounts received is conditioned upon attestation with terms and conditions that funds will be used for COVID-19 related healthcare expenses or lost revenues.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company&#8217;s assessment of whether the terms and conditions for amounts received are reasonably assured of having been met considers, among other things, the CARES Act, the COVID-19 Economic Relief Bill, enacted on December 27, 2020, and all frequently asked questions and other interpretive guidance issued by the United States Department of Health and Human Services ("HHS"), including in the Provider Relief Fund Reporting Portal and associated user guides. This guidance sets forth the allowable methods for quantifying </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="id168c29f436149949842c2edec4e47b8" continuedAt="i598d437c7a054ba1be790e4e4ccfd893"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">eligible healthcare related expenses and lost revenues. Only healthcare related expenses attributable to COVID-19 that another source has not reimbursed and is not obligated to reimburse are eligible to be claimed. Based on guidance, the Company estimates approximately $<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="sgry:GrantRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY4NDg1OQ_78a06e46-ea8d-489d-8eb0-dce36bc8a439">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="sgry:GrantRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfODI0NjMzNzI2ODg0OQ_820462a0-9010-4a23-9758-8e39ba9f4819">15.1</ix:nonFraction> million of grant funds received qualified for recognition as a reduction in operating expenses for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amounts received, but not recognized as a reduction to operating expenses, are reflected as a component of Medicare accelerated payments and deferred governmental grants in the condensed consolidated balance sheets as of both March&#160;31, 2022 and December 31, 2021. Any unrecognized amounts may be recognized as a reduction in operating expenses in subsequent periods if the underlying conditions for recognition are met. Additional guidance or new and amended interpretations of existing guidance on the terms and conditions of such payments may result in the Company&#8217;s inability to recognize certain payments, changes in the estimate of amounts recognized, or the derecognition of amounts previously recognized, which may be material.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As a way to increase cash flow to Medicare providers impacted by the COVID-19 pandemic, the CARES Act expanded the Medicare Accelerated and Advance Payment Program, which allowed for most providers and suppliers, including the Company&#8217;s surgical hospitals and ASCs to request an advance payment of anticipated Medicare revenues. The Company received approximately $<ix:nonFraction unitRef="usd" contextRef="if6defdbda29a4879a3bd483aed3cec04_D20210101-20210630" decimals="-6" name="sgry:CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfNzc2NQ_5df7b2d9-5470-466e-a7b9-a11f95285ff8">120</ix:nonFraction>&#160;million of accelerated payments during the year ended December 31, 2020. The payments received were deferred and included in the condensed consolidated balance sheets. During the three months ended March 31, 2022, approximately $<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-6" name="sgry:CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY4NDE5OA_b381a5e5-b56a-4af2-8e98-dab5e3a481f5">18</ix:nonFraction>&#160;million has been repaid in accordance with the terms of the program. These repayments are included as a component of the change in Medicare accelerated payments and deferred government grants in the condensed consolidated statements of cash flows. Under these terms, repayment started one year after the initial funding by offsetting 25% of new claims paid by CMS. After 11 months of repayment at this level, the repayments will increase to 50% of new claims paid by CMS for a period of six months. Any outstanding amounts due at the end of the repayment period are subject to interest at a rate of 4%. As of March 31, 2022 and December 31, 2021, the remaining deferred accelerated payments was approximately $<ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-6" name="sgry:CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY4NDI0MA_56b54cee-ef7b-4050-9e5d-c0a2d4f1f03a">42</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-6" name="sgry:CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY2OTc3MA_ba9b12a6-c025-43f2-891f-d53224057c6d">60</ix:nonFraction>&#160;million, respectively, which was included as a component of Medicare accelerated payments and deferred governmental grants in the condensed consolidated balance sheets. The Company does not expect to receive additional Medicare accelerated payments. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The CARES Act also provided for the deferral of the Company's portion of social security payroll taxes during 2020. Under the CARES Act, half of the deferred amount was paid in December 2021 and the remaining portion will be paid in December 2022. As of both March&#160;31, 2022 and December 31, 2021, the Company had deferred approximately $<ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="sgry:DeferredEmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY3MjUyNA_0db62248-7e6c-4ac9-96c2-a8586e8ad2b8"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="sgry:DeferredEmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY3MjUyNA_92613c2a-ea06-4673-80d3-e8ad82c0a3bb">8.5</ix:nonFraction></ix:nonFraction>&#160;million, which was included as a component of accrued payroll and benefits in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is continuing to closely monitor legislative actions and regulatory guidance at the federal, state and local levels with respect to the CARES Act as other governmental assistance might become available to the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyMDQ_5ba61939-2e80-4c30-b52e-95ed5bb783ae" continuedAt="i6df4b1d9d8db4871a010de16a68d1c0b" escape="true">Variable Interest Entities</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><ix:continuation id="i6df4b1d9d8db4871a010de16a68d1c0b" continuedAt="i52e11279a2e349a7ad13e75cc5d3ac0c"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification 810, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i52e11279a2e349a7ad13e75cc5d3ac0c">". The Company has the power to direct the activities that most significantly impact a VIE's economic performance. Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur.</ix:continuation> As of March&#160;31, 2022, the Company's consolidated VIEs include <ix:nonFraction unitRef="surgical_facility" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="INF" name="sgry:VariableInterestEntityNumberOfFacilities" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA0NjE_88a624f8-0ccd-47c5-8b83-f8f942133b1d">six</ix:nonFraction> surgical facilities and <ix:nonFraction unitRef="physician_practice" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="INF" name="sgry:VariableInterestEntityNumberOfFacilities" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA0ODg_feaf302a-ae2b-4dcd-bc02-8095ab6868f8">five</ix:nonFraction> physician practices.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The total assets (excluding goodwill and intangible assets, net) of the consolidated VIEs included in the accompanying condensed consolidated balance sheets as of March&#160;31, 2022 and December&#160;31, 2021 were $<ix:nonFraction unitRef="usd" contextRef="i637e4d2ab4e8411490e75163721ebd0f_I20220331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA2OTE_f8f6b74c-0a59-4d64-8c53-ac093b42363f">71.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaf52a3e1a85b4de2af6a8274e5c65a76_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA2OTg_52c8a8d4-372b-4e13-9726-5bdcb4a97d69">48.1</ix:nonFraction> million, respectively, and the total liabilities of the consolidated VIEs were $<ix:nonFraction unitRef="usd" contextRef="i637e4d2ab4e8411490e75163721ebd0f_I20220331" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA3NzI_fce4cdc1-50e1-4b52-8e94-78bbdc2b98bc">46.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaf52a3e1a85b4de2af6a8274e5c65a76_I20211231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA3Nzk_eec53c43-1877-42c3-a041-86c99b60c1e3">20.1</ix:nonFraction> million, respectively.</span></div><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyMDU_d5c14006-8221-4660-9835-c738e942b6a0" continuedAt="i92b7af611e7040c1bf1e5f0b184dbd65" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on inputs classified into the following hierarchy:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These may include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, depending on the nature of the item being valued.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, restricted invested assets and accounts payable approximate their fair values under Level 3 calculations.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i598d437c7a054ba1be790e4e4ccfd893" continuedAt="i641810b0a08a49e69392dc8ae12a3cf7"><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyODI_742351c2-26d8-43b0-8f7b-1d8a5c252403" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of the carrying amounts and estimated fair values of the Company's long-term debt follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior secured term loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i506df12890674df3996c010a349ca7c0_I20220331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfMy0yLTEtMS0zOTkzNg_fe410891-4877-4a0f-b1b5-fd5a860f89e5">1,527.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db8fa84c09d480799b76b68681936d9_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfMy00LTEtMS0zOTkzNg_eb73a5c8-fd30-4a19-9e8d-9355e2027345">1,530.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ad5676bd3f84e0d8244dd53d99a6a10_I20220331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfMy02LTEtMS0zOTkzNg_c1be8d59-97a4-49bb-936a-250c4b6bb7be">1,504.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ed8c6b6471245ee8d17d81941bd3725_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfMy04LTEtMS0zOTkzNg_c72150f8-bcdd-450c-a573-c481a57c2ffe">1,530.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idcfcf6c0b474488abf86dd8a19ab641d_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfNC0wLTEtMS0zOTkzNi90ZXh0cmVnaW9uOjM2NjdjNWYwMGJiNzQ5ZmE4MDZiY2ZiMDhlMzM2YzFkXzQ_54be529a-b9d8-481b-86a9-1ec69c02da58">6.750</ix:nonFraction>% senior unsecured notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8e675c069904c2e8d2f8233b2f7c50c_I20220331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfNC0yLTEtMS0zOTkzNg_e65c7c3d-da3f-4ac6-8feb-082ff133a4e0">370.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfcab3d9997245d19b06ae33b0d19589_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfNC00LTEtMS0zOTkzNg_db857ab2-263d-441d-8d61-e13037ae7bb6">370.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13642547953b42fdb47054b1218975af_I20220331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfNC02LTEtMS0zOTkzNg_b5c89680-255f-4b15-838d-d7e7edddd5ff">367.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966e8ae61ccd4f959e269cc4f8b50a26_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfNC04LTEtMS0zOTkzNg_80c79baa-133f-4817-bf80-28f070bc7978">371.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia4c64a5508684384921c71fc65d53263_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfNS0wLTEtMS0zOTkzNi90ZXh0cmVnaW9uOjcwYzBhY2VkMDc5OTQ4YWE4OGFkZDVkMWY5NDBkNDMyXzQ_8ae946db-f983-4a17-a62c-9a316fe34c11">10.000</ix:nonFraction>% senior unsecured notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc4246d5efcb4678b5c651d7a3105ea2_I20220331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfNS0yLTEtMS0zOTkzNg_41c45907-9c34-4188-b029-33a192066b78">545.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia76476dcbd9b4daa8c5d611fe63a4b6f_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfNS00LTEtMS0zOTkzNg_8dbcf7eb-d5c9-433c-895c-8cb215a3cba3">545.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdeef4374f4d4416b5733b872ca3567b_I20220331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfNS02LTEtMS0zOTkzNg_6c212d74-fc97-4483-8b3e-962c4e86cb24">570.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccee81bad7154b409425f6d227df3575_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfNS04LTEtMS0zOTkzNg_f096eadd-59d3-4a6a-80e4-ad43c63a226e">577.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i92b7af611e7040c1bf1e5f0b184dbd65">The fair values in the table above were based on Level 2 inputs using quoted prices for identical liabilities in inactive markets. The carrying amounts related to the Company's other long-term debt obligations, including finance lease obligations, approximate their fair values based on Level 3 inputs.</ix:continuation></span></div><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyNDk_c31dcaa5-fd23-4699-9a2c-7496286627b2" continuedAt="i3f5483a01f214d3d91a6f274199320d4" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's revenues generally relate to contracts with patients in which the performance obligations are to provide health care services. The Company recognizes revenues in the period in which its obligations to provide health care services are satisfied and reports the amount that reflects the consideration the Company expects to be entitled to receive. The contractual relationships with patients, in most cases, also involve a third-party payor (e.g., Medicare, Medicaid and private insurance organizations, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by or negotiated with the third-party payors. The payment arrangements with third-party payors for the services provided to the related patients typically specify payments at amounts less than the Company's standard charges. The Company continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyMzk_c6ffbff8-98cb-4723-b98b-37041cd06dae" continuedAt="i3f45b4d7f84c47539f812c74b5250ad8" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of revenues by service type as a percentage of total revenues follows:</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Surgical facilities revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibc7c7055d90440d89c4a9125446ce784_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjFkNWE1NWJiNGVhNTQ0YjVhNjQ2ZTkzYmQ0NGQzZThiL3RhYmxlcmFuZ2U6MWQ1YTU1YmI0ZWE1NDRiNWE2NDZlOTNiZDQ0ZDNlOGJfMy0yLTEtMS0zOTkzNg_e2dbbd47-94e2-4617-8be5-9bbedab19a41">95.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id4d0a1269abf4dceb2f3b53070b65c94_D20210101-20210331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjFkNWE1NWJiNGVhNTQ0YjVhNjQ2ZTkzYmQ0NGQzZThiL3RhYmxlcmFuZ2U6MWQ1YTU1YmI0ZWE1NDRiNWE2NDZlOTNiZDQ0ZDNlOGJfMy00LTEtMS0zOTkzNg_c03cf99f-e979-4924-b460-34004d6841cd">95.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Ancillary services revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifa35c00cc5c94cc98aa5fc428cac0a9a_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjFkNWE1NWJiNGVhNTQ0YjVhNjQ2ZTkzYmQ0NGQzZThiL3RhYmxlcmFuZ2U6MWQ1YTU1YmI0ZWE1NDRiNWE2NDZlOTNiZDQ0ZDNlOGJfNC0yLTEtMS0zOTkzNg_4c8f6b9f-b2f0-4f30-b520-6679e84a7632">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60c5087599d24a0695f4e51d9b7328cd_D20210101-20210331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjFkNWE1NWJiNGVhNTQ0YjVhNjQ2ZTkzYmQ0NGQzZThiL3RhYmxlcmFuZ2U6MWQ1YTU1YmI0ZWE1NDRiNWE2NDZlOTNiZDQ0ZDNlOGJfNC00LTEtMS0zOTkzNg_c4199153-890b-4bf1-a53b-6ba433d1b8fb">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total patient service revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5fdee6a1e69f430b9fc7afc764249da1_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjFkNWE1NWJiNGVhNTQ0YjVhNjQ2ZTkzYmQ0NGQzZThiL3RhYmxlcmFuZ2U6MWQ1YTU1YmI0ZWE1NDRiNWE2NDZlOTNiZDQ0ZDNlOGJfNS0yLTEtMS0zOTkzNg_09cda3db-81e0-4d30-aea0-c36b09c8bff2">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c305d408ef046519c734c40b5368141_D20210101-20210331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjFkNWE1NWJiNGVhNTQ0YjVhNjQ2ZTkzYmQ0NGQzZThiL3RhYmxlcmFuZ2U6MWQ1YTU1YmI0ZWE1NDRiNWE2NDZlOTNiZDQ0ZDNlOGJfNS00LTEtMS0zOTkzNg_368b7593-ce8d-4a51-a839-a486456513e5">98.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other service revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib886d75d98b64a8ba3306ec5ed447ea9_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjFkNWE1NWJiNGVhNTQ0YjVhNjQ2ZTkzYmQ0NGQzZThiL3RhYmxlcmFuZ2U6MWQ1YTU1YmI0ZWE1NDRiNWE2NDZlOTNiZDQ0ZDNlOGJfNi0yLTEtMS0zOTkzNg_4b99a37f-2ca7-418c-92c4-b65b7106f909">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69bd64deadca4e6987ccdd1fe1a5acd1_D20210101-20210331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjFkNWE1NWJiNGVhNTQ0YjVhNjQ2ZTkzYmQ0NGQzZThiL3RhYmxlcmFuZ2U6MWQ1YTU1YmI0ZWE1NDRiNWE2NDZlOTNiZDQ0ZDNlOGJfNi00LTEtMS0zOTkzNg_f6d7666f-599a-4ea0-99ad-bf13b5b5402d">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i959b5b49ffbc4125a8ae719a2e147008_D20220101-20220331" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjFkNWE1NWJiNGVhNTQ0YjVhNjQ2ZTkzYmQ0NGQzZThiL3RhYmxlcmFuZ2U6MWQ1YTU1YmI0ZWE1NDRiNWE2NDZlOTNiZDQ0ZDNlOGJfNy0yLTEtMS0zOTkzNg_4f9e29bd-0c9c-4323-8e15-c6c1413fe00d">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2a4abce686244862adef8618f10a35ed_D20210101-20210331" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjFkNWE1NWJiNGVhNTQ0YjVhNjQ2ZTkzYmQ0NGQzZThiL3RhYmxlcmFuZ2U6MWQ1YTU1YmI0ZWE1NDRiNWE2NDZlOTNiZDQ0ZDNlOGJfNy00LTEtMS0zOTkzNg_7909f959-c54e-4c07-a8ee-e2b34339b494">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:continuation id="i3f5483a01f214d3d91a6f274199320d4"><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Patient service revenues.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This revenue is related to charging facility fees in exchange for providing patient care. The fee charged for health care procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications. The fee does not normally include professional fees charged by the patient&#8217;s surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patient service revenues are recognized as performance obligations are satisfied. Performance obligations are based on the nature of services provided. Typically, the Company recognizes revenue at a point in time in which services are rendered and the Company has no obligation to provide further patient services. As the Company primarily performs outpatient procedures, performance obligations are generally satisfied same day and revenue is recognized on the date of service.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments and discounts from third-party payors. The Company estimates its contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. Changes in estimated contractual adjustments and discounts are recorded in the period of change. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other service revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other service revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets. These agreements typically require the Company to provide recurring management services over a multi-year period, which are billed and collected on a monthly basis. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which management services are rendered and billed.</span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i641810b0a08a49e69392dc8ae12a3cf7" continuedAt="ie010aa8963ce460ea6496ce60f701466"><ix:continuation id="i3f45b4d7f84c47539f812c74b5250ad8" continuedAt="i33d9e67351c1482eba02fda713ed6da7"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in millions):</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.238%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Private insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2581fac27134361aaf1f3ca3c3db4de_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNC0yLTEtMS0zOTkzNg_7688d336-3b9c-45ad-92c5-87feb498bfc6">300.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i32fa0d6361714af289d98b250659260a_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNC00LTEtMS0zOTkzNg_37602c38-15bd-4b72-8982-70e83f57e1c1">51.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib355fe300c3849b69133727cc10b4d92_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNC02LTEtMS0zOTkzNg_538d6615-153c-48cc-bcce-4324e47c5205">246.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i27472f8f1c174b2aa18b1c47df6601f6_D20210101-20210331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNC04LTEtMS0zOTkzNg_cd0694a0-7fc8-43e6-b60e-46ce850bf764">48.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b35f441d1234c148a0c51b5feb19edd_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNS0yLTEtMS0zOTkzNg_30ec11d0-382a-45d3-baa5-c1c9a438ce1c">249.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic27723e5b1494789a14c6e03c6cef1d1_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNS00LTEtMS0zOTkzNg_66d4a26a-3cf4-4455-a462-1c9a22a27d82">42.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia93d7f09a5db46538ab762616820eb2b_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNS02LTEtMS0zOTkzNg_d1abb1dd-4395-4ae8-9b97-e3722ac8c786">226.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i319afcfd65824c03b4113efb64fc3b29_D20210101-20210331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNS04LTEtMS0zOTkzNg_a4181b71-74dc-4b95-9165-f2732c2edda2">44.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Self-pay</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6669ea6cc07c457ab9a998a810a31b86_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNi0yLTEtMS0zOTkzNg_c784dbb0-a569-4f71-9012-40c4b7895986">16.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iccb4e1634f8c4cbf9f988a392008a061_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNi00LTEtMS0zOTkzNg_4b494b30-57be-4d93-881f-29296b9de794">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a3ac13dcce1497ea3da4a85c473c3c3_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNi02LTEtMS0zOTkzNg_8fb10bb0-b5c8-4fa6-a680-0d9800536ace">13.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ad6e3e1169d4e76ac6ee8f514dd661a_D20210101-20210331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNi04LTEtMS0zOTkzNg_8bf3107a-cf5c-4613-8424-d1055b7480cc">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8520c7f7026a4db4b18532d86207d82e_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNy0yLTEtMS0zOTkzNg_ac2a398e-dd90-4723-bb2a-dfa4de11763a">21.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i47646e2fdd1a4fe7a52ba359cf577a71_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNy00LTEtMS0zOTkzNg_e0c69f39-7184-430d-9f44-7629f883f9c6">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2c5800e21be4fe29d33c18b7bcf1f2a_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNy02LTEtMS0zOTkzNg_c785457a-7128-43b2-b83b-0cea5c49580a">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0024968fe06e453fbbb57a1a738a5ea7_D20210101-20210331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNy04LTEtMS0zOTkzNg_36b585da-ce0b-4b4b-b4c3-e2ab83e28c29">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total patient service revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i094886c1cfb34257a319635071262fdd_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfOC0yLTEtMS0zOTkzNg_2c7c28ad-ce73-49f8-a317-759c80b8971e">587.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibc8bc1d058e74796a84a897fcabea948_D20220101-20220331" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfOC00LTEtMS0zOTkzNg_e83a178a-d12b-4612-9296-f124bd1c345f">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccfe7b6d79b74feb8e7a7078913f412a_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfOC02LTEtMS0zOTkzNg_2d51c18c-7242-4868-b9bd-27918d939b8e">505.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6bffa160d95c4aa38530da4f45398c33_D20210101-20210331" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfOC04LTEtMS0zOTkzNg_f69091f7-1e52-4b00-9173-e469fb9817f6">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other service revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23a8281e1b3a4519bcf1d6d34c3cddf9_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfOS0yLTEtMS0zOTkzNg_b2e52599-3c1f-47b3-9d13-84674821f025">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13eb2c0495f34e2bbb3d47dd7920135f_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfOS02LTEtMS0zOTkzNg_b0ede8ce-a1a4-4fe0-8b25-19a6e119665a">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfMTAtMi0xLTEtMzk5MzY_580bbc89-cea0-4ff9-9501-e8ca5ec8c67c">596.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfMTAtNi0xLTEtMzk5MzY_2aa9424e-fdbb-48df-b15c-ab34825c53ff">512.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:continuation id="i33d9e67351c1482eba02fda713ed6da7" continuedAt="i70cbe1f99c984c4fb7669e2be71fabcc">(1)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"><ix:continuation id="i70cbe1f99c984c4fb7669e2be71fabcc">Other is comprised of anesthesia service agreements, automobile liability, letters of protection and other payor types.</ix:continuation> </span></div><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyNjc_f753b548-6ba0-4097-8ba4-9f9cfa09e606" escape="true"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company maintains its cash and cash equivalent balances at high credit quality financial institutions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyOTE_02b5a57b-ea7d-4c67-af73-ede59986963d" continuedAt="i7b8909e856dc492da97544335464ddd4" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable from third-party payors are recorded net of estimated implicit price concessions, which are estimated based on the historical trend of the Company's surgical hospitals&#8217; cash collections and contractual write-offs, and for the Company's surgical facilities in general, established fee schedules, relationships with payors and procedure statistics. While changes in estimated reimbursement from third-party payors remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on its financial condition or results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), private insurance organizations, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. Amounts are classified outside of self-pay if the Company has an agreement with the third-party payor or has verified a patient&#8217;s coverage prior to services rendered. The Company's policy is to collect co-payments and deductibles prior to providing medical services. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i7b8909e856dc492da97544335464ddd4">The Company's collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of its surgical facilities to ensure the proper collection and aged category. Collection efforts include direct contact with third-party payors or patients, written correspondence and the use of legal or collection agency assistance, as required.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyODQ_337d9282-fbdf-49b6-8329-166513084188" continuedAt="i753006f6dff241a0bb5d5b7edb99c2ce" escape="true">Goodwill</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i753006f6dff241a0bb5d5b7edb99c2ce">Goodwill represents the fair value of the consideration provided in an acquisition over the fair value of net assets acquired and is not amortized. Additions to goodwill include amounts resulting from new business combinations and incremental ownership purchases in the Company's subsidiaries.</ix:continuation> A summary of the Company's acquisitions and dispositions for the three months ended March&#160;31, 2022 is included in Note 2. "Acquisitions and Disposals."</span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ie010aa8963ce460ea6496ce60f701466" continuedAt="if0d641f9e8c548d6b888d5982cd11e48"><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyMzA_98f4376f-7614-4519-aab3-e74249502b2e" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of activity related to goodwill for the three months ended March&#160;31, 2022 is as follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmIyMTlkM2I2NmIxNjQ2OTRiNzMyZmYwNDVmOTU1NDIxL3RhYmxlcmFuZ2U6YjIxOWQzYjY2YjE2NDY5NGI3MzJmZjA0NWY5NTU0MjFfMC0yLTEtMS0zOTkzNg_b416c8d4-0660-47f6-82c2-6a7609a2a7e0">3,911.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions, including post acquisition adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmIyMTlkM2I2NmIxNjQ2OTRiNzMyZmYwNDVmOTU1NDIxL3RhYmxlcmFuZ2U6YjIxOWQzYjY2YjE2NDY5NGI3MzJmZjA0NWY5NTU0MjFfMS0yLTEtMS0zOTkzNg_32995c4e-2ccf-47dc-88c5-e1e5703647f5">43.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Disposals and deconsolidations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="sgry:GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmIyMTlkM2I2NmIxNjQ2OTRiNzMyZmYwNDVmOTU1NDIxL3RhYmxlcmFuZ2U6YjIxOWQzYjY2YjE2NDY5NGI3MzJmZjA0NWY5NTU0MjFfMi0yLTEtMS0zOTkzNg_83b24e56-b420-408c-a094-08118facf237">29.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmIyMTlkM2I2NmIxNjQ2OTRiNzMyZmYwNDVmOTU1NDIxL3RhYmxlcmFuZ2U6YjIxOWQzYjY2YjE2NDY5NGI3MzJmZjA0NWY5NTU0MjFfMy0yLTEtMS0zOTkzNg_1a169744-a8c7-43ed-9fc4-27a7fa618f6a">3,925.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:11pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A detailed evaluation of potential impairment indicators was performed as of March 31, 2022, which specifically considered the ongoing impact of the COVID-19 pandemic. On the basis of available evidence as of March 31, 2022, no indicators of impairment were identified. Future estimates of fair value could be adversely affected if the actual outcome of one or more of the Company's assumptions changes materially in the future, including a material decline in the Company&#8217;s stock price and the fair value of its long-term debt, lower than expected surgical case volumes, higher market interest rates or increased operating costs. Such changes impacting the calculation of fair value, the risks of which are amplified by the COVID-19 pandemic, could result in a material impairment charge in the future.</span></div><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyNzI_3eea38f7-11ba-4e35-981a-cfe7cf009104" continuedAt="i47de296127bc47cc820f7f1b16e55cb0" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records all derivatives on the balance sheet at fair value and any financing elements treated as debt instruments are recorded at amortized cost. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain of its risk, even though hedge accounting does not apply or the Company elects not to apply hedge accounting.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="sgry:RedeemableNoncontrollingInterestPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyMjE_dbaba9a9-0463-4db9-8a07-6af47c61c8ef" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-Controlling Interests&#8212;Redeemable</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively.&#160;In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners&#8217; or physician minority members&#8217;, as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility.&#160;The non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">redeemable are reported outside of stockholders' equity in the condensed consolidated balance sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:RedeemableNoncontrollingInterestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyMTY_4f49dfe0-bbfd-48a1-9fb9-15cd0bcc4f3b" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of activity related to non-controlling interests&#8212;redeemable is as follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at&#160;beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjZiMGM1MDdmNTJjYTQxZGE4NGFhMGJlNjNiMjAyZmJlL3RhYmxlcmFuZ2U6NmIwYzUwN2Y1MmNhNDFkYTg0YWEwYmU2M2IyMDJmYmVfMi0yLTEtMS0zOTkzNg_ab0054b4-d985-433e-b77c-f4a173ac3092">330.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64de719b0ad14503b4dba6762866534b_I20201231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjZiMGM1MDdmNTJjYTQxZGE4NGFhMGJlNjNiMjAyZmJlL3RhYmxlcmFuZ2U6NmIwYzUwN2Y1MmNhNDFkYTg0YWEwYmU2M2IyMDJmYmVfMi00LTEtMS0zOTkzNg_a1394354-ebee-421d-924d-d55a07a9229d">306.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests&#8212;redeemable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjZiMGM1MDdmNTJjYTQxZGE4NGFhMGJlNjNiMjAyZmJlL3RhYmxlcmFuZ2U6NmIwYzUwN2Y1MmNhNDFkYTg0YWEwYmU2M2IyMDJmYmVfMy0yLTEtMS0zOTkzNg_480aa369-5293-4fa7-b544-ea1389c33387">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjZiMGM1MDdmNTJjYTQxZGE4NGFhMGJlNjNiMjAyZmJlL3RhYmxlcmFuZ2U6NmIwYzUwN2Y1MmNhNDFkYTg0YWEwYmU2M2IyMDJmYmVfMy00LTEtMS0zOTkzNg_423aa092-f10f-4f67-8f7e-c34f425f405a">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of shares of non-controlling interests, net&#8212;redeemable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="sgry:RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjZiMGM1MDdmNTJjYTQxZGE4NGFhMGJlNjNiMjAyZmJlL3RhYmxlcmFuZ2U6NmIwYzUwN2Y1MmNhNDFkYTg0YWEwYmU2M2IyMDJmYmVfNC0yLTEtMS0zOTkzNg_a1ea0243-3eb2-4473-9d16-5c0b1c392467">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="sgry:RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjZiMGM1MDdmNTJjYTQxZGE4NGFhMGJlNjNiMjAyZmJlL3RhYmxlcmFuZ2U6NmIwYzUwN2Y1MmNhNDFkYTg0YWEwYmU2M2IyMDJmYmVfNC00LTEtMS0zOTkzNg_5d43d290-9650-492c-a702-9e351def60ca">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to non-controlling interest&#8212;redeemable holders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="sgry:RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjZiMGM1MDdmNTJjYTQxZGE4NGFhMGJlNjNiMjAyZmJlL3RhYmxlcmFuZ2U6NmIwYzUwN2Y1MmNhNDFkYTg0YWEwYmU2M2IyMDJmYmVfNS0yLTEtMS0zOTkzNg_f719c5fb-33d5-4040-940a-3bac8b0cab22">11.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="sgry:RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjZiMGM1MDdmNTJjYTQxZGE4NGFhMGJlNjNiMjAyZmJlL3RhYmxlcmFuZ2U6NmIwYzUwN2Y1MmNhNDFkYTg0YWEwYmU2M2IyMDJmYmVfNS00LTEtMS0zOTkzNg_9692a73f-a729-4715-b40f-e2a457c537d8">10.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at&#160;end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjZiMGM1MDdmNTJjYTQxZGE4NGFhMGJlNjNiMjAyZmJlL3RhYmxlcmFuZ2U6NmIwYzUwN2Y1MmNhNDFkYTg0YWEwYmU2M2IyMDJmYmVfNi0yLTEtMS0zOTkzNg_04515f70-0dfa-42e0-8659-10726eceef95">341.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia510a69b8e64403eb11f83898b8a08ec_I20210331" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjZiMGM1MDdmNTJjYTQxZGE4NGFhMGJlNjNiMjAyZmJlL3RhYmxlcmFuZ2U6NmIwYzUwN2Y1MmNhNDFkYTg0YWEwYmU2M2IyMDJmYmVfNi00LTEtMS0zOTkzNg_bd6bfa5c-ed5a-4753-8170-5f219276809e">308.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyNzM_266dc554-e4d6-46da-9c75-755e681dfa47" continuedAt="i907a2db91c10474380b4f293a866c4c7" escape="true"><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a carryforward exists, the Company makes a determination as to whether the carryforward will be utilized in the future. A valuation allowance is established for certain carryforwards when their recoverability is deemed to be uncertain. The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions. If our expectations for future operating results on a consolidated basis or at the state jurisdiction level vary from actual results due to changes in health care regulations, general economic conditions, or other factors, we may need to adjust the valuation allowance, for </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="if0d641f9e8c548d6b888d5982cd11e48"><ix:continuation id="i907a2db91c10474380b4f293a866c4c7"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">all or a portion of our deferred tax assets. Our income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on our future earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company and certain of its subsidiaries file a consolidated federal income tax return. The partnerships, limited liability companies, and certain non-consolidated physician practice corporations also file separate income tax returns. The Company's allocable portion of each partnership's and limited liability company's income or loss is included in taxable income of the Company. The remaining income or loss of each partnership and limited liability company is allocated to the other owners.</span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company's effective tax rate was <ix:nonFraction unitRef="number" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjYwMDE_79963895-67e1-457d-b234-8a028b8e6523">2.9</ix:nonFraction>% for the three months ended March&#160;31, 2022 compared to <ix:nonFraction unitRef="number" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjYwNDM_759325a3-aa36-4008-b2f4-f8184f27846e">1.8</ix:nonFraction>% for the three months ended March&#160;31, 2021. For the three months ended March&#160;31, 2022, the effective tax rate differed from 21% primarily due to earnings attributable to non-controlling interests, an increase in the Company&#8217;s valuation allowance attributable to interest expense limitations, and discrete tax benefits of (a) $<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY4NzY0Ng_50fdfc2b-e68c-475f-9463-878e428602b4">4.6</ix:nonFraction>&#160;million related to the vesting of restricted stock awards, (b) $<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY4NzcwMw_3f417347-202a-48ec-85f8-701c4539789a">1.8</ix:nonFraction>&#160;million attributable to non-recurring earnings&#8217; impact on the Company&#8217;s valuation allowance, and (c) $<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationDispositionOfBusiness" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY4ODAzNQ_6fb7b064-a7ea-4c26-a13f-3d0f15df5247">1.0</ix:nonFraction>&#160;million related to entity divestitures. For the three months ended March&#160;31, 2021, the effective tax rate differed from 21% due to tax benefits of $<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY4MTQ3Nw_5d6bbbf3-f701-4a69-a2bb-fd312dd3bb17">2.2</ix:nonFraction>&#160;million related to the vesting of restricted stock awards. Based upon the application of interim accounting guidance, the tax rate as a percentage of net income after income attributable to non-controlling interests will vary based upon the relative net income from period to period.</span></div></ix:continuation><div id="i8d24edc59a384ef08748223de247b6a7_34"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2.  <ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfMTQyMg_a30570ec-8529-4ace-aa25-2f9dee9abc65" continuedAt="i53b4509e15174a8383d559f1e15da7e2" escape="true">Acquisitions and Disposals</ix:nonNumeric></span></div><ix:continuation id="i53b4509e15174a8383d559f1e15da7e2" continuedAt="ic5bbff72884f41b5ad82ffc36ccd7a1d"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, the Company acquired a controlling interest in <ix:nonFraction unitRef="surgical_facility" contextRef="ie823b906c9164e118eff58dafb9c18ce_D20210101-20210331" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfMzI5ODUzNDg5MDczMg_e9127bd7-aea5-460f-bee9-4ff5a7ec329f">two</ix:nonFraction> surgical facilities, <ix:nonFraction unitRef="surgical_facility" contextRef="id6de0b52340d4ee0be44beb83074a915_D20210101-20210331" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfMzI5ODUzNDg5MDc0MA_dc3a29b9-ff74-45bd-95c3-85ff3d56056f">one</ix:nonFraction> of which was merged into an existing surgical facility, for aggregate cash consideration of $<ix:nonFraction unitRef="usd" contextRef="idc9abc5f15644909ae180fa28f65f13e_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfMjYy_db4c7293-a0ec-4247-9242-0a06bc121d05">31.1</ix:nonFraction>&#160;million, net of cash acquired, and non-cash consideration of $<ix:nonFraction unitRef="usd" contextRef="idc9abc5f15644909ae180fa28f65f13e_D20220101-20220331" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfODI0NjMzNzIxNDg2Ng_888d53d3-0d56-4aa8-b294-dca254be095e">2.6</ix:nonFraction>&#160;million. The cash consideration was funded through available resources and the non-cash consideration consisted of a non-controlling interest in one of the Company's existing surgical facilities. The total consideration was allocated to the assets acquired and liabilities assumed based upon the respective acquisition date fair values. <ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfMTQyOQ_9127ee51-b527-473f-9bf6-af34bd518d0d" continuedAt="idba45b7924684b1f909b90fb23bf7d58" escape="true">The aggregate amounts preliminarily recognized for each major class of assets acquired and liabilities assumed for the acquisitions are as follows (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><ix:continuation id="idba45b7924684b1f909b90fb23bf7d58"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.955%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc9abc5f15644909ae180fa28f65f13e_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RhYmxlOjRhYTZmNjY4NDQzZDRkMTFiNGQ1MWMxOGNiYWQ5MWZkL3RhYmxlcmFuZ2U6NGFhNmY2Njg0NDNkNGQxMWI0ZDUxYzE4Y2JhZDkxZmRfMS0yLTEtMS0zOTkzNg_aea7acb0-f0f3-468d-b768-681fb7aea6e1">34.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib803580ff3fd404097fe48426bec1d0b_I20220331" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RhYmxlOjRhYTZmNjY4NDQzZDRkMTFiNGQ1MWMxOGNiYWQ5MWZkL3RhYmxlcmFuZ2U6NGFhNmY2Njg0NDNkNGQxMWI0ZDUxYzE4Y2JhZDkxZmRfMi0yLTEtMS0zOTkzNg_7a43af39-c6a1-4292-885c-9682da283c0e">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aggregate acquisition date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib803580ff3fd404097fe48426bec1d0b_I20220331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RhYmxlOjRhYTZmNjY4NDQzZDRkMTFiNGQ1MWMxOGNiYWQ5MWZkL3RhYmxlcmFuZ2U6NGFhNmY2Njg0NDNkNGQxMWI0ZDUxYzE4Y2JhZDkxZmRfMy0yLTEtMS0zOTkzNg_bcf9deac-7288-4ca6-ba87-323b51833afd">45.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib803580ff3fd404097fe48426bec1d0b_I20220331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RhYmxlOjRhYTZmNjY4NDQzZDRkMTFiNGQ1MWMxOGNiYWQ5MWZkL3RhYmxlcmFuZ2U6NGFhNmY2Njg0NDNkNGQxMWI0ZDUxYzE4Y2JhZDkxZmRfNS0yLTEtMS0zOTkzNg_9940c2fa-668e-4e08-aab8-bfec7d10a824">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib803580ff3fd404097fe48426bec1d0b_I20220331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RhYmxlOjRhYTZmNjY4NDQzZDRkMTFiNGQ1MWMxOGNiYWQ5MWZkL3RhYmxlcmFuZ2U6NGFhNmY2Njg0NDNkNGQxMWI0ZDUxYzE4Y2JhZDkxZmRfNi0yLTEtMS0zOTkzNg_08c6631b-8ced-4514-97c8-03ae3f4e3ed7">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib803580ff3fd404097fe48426bec1d0b_I20220331" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RhYmxlOjRhYTZmNjY4NDQzZDRkMTFiNGQ1MWMxOGNiYWQ5MWZkL3RhYmxlcmFuZ2U6NGFhNmY2Njg0NDNkNGQxMWI0ZDUxYzE4Y2JhZDkxZmRfNy0yLTEtMS0zOTkzNg_41676fa1-89fd-49bd-bf50-8f9344a12410">42.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib803580ff3fd404097fe48426bec1d0b_I20220331" decimals="-5" name="sgry:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RhYmxlOjRhYTZmNjY4NDQzZDRkMTFiNGQ1MWMxOGNiYWQ5MWZkL3RhYmxlcmFuZ2U6NGFhNmY2Njg0NDNkNGQxMWI0ZDUxYzE4Y2JhZDkxZmRfOC0yLTEtMS0zOTkzNg_13a2882b-cac6-4afe-9197-40c3a9f18847">20.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib803580ff3fd404097fe48426bec1d0b_I20220331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RhYmxlOjRhYTZmNjY4NDQzZDRkMTFiNGQ1MWMxOGNiYWQ5MWZkL3RhYmxlcmFuZ2U6NGFhNmY2Njg0NDNkNGQxMWI0ZDUxYzE4Y2JhZDkxZmRfMTAtMi0xLTEtMzk5MzY_b46c1634-64bf-4387-90f7-a9d035776563">5.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib803580ff3fd404097fe48426bec1d0b_I20220331" decimals="-5" name="sgry:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RhYmxlOjRhYTZmNjY4NDQzZDRkMTFiNGQ1MWMxOGNiYWQ5MWZkL3RhYmxlcmFuZ2U6NGFhNmY2Njg0NDNkNGQxMWI0ZDUxYzE4Y2JhZDkxZmRfMTItMi0xLTEtMzk5MzY_5b6100ee-9204-4abd-84da-a01d48db8d00">19.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aggregate acquisition date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib803580ff3fd404097fe48426bec1d0b_I20220331" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RhYmxlOjRhYTZmNjY4NDQzZDRkMTFiNGQ1MWMxOGNiYWQ5MWZkL3RhYmxlcmFuZ2U6NGFhNmY2Njg0NDNkNGQxMWI0ZDUxYzE4Y2JhZDkxZmRfMTMtMi0xLTEtMzk5MzY_4ea94c1b-bb36-44af-8d3b-c3c6b1b89b84">45.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values assigned to certain assets acquired and liabilities assumed by the Company have been estimated on a preliminary basis and are subject to change as new facts and circumstances emerge that were present at the date of acquisition. During the three months ended March&#160;31, 2022, no significant changes were made to the purchase price allocation of assets and liabilities, existing at the date of acquisition, related to individual acquisitions completed in 2021. The goodwill acquired was allocated to the Company's Surgical Facility services reportable segment. The results of operations of the acquisitions were included in the Company&#8217;s results of operations beginning on the dates of acquisition and were not considered significant for the three months ended March&#160;31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Disposals and Deconsolidations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, the Company sold its interests in a surgical facility, which was previously accounted for as an equity method investment, for net cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i97af3ba9bf154ce48824c269e037ff4f_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfODI0NjMzNzIxNTMxOA_bb975e60-79e9-4e77-a502-918647e33978">11.5</ix:nonFraction>&#160;million, and recognized a pre-tax loss of $<ix:nonFraction unitRef="usd" contextRef="i64cc0a22695c41e39895df392aa6ef14_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfODI0NjMzNzIxNTM1Nw_c3cef8d7-a922-4013-9d21-3f139b081592">0.4</ix:nonFraction>&#160;million included in loss on disposals and deconsolidations, net in the condensed consolidated statements of operations for the three months ended March 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, the Company contributed its interests in <ix:nonFraction unitRef="surgical_facility" contextRef="i97af3ba9bf154ce48824c269e037ff4f_D20220101-20220331" decimals="INF" name="sgry:DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfMTY0OTI2NzQ0OTA4NA_59e7ce6d-2b09-43d2-9ea4-9f25c18c938b">two</ix:nonFraction> surgical facilities as non-cash consideration for non-controlling interests in <ix:nonFraction unitRef="business_entity" contextRef="i23157d624d184f359c7bfa4ba8b5e305_D20210101-20210331" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfMTY0OTI2NzQ0OTE1Ng_22f4695a-3415-4d5d-a171-0644dda9f08b">two</ix:nonFraction> new separate entities. As a result of these transactions, the Company lost control of the previously controlled surgical facilities but retains a non-controlling interest in each, resulting in the deconsolidation of the previously consolidated entities. The remaining non-controlling interests were accounted for as equity method investments, and initially measured and recorded at fair value as of the dates of the transactions. The fair value measurement utilizes Level 3 inputs, which includes unobservable data, to measure the fair value of the retained non-controlling interests. The fair value determination was based on a combination of multiple valuation methods, which included discounted cash flow and market value approach, which incorporates estimates of future earnings and market valuation multiples for certain guideline companies. The preliminary fair value of the investments of $<ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:InvestmentOwnedAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfMTA5OTUxMTYzMzY5MA_01c29b16-ee51-430c-9493-b2a2b200b1f7">9.8</ix:nonFraction>&#160;million was recorded as a component of investments in and advances to affiliates in the accompanying condensed consolidated balance sheets. Further, </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="ic5bbff72884f41b5ad82ffc36ccd7a1d">based on the preliminary valuation, the transactions resulted in a pretax net loss on deconsolidations of $<ix:nonFraction unitRef="usd" contextRef="i97af3ba9bf154ce48824c269e037ff4f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfMTA5OTUxMTYzMzczNw_59331d41-d3b1-420d-b0ca-3a663a97ac03">5.6</ix:nonFraction>&#160;million, which is included in gain on disposals and deconsolidations, net, in the accompanying condensed consolidated statement of operations for the three months ended March&#160;31, 2022. The gains were determined based on the difference between the fair value of the Company's retained interests in the entities and the carrying values of both the tangible and intangible assets of the entities immediately prior to the transactions.</ix:continuation></span></div><div id="i8d24edc59a384ef08748223de247b6a7_37"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3.  <ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RleHRyZWdpb246OTVmMGMwZTU0NGYwNDY0NTk0OGU4ZDFmZDc3M2RkMTFfMzExMQ_f4d4d8b6-c365-4c87-974e-fed4e726ffc0" continuedAt="ic91bf917887a4e6a9f293b612d86567d" escape="true">Long-Term Debt</ix:nonNumeric></span></div><ix:continuation id="ic91bf917887a4e6a9f293b612d86567d" continuedAt="i0a63ce81118147aba3f0b6c3f75609a3"><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RleHRyZWdpb246OTVmMGMwZTU0NGYwNDY0NTk0OGU4ZDFmZDc3M2RkMTFfMzExNg_162ddf48-5392-4711-a7c5-697a7bf0bd82" continuedAt="ie4b800eae51643b88938510c8128f071" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of long-term debt follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior secured term loan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabc81fe53c8740a5835ce19d18a21d80_I20220331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfMi0yLTEtMS0zOTkzNg_9ba99db7-e864-41f4-a461-a8544b9d88a2">1,527.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6502e60a4b4f40b2ab3906a1e7320a_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfMi00LTEtMS0zOTkzNg_d7026d9d-3103-466f-b0a2-b3c24e3b6b27">1,530.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idcfcf6c0b474488abf86dd8a19ab641d_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfMy0wLTEtMS0zOTkzNi90ZXh0cmVnaW9uOmQ4ZjEwZTlkODkxZjQ2ZWE5NDdiNzFjZDdlZGM2ZTE4XzQ_54be529a-b9d8-481b-86a9-1ec69c02da58">6.750</ix:nonFraction>% senior unsecured notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcfcf6c0b474488abf86dd8a19ab641d_I20220331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfMy0yLTEtMS0zOTkzNg_35f759f1-ee4d-4e94-a9fd-ac9e212ec9fa">370.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6f81ce56efe4167827c87bda7c7d7ae_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfMy00LTEtMS0zOTkzNg_e95873af-6780-4ea3-8984-949ec8aeb922">370.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia4c64a5508684384921c71fc65d53263_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfNC0wLTEtMS0zOTkzNi90ZXh0cmVnaW9uOjdiMDZhODFmNmQ2NDRiMDg5MWRkNjJlNDE3YjEyODBhXzQ_8ae946db-f983-4a17-a62c-9a316fe34c11">10.000</ix:nonFraction>% senior unsecured notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c64a5508684384921c71fc65d53263_I20220331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfNC0yLTEtMS0zOTkzNg_60291b9c-80c9-4309-8c18-3beca4d23511">545.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic09d86ac1f06413595ed16720d86db9a_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfNC00LTEtMS0zOTkzNg_e2ec2267-9598-4461-aa97-24b362f11020">545.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable and other secured loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6efe1dcecbea4bcbbe13edfdc24585b8_I20220331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfNS0yLTEtMS0zOTkzNg_252a026d-c0df-473b-94cc-c1f801cfb18c">159.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d53ad311174404c83910a5b4a784afd_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfNS00LTEtMS0zOTkzNg_64ffa869-136c-4d94-a86c-5103edf047ac">145.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfNi0yLTEtMS0zOTkzNg_3804d54e-05f5-4781-b3e2-239a7afcc618">507.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfNi00LTEtMS0zOTkzNg_0fb80184-45a7-44e5-9344-9057a02a9ab0">364.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs and discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfNy0yLTEtMS0zOTkzNg_90a3f4ef-b0cc-4500-ae55-a774a8db0af2">15.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfNy00LTEtMS0zOTkzNg_0f963e8b-ed34-427e-9b04-ce20ebda59c5">16.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfOC0yLTEtMS0zOTkzNg_3dba12b8-d9e5-4b2b-9a6a-d411eb265a0a">3,093.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfOC00LTEtMS0zOTkzNg_14a7adf0-cf13-4a01-acd7-7ce10164890f">2,938.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current maturities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfOS0yLTEtMS0zOTkzNg_533e7844-c41d-4269-afb7-d1ecffbe43a5">68.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfOS00LTEtMS0zOTkzNg_d6f6e91b-084a-40e1-af95-3bde3f3461ae">60.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfMTAtMi0xLTEtMzk5MzY_ebdc011f-3591-4eda-b001-feec4a9716b5">3,025.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfMTAtNC0xLTEtMzk5MzY_502b6bc5-a117-4382-a453-77bc2c319bbb">2,878.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:4pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><ix:continuation id="ie4b800eae51643b88938510c8128f071" continuedAt="i56de26c3005b4eb1aced2df655df43bd"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Includes unamortized fair value discount of $<ix:nonFraction unitRef="usd" contextRef="iabc81fe53c8740a5835ce19d18a21d80_I20220331" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RleHRyZWdpb246OTVmMGMwZTU0NGYwNDY0NTk0OGU4ZDFmZDc3M2RkMTFfMTIy_859cf0ef-6f03-48a6-8619-1599df533193">2.8</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="i1c6502e60a4b4f40b2ab3906a1e7320a_I20211231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RleHRyZWdpb246OTVmMGMwZTU0NGYwNDY0NTk0OGU4ZDFmZDc3M2RkMTFfMTA5OTUxMTYzMDkxNg_27a1d1cc-a913-4add-bde1-4fe06c148cc4">3.0</ix:nonFraction>&#160;million as of March&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:continuation id="i56de26c3005b4eb1aced2df655df43bd">December&#160;31, 2021, respectively.</ix:continuation> </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The increase in finance lease obligations is a result of the modification of certain existing facility real estate leases that were previously classified as operating leases. See Note 4. "Leases" for further discussion.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revolving Credit Facility</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i0a63ce81118147aba3f0b6c3f75609a3">As of March 31, 2022, the Company's availability on its revolving credit facility (the "Revolver") was $<ix:nonFraction unitRef="usd" contextRef="i6d81a2e35ef544709f6c3c5a6ec09d33_I20220331" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RleHRyZWdpb246OTVmMGMwZTU0NGYwNDY0NTk0OGU4ZDFmZDc3M2RkMTFfNzU3_2d4b1ac2-c8e5-4d5e-85bf-b84faf22cab8">203.0</ix:nonFraction> million (including outstanding letters of credit of $<ix:nonFraction unitRef="usd" contextRef="ib597d64d1a7b476fa1d8e9c70fa2d9c6_I20220331" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RleHRyZWdpb246OTVmMGMwZTU0NGYwNDY0NTk0OGU4ZDFmZDc3M2RkMTFfODA0_17e5578d-1340-4183-a5c1-53321a2a013e">7.0</ix:nonFraction> million). There were <ix:nonFraction unitRef="usd" contextRef="i6ed7fc212be442dab6bdeb5bf9fc9902_I20220331" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RleHRyZWdpb246OTVmMGMwZTU0NGYwNDY0NTk0OGU4ZDFmZDc3M2RkMTFfODIw_de5cb57a-7424-4e2c-8bfa-773c2e6c1772"><ix:nonFraction unitRef="usd" contextRef="ic6f105cec2c74bac8f0818b041444a8f_I20211231" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RleHRyZWdpb246OTVmMGMwZTU0NGYwNDY0NTk0OGU4ZDFmZDc3M2RkMTFfODIw_f214c01e-805d-4bbc-a768-b435af07a164">no</ix:nonFraction></ix:nonFraction> outstanding borrowings under the Revolver as of both March 31, 2022 and December 31, 2021</ix:continuation>.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i8d24edc59a384ef08748223de247b6a7_40"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RleHRyZWdpb246MWE1ODhhMGQ1M2JhNGVkYjlmOWVhZmJkNDQzZTYxOGFfNTQ1_1fa7930e-36af-461c-8c5e-d93cd0245f33" continuedAt="ifec2dfcac9d94474a1f6c56a1eb767ce" escape="true"><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RleHRyZWdpb246MWE1ODhhMGQ1M2JhNGVkYjlmOWVhZmJkNDQzZTYxOGFfNTQ1_6f53aa97-c188-4f59-b18b-a44676115a10" continuedAt="ie1f9cc98db914e43808913a4571829db" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="ifec2dfcac9d94474a1f6c56a1eb767ce" continuedAt="i8e6d830ee2934436b2eea4a94cb8cf7e"><ix:continuation id="ie1f9cc98db914e43808913a4571829db" continuedAt="ib0698e27a8f14f6b842dcb7901bd0254"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets. </span></div><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="sgry:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RleHRyZWdpb246MWE1ODhhMGQ1M2JhNGVkYjlmOWVhZmJkNDQzZTYxOGFfMzI5ODUzNDg4NTk3Nw_5fe61bec-63f8-4ecf-873d-14e37348394e" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the consolidated balance sheets (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.941%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMy00LTEtMS00NTQwNw_ec983d65-c4f5-4917-b367-365bcfc928a0">277.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMy02LTEtMS00NTQwNw_07a53df0-3e60-4c65-9ab4-b8160628bee4">324.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNC0yLTEtMS00NjQ2Ng_0f2dda77-9e14-4a9d-bd4c-1fca9c544334"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNC0yLTEtMS00NjQ2Ng_32523eef-34e6-4b2a-913b-0c4967f1b23d">Property and equipment, net of accumulated depreciation</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNC00LTEtMS00NTQwNw_28195c66-e827-45e5-b65f-3876ac8d8ade">467.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNC02LTEtMS00NTQwNw_95591a3c-2952-436b-a216-fcceada0aa48">329.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="sgry:LeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNS00LTEtMS00NjQ2Mw_5e5d1011-fb75-4a5f-9fc5-d8608f5a1d83">745.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="sgry:LeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNS02LTEtMS00NjQ2Mw_dbcf7e90-2145-4802-bd93-2d32720d2d36">653.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfOS0yLTEtMS00NjQ2OA_4491f22a-c2d0-4ffb-9a7d-8129b50d1a26"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfOS0yLTEtMS00NjQ2OA_e2b110e3-da5b-424a-8c7d-d3e258e86a47">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfOS00LTEtMS00NTQwNw_445d8979-d865-44e8-8195-4050411b0d8e">35.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfOS02LTEtMS00NTQwNw_26d20620-d18e-4d28-9a5f-eb2c0d6f83c4">40.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTAtNC0xLTEtNDU0MDc_d80b636b-c834-4ef2-a238-22daf79287d7">272.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTAtNi0xLTEtNDU0MDc_4bd03f47-8c0c-4e67-83ed-a53db1288314">315.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTEtNC0xLTEtNDY0NjM_78db5665-6a4f-4af7-9e2b-8d3b52e7f01c">307.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTEtNi0xLTEtNDY0NjM_c9f679fd-8f4d-46bf-a6c2-75faa6393bc5">355.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTMtMi0xLTEtNDY0NzI_4d4afb66-9139-4863-9c1e-c7148377256b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTMtMi0xLTEtNDY0NzI_822c6ee1-f967-42b7-8426-35b31d91efae">Current maturities of long-term debt</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTMtNC0xLTEtNDU0MDc_320de23a-9743-4231-891f-4ab6c9c4cc3d">22.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTMtNi0xLTEtNDU0MDc_4ceb7782-66cd-4e71-8d4e-5fcb84def651">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTQtMi0xLTEtNDY0Nzc_9fb4ebe5-aa6a-445d-86cd-135374660488"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTQtMi0xLTEtNDY0Nzc_f854c062-dd64-4d2b-a477-9bd1f49a42d6">Long-term debt, less current maturities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTQtNC0xLTEtNDU0MDc_f4cded43-21f2-43b8-a61a-a62dfc6e698c">484.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTQtNi0xLTEtNDU0MDc_907006fb-ec90-41f5-abf4-6e9ea70aed6d">345.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTUtNC0xLTEtNDY0NjM_16a9bfd8-4e5e-4045-b724-74e321312792">507.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTUtNi0xLTEtNDY0NjM_702d309c-859d-4686-9f72-0a404b66e249">364.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="sgry:LeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTYtNC0xLTEtNDY0NjM_aa81219c-7622-49fc-a030-d81dc51fc5cd">815.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="sgry:LeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTYtNi0xLTEtNDY0NjM_21433c6f-8776-4e0d-ac50-439ef907c027">720.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, the Company extended certain existing facility real estate leases, resulting in the reclassification of the leases from operating to finance. The modifications resulted in an increase to finance lease liabilities and assets of $<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="sgry:IncreaseDecreaseInFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RleHRyZWdpb246MWE1ODhhMGQ1M2JhNGVkYjlmOWVhZmJkNDQzZTYxOGFfODI0NjMzNzIxMDI4OA_f6269c5b-2765-45b6-a2be-0d146fc934b8">146.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="sgry:IncreaseDecreaseInFinanceLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RleHRyZWdpb246MWE1ODhhMGQ1M2JhNGVkYjlmOWVhZmJkNDQzZTYxOGFfODI0NjMzNzIxMDM0OQ_4f58bd8a-dd24-4898-9155-9228653e4511">145.0</ix:nonFraction>&#160;million, respectively, including the reclassification of existing operating lease liabilities and assets of $<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RleHRyZWdpb246MWE1ODhhMGQ1M2JhNGVkYjlmOWVhZmJkNDQzZTYxOGFfODI0NjMzNzIxMDM5Mw_4880422f-a73e-4d92-95d9-510d37ce4bb1">60.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" sign="-" name="sgry:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RleHRyZWdpb246MWE1ODhhMGQ1M2JhNGVkYjlmOWVhZmJkNDQzZTYxOGFfODI0NjMzNzIxMDQwMQ_8efec604-32a5-42b7-b57a-7c4c1a5b4e50">59.3</ix:nonFraction>&#160;million, respectively. </span></div><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RleHRyZWdpb246MWE1ODhhMGQ1M2JhNGVkYjlmOWVhZmJkNDQzZTYxOGFfNTU2_e8ccde82-bd36-4132-820d-766da785fda5" continuedAt="i68a9748aaacb4de1840b4891b7a366b2" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's lease expense and their classification in the condensed consolidated statement of operations (in millions):</span></div><div style="margin-bottom:12pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfMi0yLTEtMS0zOTkzNg_e2d4d348-28a0-4157-bda4-cc9188109952">16.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfMi00LTEtMS0zOTkzNg_29e5feb9-eb46-43bd-a307-af74a314b0ae">18.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfNC0yLTEtMS0zOTkzNg_ac303573-4fc2-4969-90ef-8fcb94ffeff5">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfNC00LTEtMS0zOTkzNg_888cf9b4-7f66-4db2-8798-adfe3851677f">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfNS0yLTEtMS0zOTkzNg_3126dd07-dbb8-42ef-a2d6-7be0cbc36839">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfNS00LTEtMS0zOTkzNg_4c2e8f82-35d6-4959-a0a5-dd59fe6a2a91">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="sgry:FinanceLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfNi0yLTEtMS0zOTkzNg_b1233ca4-4f29-49fc-b5b6-3e6c2601ca57">19.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="sgry:FinanceLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfNi00LTEtMS0zOTkzNg_627dbdd0-fd88-4405-9dc5-79410c5872dd">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable and short-term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="sgry:VariableAndShortTermLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfNy0yLTEtMS0zOTkzNg_39efdea6-102f-4e29-a102-4004d2a56b03">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="sgry:VariableAndShortTermLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfNy00LTEtMS0zOTkzNg_ebca1856-d81c-4307-a923-3470eb504842">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfOC0yLTEtMS0zOTkzNg_dd51f891-f4cd-4976-a139-f7da2cbcb59c">39.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfOC00LTEtMS0zOTkzNg_5b484333-abed-4a26-a4fd-2a8a85a806cc">37.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i8e6d830ee2934436b2eea4a94cb8cf7e"><ix:continuation id="ib0698e27a8f14f6b842dcb7901bd0254"><ix:continuation id="i68a9748aaacb4de1840b4891b7a366b2"><div style="margin-bottom:6pt;margin-top:1pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information (dollars in millions):</span></div><div style="margin-bottom:12pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from operating leases </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjdkZGNkYTY1NmQ5ZjRkMTJiY2E5YjI0ODYwY2RkMzQ2L3RhYmxlcmFuZ2U6N2RkY2RhNjU2ZDlmNGQxMmJjYTliMjQ4NjBjZGQzNDZfMy0xLTEtMS0zOTkzNg_4525ce75-c7bf-45d3-b435-48b3732fbd83">15.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjdkZGNkYTY1NmQ5ZjRkMTJiY2E5YjI0ODYwY2RkMzQ2L3RhYmxlcmFuZ2U6N2RkY2RhNjU2ZDlmNGQxMmJjYTliMjQ4NjBjZGQzNDZfMy0zLTEtMS0zOTkzNg_63cdbecc-c856-4e48-8dd1-283a8a3762e0">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjdkZGNkYTY1NmQ5ZjRkMTJiY2E5YjI0ODYwY2RkMzQ2L3RhYmxlcmFuZ2U6N2RkY2RhNjU2ZDlmNGQxMmJjYTliMjQ4NjBjZGQzNDZfNC0xLTEtMS0zOTkzNg_165937c1-fc23-4ae2-9f00-7fdb10a70d47">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjdkZGNkYTY1NmQ5ZjRkMTJiY2E5YjI0ODYwY2RkMzQ2L3RhYmxlcmFuZ2U6N2RkY2RhNjU2ZDlmNGQxMmJjYTliMjQ4NjBjZGQzNDZfNC0zLTEtMS0zOTkzNg_345bf7e6-dfdc-4277-aca5-a06231546c76">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing cash outflows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjdkZGNkYTY1NmQ5ZjRkMTJiY2E5YjI0ODYwY2RkMzQ2L3RhYmxlcmFuZ2U6N2RkY2RhNjU2ZDlmNGQxMmJjYTliMjQ4NjBjZGQzNDZfNS0xLTEtMS0zOTkzNg_570077e2-ce7c-49b8-9d63-d97555854323">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjdkZGNkYTY1NmQ5ZjRkMTJiY2E5YjI0ODYwY2RkMzQ2L3RhYmxlcmFuZ2U6N2RkY2RhNjU2ZDlmNGQxMmJjYTliMjQ4NjBjZGQzNDZfNS0zLTEtMS0zOTkzNg_94d08d8e-3448-4dc6-a479-43946d88b5ef">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjdkZGNkYTY1NmQ5ZjRkMTJiY2E5YjI0ODYwY2RkMzQ2L3RhYmxlcmFuZ2U6N2RkY2RhNjU2ZDlmNGQxMmJjYTliMjQ4NjBjZGQzNDZfOC0xLTEtMS0zOTkzNg_d9a6944a-f70a-4f74-a9d9-2a268784b4fc">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjdkZGNkYTY1NmQ5ZjRkMTJiY2E5YjI0ODYwY2RkMzQ2L3RhYmxlcmFuZ2U6N2RkY2RhNjU2ZDlmNGQxMmJjYTliMjQ4NjBjZGQzNDZfOC0zLTEtMS0zOTkzNg_881efa0a-366e-4807-b3fd-7c59e1cfe262">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjdkZGNkYTY1NmQ5ZjRkMTJiY2E5YjI0ODYwY2RkMzQ2L3RhYmxlcmFuZ2U6N2RkY2RhNjU2ZDlmNGQxMmJjYTliMjQ4NjBjZGQzNDZfOS0xLTEtMS0zOTkzNg_40e2ecca-c29a-4e63-bccb-7fe000d59639">89.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjdkZGNkYTY1NmQ5ZjRkMTJiY2E5YjI0ODYwY2RkMzQ2L3RhYmxlcmFuZ2U6N2RkY2RhNjU2ZDlmNGQxMmJjYTliMjQ4NjBjZGQzNDZfOS0zLTEtMS0zOTkzNg_68a8bbe4-ab29-42ff-b655-747ee24ea35f">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation></ix:continuation><div id="i8d24edc59a384ef08748223de247b6a7_46"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5.  <ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfNjI0NA_6237b0ca-7263-446f-b14d-ebf88171d160" continuedAt="i288175317c454df780c9fed290037b3d" escape="true">Derivatives and Hedging Activities</ix:nonNumeric></span></div><ix:continuation id="i288175317c454df780c9fed290037b3d" continuedAt="i2a749730d5b44965898355727a8d2294"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps and interest rate caps as part of its interest rate risk management strategy. During 2022 and 2021, such derivatives have been used to hedge the variable cash flows associated with existing variable-rate debt.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i47de296127bc47cc820f7f1b16e55cb0">For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income ("OCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings, as documented at hedge inception in accordance with the Company&#8217;s accounting policy election. Amounts reported in accumulated OCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company&#8217;s variable-rate debt.</ix:continuation> Over the next 12 months, the Company estimates that an additional $<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfMTEyNg_bcb3b782-e8bd-4ff8-8a8f-21ebde94df39">12.0</ix:nonFraction> million will be reclassified as an increase to interest expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company had <ix:nonFraction unitRef="interest_rate_swap" contextRef="i83e7577cfc3e485fa204871cd2bebed9_I20220331" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfMTM4Mg_f7b6888d-c23c-454f-b7ad-3badd0d3d00f">nine</ix:nonFraction> interest rate swaps with a total net hedged notional amount of $<ix:nonFraction unitRef="usd" contextRef="ia5195b743fe34283b9ca5fca00063c24_I20220331" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfMTQ0OA_5b9beb48-76ee-4895-8568-fbb485038538">1.2</ix:nonFraction>&#160;billion and <ix:nonFraction unitRef="interest_rate_swap" contextRef="ia71c20142f984a65b73126b2fc598e6b_I20220331" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfMzI5ODUzNDg5MzExMg_d0979c38-c8b7-45dc-a2de-9ef6da393c2d">two</ix:nonFraction> interest rate caps with a total hedged notional amount of $<ix:nonFraction unitRef="usd" contextRef="ibfefa22461da4d3d8abc5576226480fb_I20220331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfOTM0NTg0ODg0NTg2Mw_95e6b85e-b768-43ad-adf8-aab3cbe21b17">329.8</ix:nonFraction>&#160;million. Of the <ix:nonFraction unitRef="interest_rate_swap" contextRef="i83e7577cfc3e485fa204871cd2bebed9_I20220331" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfMTQ1OQ_86cd00ec-5e6d-4457-a14e-5eded8eaa42c">nine</ix:nonFraction> interest rate swaps, three are pay-fixed, receive 1-Month LIBOR (subject to a minimum of <ix:nonFraction unitRef="number" contextRef="iae1b34f8d424499badf3a4c4c1482bff_I20220331" decimals="INF" name="us-gaap:DerivativeVariableInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfMTU0OA_53dff8d9-b01e-4ab2-9ba2-f53a43fec338">0.75</ix:nonFraction>%) interest rate swaps designated in cash flow hedging relationships with a total notional amount of $<ix:nonFraction unitRef="usd" contextRef="ia5195b743fe34283b9ca5fca00063c24_I20220331" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfMTY1MA_09a4af2b-092d-4d42-a89a-111e107dfbb6">1.2</ix:nonFraction>&#160;billion and a termination date of March 31, 2025. The remaining six interest rate swaps are undesignated and consist of three pay-fixed, receive 1-Month LIBOR (subject to a minimum of <ix:nonFraction unitRef="number" contextRef="ie0cd5769098e47f6a43dac3d7b1801fc_I20220331" decimals="INF" name="us-gaap:DerivativeVariableInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfMTgxMw_2aca3d3d-6df4-42e2-a558-e2c74f54ccce">1.00</ix:nonFraction>%) interest rate swaps and three pay 1-Month LIBOR (subject to a minimum of <ix:nonFraction unitRef="number" contextRef="i35f44859d11f47c1b1e53d1b04378a95_I20220331" decimals="INF" name="us-gaap:DerivativeVariableInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfMTg4Nw_22e91a32-517c-47ff-a5b4-d11ed1390599">1.00</ix:nonFraction>%), receive-fixed interest rate swaps with a termination date of November 30, 2023. The pay-floating, receive-fixed swaps are designed to economically offset the undesignated pay-fixed, receive-floating swaps. The interest rate caps each have a termination date of March&#160;31, 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The pay-fixed, receive floating interest rate swaps did not meet the requirements to be considered derivatives in their entirety as a result of the financing component. Accordingly, the swaps are considered hybrid instruments, consisting of a financing element treated as a debt instrument and an embedded at-market derivative that was designated as a cash flow hedge. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Within the Company&#8217;s condensed consolidated balance sheets, the financing elements treated as debt instruments described above are carried at amortized cost and the embedded at-market derivatives and the undesignated swaps are recorded at fair value. The cash flows related to the portion treated as debt are classified as financing activities in the condensed consolidated statements of cash flows while the portion treated as an at-market derivative are classified as operating activities. Cash settlements related to the undesignated swaps will offset and are classified as operating activities in the condensed consolidated cash flows. Within the Company&#8217;s condensed consolidated balance sheets, the interest rate caps are recorded at fair value. The cash flows related to the interest rate caps are classified as operating activities in the condensed consolidated statements of cash flows.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i2a749730d5b44965898355727a8d2294"><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfNjI0MA_e4cf527f-fef5-4d26-b801-40b5985fa385" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The key terms of interest rate swaps and interest rate caps outstanding are presented below:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.743%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 7, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i612b998bf6814f52b34921481a7fed42_I20220331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMi00LTEtMS0zOTkzNg_413e6c52-cce5-4ab6-8203-49c02d58a9da">435.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6feaa769eee6494280e04ca4428e2d1e_I20211231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMi04LTEtMS0zOTkzNg_9f5f8a2b-4e4e-4038-b370-ef17e6535fb9">435.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 7, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id325fcdc0f7c47528506f54fa3611300_I20220331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMy00LTEtMS0zOTkzNg_6e7e1539-856f-4627-b4bb-8cb521ad30f3">330.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b44c0e1c7740bd90f41c1945029459_I20211231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMy04LTEtMS0zOTkzNg_c8b80777-6786-48af-a7d0-ea14ae41d017">330.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 7, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia15782f2cb274cddb56795539491873a_I20220331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfNC00LTEtMS0zOTkzNg_bfc7b9fd-3f9b-45ec-b65a-c6fe38078948">435.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d8edabf0d9426fb79d750950a72128_I20211231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfNC04LTEtMS0zOTkzNg_fd5cef67-730d-4f79-8c10-466bd5697a50">435.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate cap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110b4a998ba9459cb22bd9c1786eb35f_I20220331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfNS00LTEtMS0zOTkzNg_bc7300c4-f6d9-4e40-adb9-535e726e42c5">164.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36389bf37a7143988be57524833186e1_I20211231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfNS04LTEtMS0zOTkzNg_df5d9b65-24c4-4584-a541-047275e70920">166.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate cap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if939f474cbd9448a890aaa8ad9497a6c_I20220331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfNi00LTEtMS0zOTkzNg_ffd02e0b-cc7b-45eb-8f06-1af353ec13df">164.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i470b3213c5384e66a7ea1d5fe3c19aec_I20211231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfNi04LTEtMS0zOTkzNg_537f8237-cb67-43f3-80b9-003fb258e641">166.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i482b7170e0e44958a6bccac3fb8b4bb1_I20220331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfNy00LTEtMS0zOTkzNg_2fe9834e-cec1-41f7-90a1-9d6673b2a3e1">165.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2a066e204b487d9b869bbac4264ca0_I20211231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfNy04LTEtMS0zOTkzNg_c47a4149-8547-4a46-a14d-212a476ddbfd">165.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b59666e5a6445af800a6e82b2247fa6_I20220331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfOC00LTEtMS0zOTkzNg_a7fe934f-2e0a-41c1-b16b-219c5db687a7">120.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72dbce711df14aa19565cfda8712ae96_I20211231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfOC04LTEtMS0zOTkzNg_4f770d2c-4065-47be-96cc-2ecb5ae238eb">120.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 28, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i279c0b5c9ef6400db373978fe16df294_I20220331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfOS00LTEtMS0zOTkzNg_5d80ca50-1262-4acf-83a2-195cf4e5544d">150.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8205810c50914fc8b2ee5716cdd1e3ef_I20211231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfOS04LTEtMS0zOTkzNg_3d8bba95-d714-4009-b014-ea2843d02196">150.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receive-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5179e2adfc75478a8bceb8a842e8343d_I20220331" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMTAtNC0xLTEtMzk5MzY_3dd107be-b8d3-4a78-bdc3-347b4c97d7db">165.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06b61d1351f642c39e07376db16278bf_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMTAtOC0xLTEtMzk5MzY_6cffbd89-8fd2-48d4-8d2f-d2fbe037e63d">165.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receive-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c751ca3945547ff89766e783b1692c2_I20220331" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMTEtNC0xLTEtMzk5MzY_24b6d07a-5085-4994-ae30-836793ce01a9">120.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifec07c218a224559988b65a85dca34bd_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMTEtOC0xLTEtMzk5MzY_b23143be-3865-4458-9fb4-39bf3bbd4eb4">120.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receive-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75a4d54131d04ec7a9ad66d50af16a7e_I20220331" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMTItNC0xLTEtMzk5MzY_347a50f7-a326-490b-9abb-370769569410">150.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i746cdb6a8857465b8789529fa778ae72_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMTItOC0xLTEtMzk5MzY_64de3d2b-d2df-4c69-93ac-04cec99d4423">150.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMTctNC0xLTEtMzk5MzY_d19d88c8-8682-4c65-aa3e-1048ef7f1bf1">1,529.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMTctOC0xLTEtMzk5MzY_ceefc1ad-94e5-4ca7-bd5d-8e47aef4ea68">1,533.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our interest rate swap agreements, excluding the portion treated as debt, are recognized at fair value in the condensed consolidated balance sheets and are valued using pricing models that rely on market observable inputs such as yield curve data, which are classified as Level 2 inputs within the fair value hierarchy. The fair value of the interest rate caps are determined using the market standard methodology of discounting the future expected cash receipts that would occur if variable interest rates rise above the strike rate of the caps. The variable interest rates used in the calculation of projected receipts on the caps are based on an expectation of future interest rates derived from observable market interest rate curves and volatilities. The interest rate caps are classified using Level 2 inputs within the fair value hierarchy.</span></div><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfNjI0Mw_e9569218-9c46-4752-ae78-5152bec0a01f" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the fair values of our derivatives and their location on the condensed consolidated balance sheets (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.995%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i052e333e8fbc4c8d828f8652b2a87288_I20220331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfMy00LTEtMS0zOTkzNg_c20762a6-f398-4b25-8ade-e6d904b9de87">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie234fc584e43432db473ff2d1b925b9b_I20211231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfMy04LTEtMS0zOTkzNg_e27e631c-6a46-4236-8bcd-7f6131bf4e76">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5395316d4cc4c4cb5531fc9710de0ef_I20220331" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfNC02LTEtMS0zOTkzNg_117c5a1f-e0d5-41bc-9d74-bf2a992cc4aa">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ed5590de58f45ffa296c26e82b8cb5d_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfNC0xMC0xLTEtMzk5MzY_bbad4e5e-3332-47e2-ad3f-88c265437282">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate caps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dd7a0c476e3425a9cd8fdf81d246d59_I20220331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfNy00LTEtMS00MjIzOA_16af8b25-6a64-4153-9f2d-ded5731e1f25">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290ced8dda3d48ff99a0576554a33576_I20211231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfNy04LTEtMS00MjIzNA_2eb559fe-9505-42cd-aaa3-656a20a4f9ea">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86d66d0402e1453c9f1b3777c6d974bd_I20220331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfNy00LTEtMS0zOTkzNg_6c224026-ed28-4a48-9647-ecddc3e1006f">51.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ff93bdfad7b424a8bf0ec3d14822809_I20211231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfNy04LTEtMS0zOTkzNg_ac1d1c46-8525-41b0-a4fd-fdc31cb13129">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83e7577cfc3e485fa204871cd2bebed9_I20220331" decimals="-5" name="sgry:DerivativeLiabilityNotionalAmountFinancingComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfOC02LTEtMS0zOTkzNg_9c7ef40a-3fcc-4fdf-af6f-851d3e6d252e">42.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i774a5b342a17415398ee546db06a900e_I20211231" decimals="-5" name="sgry:DerivativeLiabilityNotionalAmountFinancingComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfOC0xMC0xLTEtMzk5MzY_2e635120-06d2-46db-a68a-e9435e274cdc">45.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfOS00LTEtMS0zOTkzNg_2d8db358-bb67-4a5c-9d9d-208321a5fc80">67.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfOS02LTEtMS0zOTkzNg_26cf3ccc-163f-4d54-b280-7414b89086ab">47.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfOS04LTEtMS0zOTkzNg_873d9986-3349-46d6-848f-b8d922968be5">23.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfOS0xMC0xLTEtMzk5MzY_136a544b-f1b0-432e-b888-fcfa8a5739fb">58.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">The balance as of March&#160;31, 2022 and December 31, 2021 is related to the financing component of the pay-fixed, receive floating interest rate swaps.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfNjI0MQ_10581483-5c1b-4e1b-be6e-6d3d67f7fe97" escape="true"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the pre-tax effect of the interest rate swaps and caps on the Company's accumulated OCI and condensed consolidated statement of operations (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.542%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss recognized in income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i393e1260928244db91312ff5bdb20b39_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOmEyZWVkYTFmNDU0ZjQxZDM4ZDY3ZGVjYWI5OWQ2YWY5L3RhYmxlcmFuZ2U6YTJlZWRhMWY0NTRmNDFkMzhkNjdkZWNhYjk5ZDZhZjlfMy0zLTEtMS0zOTkzNg_d98d02dc-8f52-440d-a813-449681d0c6ef">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i187ebd1016734402ac3d28311bd88d06_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOmEyZWVkYTFmNDU0ZjQxZDM4ZDY3ZGVjYWI5OWQ2YWY5L3RhYmxlcmFuZ2U6YTJlZWRhMWY0NTRmNDFkMzhkNjdkZWNhYjk5ZDZhZjlfMy01LTEtMS0zOTkzNg_a586be91-efde-462d-a8ab-d55e242ce63d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain recognized in OCI (effective portion)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1b3debb3c6a4868aa2e70b6925bc311_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOmEyZWVkYTFmNDU0ZjQxZDM4ZDY3ZGVjYWI5OWQ2YWY5L3RhYmxlcmFuZ2U6YTJlZWRhMWY0NTRmNDFkMzhkNjdkZWNhYjk5ZDZhZjlfNi0zLTEtMS0zOTkzNg_e915ce34-aed6-477a-95d4-447b3478c9da">50.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6066679117046deaa28e14ca575fd6b_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOmEyZWVkYTFmNDU0ZjQxZDM4ZDY3ZGVjYWI5OWQ2YWY5L3RhYmxlcmFuZ2U6YTJlZWRhMWY0NTRmNDFkMzhkNjdkZWNhYjk5ZDZhZjlfNi01LTEtMS0zOTkzNg_1ac9309a-a6e3-4127-88cb-357cd30adc07">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss reclassified from accumulated OCI into income (effective portion) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79f21a0125dd44b3a07effa007c432cf_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOmEyZWVkYTFmNDU0ZjQxZDM4ZDY3ZGVjYWI5OWQ2YWY5L3RhYmxlcmFuZ2U6YTJlZWRhMWY0NTRmNDFkMzhkNjdkZWNhYjk5ZDZhZjlfNy0zLTEtMS0zOTkzNg_a6488f87-7968-464f-aea9-0117db35c025">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d0118a56e5349658c4a7dc1533913ce_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOmEyZWVkYTFmNDU0ZjQxZDM4ZDY3ZGVjYWI5OWQ2YWY5L3RhYmxlcmFuZ2U6YTJlZWRhMWY0NTRmNDFkMzhkNjdkZWNhYjk5ZDZhZjlfNy01LTEtMS0zOTkzNg_dfdbd5b2-8ea2-4cae-8903-090056a415a9">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Includes amortization of accumulated OCI related to de-designated and terminated interest rate swaps of $<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfNjE4Mg_32dc6ce0-2e64-4719-8be4-484d5ce3c17d">5.3</ix:nonFraction> million for the three months ended March&#160;31, 2022 with <ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfMTY0OTI2NzQ1MTExNg_50ef4891-f603-4725-92ef-117bd6c30d87">no</ix:nonFraction> related amortization for the three months ended March&#160;31, 2021.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i8d24edc59a384ef08748223de247b6a7_49"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6.  <ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RleHRyZWdpb246NGIxY2MxMDVkYjRiNDFkYjg1OThhOGZkMjk3YWE3MzVfMjA5NQ_0a539e2a-7bd3-4c9e-bea2-ba1289d503c4" continuedAt="i3840c7f016ed44c0b88281328544880b" escape="true">Earnings Per Share</ix:nonNumeric></span></div><ix:continuation id="i3840c7f016ed44c0b88281328544880b"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic and diluted earnings per share are calculated based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities exist and have a dilutive effect on earnings per share. The Company computes basic and diluted earnings per share using the two-class method. The two-class method of computing earnings per share is an earnings allocation method that determines earnings per share for common shares and participating securities according to their participation rights in dividends and undistributed earnings.</span></div><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RleHRyZWdpb246NGIxY2MxMDVkYjRiNDFkYjg1OThhOGZkMjk3YWE3MzVfMjA4OA_d3950163-b5e4-4ef2-a37e-a66ca120b388" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator of basic and diluted earnings per share follows (dollars in millions, except per share amounts; shares in thousands): </span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) attributable to Surgery Partners, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfMy0xLTEtMS0zOTkzNg_021d40ac-326a-4613-9348-957adbe20857">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfMy0zLTEtMS0zOTkzNg_f564e7f8-459e-4b47-a968-80f0d162def9">21.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: amounts allocated to participating securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfNC0xLTEtMS0zOTkzNg_5d7d9d8d-7ae4-4224-b410-e3616ab0ef6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfNC0zLTEtMS0zOTkzNg_d442ff81-613e-421c-a6c8-e3089b58b463">10.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfNS0xLTEtMS0zOTkzNg_4ba73752-290e-4054-98fb-97bd49ec948b">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfNS0zLTEtMS0zOTkzNg_198893c3-d802-43f2-9b21-41f6698d378a">31.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding- basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfOC0xLTEtMS0zOTkzNg_5d0914fb-0493-441d-9079-28598465eacd">87,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfOC0zLTEtMS0zOTkzNg_7bd06b61-561e-4b55-95a8-e2c5e7ed9b02">54,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding- diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfOS0xLTEtMS00NTE5OQ_19167194-0235-42ec-8b5c-51a5c1cb029c">90,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfOS0zLTEtMS00NjUyMw_31cb36f3-e489-48fe-a9cd-1517c6757671">54,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income (loss) per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfMTEtMS0xLTEtMzk5MzY_368e382a-e9c3-42a8-aee0-76f832f3a854">0.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfMTEtMy0xLTEtMzk5MzY_747bf581-3537-4241-898e-b83d431f2851">0.57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfMTMtMS0xLTEtNDUyMDE_650b7a44-16e6-4a20-926d-815a6c759ccc">0.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfMTMtMy0xLTEtNDY1MjY_c9e7695f-111d-4850-8ac8-6d409a0b8848">0.57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dilutive securities outstanding not included in the computation of income (loss) per share as their effect is antidilutive:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67c06ab0cc1645feb07263a0b462f478_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfMTQtMS0xLTEtMzk5MzY_3d6597ee-5826-4c20-a226-05cfcb5042ba">1,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06587c3ef400423ab6d0e0c77f4b8182_D20210101-20210331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfMTQtMy0xLTEtMzk5MzY_0105615b-1297-4d81-aad2-705710d06a49">1,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17ca4d1cea4549488f03f41d62feb261_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfMTUtMS0xLTEtMzk5MzY_29296d3e-68c7-4a3d-a943-9d83827cd79d">643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39d94629b8b54e53a9a62a201b44250b_D20210101-20210331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfMTUtMy0xLTEtMzk5MzY_35d6cba0-62e4-444a-8d11-3484e55a9613">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Includes dividends accrued for the Series A Preferred Stock for the three months ended March 31, 2021. The Series A Preferred Stock did  not participate in undistributed losses and was converted to common stock during the second quarter of 2021. There were <ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RleHRyZWdpb246NGIxY2MxMDVkYjRiNDFkYjg1OThhOGZkMjk3YWE3MzVfMTY0OTI2NzQ0NDk2Nw_a2269af5-8f9f-4e20-b9ba-7c7ed52cad35">no</ix:nonFraction> participating securities for the three months ended March 31, 2022.</span></div><div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">The impact of potentially dilutive securities for the three months ended March 31, 2021, was not considered because the effect would be anti-dilutive.</span></div></ix:nonNumeric></ix:continuation><div id="i8d24edc59a384ef08748223de247b6a7_52"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7.  <ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RleHRyZWdpb246YzI1OGE5Mjg3NzE5NDVmY2EyODRmYzQ1NjJlYmJiN2NfMTc1_dee698fc-b116-4230-9bf9-0f984d29d832" continuedAt="i528d0501a79549f5898297ef1628e340" escape="true">Other Current Liabilities</ix:nonNumeric></span></div><ix:continuation id="i528d0501a79549f5898297ef1628e340"><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RleHRyZWdpb246YzI1OGE5Mjg3NzE5NDVmY2EyODRmYzQ1NjJlYmJiN2NfMTc5_c33022d5-31ef-4840-a43f-76367f79f112" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of other current liabilities is as follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfMi0yLTEtMS0zOTkzNg_239e961d-3ee5-484a-97f2-c37f1182bb5a">35.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfMi00LTEtMS0zOTkzNg_f9469821-0c73-4ece-b5b9-82e92860c53c">40.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfMy0yLTEtMS0zOTkzNg_9ad9db2f-bcc4-4573-b11c-81d52d27f78a">36.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfMy00LTEtMS0zOTkzNg_a8a19f09-7e44-4df7-9b53-a8b9a5bd287e">29.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts due to patients and payors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="srt:PayablesToCustomers" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfNC0yLTEtMS00NTc0NA_380153b8-94cd-440c-bb5f-ce5c6c5eaa4d">32.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="srt:PayablesToCustomers" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfNC00LTEtMS00NTc0NA_9ca9813f-f883-4913-9d2a-37f6b0f8fdd3">26.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost report liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="sgry:CostReportLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfNC0yLTEtMS0zOTkzNg_0f34180f-94da-4ec6-b5bc-a511e9394dac">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="sgry:CostReportLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfNC00LTEtMS0zOTkzNg_27aacb11-5ac6-4d48-ab70-7c9857e9b09b">26.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax receivable agreement liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="sgry:TaxReceivableAgreementLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfNi0yLTEtMS0zOTkzNg_e8dcbff9-a1d2-4507-8dc2-55359829b15f">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="sgry:TaxReceivableAgreementLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfNi00LTEtMS0zOTkzNg_a2545559-dec9-499c-91d5-f172e87f74be">19.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfOC0yLTEtMS0zOTkzNg_afa34a5c-20b3-4f49-ad3b-4fced20180a9">74.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfOC00LTEtMS0zOTkzNg_d40b3707-ba0c-4537-a06c-0d636259b143">68.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfOS0yLTEtMS0zOTkzNg_d05b0a5a-9457-4746-a8f7-1f8c15fb2dc0">221.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfOS00LTEtMS0zOTkzNg_0f10c6c4-bed4-4496-b15e-51e3c99c04bd">210.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i8d24edc59a384ef08748223de247b6a7_55"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8.  <ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTE1ODA_e82254f2-8e02-475e-8f19-44f6b6a0f2f2" continuedAt="id827dc18bb8144669a787e68027d4ed3" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="id827dc18bb8144669a787e68027d4ed3" continuedAt="i8dd22360467141819ee229e76009f16b"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Professional, General and Workers' Compensation Liability Risks</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is subject to claims and legal actions in the ordinary course of business, including claims relating to patient treatment, employment practices and personal injuries. The Company maintains professional, general and workers' compensation liability insurance in excess of self-insured retentions through third party commercial insurance carriers. Although management believes the coverage is sufficient for the Company's operations, some claims may potentially exceed the scope of coverage in effect. Plaintiffs in these matters may </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i8dd22360467141819ee229e76009f16b" continuedAt="i0f8207d61abd4f35927798dbbce38653"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">request punitive or other damages that may not be covered by insurance. The Company is not aware of any such proceedings that are reasonably possible to have a material adverse effect on the Company's business, financial position, results of operations or liquidity. Total professional, general and workers' compensation claim liabilities as of March&#160;31, 2022 and December&#160;31, 2021 were $<ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:SelfInsuranceReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTA5OTUxMTY3NDMxOQ_b28a7d8a-048f-4534-ab2a-d2e4c77511ad">18.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:SelfInsuranceReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTA5OTUxMTY3NDMyMw_aeee8c94-94d6-43f4-8b92-12bb96f999fd">19.8</ix:nonFraction> million, respectively. Expected insurance recoveries of $<ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:EstimatedInsuranceRecoveries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTA5OTUxMTY3NDMzNQ_21a68e21-3344-4401-a4e2-9eb510b73dcf"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:EstimatedInsuranceRecoveries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTA5OTUxMTY3NDMzNQ_c8df912c-fdf9-4038-93be-ba33b214c8c7">8.7</ix:nonFraction></ix:nonFraction> million as of both March&#160;31, 2022 and December&#160;31, 2021, are included as a component of other current assets and other long-term assets in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Laws and Regulations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Laws and regulations governing the Company's business, including those relating to the Medicare and Medicaid programs, are complex and subject to interpretation. These laws and regulations govern every aspect of how the Company's surgical facilities conduct their operations, from licensing requirements to how and whether the Company's facilities may receive payments pursuant to the Medicare and Medicaid programs. Compliance with such laws and regulations can be subject to future government agency review and interpretation as well as legislative changes to such laws. Noncompliance with such laws and regulations may subject the Company to significant regulatory sanctions including fines, penalties, and exclusion from the Medicare, Medicaid and other federal health care programs. From time to time, governmental regulatory agencies will conduct inquiries of the Company's practices, including, but not limited to, the Company's compliance with federal and state fraud and abuse laws, billing practices and relationships with physicians.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stockholder Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On December 4, 2017, a purported Company stockholder filed an action in the Delaware Court of Chancery (the "Delaware Action"). That action is captioned Witmer v. H.I.G. Capital, L.L.C., et al., C.A. No. 2017-0862. The plaintiff in the Delaware Action asserted claims against (i) certain current and former members of the Company&#8217;s Board of Directors (together, the "Directors"); (ii) H.I.G. Capital, LLC and certain of its affiliates (collectively, "H.I.G."); and (iii) Bain Capital Private Equity, L.P. and certain of its affiliates (collectively, "Bain Capital" and, together with the Directors and H.I.G., the "Defendants"). The parties to the Delaware Action negotiated a final stipulation of settlement (the &#8220;Settlement Stipulation&#8221;), which governs the terms of the settlement of the Delaware Action, and which they filed with the Court of Chancery on November 22, 2021. On February 11, 2022, the Court of Chancery approved the settlement of the Delaware Action as memorialized in the Settlement Stipulation. That decision became final and non-appealable on March 14, 2022. The case is now closed. Pursuant to the settlement, the Company received $<ix:nonFraction unitRef="usd" contextRef="i49e70dcd4ab4442e93dc776b77191c75_D20220301-20220331" decimals="-5" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfOTM0NTg0ODg4NDc0Nw_c09135a7-80a8-42c7-a5a4-9f01a4347784">32.8</ix:nonFraction>&#160;million in March 2022, which was included in litigation settlement in the condensed consolidated statements of operations for the three months ended March 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Acquired Facilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company, through its wholly-owned subsidiaries or controlled partnerships and limited liability companies, has acquired and will continue to acquire surgical facilities with prior operating histories. Such facilities may have unknown or contingent liabilities, including liabilities for failure to comply with health care laws and regulations, such as billing and reimbursement laws and regulations, the Stark Law, the Anti-Kickback Statute, the FCA, and similar fraud and abuse laws. Although the Company attempts to assure that no such liabilities exist, obtain indemnification from prospective sellers covering such matters and institute policies designed to conform centers to its standards following completion of acquisitions, there can be no assurance that the Company will not become liable for past activities that may later be asserted to be improper by private plaintiffs or government agencies. There can be no assurance that any such matter will be covered by indemnification or, if covered, that the liability sustained will not exceed contractual limits or the financial capacity of the indemnifying party.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company cannot predict whether federal or state statutory or regulatory provisions will be enacted that would prohibit or otherwise regulate relationships which the Company has established or may establish with other health care providers or have materially adverse effects on its business or revenues arising from such future actions. Management believes, however, that it will be able to adjust the Company's operations so as to be in compliance with any statutory or regulatory provision as may be applicable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Potential Physician Investor Liability</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A majority of the physician investors in the partnerships and limited liability companies which operate the Company's surgical facilities carry general and professional liability insurance on a claims-made basis. Each partnership or limited liability company may, however, be liable for damages to persons or property arising from occurrences at the surgical facilities. Although the various physician investors and other surgeons generally are required to obtain general and professional liability insurance with tail coverage that extends beyond the period of any claims-made policies, such individuals may not be able to obtain coverage in amounts sufficient to cover all potential liability. Since most insurance policies contain exclusions, the physician investors will not be insured against all possible occurrences. In the event of an uninsured or underinsured loss, the value of an investment in the partnership interests or limited liability company membership units and the amount of distributions could be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Tax Receivable Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On May 9, 2017, the Company entered into an agreement to amend that certain Income Tax Receivable Agreement, dated September 30, 2015 (as amended, the "TRA"), by and between the Company, and the other parties referred to therein, which amendment became effective on August 31, 2017. Pursuant to the amendment to the TRA, the Company agreed to make payments to H.I.G., the Company's former controlling shareholder, in its capacity as the stockholders representative pursuant to a fixed payment schedule. The amounts payable under the TRA are calculated as the product of (i) an annual base amount and (ii) the maximum corporate federal income tax rate for the applicable year plus <ix:nonFraction unitRef="number" contextRef="icf580ac915f4455f888d4bffc00ceccd_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfOTg2OA_c7f3e0e0-a712-4cd7-973d-b5709897f308">three</ix:nonFraction> percent. The amounts payable under the TRA are related to the Company&#8217;s projected realized tax savings </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i0f8207d61abd4f35927798dbbce38653" continuedAt="i268512cac8364416b9b3641a59e71aab">over the next <ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="sgry:CollaborativeTaxAgreementProjectedTaxSavingsTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfOTk4OA_e58629d9-970a-4218-8f30-318a82ae288a">five years</ix:nonNumeric> and are not dependent on the Company&#8217;s actual tax savings over such period. The calculation of amounts payable pursuant to the TRA is thus dependent on the maximum corporate federal income tax rate. To the extent that the Company is unable to make payments under the TRA, such payments will be deferred and will accrue interest at a rate of the LIBOR plus <ix:nonFraction unitRef="number" contextRef="i62d2751322cd45d690eae0422a55f102_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTAzNDc_6da378be-ed95-4ad4-a1a4-cc18c2c52f85">500</ix:nonFraction> basis points until paid. If the terms of credit agreements and other debt documents cause the Company to be unable to make payments under the TRA and such terms are not materially more restrictive than those existing as of September 30, 2015, such payments will be deferred and will accrue interest at a rate of LIBOR plus <ix:nonFraction unitRef="number" contextRef="i2ae955700f5a407192e0f30ca8c9cef7_D20220101-20220331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTA2NzM_9dbd329b-ce46-46c5-9279-632380741d60">300</ix:nonFraction> basis points until paid.</ix:continuation></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i268512cac8364416b9b3641a59e71aab">Assuming the Company's tax rate is <ix:nonFraction unitRef="number" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTA3MzY_f2222f84-6f89-47a0-95d4-9f1524414d67">24</ix:nonFraction>%, calculated as the maximum corporate federal tax rate plus <ix:nonFraction unitRef="number" contextRef="icf580ac915f4455f888d4bffc00ceccd_D20220101-20220331" decimals="2" name="sgry:CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTA3OTg_a6e4e082-76b5-4183-b762-696c29b6e9dd">three</ix:nonFraction> percent, throughout the remaining term of the TRA, the Company estimates the total remaining amounts payable under the TRA was approximately $<ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:TaxesPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTA5OTUxMTY3NDM4NA_3adf0fe4-7290-4730-bb8a-ab76e3d7bc3e"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:TaxesPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTA5OTUxMTY3NDM4NA_659ed8cc-1152-4f72-bd19-ea6bbd31cd8f">22.0</ix:nonFraction></ix:nonFraction> million as of both March&#160;31, 2022 and December&#160;31, 2021. As a result of the amendment to the TRA, the Company was required to value the liability under the TRA by discounting the fixed payment schedule using the Company&#8217;s incremental borrowing rate. The carrying value of the liability under the TRA, reflecting the discount, was $<ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="sgry:DeferredIncomeTaxLiabilitiesNetOfDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTA5OTUxMTY3NDM5Mg_3316d2c8-ece5-4f9b-9f1b-5e0a7084de9c">20.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="sgry:DeferredIncomeTaxLiabilitiesNetOfDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTA5OTUxMTY3NDM5Ng_10c12ca1-6469-4bf0-9059-75370e57ab0f">19.7</ix:nonFraction> million as of March&#160;31, 2022 and December&#160;31, 2021, respectively, and is included as a component of other current liabilities in the condensed consolidated balance sheets.</ix:continuation> </span></div><div id="i8d24edc59a384ef08748223de247b6a7_58"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9.  <ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfMjA0OQ_34a3a653-236d-444b-ba49-03e2f065817f" continuedAt="i1440d7ce8a0e4d9287df474b679ab121" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="i1440d7ce8a0e4d9287df474b679ab121" continuedAt="ie5cb2b075067446b9789413f1f385673"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company currently operates in&#160;<ix:nonFraction unitRef="segment" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfNjI_cf3a1e90-212f-4fa0-a522-4a55d428ebac">two</ix:nonFraction>&#160;major lines of business that are also the Company's reportable operating segments - the operation of surgical facilities and the operation of ancillary services. The Surgical Facility Services segment consists of the operation of ASCs, surgical hospitals and anesthesia services. The Ancillary Services segment consists of multi-specialty physician practices. The "All other" line item primarily consists of the Company's corporate general and administrative functions.</span></div><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfMjAzOQ_4d00c862-e0cb-4947-8f4f-748144d68b56" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables present financial information for each reportable segment (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f4c1e12ebf42428954114c64170b8b_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMy0yLTEtMS0zOTkzNg_41115043-4453-4372-83d7-70a4f4168d7e">578.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95c194ebfbd94fa8a271308daec9afbb_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMy00LTEtMS0zOTkzNg_ed6155c8-2763-4547-9dae-a056b9497bfb">495.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id484bee12a474b8bbcedacad3a0e452e_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfNC0yLTEtMS0zOTkzNg_67df8930-f8fc-4ebd-b2f0-54167570a649">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia230717bfdb149e5b55ed8b1922373c3_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfNC00LTEtMS0zOTkzNg_cabe2302-37fd-4d54-b942-063b3bdacb3e">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfNi0yLTEtMS0zOTkzNg_a6fc1d94-c23d-4cfa-ba49-11fc66b6934c">596.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfNi00LTEtMS0zOTkzNg_4410a06e-9ef0-4059-be1c-5777ace8334e">512.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f4c1e12ebf42428954114c64170b8b_D20220101-20220331" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfOS0yLTEtMS0zOTkzNg_2e6c6d4d-3a75-4e28-832d-80d64af6c31c">101.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95c194ebfbd94fa8a271308daec9afbb_D20210101-20210331" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfOS00LTEtMS0zOTkzNg_8416b4e3-9793-4472-add3-589c0982ae16">95.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id484bee12a474b8bbcedacad3a0e452e_D20220101-20220331" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTAtMi0xLTEtMzk5MzY_ac1dec48-23c1-446c-9854-c7bd25ff7dfc">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia230717bfdb149e5b55ed8b1922373c3_D20210101-20210331" decimals="-5" sign="-" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTAtNC0xLTEtMzk5MzY_4c6b1301-07c3-4a68-8e50-22e3345abbb2">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37cfe03bc9ed4713b3b1e61e87a612c2_D20220101-20220331" decimals="-5" sign="-" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTItMi0xLTEtMzk5MzY_a03bf046-a334-47e9-b967-8d9d643cb264">24.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id144f2f56936461e8128c2d94933dc55_D20210101-20210331" decimals="-5" sign="-" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTItNC0xLTEtMzk5MzY_02a18595-6118-43e5-a70d-5769a62b4735">21.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTMtMi0xLTEtMzk5MzY_9f8a955d-88a9-4f14-a240-5a211e75c821">77.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTMtNC0xLTEtMzk5MzY_f9e59bc9-f299-42a0-a574-ce7aabf4ae18">72.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reconciliation of Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTYtMi0xLTEtMzk5MzY_f5b39e2b-307b-436b-9cec-0672e68440ec">44.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTYtNC0xLTEtMzk5MzY_b3f9af87-e968-4d4c-acbc-e45d616ae200">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTgtMi0xLTEtMzk5MzY_87485d51-fa51-440f-b4b0-0fda72afc15a">30.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTgtNC0xLTEtMzk5MzY_7e4f2746-0610-45b0-8df9-bb2c26c641d8">31.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTktMi0xLTEtMzk5MzY_e56eb0c0-ae25-4b31-aa51-e1e915e531e6">27.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTktNC0xLTEtMzk5MzY_b554a520-1ae0-41a5-b0d2-2d5acbee98c0">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjAtMi0xLTEtMzk5MzY_ddc2eb9b-469b-41d8-b326-ffbf56a33b71">56.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjAtNC0xLTEtMzk5MzY_5f9f6ea3-9642-4998-ad27-6e5685821cd3">53.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjEtMi0xLTEtMzk5MzY_910a3749-356e-4ae9-8d27-c32f4ce8d04c">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjEtNC0xLTEtMzk5MzY_3525a103-5bbc-448d-83d2-d0b6f4d2cdd7">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction, integration and acquisition costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="sgry:BusinessCombinationIntegrationRelatedCostsAndMergerCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjItMi0xLTEtMzk5MzY_9aaa879f-70b6-4fab-8852-381b105f2831">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="sgry:BusinessCombinationIntegrationRelatedCostsAndMergerCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjItNC0xLTEtMzk5MzY_e7a92ac9-f458-4d97-b4a1-9bf1651309ed">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on disposals and deconsolidations, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="sgry:GainLossOnDispositionOfAssetsAndDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjQtMi0xLTEtMzk5MzY_452672f5-4a25-4a39-a763-ede31cd47604">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="sgry:GainLossOnDispositionOfAssetsAndDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjQtNC0xLTEtMzk5MzY_26ce70d3-5d29-4bf4-b19f-02c41e18bd2f">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on litigation settlement and other litigation costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="sgry:GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjUtMi0xLTEtMzk5MzY_bc98a9ef-47b5-4e43-a0c2-a0af2e237c10">30.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" sign="-" name="sgry:GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjUtNC0xLTEtMzk5MzY_dd790fd5-0b5b-41cb-a6ba-c1fcf46c14a1">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjktMi0xLTEtMzk5MzY_e0f239be-3f8f-476b-97d3-ec9282c5f736">77.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjktNC0xLTEtMzk5MzY_2df6281b-b0f1-40b4-a521-629e76ab7d4c">72.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount includes transaction and integration costs of $<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfOTgx_8c7e2850-0b58-466a-86b1-30816aa08351">7.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfOTg4_a4a535b0-c5fd-4bf7-abcc-31d16df45152">5.3</ix:nonFraction> million for the three months ended March&#160;31, 2022 and 2021, respectively. This amount further includes start-up costs related to a de novo surgical hospital of $<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfMTEyNg_082166d8-168a-44fe-88cb-8a9c849abdf8">4.1</ix:nonFraction> million for the three months ended March 31, 2021. </span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount includes other litigation costs of $<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfMTQ4Mg_84db0156-b1f5-4334-b173-c07877cfab7f">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfMTQ4OQ_9362bcc7-8359-482f-a8f1-d8a5126897ed">1.0</ix:nonFraction> million for the three months ended March&#160;31, 2022 and 2021, respectively. This amount also includes gain on litigation settlement of $<ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfMTA5OTUxMTYzMTE5Nw_a6d2358f-29c1-4476-ac53-ff2b657ef40e">32.8</ix:nonFraction> million for the three months ended March&#160;31, 2022, with <ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfMTY0OTI2NzQ0NTI0NA_18221a30-4f69-4a2b-8cf7-92a2cb5a57dd">no</ix:nonFraction> comparable activity in the 2021 period.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ie5cb2b075067446b9789413f1f385673"><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfMjAyMw_ce3b590c-ca09-4f1c-9061-48bac304bb9e" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2df432d764946c98419eddd4b217200_I20220331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOmJmYTEzMmYyZDhhNDQ0N2Y5MWM2NmMwNDIzZjdlYTA3L3RhYmxlcmFuZ2U6YmZhMTMyZjJkOGE0NDQ3ZjkxYzY2YzA0MjNmN2VhMDdfMi0yLTEtMS0zOTkzNg_b7af0f55-89d0-4280-93af-bb4ffdc708eb">5,651.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30d11e9517014207867a3d78c850cb1c_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOmJmYTEzMmYyZDhhNDQ0N2Y5MWM2NmMwNDIzZjdlYTA3L3RhYmxlcmFuZ2U6YmZhMTMyZjJkOGE0NDQ3ZjkxYzY2YzA0MjNmN2VhMDdfMi00LTEtMS0zOTkzNg_968afb0d-17f3-49d7-a7ec-cb1cc0ad6548">5,552.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i241a5e9cb633484a83e8b37dd0d53c59_I20220331" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOmJmYTEzMmYyZDhhNDQ0N2Y5MWM2NmMwNDIzZjdlYTA3L3RhYmxlcmFuZ2U6YmZhMTMyZjJkOGE0NDQ3ZjkxYzY2YzA0MjNmN2VhMDdfMy0yLTEtMS0zOTkzNg_0ca8ca53-a6a3-4a98-938c-62987b3d3752">44.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i405edebb54534016a7214669c2bd5d18_I20211231" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOmJmYTEzMmYyZDhhNDQ0N2Y5MWM2NmMwNDIzZjdlYTA3L3RhYmxlcmFuZ2U6YmZhMTMyZjJkOGE0NDQ3ZjkxYzY2YzA0MjNmN2VhMDdfMy00LTEtMS0zOTkzNg_928fb058-c8fd-4d74-9b9d-94c5e87be250">47.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67f8f1225fb34764b0261414fc217735_I20220331" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOmJmYTEzMmYyZDhhNDQ0N2Y5MWM2NmMwNDIzZjdlYTA3L3RhYmxlcmFuZ2U6YmZhMTMyZjJkOGE0NDQ3ZjkxYzY2YzA0MjNmN2VhMDdfNC0yLTEtMS0zOTkzNg_351a13c5-9bc9-4ade-8ec1-f494c2fb3431">593.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a3f22cbbd5f47d4955fd2c0473366ea_I20211231" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOmJmYTEzMmYyZDhhNDQ0N2Y5MWM2NmMwNDIzZjdlYTA3L3RhYmxlcmFuZ2U6YmZhMTMyZjJkOGE0NDQ3ZjkxYzY2YzA0MjNmN2VhMDdfNC00LTEtMS0zOTkzNg_6bf4e9b5-3812-4de3-80b2-04dbeb058cee">517.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOmJmYTEzMmYyZDhhNDQ0N2Y5MWM2NmMwNDIzZjdlYTA3L3RhYmxlcmFuZ2U6YmZhMTMyZjJkOGE0NDQ3ZjkxYzY2YzA0MjNmN2VhMDdfNS0yLTEtMS0zOTkzNg_af1000d8-3340-4678-850c-50be5ee19e3a">6,289.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOmJmYTEzMmYyZDhhNDQ0N2Y5MWM2NmMwNDIzZjdlYTA3L3RhYmxlcmFuZ2U6YmZhMTMyZjJkOGE0NDQ3ZjkxYzY2YzA0MjNmN2VhMDdfNS00LTEtMS0zOTkzNg_e3f38f6b-7266-4449-8bff-f3286e8a67f3">6,117.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfMjAzNg_c60daae7-aa2d-4d45-8bfd-9f672ec781d3" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash purchases of property and equipment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06f4c1e12ebf42428954114c64170b8b_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjU4ZDEwZmVlZTdiNDRmY2RhZWRlMjZhYjRmZGQ4ODE2L3RhYmxlcmFuZ2U6NThkMTBmZWVlN2I0NGZjZGFlZGUyNmFiNGZkZDg4MTZfMy0yLTEtMS0zOTkzNg_20dd5cac-390f-49fa-9570-506290214c0d">17.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95c194ebfbd94fa8a271308daec9afbb_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjU4ZDEwZmVlZTdiNDRmY2RhZWRlMjZhYjRmZGQ4ODE2L3RhYmxlcmFuZ2U6NThkMTBmZWVlN2I0NGZjZGFlZGUyNmFiNGZkZDg4MTZfMy00LTEtMS0zOTkzNg_56f0e970-b8cd-49ab-b392-8f4556c9cf40">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id484bee12a474b8bbcedacad3a0e452e_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjU4ZDEwZmVlZTdiNDRmY2RhZWRlMjZhYjRmZGQ4ODE2L3RhYmxlcmFuZ2U6NThkMTBmZWVlN2I0NGZjZGFlZGUyNmFiNGZkZDg4MTZfNC0yLTEtMS0zOTkzNg_0bd117d4-20d2-4e1c-aaf8-7a25f0980085">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia230717bfdb149e5b55ed8b1922373c3_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjU4ZDEwZmVlZTdiNDRmY2RhZWRlMjZhYjRmZGQ4ODE2L3RhYmxlcmFuZ2U6NThkMTBmZWVlN2I0NGZjZGFlZGUyNmFiNGZkZDg4MTZfNC00LTEtMS0zOTkzNg_36f3da20-4851-47ba-a7ba-29f786ddceb1">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37cfe03bc9ed4713b3b1e61e87a612c2_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjU4ZDEwZmVlZTdiNDRmY2RhZWRlMjZhYjRmZGQ4ODE2L3RhYmxlcmFuZ2U6NThkMTBmZWVlN2I0NGZjZGFlZGUyNmFiNGZkZDg4MTZfNi0yLTEtMS0zOTkzNg_ad7a5bed-10dd-4d5a-bfbd-7fc0169f3ac0">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id144f2f56936461e8128c2d94933dc55_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjU4ZDEwZmVlZTdiNDRmY2RhZWRlMjZhYjRmZGQ4ODE2L3RhYmxlcmFuZ2U6NThkMTBmZWVlN2I0NGZjZGFlZGUyNmFiNGZkZDg4MTZfNi00LTEtMS0zOTkzNg_1b1739f1-7e10-4ea5-8b49-791687e7d838">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjU4ZDEwZmVlZTdiNDRmY2RhZWRlMjZhYjRmZGQ4ODE2L3RhYmxlcmFuZ2U6NThkMTBmZWVlN2I0NGZjZGFlZGUyNmFiNGZkZDg4MTZfNy0yLTEtMS0zOTkzNg_a37bc63a-1fad-4a9d-a4da-212c99d98314">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjU4ZDEwZmVlZTdiNDRmY2RhZWRlMjZhYjRmZGQ4ODE2L3RhYmxlcmFuZ2U6NThkMTBmZWVlN2I0NGZjZGFlZGUyNmFiNGZkZDg4MTZfNy00LTEtMS0zOTkzNg_dd263da4-4593-49c7-b4f4-4121df33d18b">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="i8d24edc59a384ef08748223de247b6a7_61"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10.  <ix:nonNumeric contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN182MS9mcmFnOjUwN2U1MTllYmQ1ZTQxYTI5Y2YxYzUxMTFmZTRiMzc5L3RleHRyZWdpb246NTA3ZTUxOWViZDVlNDFhMjljZjFjNTExMWZlNGIzNzlfMjA5_8d89d024-4cb7-4c4b-bab2-ccb6bf479a40" continuedAt="icdbb365cd3c7449fa9bdf1474043eb99" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><ix:continuation id="icdbb365cd3c7449fa9bdf1474043eb99"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2022, the Company acquired non-controlling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interests in <ix:nonFraction unitRef="non-controlling_interest" contextRef="i95727e44b2eb479d8bbcd65296068f83_D20220401-20220430" decimals="INF" name="sgry:NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN182MS9mcmFnOjUwN2U1MTllYmQ1ZTQxYTI5Y2YxYzUxMTFmZTRiMzc5L3RleHRyZWdpb246NTA3ZTUxOWViZDVlNDFhMjljZjFjNTExMWZlNGIzNzlfMTY0OTI2NzQ0MjY3MQ_05b9c783-2119-482d-a1f1-a9a0ed090ebe">three</ix:nonFraction> surgical facilities and <ix:nonFraction unitRef="non-controlling_interest" contextRef="i95727e44b2eb479d8bbcd65296068f83_D20220401-20220430" decimals="INF" name="sgry:NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN182MS9mcmFnOjUwN2U1MTllYmQ1ZTQxYTI5Y2YxYzUxMTFmZTRiMzc5L3RleHRyZWdpb246NTA3ZTUxOWViZDVlNDFhMjljZjFjNTExMWZlNGIzNzlfMTY0OTI2NzQ0MjY3OQ_514a19fa-1238-4985-9c27-46dfeb50e576">four</ix:nonFraction> in-development de novo surgical facilities for a combined purchase price of $<ix:nonFraction unitRef="usd" contextRef="iea161d59c161497f8a5bb07b4bdb04b9_D20220401-20220430" decimals="-5" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN182MS9mcmFnOjUwN2U1MTllYmQ1ZTQxYTI5Y2YxYzUxMTFmZTRiMzc5L3RleHRyZWdpb246NTA3ZTUxOWViZDVlNDFhMjljZjFjNTExMWZlNGIzNzlfODI0NjMzNzIwOTMwNQ_32915316-2c3d-4ff9-a0e2-d5b1787fc4de">48.6</ix:nonFraction>&#160;million. The non-controlling interests will be accounted for as equity method investments.</span></ix:continuation></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i8d24edc59a384ef08748223de247b6a7_64"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and related notes included elsewhere in this report and our 2021 Annual Report on Form 10-K. Unless the context otherwise indicates, the terms "Surgery Partners," "we," "us," "our" or the "Company," as used herein, refer to Surgery Partners, Inc. and its subsidiaries. Unless the context implies otherwise, the term &#8220;affiliates&#8221; means direct and indirect subsidiaries of Surgery Partners, Inc. and partnerships and joint ventures in which such subsidiaries are partners. The terms &#8220;facilities&#8221; or &#8220;hospitals&#8221; refer to entities owned and operated by affiliates of Surgery Partners, Inc. and the term &#8220;employees&#8221; refers to employees of affiliates of Surgery Partners, Inc.</span></div><div id="i8d24edc59a384ef08748223de247b6a7_67"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward-Looking Statements</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This report contains forward-looking statements, which are based on our current expectations, estimates and assumptions about future events. All statements other than statements of current or historical fact contained in this report are forward-looking statements. These statements include, but are not limited to, statements regarding our future financial position, business strategy, budgets, effective tax rate, projected costs and plans and objectives of management for future operations. The words "projections," "believe," "continue," "drive," "estimate," "expect," "intend," "may," "plan," "will," "could," "would" and similar expressions are generally intended to identify forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results to differ from the expectations expressed in the statements. Many of these factors are beyond our ability to control or predict. These factors include, without limitation, the effects of the ongoing COVID-19 pandemic in the United States and the regions in which we operate; the impact to the state and local economies of restrictive orders, vaccine and other mandates and the pandemic generally; our ability to respond nimbly to challenging economic conditions; the unpredictability of our case volume in the current environment; our ability to preserve or raise sufficient funds to continue operations throughout this period of uncertainty; the impact of our cost-cutting measures on our future performance; our ability to cause distributions from our subsidiaries; the responsiveness of our payors, including Medicaid and Medicare, to the challenging operating conditions, including their willingness and ability to continue paying in a timely manner and to advance payments in a timely manner, if at all; the impact of COVID-19 related stimulus programs, including the CARES Act, and uncertainty in how these programs may be administered, monitored and modified in the future; our ability to execute on our operational and strategic initiatives; the timing and impact of our portfolio optimization efforts; our ability to continue to improve same-facility volume and revenue growth on the timeline anticipated, if at all; our ability to successfully integrate acquisitions; the anticipated impact and timing of our ongoing efficiency efforts; the impact of adverse weather conditions and other events outside of our control; and the risks and uncertainties set forth under the heading "Risk Factors" in our 2021 Annual Report on Form 10-K and discussed from time to time in our reports filed with the SEC.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Considering these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. When you consider these forward-looking statements, you should keep in mind these risk factors and other cautionary statements in this report.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These forward-looking statements speak only as of the date made. Other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events or otherwise.</span></div><div id="i8d24edc59a384ef08748223de247b6a7_70"></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Executive Overview</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenues for the first quarter of 2022 increased 16.4% to&#160;$596.2 million&#160;from&#160;$512.4 million&#160;for the first quarter of 2021. Days adjusted same-facility revenues for the first quarter of 2022 increased 8.2% from the same period last year, with a 1.7% increase in revenue per case and a 6.3% increase in same-facility cases. For the first quarter of 2022, the Company&#8217;s net income attributable to common stockholders and Adjusted EBITDA was&#160;$12.2 million and $77.1 million, respectively.&#160;For the first quarter of 2021, the Company&#8217;s net loss attributable to common stockholders and Adjusted EBITDA was&#160;$31.3 million and $72.9 million, respectively. A reconciliation of non-GAAP financial measures appears below under "Certain Non-GAAP Measures." </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We&#160;had cash and cash equivalents of&#160;$378.9 million&#160;and $203.0 million of borrowing capacity under our revolving credit facility at March&#160;31, 2022. Operating cash inflows were $79.8 million in the first quarter of 2022, an increase of $29.6 million compared to the prior-year period. Net operating cash flows, including operating cash flows less distributions to non-controlling interests, were an inflow of&#160;$43.6 million and $18.9 million for the first quarter of 2022 and 2021, respectively. The increase in operating cash flows and net operating cash flows compared to the same period in 2021 is primarily due to proceeds received in the first quarter of 2022 from the settlement of a stockholder litigation matter.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The COVID-19 pandemic has significantly affected our facilities, employees, patients, communities, business operations and financial performance, as well as the U.S. economy and financial markets. The impact of the COVID-19 pandemic on our surgical facilities varies based on the market in which the facility operates, the type of surgical facility and the procedures typically performed. We cannot provide any certainty regarding the length and severity of the impact of the COVID-19 pandemic, which is difficult to predict and is dependent on factors beyond our control.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is monitoring legislative actions at federal and state levels, including the impact of the CARES Act and other governmental assistance that might be available.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i8d24edc59a384ef08748223de247b6a7_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our revenues consist of patient service revenues and other service revenues. Patient service revenues consist of revenue from our surgical facility services and ancillary services segments. Specifically, patient service revenues include fees for surgical or diagnostic procedures performed at surgical facilities that we consolidate for financial reporting purposes, as well as for patient visits to our physician practices, anesthesia services, pharmacy services and diagnostic screens ordered by our physicians. Other service revenues include management and administrative service fees derived from our non-consolidated facilities that we account for under the equity method, management of surgical facilities and physician practices in which we do not own an interest and management services we provide to physician practices for which we are not required to provide capital or additional assets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes our revenues by service type as a percentage of total revenues for the periods indicated: </span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical facilities revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total patient service revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other service revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Payor Mix</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth by type of payor the percentage of our patient service revenues generated at the surgical facilities which we consolidate for financial reporting purposes in the periods indicated: </span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Private insurance payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government payors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Self-pay payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other payors </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:1pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Other is comprised of anesthesia service agreements, automobile liability, letters of protection and other payor types. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Surgical Case Mix</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We primarily operate multi-specialty surgical facilities where physicians perform a variety of procedures in various specialties. We believe this diversification helps to protect us from adverse pricing and utilization trends in any individual procedure type and results in greater consistency in our case volume. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth the percentage of cases in each specialty performed at the surgical facilities which we consolidate for financial reporting purposes for the periods indicated:</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orthopedic and pain management</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ophthalmology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gastrointestinal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General surgery</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i8d24edc59a384ef08748223de247b6a7_79"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Critical Accounting Policies </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of significant accounting policies is disclosed in our 2021 Annual Report on Form 10-K under the caption &#8220;Critical Accounting Policies&#8221; in the Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations section. There have been no material changes in the nature of our critical accounting policies or the application of those policies since December 31, 2021.</span></div><div id="i8d24edc59a384ef08748223de247b6a7_82"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended March&#160;31, 2022 Compared to Three Months Ended March&#160;31, 2021 </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes certain results from the statements of operations for the three months ended March&#160;31, 2022 and 2021 (dollars in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction and integration costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on disposals and deconsolidations, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from equity investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Litigation settlement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 25.75pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income taxes </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:  Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) attributable to Surgery Partners, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Overview.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, our revenues increased 16.4% to $596.2 million compared to $512.4 million for the three months ended March&#160;31, 2021. Net income attributable to Surgery Partners, Inc. was $12.2 million for the 2022 period, compared to a net loss of $21.0 million for the 2021 period. The increase in revenues was primarily attributable to increases in surgical case volumes and acquisitions completed since the prior-year period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenues.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues for the three months ended March&#160;31, 2022 compared to the three months ended March&#160;31, 2021 were as follows (dollars in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patient service revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">587.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other service revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patient service revenues increased 16.2% to $587.7 million for the three months ended March&#160;31, 2022 compared to $505.7 million for the three months ended March&#160;31, 2021. The increase of 16.2% was driven by a 6.3% increase in days adjusted same-facility case volume, a 1.7% increase in same-facility revenue per case and acquisitions completed since the prior-year period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenues.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of revenues were $471.4 million for the three months ended March&#160;31, 2022 compared to $408.9 million for the three months ended March&#160;31, 2021. The increase was primarily driven by continued case count recovery and acquisitions completed </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">since the prior-year period. As a percentage of revenues, cost of revenues decreased to 79.1% for the 2022 period compared to 79.8% for the 2021 period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  General and administrative expenses were $29.5 million for the three months ended March&#160;31, 2022 compared to $26.8 million for the three months ended March&#160;31, 2021. As a percentage of revenues, general and administrative expenses decreased to 4.9% for the 2022 period compared to 5.2% for the 2021 period. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization was $27.4 million and $25.7 million for the three months ended March&#160;31, 2022 and 2021, respectively. As a percentage of revenues, depreciation and amortization expenses decreased to 4.6% for the 2022 period compared to 5.0% for the 2021 period. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Transaction and Integration Costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  We incurred $7.1 million of transaction and integration costs for the three months ended March&#160;31, 2022 compared to $5.3 million for the three months ended March&#160;31, 2021. The increase primarily relates to costs for ongoing development initiatives and the integration of acquisitions we completed in 2022 and 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Grant Funds.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, the Company received approximately $1&#160;million of additional grants from HHS. Based on guidance from HHS and other authorities, the Company updated its estimate of the amount of grant funds received that qualified for recognition, resulting in the recognition of $1.2&#160;million during the three months ended March 31, 2022. Grant funds recognized in the three months ended March 31, 2021 were $15.1&#160;million. For further discussion, see Note 1. "Organization and Summary of Accounting Polices - COVID-19 Pandemic" to our condensed consolidated financial statements included elsewhere in this report.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Litigation Settlement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  Gain on litigation settlement was $32.8&#160;million for the three months ended March&#160;31, 2022, related to the resolution of the stockholder litigation matter, as discussed in Note 9. "Commitments and Contingencies" to our condensed consolidated financial statements included elsewhere in this report. There was no comparable activity for the 2021 period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense, Net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  Interest expense, net, increased to $56.3 million for the three months ended March&#160;31, 2022 compared to $53.3 million for the three months ended March&#160;31, 2021. As a percentage of revenues, interest expense, net decreased to 9.4% for the 2022 period compared to 10.4% for the 2021 period. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Income Tax Expense.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#160; The income tax expense was $1.3 million and $0.2 million for the three months ended March&#160;31, 2022 and 2021, respectively. The effective tax rate was 2.9% for the three months ended March&#160;31, 2022 compared to 1.8% for the three months ended March&#160;31, 2021. For the three months ended March&#160;31, 2022, the effective tax rate differed from 21% primarily due to earnings attributable to non-controlling interests, an increase in the Company&#8217;s valuation allowance attributable to interest expense limitations, and discrete tax benefits of (a) $4.6&#160;million related to the vesting of restricted stock awards, (b) $1.8&#160;million attributable to non-recurring earnings&#8217; impact on the Company&#8217;s valuation allowance, and (c) $1.0&#160;million related to entity divestitures. For the three months ended March&#160;31, 2021, the effective tax rate differed from 21% due to tax benefits of $2.2&#160;million related to the vesting of restricted stock awards. Based upon the application of interim accounting guidance, the tax rate as a percentage of net income after income attributable to non-controlling interests will vary based upon the relative net income from period to period.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Net Income Attributable to Non-Controlling Interests. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Net income attributable to non-controlling interests was $30.6 million for the three months ended March&#160;31, 2022 compared to $31.8 million for the three months ended March&#160;31, 2021. As a percentage of revenues, net income attributable to non-controlling interests was 5.1% for the 2022 period and 6.2% for the 2021 period.</span></div><div id="i8d24edc59a384ef08748223de247b6a7_85"></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The primary source of our operating cash flow is the collection of accounts receivable from federal and state agencies (under the Medicare and Medicaid programs), private insurance companies and individuals. During the three months ended March&#160;31, 2022, our cash flow provided by operating activities was $79.8 million compared to $50.2 million in the three months ended March&#160;31, 2021. The increase is primarily due</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> to settlement proceeds related to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">resolution of a stockholder litigation matter.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash used in investing activities during the three months ended March&#160;31, 2022, was $47.1 million, which included $18.2 million related to purchases of property and equipment. We paid $31.1 million in cash for acquisitions (net of cash acquired), which included controlling interests in two surgical facilities, one of which was merged into an existing surgical facility. Additionally, we received cash proceeds of $11.5 million related to the sale of interests in a surgical facility, which was previously accounted for as an equity method investment.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net cash used in investing activities during the three months ended March 31, 2021, was $14.3 million, which included $14.5 million related to purchases of property and equipment. We paid $2.1 million in cash for acquisitions (net of cash acquired), which included controlling interests in two surgical facilities in existing markets that were merged into existing facilities. Additionally, we received cash proceeds of $2.3 million related to the disposal of certain long-lived assets.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash used in financing activities during the three months ended March&#160;31, 2022 was $43.7 million. During this period, we made distributions to non-controlling interest holders of $36.2 million and made payments related to ownership transactions with consolidated affiliates of $3.1 million. We repaid $17.0 million of our long-term debt and had borrowings on long-term debt of $11.9 million. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash provided by financing activities during the three months ended March 31, 2021 was $187.8 million. During this period, we received gross proceeds of $260.9 million from an equity offering which was partially offset by equity offering costs paid of $12.6 million. We made distributions to non-controlling interest holders of $31.3 million and received proceeds related to ownership transactions with consolidated affiliates of $1.0 million. We repaid $16.6 million of our long-term debt, which was offset by borrowings of $0.6 million. We also paid a cash dividend of $5.1 million related to the Series A preferred stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Debt</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the carrying value of our total indebtedness was $3.093 billion, which includes unamortized fair value discount of $2.8 million and unamortized deferred financing costs and issuance discount of $15.8 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Term Loan and Revolving Credit Facility</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had term loan borrowings with a carrying value of $1.527 billion, consisting of outstanding aggregate principal of $1.530 billion and unamortized fair value discount of $2.8 million (the "Term Loan"). The Term Loan matures on August 31, 2026 (or, if at least $185 million of the Borrower&#8217;s 6.750% senior unsecured notes due 2025 shall have not either been repaid, repurchased or redeemed or refinanced with indebtedness having a maturity date not earlier than 91 days after August 31, 2026 by no later than April 1, 2025, then April 1, 2025) and amortizes in equal quarterly installments of 0.25% of the aggregate original principal amount.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have a revolving credit facility providing for revolving borrowings of up to $210.0 million ("the Revolver" and, together with the Term Loan, the "Senior Secured Credit Facilities"). The Revolver will mature on February 1, 2026. As of March&#160;31, 2022, our availability on the Revolver was $203.0 million (including outstanding letters of credit of $7.0 million).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Revolver may be utilized for working capital, capital expenditures and general corporate purposes. Subject to certain conditions and requirements set forth in the credit agreement, we may request one or more additional incremental term loan facilities or one or more increases in the commitments on the Revolver.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities bear interest at a rate per annum equal to (x) LIBOR plus a margin of 3.75% per annum (LIBOR with respect to the Term Loan shall be subject to a floor of 0.75%) or (y) an alternate base rate (which will be the highest of (i) the prime rate, (ii) 0.5% per annum above the federal funds effective rate and (iii) one-month LIBOR plus 1.00% per annum (the alternate base rate with respect to the Term Loan shall be subject to a floor of 1.75%)) plus a margin of 2.75% per annum. In addition, we are required to pay a commitment fee of 0.50% per annum in respect of unused commitments under the Revolver.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have $545.0 million aggregate principal amount of senior unsecured notes due April 15, 2027, which bear interest at the rate of 10.000% per year, payable semi-annually on April 15 and October 15 of each year.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have $370.0 million aggregate principal amount of senior unsecured notes due July 1, 2025, which bear interest at the rate of 6.750% per year, payable semi-annually on January 1 and July 1 of each year.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Debt</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We and certain of our subsidiaries have other debt consisting of outstanding bank indebtedness of $159.3 million, which is collateralized by the real estate and equipment owned by the surgical facilities to which the loans were made, and right-of-use finance lease obligations of $507.7 million for which we are liable to various vendors for several property and equipment leases classified as finance leases.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Material Cash Requirements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the cash requirements related to our long-term debt, operating lease obligations and the tax receivable agreement, pursuant to the CARES Act, repayment of certain advanced payments and other deferrals received as part of relief during 2020 will continue during 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We received approximately $120&#160;million of accelerated payments during the year ended December 31, 2020. Through March&#160;31, 2022, approximately $78&#160;million has been repaid including approximately $18&#160;million during the three months ended March 31, 2022. In addition to the continued repayment of the advanced payments received under the CARES Act, we anticipate additional cash outflows during 2022 for the repayment of the remaining payroll taxes deferred in 2020 pursuant to the CARES Act. See Note 1. "Organization and Summary of Accounting Policies" for a further discussion of the accelerated payments and payroll tax deferral.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Capital Resources</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to cash flows from operations, available cash and capacity on our Revolver, other sources of capital include funds we have received under the CARES Act as well as continued access to the capital markets. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Summary</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The COVID-19 pandemic has resulted in, and may continue to result in, significant disruptions of financial and capital markets, which could reduce our ability to access capital and negatively affect our liquidity in the future. Additionally, while we have received grants and accelerated payments under the CARES Act and other government assistance programs and may receive additional amounts in the future, there is no assurance regarding the extent to which anticipated negative impacts arising from the COVID-19 pandemic will be offset by amounts and benefits received under the CARES Act or future legislation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Although we have seen continued improvement in surgical case volumes as states re-opened and allowed for non-emergent procedures, broad economic factors resulting from the ongoing COVID-19 pandemic could negatively affect our payor mix, increase the relative proportion of lower margin services we provide and reduce patient volumes, as well as diminish our ability to collect outstanding receivables. Business closings and layoffs in the areas in which we operate may lead to increases in the uninsured and underinsured populations and adversely affect demand for our services, as well as the ability of payors to pay for services as rendered. Any increase in the amount or deterioration in the collectability of patient accounts receivable will adversely affect our cash flows and results of operations, requiring an increased level of working capital. If general economic conditions continue to deteriorate or remain uncertain for an extended period of time, our liquidity and ability to repay our outstanding debt may be harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Based on our current level of operations, we believe cash flows from operations, available cash, available capacity on our Revolver, funds we have received under the CARES Act, funds we may receive in the future and continued access to capital markets, will be adequate to meet our short-term (i.e., 12 months) and long-term (beyond 12 months) liquidity needs.</span></div><div id="i8d24edc59a384ef08748223de247b6a7_88"></div><div style="margin-bottom:5pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Certain Non-GAAP Measures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjusted EBITDA and Adjusted EBITDA excluding grant funds are not measurements of financial performance under GAAP and should not be considered in isolation or as a substitute for net income, operating income or any other measure calculated in accordance with GAAP. The items excluded from these non-GAAP metrics are significant components in understanding and evaluating our financial performance. We believe such adjustments are appropriate, as the magnitude and frequency of such items can vary significantly and are not related to the assessment of normal operating performance. Our calculation of Adjusted EBITDA and Adjusted EBITDA excluding grant funds may not be comparable to similarly titled measures reported by other companies. We use Adjusted EBITDA and Adjusted EBITDA excluding grant funds as measures of financial performance. Adjusted EBITDA and Adjusted EBITDA excluding grant funds are key measures used by our management to assess operating performance, make business decisions and allocate resources.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table reconciles Adjusted EBITDA and Adjusted EBITDA excluding grant funds to income before income taxes, the most directly comparable GAAP financial measure (in millions and unaudited):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Condensed Consolidated Statements of Operations Data:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Plus (minus):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction, integration and acquisition costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on disposals and deconsolidations, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on litigation settlement and other litigation costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Impact of grant funds </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjusted EBITDA excluding grant funds</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount includes transaction and integration costs of $7.1 million and $5.3 million for the three months ended March&#160;31, 2022 and 2021, respectively. This amount further includes start-up costs related to a de novo surgical hospital of $4.1 million for the three months ended March 31, 2021. </span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount includes other litigation costs of $2.0 million and $1.0 million for the three months ended March&#160;31, 2022 and 2021, respectively. This amount also includes a litigation settlement gain of $32.8 million for the three months ended March&#160;31, 2022, with no comparable activity in the 2021 period.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Represents the impact of grant funds recognized, net of amounts attributable to non-controlling interests.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We use Credit Agreement EBITDA as a measure of liquidity and to determine our compliance under certain covenants pursuant to our credit facilities. Credit Agreement EBITDA is determined on a trailing twelve-month basis. We have included it because we believe that it </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">provides investors with additional information about our ability to incur and service debt and make capital expenditures. Credit Agreement EBITDA is not a measurement of liquidity under GAAP and should not be considered in isolation or as a substitute for any other measure calculated in accordance with GAAP. The items excluded from Credit Agreement EBITDA are significant components in understanding and evaluating our liquidity. Our calculation of Credit Agreement EBITDA may not be comparable to similarly titled measures reported by other companies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">When we use the term &#8220;Credit Agreement EBITDA,&#8221; we are referring to Adjusted EBITDA, as defined above, further adjusted for acquisitions and synergies. These adjustments do not relate to our historical financial performance and instead relate to estimates compiled by our management and calculated in conformance with the definition of &#8220;Consolidated EBITDA&#8221; used in the credit agreements governing our credit facilities. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table reconciles Credit Agreement EBITDA to cash flows from operating activities, the most directly comparable GAAP financial measure (in millions and unaudited):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended March 31, 2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Plus (minus):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of unconsolidated affiliates, net of distributions received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of acquisitions and divestitures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(140.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction, integration and acquisition costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Litigation settlement and other litigation costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hurricane-related impacts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions and synergies </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Credit Agreement EBITDA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">415.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Reflects the impact of insurance proceeds received net of operating losses incurred in the six months ended December 31, 2021, at a surgical facility that was closed following Hurricane Ida.</span></div><div style="margin-bottom:9pt;margin-top:1pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Represents impact of acquisitions as if each acquisition had occurred on April 1, 2021. Further this includes revenue and cost synergies from other business initiatives and de novo facilities and an adjustment for the effects of adopting the new lease accounting standard, as defined in the credit agreement governing the Senior Secured Credit Facilities.</span></div><div id="i8d24edc59a384ef08748223de247b6a7_94"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 3.  Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are subject to market risk primarily from exposure to changes in interest rates based on our financing, investing and cash management activities.&#160;We utilize a balanced mix of maturities along with both fixed rate and variable rate debt to manage our exposures to changes in interest rates.&#160;Additionally, we periodically enter into interest rate swap and cap agreements to manage our exposure to interest rate fluctuations. Our interest rate swap and cap agreements involve the exchange of fixed and variable rate interest payments between two parties, based on common notional principal amounts and maturity dates. The notional amounts of the interest rate swap and cap agreements represent balances used to calculate the exchange of cash flows and are not our assets or liabilities. Our credit risk related to these agreements is considered low because the interest rate swap and cap agreements are with creditworthy financial institutions. The interest payments under these agreements are settled on a net basis. These derivatives have been recognized in the financial statements at their respective fair values. Changes in the fair value of these derivatives, which are designated as cash flow hedges, are included in other comprehensive income.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our variable rate debt instruments are primarily indexed to the prime rate or LIBOR.&#160;Without derivatives, interest rate changes would result in gains or losses in the market value of our fixed rate debt portfolio due to differences in market interest rates and the rates at the inception of the debt agreements. Based on our indebtedness and the effectiveness of our interest rate swap and cap agreements at March&#160;31, 2022, we do not expect changes in interest rates to have a material effect on our net earnings or cash flows in 2022.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i8d24edc59a384ef08748223de247b6a7_97"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 4.  Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">An evaluation was performed under the supervision and with the participation of our management, including the chief executive officer and the chief financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended) as of March&#160;31, 2022. Based on that evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective. </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended March&#160;31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i8d24edc59a384ef08748223de247b6a7_100"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div id="i8d24edc59a384ef08748223de247b6a7_103"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Stockholder Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.  Please refer to the disclosure in Note 8. "Commitments and Contingencies - Stockholder Litigation" to our condensed consolidated financial statements included elsewhere in this report, which is incorporated into this item by reference.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Litigation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  In addition, we are, from time to time, subject to claims and suits, or threats of claims or suits, relating to our business, including claims for damages for personal injuries, breach of management contracts and employment related claims. In certain of these actions, plaintiffs request payment for damages, including punitive damages, which may not be covered by insurance or may otherwise have a material adverse effect on our business or results of operations.</span></div><div id="i8d24edc59a384ef08748223de247b6a7_106"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1A.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There have been no material changes with respect to the risk factors discussed in our 2021 Annual Report on Form 10-K.</span></div><div id="i8d24edc59a384ef08748223de247b6a7_109"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company did not repurchase any shares of common stock during the three months ended March 31, 2022. At March 31, 2022, the Company continued to have authority to repurchase up to $46.0 million of shares of common stock under its Board-authorized share repurchase program.</span></div><div id="i8d24edc59a384ef08748223de247b6a7_112"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 3.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Defaults Upon Senior Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None.</span></div><div id="i8d24edc59a384ef08748223de247b6a7_115"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 4.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Mine Safety Disclosures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i8d24edc59a384ef08748223de247b6a7_118"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 5.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Other Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i8d24edc59a384ef08748223de247b6a7_121"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 6.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.905%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q1exhibit101.htm">Amended and Restated Employment Agreement, effective as of March 11, 2022, between Surgery Partners, Inc. and Jennifer Baldock.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q1exhibit102.htm">Amended and Restated Employment Agreement, effective as of March 8, 2022, between Surgery Partners, Inc. and Anthony W. Taparo.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q1exhibit103.htm">Amended and Restated Employment Agreement, effective as of March 8, 2022, between Surgery Partners, Inc. and Bradley Owens.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883322000002/a20220110dohertyexecutivee.htm">Employment Agreement, dated January 7, 2022, by and between Surgery Partners, Inc. and David T. Doherty (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883322000002/a20220110dohertyexecutivee.htm">K </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883322000002/a20220110dohertyexecutivee.htm">filed January 10, 2022).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883322000019/ye2021exhibit1041.htm">Retirement and Con</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883322000019/ye2021exhibit1041.htm">sulting </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883322000019/ye2021exhibit1041.htm">Agreement, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883322000019/ye2021exhibit1041.htm">February 25</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883322000019/ye2021exhibit1041.htm">, 2022, by and between Surgery Partners, Inc. and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883322000019/ye2021exhibit1041.htm">George M. Goodwin</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883322000019/ye2021exhibit1041.htm"> (incorporated herein by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883322000019/ye2021exhibit1041.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883322000019/ye2021exhibit1041.htm">1 to the Company's </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883322000019/ye2021exhibit1041.htm">Annual</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883322000019/ye2021exhibit1041.htm"> Report on Form </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883322000019/ye2021exhibit1041.htm">10</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883322000019/ye2021exhibit1041.htm">-K filed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883322000019/ye2021exhibit1041.htm">March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883322000019/ye2021exhibit1041.htm"> 1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883322000019/ye2021exhibit1041.htm">, 2022).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q1exhibit311.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q1exhibit312.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q1exhibit321.htm">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Instance Document - the instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The cover page from the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, formatted in Inline XBRL (included in Exhibit 101).</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i8d24edc59a384ef08748223de247b6a7_124"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8d24edc59a384ef08748223de247b6a7_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:12pt;margin-top:5pt;padding-left:180pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:304.50pt"><tr><td style="width:1.0pt"></td><td style="width:22.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SURGERY PARTNERS,&#160;INC.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">/s/  David T. Doherty</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">David T. Doherty</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date: May&#160;3, 2022 </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>a2022q1exhibit101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3c1c57e2401f4e62a5b3c798678bfc16_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-bottom:12pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">AMENDED AND RESTATED EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is hereby entered into effective as of March 11, 2022 (the &#8220;Effective Date&#8221;), between Surgery Partners, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and Jennifer Baldock (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company shall employ Executive, and Executive hereby accepts continued employment with the Company, upon the terms and conditions set forth in this Agreement for the period beginning on March 11, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and ending on the Termination Date, as provided for in Section 4 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Position and Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">During the Employment Period, Executive shall serve as Executive Vice President, Chief Administrative and Development Officer and General Counsel of the Company reporting to the CEO.  Executive shall have such responsibilities, duties and authorities, and will render such services for the Company and its Subsidiaries or Affiliates as the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) may from time to time direct.  Executive will devote his best efforts, energies and abilities and his&#47;her full business time, skill and attention to the business and affairs of the Company and its Subsidiaries, and shall perform his&#47;her duties and responsibilities to the best of his&#47;her ability, in a diligent, trustworthy, businesslike and efficient manner for the purpose of advancing the businesses of Company and its Subsidiaries.  Executive acknowledges that his&#47;her duties and responsibilities will require his&#47;her full time business efforts and agrees that during the Employment Period he&#47;she will not engage in any other business activity or have any business pursuits that interfere with Executive&#8217;s duties and responsibilities under this Agreement or are competitive with the businesses of the Company.  Notwithstanding the foregoing, Executive shall be permitted to devote a reasonable amount of time and effort to (i) providing service to, or serving on governing boards of, civic and charitable organizations, and (ii) personally investing and managing personal and family investments in real estate and in any corporation, partnership or other entity&#59; but in each case, only to the extent that any of the activities described in clauses (i) or (ii), individually or as a whole, do not (A) require or involve the active participation of Executive in the management of any corporation, partnership or other entity or interfere with the execution of Executive&#8217;s duties hereunder, or (B) otherwise violate any provision of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">For purposes of this Agreement, (i) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any corporation or other entity (A) of which the securities or other ownership interests having the voting power to elect a majority of the board of directors or other governing body are, at the time of determination, owned by the Company, directly or through one or more subsidiaries or (B) to which the Company or any of its Affiliates provide management services, and (ii) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; of an entity means any other person or entity, directly or indirectly controlling, controlled by or under common control with an entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Compensation and Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">Effective March 27, 2022, during the Employment Period, Executive&#8217;s base salary shall increase from $420,000 to $535,000 per annum, payable by the Company in regular installments in accordance with the Company&#8217;s general payroll practices, less taxes and other applicable withholdings, and subject to review and adjustment from time to time by the Board or the Compensation Committee thereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), in either case, in its discretion (as modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">In addition, during the Employment Period, Executive shall be entitled to participate in all of the Company&#8217;s benefit programs for which employees of the Company are generally eligible, subject to the eligibility and participation requirements thereof, including, but not limited to, the following&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.69pt">medical, dental, vision, life and disability insurance, as is generally provided to other employees of the Company&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">eligibility for vacation time in accordance with the policies of the Company as from time to time in effect.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.03pt">participation in the existing Symbion, Inc. supplemental Executive Retirement Plan, or its equivalent or a successor plan, with a minimum of a two percent (2%) match for executive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">During the Employment Period, the Company shall reimburse Executive for all reasonable out-of-pocket expenses incurred by his&#47;her in the course of performing his&#47;her duties and responsibilities under this Agreement which are consistent with the Company&#8217;s policies in effect from time to time with respect to travel, entertainment and other business expenses, subject to the Company&#8217;s requirements with respect to reporting and documentation of such expenses. Executive&#8217;s right to payment or reimbursement for business expenses hereunder will be subject to the following additional rules&#58; (i) no reimbursement of any expense shall affect Executive&#8217;s right to reimbursement of any other expense in any other taxable year&#59; (ii) the amount of expenses eligible for payment or reimbursement during any calendar year will not affect the expenses eligible for payment or reimbursement in any other taxable year&#59; (iii) payment or reimbursement will be made not later than December 31 of the calendar year following the calendar year in which the expense was incurred or paid, and (iv) the right to payment or reimbursement is not subject to liquidation or exchange for any other benefit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">In addition to the Base Salary, Executive will be eligible to receive an annual bonus of eighty percent (80%) of the Base Salary, with the actual amount of any such bonus being determined by the Board or the Committee, in either case, in its discretion, based on the achievement of performance goals established annually by the Board or the Committee, as applicable.  Any annual bonus payable under this Section 3(d) will be paid no later than March 31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> following the close of the year for which the bonus is earned.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">Executive shall be eligible to participate in the Surgery Partners, Inc. 2015 Omnibus Incentive Plan (as amended from time to time, (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Equity Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) on terms and conditions set forth therein and in the relevant award agreement unless specifically stated otherwise in this Agreement. Executive will be eligible for annual equity grants under the Equity Plan. Initially, the targeted equity grant will be $800,000, subject to approval of the Board (or an authorized committee thereof), in such forms as determined by the Board or its designee in its discretion.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.03pt">All amounts payable to Executive hereunder shall be subject to all required withholdings by the Company.  If additional guidance is issued under, or modifications are made to, Section 409A of the Internal Revenue Code of the Internal Revenue Code and the regulations and other interpretive guidance issued thereunder (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), or any other law affecting payments to be made under this Agreement, Executive agrees that the Company may take such reasonable actions and adopt such reasonable amendments as the Company believes are necessary to ensure continued compliance with the Internal Revenue Code, including Section 409A.  However, the Company does not hereby or otherwise represent or warrant that any payments hereunder are or will be in compliance with Section 409A, and Executive shall be responsible for obtaining his&#47;her own tax advice with regard to such matters.  </font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination by Executive or the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Employment Period (i) shall terminate upon Executive&#8217;s resignation with Good Reason (as defined below) or without Good Reason, death or Incapacity (as defined below) or (ii) may be terminated by the Company at any time for Cause (as defined below) or without Cause.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean without the written consent of Executive&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.69pt">without the express written consent of Executive, a material diminution of his&#47;her position, duties, responsibilities, and status with the Company as in effect as of the Commencement Date (except Executive expressly agrees that this Section 4(b)(i) shall not be triggered by any removal of Executive&#8217;s position, duties, responsibilities of either Chief Development Officer or Chief Administrative Officer and General Counsel) or a material reduction of Executive&#8217;s resources as in effect on the Commencement Date&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">a material reduction in Executive&#8217;s Base Salary or annual bonus target percentage&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.03pt">a material reduction in the level of benefits available or awarded to Executive, other than any reduction in connection with a Company-wide reduction applicable generally to similarly situated executive officers of the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">within twelve months of a Change in Control (as defined herein), a material increase in Executive&#8217;s core functional responsibilities with a corresponding material change in Executive&#8217;s core functional role without a corresponding increase in compensation, provided, however, the addition of additional facilities or territories to Executive&#8217;s oversight responsibilities or other ordinary course growth of the Company or any of its Subsidiaries or Affiliates shall not be a material increase in Executive&#8217;s core functional responsibilities&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">a relocation by the Company of Executive&#8217;s primary employment location to a location which is more than 50 miles from Executive&#8217;s primary employment location on the date hereof&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">a material breach by the Company of the terms of this Agreement, which shall include, without limitation, a change from Executive reporting directly to the CEO&#59; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">but only if (x) Executive notifies the Company in writing within 90 days after the initial existence or occurrence of any of these conditions which notice describes in reasonable detail the basis for Executive&#8217;s belief that Good Reason exists and that Executive intends to resign for Good Reason and the Company, within 30 days after receipt of such notice, either fails to cure the condition or delivers a written notice to Executive that the Company intends not to cure such condition and (y) Executive actually resigns prior to 15 days after the earlier to occur of either the end of such 30-day cure period or delivery of such written notice by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Incapacity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as used herein shall mean that Executive is unable to perform, with or without reasonable accommodation, by reason of physical or mental incapacity, the essential duties, responsibilities and functions of his&#47;her position.  A medical examination by a physician selected by the Company to whom Executive or his&#47;her duly appointed guardian, if any, has no reasonable objection shall determine, according to the facts then available, whether and when Incapacity has occurred.  Such determination shall not be arbitrary or unreasonable, and shall be final and binding on the parties hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as used herein means the occurrence of any of the following events&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.69pt">a material breach by Executive of any of the terms and conditions of this Agreement&#59; provided that, if curable, Executive shall have a reasonable period of time (which in no event shall exceed 45 days) during which to cure such material breach following the date on which Executive receives the Company&#8217;s written notice of such material breach&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">Executive&#8217;s reporting to work (A) intoxicated (other than Executive&#8217;s reasonable use of alcohol in connection with business entertainment, provided, that such use of alcohol does not cause the Company or any of its Subsidiaries or Affiliates substantial public disgrace or disrepute or economic harm) or (B) under the influence of illegal drugs&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.03pt">Executive&#8217;s use of illegal drugs (whether or not at the workplace) or other conduct causing the Company or any of its Subsidiaries or Affiliates substantial public disgrace or disrepute or economic harm&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">breach of fiduciary duty, gross negligence or willful misconduct with respect to the Company or any of its Subsidiaries or Affiliates&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">chronic absenteeism, which shall be deemed to have occurred if Executive has at least ten absences unrelated to paid time off, disability or illness in any ten week period&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">Executive&#8217;s material failure or willful refusal to substantially perform his&#47;her duties, responsibilities and functions&#59; provided that, if curable, Executive shall have a reasonable period of time (which in no event shall exceed 45 days) during which to cure such failure following the date on which Executive receives the Company&#8217;s written notice of such failure&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.36pt">Executive&#8217;s failure to comply with any of the Company&#8217;s or any of its Subsidiaries&#8217; written guidelines or procedures promulgated by the Company or any such Subsidiary and furnished to Executive, including, without limitation, any guidelines or procedures relating to marketing or community relations&#59; provided that, if curable, Executive shall have a reasonable period of time (which in no event shall exceed 45 days) during which to cure such failure following the date on which Executive receives the Company&#8217;s written notice of such failure&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:12.03pt">Executive has committed an act or acts constituting a felony or any other act or omission involving theft, dishonesty or fraud against the Company or any of its Subsidiaries or any of their respective customers or suppliers or other business relationships.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">A &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall be deemed to have occurred upon any of the following events, provided that, to the extent required by Section 409A, such events would also qualify as a &#8220;change in control event&#8221; under Treas. Reg. &#167;1.409A-3(i)(5)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.69pt">Upon the closing of a reorganization, merger, share exchange or consolidation, other than a reorganization, merger, share exchange or consolidation with respect to which those persons who were the beneficial owners, immediately prior to such reorganization, merger, share exchange or consolidation, of outstanding securities of the Company ordinarily having the right to vote in the election of directors own, immediately after the closing of such transaction, more than 51% of the outstanding securities of the resulting corporation ordinarily having the right to vote in the election of directors&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">Upon approval by the stockholders of a complete liquidation and dissolution of the Company or the sale or other disposition of all or substantially all of the assets of the Company other than to a Subsidiary or Affiliate.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-4-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Termination by Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive has the right to terminate his&#47;her employment under this Agreement at any time, for any or no reason, but only after giving the Company (i) 30 days prior written notice with respect to any termination without Good Reason or (ii) the number of days prior written notice set forth in the last sentence of Section 4(b) with respect to any termination with Good Reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Compensation after Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.69pt">If the Employment Period is terminated pursuant to Executive&#8217;s resignation without Good Reason, death or Incapacity, Executive shall only be entitled to receive his&#47;her Base Salary through the date of termination and shall not be entitled to any other salary, bonus, compensation or benefits from the Company or its Subsidiaries, except as may be required by applicable law.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">If the Employment Period is terminated by the Company for Cause, Executive shall only be entitled to his&#47;her Base Salary through the date of termination and shall not be entitled to any other salary, bonus, compensation or benefits from the Company or its Subsidiaries, except as may be required by applicable law.  In addition, in such event, Executive shall automatically forfeit any rights to any unvested equity owned by Executive in the Company or any Subsidiary.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.03pt">If the Employment Period is terminated by the Company without Cause or by Executive for Good Reason, then subject to the conditions described in Section 4(g)(v) below, Executive shall be entitled to receive as severance compensation the following (collectively, &#8220;Severance Pay&#8221;)&#58; (A) an amount equal to twelve (12) months of Executive&#8217;s then-current annual Base Salary, payable in regular installments beginning within 30 days following the Termination Date in accordance with the Company&#8217;s general payroll practices for salaried employees&#59; (B) continuation of the welfare benefits described in Section 3(b) for twelve (12) months to the extent permissible under the terms of the relevant benefit plans at the same cost to Executive as if Executive were an active employee of the Company&#59; (C) the Bonus payable to Executive within 3 months after the end of the then current year, paid in a lump sum&#59; (D) with respect to the portion of each restricted stock award held by Executive as of date on which the Employment Period is terminated that is subject to time-based vesting (the &#8220;Time-Based RSA&#8221;), accelerated vesting of the Time-Based RSA to the vesting event next following the date on which the Employment Period is terminated&#59; and (E) with respect to the portion of each performance stock unit award held by the Executive as of the date on which the Employment Period is terminated that has been converted into &#8220;earned shares&#8221; (the &#8220;Earned PSUs&#8221;), accelerated vesting of the Earned PSUs to the vesting event next following the date on which the Employment Period is terminated&#59; and (F) with respect to each performance stock unit award issued after December 31, 2021, held by the executive as of the date on which the Employment Period ends that have not been converted to Earned PSUs, the Executive&#8217;s rights under the award will be fully vested based on the number of shares that would be earned under the award based on performance measured through the end of Employment Period.  For purposes of this Section 4(g), &#8220;Bonus&#8221; shall mean an amount equal to Executive&#8217;s then-current annual Base Salary, multiplied by the percentage contained in Section 3(d) hereof. For the avoidance of doubt, the unvested portion of any restricted stock awards and performance share unit awards held by Executive as of the date on which the Employment Period ends (after giving effect to the acceleration provisions set forth in subsections (D), (E) and (F) herein and the terms and conditions of the applicable award agreements and the Surgery Partners, Inc. 2015 Omnibus Incentive Plan (as amended from time to time)) shall be forfeited and of no further force and effect.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">If, within 90 days prior to or 12 months following a Change in Control, either (A) the Company terminates the employment of Executive hereunder without Cause under Section 4(a) above, or (B) Executive terminates his&#47;her employment for Good Reason under Section 4(b) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-5-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">above, then, in lieu of any other compensation that may be specified in this Agreement, the Company will pay Executive the Severance Pay in a single lump-sum payment not later than 30 days after termination.  If any payment obligation under this Section 4(g) arises, no compensation received from other employment (or otherwise) will reduce the Company&#8217;s obligation to make the payment(s) described in this paragraph.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">Notwithstanding Sections 4(g)(iii) or (iv), Executive&#8217;s right to receive Severance Pay hereunder is conditioned upon&#58; (A) Executive executing, and not revoking, a written separation agreement and general release of all claims against the Company, its Subsidiaries and Affiliates and their respective managers, directors, officers, shareholders, members, representatives, agents, attorneys, predecessors, successors and assigns (other than a claim for the severance payments described in Section 4(g)(iii) or (iv) and Executive&#8217;s rights to future distributions and payments related to the continued ownership of any equity securities in the Company that Executive will continue to own after such termination), in form and substance acceptable to the Company, which shall among other things, contain a general release by Executive of all claims arising out of his&#47;her employment and termination of employment by the Company (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Release Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) within 30 days of Executive&#8217;s Termination Date&#59; and (B) Executive&#8217;s material compliance with all of his&#47;her obligations which survive termination of this Agreement.  The Severance Pay is intended to be in lieu of all other payments to which Executive might otherwise be entitled in respect of his&#47;her termination without Cause or resignation with Good Reason.  The Company and its Subsidiaries and Affiliates shall have no further obligations hereunder or otherwise with respect to Executive&#8217;s employment from and after the date of termination of employment with the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and the Company and its Subsidiaries and Affiliates shall continue to have all other rights available hereunder (including without limitation, all rights hereunder at law or in equity).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">Notwithstanding the foregoing, the Release Agreement (x) shall not require the release of Executive&#8217;s rights arising from the express terms of this Agreement or any applicable award agreement that are associated with a termination of employment&#59; (y) shall not impose any postemployment restrictions other than those set forth in this Agreement, and (z) shall take into account and preserve Executive&#8217;s rights in the event that a Change in Control occurs within 90 days after termination of employment (or such longer tail period as may be provided by any agreement between Executive and the Company).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.36pt">Except as otherwise expressly provided herein, all of Executive&#8217;s rights to salary, bonuses, benefits and other compensation hereunder which might otherwise accrue or become payable after the termination of the Employment Period shall cease upon such termination, other than those expressly required under applicable law (such as COBRA).  All amounts payable to Executive as severance hereunder shall be subject to all required withholdings by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company may offset any amount Executive owes the Company or its Subsidiaries or Affiliates against any amount they or their Subsidiaries or Affiliates owe Executive hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Confidential Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other than in the performance of his&#47;her duties hereunder, during the Restrictive Period (as defined below) and thereafter, Executive shall keep secret and retain in strictest confidence, and shall not, without the prior written consent of the Company, furnish, make available or disclose to any third party or use for the benefit of himself or any third party, any Confidential Information.  As used in this Agreement, &#8220;Confidential Information&#8221; shall mean any information relating to the business or affairs of the Company or any of its Subsidiaries or Affiliates or the Business, including but not limited to any technical or non-technical data, formulae, compilations, programs, devices, methods, techniques, designs, processes, procedures, improvements, models, manuals, financial data, acquisition strategies and information, information relating to operating procedures and marketing strategies, and any other proprietary information used by the Company or any of its Subsidiaries or Affiliates in connection with the Business, irrespective of its form&#59; provided, however, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-6-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that Confidential Information shall not include any information which is in the public domain or becomes known in the industry, in each case through no wrongful act on the part of Executive.  Executive acknowledges that the Confidential Information is vital, sensitive, confidential and proprietary to the Company and its Subsidiaries and Affiliates.  Executive will immediately notify the Company of any unauthorized possession, use, disclosure, copying, removal or destruction, or attempt thereof, of any Confidential Information by anyone of which Executive becomes aware and of all details thereof.  Executive shall take all reasonably appropriate steps to safeguard Confidential Information and to protect it against disclosure, misuse, espionage, loss and theft.  Executive shall deliver to the Company at the termination or expiration of the Employment Period, or at any other time the Company may request, all memoranda, notes, plans, records, reports, computer tapes, computers, printouts and software and other documents and data (and copies thereof) embodying or relating to the Confidential Information, Inventions and Discoveries (as defined below) or the business of the Company or any of its Subsidiaries or Affiliates which Executive may then possess or have under his&#47;her control.  Nothing in this Agreement limits, restricts or in any other way affects Executive&#8217;s communicating with any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, concerning matters relevant to the governmental agency or entity, or requires Executive to provide notice to the Company of the same.  Executive cannot be held criminally or civilly liable under any federal or state trade secret law for disclosing a trade secret (1) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating a suspended violation of law, or (2) in a compliant or other document filed under seal in a lawsuit or other proceeding.  Notwithstanding this immunity from liability, Executive may be held liable if Executive unlawfully accesses trade secrets by unauthorized means.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as used herein means the business of owning, operating, developing and&#47;or managing, or providing management or administrative services to, (a) ambulatory surgery centers anywhere in the United States or (b) physician-owned surgical hospitals within a 50 mile radius of any hospital that is owned, operated, developed or managed by the Company or any Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Inventions and Discoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">Executive understands and agrees that all inventions, discoveries, ideas, improvements, whether patentable, copyrightable or not, pertaining to the Business or relating to Company&#8217;s or any of its Subsidiaries&#8217; or Affiliates&#8217; actual or demonstrably anticipated research, development or inventions (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Inventions and Discoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that result from any work performed by Executive solely or jointly with others for the Company or any of its Subsidiaries or Affiliates which Executive, solely or jointly with others, conceives, develops, or reduces to practice during the course of Executive&#8217;s employment with the Company or any of its Subsidiaries, are the sole and exclusive property of the Company.  Executive will promptly disclose all such matters to the Company and will assist the Company in obtaining legal protection for Inventions and Discoveries.  Executive hereby agrees on behalf of himself, his&#47;her executors, legal representatives and assignees that he&#47;she will assign, transfer and convey to the Company, its successors and assigns the Inventions and Discoveries.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">THE COMPANY AND EXECUTIVE ACKNOWLEDGE AND AGREE THAT SECTION 6(a) SHALL NOT APPLY TO AN INVENTION OF EXECUTIVE FOR WHICH NO EQUIPMENT, SUPPLIES, FACILITY OR TRADE SECRET INFORMATION OF THE COMPANY OR ANY OF ITS SUBSIDIARIES WAS USED AND WHICH WAS DEVELOPED ENTIRELY ON EXECUTIVE&#8217;S OWN TIME, UNLESS (A) THE INVENTION RELATED (I) TO THE BUSINESS OF THE COMPANY OR ANY OF ITS SUBSIDIARIES OR AFFILIATES OR (II) TO THE COMPANY&#8217;S OR ANY OF ITS SUBSIDIARIES&#8217; OR AFFILIATES&#8217; ACTUAL OR DEMONSTRABLY ANTICIPATED RESEARCH OR DEVELOPMENT, OR (B) THE INVENTION RESULTS FROM ANY WORK PERFORMED BY EXECUTIVE FOR THE COMPANY OR ANY OF ITS SUBSIDIARIES OR AFFILIATES.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-7-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">EXECUTIVE ACKNOWLEDGES THAT HE&#47;SHE HAS READ THIS SECTION 6 AND FULLY UNDERSTANDS THE LIMITATIONS WHICH IT IMPOSES UPON HIM AND HAS RECEIVED A DUPLICATE COPY OF THIS AGREEMENT FOR HIS&#47;HER RECORDS.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive acknowledges that in the course of his&#47;her employment with the Company or any of its Subsidiaries or Affiliates, or their predecessors or successors, he&#47;she has been and will be given access to and has and will become familiar with their trade secrets and with other Confidential Information and that his&#47;her services have been and shall be of special, unique and extraordinary value to the Company and its Subsidiaries or Affiliates.  Therefore, and in further consideration of the compensation to be paid to Executive hereunder and in connection with his&#47;her employment, and to protect the Company&#8217;s and its Subsidiaries&#8217; and Affiliates&#8217; Confidential Information, business interests and goodwill&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Non-compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive hereby agrees that for a period commencing on the date hereof and ending on the Termination Date, and thereafter, through the period ending twelve (12) months after the Termination Date (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictive Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), he&#47;she shall not, directly or indirectly, as employee, agent, consultant, stockholder, director, co-partner or in any other individual or representative capacity, own, operate, manage, control, engage in, invest in or participate in any manner in, act as a consultant or advisor to, render services for (alone or in association with any person, firm, corporation or entity), or otherwise assist any person or entity (other than the Company and its Subsidiaries) that engages in or owns, invests in, operates, manages or controls any venture or enterprise that directly or indirectly engages or is actively developing or attempting to develop in any element of the Business anywhere within a 50-mile radius of the Nashville, Tennessee metropolitan area or within a 50-mile radius of any area (or in the event such area is a major city, the metropolitan area relating to such city) in which the Company or any of its Subsidiaries on the Termination Date actively engages or is actively developing or attempting to develop in any element of the Business (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; provided, however, that nothing contained herein shall be construed to prevent Executive from investing in the stock of any competing corporation listed on a national securities exchange or traded in the over-the-counter market, but only if Executive is not involved in the business of said corporation and if Executive and his&#47;her associates (as such term is defined in Regulation 14(A) promulgated under the Securities Exchange Act of 1934, as in effect on the date hereof), collectively, do not own more than an aggregate of 3% of the stock of such corporation&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and provided further that nothing contained here shall be construed to prevent Executive from being a partner in, employed by or consulting with a law firm that represents clients that, if Executive were employed by or otherwise work directly with such clients, would be a violation of this Agreement so long as Executive is not assigned by the law firm to work directly with such clients.  With respect to the Territory, Executive specifically acknowledges that the Company and its Subsidiaries intend to expand the Business into and throughout the United States.  Notwithstanding the foregoing, the activity proscribed by this Section 7(a) shall not constitute a violation of this Section 7(a) where performed for (x) an entity where no more than a de minimis amount of revenue is derived from a business that is competitive with the business of the Company or any of its Affiliates&#59; or (y) an entity that derives no more than $100 million in revenue from one or more divisions, departments or segments, in the aggregate, that are engaged in any business competitive with the business of the Company or any of its Affiliates&#59; provided, that in either case, you are not responsible for (and do not engage or participate in) the day-to-day management, oversight or supervision of such business and provided you do not have direct supervision over the individual or individuals who are so responsible for such day-to-day management, oversight or supervision.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Interference with Relationships</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Without limiting the generality of the provisions of Section 7(a) hereof, Executive hereby agrees that, for a period commencing on the Commencement Date and ending on the Termination Date, and thereafter, through the period ending twelve (12) months after the Termination Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Solicit Restrictive Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), he&#47;she will not, directly or indirectly, as employee, agent, consultant, stockholder, director, partner or in any other individual or representative capacity, (i) solicit or encourage, or participate in any business which solicits or encourages (A) any person, firm, corporation or other entity which has executed, or proposes to execute, a management </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-8-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">services agreement or other services agreement with the Company or any of its Subsidiaries at any time during the term of this Agreement, or any successor in interest to any such person, firm, corporation or other entity, for the purpose of securing business or contracts related to any element of the Business, or (B) any present customer or patient of the Company or any of its Subsidiaries or any of their Affiliated Practices to terminate or otherwise alter his, her or its relationship with the Company or any of its Subsidiaries or such Affiliated Practice&#59; provided, however, that nothing contained herein shall be construed to prohibit or restrict Executive from soliciting business from any such parties on behalf of the Company or any of its Subsidiaries in performance of his&#47;her duties as an employee of the Company required under and as specifically contemplated by Section 2 above or (ii) divert, entice away, solicit or encourage, or attempt to divert, entice away, solicit or encourage, any physician who utilizes or has invested in an Affiliated Practice to become an owner, investor or user of another practice or facility that is not an Affiliated Practice or approach any such physician for any of the foregoing purposes or authorize or assist in the taking of any such action by any third party.  In addition, at all times from and after the Termination Date, Executive shall not contact or communicate in any manner with any of Company&#8217;s, or any of its Subsidiaries&#8217; or Affiliates&#8217; suppliers or vendors, or any other third party providing services to the Company or any of its Subsidiaries, regarding the Company or any of its Subsidiaries or any Company- or any such Subsidiary-related matter (which suppliers, vendors or third party service providers will include, without limitation, any third party with whom the Company or any of its Subsidiaries was, during the term of Executive&#8217;s employment with the Company or any of its Subsidiaries, contemplating engaging, or negotiating with, for the future provision of products or services).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provided, however, that these restrictions shall apply (x) only with respect to those persons who are or have been a business partner of the Company or any of its Affiliates at any time within the immediately preceding two (2)-year period or whose business has been solicited on behalf of the Company or any of the Affiliates by any of their officers, employees or agents within such two (2)-year period, other than by form letter, blanket mailing or published advertisement, and (y) only if Executive has performed work for such person during his employment with the Company or one of its Affiliates or been introduced to, or otherwise had contact with, such person as a result of his employment or other associations with the Company or one of its Affiliates or have had access to Confidential Information which would assist in his solicitation of such person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Non-solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Other than in the performance of his&#47;her duties hereunder, during the Non-Solicit Restrictive Period, Executive shall not, directly or indirectly, as employee, agent, consultant, stockholder, director, co partner or in any other individual or representative capacity, employ, recruit or solicit for employment or engagement, any person who is employed or engaged by the Company or any of its Subsidiaries or any of its Affiliated Practices during the Non- Solicit Restrictive Period, or otherwise seek to influence or alter any such person&#8217;s relationship with any of the Affiliated Practices, the Company or any of its Subsidiaries&#59; provided, however that responses to a general solicitation (such as an internet or newspaper solicitation) that are not targeted towards any particular person shall not be deemed to be a violation of the restrictions set forth in this Section 7(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Affiliated Practice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For purposes of this Agreement, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliated Practice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall include any practice or facility (i) in which the Company or any of its Subsidiaries has an ownership interest or (ii) that is managed by or receives other services from the Company or any of its Subsidiaries in connection with any element of the Business.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Blue Pencil</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If any court of competent jurisdiction shall at any time deem the term of this Agreement or any particular Restrictive Covenant (as defined below) too lengthy or the Territory too extensive, the other provisions of this Section 7 shall nevertheless stand, the Restrictive Period herein shall be deemed to be the longest period permissible by law under the circumstances and the Territory herein shall be deemed to comprise the largest territory permissible by law under the circumstances.  The court in each case shall reduce the time period and&#47;or Territory to permissible duration or size.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Covenant Not to Disparage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  During the Restrictive Period and thereafter, Executive shall not disparage, denigrate or derogate in any way, directly or indirectly, the Company, any of its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-9-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subsidiaries or Affiliates, or any of its or their respective agents, officers, directors, employees, parent, subsidiaries, affiliates, Affiliated Practices, affiliated doctors (including any physicians who utilize or have invested in any Affiliated Practice), representatives, attorneys, executors, administrators, successors and assigns (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Protected Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), nor shall Executive disparage, denigrate or derogate in any way, directly or indirectly, his&#47;her experience with any Protected Party, or any actions or decisions made by any Protected Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive acknowledges and agrees that the covenants set forth in this Section 7 and the preceding Sections 5 and 6 (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) are reasonable and necessary for the protection of the business interests of the Company and its Subsidiaries and Affiliates, that irreparable injury may result to the Company and its Subsidiaries and Affiliates if Executive breaches any of the terms of said Restrictive Covenants, and that in the event of Executive&#8217;s actual or threatened breach of any such Restrictive Covenants, the Company and its Subsidiaries and Affiliates will have no adequate remedy at law.  Executive accordingly agrees that in the event of any actual or threatened breach by him of any of the Restrictive Covenants, the Company and its Subsidiaries and Affiliates shall be entitled to immediate temporary injunctive and other equitable relief subject to hearing as soon thereafter as possible.  Nothing contained herein shall be construed as prohibiting the Company or any of its Subsidiaries or Affiliates from pursuing any other remedies available to it for such breach or threatened breach, including the recovery of any damages which it is able to prove.  In addition and supplementary to other rights and remedies existing in its (or their) favor, in the event of the material breach by Executive of any of the provisions of this Section 7, the Company (and&#47;or its Subsidiaries or Affiliates) shall be entitled to require Executive to account for and pay over to the Company (and&#47;or its Subsidiaries or Affiliates) all compensation, profits, moneys, accruals, increments or other benefits actually derived from or received as a result of any transactions constituting a breach of the covenants contained in this Agreement which may require Executive to repay any severance.  In addition, in the event of an alleged breach or violation by Executive of this Section 7, the restricted periods set forth in this Section 7 shall be tolled until such breach or violation has been duly cured.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">Executive understands that the foregoing restrictions may limit his&#47;her ability to earn a livelihood in a business similar to the business of the Company and its Subsidiaries or Affiliates, but he&#47;she nevertheless believes that he&#47;she has received and will receive sufficient consideration and other benefits as an executive of the Company and as otherwise provided hereunder to clearly justify such restrictions which, in any event (given his&#47;her education, skills and ability), Executive does not believe would prevent him from otherwise earning a living.  Executive acknowledges that the Restrictive Covenants are reasonable and that he&#47;she has reviewed the provisions of this Agreement with his&#47;her legal counsel.  During the Restricted Period, Executive shall inform any prospective or future employer of any and all restrictions contained in this Agreement and provide such employer with a copy of such restrictions, prior to the commencement of that employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Executive&#8217;s Representations and Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">Executive hereby represents and warrants to the Company that (i) the execution, delivery and performance of this Agreement by Executive do not and shall not conflict with, breach, violate or cause a default under any contract, agreement, instrument, order, judgment or decree to which Executive is a party or by which he&#47;she is bound, (ii) Executive is not a party to or bound by any employment agreement, non-compete agreement or confidentiality agreement with any other person or entity and (iii) upon the execution and delivery of this Agreement by the Company, this Agreement shall be the valid and binding obligation of Executive, enforceable in accordance with its terms.  Executive hereby acknowledges and represents that he&#47;she has consulted with independent legal counsel regarding his&#47;her rights and obligations under this Agreement and that he&#47;she fully understands the terms and conditions contained herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">During the Employment Period and thereafter, Executive shall cooperate with the Company and its Subsidiaries and Affiliates in any internal investigation or administrative, regulatory or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-10-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">judicial proceeding as reasonably requested by the Company (including, without limitation, Executive being available to the Company upon reasonable notice for interviews and factual investigations, appearing at the Company&#8217;s request to give testimony without requiring service of a subpoena or other legal process, volunteering to the Company all pertinent information and turning over to the Company all relevant documents which are in or may come into Executive&#8217;s possession, all at times and on schedules that are reasonably consistent with Executive&#8217;s other permitted activities and commitments).  In the event the Company requires Executive&#8217;s cooperation in accordance with this Section 8(b), the Company shall reimburse Executive for reasonable travel expenses (including, without limitation, travel expenses, lodging and meals, and reasonable attorneys&#8217; fees upon submission of receipts).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Sections 4 through 22 shall survive and continue in full force in accordance with their terms notwithstanding the expiration or termination of the Employment Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any notices provided for in this Agreement shall be in writing and shall be effective when delivered in person or deposited in the United States mail, postage prepaid, and addressed to Executive at his&#47;her last known address on the books of the Company or, in the case of the Company, to it at its principal place of business, attention of the Chief Executive Officer, or to such other address as either party may specify by notice to the other actually received.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Complete Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement, those documents expressly referred to herein and other documents of even date herewith, embody the complete agreement and understanding among Executive and the Company and its Subsidiaries and, as of the Effective Date, shall supersede and preempt any prior understandings, agreements or representations by or among the parties, written or oral, which may have related to the subject matter hereof in any way, including, for the avoidance of doubt, the Employment Agreement, dated June 13, 2014, as amended, between the Company and the Executive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">No Strict Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The language used in this Agreement will be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction will be applied against any party hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement may be executed in separate counterparts (including by facsimile or PDF signature pages), each of which is deemed to be an original and all of which taken together constitute one and the same agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company and its successors and permitted assigns.  Executive may not assign any of his&#47;her rights or obligations hereunder without the prior written consent of the Company.  The Company may (a) assign any or all of its respective rights and interests hereunder to one or more Subsidiaries or Affiliates of the Company, (b) designate one or more Subsidiaries or Affiliates of the Company to perform its obligations hereunder (in any or all of which cases the Company nonetheless shall remain responsible for the performance of all of its obligations hereunder), (c) assign its rights hereunder in connection with the sale of all or a substantial part of the business or assets of the Company or one of its Subsidiaries (whether by merger, sale of stock or assets, recapitalization or otherwise) and (d) merge any of the Subsidiaries or Affiliates with or into the Company (or vice versa).  The rights of the Company hereunder are enforceable by the Company or its Subsidiaries or Affiliates, which are the intended third party beneficiaries hereof and no other third party beneficiary is so otherwise intended.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-11-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Delivery by Facsimile or PDF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement and any amendments hereto, to the extent signed and delivered by means of a facsimile machine or PDF, shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.  At the request of any party hereto, each other party hereto shall re-execute original forms thereof and deliver them to the other party.  No party hereto shall raise the use of a facsimile machine or PDF to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of a facsimile machine or PDF as a defense to the formation or enforceability of a contract and each such party forever waives any such defense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Income Tax Treatment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive and the Company acknowledge that it is the intention of the Company to deduct all cash amounts paid under this Agreement as ordinary and necessary business expenses for income tax purposes.  Executive agrees and represents that he&#47;she will treat all such non-reimbursable amounts as ordinary income for income tax purposes, and should he&#47;she report such amounts as other than ordinary income for income tax purposes, he&#47;she will indemnify and hold the Company harmless from and against any and all taxes, penalties, interest, costs and expenses, including reasonable attorneys&#8217; and accounting fees and costs, which are incurred by Company directly or indirectly as a result thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Agreement shall be governed by, the laws of the state in which Executive resides, without giving effect to provisions thereof regarding conflict of laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  THE PARTIES HERETO HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT.  THE PARTIES HERETO ALSO WAIVE ANY BOND OR SURETY OR SECURITY UPON SUCH BOND WHICH MIGHT, BUT FOR THIS WAIVER, BE REQUIRED OF THE OTHER PARTY.  THE PARTIES HERETO ACKNOWLEDGE THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS ALREADY RELIED ON THE WAIVER IN ENTERING INTO THIS AGREEMENT AND THAT EACH WILL CONTINUE TO RELY ON THE WAIVER IN THEIR RELATED FUTURE DEALINGS.  THE COMPANY AND EXECUTIVE FURTHER WARRANT AND REPRESENT THAT EACH HAS REVIEWED THIS WAIVER WITH THEIR RESPECTIVE LEGAL COUNSEL, AND THAT EACH KNOWINGLY AND VOLUNTARILY WAIVES THEIR RESPECTIVE JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.  THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING, AND THE WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THE TRANSACTION CONTEMPLATED HEREBY.  IN THE EVENT OF LITIGATION, THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Consent to Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">THE COMPANY AND EXECUTIVE HEREBY CONSENT TO THE JURISDICTION OF ANY STATE OR FEDERAL COURT LOCATED WITHIN THE STATE IN WHICH EXECUTIVE RESIDES AND IRREVOCABLY AGREE THAT SUBJECT TO THE COMPANY&#8217;S ELECTION, ALL ACTIONS OR PROCEEDINGS ARISING OUT OF OR RELATING TO THIS AGREEMENT SHALL BE LITIGATED IN SUCH COURTS.  EXECUTIVE ACCEPTS FOR HIMSELF&#47;HERSELF AND IN CONNECTION WITH HIS&#47;HER PROPERTIES, GENERALLY AND UNCONDITIONALLY, THE NONEXCLUSIVE JURISDICTION OF THE AFORESAID COURTS AND WAIVES ANY DEFENSE OF FORUM NON CONVENIENS, AND IRREVOCABLY AGREES TO BE BOUND BY ANY JUDGMENT RENDERED THEREBY IN CONNECTION WITH THIS AGREEMENT.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-12-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">Notwithstanding Section 20(a), the parties intend to and hereby confer jurisdiction to enforce the covenants contained in Sections 5 through 7 upon the courts of any jurisdiction within the geographical scope of such covenants.  If the courts of any one or more of such jurisdictions hold such covenants wholly or partially invalid or unenforceable by reason of the breadth of such scope or otherwise, it is the intention of the parties that such determination not bar or in any way affect the Company&#8217;s right to the relief provided above in the courts of any other jurisdiction within the geographical scope of such covenants, as to breaches of such covenants in such other respective jurisdictions, such covenants as they relate to each jurisdiction being, for this purpose, severable into diverse and independent covenants.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Amendment and Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any provision of this Agreement may be amended or waived only with the prior written consent of the Company and Executive, and no course of conduct or course of dealing or failure or delay by any party hereto in enforcing or exercising any of the provisions of this Agreement shall affect the validity, binding effect or enforceability of this Agreement or be deemed to be an implied waiver of any provision of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To the maximum extent permitted by law, this Agreement shall be interpreted in such a manner that the payments to Executive under this Agreement are either exempt from, or comply with, Section 409A, including without limitation any such regulations or other guidance that may be issued after the date hereof.  For purposes of Section 409A, each payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments.  Notwithstanding anything to the contrary in this Agreement, if Executive is a &#8220;specified employee&#8221; as defined below, as of Executive&#8217;s termination of employment, then, to the extent any payment under this Agreement resulting from Executive&#8217;s termination of employment constitutes deferred compensation (after taking into account any applicable exemptions from Section 409A) and to the extent required by Section 409A, no payments due under this Agreement as a result of Executive&#8217;s termination of employment may be made until the earlier of (a) the first day following the six-month anniversary of Executive&#8217;s date of termination and (b) Executive&#8217;s date of death&#59; provided, however, that any payments delayed during this six-month period shall be paid in the aggregate in a lump sum as soon as reasonably practicable following the sixth month anniversary of Executive&#8217;s date of termination.  For purposes of this Agreement, all references to &#8220;termination of employment&#8221; and correlative phrases shall be construed to require a &#8220;separation from service&#8221; (as defined in Treas. Reg. &#167;1.409A-1(h) after giving effect to the presumptions contained therein), and the term &#8220;specified employee&#8221; means an individual determined by the Company to be a specified employee under Treas. Reg. &#167;409A-1(i).</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">*    *    *    *    *    *    *    * </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-13-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have executed this Employment Agreement as of the date first written above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SURGERY PARTNERS, INC.<br><br><br><br>By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; J. Eric Evans&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><br>      J. Eric Evans</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">      Chief Executive Officer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accepted and Agreed&#58;<br><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jennifer Baldock&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><br>Jennifer Baldock</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;3&#47;11&#47;2022&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-14-</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>a2022q1exhibit102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1a18f220069544b1839e0bea9b1a366a_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div></div><div style="margin-bottom:12pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">AMENDED AND RESTATED EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is hereby entered into effective as of March 8, 2022 (the &#8220;Effective Date&#8221;), between Surgery Partners, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and Anthony W. Taparo (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company shall employ Executive, and Executive hereby accepts continued employment with the Company, upon the terms and conditions set forth in this Agreement for the period beginning on March 11, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and ending on the Termination Date, as provided for in Section 4 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Position and Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">During the Employment Period, Executive shall serve as Executive Vice President, Chief Growth Officer reporting to the CEO.  Executive shall have such responsibilities, duties and authorities, and will render such services for the Company and its Subsidiaries or Affiliates as the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) may from time to time direct.  Executive will devote his best efforts, energies and abilities and his&#47;her full business time, skill and attention to the business and affairs of the Company and its Subsidiaries, and shall perform his&#47;her duties and responsibilities to the best of his&#47;her ability, in a diligent, trustworthy, businesslike and efficient manner for the purpose of advancing the businesses of Company and its Subsidiaries.  Executive acknowledges that his&#47;her duties and responsibilities will require his&#47;her full time business efforts and agrees that during the Employment Period he&#47;she will not engage in any other business activity or have any business pursuits that interfere with Executive&#8217;s duties and responsibilities under this Agreement or are competitive with the businesses of the Company.  Notwithstanding the foregoing, Executive shall be permitted to devote a reasonable amount of time and effort to (i) providing service to, or serving on governing boards of, civic and charitable organizations, and (ii) personally investing and managing personal and family investments in real estate and in any corporation, partnership or other entity&#59; but in each case, only to the extent that any of the activities described in clauses (i) or (ii), individually or as a whole, do not (A) require or involve the active participation of Executive in the management of any corporation, partnership or other entity or interfere with the execution of Executive&#8217;s duties hereunder, or (B) otherwise violate any provision of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">For purposes of this Agreement, (i) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any corporation or other entity (A) of which the securities or other ownership interests having the voting power to elect a majority of the board of directors or other governing body are, at the time of determination, owned by the Company, directly or through one or more subsidiaries or (B) to which the Company or any of its Affiliates provide management services, and (ii) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; of an entity means any other person or entity, directly or indirectly controlling, controlled by or under common control with an entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Compensation and Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">Effective March 27, 2022, during the Employment Period, Executive&#8217;s base salary shall increase from $410,000 to $450,000 per annum, payable by the Company in regular installments in accordance with the Company&#8217;s general payroll practices, less taxes and other applicable withholdings, and subject to review and adjustment from time to time by the Board or the Compensation Committee thereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), in either case, in its discretion (as modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">In addition, during the Employment Period, Executive shall be entitled to participate in all of the Company&#8217;s benefit programs for which employees of the Company are generally eligible, subject to the eligibility and participation requirements thereof, including, but not limited to, the following&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.69pt">medical, dental, vision, life and disability insurance, as is generally provided to other employees of the Company&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">eligibility for vacation time in accordance with the policies of the Company as from time to time in effect.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.03pt">participation in the existing Symbion, Inc. supplemental Executive Retirement Plan, or its equivalent or a successor plan, with a minimum of a two percent (2%) match for executive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">During the Employment Period, the Company shall reimburse Executive for all reasonable out-of-pocket expenses incurred by his&#47;her in the course of performing his&#47;her duties and responsibilities under this Agreement which are consistent with the Company&#8217;s policies in effect from time to time with respect to travel, entertainment and other business expenses, subject to the Company&#8217;s requirements with respect to reporting and documentation of such expenses. Executive&#8217;s right to payment or reimbursement for business expenses hereunder will be subject to the following additional rules&#58; (i) no reimbursement of any expense shall affect Executive&#8217;s right to reimbursement of any other expense in any other taxable year&#59; (ii) the amount of expenses eligible for payment or reimbursement during any calendar year will not affect the expenses eligible for payment or reimbursement in any other taxable year&#59; (iii) payment or reimbursement will be made not later than December 31 of the calendar year following the calendar year in which the expense was incurred or paid, and (iv) the right to payment or reimbursement is not subject to liquidation or exchange for any other benefit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">In addition to the Base Salary, Executive will be eligible to receive an annual bonus of sixty percent (60%) of the Base Salary, with the actual amount of any such bonus being determined by the Board or the Committee, in either case, in its discretion, based on the achievement of performance goals established annually by the Board or the Committee, as applicable.  Any annual bonus payable under this Section 3(d) will be paid no later than March 31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> following the close of the year for which the bonus is earned.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">Executive shall be eligible to participate in the Surgery Partners, Inc. 2015 Omnibus Incentive Plan (as amended from time to time, (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Equity Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) on terms and conditions set forth therein and in the relevant award agreement unless specifically stated otherwise in this Agreement. Executive will be eligible for annual equity grants under the Equity Plan. Initially, the targeted equity grant will be $650,000, subject to approval of the Board (or an authorized committee thereof), in such forms as determined by the Board or its designee in its discretion.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.03pt">All amounts payable to Executive hereunder shall be subject to all required withholdings by the Company.  If additional guidance is issued under, or modifications are made to, Section 409A of the Internal Revenue Code of the Internal Revenue Code and the regulations and other interpretive guidance issued thereunder (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), or any other law affecting payments to be made under this Agreement, Executive agrees that the Company may take such reasonable actions and adopt such reasonable amendments as the Company believes are necessary to ensure continued compliance with the Internal Revenue Code, including Section 409A.  However, the Company does not hereby or otherwise represent or warrant that any payments hereunder are or will be in compliance with Section 409A, and Executive shall be responsible for obtaining his&#47;her own tax advice with regard to such matters.  </font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination by Executive or the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Employment Period (i) shall terminate upon Executive&#8217;s resignation with Good Reason (as defined below) or without Good Reason, death or Incapacity (as defined below) or (ii) may be terminated by the Company at any time for Cause (as defined below) or without Cause.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean without the written consent of Executive&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.69pt">without the express written consent of Executive, a material diminution of his&#47;her position, duties, responsibilities, and status with the Company as in effect as of the Commencement Date or a material reduction of Executive&#8217;s resources as in effect on the Commencement Date&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">a material reduction in Executive&#8217;s Base Salary or annual bonus target percentage&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.03pt">a material reduction in the level of benefits available or awarded to Executive, other than any reduction in connection with a Company-wide reduction applicable generally to similarly situated executive officers of the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">within twelve months of a Change in Control (as defined herein), a material increase in Executive&#8217;s core functional responsibilities with a corresponding material change in Executive&#8217;s core functional role without a corresponding increase in compensation, provided, however, the addition of additional facilities or territories to Executive&#8217;s oversight responsibilities or other ordinary course growth of the Company or any of its Subsidiaries or Affiliates shall not be a material increase in Executive&#8217;s core functional responsibilities&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">a relocation by the Company of Executive&#8217;s primary employment location to a location which is more than 50 miles from Executive&#8217;s primary employment location on the date hereof&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">a material breach by the Company of the terms of this Agreement&#59; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">but only if (x) Executive notifies the Company in writing within 90 days after the initial existence or occurrence of any of these conditions which notice describes in reasonable detail the basis for Executive&#8217;s belief that Good Reason exists and that Executive intends to resign for Good Reason and the Company, within 30 days after receipt of such notice, either fails to cure the condition or delivers a written notice to Executive that the Company intends not to cure such condition and (y) Executive actually resigns prior to 15 days after the earlier to occur of either the end of such 30-day cure period or delivery of such written notice by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Incapacity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as used herein shall mean that Executive is unable to perform, with or without reasonable accommodation, by reason of physical or mental incapacity, the essential duties, responsibilities and functions of his&#47;her position.  A medical examination by a physician selected by the Company to whom Executive or his&#47;her duly appointed guardian, if any, has no reasonable objection shall determine, according to the facts then available, whether and when Incapacity has occurred.  Such determination shall not be arbitrary or unreasonable, and shall be final and binding on the parties hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as used herein means the occurrence of any of the following events&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.69pt">a material breach by Executive of any of the terms and conditions of this Agreement&#59; provided that, if curable, Executive shall have a reasonable period of time (which in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">no event shall exceed 45 days) during which to cure such material breach following the date on which Executive receives the Company&#8217;s written notice of such material breach&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">Executive&#8217;s reporting to work (A) intoxicated (other than Executive&#8217;s reasonable use of alcohol in connection with business entertainment, provided, that such use of alcohol does not cause the Company or any of its Subsidiaries or Affiliates substantial public disgrace or disrepute or economic harm) or (B) under the influence of illegal drugs&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.03pt">Executive&#8217;s use of illegal drugs (whether or not at the workplace) or other conduct causing the Company or any of its Subsidiaries or Affiliates substantial public disgrace or disrepute or economic harm&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">breach of fiduciary duty, gross negligence or willful misconduct with respect to the Company or any of its Subsidiaries or Affiliates&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">chronic absenteeism, which shall be deemed to have occurred if Executive has at least ten absences unrelated to paid time off, disability or illness in any ten week period&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">Executive&#8217;s material failure or willful refusal to substantially perform his&#47;her duties, responsibilities and functions&#59; provided that, if curable, Executive shall have a reasonable period of time (which in no event shall exceed 45 days) during which to cure such failure following the date on which Executive receives the Company&#8217;s written notice of such failure&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.36pt">Executive&#8217;s failure to comply with any of the Company&#8217;s or any of its Subsidiaries&#8217; written guidelines or procedures promulgated by the Company or any such Subsidiary and furnished to Executive, including, without limitation, any guidelines or procedures relating to marketing or community relations&#59; provided that, if curable, Executive shall have a reasonable period of time (which in no event shall exceed 45 days) during which to cure such failure following the date on which Executive receives the Company&#8217;s written notice of such failure&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:12.03pt">Executive has committed an act or acts constituting a felony or any other act or omission involving theft, dishonesty or fraud against the Company or any of its Subsidiaries or any of their respective customers or suppliers or other business relationships.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">A &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall be deemed to have occurred upon any of the following events, provided that, to the extent required by Section 409A, such events would also qualify as a &#8220;change in control event&#8221; under Treas. Reg. &#167;1.409A-3(i)(5)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.69pt">Upon the closing of a reorganization, merger, share exchange or consolidation, other than a reorganization, merger, share exchange or consolidation with respect to which those persons who were the beneficial owners, immediately prior to such reorganization, merger, share exchange or consolidation, of outstanding securities of the Company ordinarily having the right to vote in the election of directors own, immediately after the closing of such transaction, more than 51% of the outstanding securities of the resulting corporation ordinarily having the right to vote in the election of directors&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">Upon approval by the stockholders of a complete liquidation and dissolution of the Company or the sale or other disposition of all or substantially all of the assets of the Company other than to a Subsidiary or Affiliate.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Termination by Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive has the right to terminate his&#47;her employment under this Agreement at any time, for any or no reason, but only after giving the Company (i) 30 days prior written notice with respect to any termination without Good Reason or (ii) the number of days prior </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-4-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">written notice set forth in the last sentence of Section 4(b) with respect to any termination with Good Reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Compensation after Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.69pt">If the Employment Period is terminated pursuant to Executive&#8217;s resignation without Good Reason, death or Incapacity, Executive shall only be entitled to receive his&#47;her Base Salary through the date of termination and shall not be entitled to any other salary, bonus, compensation or benefits from the Company or its Subsidiaries, except as may be required by applicable law.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">If the Employment Period is terminated by the Company for Cause, Executive shall only be entitled to his&#47;her Base Salary through the date of termination and shall not be entitled to any other salary, bonus, compensation or benefits from the Company or its Subsidiaries, except as may be required by applicable law.  In addition, in such event, Executive shall automatically forfeit any rights to any unvested equity owned by Executive in the Company or any Subsidiary.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.03pt">If the Employment Period is terminated by the Company without Cause or by Executive for Good Reason, then subject to the conditions described in Section 4(g)(v) below, Executive shall be entitled to receive as severance compensation the following (collectively, &#8220;Severance Pay&#8221;)&#58; (A) an amount equal to twelve (12) months of Executive&#8217;s then-current annual Base Salary, payable in regular installments beginning within 30 days following the Termination Date in accordance with the Company&#8217;s general payroll practices for salaried employees&#59; (B) continuation of the welfare benefits described in Section 3(b) for twelve (12) months to the extent permissible under the terms of the relevant benefit plans at the same cost to Executive as if Executive were an active employee of the Company&#59; (C) the Bonus payable to Executive within 3 months after the end of the applicable year (to the extent not previously paid), paid in a lump sum at the time that bonuses are regularly paid to employees&#59; (D) with respect to the portion of each restricted stock award held by Executive as of date on which the Employment Period is terminated that is subject to time-based vesting (the &#8220;Time-Based RSA&#8221;), accelerated vesting of the Time-Based RSA to the vesting event next following the date on which the Employment Period is terminated&#59; and (E) with respect to the portion of each performance stock unit award held by the Executive as of the date on which the Employment Period is terminated that has been converted into &#8220;earned shares&#8221; (the &#8220;Earned PSUs&#8221;), accelerated vesting of the Earned PSUs to the vesting event next following the date on which the Employment Period is terminated&#59; and (F) with respect to each performance stock unit award issued after December 31, 2021, held by the executive as of the date on which the Employment Period ends that have not been converted to Earned PSUs, the Executive&#8217;s rights under the award will be fully vested based on the number of shares that would be earned under the award based on performance measured through the end of Employment Period.  For purposes of this Section 4(g), &#8220;Bonus&#8221; shall mean an amount equal to Executive&#8217;s then-current annual Base Salary, multiplied by the percentage contained in Section 3(d) hereof. For the avoidance of doubt, the unvested portion of any restricted stock awards and performance share unit awards held by Executive as of the date on which the Employment Period ends (after giving effect to the acceleration provisions set forth in subsections (D), (E) and (F) herein and the terms and conditions of the applicable award agreements and the Surgery Partners, Inc. 2015 Omnibus Incentive Plan (as amended from time to time)) shall be forfeited and of no further force and effect.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">If, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within 90 days prior to or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12 months following a Change in Control, either (A) the Company terminates the employment of Executive hereunder without Cause under Section 4(a) above, or (B) Executive terminates his&#47;her employment for Good Reason under Section 4(b) above, then, in lieu of any other compensation that may be specified in this Agreement, the Company will pay Executive the Severance Pay in a single lump-sum payment </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-5-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">not later than 30 days after termination.  If any payment obligation under this Section 4(g) arises, no compensation received from other employment (or otherwise) will reduce the Company&#8217;s obligation to make the payment(s) described in this paragraph.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">Notwithstanding Sections 4(g)(iii) or (iv), Executive&#8217;s right to receive Severance Pay hereunder is conditioned upon&#58; (A) Executive executing, and not revoking, a written separation agreement and general release of all claims against the Company, its Subsidiaries and Affiliates and their respective managers, directors, officers, shareholders, members, representatives, agents, attorneys, predecessors, successors and assigns (other than a claim for the severance payments described in Section 4(g)(iii) or (iv) and Executive&#8217;s rights to future distributions and payments related to the continued ownership of any equity securities in the Company that Executive will continue to own after such termination), in form and substance acceptable to the Company, which shall among other things, contain a general release by Executive of all claims arising out of his&#47;her employment and termination of employment by the Company (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Release Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) within 30 days of Executive&#8217;s Termination Date&#59; and (B) Executive&#8217;s material compliance with all of his&#47;her obligations which survive termination of this Agreement.  The Severance Pay is intended to be in lieu of all other payments to which Executive might otherwise be entitled in respect of his&#47;her termination without Cause or resignation with Good Reason.  The Company and its Subsidiaries and Affiliates shall have no further obligations hereunder or otherwise with respect to Executive&#8217;s employment from and after the date of termination of employment with the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and the Company and its Subsidiaries and Affiliates shall continue to have all other rights available hereunder (including without limitation, all rights hereunder at law or in equity).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">Notwithstanding the foregoing, the Release Agreement (x) shall not require the release of Executive&#8217;s rights arising from the express terms of this Agreement or any applicable award agreement that are associated with a termination of employment&#59; (y) shall not impose any postemployment restrictions other than those set forth in this Agreement, and (z) shall take into account and preserve Executive&#8217;s rights in the event that a Change in Control occurs within 90 days after termination of employment (or such longer tail period as may be provided by any agreement between Executive and the Company).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.36pt">Except as otherwise expressly provided herein, all of Executive&#8217;s rights to salary, bonuses, benefits and other compensation hereunder which might otherwise accrue or become payable after the termination of the Employment Period shall cease upon such termination, other than those expressly required under applicable law (such as COBRA).  All amounts payable to Executive as severance hereunder shall be subject to all required withholdings by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company may offset any amount Executive owes the Company or its Subsidiaries or Affiliates against any amount they or their Subsidiaries or Affiliates owe Executive hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Confidential Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other than in the performance of his&#47;her duties hereunder, during the Restrictive Period (as defined below) and thereafter, Executive shall keep secret and retain in strictest confidence, and shall not, without the prior written consent of the Company, furnish, make available or disclose to any third party or use for the benefit of himself or any third party, any Confidential Information.  As used in this Agreement, &#8220;Confidential Information&#8221; shall mean any information relating to the business or affairs of the Company or any of its Subsidiaries or Affiliates or the Business, including but not limited to any technical or non-technical data, formulae, compilations, programs, devices, methods, techniques, designs, processes, procedures, improvements, models, manuals, financial data, acquisition strategies and information, information relating to operating procedures and marketing strategies, and any other proprietary information used by the Company or any of its Subsidiaries or Affiliates in connection with the Business, irrespective of its form&#59; provided, however, that Confidential Information shall not include any information which is in the public domain or becomes known in the industry, in each case through no wrongful act on the part of Executive.  Executive </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-6-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">acknowledges that the Confidential Information is vital, sensitive, confidential and proprietary to the Company and its Subsidiaries and Affiliates.  Executive will immediately notify the Company of any unauthorized possession, use, disclosure, copying, removal or destruction, or attempt thereof, of any Confidential Information by anyone of which Executive becomes aware and of all details thereof.  Executive shall take all reasonably appropriate steps to safeguard Confidential Information and to protect it against disclosure, misuse, espionage, loss and theft.  Executive shall deliver to the Company at the termination or expiration of the Employment Period, or at any other time the Company may request, all memoranda, notes, plans, records, reports, computer tapes, computers, printouts and software and other documents and data (and copies thereof) embodying or relating to the Confidential Information, Inventions and Discoveries (as defined below) or the business of the Company or any of its Subsidiaries or Affiliates which Executive may then possess or have under his&#47;her control.  Nothing in this Agreement limits, restricts or in any other way affects Executive&#8217;s communicating with any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, concerning matters relevant to the governmental agency or entity, or requires Executive to provide notice to the Company of the same.  Executive cannot be held criminally or civilly liable under any federal or state trade secret law for disclosing a trade secret (1) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating a suspended violation of law, or (2) in a compliant or other document filed under seal in a lawsuit or other proceeding.  Notwithstanding this immunity from liability, Executive may be held liable if Executive unlawfully accesses trade secrets by unauthorized means.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as used herein means the business of owning, operating, developing and&#47;or managing, or providing management or administrative services to, (a) ambulatory surgery centers anywhere in the United States or (b) physician-owned surgical hospitals within a 50 mile radius of any hospital that is owned, operated, developed or managed by the Company or any Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Inventions and Discoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">Executive understands and agrees that all inventions, discoveries, ideas, improvements, whether patentable, copyrightable or not, pertaining to the Business or relating to Company&#8217;s or any of its Subsidiaries&#8217; or Affiliates&#8217; actual or demonstrably anticipated research, development or inventions (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Inventions and Discoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that result from any work performed by Executive solely or jointly with others for the Company or any of its Subsidiaries or Affiliates which Executive, solely or jointly with others, conceives, develops, or reduces to practice during the course of Executive&#8217;s employment with the Company or any of its Subsidiaries, are the sole and exclusive property of the Company.  Executive will promptly disclose all such matters to the Company and will assist the Company in obtaining legal protection for Inventions and Discoveries.  Executive hereby agrees on behalf of himself, his&#47;her executors, legal representatives and assignees that he&#47;she will assign, transfer and convey to the Company, its successors and assigns the Inventions and Discoveries.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">THE COMPANY AND EXECUTIVE ACKNOWLEDGE AND AGREE THAT SECTION 6(a) SHALL NOT APPLY TO AN INVENTION OF EXECUTIVE FOR WHICH NO EQUIPMENT, SUPPLIES, FACILITY OR TRADE SECRET INFORMATION OF THE COMPANY OR ANY OF ITS SUBSIDIARIES WAS USED AND WHICH WAS DEVELOPED ENTIRELY ON EXECUTIVE&#8217;S OWN TIME, UNLESS (A) THE INVENTION RELATED (I) TO THE BUSINESS OF THE COMPANY OR ANY OF ITS SUBSIDIARIES OR AFFILIATES OR (II) TO THE COMPANY&#8217;S OR ANY OF ITS SUBSIDIARIES&#8217; OR AFFILIATES&#8217; ACTUAL OR DEMONSTRABLY ANTICIPATED RESEARCH OR DEVELOPMENT, OR (B) THE INVENTION RESULTS FROM ANY WORK PERFORMED BY EXECUTIVE FOR THE COMPANY OR ANY OF ITS SUBSIDIARIES OR AFFILIATES.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">EXECUTIVE ACKNOWLEDGES THAT HE&#47;SHE HAS READ THIS SECTION 6 AND FULLY UNDERSTANDS THE LIMITATIONS WHICH IT IMPOSES UPON HIM AND HAS RECEIVED A DUPLICATE COPY OF THIS AGREEMENT FOR HIS&#47;HER RECORDS.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-7-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive acknowledges that in the course of his&#47;her employment with the Company or any of its Subsidiaries or Affiliates, or their predecessors or successors, he&#47;she has been and will be given access to and has and will become familiar with their trade secrets and with other Confidential Information and that his&#47;her services have been and shall be of special, unique and extraordinary value to the Company and its Subsidiaries or Affiliates.  Therefore, and in further consideration of the compensation to be paid to Executive hereunder and in connection with his&#47;her employment, and to protect the Company&#8217;s and its Subsidiaries&#8217; and Affiliates&#8217; Confidential Information, business interests and goodwill&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Non-compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive hereby agrees that for a period commencing on the date hereof and ending on the Termination Date, and thereafter, through the period ending twelve (12) months after the Termination Date (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictive Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), he&#47;she shall not, directly or indirectly, as employee, agent, consultant, stockholder, director, co-partner or in any other individual or representative capacity, own, operate, manage, control, engage in, invest in or participate in any manner in, act as a consultant or advisor to, render services for (alone or in association with any person, firm, corporation or entity), or otherwise assist any person or entity (other than the Company and its Subsidiaries) that engages in or owns, invests in, operates, manages or controls any venture or enterprise that directly or indirectly engages or is actively developing or attempting to develop in any element of the Business anywhere within a 50-mile radius of the Nashville, Tennessee metropolitan area or within a 50-mile radius of any area (or in the event such area is a major city, the metropolitan area relating to such city) in which the Company or any of its Subsidiaries on the Termination Date actively engages or is actively developing or attempting to develop in any element of the Business (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; provided, however, that nothing contained herein shall be construed to prevent Executive from investing in the stock of any competing corporation listed on a national securities exchange or traded in the over-the-counter market, but only if Executive is not involved in the business of said corporation and if Executive and his&#47;her associates (as such term is defined in Regulation 14(A) promulgated under the Securities Exchange Act of 1934, as in effect on the date hereof), collectively, do not own more than an aggregate of 3% of the stock of such corporation.  With respect to the Territory, Executive specifically acknowledges that the Company and its Subsidiaries intend to expand the Business into and throughout the United States.  Notwithstanding the foregoing, the activity proscribed by this Section 7(a) shall not constitute a violation of this Section 7(a) where performed for (x) an entity where no more than a de minimis amount of revenue is derived from a business that is competitive with the business of the Company or any of its Affiliates&#59; or (y) an entity that derives no more than $100 million in revenue from one or more divisions, departments or segments, in the aggregate, that are engaged in any business competitive with the business of the Company or any of its Affiliates&#59; provided, that in either case, you are not responsible for (and do not engage or participate in) the day-to-day management, oversight or supervision of such business and provided you do not have direct supervision over the individual or individuals who are so responsible for such day-to-day management, oversight or supervision.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Interference with Relationships</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Without limiting the generality of the provisions of Section 7(a) hereof, Executive hereby agrees that, for a period commencing on the Commencement Date and ending on the Termination Date, and thereafter, through the period ending twelve (12) months after the Termination Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Solicit Restrictive Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), he&#47;she will not, directly or indirectly, as employee, agent, consultant, stockholder, director, partner or in any other individual or representative capacity, (i) solicit or encourage, or participate in any business which solicits or encourages (A) any person, firm, corporation or other entity which has executed, or proposes to execute, a management services agreement or other services agreement with the Company or any of its Subsidiaries at any time during the term of this Agreement, or any successor in interest to any such person, firm, corporation or other entity, for the purpose of securing business or contracts related to any element of the Business, or (B) any present customer or patient of the Company or any of its Subsidiaries or any of their Affiliated Practices to terminate or otherwise alter his, her or its relationship with the Company or any of its Subsidiaries or such Affiliated Practice&#59; provided, however, that nothing contained herein shall be construed to prohibit or restrict Executive from soliciting business from any such parties on behalf of the Company or any of its Subsidiaries in performance of his&#47;her duties as an employee of the Company </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-8-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">required under and as specifically contemplated by Section 2 above or (ii) divert, entice away, solicit or encourage, or attempt to divert, entice away, solicit or encourage, any physician who utilizes or has invested in an Affiliated Practice to become an owner, investor or user of another practice or facility that is not an Affiliated Practice or approach any such physician for any of the foregoing purposes or authorize or assist in the taking of any such action by any third party.  In addition, at all times from and after the Termination Date, Executive shall not contact or communicate in any manner with any of Company&#8217;s, or any of its Subsidiaries&#8217; or Affiliates&#8217; suppliers or vendors, or any other third party providing services to the Company or any of its Subsidiaries, regarding the Company or any of its Subsidiaries or any Company- or any such Subsidiary-related matter (which suppliers, vendors or third party service providers will include, without limitation, any third party with whom the Company or any of its Subsidiaries was, during the term of Executive&#8217;s employment with the Company or any of its Subsidiaries, contemplating engaging, or negotiating with, for the future provision of products or services).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provided, however, that these restrictions shall apply (x) only with respect to those persons who are or have been a business partner of the Company or any of its Affiliates at any time within the immediately preceding two (2)-year period or whose business has been solicited on behalf of the Company or any of the Affiliates by any of their officers, employees or agents within such two (2)-year period, other than by form letter, blanket mailing or published advertisement, and (y) only if Executive has performed work for such person during his employment with the Company or one of its Affiliates or been introduced to, or otherwise had contact with, such person as a result of his employment or other associations with the Company or one of its Affiliates or have had access to Confidential Information which would assist in his solicitation of such person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Non-solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Other than in the performance of his&#47;her duties hereunder, during the Non-Solicit Restrictive Period, Executive shall not, directly or indirectly, as employee, agent, consultant, stockholder, director, co partner or in any other individual or representative capacity, employ, recruit or solicit for employment or engagement, any person who is employed or engaged by the Company or any of its Subsidiaries or any of its Affiliated Practices during the Non- Solicit Restrictive Period, or otherwise seek to influence or alter any such person&#8217;s relationship with any of the Affiliated Practices, the Company or any of its Subsidiaries&#59; provided, however that responses to a general solicitation (such as an internet or newspaper solicitation) that are not targeted towards any particular person shall not be deemed to be a violation of the restrictions set forth in this Section 7(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Affiliated Practice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For purposes of this Agreement, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliated Practice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall include any practice or facility (i) in which the Company or any of its Subsidiaries has an ownership interest or (ii) that is managed by or receives other services from the Company or any of its Subsidiaries in connection with any element of the Business.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Blue Pencil</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If any court of competent jurisdiction shall at any time deem the term of this Agreement or any particular Restrictive Covenant (as defined below) too lengthy or the Territory too extensive, the other provisions of this Section 7 shall nevertheless stand, the Restrictive Period herein shall be deemed to be the longest period permissible by law under the circumstances and the Territory herein shall be deemed to comprise the largest territory permissible by law under the circumstances.  The court in each case shall reduce the time period and&#47;or Territory to permissible duration or size.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Covenant Not to Disparage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  During the Restrictive Period and thereafter, Executive shall not disparage, denigrate or derogate in any way, directly or indirectly, the Company, any of its Subsidiaries or Affiliates, or any of its or their respective agents, officers, directors, employees, parent, subsidiaries, affiliates, Affiliated Practices, affiliated doctors (including any physicians who utilize or have invested in any Affiliated Practice), representatives, attorneys, executors, administrators, successors and assigns (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Protected Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), nor shall Executive disparage, denigrate or derogate in any way, directly or indirectly, his&#47;her experience with any Protected Party, or any actions or decisions made by any Protected Party.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-9-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive acknowledges and agrees that the covenants set forth in this Section 7 and the preceding Sections 5 and 6 (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) are reasonable and necessary for the protection of the business interests of the Company and its Subsidiaries and Affiliates, that irreparable injury may result to the Company and its Subsidiaries and Affiliates if Executive breaches any of the terms of said Restrictive Covenants, and that in the event of Executive&#8217;s actual or threatened breach of any such Restrictive Covenants, the Company and its Subsidiaries and Affiliates will have no adequate remedy at law.  Executive accordingly agrees that in the event of any actual or threatened breach by him of any of the Restrictive Covenants, the Company and its Subsidiaries and Affiliates shall be entitled to immediate temporary injunctive and other equitable relief subject to hearing as soon thereafter as possible.  Nothing contained herein shall be construed as prohibiting the Company or any of its Subsidiaries or Affiliates from pursuing any other remedies available to it for such breach or threatened breach, including the recovery of any damages which it is able to prove.  In addition and supplementary to other rights and remedies existing in its (or their) favor, in the event of the material breach by Executive of any of the provisions of this Section 7, the Company (and&#47;or its Subsidiaries or Affiliates) shall be entitled to require Executive to account for and pay over to the Company (and&#47;or its Subsidiaries or Affiliates) all compensation, profits, moneys, accruals, increments or other benefits actually derived from or received as a result of any transactions constituting a breach of the covenants contained in this Agreement which may require Executive to repay any severance.  In addition, in the event of an alleged breach or violation by Executive of this Section 7, the restricted periods set forth in this Section 7 shall be tolled until such breach or violation has been duly cured.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">Executive understands that the foregoing restrictions may limit his&#47;her ability to earn a livelihood in a business similar to the business of the Company and its Subsidiaries or Affiliates, but he&#47;she nevertheless believes that he&#47;she has received and will receive sufficient consideration and other benefits as an executive of the Company and as otherwise provided hereunder to clearly justify such restrictions which, in any event (given his&#47;her education, skills and ability), Executive does not believe would prevent him from otherwise earning a living.  Executive acknowledges that the Restrictive Covenants are reasonable and that he&#47;she has reviewed the provisions of this Agreement with his&#47;her legal counsel.  During the Restricted Period, Executive shall inform any prospective or future employer of any and all restrictions contained in this Agreement and provide such employer with a copy of such restrictions, prior to the commencement of that employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Executive&#8217;s Representations and Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">Executive hereby represents and warrants to the Company that (i) the execution, delivery and performance of this Agreement by Executive do not and shall not conflict with, breach, violate or cause a default under any contract, agreement, instrument, order, judgment or decree to which Executive is a party or by which he&#47;she is bound, (ii) Executive is not a party to or bound by any employment agreement, non-compete agreement or confidentiality agreement with any other person or entity and (iii) upon the execution and delivery of this Agreement by the Company, this Agreement shall be the valid and binding obligation of Executive, enforceable in accordance with its terms.  Executive hereby acknowledges and represents that he&#47;she has consulted with independent legal counsel regarding his&#47;her rights and obligations under this Agreement and that he&#47;she fully understands the terms and conditions contained herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">During the Employment Period and thereafter, Executive shall cooperate with the Company and its Subsidiaries and Affiliates in any internal investigation or administrative, regulatory or judicial proceeding as reasonably requested by the Company (including, without limitation, Executive being available to the Company upon reasonable notice for interviews and factual investigations, appearing at the Company&#8217;s request to give testimony without requiring service of a subpoena or other legal process, volunteering to the Company all pertinent information and turning over to the Company all relevant documents which are in or may come into Executive&#8217;s possession, all at times and on schedules that are reasonably consistent with Executive&#8217;s other permitted activities and commitments).  In the event the Company requires Executive&#8217;s cooperation in accordance with this Section 8(b), the Company shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-10-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">reimburse Executive for reasonable travel expenses (including, without limitation, travel expenses, lodging and meals, and reasonable attorneys&#8217; fees upon submission of receipts).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Sections 4 through 22 shall survive and continue in full force in accordance with their terms notwithstanding the expiration or termination of the Employment Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any notices provided for in this Agreement shall be in writing and shall be effective when delivered in person or deposited in the United States mail, postage prepaid, and addressed to Executive at his&#47;her last known address on the books of the Company or, in the case of the Company, to it at its principal place of business, attention of the Chief Executive Officer, or to such other address as either party may specify by notice to the other actually received.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Complete Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement, those documents expressly referred to herein and other documents of even date herewith, embody the complete agreement and understanding among Executive and the Company and its Subsidiaries and, as of the Effective Date, shall supersede and preempt any prior understandings, agreements or representations by or among the parties, written or oral, which may have related to the subject matter hereof in any way, including, for the avoidance of doubt, the Employment Agreement, dated June 13, 2014, as amended, between the Company and the Executive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">No Strict Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The language used in this Agreement will be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction will be applied against any party hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement may be executed in separate counterparts (including by facsimile or PDF signature pages), each of which is deemed to be an original and all of which taken together constitute one and the same agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company and its successors and permitted assigns.  Executive may not assign any of his&#47;her rights or obligations hereunder without the prior written consent of the Company.  The Company may (a) assign any or all of its respective rights and interests hereunder to one or more Subsidiaries or Affiliates of the Company, (b) designate one or more Subsidiaries or Affiliates of the Company to perform its obligations hereunder (in any or all of which cases the Company nonetheless shall remain responsible for the performance of all of its obligations hereunder), (c) assign its rights hereunder in connection with the sale of all or a substantial part of the business or assets of the Company or one of its Subsidiaries (whether by merger, sale of stock or assets, recapitalization or otherwise) and (d) merge any of the Subsidiaries or Affiliates with or into the Company (or vice versa).  The rights of the Company hereunder are enforceable by the Company or its Subsidiaries or Affiliates, which are the intended third party beneficiaries hereof and no other third party beneficiary is so otherwise intended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Delivery by Facsimile or PDF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement and any amendments hereto, to the extent signed and delivered by means of a facsimile machine or PDF, shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.  At the request of any party hereto, each other party hereto shall re-execute original forms thereof and deliver them to the other party.  No party hereto shall raise the use of a facsimile machine or PDF to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of a facsimile </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-11-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">machine or PDF as a defense to the formation or enforceability of a contract and each such party forever waives any such defense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Income Tax Treatment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive and the Company acknowledge that it is the intention of the Company to deduct all cash amounts paid under this Agreement as ordinary and necessary business expenses for income tax purposes.  Executive agrees and represents that he&#47;she will treat all such non-reimbursable amounts as ordinary income for income tax purposes, and should he&#47;she report such amounts as other than ordinary income for income tax purposes, he&#47;she will indemnify and hold the Company harmless from and against any and all taxes, penalties, interest, costs and expenses, including reasonable attorneys&#8217; and accounting fees and costs, which are incurred by Company directly or indirectly as a result thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Agreement shall be governed by, the laws of the state in which Executive resides, without giving effect to provisions thereof regarding conflict of laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  THE PARTIES HERETO HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT.  THE PARTIES HERETO ALSO WAIVE ANY BOND OR SURETY OR SECURITY UPON SUCH BOND WHICH MIGHT, BUT FOR THIS WAIVER, BE REQUIRED OF THE OTHER PARTY.  THE PARTIES HERETO ACKNOWLEDGE THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS ALREADY RELIED ON THE WAIVER IN ENTERING INTO THIS AGREEMENT AND THAT EACH WILL CONTINUE TO RELY ON THE WAIVER IN THEIR RELATED FUTURE DEALINGS.  THE COMPANY AND EXECUTIVE FURTHER WARRANT AND REPRESENT THAT EACH HAS REVIEWED THIS WAIVER WITH THEIR RESPECTIVE LEGAL COUNSEL, AND THAT EACH KNOWINGLY AND VOLUNTARILY WAIVES THEIR RESPECTIVE JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.  THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING, AND THE WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THE TRANSACTION CONTEMPLATED HEREBY.  IN THE EVENT OF LITIGATION, THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Consent to Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">THE COMPANY AND EXECUTIVE HEREBY CONSENT TO THE JURISDICTION OF ANY STATE OR FEDERAL COURT LOCATED WITHIN THE STATE IN WHICH EXECUTIVE RESIDES AND IRREVOCABLY AGREE THAT SUBJECT TO THE COMPANY&#8217;S ELECTION, ALL ACTIONS OR PROCEEDINGS ARISING OUT OF OR RELATING TO THIS AGREEMENT SHALL BE LITIGATED IN SUCH COURTS.  EXECUTIVE ACCEPTS FOR HIMSELF&#47;HERSELF AND IN CONNECTION WITH HIS&#47;HER PROPERTIES, GENERALLY AND UNCONDITIONALLY, THE NONEXCLUSIVE JURISDICTION OF THE AFORESAID COURTS AND WAIVES ANY DEFENSE OF FORUM NON CONVENIENS, AND IRREVOCABLY AGREES TO BE BOUND BY ANY JUDGMENT RENDERED THEREBY IN CONNECTION WITH THIS AGREEMENT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">Notwithstanding Section 20(a), the parties intend to and hereby confer jurisdiction to enforce the covenants contained in Sections 5 through 7 upon the courts of any jurisdiction within the geographical scope of such covenants.  If the courts of any one or more of such jurisdictions hold such covenants wholly or partially invalid or unenforceable by reason of the breadth of such scope or otherwise, it is the intention of the parties that such determination not bar or in any way affect the Company&#8217;s right to the relief provided above in the courts of any other jurisdiction within the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-12-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">geographical scope of such covenants, as to breaches of such covenants in such other respective jurisdictions, such covenants as they relate to each jurisdiction being, for this purpose, severable into diverse and independent covenants.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Amendment and Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any provision of this Agreement may be amended or waived only with the prior written consent of the Company and Executive, and no course of conduct or course of dealing or failure or delay by any party hereto in enforcing or exercising any of the provisions of this Agreement shall affect the validity, binding effect or enforceability of this Agreement or be deemed to be an implied waiver of any provision of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To the maximum extent permitted by law, this Agreement shall be interpreted in such a manner that the payments to Executive under this Agreement are either exempt from, or comply with, Section 409A, including without limitation any such regulations or other guidance that may be issued after the date hereof.  For purposes of Section 409A, each payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments.  Notwithstanding anything to the contrary in this Agreement, if Executive is a &#8220;specified employee&#8221; as defined below, as of Executive&#8217;s termination of employment, then, to the extent any payment under this Agreement resulting from Executive&#8217;s termination of employment constitutes deferred compensation (after taking into account any applicable exemptions from Section 409A) and to the extent required by Section 409A, no payments due under this Agreement as a result of Executive&#8217;s termination of employment may be made until the earlier of (a) the first day following the six-month anniversary of Executive&#8217;s date of termination and (b) Executive&#8217;s date of death&#59; provided, however, that any payments delayed during this six-month period shall be paid in the aggregate in a lump sum as soon as reasonably practicable following the sixth month anniversary of Executive&#8217;s date of termination.  For purposes of this Agreement, all references to &#8220;termination of employment&#8221; and correlative phrases shall be construed to require a &#8220;separation from service&#8221; (as defined in Treas. Reg. &#167;1.409A-1(h) after giving effect to the presumptions contained therein), and the term &#8220;specified employee&#8221; means an individual determined by the Company to be a specified employee under Treas. Reg. &#167;409A-1(i).</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">*    *    *    *    *    *    *    * </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-13-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have executed this Employment Agreement as of the date first written above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SURGERY PARTNERS, INC.<br><br><br><br>By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; Jennifer Baldock&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><br>      Jennifer Baldock<br>      Executive Vice President and Chief Legal Officer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accepted and Agreed&#58;<br><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Anthony W. Taparo&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><br>Anthony W. Taparo</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;3&#47;8&#47;2022&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-14-</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>a2022q1exhibit103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ibb2e47988885449e9a2ebc27bbef0e76_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.3</font></div></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">AMENDED AND RESTATED EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">THIS AMENDED AND RESTATED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> EMPLOYMENT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is hereby entered into effective as of March 8, 2022 (the &#8220;Effective Date&#8221;), between Surgery Partners, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and Bradley Owens (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company shall employ Executive, and Executive hereby accepts continued employment with the Company, upon the terms and conditions set forth in this Agreement for the period beginning on March 11, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and ending on the Termination Date, as provided for in Section 4 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Position and Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">During the Employment Period, Executive shall serve as Group President.  Executive shall have such responsibilities, duties and authorities, and will render such services for the Company and its Subsidiaries or Affiliates as the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) may from time to time direct.  Executive will devote his&#47;her best efforts, energies and abilities and his&#47;her full business time, skill and attention to the business and affairs of the Company and its Subsidiaries, and shall perform his&#47;her duties and responsibilities to the best of his&#47;her ability, in a diligent, trustworthy, businesslike and efficient manner for the purpose of advancing the businesses of Company and its Subsidiaries.  Executive acknowledges that his&#47;her duties and responsibilities will require his&#47;her full time business efforts and agrees that during the Employment Period he&#47;she will not engage in any other business activity or have any business pursuits that interfere with Executive&#8217;s duties and responsibilities under this Agreement or are competitive with the businesses of the Company.  Notwithstanding the foregoing, Executive shall be permitted to devote a reasonable amount of time and effort to (i) providing service to, or serving on governing boards of, civic and charitable organizations, and (ii) personally investing and managing personal and family investments in real estate and in any corporation, partnership or other entity&#59; but in each case, only to the extent that any of the activities described in clauses (i) or (ii), individually or as a whole, do not (A) require or involve the active participation of Executive in the management of any corporation, partnership or other entity or interfere with the execution of Executive&#8217;s duties hereunder, or (B) otherwise violate any provision of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">For purposes of this Agreement, (i) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any corporation or other entity (A) of which the securities or other ownership interests having the voting power to elect a majority of the board of directors or other governing body are, at the time of determination, owned by the Company, directly or through one or more subsidiaries or (B) to which the Company or any of its Affiliates provide management services, and (ii) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; of an entity means any other person or entity, directly or indirectly controlling, controlled by or under common control with an entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Compensation and Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">(a)&#160;&#160;&#160;&#160;Effective March 20, 2022, during the Employment Period, Executive&#8217;s base salary shall increase from $400,000 to $500,000 per annum, payable by the Company in regular installments in accordance with the Company&#8217;s general payroll practices, less taxes and other applicable withholdings, and subject to review and adjustment from time to time by the Board or the Compensation Committee thereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), in either case, in its discretion (as modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">In addition, during the Employment Period, Executive shall be entitled to participate in all of the Company&#8217;s benefit programs for which employees of the Company are generally eligible, subject to the eligibility and participation requirements thereof, including, but not limited to, the following&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.69pt">medical, dental, vision, life and disability insurance, as is generally provided to other employees of the Company&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">eligibility for vacation time in accordance with the policies of the Company as from time to time in effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">During the Employment Period, the Company shall reimburse Executive for all reasonable out-of-pocket expenses incurred by his&#47;her in the course of performing his&#47;her duties and responsibilities under this Agreement which are consistent with the Company&#8217;s policies in effect from time to time with respect to travel, entertainment and other business expenses, subject to the Company&#8217;s requirements with respect to reporting and documentation of such expenses. Executive&#8217;s right to payment or reimbursement for business expenses hereunder will be subject to the following additional rules&#58; (i) no reimbursement of any expense shall affect Executive&#8217;s right to reimbursement of any other expense in any other taxable year&#59; (ii) the amount of expenses eligible for payment or reimbursement during any calendar year will not affect the expenses eligible for payment or reimbursement in any other taxable year&#59; (iii) payment or reimbursement will be made not later than December 31 of the calendar year following the calendar year in which the expense was incurred or paid, and (iv) the right to payment or reimbursement is not subject to liquidation or exchange for any other benefit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">In addition to the Base Salary, Executive will be eligible to receive an annual bonus of sixty percent (60%) of the Base Salary, with the actual amount of any such bonus being determined by the Board or the Committee, in either case, in its discretion, based on the achievement of performance goals established annually by the Board or the Committee, as applicable.  Any annual bonus payable under this Section 3(d) will be paid no later than March 31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> following the close of the year for which the bonus is earned.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">Executive shall be eligible to participate in the Surgery Partners, Inc. 2015 Omnibus Incentive Plan (as amended from time to time, (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Equity Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) on terms and conditions set forth therein and in the relevant award agreement unless specifically stated otherwise in this Agreement. Executive will be eligible for annual equity grants under the Equity Plan. Initially, the targeted equity grant will be $800,000, subject to approval of the Board (or an authorized committee thereof), in such forms as determined by the Board or its designee in its discretion.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.03pt">All amounts payable to Executive hereunder shall be subject to all required withholdings by the Company.  If additional guidance is issued under, or modifications are made to, Section 409A of the Internal Revenue Code of the Internal Revenue Code and the regulations and other interpretive guidance issued thereunder (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), or any other law affecting payments to be made under this Agreement, Executive agrees that the Company may take such reasonable actions and adopt such reasonable amendments as the Company believes are necessary to ensure continued compliance with the Internal Revenue Code, including Section 409A.  However, the Company does not hereby or otherwise represent or warrant that any payments hereunder are or will be in compliance with Section 409A, and Executive shall be responsible for obtaining his&#47;her own tax advice with regard to such matters.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination by Executive or the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Employment Period (i) shall terminate upon Executive&#8217;s resignation with Good Reason (as defined below) or without Good Reason, death or Incapacity (as defined below) or (ii) may be terminated by the Company at any time for Cause (as defined below) or without Cause.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean without the written consent of Executive&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.69pt">without the express written consent of Executive, a material diminution of his&#47;her position, duties, responsibilities, and status with the Company as in effect as of the Commencement Date or a material reduction of Executive&#8217;s resources as in effect on the Commencement Date&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">a material reduction in Executive&#8217;s Base Salary or annual bonus target percentage&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.03pt">a material reduction in the level of benefits available or awarded to Executive, other than any reduction in connection with a Company-wide reduction applicable generally to similarly situated executive officers of the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">within twelve months of a Change in Control (as defined herein), a material increase in Executive&#8217;s core functional responsibilities with a corresponding material change in Executive&#8217;s core functional role without a corresponding increase in compensation, provided, however, the addition of additional facilities or territories to Executive&#8217;s oversight responsibilities or other ordinary course growth of the Company or any of its Subsidiaries or Affiliates shall not be a material increase in Executive&#8217;s core functional responsibilities&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">a relocation by the Company of Executive&#8217;s primary employment location to a location which is more than 50 miles from Executive&#8217;s primary employment location on the date hereof&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">a material breach by the Company of the terms of this Agreement&#59; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">but only if (x) Executive notifies the Company in writing within 90 days after the initial existence or occurrence of any of these conditions which notice describes in reasonable detail the basis for Executive&#8217;s belief that Good Reason exists and that Executive intends to resign for Good Reason and the Company, within 30 days after receipt of such notice, either fails to cure the condition or delivers a written notice to Executive that the Company intends not to cure such condition and (y) Executive actually resigns prior to 15 days after the earlier to occur of either the end of such 30-day cure period or delivery of such written notice by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Incapacity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as used herein shall mean that Executive is unable to perform, with or without reasonable accommodation, by reason of physical or mental incapacity, the essential duties, responsibilities and functions of his&#47;her position.  A medical examination by a physician selected by the Company to whom Executive or his&#47;her duly appointed guardian, if any, has no reasonable objection shall determine, according to the facts then available, whether and when Incapacity has occurred.  Such determination shall not be arbitrary or unreasonable, and shall be final and binding on the parties hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as used herein means the occurrence of any of the following events&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.69pt">a material breach by Executive of any of the terms and conditions of this Agreement&#59; provided that, if curable, Executive shall have a reasonable period of time (which in no event shall exceed 45 days) during which to cure such material breach following the date on which Executive receives the Company&#8217;s written notice of such material breach&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">Executive&#8217;s reporting to work (A) intoxicated (other than Executive&#8217;s reasonable use of alcohol in connection with business entertainment, provided, that such use of alcohol does not cause the Company or any of its Subsidiaries or Affiliates substantial public disgrace or disrepute or economic harm) or (B) under the influence of illegal drugs&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.03pt">Executive&#8217;s use of illegal drugs (whether or not at the workplace) or other conduct causing the Company or any of its Subsidiaries or Affiliates substantial public disgrace or disrepute or economic harm&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">breach of fiduciary duty, gross negligence or willful misconduct with respect to the Company or any of its Subsidiaries or Affiliates&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">chronic absenteeism, which shall be deemed to have occurred if Executive has at least ten absences unrelated to paid time off, disability or illness in any ten week period&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">Executive&#8217;s material failure or willful refusal to substantially perform his&#47;her duties, responsibilities and functions&#59; provided that, if curable, Executive shall have a reasonable period of time (which in no event shall exceed 45 days) during which to cure such failure following the date on which Executive receives the Company&#8217;s written notice of such failure&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.36pt">Executive&#8217;s failure to comply with any of the Company&#8217;s or any of its Subsidiaries&#8217; written guidelines or procedures promulgated by the Company or any such Subsidiary and furnished to Executive, including, without limitation, any guidelines or procedures relating to marketing or community relations&#59; provided that, if curable, Executive shall have a reasonable period of time (which in no event shall exceed 45 days) during which to cure such failure following the date on which Executive receives the Company&#8217;s written notice of such failure&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:12.03pt">Executive has committed an act or acts constituting a felony or any other act or omission involving theft, dishonesty or fraud against the Company or any of its Subsidiaries or any of their respective customers or suppliers or other business relationships.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">A &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall be deemed to have occurred upon any of the following events, provided that, to the extent required by Section 409A, such events would also qualify as a &#8220;change in control event&#8221; under Treas. Reg. &#167;1.409A-3(i)(5)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.69pt">Upon the closing of a reorganization, merger, share exchange or consolidation, other than a reorganization, merger, share exchange or consolidation with respect to which those persons who were the beneficial owners, immediately prior to such reorganization, merger, share exchange or consolidation, of outstanding securities of the Company ordinarily having the right to vote in the election of directors own, immediately after the closing of such transaction, more than 51% of the outstanding securities of the resulting corporation ordinarily having the right to vote in the election of directors&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">Upon approval by the stockholders of a complete liquidation and dissolution of the Company or the sale or other disposition of all or substantially all of the assets of the Company other than to a Subsidiary or Affiliate.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Termination by Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive has the right to terminate his&#47;her employment under this Agreement at any time, for any or no reason, but only after giving the Company (i) 30 days prior written notice with respect to any termination without Good Reason or (ii) the number of days prior written notice set forth in the last sentence of Section 4(b) with respect to any termination with Good Reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Compensation after Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.69pt">If the Employment Period is terminated pursuant to Executive&#8217;s resignation without Good Reason, death or Incapacity, Executive shall only be entitled to receive his&#47;her Base Salary through the date of termination and shall not be entitled to any other salary, bonus, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-4-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">compensation or benefits from the Company or its Subsidiaries, except as may be required by applicable law.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">If the Employment Period is terminated by the Company for Cause, Executive shall only be entitled to his&#47;her Base Salary through the date of termination and shall not be entitled to any other salary, bonus, compensation or benefits from the Company or its Subsidiaries, except as may be required by applicable law.  In addition, in such event, Executive shall automatically forfeit any rights to any unvested equity owned by Executive in the Company or any Subsidiary.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.03pt">If the Employment Period is terminated by the Company without Cause or by Executive for Good Reason, then subject to the conditions described in Section 4(g)(v) below, Executive shall be entitled to receive as severance compensation the following (collectively, &#8220;Severance Pay&#8221;)&#58; (A) an amount equal to twelve (12) months of Executive&#8217;s then-current annual Base Salary, payable in regular installments beginning within 30 days following the Termination Date in accordance with the Company&#8217;s general payroll practices for salaried employees&#59; (B) continuation of the welfare benefits described in Section 3(b) for twelve (12) months to the extent permissible under the terms of the relevant benefit plans at the same cost to Executive as if Executive were an active employee of the Company&#59; (C) the Bonus payable to Executive within 3 months after the end of the applicable year (to the extent not previously paid), paid in a lump sum at the time that bonuses are regularly paid to employees&#59; (D) with respect to the portion of each restricted stock award held by Executive as of date on which the Employment Period is terminated that is subject to time-based vesting (the &#8220;Time-Based RSA&#8221;), accelerated vesting of the Time-Based RSA to the vesting event next following the date on which the Employment Period is terminated&#59; and (E) with respect to the portion of each performance stock unit award held by the Executive as of the date on which the Employment Period is terminated that has been converted into &#8220;earned shares&#8221; (the &#8220;Earned PSUs&#8221;), accelerated vesting of the Earned PSUs to the vesting event next following the date on which the Employment Period is terminated&#59; and (F) with respect to each performance stock unit award issued after December 31, 2021, held by the executive as of the date on which the Employment Period ends that have not been converted to Earned PSUs, the Executive&#8217;s rights under the award will be fully vested based on the number of shares that would be earned under the award based on performance measured through the end of Employment Period.  For purposes of this Section 4(g), &#8220;Bonus&#8221; shall mean an amount equal to Executive&#8217;s then-current annual Base Salary, multiplied by the percentage contained in Section 3(d) hereof. For the avoidance of doubt, the unvested portion of any restricted stock awards and performance share unit awards held by Executive as of the date on which the Employment Period ends (after giving effect to the acceleration provisions set forth in subsections (D), (E) and (F) herein and the terms and conditions of the applicable award agreements and the Surgery Partners, Inc. 2015 Omnibus Incentive Plan (as amended from time to time)) shall be forfeited and of no further force and effect.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">If, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within 90 days prior to or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12 months following a Change in Control, either (A) the Company terminates the employment of Executive hereunder without Cause under Section 4(a) above, or (B) Executive terminates his&#47;her employment for Good Reason under Section 4(b) above, then, in lieu of any other compensation that may be specified in this Agreement, the Company will pay Executive the Severance Pay in a single lump-sum payment not later than 30 days after termination.  If any payment obligation under this Section 4(g) arises, no compensation received from other employment (or otherwise) will reduce the Company&#8217;s obligation to make the payment(s) described in this paragraph.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">Notwithstanding Sections 4(g)(iii) or (iv), Executive&#8217;s right to receive Severance Pay hereunder is conditioned upon&#58; (A) Executive executing, and not revoking, a written separation agreement and general release of all claims against the Company, its Subsidiaries and Affiliates and their respective managers, directors, officers, shareholders, members, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-5-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">representatives, agents, attorneys, predecessors, successors and assigns (other than a claim for the severance payments described in Section 4(g)(iii) or (iv) and Executive&#8217;s rights to future distributions and payments related to the continued ownership of any equity securities in the Company that Executive will continue to own after such termination), in form and substance acceptable to the Company, which shall among other things, contain a general release by Executive of all claims arising out of his&#47;her employment and termination of employment by the Company (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Release Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) within 30 days of Executive&#8217;s Termination Date&#59; and (B) Executive&#8217;s material compliance with all of his&#47;her obligations which survive termination of this Agreement.  The Severance Pay is intended to be in lieu of all other payments to which Executive might otherwise be entitled in respect of his&#47;her termination without Cause or resignation with Good Reason.  The Company and its Subsidiaries and Affiliates shall have no further obligations hereunder or otherwise with respect to Executive&#8217;s employment from and after the date of termination of employment with the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and the Company and its Subsidiaries and Affiliates shall continue to have all other rights available hereunder (including without limitation, all rights hereunder at law or in equity).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">Notwithstanding the foregoing, the Release Agreement (x) shall not require the release of Executive&#8217;s rights arising from the express terms of this Agreement or any applicable award agreement that are associated with a termination of employment&#59; (y) shall not impose any postemployment restrictions other than those set forth in this Agreement, and (z) shall take into account and preserve Executive&#8217;s rights in the event that a Change in Control occurs within 90 days after termination of employment (or such longer tail period as may be provided by any agreement between Executive and the Company).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.36pt">Except as otherwise expressly provided herein, all of Executive&#8217;s rights to salary, bonuses, benefits and other compensation hereunder which might otherwise accrue or become payable after the termination of the Employment Period shall cease upon such termination, other than those expressly required under applicable law (such as COBRA).  All amounts payable to Executive as severance hereunder shall be subject to all required withholdings by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company may offset any amount Executive owes the Company or its Subsidiaries or Affiliates against any amount they or their Subsidiaries or Affiliates owe Executive hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Confidential Information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other than in the performance of his&#47;her duties hereunder, during the Restrictive Period (as defined below) and thereafter, Executive shall keep secret and retain in strictest confidence, and shall not, without the prior written consent of the Company, furnish, make available or disclose to any third party or use for the benefit of himself or any third party, any Confidential Information.  As used in this Agreement, &#8220;Confidential Information&#8221; shall mean any information relating to the business or affairs of the Company or any of its Subsidiaries or Affiliates or the Business, including but not limited to any technical or non-technical data, formulae, compilations, programs, devices, methods, techniques, designs, processes, procedures, improvements, models, manuals, financial data, acquisition strategies and information, information relating to operating procedures and marketing strategies, and any other proprietary information used by the Company or any of its Subsidiaries or Affiliates in connection with the Business, irrespective of its form&#59; provided, however, that Confidential Information shall not include any information which is in the public domain or becomes known in the industry, in each case through no wrongful act on the part of Executive.  Executive acknowledges that the Confidential Information is vital, sensitive, confidential and proprietary to the Company and its Subsidiaries and Affiliates.  Executive will immediately notify the Company of any unauthorized possession, use, disclosure, copying, removal or destruction, or attempt thereof, of any Confidential Information by anyone of which Executive becomes aware and of all details thereof.  Executive shall take all reasonably appropriate steps to safeguard Confidential Information and to protect it against disclosure, misuse, espionage, loss and theft.  Executive shall deliver to the Company at the termination or expiration of the Employment Period, or at any other time the Company may request, all memoranda, notes, plans, records, reports, computer tapes, computers, printouts and software and other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-6-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">documents and data (and copies thereof) embodying or relating to the Confidential Information, Inventions and Discoveries (as defined below) or the business of the Company or any of its Subsidiaries or Affiliates which Executive may then possess or have under his&#47;her control.  Nothing in this Agreement limits, restricts or in any other way affects Executive&#8217;s communicating with any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, concerning matters relevant to the governmental agency or entity, or requires Executive to provide notice to the Company of the same.  Executive cannot be held criminally or civilly liable under any federal or state trade secret law for disclosing a trade secret (1) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating a suspended violation of law, or (2) in a compliant or other document filed under seal in a lawsuit or other proceeding.  Notwithstanding this immunity from liability, Executive may be held liable if Executive unlawfully accesses trade secrets by unauthorized means.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as used herein means the business of owning, operating, developing and&#47;or managing, or providing management or administrative services to, (a) ambulatory surgery centers anywhere in the United States or (b) physician-owned surgical hospitals within a 50 mile radius of any hospital that is owned, operated, developed or managed by the Company or any Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Inventions and Discoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">Executive understands and agrees that all inventions, discoveries, ideas, improvements, whether patentable, copyrightable or not, pertaining to the Business or relating to Company&#8217;s or any of its Subsidiaries&#8217; or Affiliates&#8217; actual or demonstrably anticipated research, development or inventions (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Inventions and Discoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that result from any work performed by Executive solely or jointly with others for the Company or any of its Subsidiaries or Affiliates which Executive, solely or jointly with others, conceives, develops, or reduces to practice during the course of Executive&#8217;s employment with the Company or any of its Subsidiaries, are the sole and exclusive property of the Company.  Executive will promptly disclose all such matters to the Company and will assist the Company in obtaining legal protection for Inventions and Discoveries.  Executive hereby agrees on behalf of himself, his&#47;her executors, legal representatives and assignees that he&#47;she will assign, transfer and convey to the Company, its successors and assigns the Inventions and Discoveries.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">THE COMPANY AND EXECUTIVE ACKNOWLEDGE AND AGREE THAT SECTION 6(a) SHALL NOT APPLY TO AN INVENTION OF EXECUTIVE FOR WHICH NO EQUIPMENT, SUPPLIES, FACILITY OR TRADE SECRET INFORMATION OF THE COMPANY OR ANY OF ITS SUBSIDIARIES WAS USED AND WHICH WAS DEVELOPED ENTIRELY ON EXECUTIVE&#8217;S OWN TIME, UNLESS (A) THE INVENTION RELATED (I) TO THE BUSINESS OF THE COMPANY OR ANY OF ITS SUBSIDIARIES OR AFFILIATES OR (II) TO THE COMPANY&#8217;S OR ANY OF ITS SUBSIDIARIES&#8217; OR AFFILIATES&#8217; ACTUAL OR DEMONSTRABLY ANTICIPATED RESEARCH OR DEVELOPMENT, OR (B) THE INVENTION RESULTS FROM ANY WORK PERFORMED BY EXECUTIVE FOR THE COMPANY OR ANY OF ITS SUBSIDIARIES OR AFFILIATES.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">EXECUTIVE ACKNOWLEDGES THAT HE&#47;SHE HAS READ THIS SECTION 6 AND FULLY UNDERSTANDS THE LIMITATIONS WHICH IT IMPOSES UPON HIM AND HAS RECEIVED A DUPLICATE COPY OF THIS AGREEMENT FOR HIS&#47;HER RECORDS.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive acknowledges that in the course of his&#47;her employment with the Company or any of its Subsidiaries or Affiliates, or their predecessors or successors, he&#47;she has been and will be given access to and has and will become familiar with their trade secrets and with other Confidential Information and that his&#47;her services have been and shall be of special, unique and extraordinary value to the Company and its Subsidiaries or Affiliates.  Therefore, and in further consideration of the compensation to be paid to Executive hereunder and in connection with his&#47;her </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-7-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">employment, and to protect the Company&#8217;s and its Subsidiaries&#8217; and Affiliates&#8217; Confidential Information, business interests and goodwill&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Non-compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive hereby agrees that for a period commencing on the date hereof and ending on the Termination Date, and thereafter, through the period ending twelve (12) months after the Termination Date (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictive Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), he&#47;she shall not, directly or indirectly, as employee, agent, consultant, stockholder, director, co-partner or in any other individual or representative capacity, own, operate, manage, control, engage in, invest in or participate in any manner in, act as a consultant or advisor to, render services for (alone or in association with any person, firm, corporation or entity), or otherwise assist any person or entity (other than the Company and its Subsidiaries) that engages in or owns, invests in, operates, manages or controls any venture or enterprise that directly or indirectly engages or is actively developing or attempting to develop in any element of the Business anywhere within a 50-mile radius of the Nashville, Tennessee metropolitan area or within a 50-mile radius of any area (or in the event such area is a major city, the metropolitan area relating to such city) in which the Company or any of its Subsidiaries on the Termination Date actively engages or is actively developing or attempting to develop in any element of the Business (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; provided, however, that nothing contained herein shall be construed to prevent Executive from investing in the stock of any competing corporation listed on a national securities exchange or traded in the over-the-counter market, but only if Executive is not involved in the business of said corporation and if Executive and his&#47;her associates (as such term is defined in Regulation 14(A) promulgated under the Securities Exchange Act of 1934, as in effect on the date hereof), collectively, do not own more than an aggregate of 3% of the stock of such corporation.  With respect to the Territory, Executive specifically acknowledges that the Company and its Subsidiaries intend to expand the Business into and throughout the United States.  Notwithstanding the foregoing, the activity proscribed by this Section 7(a) shall not constitute a violation of this Section 7(a) where performed for (x) an entity where no more than a de minimis amount of revenue is derived from a business that is competitive with the business of the Company or any of its Affiliates&#59; or (y) an entity that derives no more than $100 million in revenue from one or more divisions, departments or segments, in the aggregate, that are engaged in any business competitive with the business of the Company or any of its Affiliates&#59; provided, that in either case, you are not responsible for (and do not engage or participate in) the day-to-day management, oversight or supervision of such business and provided you do not have direct supervision over the individual or individuals who are so responsible for such day-to-day management, oversight or supervision.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Interference with Relationships</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Without limiting the generality of the provisions of Section 7(a) hereof, Executive hereby agrees that, for a period commencing on the Commencement Date and ending on the Termination Date, and thereafter, through the period ending twelve (12) months after the Termination Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Solicit Restrictive Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), he&#47;she will not, directly or indirectly, as employee, agent, consultant, stockholder, director, partner or in any other individual or representative capacity, (i) solicit or encourage, or participate in any business which solicits or encourages (A) any person, firm, corporation or other entity which has executed, or proposes to execute, a management services agreement or other services agreement with the Company or any of its Subsidiaries at any time during the term of this Agreement, or any successor in interest to any such person, firm, corporation or other entity, for the purpose of securing business or contracts related to any element of the Business, or (B) any present customer or patient of the Company or any of its Subsidiaries or any of their Affiliated Practices to terminate or otherwise alter his, her or its relationship with the Company or any of its Subsidiaries or such Affiliated Practice&#59; provided, however, that nothing contained herein shall be construed to prohibit or restrict Executive from soliciting business from any such parties on behalf of the Company or any of its Subsidiaries in performance of his&#47;her duties as an employee of the Company required under and as specifically contemplated by Section 2 above or (ii) divert, entice away, solicit or encourage, or attempt to divert, entice away, solicit or encourage, any physician who utilizes or has invested in an Affiliated Practice to become an owner, investor or user of another practice or facility that is not an Affiliated Practice or approach any such physician for any of the foregoing purposes or authorize or assist in the taking of any such action by any third party.  In addition, at all times from and after the Termination Date, Executive shall not contact or communicate in any manner with any of Company&#8217;s, or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-8-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">any of its Subsidiaries&#8217; or Affiliates&#8217; suppliers or vendors, or any other third party providing services to the Company or any of its Subsidiaries, regarding the Company or any of its Subsidiaries or any Company- or any such Subsidiary-related matter (which suppliers, vendors or third party service providers will include, without limitation, any third party with whom the Company or any of its Subsidiaries was, during the term of Executive&#8217;s employment with the Company or any of its Subsidiaries, contemplating engaging, or negotiating with, for the future provision of products or services).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provided, however, that these restrictions shall apply (x) only with respect to those persons who are or have been a business partner of the Company or any of its Affiliates at any time within the immediately preceding two (2)-year period or whose business has been solicited on behalf of the Company or any of the Affiliates by any of their officers, employees or agents within such two (2)-year period, other than by form letter, blanket mailing or published advertisement, and (y) only if Executive has performed work for such person during his employment with the Company or one of its Affiliates or been introduced to, or otherwise had contact with, such person as a result of his employment or other associations with the Company or one of its Affiliates or have had access to Confidential Information which would assist in his solicitation of such person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Non-solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Other than in the performance of his&#47;her duties hereunder, during the Non-Solicit Restrictive Period, Executive shall not, directly or indirectly, as employee, agent, consultant, stockholder, director, co partner or in any other individual or representative capacity, employ, recruit or solicit for employment or engagement, any person who is employed or engaged by the Company or any of its Subsidiaries or any of its Affiliated Practices during the Non- Solicit Restrictive Period, or otherwise seek to influence or alter any such person&#8217;s relationship with any of the Affiliated Practices, the Company or any of its Subsidiaries&#59; provided, however that responses to a general solicitation (such as an internet or newspaper solicitation) that are not targeted towards any particular person shall not be deemed to be a violation of the restrictions set forth in this Section 7(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Affiliated Practice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For purposes of this Agreement, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliated Practice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall include any practice or facility (i) in which the Company or any of its Subsidiaries has an ownership interest or (ii) that is managed by or receives other services from the Company or any of its Subsidiaries in connection with any element of the Business.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Blue Pencil</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If any court of competent jurisdiction shall at any time deem the term of this Agreement or any particular Restrictive Covenant (as defined below) too lengthy or the Territory too extensive, the other provisions of this Section 7 shall nevertheless stand, the Restrictive Period herein shall be deemed to be the longest period permissible by law under the circumstances and the Territory herein shall be deemed to comprise the largest territory permissible by law under the circumstances.  The court in each case shall reduce the time period and&#47;or Territory to permissible duration or size.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Covenant Not to Disparage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  During the Restrictive Period and thereafter, Executive shall not disparage, denigrate or derogate in any way, directly or indirectly, the Company, any of its Subsidiaries or Affiliates, or any of its or their respective agents, officers, directors, employees, parent, subsidiaries, affiliates, Affiliated Practices, affiliated doctors (including any physicians who utilize or have invested in any Affiliated Practice), representatives, attorneys, executors, administrators, successors and assigns (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Protected Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), nor shall Executive disparage, denigrate or derogate in any way, directly or indirectly, his&#47;her experience with any Protected Party, or any actions or decisions made by any Protected Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive acknowledges and agrees that the covenants set forth in this Section 7 and the preceding Sections 5 and 6 (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) are reasonable and necessary for the protection of the business interests of the Company and its Subsidiaries and Affiliates, that irreparable injury may result to the Company and its Subsidiaries and Affiliates if Executive breaches any of the terms of said Restrictive Covenants, and that in the event of Executive&#8217;s actual or threatened breach of any such Restrictive Covenants, the Company and its Subsidiaries and Affiliates will have no adequate remedy at law.  Executive accordingly agrees that in the event of any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-9-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">actual or threatened breach by him of any of the Restrictive Covenants, the Company and its Subsidiaries and Affiliates shall be entitled to immediate temporary injunctive and other equitable relief subject to hearing as soon thereafter as possible.  Nothing contained herein shall be construed as prohibiting the Company or any of its Subsidiaries or Affiliates from pursuing any other remedies available to it for such breach or threatened breach, including the recovery of any damages which it is able to prove.  In addition and supplementary to other rights and remedies existing in its (or their) favor, in the event of the material breach by Executive of any of the provisions of this Section 7, the Company (and&#47;or its Subsidiaries or Affiliates) shall be entitled to require Executive to account for and pay over to the Company (and&#47;or its Subsidiaries or Affiliates) all compensation, profits, moneys, accruals, increments or other benefits actually derived from or received as a result of any transactions constituting a breach of the covenants contained in this Agreement which may require Executive to repay any severance.  In addition, in the event of an alleged breach or violation by Executive of this Section 7, the restricted periods set forth in this Section 7 shall be tolled until such breach or violation has been duly cured.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">Executive understands that the foregoing restrictions may limit his&#47;her ability to earn a livelihood in a business similar to the business of the Company and its Subsidiaries or Affiliates, but he&#47;she nevertheless believes that he&#47;she has received and will receive sufficient consideration and other benefits as an executive of the Company and as otherwise provided hereunder to clearly justify such restrictions which, in any event (given his&#47;her education, skills and ability), Executive does not believe would prevent him from otherwise earning a living.  Executive acknowledges that the Restrictive Covenants are reasonable and that he&#47;she has reviewed the provisions of this Agreement with his&#47;her legal counsel.  During the Restricted Period, Executive shall inform any prospective or future employer of any and all restrictions contained in this Agreement and provide such employer with a copy of such restrictions, prior to the commencement of that employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Executive&#8217;s Representations and Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">Executive hereby represents and warrants to the Company that (i) the execution, delivery and performance of this Agreement by Executive do not and shall not conflict with, breach, violate or cause a default under any contract, agreement, instrument, order, judgment or decree to which Executive is a party or by which he&#47;she is bound, (ii) Executive is not a party to or bound by any employment agreement, non-compete agreement or confidentiality agreement with any other person or entity and (iii) upon the execution and delivery of this Agreement by the Company, this Agreement shall be the valid and binding obligation of Executive, enforceable in accordance with its terms.  Executive hereby acknowledges and represents that he&#47;she has consulted with independent legal counsel regarding his&#47;her rights and obligations under this Agreement and that he&#47;she fully understands the terms and conditions contained herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">During the Employment Period and thereafter, Executive shall cooperate with the Company and its Subsidiaries and Affiliates in any internal investigation or administrative, regulatory or judicial proceeding as reasonably requested by the Company (including, without limitation, Executive being available to the Company upon reasonable notice for interviews and factual investigations, appearing at the Company&#8217;s request to give testimony without requiring service of a subpoena or other legal process, volunteering to the Company all pertinent information and turning over to the Company all relevant documents which are in or may come into Executive&#8217;s possession, all at times and on schedules that are reasonably consistent with Executive&#8217;s other permitted activities and commitments).  In the event the Company requires Executive&#8217;s cooperation in accordance with this Section 8(b), the Company shall reimburse Executive for reasonable travel expenses (including, without limitation, travel expenses, lodging and meals, and reasonable attorneys&#8217; fees upon submission of receipts).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Sections 4 through 22 shall survive and continue in full force in accordance with their terms notwithstanding the expiration or termination of the Employment Period.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-10-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any notices provided for in this Agreement shall be in writing and shall be effective when delivered in person or deposited in the United States mail, postage prepaid, and addressed to Executive at his&#47;her last known address on the books of the Company or, in the case of the Company, to it at its principal place of business, attention of the Chief Executive Officer, or to such other address as either party may specify by notice to the other actually received.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Complete Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement, those documents expressly referred to herein and other documents of even date herewith, embody the complete agreement and understanding among Executive and the Company and its Subsidiaries and, as of the Effective Date, shall supersede and preempt any prior understandings, agreements or representations by or among the parties, written or oral, which may have related to the subject matter hereof in any way, including, for the avoidance of doubt, the Employment Agreement, dated November 12, 2019, between the Company and the Executive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">No Strict Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The language used in this Agreement will be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction will be applied against any party hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement may be executed in separate counterparts (including by facsimile or PDF signature pages), each of which is deemed to be an original and all of which taken together constitute one and the same agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company and its successors and permitted assigns.  Executive may not assign any of his&#47;her rights or obligations hereunder without the prior written consent of the Company.  The Company may (a) assign any or all of its respective rights and interests hereunder to one or more Subsidiaries or Affiliates of the Company, (b) designate one or more Subsidiaries or Affiliates of the Company to perform its obligations hereunder (in any or all of which cases the Company nonetheless shall remain responsible for the performance of all of its obligations hereunder), (c) assign its rights hereunder in connection with the sale of all or a substantial part of the business or assets of the Company or one of its Subsidiaries (whether by merger, sale of stock or assets, recapitalization or otherwise) and (d) merge any of the Subsidiaries or Affiliates with or into the Company (or vice versa).  The rights of the Company hereunder are enforceable by the Company or its Subsidiaries or Affiliates, which are the intended third party beneficiaries hereof and no other third party beneficiary is so otherwise intended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Delivery by Facsimile or PDF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement and any amendments hereto, to the extent signed and delivered by means of a facsimile machine or PDF, shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.  At the request of any party hereto, each other party hereto shall re-execute original forms thereof and deliver them to the other party.  No party hereto shall raise the use of a facsimile machine or PDF to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of a facsimile machine or PDF as a defense to the formation or enforceability of a contract and each such party forever waives any such defense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Income Tax Treatment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive and the Company acknowledge that it is the intention of the Company to deduct all cash amounts paid under this Agreement as ordinary and necessary business expenses for income tax purposes.  Executive agrees and represents that he&#47;she will treat all such non-</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-11-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">reimbursable amounts as ordinary income for income tax purposes, and should he&#47;she report such amounts as other than ordinary income for income tax purposes, he&#47;she will indemnify and hold the Company harmless from and against any and all taxes, penalties, interest, costs and expenses, including reasonable attorneys&#8217; and accounting fees and costs, which are incurred by Company directly or indirectly as a result thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Agreement shall be governed by, the laws of the state in which Executive resides, without giving effect to provisions thereof regarding conflict of laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  THE PARTIES HERETO HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT.  THE PARTIES HERETO ALSO WAIVE ANY BOND OR SURETY OR SECURITY UPON SUCH BOND WHICH MIGHT, BUT FOR THIS WAIVER, BE REQUIRED OF THE OTHER PARTY.  THE PARTIES HERETO ACKNOWLEDGE THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS ALREADY RELIED ON THE WAIVER IN ENTERING INTO THIS AGREEMENT AND THAT EACH WILL CONTINUE TO RELY ON THE WAIVER IN THEIR RELATED FUTURE DEALINGS.  THE COMPANY AND EXECUTIVE FURTHER WARRANT AND REPRESENT THAT EACH HAS REVIEWED THIS WAIVER WITH THEIR RESPECTIVE LEGAL COUNSEL, AND THAT EACH KNOWINGLY AND VOLUNTARILY WAIVES THEIR RESPECTIVE JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.  THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING, AND THE WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THE TRANSACTION CONTEMPLATED HEREBY.  IN THE EVENT OF LITIGATION, THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Consent to Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.7pt">THE COMPANY AND EXECUTIVE HEREBY CONSENT TO THE JURISDICTION OF ANY STATE OR FEDERAL COURT LOCATED WITHIN THE STATE IN WHICH EXECUTIVE RESIDES AND IRREVOCABLY AGREE THAT SUBJECT TO THE COMPANY&#8217;S ELECTION, ALL ACTIONS OR PROCEEDINGS ARISING OUT OF OR RELATING TO THIS AGREEMENT SHALL BE LITIGATED IN SUCH COURTS.  EXECUTIVE ACCEPTS FOR HIMSELF&#47;HERSELF AND IN CONNECTION WITH HIS&#47;HER PROPERTIES, GENERALLY AND UNCONDITIONALLY, THE NONEXCLUSIVE JURISDICTION OF THE AFORESAID COURTS AND WAIVES ANY DEFENSE OF FORUM NON CONVENIENS, AND IRREVOCABLY AGREES TO BE BOUND BY ANY JUDGMENT RENDERED THEREBY IN CONNECTION WITH THIS AGREEMENT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.02pt">Notwithstanding Section 20(a), the parties intend to and hereby confer jurisdiction to enforce the covenants contained in Sections 5 through 7 upon the courts of any jurisdiction within the geographical scope of such covenants.  If the courts of any one or more of such jurisdictions hold such covenants wholly or partially invalid or unenforceable by reason of the breadth of such scope or otherwise, it is the intention of the parties that such determination not bar or in any way affect the Company&#8217;s right to the relief provided above in the courts of any other jurisdiction within the geographical scope of such covenants, as to breaches of such covenants in such other respective jurisdictions, such covenants as they relate to each jurisdiction being, for this purpose, severable into diverse and independent covenants.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Amendment and Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any provision of this Agreement may be amended or waived only with the prior written consent of the Company and Executive, and no course of conduct or course of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-12-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">dealing or failure or delay by any party hereto in enforcing or exercising any of the provisions of this Agreement shall affect the validity, binding effect or enforceability of this Agreement or be deemed to be an implied waiver of any provision of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To the maximum extent permitted by law, this Agreement shall be interpreted in such a manner that the payments to Executive under this Agreement are either exempt from, or comply with, Section 409A, including without limitation any such regulations or other guidance that may be issued after the date hereof.  For purposes of Section 409A, each payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments.  Notwithstanding anything to the contrary in this Agreement, if Executive is a &#8220;specified employee&#8221; as defined below, as of Executive&#8217;s termination of employment, then, to the extent any payment under this Agreement resulting from Executive&#8217;s termination of employment constitutes deferred compensation (after taking into account any applicable exemptions from Section 409A) and to the extent required by Section 409A, no payments due under this Agreement as a result of Executive&#8217;s termination of employment may be made until the earlier of (a) the first day following the six-month anniversary of Executive&#8217;s date of termination and (b) Executive&#8217;s date of death&#59; provided, however, that any payments delayed during this six-month period shall be paid in the aggregate in a lump sum as soon as reasonably practicable following the sixth month anniversary of Executive&#8217;s date of termination.  For purposes of this Agreement, all references to &#8220;termination of employment&#8221; and correlative phrases shall be construed to require a &#8220;separation from service&#8221; (as defined in Treas. Reg. &#167;1.409A-1(h) after giving effect to the presumptions contained therein), and the term &#8220;specified employee&#8221; means an individual determined by the Company to be a specified employee under Treas. Reg. &#167;409A-1(i).</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">*    *    *    *    *    *    *    * </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-13-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have executed this Employment Agreement as of the date first written above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SURGERY PARTNERS, INC.<br><br><br><br>By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; Jennifer Baldock&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><br>      Jennifer Baldock<br>      Executive Vice President and Chief Legal Officer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accepted and Agreed&#58;<br><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Bradley Owens&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><br>Bradley Owens</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;3&#47;8&#47;2022&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-14-</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>a2022q1exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib887e77ad5b34ccba78c39215de86c73_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;text-align:right;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="padding-left:18pt;text-align:right;text-indent:-18pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">I, J. Eric Evans, certify that&#58; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1. &#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Surgery Partners, Inc.&#59;</font></div><div style="text-align:justify;text-indent:13.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2. &#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify;text-indent:13.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3. &#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify;text-indent:13.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:20.25pt"><font><br></font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c) &#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:20.25pt"><font><br></font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:180pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:304.50pt"><tr><td style="width:1.0pt"></td><td style="width:22.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;  J. Eric Evans</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J. Eric Evans</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date&#58;  May&#160;3, 2022 </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>a2022q1exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6b11bff1c87146da9281883d9cd47184_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="padding-left:18pt;text-align:right;text-indent:-18pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">I, David T. Doherty, certify that&#58; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1. &#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Surgery Partners, Inc.&#59;</font></div><div style="text-align:justify;text-indent:13.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2. &#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify;text-indent:13.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3. &#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify;text-indent:13.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:20.25pt"><font><br></font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:20.25pt"><font><br></font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:180pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:304.50pt"><tr><td style="width:1.0pt"></td><td style="width:22.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;  David T. Doherty</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">David T. Doherty</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date&#58;  May&#160;3, 2022</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>a2022q1exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i24822a9af18a415db481b22d46310eba_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the quarterly report of Surgery Partners, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned certifies, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:180pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:304.50pt"><tr><td style="width:1.0pt"></td><td style="width:22.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;  J. Eric Evans</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J. Eric Evans</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date&#58;  May&#160;3, 2022 </font></div><div style="padding-left:180pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:304.50pt"><tr><td style="width:1.0pt"></td><td style="width:22.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;  David T. Doherty</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">David T. Doherty</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date&#58;  May&#160;3, 2022 </font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>sgry-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b4dabe6f-88db-4fc2-b66b-139c1a2f1a72,g:e82a3438-fa59-433e-866a-e64d4d57702b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sgry="http://www.surgerypartners.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.surgerypartners.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgry-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgry-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgry-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgry-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.surgerypartners.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPolicies" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesPolicies" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesTables" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables">
        <link:definition>2303301 - Disclosure - Organization and Summary of Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesOrganizationDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails">
        <link:definition>2404401 - Disclosure - Organization and Summary of Accounting Policies - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesCARESACTDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails">
        <link:definition>2405402 - Disclosure - Organization and Summary of Accounting Policies - CARES ACT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails">
        <link:definition>2406403 - Disclosure - Organization and Summary of Accounting Policies - Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails">
        <link:definition>2407404 - Disclosure - Organization and Summary of Accounting Policies - Carrying Amount and Fair Value of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails">
        <link:definition>2408405 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails">
        <link:definition>2409406 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Revenues by Sources (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesRollforwardofGoodwillDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRollforwardofGoodwillDetails">
        <link:definition>2410407 - Disclosure - Organization and Summary of Accounting Policies - Rollforward of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails">
        <link:definition>2411408 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Non-Controlling Interests - Redeemable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails">
        <link:definition>2412409 - Disclosure - Organization and Summary of Accounting Policies - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDisposals" roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposals">
        <link:definition>2113102 - Disclosure - Acquisitions and Disposals</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDisposalsTables" roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsTables">
        <link:definition>2314302 - Disclosure - Acquisitions and Disposals (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDisposalsAcquisitionsDetails" roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails">
        <link:definition>2415410 - Disclosure - Acquisitions and Disposals - Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDisposalsSummaryDetails" roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails">
        <link:definition>2416411 - Disclosure - Acquisitions and Disposals - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails" roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails">
        <link:definition>2417412 - Disclosure - Acquisitions and Disposals - Disposals and Deconsolidations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.surgerypartners.com/role/LongTermDebt">
        <link:definition>2118103 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtTables" roleURI="http://www.surgerypartners.com/role/LongTermDebtTables">
        <link:definition>2319303 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtSummaryDetails" roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryDetails">
        <link:definition>2420413 - Disclosure - Long-Term Debt - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtSummaryDetails_1" roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryDetails_1">
        <link:definition>2420413 - Disclosure - Long-Term Debt - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNarrativeDetails" roleURI="http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails">
        <link:definition>2421414 - Disclosure - Long-Term Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.surgerypartners.com/role/Leases">
        <link:definition>2122104 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.surgerypartners.com/role/LeasesTables">
        <link:definition>2323304 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails" roleURI="http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails">
        <link:definition>2424415 - Disclosure - Leases - Components of Right-of-us Assets and Liabilities Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.surgerypartners.com/role/LeasesNarrativeDetails">
        <link:definition>2425416 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseExpenseandCashFlowInformationDetails" roleURI="http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails">
        <link:definition>2426417 - Disclosure - Leases - Lease Expense and Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandHedgingActivities" roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivities">
        <link:definition>2127105 - Disclosure - Derivatives and Hedging Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandHedgingActivitiesTables" roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables">
        <link:definition>2328305 - Disclosure - Derivatives and Hedging Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandHedgingActivitiesNarrativeDetails" roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails">
        <link:definition>2429418 - Disclosure - Derivatives and Hedging Activities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails" roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails">
        <link:definition>2430419 - Disclosure - Derivatives and Hedging Activities - Interest Rate Swaps and Interest Rate Caps Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails" roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails">
        <link:definition>2431420 - Disclosure - Derivatives and Hedging Activities - Derivatives Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails" roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails">
        <link:definition>2432421 - Disclosure - Derivatives and Hedging Activities - Pre-tax Effect of Derivatives on AOCI and Statement of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.surgerypartners.com/role/EarningsPerShare">
        <link:definition>2133106 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.surgerypartners.com/role/EarningsPerShareTables">
        <link:definition>2334306 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareSummaryDetails" roleURI="http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails">
        <link:definition>2435422 - Disclosure - Earnings Per Share - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentLiabilities" roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilities">
        <link:definition>2136107 - Disclosure - Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentLiabilitiesTables" roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables">
        <link:definition>2337307 - Disclosure - Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentLiabilitiesSummaryDetails" roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails">
        <link:definition>2438423 - Disclosure - Other Current Liabilities - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.surgerypartners.com/role/CommitmentsandContingencies">
        <link:definition>2139108 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2440424 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.surgerypartners.com/role/SegmentReporting">
        <link:definition>2141109 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.surgerypartners.com/role/SegmentReportingTables">
        <link:definition>2342308 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails" roleURI="http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails">
        <link:definition>2443425 - Disclosure - Segment Reporting - Revenues and Operating Income by Reportable Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails" roleURI="http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails">
        <link:definition>2444426 - Disclosure - Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.surgerypartners.com/role/SubsequentEvents">
        <link:definition>2145110 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.surgerypartners.com/role/SubsequentEventsDetails">
        <link:definition>2446427 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate" abstract="false" name="CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sgry_PrivateInsuranceMember" abstract="true" name="PrivateInsuranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_VariableAndShortTermLeaseCost" abstract="false" name="VariableAndShortTermLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" abstract="false" name="RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_SurgicalFacilitiesMember" abstract="true" name="SurgicalFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_RedeemableNoncontrollingInterestRollForward" abstract="true" name="RedeemableNoncontrollingInterestRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgry_FinanceLeaseCost" abstract="false" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_DisposalGroupOneMember" abstract="true" name="DisposalGroupOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_SeniorUnsecuredNotesDue2027Member" abstract="true" name="SeniorUnsecuredNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_SelfPayRevenueMember" abstract="true" name="SelfPayRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_VariableInterestEntityNumberOfFacilities" abstract="false" name="VariableInterestEntityNumberOfFacilities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_SeniorUnsecuredNotesDue2025Member" abstract="true" name="SeniorUnsecuredNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_SurgicalFacilitiesExistingMarketsMember" abstract="true" name="SurgicalFacilitiesExistingMarketsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_A2017SeniorSecuredCreditFacilityMember" abstract="true" name="A2017SeniorSecuredCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_PayFixedSwapSixMember" abstract="true" name="PayFixedSwapSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_CashFlowLesseeAbstract" abstract="true" name="CashFlowLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgry_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_PayFixedSwapOneMember" abstract="true" name="PayFixedSwapOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_ThreeReceiveFixedInterestRateSwapsMember" abstract="true" name="ThreeReceiveFixedInterestRateSwapsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_PayFixedSwapThreeMember" abstract="true" name="PayFixedSwapThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired" abstract="false" name="NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_ThreePayFixedInterestRateSwapsMember" abstract="true" name="ThreePayFixedInterestRateSwapsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sgry_ReceiveFixedSwapTwoMember" abstract="true" name="ReceiveFixedSwapTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_NotesPayableAndSecuredLoansMember" abstract="true" name="NotesPayableAndSecuredLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments" abstract="false" name="CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_InterestRateCapTwoMember" abstract="true" name="InterestRateCapTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_RedeemableNoncontrollingInterestPolicyTextBlock" abstract="false" name="RedeemableNoncontrollingInterestPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sgry_InterestRateCapOneMember" abstract="true" name="InterestRateCapOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_PayFixedSwapTwoMember" abstract="true" name="PayFixedSwapTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_MateriallyMoreRestrictiveMember" abstract="true" name="MateriallyMoreRestrictiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization" abstract="false" name="EarningsBeforeInterestTaxesDepreciationAndAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired" abstract="false" name="NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_OtherServicesMember" abstract="true" name="OtherServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts" abstract="false" name="BusinessCombinationIntegrationRelatedCostsAndMergerCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_CostReportLiabilitiesCurrent" abstract="false" name="CostReportLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_OperatingAndFinanceLeaseExpense" abstract="false" name="OperatingAndFinanceLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_OtherPatientServiceRevenueSourcesMember" abstract="true" name="OtherPatientServiceRevenueSourcesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_HealthcareOrganizationPatientServiceMember" abstract="true" name="HealthcareOrganizationPatientServiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_ProceedsFromGovernmentAssistance" abstract="false" name="ProceedsFromGovernmentAssistance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_FacilitiesAmbulatorySurgeryCentersMember" abstract="true" name="FacilitiesAmbulatorySurgeryCentersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_IncreaseDecreaseInFinanceLeaseLiability" abstract="false" name="IncreaseDecreaseInFinanceLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent" abstract="false" name="MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" abstract="false" name="RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_ReceiveFixedSwapThreeMember" abstract="true" name="ReceiveFixedSwapThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" abstract="false" name="NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest" abstract="false" name="NumberOfSurgicalFacilitiesOwnedMajorityInterest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_ProductsAndServicesLineItems" abstract="true" name="ProductsAndServicesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgry_SurgicalFacilityServicesMember" abstract="true" name="SurgicalFacilityServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration" abstract="false" name="DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_FinanceLeaseCost1Abstract" abstract="true" name="FinanceLeaseCost1Abstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgry_FacilitiesSurgicalHospitalsMember" abstract="true" name="FacilitiesSurgicalHospitalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_DeferredEmployeeRelatedLiabilitiesCurrent" abstract="false" name="DeferredEmployeeRelatedLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_NumberOfSurgicalFacilitiesOwned" abstract="false" name="NumberOfSurgicalFacilitiesOwned" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_PayFixedSwapFiveMember" abstract="true" name="PayFixedSwapFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_A2017TermLoanMaturing2024Member" abstract="true" name="A2017TermLoanMaturing2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidation" abstract="false" name="GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" abstract="false" name="GainLossOnDispositionOfAssetsAndDeconsolidation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_DerivativeLiabilityNotionalAmountFinancingComponent" abstract="false" name="DerivativeLiabilityNotionalAmountFinancingComponent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_NotMateriallyMoreRestrictiveMember" abstract="true" name="NotMateriallyMoreRestrictiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_IncreaseDecreaseInFinanceLeaseRightOfUseAssets" abstract="false" name="IncreaseDecreaseInFinanceLeaseRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_GrantRevenue" abstract="false" name="GrantRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_NoncashInterestIncomeExpenseNet" abstract="false" name="NoncashInterestIncomeExpenseNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" abstract="false" name="IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments" abstract="false" name="CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount" abstract="false" name="DeferredIncomeTaxLiabilitiesNetOfDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_ReceiveFixedSwapOneMember" abstract="true" name="ReceiveFixedSwapOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_LeaseRightOfUseAsset" abstract="false" name="LeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_TaxReceivableAgreementLiabilityCurrent" abstract="false" name="TaxReceivableAgreementLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments" abstract="false" name="CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm" abstract="false" name="CollaborativeTaxAgreementProjectedTaxSavingsTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgry_NumberOfSurgicalFacilitiesOwnedConsolidated" abstract="false" name="NumberOfSurgicalFacilitiesOwnedConsolidated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_PayFixedSwapFourMember" abstract="true" name="PayFixedSwapFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts" abstract="false" name="GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_AncillaryServicesMember" abstract="true" name="AncillaryServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>sgry-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b4dabe6f-88db-4fc2-b66b-139c1a2f1a72,g:e82a3438-fa59-433e-866a-e64d4d57702b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sgry-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4eba31ea-7e7f-4fc4-8c94-b40239671e42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_896bda0a-940c-475a-9e06-a1ba40087b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4eba31ea-7e7f-4fc4-8c94-b40239671e42" xlink:to="loc_us-gaap_AccountsPayableCurrent_896bda0a-940c-475a-9e06-a1ba40087b46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0bb9d41-e97a-4229-84df-39ed8d5c1181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4eba31ea-7e7f-4fc4-8c94-b40239671e42" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0bb9d41-e97a-4229-84df-39ed8d5c1181" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent_6002d673-1d07-4654-8264-720a9880abec" xlink:href="sgry-20220331.xsd#sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4eba31ea-7e7f-4fc4-8c94-b40239671e42" xlink:to="loc_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent_6002d673-1d07-4654-8264-720a9880abec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ad40c901-7447-44b1-90d8-9568cf66ad94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4eba31ea-7e7f-4fc4-8c94-b40239671e42" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ad40c901-7447-44b1-90d8-9568cf66ad94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_8813f46f-406c-4fc1-8355-47ffcf0e586f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4eba31ea-7e7f-4fc4-8c94-b40239671e42" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_8813f46f-406c-4fc1-8355-47ffcf0e586f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_34418ae4-7f3b-4799-a070-db602d2ec1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ec81da78-e809-4801-9fd1-99689f1dfb10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_34418ae4-7f3b-4799-a070-db602d2ec1fc" xlink:to="loc_us-gaap_LiabilitiesCurrent_ec81da78-e809-4801-9fd1-99689f1dfb10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_2544d6ec-bec5-4fe4-8c64-a45d27c3e7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_34418ae4-7f3b-4799-a070-db602d2ec1fc" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_2544d6ec-bec5-4fe4-8c64-a45d27c3e7cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4b5e4cdd-2393-423f-ad3f-777275ec8e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_34418ae4-7f3b-4799-a070-db602d2ec1fc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4b5e4cdd-2393-423f-ad3f-777275ec8e0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_dccf5477-5e09-4a98-a34b-ddb9f1cdfacb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_34418ae4-7f3b-4799-a070-db602d2ec1fc" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_dccf5477-5e09-4a98-a34b-ddb9f1cdfacb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_024fe1b0-9d01-4745-9655-10c7546cc9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_34418ae4-7f3b-4799-a070-db602d2ec1fc" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_024fe1b0-9d01-4745-9655-10c7546cc9cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_270b0bae-e718-49f1-aeed-898962eec5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_34418ae4-7f3b-4799-a070-db602d2ec1fc" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_270b0bae-e718-49f1-aeed-898962eec5c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ffe65021-fd25-4a43-92e3-485924f2ecaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3574ea76-9579-4a76-b753-388254b377a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ffe65021-fd25-4a43-92e3-485924f2ecaa" xlink:to="loc_us-gaap_PreferredStockValue_3574ea76-9579-4a76-b753-388254b377a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_765572b1-9aae-4b08-b30d-394628183f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ffe65021-fd25-4a43-92e3-485924f2ecaa" xlink:to="loc_us-gaap_CommonStockValueOutstanding_765572b1-9aae-4b08-b30d-394628183f78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_0865c32a-5419-4376-9069-a27fc5d24338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ffe65021-fd25-4a43-92e3-485924f2ecaa" xlink:to="loc_us-gaap_AdditionalPaidInCapital_0865c32a-5419-4376-9069-a27fc5d24338" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ccbdae8d-fcd3-4571-8d36-73dc2f66edcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ffe65021-fd25-4a43-92e3-485924f2ecaa" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ccbdae8d-fcd3-4571-8d36-73dc2f66edcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2309cf41-30a5-4de9-9a63-4bfac9393c95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ffe65021-fd25-4a43-92e3-485924f2ecaa" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2309cf41-30a5-4de9-9a63-4bfac9393c95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c2ca9b81-88cf-4b3f-acae-582102a782c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1c775b96-af3a-48b8-bbb7-89a1e060b36e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c2ca9b81-88cf-4b3f-acae-582102a782c1" xlink:to="loc_us-gaap_AssetsCurrent_1c775b96-af3a-48b8-bbb7-89a1e060b36e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b8e19ad5-485f-49fd-bb26-2d82941af8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c2ca9b81-88cf-4b3f-acae-582102a782c1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b8e19ad5-485f-49fd-bb26-2d82941af8b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_b0d90e72-8e09-4895-9718-4cab3b1c9203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c2ca9b81-88cf-4b3f-acae-582102a782c1" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_b0d90e72-8e09-4895-9718-4cab3b1c9203" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_588dc194-9573-40ce-b257-7377f3e9fa16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c2ca9b81-88cf-4b3f-acae-582102a782c1" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_588dc194-9573-40ce-b257-7377f3e9fa16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d9fc52bd-e174-4134-8078-df45580cc3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c2ca9b81-88cf-4b3f-acae-582102a782c1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d9fc52bd-e174-4134-8078-df45580cc3f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_d2772430-90ee-45cc-a241-27189ded622c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c2ca9b81-88cf-4b3f-acae-582102a782c1" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_d2772430-90ee-45cc-a241-27189ded622c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_170d58d4-b973-46a0-87e7-eedd5eeffdeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c2ca9b81-88cf-4b3f-acae-582102a782c1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_170d58d4-b973-46a0-87e7-eedd5eeffdeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_128e69d2-ba1a-4e74-ab83-43d76ed98b01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_97d52b69-a46c-4651-b8f6-8afd45a86220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_128e69d2-ba1a-4e74-ab83-43d76ed98b01" xlink:to="loc_us-gaap_StockholdersEquity_97d52b69-a46c-4651-b8f6-8afd45a86220" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_1b5f0cc3-73a8-41fc-8d56-08ab04d95a71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_128e69d2-ba1a-4e74-ab83-43d76ed98b01" xlink:to="loc_us-gaap_MinorityInterest_1b5f0cc3-73a8-41fc-8d56-08ab04d95a71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4dac81d8-366a-438d-9f3a-0a4143d82554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_11b1e443-690e-402b-b3c4-a2e828ac33cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4dac81d8-366a-438d-9f3a-0a4143d82554" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_11b1e443-690e-402b-b3c4-a2e828ac33cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_73288166-b3ed-4199-b03c-e814659318f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4dac81d8-366a-438d-9f3a-0a4143d82554" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_73288166-b3ed-4199-b03c-e814659318f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ec4cc30b-d904-4cfb-b665-2fa4150c35d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4dac81d8-366a-438d-9f3a-0a4143d82554" xlink:to="loc_us-gaap_InventoryNet_ec4cc30b-d904-4cfb-b665-2fa4150c35d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_ad102555-1119-41e4-9824-b33c0e2e1bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4dac81d8-366a-438d-9f3a-0a4143d82554" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_ad102555-1119-41e4-9824-b33c0e2e1bb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_632640db-8bcd-4761-91b0-75c9ab7651bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4dac81d8-366a-438d-9f3a-0a4143d82554" xlink:to="loc_us-gaap_OtherAssetsCurrent_632640db-8bcd-4761-91b0-75c9ab7651bf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sgry-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1360e93f-7bda-4bc0-b6e7-00258166aeea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e8724cac-9fb4-4dea-b723-e1a62ee3cbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1360e93f-7bda-4bc0-b6e7-00258166aeea" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e8724cac-9fb4-4dea-b723-e1a62ee3cbf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0e115eea-913d-4709-9cfb-f1ddfd652113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1360e93f-7bda-4bc0-b6e7-00258166aeea" xlink:to="loc_us-gaap_OperatingIncomeLoss_0e115eea-913d-4709-9cfb-f1ddfd652113" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e3feff09-294b-4c17-99ef-51433cd76a02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b5d4f417-af25-451c-801f-5b4d87f67f03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e3feff09-294b-4c17-99ef-51433cd76a02" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b5d4f417-af25-451c-801f-5b4d87f67f03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_cfefd3c8-946a-406d-9e89-68b25a57f8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e3feff09-294b-4c17-99ef-51433cd76a02" xlink:to="loc_us-gaap_OperatingExpenses_cfefd3c8-946a-406d-9e89-68b25a57f8fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ac7e521e-441e-4a6c-ba0f-1b851cccf71d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c5a5d706-1f72-4e21-ab23-fc4716418602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ac7e521e-441e-4a6c-ba0f-1b851cccf71d" xlink:to="loc_us-gaap_ProfitLoss_c5a5d706-1f72-4e21-ab23-fc4716418602" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8ea71a9d-6518-40a5-862a-8e317cde7fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ac7e521e-441e-4a6c-ba0f-1b851cccf71d" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8ea71a9d-6518-40a5-862a-8e317cde7fd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5bd6b96c-faa3-4c34-8bdf-461538f773c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_3711630b-2944-41d9-8265-d3514a0eea7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5bd6b96c-faa3-4c34-8bdf-461538f773c5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_3711630b-2944-41d9-8265-d3514a0eea7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2ae49ff9-ca8d-4308-b7fb-24cc81dad419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5bd6b96c-faa3-4c34-8bdf-461538f773c5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2ae49ff9-ca8d-4308-b7fb-24cc81dad419" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_d7ac94a6-2cef-4b24-ae77-61e441a853cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_a3228b98-211c-4b76-a3ba-ea152b62eec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_d7ac94a6-2cef-4b24-ae77-61e441a853cc" xlink:to="loc_us-gaap_LaborAndRelatedExpense_a3228b98-211c-4b76-a3ba-ea152b62eec6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_1a2f46a1-629c-42af-86bc-ecd1abeb4bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_d7ac94a6-2cef-4b24-ae77-61e441a853cc" xlink:to="loc_us-gaap_SuppliesExpense_1a2f46a1-629c-42af-86bc-ecd1abeb4bc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_034a67b2-5d62-45dd-a946-fd256e16d4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_d7ac94a6-2cef-4b24-ae77-61e441a853cc" xlink:to="loc_us-gaap_ProfessionalFees_034a67b2-5d62-45dd-a946-fd256e16d4a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OperatingAndFinanceLeaseExpense_e8e31eb8-ab2a-42b7-9a49-4ea0eef60a7b" xlink:href="sgry-20220331.xsd#sgry_OperatingAndFinanceLeaseExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_d7ac94a6-2cef-4b24-ae77-61e441a853cc" xlink:to="loc_sgry_OperatingAndFinanceLeaseExpense_e8e31eb8-ab2a-42b7-9a49-4ea0eef60a7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_383dd621-543b-466d-b2ec-28983981e55e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_d7ac94a6-2cef-4b24-ae77-61e441a853cc" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_383dd621-543b-466d-b2ec-28983981e55e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f82b1cc7-a60e-40f2-b194-afcb54313824" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_c1231c04-2b12-422d-94e0-45920e42dfd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f82b1cc7-a60e-40f2-b194-afcb54313824" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_c1231c04-2b12-422d-94e0-45920e42dfd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5879303f-3361-4513-9bba-0d3e3bbe4d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f82b1cc7-a60e-40f2-b194-afcb54313824" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5879303f-3361-4513-9bba-0d3e3bbe4d62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_0faad204-09db-4390-b921-0b54ad2b548d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f82b1cc7-a60e-40f2-b194-afcb54313824" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_0faad204-09db-4390-b921-0b54ad2b548d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_075ae627-ec7c-4200-b3f9-799ef95877d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f82b1cc7-a60e-40f2-b194-afcb54313824" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_075ae627-ec7c-4200-b3f9-799ef95877d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_03423ac0-d09b-43de-ac38-089106c445dd" xlink:href="sgry-20220331.xsd#sgry_GainLossOnDispositionOfAssetsAndDeconsolidation"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f82b1cc7-a60e-40f2-b194-afcb54313824" xlink:to="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_03423ac0-d09b-43de-ac38-089106c445dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_42968baf-f038-470f-9f94-f4cc814c124a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f82b1cc7-a60e-40f2-b194-afcb54313824" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_42968baf-f038-470f-9f94-f4cc814c124a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GrantRevenue_a09b6609-482c-40a4-8d2e-ffb425e4a1c5" xlink:href="sgry-20220331.xsd#sgry_GrantRevenue"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f82b1cc7-a60e-40f2-b194-afcb54313824" xlink:to="loc_sgry_GrantRevenue_a09b6609-482c-40a4-8d2e-ffb425e4a1c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_74a130cc-5591-4343-9298-4bd4a7d9726b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f82b1cc7-a60e-40f2-b194-afcb54313824" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_74a130cc-5591-4343-9298-4bd4a7d9726b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonrecurringIncomeExpense_17b2dfa5-88af-48fb-b9e6-15896f07dbc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonrecurringIncomeExpense"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f82b1cc7-a60e-40f2-b194-afcb54313824" xlink:to="loc_us-gaap_OtherNonrecurringIncomeExpense_17b2dfa5-88af-48fb-b9e6-15896f07dbc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_cc9c81e5-6825-433e-bc9e-1ae5a8756c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2c26e6ea-f7d0-4c99-af7b-65dd474b6997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_cc9c81e5-6825-433e-bc9e-1ae5a8756c0f" xlink:to="loc_us-gaap_NetIncomeLoss_2c26e6ea-f7d0-4c99-af7b-65dd474b6997" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_6542c846-7e25-4622-882e-19bab45b30dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_cc9c81e5-6825-433e-bc9e-1ae5a8756c0f" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_6542c846-7e25-4622-882e-19bab45b30dc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="sgry-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b070f601-a0ca-44f4-ace5-de727263fade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2ac4f73e-1102-43ac-9275-e6074f4e9a98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b070f601-a0ca-44f4-ace5-de727263fade" xlink:to="loc_us-gaap_ProfitLoss_2ac4f73e-1102-43ac-9275-e6074f4e9a98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_0e171425-6e65-43db-a34d-72dd0775859c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b070f601-a0ca-44f4-ace5-de727263fade" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_0e171425-6e65-43db-a34d-72dd0775859c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f17235eb-b138-4d5c-b858-0901f6bd07b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_731af555-c315-4a18-8563-89a7617cfe86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f17235eb-b138-4d5c-b858-0901f6bd07b4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_731af555-c315-4a18-8563-89a7617cfe86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_b0e5cf4f-1e8d-4f5f-b443-b747eba488da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f17235eb-b138-4d5c-b858-0901f6bd07b4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_b0e5cf4f-1e8d-4f5f-b443-b747eba488da" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sgry-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_80db7415-e039-433a-9d88-a6a861e3d038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d1eb5493-a36d-458c-bcc8-c7004c00f606" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_80db7415-e039-433a-9d88-a6a861e3d038" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d1eb5493-a36d-458c-bcc8-c7004c00f606" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6ac57e92-13a8-4d87-b552-5c5bd518c7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_80db7415-e039-433a-9d88-a6a861e3d038" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6ac57e92-13a8-4d87-b552-5c5bd518c7ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2cbf3f51-35e7-42d4-8a43-d1244160a7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_80db7415-e039-433a-9d88-a6a861e3d038" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2cbf3f51-35e7-42d4-8a43-d1244160a7d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ead90be3-0084-40bb-a6ab-03cb856116c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_17cb0e28-8ea9-4bf2-8f8d-119868edb197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ead90be3-0084-40bb-a6ab-03cb856116c8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_17cb0e28-8ea9-4bf2-8f8d-119868edb197" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ebcb680a-aac5-4bd8-9775-f69da10de486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ead90be3-0084-40bb-a6ab-03cb856116c8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ebcb680a-aac5-4bd8-9775-f69da10de486" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_04159a7a-f82c-4210-b292-2c31cbee2197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ead90be3-0084-40bb-a6ab-03cb856116c8" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_04159a7a-f82c-4210-b292-2c31cbee2197" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_61bfa721-9bc4-418b-95d0-925a9000f500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ead90be3-0084-40bb-a6ab-03cb856116c8" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_61bfa721-9bc4-418b-95d0-925a9000f500" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_4044fd15-6d08-45c0-89ee-f9b04956a37f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ead90be3-0084-40bb-a6ab-03cb856116c8" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_4044fd15-6d08-45c0-89ee-f9b04956a37f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01a616a1-0a30-4269-aaa9-e07fd26030c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_0a0f51f6-0dc1-4156-896d-aff0e2abaeff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01a616a1-0a30-4269-aaa9-e07fd26030c9" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_0a0f51f6-0dc1-4156-896d-aff0e2abaeff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_d16d7632-4ba4-483e-a6c5-4ea053024dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01a616a1-0a30-4269-aaa9-e07fd26030c9" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_d16d7632-4ba4-483e-a6c5-4ea053024dd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_b757ee10-124f-48bd-87dd-3ec3d22c46f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01a616a1-0a30-4269-aaa9-e07fd26030c9" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_b757ee10-124f-48bd-87dd-3ec3d22c46f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_419f3d0a-8bd9-45bc-bb87-35dc743625ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01a616a1-0a30-4269-aaa9-e07fd26030c9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_419f3d0a-8bd9-45bc-bb87-35dc743625ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_005249db-0b60-428f-8923-1abdf3d8d000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01a616a1-0a30-4269-aaa9-e07fd26030c9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_005249db-0b60-428f-8923-1abdf3d8d000" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsMinorityInterest_42a7ac73-1c39-4903-9e44-1eb5a81c05bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsMinorityInterest"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01a616a1-0a30-4269-aaa9-e07fd26030c9" xlink:to="loc_us-gaap_PaymentsOfDividendsMinorityInterest_42a7ac73-1c39-4903-9e44-1eb5a81c05bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_e0788629-337d-49d5-882d-4624b44956b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01a616a1-0a30-4269-aaa9-e07fd26030c9" xlink:to="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_e0788629-337d-49d5-882d-4624b44956b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_568c45f4-5b95-4a55-9bbf-4832fd793949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01a616a1-0a30-4269-aaa9-e07fd26030c9" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_568c45f4-5b95-4a55-9bbf-4832fd793949" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_3f4d3498-e42b-406c-8aa8-50937eda807c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01a616a1-0a30-4269-aaa9-e07fd26030c9" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_3f4d3498-e42b-406c-8aa8-50937eda807c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_86635d39-7b49-4b8b-8986-adc5ebdf482c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01a616a1-0a30-4269-aaa9-e07fd26030c9" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_86635d39-7b49-4b8b-8986-adc5ebdf482c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_872a2d24-c921-43a6-b15c-766bcf27d2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_291568cd-1ede-4317-910d-4434e11d5138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_872a2d24-c921-43a6-b15c-766bcf27d2ec" xlink:to="loc_us-gaap_ProfitLoss_291568cd-1ede-4317-910d-4434e11d5138" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6eccc71d-a6f5-41f9-a60c-08d100283500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_872a2d24-c921-43a6-b15c-766bcf27d2ec" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6eccc71d-a6f5-41f9-a60c-08d100283500" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NoncashInterestIncomeExpenseNet_6816c305-282c-433c-8ec2-3213879fab43" xlink:href="sgry-20220331.xsd#sgry_NoncashInterestIncomeExpenseNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_872a2d24-c921-43a6-b15c-766bcf27d2ec" xlink:to="loc_sgry_NoncashInterestIncomeExpenseNet_6816c305-282c-433c-8ec2-3213879fab43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_840cc1cd-b241-4a44-9850-f8ba28ece2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_872a2d24-c921-43a6-b15c-766bcf27d2ec" xlink:to="loc_us-gaap_ShareBasedCompensation_840cc1cd-b241-4a44-9850-f8ba28ece2f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_ce6213d5-c8bb-446d-894d-9b15bf308bba" xlink:href="sgry-20220331.xsd#sgry_GainLossOnDispositionOfAssetsAndDeconsolidation"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_872a2d24-c921-43a6-b15c-766bcf27d2ec" xlink:to="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_ce6213d5-c8bb-446d-894d-9b15bf308bba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bb16b4f5-dcea-42ac-a5e7-52b2edc4134c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_872a2d24-c921-43a6-b15c-766bcf27d2ec" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bb16b4f5-dcea-42ac-a5e7-52b2edc4134c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_71b26941-2f31-4ed6-83ec-73632b3c1dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_872a2d24-c921-43a6-b15c-766bcf27d2ec" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_71b26941-2f31-4ed6-83ec-73632b3c1dcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_60dcdc80-b509-456e-a438-194004de2c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_872a2d24-c921-43a6-b15c-766bcf27d2ec" xlink:to="loc_us-gaap_OperatingLeaseExpense_60dcdc80-b509-456e-a438-194004de2c9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5786446c-ce88-475f-91ab-7ea8ff85ab82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_872a2d24-c921-43a6-b15c-766bcf27d2ec" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5786446c-ce88-475f-91ab-7ea8ff85ab82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants_1de32fc5-c2f4-414e-b62d-7825a562b9e1" xlink:href="sgry-20220331.xsd#sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_872a2d24-c921-43a6-b15c-766bcf27d2ec" xlink:to="loc_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants_1de32fc5-c2f4-414e-b62d-7825a562b9e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_f8b8cc81-eab2-47ef-a4db-84516b2ad955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_872a2d24-c921-43a6-b15c-766bcf27d2ec" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_f8b8cc81-eab2-47ef-a4db-84516b2ad955" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#AcquisitionsandDisposalsSummaryDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_38d98cab-d8e2-4310-9765-dbec9560c300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_451c20c5-54e5-462a-9a0a-d6165b2629ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_38d98cab-d8e2-4310-9765-dbec9560c300" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_451c20c5-54e5-462a-9a0a-d6165b2629ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_ad612302-851e-4745-8ddd-b1d9cd7387e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_38d98cab-d8e2-4310-9765-dbec9560c300" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_ad612302-851e-4745-8ddd-b1d9cd7387e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ed356f84-7814-45c0-8414-69874664cdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_38d98cab-d8e2-4310-9765-dbec9560c300" xlink:to="loc_us-gaap_Goodwill_ed356f84-7814-45c0-8414-69874664cdcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets_7e871abe-b571-48a8-a811-8b658358d9af" xlink:href="sgry-20220331.xsd#sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_38d98cab-d8e2-4310-9765-dbec9560c300" xlink:to="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets_7e871abe-b571-48a8-a811-8b658358d9af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_8ee2f866-2a0b-4b12-a0fb-73a96f4f8a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_38d98cab-d8e2-4310-9765-dbec9560c300" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_8ee2f866-2a0b-4b12-a0fb-73a96f4f8a9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_c9f6cbcf-b566-4a05-89a1-3dfa6ebe73b2" xlink:href="sgry-20220331.xsd#sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_38d98cab-d8e2-4310-9765-dbec9560c300" xlink:to="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_c9f6cbcf-b566-4a05-89a1-3dfa6ebe73b2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#LongTermDebtSummaryDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_c85668cf-f3eb-441f-8efe-5c704f55ce1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_b1517f87-1c1e-4035-91b6-d799730d70a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_c85668cf-f3eb-441f-8efe-5c704f55ce1f" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_b1517f87-1c1e-4035-91b6-d799730d70a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_057ca41d-503c-4a10-bb07-f103371573b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_c85668cf-f3eb-441f-8efe-5c704f55ce1f" xlink:to="loc_us-gaap_FinanceLeaseLiability_057ca41d-503c-4a10-bb07-f103371573b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_462516fa-4946-4032-a7c8-8932337c8a08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_c85668cf-f3eb-441f-8efe-5c704f55ce1f" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_462516fa-4946-4032-a7c8-8932337c8a08" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryDetails_1" xlink:type="simple" xlink:href="sgry-20220331.xsd#LongTermDebtSummaryDetails_1"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtSummaryDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_d20c2ebe-eba1-480f-a0f3-f01a03c1df61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_91ab4460-1f3e-401a-bc6d-3abf93929001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_d20c2ebe-eba1-480f-a0f3-f01a03c1df61" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_91ab4460-1f3e-401a-bc6d-3abf93929001" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_1bf8d797-8c18-4c45-aed5-9941a911d653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_d20c2ebe-eba1-480f-a0f3-f01a03c1df61" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_1bf8d797-8c18-4c45-aed5-9941a911d653" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LeaseLiability_ac9767d1-063c-486a-93a8-fb1c1ab1de07" xlink:href="sgry-20220331.xsd#sgry_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_87a18c21-d87e-4277-b906-093112a34681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgry_LeaseLiability_ac9767d1-063c-486a-93a8-fb1c1ab1de07" xlink:to="loc_us-gaap_FinanceLeaseLiability_87a18c21-d87e-4277-b906-093112a34681" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_258048df-f17b-494c-9fa6-c591403f885f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgry_LeaseLiability_ac9767d1-063c-486a-93a8-fb1c1ab1de07" xlink:to="loc_us-gaap_OperatingLeaseLiability_258048df-f17b-494c-9fa6-c591403f885f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LeaseRightOfUseAsset_fb153f8d-2b86-480f-82b1-8e81e404e669" xlink:href="sgry-20220331.xsd#sgry_LeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4b384a03-dc63-4419-90e2-e47956567e85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgry_LeaseRightOfUseAsset_fb153f8d-2b86-480f-82b1-8e81e404e669" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4b384a03-dc63-4419-90e2-e47956567e85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_eeba0db5-8c12-4d90-9023-03b106679188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgry_LeaseRightOfUseAsset_fb153f8d-2b86-480f-82b1-8e81e404e669" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_eeba0db5-8c12-4d90-9023-03b106679188" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_30dd89fb-99fb-499f-815c-0981cfc00371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_b2b03be1-d01c-4698-9b73-0c85a24b8f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_30dd89fb-99fb-499f-815c-0981cfc00371" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_b2b03be1-d01c-4698-9b73-0c85a24b8f4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_da283901-3341-460f-bbe7-5e6d27bfd45f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_30dd89fb-99fb-499f-815c-0981cfc00371" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_da283901-3341-460f-bbe7-5e6d27bfd45f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e8ff35d6-679e-4e58-a758-f0b04250f0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_55dd28a4-6a0c-4915-9c7e-899748c96cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_e8ff35d6-679e-4e58-a758-f0b04250f0f9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_55dd28a4-6a0c-4915-9c7e-899748c96cb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a16d1d60-ba70-4b79-a81b-58883ea50f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_e8ff35d6-679e-4e58-a758-f0b04250f0f9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a16d1d60-ba70-4b79-a81b-58883ea50f0f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#LeasesLeaseExpenseandCashFlowInformationDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_03bf263e-5b0e-4486-b456-e0c79e39340b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_0f93e8c4-32e4-43eb-97ab-ce3ea913e84a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_03bf263e-5b0e-4486-b456-e0c79e39340b" xlink:to="loc_us-gaap_OperatingLeaseCost_0f93e8c4-32e4-43eb-97ab-ce3ea913e84a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FinanceLeaseCost_5bd67fe2-ffa2-4a1f-9829-96506b8ccb42" xlink:href="sgry-20220331.xsd#sgry_FinanceLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_03bf263e-5b0e-4486-b456-e0c79e39340b" xlink:to="loc_sgry_FinanceLeaseCost_5bd67fe2-ffa2-4a1f-9829-96506b8ccb42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_VariableAndShortTermLeaseCost_1151fa47-1d11-4a2f-bf2a-d3c14eeec0fd" xlink:href="sgry-20220331.xsd#sgry_VariableAndShortTermLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_03bf263e-5b0e-4486-b456-e0c79e39340b" xlink:to="loc_sgry_VariableAndShortTermLeaseCost_1151fa47-1d11-4a2f-bf2a-d3c14eeec0fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FinanceLeaseCost_7d15c2a1-e055-4f9a-bfdb-2629dd26ab04" xlink:href="sgry-20220331.xsd#sgry_FinanceLeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_509a89ad-ce65-450e-b901-a6d725a740c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgry_FinanceLeaseCost_7d15c2a1-e055-4f9a-bfdb-2629dd26ab04" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_509a89ad-ce65-450e-b901-a6d725a740c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_8c430db1-c85e-4489-a0bc-a4e057c47e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgry_FinanceLeaseCost_7d15c2a1-e055-4f9a-bfdb-2629dd26ab04" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_8c430db1-c85e-4489-a0bc-a4e057c47e6a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#OtherCurrentLiabilitiesSummaryDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_7538bad3-ada2-4673-8b61-b1ebd352cf68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b5ccfe26-e0c2-46ea-b9b4-e587b5aaa674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_7538bad3-ada2-4673-8b61-b1ebd352cf68" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b5ccfe26-e0c2-46ea-b9b4-e587b5aaa674" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_95f2ae28-c53e-4883-b361-c78563a72ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_7538bad3-ada2-4673-8b61-b1ebd352cf68" xlink:to="loc_us-gaap_InterestPayableCurrent_95f2ae28-c53e-4883-b361-c78563a72ec3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TaxReceivableAgreementLiabilityCurrent_0fb3d88f-8b07-476b-a3c2-339a89b47064" xlink:href="sgry-20220331.xsd#sgry_TaxReceivableAgreementLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_7538bad3-ada2-4673-8b61-b1ebd352cf68" xlink:to="loc_sgry_TaxReceivableAgreementLiabilityCurrent_0fb3d88f-8b07-476b-a3c2-339a89b47064" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PayablesToCustomers_058f449c-c953-48fc-ad3c-343c8e9a180d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_PayablesToCustomers"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_7538bad3-ada2-4673-8b61-b1ebd352cf68" xlink:to="loc_srt_PayablesToCustomers_058f449c-c953-48fc-ad3c-343c8e9a180d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CostReportLiabilitiesCurrent_b77fe87b-0338-4530-a4e4-bffd0849e2bc" xlink:href="sgry-20220331.xsd#sgry_CostReportLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_7538bad3-ada2-4673-8b61-b1ebd352cf68" xlink:to="loc_sgry_CostReportLiabilitiesCurrent_b77fe87b-0338-4530-a4e4-bffd0849e2bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bacee502-d7bf-4c06-9bba-99156feb8faf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_7538bad3-ada2-4673-8b61-b1ebd352cf68" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bacee502-d7bf-4c06-9bba-99156feb8faf" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>sgry-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b4dabe6f-88db-4fc2-b66b-139c1a2f1a72,g:e82a3438-fa59-433e-866a-e64d4d57702b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgry-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i6845e44f8b694cf7a59fe98b595b5028_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4bc5ea55-add7-483d-8d4d-79f9c66f9415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4bc5ea55-add7-483d-8d4d-79f9c66f9415" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_75fc5641-eb51-41ee-b926-07b98e938eba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_75fc5641-eb51-41ee-b926-07b98e938eba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_29281de7-a06c-4f58-970c-567630dd2a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_29281de7-a06c-4f58-970c-567630dd2a9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_53aa47b2-fb49-4034-a437-aa47776183fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_53aa47b2-fb49-4034-a437-aa47776183fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0015301b-b98e-45eb-aa5b-9197cd225e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0015301b-b98e-45eb-aa5b-9197cd225e2b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_81478d61-84c5-4197-8090-0dd46f6b4889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_81478d61-84c5-4197-8090-0dd46f6b4889" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_40f78aa4-8356-4974-b903-b10051d8d99d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_40f78aa4-8356-4974-b903-b10051d8d99d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1ce92358-0827-43c7-9d56-13f2adf6ba4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1ce92358-0827-43c7-9d56-13f2adf6ba4a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ab652f4-f6f5-4ded-88e4-e500946dc597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ab652f4-f6f5-4ded-88e4-e500946dc597" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_3b1dbc1e-aa2a-48d9-9e06-72cb6c87fe67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_3b1dbc1e-aa2a-48d9-9e06-72cb6c87fe67" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet_b5b7b475-bfa9-43c0-8ef2-17f07043678e" xlink:href="sgry-20220331.xsd#sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet_b5b7b475-bfa9-43c0-8ef2-17f07043678e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_66ccd204-cb2e-4548-9385-e14b3bdc2e36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_66ccd204-cb2e-4548-9385-e14b3bdc2e36" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9755606f-d763-44b4-aa32-69cf332dcbcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_530106d2-ec4b-4185-bb8f-5a5eeacd4c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e8a16465-c78c-41bf-a3d3-ce99d794d91a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4bc5ea55-add7-483d-8d4d-79f9c66f9415" xlink:to="loc_us-gaap_StatementTable_e8a16465-c78c-41bf-a3d3-ce99d794d91a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9dccb1e2-0fff-49fb-9712-b43a47eabc0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e8a16465-c78c-41bf-a3d3-ce99d794d91a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9dccb1e2-0fff-49fb-9712-b43a47eabc0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9dccb1e2-0fff-49fb-9712-b43a47eabc0d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9dccb1e2-0fff-49fb-9712-b43a47eabc0d" xlink:to="loc_us-gaap_EquityComponentDomain_9dccb1e2-0fff-49fb-9712-b43a47eabc0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fc00720f-65b0-4425-8177-312fe1df9034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9dccb1e2-0fff-49fb-9712-b43a47eabc0d" xlink:to="loc_us-gaap_EquityComponentDomain_fc00720f-65b0-4425-8177-312fe1df9034" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9ae62a2d-8c85-41de-880d-00a3757adb83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fc00720f-65b0-4425-8177-312fe1df9034" xlink:to="loc_us-gaap_CommonStockMember_9ae62a2d-8c85-41de-880d-00a3757adb83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b7e9456b-4786-47fd-98e7-768645b19e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fc00720f-65b0-4425-8177-312fe1df9034" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b7e9456b-4786-47fd-98e7-768645b19e02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dccb7ef5-f582-48f8-aa09-b43c2b04a31d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fc00720f-65b0-4425-8177-312fe1df9034" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dccb7ef5-f582-48f8-aa09-b43c2b04a31d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6c3b8937-f793-4fbb-8d56-f7e594af9b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fc00720f-65b0-4425-8177-312fe1df9034" xlink:to="loc_us-gaap_RetainedEarningsMember_6c3b8937-f793-4fbb-8d56-f7e594af9b4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_7f766a27-9389-4c7c-bae4-2d9c9e439453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fc00720f-65b0-4425-8177-312fe1df9034" xlink:to="loc_us-gaap_NoncontrollingInterestMember_7f766a27-9389-4c7c-bae4-2d9c9e439453" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#OrganizationandSummaryofAccountingPoliciesOrganizationDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails" xlink:type="extended" id="i48b9c9c4d820412faeb434b404c798d4_OrganizationandSummaryofAccountingPoliciesOrganizationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ProductsAndServicesLineItems_808d8fe4-f5a6-4994-a976-0b34ada2525c" xlink:href="sgry-20220331.xsd#sgry_ProductsAndServicesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwned_34ee3d64-f51d-446c-b991-3f3def73519c" xlink:href="sgry-20220331.xsd#sgry_NumberOfSurgicalFacilitiesOwned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_ProductsAndServicesLineItems_808d8fe4-f5a6-4994-a976-0b34ada2525c" xlink:to="loc_sgry_NumberOfSurgicalFacilitiesOwned_34ee3d64-f51d-446c-b991-3f3def73519c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_a912ef41-1759-4683-b260-880634d52d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_ProductsAndServicesLineItems_808d8fe4-f5a6-4994-a976-0b34ada2525c" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_a912ef41-1759-4683-b260-880634d52d09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest_5907b616-670c-4650-bff2-67baa8a24c5f" xlink:href="sgry-20220331.xsd#sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_ProductsAndServicesLineItems_808d8fe4-f5a6-4994-a976-0b34ada2525c" xlink:to="loc_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest_5907b616-670c-4650-bff2-67baa8a24c5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated_bf0bf986-bc88-414f-8387-a1d2f90bfdee" xlink:href="sgry-20220331.xsd#sgry_NumberOfSurgicalFacilitiesOwnedConsolidated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_ProductsAndServicesLineItems_808d8fe4-f5a6-4994-a976-0b34ada2525c" xlink:to="loc_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated_bf0bf986-bc88-414f-8387-a1d2f90bfdee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_24f98bb4-fa7f-4302-b693-2796d1cebce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AirlineProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sgry_ProductsAndServicesLineItems_808d8fe4-f5a6-4994-a976-0b34ada2525c" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_24f98bb4-fa7f-4302-b693-2796d1cebce0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0ba4af17-e0c7-4f6b-a03d-e9cffa6c9eea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_24f98bb4-fa7f-4302-b693-2796d1cebce0" xlink:to="loc_srt_ProductOrServiceAxis_0ba4af17-e0c7-4f6b-a03d-e9cffa6c9eea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0ba4af17-e0c7-4f6b-a03d-e9cffa6c9eea_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0ba4af17-e0c7-4f6b-a03d-e9cffa6c9eea" xlink:to="loc_srt_ProductsAndServicesDomain_0ba4af17-e0c7-4f6b-a03d-e9cffa6c9eea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3894eaa5-816b-4a6a-9f0c-0aa9bc6a20fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0ba4af17-e0c7-4f6b-a03d-e9cffa6c9eea" xlink:to="loc_srt_ProductsAndServicesDomain_3894eaa5-816b-4a6a-9f0c-0aa9bc6a20fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FacilitiesAmbulatorySurgeryCentersMember_9ffb3a6b-3e66-44f2-8082-6d254b4046ee" xlink:href="sgry-20220331.xsd#sgry_FacilitiesAmbulatorySurgeryCentersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3894eaa5-816b-4a6a-9f0c-0aa9bc6a20fd" xlink:to="loc_sgry_FacilitiesAmbulatorySurgeryCentersMember_9ffb3a6b-3e66-44f2-8082-6d254b4046ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FacilitiesSurgicalHospitalsMember_742c691c-945c-48f8-a3c6-4f331afb1b46" xlink:href="sgry-20220331.xsd#sgry_FacilitiesSurgicalHospitalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3894eaa5-816b-4a6a-9f0c-0aa9bc6a20fd" xlink:to="loc_sgry_FacilitiesSurgicalHospitalsMember_742c691c-945c-48f8-a3c6-4f331afb1b46" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails" xlink:type="extended" id="i7cac3af5546c443d98145b5c54da5f0d_OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_5d88d6a5-b234-433b-a50d-6f23f3a439cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_VariableInterestEntityNumberOfFacilities_80dc61b5-3902-464f-a0e2-7b879853b5fa" xlink:href="sgry-20220331.xsd#sgry_VariableInterestEntityNumberOfFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5d88d6a5-b234-433b-a50d-6f23f3a439cb" xlink:to="loc_sgry_VariableInterestEntityNumberOfFacilities_80dc61b5-3902-464f-a0e2-7b879853b5fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6b2cb2ad-9b62-466d-badf-cd6e47e81034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5d88d6a5-b234-433b-a50d-6f23f3a439cb" xlink:to="loc_us-gaap_Assets_6b2cb2ad-9b62-466d-badf-cd6e47e81034" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1a6174b7-8312-46c0-8783-f7ce08435766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5d88d6a5-b234-433b-a50d-6f23f3a439cb" xlink:to="loc_us-gaap_Liabilities_1a6174b7-8312-46c0-8783-f7ce08435766" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_b46a581b-fd97-4f40-86e5-8793c82f3c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5d88d6a5-b234-433b-a50d-6f23f3a439cb" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_b46a581b-fd97-4f40-86e5-8793c82f3c2b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_13e691c0-d50f-474a-baa4-310298084996" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_b46a581b-fd97-4f40-86e5-8793c82f3c2b" xlink:to="loc_srt_ConsolidatedEntitiesAxis_13e691c0-d50f-474a-baa4-310298084996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_13e691c0-d50f-474a-baa4-310298084996_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_13e691c0-d50f-474a-baa4-310298084996" xlink:to="loc_srt_ConsolidatedEntitiesDomain_13e691c0-d50f-474a-baa4-310298084996_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_f4349483-c0c6-4c1b-800c-ba469a39d26b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_13e691c0-d50f-474a-baa4-310298084996" xlink:to="loc_srt_ConsolidatedEntitiesDomain_f4349483-c0c6-4c1b-800c-ba469a39d26b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_038bd7e8-a556-4f88-a4ce-4792cd24126d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_f4349483-c0c6-4c1b-800c-ba469a39d26b" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_038bd7e8-a556-4f88-a4ce-4792cd24126d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails" xlink:type="extended" id="i6c20b554799e4425b130c564e945cc32_OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_47d16f46-f109-4bd2-a77b-3da44e44b5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5c82f5e1-753d-4eb5-b437-c7ed84ff444a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_47d16f46-f109-4bd2-a77b-3da44e44b5ed" xlink:to="loc_us-gaap_LongTermDebt_5c82f5e1-753d-4eb5-b437-c7ed84ff444a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c9044201-0384-454c-a362-533a2e21153d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_47d16f46-f109-4bd2-a77b-3da44e44b5ed" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c9044201-0384-454c-a362-533a2e21153d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_54595a90-93ea-4077-8b75-e242e74f000f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_47d16f46-f109-4bd2-a77b-3da44e44b5ed" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_54595a90-93ea-4077-8b75-e242e74f000f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_33adc033-3c4e-444a-a31a-90fc6c1c1aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_54595a90-93ea-4077-8b75-e242e74f000f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_33adc033-3c4e-444a-a31a-90fc6c1c1aa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_33adc033-3c4e-444a-a31a-90fc6c1c1aa0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_33adc033-3c4e-444a-a31a-90fc6c1c1aa0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_33adc033-3c4e-444a-a31a-90fc6c1c1aa0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fbce8cca-980c-45ec-b62b-4d4b7ddb4932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_33adc033-3c4e-444a-a31a-90fc6c1c1aa0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fbce8cca-980c-45ec-b62b-4d4b7ddb4932" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_b0db5373-7f80-485d-a7b3-1f75a2f21ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fbce8cca-980c-45ec-b62b-4d4b7ddb4932" xlink:to="loc_us-gaap_SecuredDebtMember_b0db5373-7f80-485d-a7b3-1f75a2f21ecc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_3a7bb8e5-671e-46be-8b18-a6143aec69da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fbce8cca-980c-45ec-b62b-4d4b7ddb4932" xlink:to="loc_us-gaap_SeniorNotesMember_3a7bb8e5-671e-46be-8b18-a6143aec69da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_eb103983-372b-4f53-bd73-57e4e31fad07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_54595a90-93ea-4077-8b75-e242e74f000f" xlink:to="loc_us-gaap_DebtInstrumentAxis_eb103983-372b-4f53-bd73-57e4e31fad07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_eb103983-372b-4f53-bd73-57e4e31fad07_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_eb103983-372b-4f53-bd73-57e4e31fad07" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_eb103983-372b-4f53-bd73-57e4e31fad07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4a565ce0-6240-404f-8855-71b63e00f36f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_eb103983-372b-4f53-bd73-57e4e31fad07" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4a565ce0-6240-404f-8855-71b63e00f36f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017TermLoanMaturing2024Member_9c6d4359-fb90-4883-ad9d-5347d10d9b0d" xlink:href="sgry-20220331.xsd#sgry_A2017TermLoanMaturing2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4a565ce0-6240-404f-8855-71b63e00f36f" xlink:to="loc_sgry_A2017TermLoanMaturing2024Member_9c6d4359-fb90-4883-ad9d-5347d10d9b0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2025Member_69ea635c-2c7e-4412-b4c2-b1c0f6d2d781" xlink:href="sgry-20220331.xsd#sgry_SeniorUnsecuredNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4a565ce0-6240-404f-8855-71b63e00f36f" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2025Member_69ea635c-2c7e-4412-b4c2-b1c0f6d2d781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2027Member_b571a381-c67c-47fd-8d24-b5947c8df91f" xlink:href="sgry-20220331.xsd#sgry_SeniorUnsecuredNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4a565ce0-6240-404f-8855-71b63e00f36f" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2027Member_b571a381-c67c-47fd-8d24-b5947c8df91f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_05444761-b897-4088-8bba-9573428f0a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_54595a90-93ea-4077-8b75-e242e74f000f" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_05444761-b897-4088-8bba-9573428f0a4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_05444761-b897-4088-8bba-9573428f0a4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_05444761-b897-4088-8bba-9573428f0a4a" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_05444761-b897-4088-8bba-9573428f0a4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_5d7ca12f-15c9-4c59-9de0-e6139dbf43e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_05444761-b897-4088-8bba-9573428f0a4a" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_5d7ca12f-15c9-4c59-9de0-e6139dbf43e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4b633c6e-d253-4f6e-98f3-f466c70fc2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_5d7ca12f-15c9-4c59-9de0-e6139dbf43e0" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4b633c6e-d253-4f6e-98f3-f466c70fc2a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_e83323fb-3866-41cb-b28a-193c3c2db8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4b633c6e-d253-4f6e-98f3-f466c70fc2a1" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_e83323fb-3866-41cb-b28a-193c3c2db8dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9a451c4f-9a22-488d-b94b-857c4804ef1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4b633c6e-d253-4f6e-98f3-f466c70fc2a1" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9a451c4f-9a22-488d-b94b-857c4804ef1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_199dd1c5-9a95-4727-b382-39808be2ec25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_54595a90-93ea-4077-8b75-e242e74f000f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_199dd1c5-9a95-4727-b382-39808be2ec25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_199dd1c5-9a95-4727-b382-39808be2ec25_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_199dd1c5-9a95-4727-b382-39808be2ec25" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_199dd1c5-9a95-4727-b382-39808be2ec25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9141b8b8-2fc5-4b65-88a1-f70d3b5eb36f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_199dd1c5-9a95-4727-b382-39808be2ec25" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9141b8b8-2fc5-4b65-88a1-f70d3b5eb36f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e0a4634e-44db-48d7-905a-0954789966ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9141b8b8-2fc5-4b65-88a1-f70d3b5eb36f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e0a4634e-44db-48d7-905a-0954789966ce" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails" xlink:type="extended" id="i2d999e9523974bdab83977589849524c_OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_84adeff4-df00-40e2-8d35-7d1828b6eb75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_d6c7aa6c-c057-41cc-8678-8c7ba0b55a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_84adeff4-df00-40e2-8d35-7d1828b6eb75" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_d6c7aa6c-c057-41cc-8678-8c7ba0b55a5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_178fd11b-68f1-4ec7-9ade-09371948a18c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_84adeff4-df00-40e2-8d35-7d1828b6eb75" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_178fd11b-68f1-4ec7-9ade-09371948a18c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_89e69f4f-e6cd-4c61-8321-ab901b15245a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_178fd11b-68f1-4ec7-9ade-09371948a18c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_89e69f4f-e6cd-4c61-8321-ab901b15245a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_89e69f4f-e6cd-4c61-8321-ab901b15245a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_89e69f4f-e6cd-4c61-8321-ab901b15245a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_89e69f4f-e6cd-4c61-8321-ab901b15245a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_85e89f20-3991-4fed-9ce3-ce96e88ff6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_89e69f4f-e6cd-4c61-8321-ab901b15245a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_85e89f20-3991-4fed-9ce3-ce96e88ff6b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_e5e8cd7b-4b9f-4fa5-b3b9-95d22db7e1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_85e89f20-3991-4fed-9ce3-ce96e88ff6b1" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_e5e8cd7b-4b9f-4fa5-b3b9-95d22db7e1f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_62d61912-ae4f-456d-b67f-fa0f0ff45007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_178fd11b-68f1-4ec7-9ade-09371948a18c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_62d61912-ae4f-456d-b67f-fa0f0ff45007" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_62d61912-ae4f-456d-b67f-fa0f0ff45007_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_62d61912-ae4f-456d-b67f-fa0f0ff45007" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_62d61912-ae4f-456d-b67f-fa0f0ff45007_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e078c0e2-6d8b-4b17-bf09-0bbca5eeb776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_62d61912-ae4f-456d-b67f-fa0f0ff45007" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e078c0e2-6d8b-4b17-bf09-0bbca5eeb776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_b1a14502-095d-43bd-abee-6663e5ec8e57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e078c0e2-6d8b-4b17-bf09-0bbca5eeb776" xlink:to="loc_us-gaap_SalesRevenueNetMember_b1a14502-095d-43bd-abee-6663e5ec8e57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bc9c7579-a92f-4a09-8adc-1e2c50bee859" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_178fd11b-68f1-4ec7-9ade-09371948a18c" xlink:to="loc_srt_ProductOrServiceAxis_bc9c7579-a92f-4a09-8adc-1e2c50bee859" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bc9c7579-a92f-4a09-8adc-1e2c50bee859_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bc9c7579-a92f-4a09-8adc-1e2c50bee859" xlink:to="loc_srt_ProductsAndServicesDomain_bc9c7579-a92f-4a09-8adc-1e2c50bee859_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3b2d699f-9e1b-423a-80b5-e44e867f2230" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bc9c7579-a92f-4a09-8adc-1e2c50bee859" xlink:to="loc_srt_ProductsAndServicesDomain_3b2d699f-9e1b-423a-80b5-e44e867f2230" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_HealthcareOrganizationPatientServiceMember_5ac84122-0607-447f-8a54-ccf2a4292e31" xlink:href="sgry-20220331.xsd#sgry_HealthcareOrganizationPatientServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3b2d699f-9e1b-423a-80b5-e44e867f2230" xlink:to="loc_sgry_HealthcareOrganizationPatientServiceMember_5ac84122-0607-447f-8a54-ccf2a4292e31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityServicesMember_f03d6e0f-c8f5-4656-b05c-b6941a10837d" xlink:href="sgry-20220331.xsd#sgry_SurgicalFacilityServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_5ac84122-0607-447f-8a54-ccf2a4292e31" xlink:to="loc_sgry_SurgicalFacilityServicesMember_f03d6e0f-c8f5-4656-b05c-b6941a10837d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AncillaryServicesMember_90fe8106-037b-4a6b-bb8d-365b1206dc9e" xlink:href="sgry-20220331.xsd#sgry_AncillaryServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_5ac84122-0607-447f-8a54-ccf2a4292e31" xlink:to="loc_sgry_AncillaryServicesMember_90fe8106-037b-4a6b-bb8d-365b1206dc9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherServicesMember_58eb1579-0b2a-4ac2-98cc-7947adad4a1b" xlink:href="sgry-20220331.xsd#sgry_OtherServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3b2d699f-9e1b-423a-80b5-e44e867f2230" xlink:to="loc_sgry_OtherServicesMember_58eb1579-0b2a-4ac2-98cc-7947adad4a1b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails" xlink:type="extended" id="i195d2049ed76440e8a64f78a2c208bf4_OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8bfd4ab2-4a16-4312-b1bb-7aa154ad8add" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_64438b05-f4bf-47cf-b147-d2276f6b87e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8bfd4ab2-4a16-4312-b1bb-7aa154ad8add" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_64438b05-f4bf-47cf-b147-d2276f6b87e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e113364f-1ca6-462a-9524-6b147ef2445b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8bfd4ab2-4a16-4312-b1bb-7aa154ad8add" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e113364f-1ca6-462a-9524-6b147ef2445b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ecba8d96-cc71-4765-bd42-12d29a35af68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8bfd4ab2-4a16-4312-b1bb-7aa154ad8add" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ecba8d96-cc71-4765-bd42-12d29a35af68" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e96db0d2-b8b6-4402-961b-bb3debf1bb25" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ecba8d96-cc71-4765-bd42-12d29a35af68" xlink:to="loc_srt_ProductOrServiceAxis_e96db0d2-b8b6-4402-961b-bb3debf1bb25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e96db0d2-b8b6-4402-961b-bb3debf1bb25_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e96db0d2-b8b6-4402-961b-bb3debf1bb25" xlink:to="loc_srt_ProductsAndServicesDomain_e96db0d2-b8b6-4402-961b-bb3debf1bb25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_14e5298e-5e59-4130-91cc-3b77f8359255" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e96db0d2-b8b6-4402-961b-bb3debf1bb25" xlink:to="loc_srt_ProductsAndServicesDomain_14e5298e-5e59-4130-91cc-3b77f8359255" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_HealthcareOrganizationPatientServiceMember_3cb24157-0b85-438d-89cc-970919639627" xlink:href="sgry-20220331.xsd#sgry_HealthcareOrganizationPatientServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_14e5298e-5e59-4130-91cc-3b77f8359255" xlink:to="loc_sgry_HealthcareOrganizationPatientServiceMember_3cb24157-0b85-438d-89cc-970919639627" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PrivateInsuranceMember_fbdfacc8-5537-4dac-85b3-741d49e4dff5" xlink:href="sgry-20220331.xsd#sgry_PrivateInsuranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_3cb24157-0b85-438d-89cc-970919639627" xlink:to="loc_sgry_PrivateInsuranceMember_fbdfacc8-5537-4dac-85b3-741d49e4dff5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractMember_f90fea3a-e24c-4f5d-8027-08e91d1406e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GovernmentContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_3cb24157-0b85-438d-89cc-970919639627" xlink:to="loc_us-gaap_GovernmentContractMember_f90fea3a-e24c-4f5d-8027-08e91d1406e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SelfPayRevenueMember_7f639d29-f685-484f-b5d8-fd3c69f9faa9" xlink:href="sgry-20220331.xsd#sgry_SelfPayRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_3cb24157-0b85-438d-89cc-970919639627" xlink:to="loc_sgry_SelfPayRevenueMember_7f639d29-f685-484f-b5d8-fd3c69f9faa9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherPatientServiceRevenueSourcesMember_b80969f9-dfff-4bae-8e87-eb6d9f5ec056" xlink:href="sgry-20220331.xsd#sgry_OtherPatientServiceRevenueSourcesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_3cb24157-0b85-438d-89cc-970919639627" xlink:to="loc_sgry_OtherPatientServiceRevenueSourcesMember_b80969f9-dfff-4bae-8e87-eb6d9f5ec056" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherServicesMember_fdad563f-f5f0-44ff-81e9-1dbb0ad84a26" xlink:href="sgry-20220331.xsd#sgry_OtherServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_14e5298e-5e59-4130-91cc-3b77f8359255" xlink:to="loc_sgry_OtherServicesMember_fdad563f-f5f0-44ff-81e9-1dbb0ad84a26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_853203e4-e32f-4397-949f-b306aff2c967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ecba8d96-cc71-4765-bd42-12d29a35af68" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_853203e4-e32f-4397-949f-b306aff2c967" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_853203e4-e32f-4397-949f-b306aff2c967_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_853203e4-e32f-4397-949f-b306aff2c967" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_853203e4-e32f-4397-949f-b306aff2c967_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4df4b04f-9bd6-4233-b151-4fae196d8369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_853203e4-e32f-4397-949f-b306aff2c967" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4df4b04f-9bd6-4233-b151-4fae196d8369" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e987d29b-4a7f-4787-bc1a-39c2733dd3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4df4b04f-9bd6-4233-b151-4fae196d8369" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e987d29b-4a7f-4787-bc1a-39c2733dd3e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6ce0983c-3bec-46b9-937a-8eb33e19b842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ecba8d96-cc71-4765-bd42-12d29a35af68" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6ce0983c-3bec-46b9-937a-8eb33e19b842" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6ce0983c-3bec-46b9-937a-8eb33e19b842_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6ce0983c-3bec-46b9-937a-8eb33e19b842" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6ce0983c-3bec-46b9-937a-8eb33e19b842_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52d28467-e76a-411c-9550-71b1c4f36e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6ce0983c-3bec-46b9-937a-8eb33e19b842" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52d28467-e76a-411c-9550-71b1c4f36e01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_a56d156e-0111-40dc-9fa5-a5a191162e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52d28467-e76a-411c-9550-71b1c4f36e01" xlink:to="loc_us-gaap_SalesRevenueNetMember_a56d156e-0111-40dc-9fa5-a5a191162e64" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#AcquisitionsandDisposalsAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails" xlink:type="extended" id="i1d4593629db546ed9d46d65ba1f3d0b1_AcquisitionsandDisposalsAcquisitionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_82207176-32c9-4456-9a43-4bb21c7a731f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_2dadb167-ec5f-4554-a55b-33bacd891939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82207176-32c9-4456-9a43-4bb21c7a731f" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_2dadb167-ec5f-4554-a55b-33bacd891939" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e501401c-8e4f-4b57-897b-04ed8d3fe726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82207176-32c9-4456-9a43-4bb21c7a731f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e501401c-8e4f-4b57-897b-04ed8d3fe726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_438a6439-13d3-4a81-9bbf-1968d69a184c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82207176-32c9-4456-9a43-4bb21c7a731f" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_438a6439-13d3-4a81-9bbf-1968d69a184c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8450ad82-f832-4332-83a3-b46b76c23fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82207176-32c9-4456-9a43-4bb21c7a731f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8450ad82-f832-4332-83a3-b46b76c23fbe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c83d1d76-0214-4a05-a2a1-7cb4b7236a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8450ad82-f832-4332-83a3-b46b76c23fbe" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c83d1d76-0214-4a05-a2a1-7cb4b7236a3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c83d1d76-0214-4a05-a2a1-7cb4b7236a3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c83d1d76-0214-4a05-a2a1-7cb4b7236a3a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c83d1d76-0214-4a05-a2a1-7cb4b7236a3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_584b0297-a2c0-49fa-a05f-8a1b20f92192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c83d1d76-0214-4a05-a2a1-7cb4b7236a3a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_584b0297-a2c0-49fa-a05f-8a1b20f92192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilitiesMember_6613d70c-46a4-4253-9629-66675bf8e87b" xlink:href="sgry-20220331.xsd#sgry_SurgicalFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_584b0297-a2c0-49fa-a05f-8a1b20f92192" xlink:to="loc_sgry_SurgicalFacilitiesMember_6613d70c-46a4-4253-9629-66675bf8e87b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilitiesExistingMarketsMember_c3fa1c9d-a11c-4e55-a2b9-84d67b972e1d" xlink:href="sgry-20220331.xsd#sgry_SurgicalFacilitiesExistingMarketsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_SurgicalFacilitiesMember_6613d70c-46a4-4253-9629-66675bf8e87b" xlink:to="loc_sgry_SurgicalFacilitiesExistingMarketsMember_c3fa1c9d-a11c-4e55-a2b9-84d67b972e1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_9e43fa83-f335-44ae-9513-3b7b68473750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_584b0297-a2c0-49fa-a05f-8a1b20f92192" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_9e43fa83-f335-44ae-9513-3b7b68473750" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#AcquisitionsandDisposalsSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails" xlink:type="extended" id="ibf31b5229e9f4a7280c6563e689ea2d6_AcquisitionsandDisposalsSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_088ed97a-1e19-4563-9d71-07c943ca606e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6619399f-00a3-4a54-b067-ecf1fe07eac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_088ed97a-1e19-4563-9d71-07c943ca606e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6619399f-00a3-4a54-b067-ecf1fe07eac4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_ac76a010-13b3-4241-8cf0-0397d70683fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_088ed97a-1e19-4563-9d71-07c943ca606e" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_ac76a010-13b3-4241-8cf0-0397d70683fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2f1ae67c-c134-4b51-a510-812f1afb10af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_088ed97a-1e19-4563-9d71-07c943ca606e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2f1ae67c-c134-4b51-a510-812f1afb10af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_2866480f-132b-4df9-bffd-1308dd640e49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_088ed97a-1e19-4563-9d71-07c943ca606e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_2866480f-132b-4df9-bffd-1308dd640e49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_55ea0b99-3566-4d35-9e51-155ff8966d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_2866480f-132b-4df9-bffd-1308dd640e49" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_55ea0b99-3566-4d35-9e51-155ff8966d8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a44b54e0-cfa3-4185-a27c-90c5838e0801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_2866480f-132b-4df9-bffd-1308dd640e49" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a44b54e0-cfa3-4185-a27c-90c5838e0801" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3c4dc056-5da7-49cf-a3b1-8193601f1c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_2866480f-132b-4df9-bffd-1308dd640e49" xlink:to="loc_us-gaap_Goodwill_3c4dc056-5da7-49cf-a3b1-8193601f1c27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets_fbcfe00b-3422-4cdf-9f28-75b55901197b" xlink:href="sgry-20220331.xsd#sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_2866480f-132b-4df9-bffd-1308dd640e49" xlink:to="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets_fbcfe00b-3422-4cdf-9f28-75b55901197b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_3a98e8c9-f9c1-40a8-87eb-eb93d4757d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_2866480f-132b-4df9-bffd-1308dd640e49" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_3a98e8c9-f9c1-40a8-87eb-eb93d4757d45" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_9d3c008e-f0f4-4b2b-b585-40cb556fb3bc" xlink:href="sgry-20220331.xsd#sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_2866480f-132b-4df9-bffd-1308dd640e49" xlink:to="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_9d3c008e-f0f4-4b2b-b585-40cb556fb3bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_25aa17c7-9a80-480d-8ab4-03fa3704a02b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0ed9f496-d39b-416b-89ae-126c437b28b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_088ed97a-1e19-4563-9d71-07c943ca606e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0ed9f496-d39b-416b-89ae-126c437b28b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d6cfae92-0710-453e-adef-b8fec6d1e2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0ed9f496-d39b-416b-89ae-126c437b28b3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d6cfae92-0710-453e-adef-b8fec6d1e2b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6cfae92-0710-453e-adef-b8fec6d1e2b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d6cfae92-0710-453e-adef-b8fec6d1e2b9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6cfae92-0710-453e-adef-b8fec6d1e2b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0ea6e6f-ba4e-4d65-a38e-55796bddfde4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d6cfae92-0710-453e-adef-b8fec6d1e2b9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0ea6e6f-ba4e-4d65-a38e-55796bddfde4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilitiesMember_7659a899-6dd5-413a-ad18-55097126a3b6" xlink:href="sgry-20220331.xsd#sgry_SurgicalFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0ea6e6f-ba4e-4d65-a38e-55796bddfde4" xlink:to="loc_sgry_SurgicalFacilitiesMember_7659a899-6dd5-413a-ad18-55097126a3b6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails" xlink:type="extended" id="i46fd8d329cb442c28eb3092f15d85828_AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87fdedac-efb1-464b-880f-5ec98ee7f328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_5d3e2d4f-6de6-446a-b0cc-85a95c4b42e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87fdedac-efb1-464b-880f-5ec98ee7f328" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_5d3e2d4f-6de6-446a-b0cc-85a95c4b42e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_ffdc6033-3144-4456-94e9-6f32fc88b8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87fdedac-efb1-464b-880f-5ec98ee7f328" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_ffdc6033-3144-4456-94e9-6f32fc88b8ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration_c58cc24b-0d45-471c-8882-91ccca4db798" xlink:href="sgry-20220331.xsd#sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87fdedac-efb1-464b-880f-5ec98ee7f328" xlink:to="loc_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration_c58cc24b-0d45-471c-8882-91ccca4db798" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_764b075c-6999-4c4d-8ad5-75821fca5fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87fdedac-efb1-464b-880f-5ec98ee7f328" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_764b075c-6999-4c4d-8ad5-75821fca5fd3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtFairValue_10619425-a2dc-48f2-96a3-82e174918093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87fdedac-efb1-464b-880f-5ec98ee7f328" xlink:to="loc_us-gaap_InvestmentOwnedAtFairValue_10619425-a2dc-48f2-96a3-82e174918093" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9b4703dc-03a7-4432-baa4-bb72f2bb4145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87fdedac-efb1-464b-880f-5ec98ee7f328" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9b4703dc-03a7-4432-baa4-bb72f2bb4145" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ab88909f-f4a0-48e4-80bf-4316276e8e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9b4703dc-03a7-4432-baa4-bb72f2bb4145" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ab88909f-f4a0-48e4-80bf-4316276e8e38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ab88909f-f4a0-48e4-80bf-4316276e8e38_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ab88909f-f4a0-48e4-80bf-4316276e8e38" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ab88909f-f4a0-48e4-80bf-4316276e8e38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_97ded168-14be-4c3d-b73b-3d77694eb5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ab88909f-f4a0-48e4-80bf-4316276e8e38" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_97ded168-14be-4c3d-b73b-3d77694eb5d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupOneMember_bcd10894-8704-419b-bfce-baf7f56417da" xlink:href="sgry-20220331.xsd#sgry_DisposalGroupOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_97ded168-14be-4c3d-b73b-3d77694eb5d7" xlink:to="loc_sgry_DisposalGroupOneMember_bcd10894-8704-419b-bfce-baf7f56417da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_1b6fdb97-8cf3-4946-b58a-25b5d5c79253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9b4703dc-03a7-4432-baa4-bb72f2bb4145" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_1b6fdb97-8cf3-4946-b58a-25b5d5c79253" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_1b6fdb97-8cf3-4946-b58a-25b5d5c79253_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_1b6fdb97-8cf3-4946-b58a-25b5d5c79253" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_1b6fdb97-8cf3-4946-b58a-25b5d5c79253_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_f2acdf4b-0538-47d7-a230-72f7b415b25a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_1b6fdb97-8cf3-4946-b58a-25b5d5c79253" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_f2acdf4b-0538-47d7-a230-72f7b415b25a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_0638d35c-0958-4eb2-a609-00886ed637f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_f2acdf4b-0538-47d7-a230-72f7b415b25a" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_0638d35c-0958-4eb2-a609-00886ed637f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d0d890d2-2f22-4cb3-9348-2d15fca6e30b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9b4703dc-03a7-4432-baa4-bb72f2bb4145" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d0d890d2-2f22-4cb3-9348-2d15fca6e30b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0d890d2-2f22-4cb3-9348-2d15fca6e30b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d0d890d2-2f22-4cb3-9348-2d15fca6e30b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0d890d2-2f22-4cb3-9348-2d15fca6e30b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cfdbce3a-5d87-4c8d-b521-06f0d53536e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d0d890d2-2f22-4cb3-9348-2d15fca6e30b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cfdbce3a-5d87-4c8d-b521-06f0d53536e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_0c3368f1-774c-492e-8ef2-073444e97797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cfdbce3a-5d87-4c8d-b521-06f0d53536e9" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_0c3368f1-774c-492e-8ef2-073444e97797" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#LongTermDebtSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtSummaryDetails" xlink:type="extended" id="i95831aebbb3848559941ee543bb457d7_LongTermDebtSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_900f1c87-2ab5-4e26-85d2-2e7dad7677ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c02ff227-184b-476f-a0f9-fcd74f04f2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900f1c87-2ab5-4e26-85d2-2e7dad7677ba" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c02ff227-184b-476f-a0f9-fcd74f04f2df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_8819830c-31d5-4413-bc7a-e111b2f08abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900f1c87-2ab5-4e26-85d2-2e7dad7677ba" xlink:to="loc_us-gaap_FinanceLeaseLiability_8819830c-31d5-4413-bc7a-e111b2f08abe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ec1a7c2c-3cdb-4d3d-99e9-42370fb71718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900f1c87-2ab5-4e26-85d2-2e7dad7677ba" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ec1a7c2c-3cdb-4d3d-99e9-42370fb71718" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_8dd281cc-d47a-49cc-a9ba-704b8edcfe91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900f1c87-2ab5-4e26-85d2-2e7dad7677ba" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_8dd281cc-d47a-49cc-a9ba-704b8edcfe91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_f2abcbfe-bacc-49cc-afc5-42219ad36807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900f1c87-2ab5-4e26-85d2-2e7dad7677ba" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_f2abcbfe-bacc-49cc-afc5-42219ad36807" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_ce9b5d9b-c89e-4d06-9924-d34e77399500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900f1c87-2ab5-4e26-85d2-2e7dad7677ba" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_ce9b5d9b-c89e-4d06-9924-d34e77399500" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_736afaf4-9ac2-4172-92e5-edc675da46e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900f1c87-2ab5-4e26-85d2-2e7dad7677ba" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_736afaf4-9ac2-4172-92e5-edc675da46e6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_c2d1c5a4-bde9-4111-89c0-05cbf77fe485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900f1c87-2ab5-4e26-85d2-2e7dad7677ba" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_c2d1c5a4-bde9-4111-89c0-05cbf77fe485" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_51518315-20a5-4648-ba7c-6e60dfe273dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900f1c87-2ab5-4e26-85d2-2e7dad7677ba" xlink:to="loc_us-gaap_DebtInstrumentTable_51518315-20a5-4648-ba7c-6e60dfe273dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_74f56eff-9c0f-41aa-8b03-f763e5b420d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_51518315-20a5-4648-ba7c-6e60dfe273dd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_74f56eff-9c0f-41aa-8b03-f763e5b420d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_74f56eff-9c0f-41aa-8b03-f763e5b420d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_74f56eff-9c0f-41aa-8b03-f763e5b420d1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_74f56eff-9c0f-41aa-8b03-f763e5b420d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_81ddca47-1d89-4a38-afab-9c42b181147c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_74f56eff-9c0f-41aa-8b03-f763e5b420d1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_81ddca47-1d89-4a38-afab-9c42b181147c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_8dbbe609-f08e-4bda-802b-9405e52bf0db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_81ddca47-1d89-4a38-afab-9c42b181147c" xlink:to="loc_us-gaap_SecuredDebtMember_8dbbe609-f08e-4bda-802b-9405e52bf0db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_58dc2c2d-b34e-4816-976e-ffa28170e36c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_81ddca47-1d89-4a38-afab-9c42b181147c" xlink:to="loc_us-gaap_SeniorNotesMember_58dc2c2d-b34e-4816-976e-ffa28170e36c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NotesPayableAndSecuredLoansMember_0139273f-93f7-4841-a87f-810af44cf6fa" xlink:href="sgry-20220331.xsd#sgry_NotesPayableAndSecuredLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_81ddca47-1d89-4a38-afab-9c42b181147c" xlink:to="loc_sgry_NotesPayableAndSecuredLoansMember_0139273f-93f7-4841-a87f-810af44cf6fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6660870c-21fa-4d1e-8b94-3148bbc5c4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_51518315-20a5-4648-ba7c-6e60dfe273dd" xlink:to="loc_us-gaap_DebtInstrumentAxis_6660870c-21fa-4d1e-8b94-3148bbc5c4ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6660870c-21fa-4d1e-8b94-3148bbc5c4ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6660870c-21fa-4d1e-8b94-3148bbc5c4ed" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6660870c-21fa-4d1e-8b94-3148bbc5c4ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7cee8b19-cda5-42b0-8d06-204cf6bea102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6660870c-21fa-4d1e-8b94-3148bbc5c4ed" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7cee8b19-cda5-42b0-8d06-204cf6bea102" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017TermLoanMaturing2024Member_e4d14de1-6680-4c9a-bb29-2088394d14b5" xlink:href="sgry-20220331.xsd#sgry_A2017TermLoanMaturing2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7cee8b19-cda5-42b0-8d06-204cf6bea102" xlink:to="loc_sgry_A2017TermLoanMaturing2024Member_e4d14de1-6680-4c9a-bb29-2088394d14b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2025Member_5c8f9fde-2402-49d7-8e47-47c863cf7518" xlink:href="sgry-20220331.xsd#sgry_SeniorUnsecuredNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7cee8b19-cda5-42b0-8d06-204cf6bea102" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2025Member_5c8f9fde-2402-49d7-8e47-47c863cf7518" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2027Member_7f55416d-680b-4860-94fb-646184637943" xlink:href="sgry-20220331.xsd#sgry_SeniorUnsecuredNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7cee8b19-cda5-42b0-8d06-204cf6bea102" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2027Member_7f55416d-680b-4860-94fb-646184637943" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#LongTermDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails" xlink:type="extended" id="i99ca207e8bb148c9b1ff962282fcf5c0_LongTermDebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6918afb8-5b23-425e-8ce7-d105ee3b87c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_13f52435-929c-4d44-ac1c-9e8146ee331f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6918afb8-5b23-425e-8ce7-d105ee3b87c2" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_13f52435-929c-4d44-ac1c-9e8146ee331f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_7e076777-64fb-42ba-9d6e-54f4d3e8a6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6918afb8-5b23-425e-8ce7-d105ee3b87c2" xlink:to="loc_us-gaap_LineOfCredit_7e076777-64fb-42ba-9d6e-54f4d3e8a6f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4f8b6993-fe15-4a4f-a410-23e644023217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6918afb8-5b23-425e-8ce7-d105ee3b87c2" xlink:to="loc_us-gaap_DebtInstrumentTable_4f8b6993-fe15-4a4f-a410-23e644023217" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_3ef36f77-e0d3-43c9-9c82-089b0f2d5fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4f8b6993-fe15-4a4f-a410-23e644023217" xlink:to="loc_us-gaap_CreditFacilityAxis_3ef36f77-e0d3-43c9-9c82-089b0f2d5fd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_3ef36f77-e0d3-43c9-9c82-089b0f2d5fd9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_3ef36f77-e0d3-43c9-9c82-089b0f2d5fd9" xlink:to="loc_us-gaap_CreditFacilityDomain_3ef36f77-e0d3-43c9-9c82-089b0f2d5fd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4e030d07-1ead-4403-b020-8ae64e132d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_3ef36f77-e0d3-43c9-9c82-089b0f2d5fd9" xlink:to="loc_us-gaap_CreditFacilityDomain_4e030d07-1ead-4403-b020-8ae64e132d0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_6ed27743-9de0-4051-8502-be4f7a0bb8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_4e030d07-1ead-4403-b020-8ae64e132d0e" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_6ed27743-9de0-4051-8502-be4f7a0bb8b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_b1933873-b8cc-412f-b0bd-b003b74ccef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_4e030d07-1ead-4403-b020-8ae64e132d0e" xlink:to="loc_us-gaap_LetterOfCreditMember_b1933873-b8cc-412f-b0bd-b003b74ccef1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3423f2d4-221b-40fa-a65e-4f97887432d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4f8b6993-fe15-4a4f-a410-23e644023217" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3423f2d4-221b-40fa-a65e-4f97887432d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3423f2d4-221b-40fa-a65e-4f97887432d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3423f2d4-221b-40fa-a65e-4f97887432d4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3423f2d4-221b-40fa-a65e-4f97887432d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ff3f805c-dc27-44ae-8dab-3825c865bc73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3423f2d4-221b-40fa-a65e-4f97887432d4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ff3f805c-dc27-44ae-8dab-3825c865bc73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_304ea41a-d730-4d45-8e5f-a5a6083ebb29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ff3f805c-dc27-44ae-8dab-3825c865bc73" xlink:to="loc_us-gaap_SecuredDebtMember_304ea41a-d730-4d45-8e5f-a5a6083ebb29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_aece87e5-d4eb-4ae4-96e8-9a867c7985e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4f8b6993-fe15-4a4f-a410-23e644023217" xlink:to="loc_us-gaap_DebtInstrumentAxis_aece87e5-d4eb-4ae4-96e8-9a867c7985e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_aece87e5-d4eb-4ae4-96e8-9a867c7985e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_aece87e5-d4eb-4ae4-96e8-9a867c7985e3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_aece87e5-d4eb-4ae4-96e8-9a867c7985e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fae4f4fa-72fc-401e-b697-92cb8ff2666f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_aece87e5-d4eb-4ae4-96e8-9a867c7985e3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fae4f4fa-72fc-401e-b697-92cb8ff2666f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017SeniorSecuredCreditFacilityMember_39eaa6fe-4cca-44dd-8d05-196f127a65b3" xlink:href="sgry-20220331.xsd#sgry_A2017SeniorSecuredCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fae4f4fa-72fc-401e-b697-92cb8ff2666f" xlink:to="loc_sgry_A2017SeniorSecuredCreditFacilityMember_39eaa6fe-4cca-44dd-8d05-196f127a65b3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#DerivativesandHedgingActivitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails" xlink:type="extended" id="i4752cd65d2ec41ab9401db6109bc22b2_DerivativesandHedgingActivitiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c3527002-9b49-4b0e-8b71-2379fc6f2cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_5acac37e-342d-415d-9b0b-28a70b29e830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c3527002-9b49-4b0e-8b71-2379fc6f2cc3" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_5acac37e-342d-415d-9b0b-28a70b29e830" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_fdc9f3e9-7e94-4c77-a2de-7b35ad025eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c3527002-9b49-4b0e-8b71-2379fc6f2cc3" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_fdc9f3e9-7e94-4c77-a2de-7b35ad025eda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_b04f22f0-28e6-4444-ae35-c45b7574d1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c3527002-9b49-4b0e-8b71-2379fc6f2cc3" xlink:to="loc_us-gaap_DerivativeNotionalAmount_b04f22f0-28e6-4444-ae35-c45b7574d1a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeVariableInterestRate_b50d196c-afc9-4ac8-9929-aab1fd65cb49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeVariableInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c3527002-9b49-4b0e-8b71-2379fc6f2cc3" xlink:to="loc_us-gaap_DerivativeVariableInterestRate_b50d196c-afc9-4ac8-9929-aab1fd65cb49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_db217f5f-0b37-4288-a01e-714d1352b8df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c3527002-9b49-4b0e-8b71-2379fc6f2cc3" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_db217f5f-0b37-4288-a01e-714d1352b8df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d5aa5b8c-2554-4b83-ab7f-c725be3e9aec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_db217f5f-0b37-4288-a01e-714d1352b8df" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d5aa5b8c-2554-4b83-ab7f-c725be3e9aec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d5aa5b8c-2554-4b83-ab7f-c725be3e9aec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d5aa5b8c-2554-4b83-ab7f-c725be3e9aec" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d5aa5b8c-2554-4b83-ab7f-c725be3e9aec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_588e2e11-a00d-4466-b3d7-d363af619a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d5aa5b8c-2554-4b83-ab7f-c725be3e9aec" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_588e2e11-a00d-4466-b3d7-d363af619a2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_eb0f908c-976d-482c-bde1-b146bb55c946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_588e2e11-a00d-4466-b3d7-d363af619a2d" xlink:to="loc_us-gaap_InterestRateSwapMember_eb0f908c-976d-482c-bde1-b146bb55c946" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_41a3d26b-359d-4002-8bbe-99cd41d3ded2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateCapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_588e2e11-a00d-4466-b3d7-d363af619a2d" xlink:to="loc_us-gaap_InterestRateCapMember_41a3d26b-359d-4002-8bbe-99cd41d3ded2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ThreePayFixedInterestRateSwapsMember_d5de179b-bdd8-49d8-9125-cf6ddf0b2f86" xlink:href="sgry-20220331.xsd#sgry_ThreePayFixedInterestRateSwapsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_588e2e11-a00d-4466-b3d7-d363af619a2d" xlink:to="loc_sgry_ThreePayFixedInterestRateSwapsMember_d5de179b-bdd8-49d8-9125-cf6ddf0b2f86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ThreeReceiveFixedInterestRateSwapsMember_a93d66f1-0160-44f7-81e9-ab3350d37ff6" xlink:href="sgry-20220331.xsd#sgry_ThreeReceiveFixedInterestRateSwapsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_588e2e11-a00d-4466-b3d7-d363af619a2d" xlink:to="loc_sgry_ThreeReceiveFixedInterestRateSwapsMember_a93d66f1-0160-44f7-81e9-ab3350d37ff6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_2e692df8-e1b5-4af0-a86c-e116eb84f09f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_db217f5f-0b37-4288-a01e-714d1352b8df" xlink:to="loc_us-gaap_HedgingDesignationAxis_2e692df8-e1b5-4af0-a86c-e116eb84f09f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2e692df8-e1b5-4af0-a86c-e116eb84f09f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_2e692df8-e1b5-4af0-a86c-e116eb84f09f" xlink:to="loc_us-gaap_HedgingDesignationDomain_2e692df8-e1b5-4af0-a86c-e116eb84f09f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2704769c-1fb8-438a-b9f3-7af14fa518d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_2e692df8-e1b5-4af0-a86c-e116eb84f09f" xlink:to="loc_us-gaap_HedgingDesignationDomain_2704769c-1fb8-438a-b9f3-7af14fa518d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9c84eca9-e731-4fd5-b8e1-92495e4b9343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_2704769c-1fb8-438a-b9f3-7af14fa518d8" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9c84eca9-e731-4fd5-b8e1-92495e4b9343" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_8e42741b-f364-4af3-a138-696b08c74582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_2704769c-1fb8-438a-b9f3-7af14fa518d8" xlink:to="loc_us-gaap_NondesignatedMember_8e42741b-f364-4af3-a138-696b08c74582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_3a0710c2-ac56-4de6-88cc-a06f3fc40d36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_db217f5f-0b37-4288-a01e-714d1352b8df" xlink:to="loc_us-gaap_VariableRateAxis_3a0710c2-ac56-4de6-88cc-a06f3fc40d36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_3a0710c2-ac56-4de6-88cc-a06f3fc40d36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_3a0710c2-ac56-4de6-88cc-a06f3fc40d36" xlink:to="loc_us-gaap_VariableRateDomain_3a0710c2-ac56-4de6-88cc-a06f3fc40d36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_fdbfff41-0e8e-4add-b85d-2cd9341d7a77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_3a0710c2-ac56-4de6-88cc-a06f3fc40d36" xlink:to="loc_us-gaap_VariableRateDomain_fdbfff41-0e8e-4add-b85d-2cd9341d7a77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_7186c85c-6f87-45ec-a89d-1672fa71e4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_fdbfff41-0e8e-4add-b85d-2cd9341d7a77" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_7186c85c-6f87-45ec-a89d-1672fa71e4d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e7928737-75a8-4421-8567-0ab13f6a0987" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_db217f5f-0b37-4288-a01e-714d1352b8df" xlink:to="loc_srt_RangeAxis_e7928737-75a8-4421-8567-0ab13f6a0987" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e7928737-75a8-4421-8567-0ab13f6a0987_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e7928737-75a8-4421-8567-0ab13f6a0987" xlink:to="loc_srt_RangeMember_e7928737-75a8-4421-8567-0ab13f6a0987_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f6e068d9-fa77-4016-ac8b-79989f2ed90a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e7928737-75a8-4421-8567-0ab13f6a0987" xlink:to="loc_srt_RangeMember_f6e068d9-fa77-4016-ac8b-79989f2ed90a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ca1dd3d5-e770-41c3-98d9-faa401f34028" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f6e068d9-fa77-4016-ac8b-79989f2ed90a" xlink:to="loc_srt_MinimumMember_ca1dd3d5-e770-41c3-98d9-faa401f34028" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails" xlink:type="extended" id="i248abde01cf245cfb1080fe3c75b0fa7_DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_42cddfb8-497f-4b3c-a56f-d57c6f2931d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_01569dde-e34f-4407-8fd4-57b89f0d4996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_42cddfb8-497f-4b3c-a56f-d57c6f2931d7" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_01569dde-e34f-4407-8fd4-57b89f0d4996" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_709ed5ce-2e60-4609-b6a0-25d2e540ddb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_42cddfb8-497f-4b3c-a56f-d57c6f2931d7" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_709ed5ce-2e60-4609-b6a0-25d2e540ddb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_4ffe67bc-4957-4368-87fd-dc802866ea7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_42cddfb8-497f-4b3c-a56f-d57c6f2931d7" xlink:to="loc_us-gaap_DerivativeNotionalAmount_4ffe67bc-4957-4368-87fd-dc802866ea7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_391186ca-d8b2-411e-801d-df57ab139dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_42cddfb8-497f-4b3c-a56f-d57c6f2931d7" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_391186ca-d8b2-411e-801d-df57ab139dc5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_edcdda16-0c9d-4413-99f3-10ef910742c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_391186ca-d8b2-411e-801d-df57ab139dc5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_edcdda16-0c9d-4413-99f3-10ef910742c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_edcdda16-0c9d-4413-99f3-10ef910742c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_edcdda16-0c9d-4413-99f3-10ef910742c0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_edcdda16-0c9d-4413-99f3-10ef910742c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_edcdda16-0c9d-4413-99f3-10ef910742c0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapOneMember_f4894ceb-2792-4c0d-8633-fd8e0fe0f9f5" xlink:href="sgry-20220331.xsd#sgry_PayFixedSwapOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:to="loc_sgry_PayFixedSwapOneMember_f4894ceb-2792-4c0d-8633-fd8e0fe0f9f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapTwoMember_8500900e-dd0e-46f7-9658-155426859623" xlink:href="sgry-20220331.xsd#sgry_PayFixedSwapTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:to="loc_sgry_PayFixedSwapTwoMember_8500900e-dd0e-46f7-9658-155426859623" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapThreeMember_6df78b15-606e-4da5-86ba-490f44e15c11" xlink:href="sgry-20220331.xsd#sgry_PayFixedSwapThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:to="loc_sgry_PayFixedSwapThreeMember_6df78b15-606e-4da5-86ba-490f44e15c11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_InterestRateCapOneMember_e9531de0-e9e2-41aa-94b3-f0903fc7ef25" xlink:href="sgry-20220331.xsd#sgry_InterestRateCapOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:to="loc_sgry_InterestRateCapOneMember_e9531de0-e9e2-41aa-94b3-f0903fc7ef25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_InterestRateCapTwoMember_8b672262-1e4c-4172-95a0-74d168932ada" xlink:href="sgry-20220331.xsd#sgry_InterestRateCapTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:to="loc_sgry_InterestRateCapTwoMember_8b672262-1e4c-4172-95a0-74d168932ada" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapFourMember_21896aa5-8ec5-40ae-8ae9-b3e8af65ceda" xlink:href="sgry-20220331.xsd#sgry_PayFixedSwapFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:to="loc_sgry_PayFixedSwapFourMember_21896aa5-8ec5-40ae-8ae9-b3e8af65ceda" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapFiveMember_f0ac9d6e-46d0-4b8e-bc6c-151e6f9cd5d1" xlink:href="sgry-20220331.xsd#sgry_PayFixedSwapFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:to="loc_sgry_PayFixedSwapFiveMember_f0ac9d6e-46d0-4b8e-bc6c-151e6f9cd5d1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapSixMember_8cfe8a6d-1aef-483b-b518-8f3b61e239cc" xlink:href="sgry-20220331.xsd#sgry_PayFixedSwapSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:to="loc_sgry_PayFixedSwapSixMember_8cfe8a6d-1aef-483b-b518-8f3b61e239cc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ReceiveFixedSwapOneMember_b94be124-4886-4d55-a459-4317a30ca289" xlink:href="sgry-20220331.xsd#sgry_ReceiveFixedSwapOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:to="loc_sgry_ReceiveFixedSwapOneMember_b94be124-4886-4d55-a459-4317a30ca289" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ReceiveFixedSwapTwoMember_bc0dbdfa-fd05-4a50-8bcd-ce8f38d78b2e" xlink:href="sgry-20220331.xsd#sgry_ReceiveFixedSwapTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:to="loc_sgry_ReceiveFixedSwapTwoMember_bc0dbdfa-fd05-4a50-8bcd-ce8f38d78b2e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ReceiveFixedSwapThreeMember_93ab8cf8-b376-4050-a83f-e769d4cb1890" xlink:href="sgry-20220331.xsd#sgry_ReceiveFixedSwapThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:to="loc_sgry_ReceiveFixedSwapThreeMember_93ab8cf8-b376-4050-a83f-e769d4cb1890" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails" xlink:type="extended" id="ieb557bc52d734f2cb34eb93098167fb7_DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_4624217e-6e6a-4911-a478-cb8db3330684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_92d3850c-a863-45ab-b8c2-80eebc061062" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_4624217e-6e6a-4911-a478-cb8db3330684" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_92d3850c-a863-45ab-b8c2-80eebc061062" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_fe8f60b3-09d4-4b34-a083-331f24b5e2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_4624217e-6e6a-4911-a478-cb8db3330684" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_fe8f60b3-09d4-4b34-a083-331f24b5e2b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DerivativeLiabilityNotionalAmountFinancingComponent_9ae41c74-5327-48ff-843b-3c507978e5d3" xlink:href="sgry-20220331.xsd#sgry_DerivativeLiabilityNotionalAmountFinancingComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_4624217e-6e6a-4911-a478-cb8db3330684" xlink:to="loc_sgry_DerivativeLiabilityNotionalAmountFinancingComponent_9ae41c74-5327-48ff-843b-3c507978e5d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b4c8a633-952f-48ac-8541-ae41c155d6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_4624217e-6e6a-4911-a478-cb8db3330684" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b4c8a633-952f-48ac-8541-ae41c155d6ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ece185fe-bcbf-4080-9626-cf7cf458180d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b4c8a633-952f-48ac-8541-ae41c155d6ba" xlink:to="loc_us-gaap_HedgingDesignationAxis_ece185fe-bcbf-4080-9626-cf7cf458180d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ece185fe-bcbf-4080-9626-cf7cf458180d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_ece185fe-bcbf-4080-9626-cf7cf458180d" xlink:to="loc_us-gaap_HedgingDesignationDomain_ece185fe-bcbf-4080-9626-cf7cf458180d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_16ff9492-b32a-4d6a-90e6-03d226f6385e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_ece185fe-bcbf-4080-9626-cf7cf458180d" xlink:to="loc_us-gaap_HedgingDesignationDomain_16ff9492-b32a-4d6a-90e6-03d226f6385e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_63d0aa1d-077d-43d9-823b-af078912b297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_16ff9492-b32a-4d6a-90e6-03d226f6385e" xlink:to="loc_us-gaap_NondesignatedMember_63d0aa1d-077d-43d9-823b-af078912b297" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b71e0117-1b6f-4fd8-80e8-22ca555de893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_16ff9492-b32a-4d6a-90e6-03d226f6385e" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b71e0117-1b6f-4fd8-80e8-22ca555de893" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_86b6a6ac-e6e6-48da-8bbe-c05ca724aa2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b4c8a633-952f-48ac-8541-ae41c155d6ba" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_86b6a6ac-e6e6-48da-8bbe-c05ca724aa2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_86b6a6ac-e6e6-48da-8bbe-c05ca724aa2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_86b6a6ac-e6e6-48da-8bbe-c05ca724aa2a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_86b6a6ac-e6e6-48da-8bbe-c05ca724aa2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_615127e7-d4db-4407-b5f1-b37d67edee43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_86b6a6ac-e6e6-48da-8bbe-c05ca724aa2a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_615127e7-d4db-4407-b5f1-b37d67edee43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_be53b3e9-f05b-4a93-9b2d-476d6732a946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_615127e7-d4db-4407-b5f1-b37d67edee43" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_be53b3e9-f05b-4a93-9b2d-476d6732a946" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0bba5976-1832-4803-9fcd-ae7984c1ce44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_615127e7-d4db-4407-b5f1-b37d67edee43" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0bba5976-1832-4803-9fcd-ae7984c1ce44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d49bf9e0-e2c8-42ac-b9ee-5a14e5d2a7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b4c8a633-952f-48ac-8541-ae41c155d6ba" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d49bf9e0-e2c8-42ac-b9ee-5a14e5d2a7b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d49bf9e0-e2c8-42ac-b9ee-5a14e5d2a7b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d49bf9e0-e2c8-42ac-b9ee-5a14e5d2a7b8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d49bf9e0-e2c8-42ac-b9ee-5a14e5d2a7b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_297d7d78-377d-4c2a-9185-00c96db7cd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d49bf9e0-e2c8-42ac-b9ee-5a14e5d2a7b8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_297d7d78-377d-4c2a-9185-00c96db7cd0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_842a3d57-5ad3-421d-90a2-0c0c910cfe1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_297d7d78-377d-4c2a-9185-00c96db7cd0a" xlink:to="loc_us-gaap_InterestRateSwapMember_842a3d57-5ad3-421d-90a2-0c0c910cfe1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_2f06fc0d-f1d1-4907-812d-e7d532a43ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateCapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_297d7d78-377d-4c2a-9185-00c96db7cd0a" xlink:to="loc_us-gaap_InterestRateCapMember_2f06fc0d-f1d1-4907-812d-e7d532a43ccc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails" xlink:type="extended" id="iec1cd4feacb74ad085b1b2f95795aed8_DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_59717cea-e028-4528-961b-6a23f01ced43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_1e65c045-1ad3-402f-8f3f-9ff150fb7639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_59717cea-e028-4528-961b-6a23f01ced43" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_1e65c045-1ad3-402f-8f3f-9ff150fb7639" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_6a4dbaf2-91e7-4e43-bd7c-d5153fa0e334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_59717cea-e028-4528-961b-6a23f01ced43" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_6a4dbaf2-91e7-4e43-bd7c-d5153fa0e334" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_08a16fb9-f985-4ad7-a1e5-857828c7094f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_59717cea-e028-4528-961b-6a23f01ced43" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_08a16fb9-f985-4ad7-a1e5-857828c7094f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_c91c191b-d04e-4746-98db-05215f39d844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_59717cea-e028-4528-961b-6a23f01ced43" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_c91c191b-d04e-4746-98db-05215f39d844" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7063fcbc-41d9-4a68-b88e-b3184461bc90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_c91c191b-d04e-4746-98db-05215f39d844" xlink:to="loc_us-gaap_HedgingDesignationAxis_7063fcbc-41d9-4a68-b88e-b3184461bc90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7063fcbc-41d9-4a68-b88e-b3184461bc90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_7063fcbc-41d9-4a68-b88e-b3184461bc90" xlink:to="loc_us-gaap_HedgingDesignationDomain_7063fcbc-41d9-4a68-b88e-b3184461bc90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_156df1b4-48a8-4f2f-bdd1-a4aa0c3a0587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_7063fcbc-41d9-4a68-b88e-b3184461bc90" xlink:to="loc_us-gaap_HedgingDesignationDomain_156df1b4-48a8-4f2f-bdd1-a4aa0c3a0587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_1c3591c7-e792-4dca-b204-c28f1168e8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_156df1b4-48a8-4f2f-bdd1-a4aa0c3a0587" xlink:to="loc_us-gaap_NondesignatedMember_1c3591c7-e792-4dca-b204-c28f1168e8cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_41d93ac6-1d26-4b29-87e7-d2fc502f78fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_156df1b4-48a8-4f2f-bdd1-a4aa0c3a0587" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_41d93ac6-1d26-4b29-87e7-d2fc502f78fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ef82aca8-326a-4984-b03c-22b1bc2a3013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_c91c191b-d04e-4746-98db-05215f39d844" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ef82aca8-326a-4984-b03c-22b1bc2a3013" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ef82aca8-326a-4984-b03c-22b1bc2a3013_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ef82aca8-326a-4984-b03c-22b1bc2a3013" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ef82aca8-326a-4984-b03c-22b1bc2a3013_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a6e0e681-4b61-4872-9581-714c3cdfab7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ef82aca8-326a-4984-b03c-22b1bc2a3013" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a6e0e681-4b61-4872-9581-714c3cdfab7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember_82eb71f9-9ee8-4413-a47c-c88b4bf75b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a6e0e681-4b61-4872-9581-714c3cdfab7b" xlink:to="loc_us-gaap_OtherIncomeMember_82eb71f9-9ee8-4413-a47c-c88b4bf75b4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_1608e9ed-7087-47b0-8a86-70567d7c6f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a6e0e681-4b61-4872-9581-714c3cdfab7b" xlink:to="loc_us-gaap_InterestExpenseMember_1608e9ed-7087-47b0-8a86-70567d7c6f6f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#EarningsPerShareSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails" xlink:type="extended" id="i75707a5897df47bfbbf7159809e0ac2c_EarningsPerShareSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_736911fb-c1e3-4630-b86e-23d72249a1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_7c3a0464-2424-4a50-85e1-671a3d99f35f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_736911fb-c1e3-4630-b86e-23d72249a1a0" xlink:to="loc_us-gaap_NetIncomeLossAbstract_7c3a0464-2424-4a50-85e1-671a3d99f35f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dbffe00e-dbbd-4150-abc8-164a8de28059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_7c3a0464-2424-4a50-85e1-671a3d99f35f" xlink:to="loc_us-gaap_NetIncomeLoss_dbffe00e-dbbd-4150-abc8-164a8de28059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_e51bfe12-92d1-4d1c-a050-0a795b412d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_7c3a0464-2424-4a50-85e1-671a3d99f35f" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_e51bfe12-92d1-4d1c-a050-0a795b412d23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_24aa5469-b152-4865-a1c5-2ace49668a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_7c3a0464-2424-4a50-85e1-671a3d99f35f" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_24aa5469-b152-4865-a1c5-2ace49668a0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ebc15ae2-0697-4741-b473-a4f0b923a275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_736911fb-c1e3-4630-b86e-23d72249a1a0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ebc15ae2-0697-4741-b473-a4f0b923a275" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bf0ab9b6-685b-4bd6-8e2a-c057d56269e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ebc15ae2-0697-4741-b473-a4f0b923a275" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bf0ab9b6-685b-4bd6-8e2a-c057d56269e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fa91eb05-09f7-4363-aed0-836da0d85acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ebc15ae2-0697-4741-b473-a4f0b923a275" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fa91eb05-09f7-4363-aed0-836da0d85acf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a0741e24-4387-4dda-bb27-60ad4404b726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_736911fb-c1e3-4630-b86e-23d72249a1a0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a0741e24-4387-4dda-bb27-60ad4404b726" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6f0f0a41-d524-438e-9bae-0a90da05c78f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a0741e24-4387-4dda-bb27-60ad4404b726" xlink:to="loc_us-gaap_EarningsPerShareBasic_6f0f0a41-d524-438e-9bae-0a90da05c78f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_044af1b6-de33-472b-9575-a07157099257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a0741e24-4387-4dda-bb27-60ad4404b726" xlink:to="loc_us-gaap_EarningsPerShareDiluted_044af1b6-de33-472b-9575-a07157099257" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f112d335-544e-46b0-b088-5fed5f91279b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_736911fb-c1e3-4630-b86e-23d72249a1a0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f112d335-544e-46b0-b088-5fed5f91279b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_41fdf6cd-63b7-490f-a5e7-d86586dce12a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_736911fb-c1e3-4630-b86e-23d72249a1a0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_41fdf6cd-63b7-490f-a5e7-d86586dce12a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_78a25dc7-c865-4226-8313-bc07b541498e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_41fdf6cd-63b7-490f-a5e7-d86586dce12a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_78a25dc7-c865-4226-8313-bc07b541498e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_78a25dc7-c865-4226-8313-bc07b541498e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_78a25dc7-c865-4226-8313-bc07b541498e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_78a25dc7-c865-4226-8313-bc07b541498e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a355ff4-fd04-4ad6-92d6-959d8de56631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_78a25dc7-c865-4226-8313-bc07b541498e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a355ff4-fd04-4ad6-92d6-959d8de56631" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_36defcd3-8dc0-4205-9498-e1eed8222390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a355ff4-fd04-4ad6-92d6-959d8de56631" xlink:to="loc_us-gaap_EmployeeStockOptionMember_36defcd3-8dc0-4205-9498-e1eed8222390" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_a113a308-cc31-4ec3-9f30-b7a19527855a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a355ff4-fd04-4ad6-92d6-959d8de56631" xlink:to="loc_us-gaap_RestrictedStockMember_a113a308-cc31-4ec3-9f30-b7a19527855a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i7b9747f4e54f422f93c61dae50b1266b_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsLineItems_a1d8281e-b243-4869-80ff-3a4d1134e3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserve_794c20cd-ae07-48c6-81f6-333a57cd7aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SelfInsuranceReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_a1d8281e-b243-4869-80ff-3a4d1134e3c7" xlink:to="loc_us-gaap_SelfInsuranceReserve_794c20cd-ae07-48c6-81f6-333a57cd7aea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimatedInsuranceRecoveries_e6c54a55-66bb-4cfd-8d18-afd8fad7adac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimatedInsuranceRecoveries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_a1d8281e-b243-4869-80ff-3a4d1134e3c7" xlink:to="loc_us-gaap_EstimatedInsuranceRecoveries_e6c54a55-66bb-4cfd-8d18-afd8fad7adac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_f0b0de3b-de4b-4db3-9c99-6bcd21f9b43a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_a1d8281e-b243-4869-80ff-3a4d1134e3c7" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_f0b0de3b-de4b-4db3-9c99-6bcd21f9b43a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b9640611-0967-438c-82bd-44497c506e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_a1d8281e-b243-4869-80ff-3a4d1134e3c7" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b9640611-0967-438c-82bd-44497c506e1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm_290928ae-62aa-4fba-88f6-fc43679d8cc2" xlink:href="sgry-20220331.xsd#sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_a1d8281e-b243-4869-80ff-3a4d1134e3c7" xlink:to="loc_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm_290928ae-62aa-4fba-88f6-fc43679d8cc2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6c2e946f-5513-4091-a2ad-3b1444f81452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_a1d8281e-b243-4869-80ff-3a4d1134e3c7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6c2e946f-5513-4091-a2ad-3b1444f81452" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate_3d507ca6-131e-440a-a563-1ddddc59beac" xlink:href="sgry-20220331.xsd#sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_a1d8281e-b243-4869-80ff-3a4d1134e3c7" xlink:to="loc_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate_3d507ca6-131e-440a-a563-1ddddc59beac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrentAndNoncurrent_e5814bd4-7d03-4c76-9eab-8a0f716dd0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_a1d8281e-b243-4869-80ff-3a4d1134e3c7" xlink:to="loc_us-gaap_TaxesPayableCurrentAndNoncurrent_e5814bd4-7d03-4c76-9eab-8a0f716dd0f6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount_1e9511d5-8329-4f95-b035-4b76efdb1808" xlink:href="sgry-20220331.xsd#sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_a1d8281e-b243-4869-80ff-3a4d1134e3c7" xlink:to="loc_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount_1e9511d5-8329-4f95-b035-4b76efdb1808" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_367b9085-ffae-48a3-a1de-b15db4ebb900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGuaranteeObligationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_a1d8281e-b243-4869-80ff-3a4d1134e3c7" xlink:to="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_367b9085-ffae-48a3-a1de-b15db4ebb900" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_363753e5-f10b-46cd-81c5-736a99eb36f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_367b9085-ffae-48a3-a1de-b15db4ebb900" xlink:to="loc_us-gaap_VariableRateAxis_363753e5-f10b-46cd-81c5-736a99eb36f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_363753e5-f10b-46cd-81c5-736a99eb36f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_363753e5-f10b-46cd-81c5-736a99eb36f9" xlink:to="loc_us-gaap_VariableRateDomain_363753e5-f10b-46cd-81c5-736a99eb36f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b8e1a86e-69ba-40fd-92bc-ec25d79e1d46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_363753e5-f10b-46cd-81c5-736a99eb36f9" xlink:to="loc_us-gaap_VariableRateDomain_b8e1a86e-69ba-40fd-92bc-ec25d79e1d46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_c9daf3e9-4922-4c65-8a17-b30bb4943a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_b8e1a86e-69ba-40fd-92bc-ec25d79e1d46" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_c9daf3e9-4922-4c65-8a17-b30bb4943a4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_41da6d8c-221f-4e2d-8aa8-61acb633585f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_b8e1a86e-69ba-40fd-92bc-ec25d79e1d46" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_41da6d8c-221f-4e2d-8aa8-61acb633585f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyByNatureAxis_136bb0a4-ac57-4bd4-8514-f37f6ed7aca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyByNatureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_367b9085-ffae-48a3-a1de-b15db4ebb900" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyByNatureAxis_136bb0a4-ac57-4bd4-8514-f37f6ed7aca2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain_136bb0a4-ac57-4bd4-8514-f37f6ed7aca2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyByNatureAxis_136bb0a4-ac57-4bd4-8514-f37f6ed7aca2" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain_136bb0a4-ac57-4bd4-8514-f37f6ed7aca2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain_257c62d7-b9c5-4d2b-bb16-b9015b74c68d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyByNatureAxis_136bb0a4-ac57-4bd4-8514-f37f6ed7aca2" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain_257c62d7-b9c5-4d2b-bb16-b9015b74c68d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_MateriallyMoreRestrictiveMember_1194bdaa-3410-42a8-b70a-08ea7d0f32a5" xlink:href="sgry-20220331.xsd#sgry_MateriallyMoreRestrictiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain_257c62d7-b9c5-4d2b-bb16-b9015b74c68d" xlink:to="loc_sgry_MateriallyMoreRestrictiveMember_1194bdaa-3410-42a8-b70a-08ea7d0f32a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NotMateriallyMoreRestrictiveMember_d20e0728-8c45-49e3-8a18-2b6b99b3adca" xlink:href="sgry-20220331.xsd#sgry_NotMateriallyMoreRestrictiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain_257c62d7-b9c5-4d2b-bb16-b9015b74c68d" xlink:to="loc_sgry_NotMateriallyMoreRestrictiveMember_d20e0728-8c45-49e3-8a18-2b6b99b3adca" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails" xlink:type="extended" id="i93b056571adb4a6999a25ba0e22655aa_SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_502ad5bb-0a58-4f50-b5f2-f30a62e1aed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_04fc7ec1-45b1-4e7d-ab04-c38d1bdbc2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_502ad5bb-0a58-4f50-b5f2-f30a62e1aed5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_04fc7ec1-45b1-4e7d-ab04-c38d1bdbc2a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_ec6244a5-d110-420c-8f54-e1796b955d95" xlink:href="sgry-20220331.xsd#sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_502ad5bb-0a58-4f50-b5f2-f30a62e1aed5" xlink:to="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_ec6244a5-d110-420c-8f54-e1796b955d95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_502ad5bb-0a58-4f50-b5f2-f30a62e1aed5" xlink:to="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_96182594-812c-45f9-8924-85b607622211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_96182594-812c-45f9-8924-85b607622211" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_47f0393d-cd6d-4616-8090-5804179df996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_47f0393d-cd6d-4616-8090-5804179df996" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3a24fb74-4069-49d3-8499-48ef78d5e647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3a24fb74-4069-49d3-8499-48ef78d5e647" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_50b023f2-91f6-497a-bebd-0c7300f7301b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_50b023f2-91f6-497a-bebd-0c7300f7301b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_95cdf2e0-750b-4b90-afbb-809868509355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_us-gaap_ShareBasedCompensation_95cdf2e0-750b-4b90-afbb-809868509355" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts_2504b30c-1dbd-40c3-a2e5-c1e5fa28dff7" xlink:href="sgry-20220331.xsd#sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts_2504b30c-1dbd-40c3-a2e5-c1e5fa28dff7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_3bf62bd5-a4d5-4e91-b4f7-13c91953362d" xlink:href="sgry-20220331.xsd#sgry_GainLossOnDispositionOfAssetsAndDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_3bf62bd5-a4d5-4e91-b4f7-13c91953362d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts_64b73d45-d6fe-4264-a88a-a3b6d3f9a3ea" xlink:href="sgry-20220331.xsd#sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts_64b73d45-d6fe-4264-a88a-a3b6d3f9a3ea" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_60b08c1b-4d85-4d71-88d9-316fa6b97fac" xlink:href="sgry-20220331.xsd#sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_a125c683-854e-4e86-832d-6d363cbb4eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_a125c683-854e-4e86-832d-6d363cbb4eb7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_212543ee-c231-4445-95d3-b16ec207895d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_212543ee-c231-4445-95d3-b16ec207895d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_dc0b1b16-366a-4745-80ec-ba6e8df0d952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_us-gaap_LitigationSettlementExpense_dc0b1b16-366a-4745-80ec-ba6e8df0d952" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_b27ddc1c-03c6-4250-b997-4cabc1153feb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_b27ddc1c-03c6-4250-b997-4cabc1153feb" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8e80c872-a9e4-48d5-8420-e0dad523af01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_502ad5bb-0a58-4f50-b5f2-f30a62e1aed5" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8e80c872-a9e4-48d5-8420-e0dad523af01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_a8b7f75f-d535-468f-819f-0ad4be5cc8d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8e80c872-a9e4-48d5-8420-e0dad523af01" xlink:to="loc_srt_ConsolidationItemsAxis_a8b7f75f-d535-468f-819f-0ad4be5cc8d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a8b7f75f-d535-468f-819f-0ad4be5cc8d7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_a8b7f75f-d535-468f-819f-0ad4be5cc8d7" xlink:to="loc_srt_ConsolidationItemsDomain_a8b7f75f-d535-468f-819f-0ad4be5cc8d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_015c7dda-01a7-43da-b70e-e23a73290b15" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_a8b7f75f-d535-468f-819f-0ad4be5cc8d7" xlink:to="loc_srt_ConsolidationItemsDomain_015c7dda-01a7-43da-b70e-e23a73290b15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_d66af5b2-de8e-4c6c-8455-5093a920c3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_015c7dda-01a7-43da-b70e-e23a73290b15" xlink:to="loc_us-gaap_OperatingSegmentsMember_d66af5b2-de8e-4c6c-8455-5093a920c3a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_8cd6a9cf-d10a-443d-a7b4-ff1dff29e692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_015c7dda-01a7-43da-b70e-e23a73290b15" xlink:to="loc_us-gaap_CorporateNonSegmentMember_8cd6a9cf-d10a-443d-a7b4-ff1dff29e692" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e8329fee-9827-49b7-a2d9-44d118fac942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8e80c872-a9e4-48d5-8420-e0dad523af01" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e8329fee-9827-49b7-a2d9-44d118fac942" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e8329fee-9827-49b7-a2d9-44d118fac942_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e8329fee-9827-49b7-a2d9-44d118fac942" xlink:to="loc_us-gaap_SegmentDomain_e8329fee-9827-49b7-a2d9-44d118fac942_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_30c93935-57dc-4bb6-a51f-bef9a1438c44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e8329fee-9827-49b7-a2d9-44d118fac942" xlink:to="loc_us-gaap_SegmentDomain_30c93935-57dc-4bb6-a51f-bef9a1438c44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityServicesMember_bb04b840-2351-49ed-b0c7-357de7394fe1" xlink:href="sgry-20220331.xsd#sgry_SurgicalFacilityServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_30c93935-57dc-4bb6-a51f-bef9a1438c44" xlink:to="loc_sgry_SurgicalFacilityServicesMember_bb04b840-2351-49ed-b0c7-357de7394fe1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AncillaryServicesMember_a9fb144a-c644-4749-ab0f-40c4d4cc7117" xlink:href="sgry-20220331.xsd#sgry_AncillaryServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_30c93935-57dc-4bb6-a51f-bef9a1438c44" xlink:to="loc_sgry_AncillaryServicesMember_a9fb144a-c644-4749-ab0f-40c4d4cc7117" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails" xlink:type="extended" id="i14edd1dc70f947479eecd35d75c2dfc3_SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_75aad57b-b855-4bba-82c5-343a473010dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f200ab18-9036-456b-8a26-6e26d2c5e19c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_75aad57b-b855-4bba-82c5-343a473010dd" xlink:to="loc_us-gaap_Assets_f200ab18-9036-456b-8a26-6e26d2c5e19c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f91365d4-fe02-4f84-a274-9686580adc8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_75aad57b-b855-4bba-82c5-343a473010dd" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f91365d4-fe02-4f84-a274-9686580adc8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9c4700f8-87f9-4db3-ab53-2364bcee60b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_75aad57b-b855-4bba-82c5-343a473010dd" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9c4700f8-87f9-4db3-ab53-2364bcee60b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_0153fb9c-31ac-458c-89e0-17eead0c565e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9c4700f8-87f9-4db3-ab53-2364bcee60b1" xlink:to="loc_srt_ConsolidationItemsAxis_0153fb9c-31ac-458c-89e0-17eead0c565e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_0153fb9c-31ac-458c-89e0-17eead0c565e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_0153fb9c-31ac-458c-89e0-17eead0c565e" xlink:to="loc_srt_ConsolidationItemsDomain_0153fb9c-31ac-458c-89e0-17eead0c565e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_00662626-afb9-407b-bea8-5a32e11ca2ea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_0153fb9c-31ac-458c-89e0-17eead0c565e" xlink:to="loc_srt_ConsolidationItemsDomain_00662626-afb9-407b-bea8-5a32e11ca2ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_1f06d9a5-c790-4303-900f-ef175364aa7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_00662626-afb9-407b-bea8-5a32e11ca2ea" xlink:to="loc_us-gaap_OperatingSegmentsMember_1f06d9a5-c790-4303-900f-ef175364aa7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_4c8dd543-94a9-463e-9223-70cc204081bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_00662626-afb9-407b-bea8-5a32e11ca2ea" xlink:to="loc_us-gaap_CorporateNonSegmentMember_4c8dd543-94a9-463e-9223-70cc204081bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_53c618da-0b7b-4d16-90e8-28ae482708c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9c4700f8-87f9-4db3-ab53-2364bcee60b1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_53c618da-0b7b-4d16-90e8-28ae482708c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_53c618da-0b7b-4d16-90e8-28ae482708c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_53c618da-0b7b-4d16-90e8-28ae482708c9" xlink:to="loc_us-gaap_SegmentDomain_53c618da-0b7b-4d16-90e8-28ae482708c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d076f652-0c09-4d49-b707-9b971701eb54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_53c618da-0b7b-4d16-90e8-28ae482708c9" xlink:to="loc_us-gaap_SegmentDomain_d076f652-0c09-4d49-b707-9b971701eb54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityServicesMember_532a9c23-9d13-48bb-8bc7-9822b6eee009" xlink:href="sgry-20220331.xsd#sgry_SurgicalFacilityServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d076f652-0c09-4d49-b707-9b971701eb54" xlink:to="loc_sgry_SurgicalFacilityServicesMember_532a9c23-9d13-48bb-8bc7-9822b6eee009" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AncillaryServicesMember_d696bb31-9f0c-44f7-aa24-1c3a4aea0223" xlink:href="sgry-20220331.xsd#sgry_AncillaryServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d076f652-0c09-4d49-b707-9b971701eb54" xlink:to="loc_sgry_AncillaryServicesMember_d696bb31-9f0c-44f7-aa24-1c3a4aea0223" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/SubsequentEventsDetails" xlink:type="extended" id="i4b3665b0f7d742a19d962e4ac0abb9a9_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_56f42b35-9501-4b6e-bb6c-5b759554c5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired_6b45509e-35ea-47ee-b3c9-0a3ab487cd64" xlink:href="sgry-20220331.xsd#sgry_NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_56f42b35-9501-4b6e-bb6c-5b759554c5d1" xlink:to="loc_sgry_NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired_6b45509e-35ea-47ee-b3c9-0a3ab487cd64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired_9dd86cac-bb19-402b-a545-4b0b3eac21a2" xlink:href="sgry-20220331.xsd#sgry_NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_56f42b35-9501-4b6e-bb6c-5b759554c5d1" xlink:to="loc_sgry_NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired_9dd86cac-bb19-402b-a545-4b0b3eac21a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_597605c7-2613-4f8c-a8b4-f0caea0b1961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_56f42b35-9501-4b6e-bb6c-5b759554c5d1" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_597605c7-2613-4f8c-a8b4-f0caea0b1961" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_e2898aa7-eb57-429c-9502-1ad05ce5d8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_56f42b35-9501-4b6e-bb6c-5b759554c5d1" xlink:to="loc_us-gaap_SubsequentEventTable_e2898aa7-eb57-429c-9502-1ad05ce5d8fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_195692c9-2926-4f9b-9602-8033ffc4cc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e2898aa7-eb57-429c-9502-1ad05ce5d8fe" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_195692c9-2926-4f9b-9602-8033ffc4cc3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_195692c9-2926-4f9b-9602-8033ffc4cc3b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_195692c9-2926-4f9b-9602-8033ffc4cc3b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_195692c9-2926-4f9b-9602-8033ffc4cc3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0aecf960-d62b-40a0-9db6-3c325e8ff1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_195692c9-2926-4f9b-9602-8033ffc4cc3b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0aecf960-d62b-40a0-9db6-3c325e8ff1e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_1f09e637-5c2d-4798-85e1-76e8e3750fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0aecf960-d62b-40a0-9db6-3c325e8ff1e3" xlink:to="loc_us-gaap_SubsequentEventMember_1f09e637-5c2d-4798-85e1-76e8e3750fc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_445c0956-f1bd-45b5-9008-2a2589ac3827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e2898aa7-eb57-429c-9502-1ad05ce5d8fe" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_445c0956-f1bd-45b5-9008-2a2589ac3827" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_445c0956-f1bd-45b5-9008-2a2589ac3827_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_445c0956-f1bd-45b5-9008-2a2589ac3827" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_445c0956-f1bd-45b5-9008-2a2589ac3827_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4d215a2f-e7a1-4454-a06e-2af05a628c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_445c0956-f1bd-45b5-9008-2a2589ac3827" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4d215a2f-e7a1-4454-a06e-2af05a628c09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember_43d476c9-19c9-43a9-9afb-fdb3ca48fb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4d215a2f-e7a1-4454-a06e-2af05a628c09" xlink:to="loc_us-gaap_EquityMethodInvestmentsMember_43d476c9-19c9-43a9-9afb-fdb3ca48fb6b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>sgry-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b4dabe6f-88db-4fc2-b66b-139c1a2f1a72,g:e82a3438-fa59-433e-866a-e64d4d57702b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_HedgingDesignationDomain_07d30c6c-ae2b-4053-98c4-e47d4fa1fc39_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_96c1b52e-1ee9-4b76-b7f8-22d0a5ed52aa_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal effective tax rate (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_76ae0fff-3ec6-4ed6-8a05-3e1600251ab7_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_6df2d031-9894-4df5-bb1a-ccc244096c57_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction and integration costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf97d4fb-fe8c-4fce-ad61-8173b454cfaa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a4efb0bf-a542-4e83-9f54-c17076710578_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to Surgery Partners, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2a763e2c-43e1-4316-86c2-73f17d1802f3_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to Surgery Partners, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_4772b307-18e0-4c71-af11-fa06050366af_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_3fadeef6-2ce7-49f8-acef-bcf845b47287_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_39c9f2d0-8ab3-4c52-bf4a-13382736093c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_d52dd45d-8a82-43a7-a84f-5e4422298b8e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_3e6325a8-e102-4d4c-94b9-88d36d4f62c9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_545c1ef1-ae9d-4154-b50b-7ad1c44f4ab8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_79f5e51e-7878-4d1e-b795-71975a96591b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_fbb8b3f3-e01d-44fe-88b9-463339214bdb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Start-up costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f15ff573-f918-458c-8c12-b71aea0db8a7_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_68a3e389-b11a-4f68-aec8-1c08e3400773_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Adjusted EBITDA:</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Other Significant Reconciling Item, Consolidated [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_4ff62610-cae7-4f82-b23b-72e77641533b_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_298bf496-cc25-4222-99e4-c81a0c302d93_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_079253da-e61d-4256-a89b-326ce0a06b23_terseLabel_en-US" xlink:label="lab_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted EBITDA</link:label>
    <link:label id="lab_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_label_en-US" xlink:label="lab_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Before Interest Taxes Depreciation And Amortization</link:label>
    <link:label id="lab_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_documentation_en-US" xlink:label="lab_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Before Interest Taxes Depreciation And Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:href="sgry-20220331.xsd#sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:to="lab_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1aa2b7f3-8b18-4280-8fcd-4dda6af1a67d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_8e6d7f5d-8d05-4b86-9060-175a15a0a537_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of facilities acquired</link:label>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_7f4d1498-07ba-427d-b8c4-702a43f3d7c0_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of businesses acquired</link:label>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_label_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Businesses Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfBusinessesAcquired" xlink:to="lab_us-gaap_NumberOfBusinessesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount_e09ae0ba-c017-4260-bb17-92d2aff07f2f_terseLabel_en-US" xlink:label="lab_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net long-term tax receivable agreement liability</link:label>
    <link:label id="lab_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount_label_en-US" xlink:label="lab_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net Of Discount</link:label>
    <link:label id="lab_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount_documentation_en-US" xlink:label="lab_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net Of Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount" xlink:href="sgry-20220331.xsd#sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount" xlink:to="lab_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_fec001a3-0e26-4de0-842b-0507494c399f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_99faf3e8-59a9-4d58-9acf-9c2b7b791298_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_8d2de24e-81e0-421d-b1ac-88c3536d8c56_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Payments) receipts related to ownership transactions with non-controlling interest holders</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonrecurringIncomeExpense_4eda186a-34c1-403a-a12b-80198130207d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonrecurringIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonrecurringIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonrecurringIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonrecurring (Income) Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonrecurringIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonrecurringIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonrecurringIncomeExpense" xlink:to="lab_us-gaap_OtherNonrecurringIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_13441004-d4e4-44c4-8f4a-2faefa3bbe84_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_517c6f9a-de40-4677-a70f-e4f3a1908bad_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of equity investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4a729b17-74f4-4b3c-8caf-aac96ad18d89_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_LeaseLiability_65ac8835-e830-4d60-8b55-546fd47f97b2_totalLabel_en-US" xlink:label="lab_sgry_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_sgry_LeaseLiability_label_en-US" xlink:label="lab_sgry_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_sgry_LeaseLiability_documentation_en-US" xlink:label="lab_sgry_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LeaseLiability" xlink:href="sgry-20220331.xsd#sgry_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_LeaseLiability" xlink:to="lab_sgry_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_af9bfd57-7ae7-478a-a359-c6eddfe8483c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_75ba629d-1d33-4ccb-ba14-346577721305_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other litigation costs</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_793498f9-97fa-4f99-975f-9c810d384d1a_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_1284bd43-b929-4254-98be-3bbd95d5f6d1_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash consideration</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_65e3d54e-a9cb-48dd-ba47-0a5e73bfd09e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, less current maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_e0924c13-9086-4ed2-a19f-c82be69a1477_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b9322006-11dd-4e63-98e3-18ad72b0348a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive securities outstanding not included in the computation of income (loss) per share as their effect is antidilutive (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests_16b98381-7bec-4426-a74c-065b2a313ec5_terseLabel_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of shares of non-controlling interests, net&#8212;redeemable</link:label>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests_label_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Increase (Decrease) From Redemptions Or Purchase Of Interests</link:label>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests_documentation_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Increase (Decrease) from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" xlink:href="sgry-20220331.xsd#sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" xlink:to="lab_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_c1e4add0-c445-43c8-8d74-5747bd7a9f62_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_PayFixedSwapSixMember_b6b4c08c-ca4e-4fcb-9bf8-209aa66f45ac_terseLabel_en-US" xlink:label="lab_sgry_PayFixedSwapSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed swap</link:label>
    <link:label id="lab_sgry_PayFixedSwapSixMember_label_en-US" xlink:label="lab_sgry_PayFixedSwapSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap Six [Member]</link:label>
    <link:label id="lab_sgry_PayFixedSwapSixMember_documentation_en-US" xlink:label="lab_sgry_PayFixedSwapSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap Six Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapSixMember" xlink:href="sgry-20220331.xsd#sgry_PayFixedSwapSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_PayFixedSwapSixMember" xlink:to="lab_sgry_PayFixedSwapSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_cb7e3601-a5c8-4548-b394-d4bc92e2f14b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states in which entity operates</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_289463d6-8be0-4ffb-a6bb-5c28604b99bf_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_37c6a64d-551c-48d7-bcb2-2965d0aea0c4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_2c6de363-6107-4d6f-98ef-1e2d6a7e35fb_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_PrivateInsuranceMember_2189a6a7-cc30-428c-be91-9ee93b8da2c9_terseLabel_en-US" xlink:label="lab_sgry_PrivateInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private insurance</link:label>
    <link:label id="lab_sgry_PrivateInsuranceMember_label_en-US" xlink:label="lab_sgry_PrivateInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Insurance [Member]</link:label>
    <link:label id="lab_sgry_PrivateInsuranceMember_documentation_en-US" xlink:label="lab_sgry_PrivateInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Insurance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PrivateInsuranceMember" xlink:href="sgry-20220331.xsd#sgry_PrivateInsuranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_PrivateInsuranceMember" xlink:to="lab_sgry_PrivateInsuranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f60ba033-9d1e-45cf-8291-6c9f1d5c25df_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_NotesPayableAndSecuredLoansMember_44b618b4-e038-4bed-92b8-ca8345590caa_terseLabel_en-US" xlink:label="lab_sgry_NotesPayableAndSecuredLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable and other secured loans</link:label>
    <link:label id="lab_sgry_NotesPayableAndSecuredLoansMember_label_en-US" xlink:label="lab_sgry_NotesPayableAndSecuredLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable and Secured Loans [Member]</link:label>
    <link:label id="lab_sgry_NotesPayableAndSecuredLoansMember_documentation_en-US" xlink:label="lab_sgry_NotesPayableAndSecuredLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable and Secured Loans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NotesPayableAndSecuredLoansMember" xlink:href="sgry-20220331.xsd#sgry_NotesPayableAndSecuredLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_NotesPayableAndSecuredLoansMember" xlink:to="lab_sgry_NotesPayableAndSecuredLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SuppliesExpense_3e498334-10db-4f0b-9b94-f9e50dcbcf1b_terseLabel_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies</link:label>
    <link:label id="lab_us-gaap_SuppliesExpense_label_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SuppliesExpense" xlink:to="lab_us-gaap_SuppliesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5bd0889d-efb8-42fd-b075-7fc4ba68d226_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_de1dc9fd-5a79-4ab5-a696-e8affb31ea7a_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_28927231-775f-44f9-b116-9ba49187ef0f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_468d48ac-789c-44d8-bca4-9123d25b645c_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_e9c2ec14-8d8a-4216-a313-a944d3720284_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for finance lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimatedInsuranceRecoveries_ad468175-158b-4195-a6b4-cb3f1dd4b236_terseLabel_en-US" xlink:label="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected insurance recoveries</link:label>
    <link:label id="lab_us-gaap_EstimatedInsuranceRecoveries_label_en-US" xlink:label="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Insurance Recoveries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimatedInsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimatedInsuranceRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimatedInsuranceRecoveries" xlink:to="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_89790798-2fea-4ddd-a395-6ebce644a091_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives and Hedging Activities</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_ea2fc030-36cf-47dd-8240-c835df1506ef_terseLabel_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AirlineProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable" xlink:to="lab_us-gaap_AirlineProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_a3aa2ea3-d657-4ea4-8efd-5b5b2f48808d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by service type as a proportion of total revenues (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_6408b802-e4c3-4a6a-aaac-df8fe02a8643_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.01 par value; shares authorized - 20,310,000; shares issued or outstanding - none</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_dd7332d3-f4e4-4c67-a240-92084ffc19a0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to non-controlling interests&#8212;non-redeemable holders</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_316546f9-2a23-47bd-acbc-d2c1692e1012_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefits related to the sale of partnership interests</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Business, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:to="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_8e5cc996-147d-417a-9941-0cd9f786e4af_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_85394a44-4858-4704-bb40-8383ce2e10b0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_8bb30a2c-5a04-41a3-b177-2ff94566d0c3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest_253932b3-fe48-458c-b55d-1c877201e23e_terseLabel_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of surgical facilities owned, majority interest</link:label>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest_label_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Surgical Facilities Owned, Majority Interest</link:label>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest_documentation_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Surgical Facilities Owned, Majority Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest" xlink:href="sgry-20220331.xsd#sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest" xlink:to="lab_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c7735c24-352c-44a1-b38f-37cc300f2d5d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_8d40a9e8-85ec-4272-8647-d176afd3b548_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_label_en-US" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_678b3922-ff93-4c83-b552-0f00722d2db7_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_318158c6-6221-4afa-a5c4-b8578d7ac043_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_06c6f580-c5e8-4438-9830-7554e3324b98_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidation_5492afac-e539-4016-8848-b1c018e6cc43_negatedTerseLabel_en-US" xlink:label="lab_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposals and deconsolidations</link:label>
    <link:label id="lab_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidation_label_en-US" xlink:label="lab_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit and Deconsolidation</link:label>
    <link:label id="lab_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidation_documentation_en-US" xlink:label="lab_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit and Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidation" xlink:href="sgry-20220331.xsd#sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidation" xlink:to="lab_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_973031bf-3678-448f-bf29-4fdabe3b4476_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4aadd92d-6877-4bc7-aebd-17d650caa266_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2644de26-ea8e-448e-97b0-80f72318f326_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_85159b85-e504-4492-8929-9762ebafc5b1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_3f2a8e25-1d2d-4044-8189-1a67905f4b3e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash outflows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_c51e52c2-6e7b-41f2-92d1-dd5c0924e194_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of interest rate swaps</link:label>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_label_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Interest Rate Derivatives Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:to="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_GrantRevenue_34af15ad-9c58-432d-83ee-3d8e45931b22_negatedTerseLabel_en-US" xlink:label="lab_sgry_GrantRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funds</link:label>
    <link:label id="lab_sgry_GrantRevenue_5018c23f-e8b5-4546-bf7c-3a9156d8a91c_terseLabel_en-US" xlink:label="lab_sgry_GrantRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funds</link:label>
    <link:label id="lab_sgry_GrantRevenue_label_en-US" xlink:label="lab_sgry_GrantRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Revenue</link:label>
    <link:label id="lab_sgry_GrantRevenue_documentation_en-US" xlink:label="lab_sgry_GrantRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GrantRevenue" xlink:href="sgry-20220331.xsd#sgry_GrantRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_GrantRevenue" xlink:to="lab_sgry_GrantRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_29deb2f5-7f35-498d-9c5f-192577df1965_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_773b60a4-f947-43f8-a987-45c469a03002_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Availability on line of credit instrument</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_2d2d9067-0bba-4b85-a6f1-3e0ab8acfb2d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_90fffa30-48cd-4040-893d-0a86ff5af2e0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ReceiveFixedSwapThreeMember_f63f6f84-954d-45a8-b7ee-5e369261ad19_terseLabel_en-US" xlink:label="lab_sgry_ReceiveFixedSwapThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receive-fixed swap</link:label>
    <link:label id="lab_sgry_ReceiveFixedSwapThreeMember_label_en-US" xlink:label="lab_sgry_ReceiveFixedSwapThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receive-fixed Swap Three [Member]</link:label>
    <link:label id="lab_sgry_ReceiveFixedSwapThreeMember_documentation_en-US" xlink:label="lab_sgry_ReceiveFixedSwapThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receive-fixed Swap Three Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ReceiveFixedSwapThreeMember" xlink:href="sgry-20220331.xsd#sgry_ReceiveFixedSwapThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ReceiveFixedSwapThreeMember" xlink:to="lab_sgry_ReceiveFixedSwapThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_243e86c7-ebdd-4902-aa85-db544da9c189_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_13dcd455-a31c-475d-a6ef-59a2a4c6393e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_57c70e34-1ebc-4342-94e4-c1b01a425f0a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash outflows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_0837550e-8240-4905-8b5a-670b8b0a8bdc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain recognized in OCI (effective portion)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_A2017SeniorSecuredCreditFacilityMember_d138d95d-8668-4f56-804b-00401adb459a_terseLabel_en-US" xlink:label="lab_sgry_A2017SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Revolver</link:label>
    <link:label id="lab_sgry_A2017SeniorSecuredCreditFacilityMember_label_en-US" xlink:label="lab_sgry_A2017SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Senior Secured Credit Facility [Member]</link:label>
    <link:label id="lab_sgry_A2017SeniorSecuredCreditFacilityMember_documentation_en-US" xlink:label="lab_sgry_A2017SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Senior Secured Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017SeniorSecuredCreditFacilityMember" xlink:href="sgry-20220331.xsd#sgry_A2017SeniorSecuredCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_A2017SeniorSecuredCreditFacilityMember" xlink:to="lab_sgry_A2017SeniorSecuredCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_10195511-5a01-4825-8897-e3c52eaad2a3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_45828dee-553a-4d4f-b857-41d074647583_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_bb585fe2-7b23-464a-9f49-d50af1ef160d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_7fae4bdf-2819-492c-96b8-edf666dbd02b_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current maturities of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_deddf004-73d5-4c31-90a5-14db4425f27b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_FacilitiesSurgicalHospitalsMember_f1640328-e8bb-41f7-aa7a-63d89aae504a_terseLabel_en-US" xlink:label="lab_sgry_FacilitiesSurgicalHospitalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities, Surgical Hospitals</link:label>
    <link:label id="lab_sgry_FacilitiesSurgicalHospitalsMember_label_en-US" xlink:label="lab_sgry_FacilitiesSurgicalHospitalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities, Surgical Hospitals [Member]</link:label>
    <link:label id="lab_sgry_FacilitiesSurgicalHospitalsMember_documentation_en-US" xlink:label="lab_sgry_FacilitiesSurgicalHospitalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities, Surgical Hospitals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FacilitiesSurgicalHospitalsMember" xlink:href="sgry-20220331.xsd#sgry_FacilitiesSurgicalHospitalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_FacilitiesSurgicalHospitalsMember" xlink:to="lab_sgry_FacilitiesSurgicalHospitalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_28fda2d6-9f7e-40d1-98d2-88c9e7e89221_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_9b3ef3c7-feac-444f-9bd0-4fe080804c79_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts_18696d21-570d-4a2d-b215-2cd03763eb2d_terseLabel_en-US" xlink:label="lab_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction, integration and acquisition costs</link:label>
    <link:label id="lab_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts_label_en-US" xlink:label="lab_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs, And Merger Costs</link:label>
    <link:label id="lab_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts_documentation_en-US" xlink:label="lab_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs, And Merger Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts" xlink:href="sgry-20220331.xsd#sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts" xlink:to="lab_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_254a1384-ed82-4827-a35c-83019408342e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_TaxReceivableAgreementLiabilityCurrent_af68409f-f80b-496f-86e9-0ecb09371ec6_terseLabel_en-US" xlink:label="lab_sgry_TaxReceivableAgreementLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax receivable agreement liability</link:label>
    <link:label id="lab_sgry_TaxReceivableAgreementLiabilityCurrent_label_en-US" xlink:label="lab_sgry_TaxReceivableAgreementLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement Liability, Current</link:label>
    <link:label id="lab_sgry_TaxReceivableAgreementLiabilityCurrent_documentation_en-US" xlink:label="lab_sgry_TaxReceivableAgreementLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TaxReceivableAgreementLiabilityCurrent" xlink:href="sgry-20220331.xsd#sgry_TaxReceivableAgreementLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_TaxReceivableAgreementLiabilityCurrent" xlink:to="lab_sgry_TaxReceivableAgreementLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_1aa0c4fa-5abd-494e-a5f8-5010ab0cfbf7_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f8155982-fff7-4f0c-9ed2-767927a0fa33_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_5b27aed9-298b-4fdd-a7eb-13a4f45d54a1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_18e98d0d-b613-4390-9b4e-d90a1a543c0e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative activity</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_216384d9-ce34-4ae9-9417-d727cdd385fb_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_57e53213-0225-4c9c-bba6-a2e084d924a7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefits related to vesting of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_PayFixedSwapFiveMember_f2c66dcd-6c55-471e-88f4-ac0b965c43fe_terseLabel_en-US" xlink:label="lab_sgry_PayFixedSwapFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed swap</link:label>
    <link:label id="lab_sgry_PayFixedSwapFiveMember_label_en-US" xlink:label="lab_sgry_PayFixedSwapFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap Five [Member]</link:label>
    <link:label id="lab_sgry_PayFixedSwapFiveMember_documentation_en-US" xlink:label="lab_sgry_PayFixedSwapFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap Five Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapFiveMember" xlink:href="sgry-20220331.xsd#sgry_PayFixedSwapFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_PayFixedSwapFiveMember" xlink:to="lab_sgry_PayFixedSwapFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_bb078094-0626-4e42-88f3-710f1a6dbd9b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SeniorUnsecuredNotesDue2027Member_fd9985e6-ca9b-4d3c-bfe7-dbf26e2fd7ec_terseLabel_en-US" xlink:label="lab_sgry_SeniorUnsecuredNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">10.000% senior unsecured notes due 2027</link:label>
    <link:label id="lab_sgry_SeniorUnsecuredNotesDue2027Member_label_en-US" xlink:label="lab_sgry_SeniorUnsecuredNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes, Due 2027 [Member]</link:label>
    <link:label id="lab_sgry_SeniorUnsecuredNotesDue2027Member_documentation_en-US" xlink:label="lab_sgry_SeniorUnsecuredNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes, Due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2027Member" xlink:href="sgry-20220331.xsd#sgry_SeniorUnsecuredNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SeniorUnsecuredNotesDue2027Member" xlink:to="lab_sgry_SeniorUnsecuredNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_596825f4-6b80-4fad-8eed-e5d095bb8b50_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_1bbcf9d7-6275-4840-a67c-ccdc40292611_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_FinanceLeaseCost1Abstract_bf9c3e0d-272d-4ea7-998c-f6599e51abc5_terseLabel_en-US" xlink:label="lab_sgry_FinanceLeaseCost1Abstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease costs:</link:label>
    <link:label id="lab_sgry_FinanceLeaseCost1Abstract_label_en-US" xlink:label="lab_sgry_FinanceLeaseCost1Abstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost1 [Abstract]</link:label>
    <link:label id="lab_sgry_FinanceLeaseCost1Abstract_documentation_en-US" xlink:label="lab_sgry_FinanceLeaseCost1Abstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost1 [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FinanceLeaseCost1Abstract" xlink:href="sgry-20220331.xsd#sgry_FinanceLeaseCost1Abstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_FinanceLeaseCost1Abstract" xlink:to="lab_sgry_FinanceLeaseCost1Abstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_c72026ab-6e74-45a3-bdba-884781cc9389_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_40919696-e2e4-421e-9b08-943630276af1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_ce544172-0ee0-4f9a-99a9-d2df337f4786_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_de1ffb9a-cc4f-4f33-a858-4564cd26c368_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_1194f163-881c-464e-a5a3-c2360133b0ea_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Assets from Segment to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_fb2a406d-c55a-4ce3-b31d-355894c73c0f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_0da17717-500e-4dc3-b562-5da2f6f9d592_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of line of credit outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts_2976104e-f956-4888-afee-f9c06922d2fd_negatedTerseLabel_en-US" xlink:label="lab_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on litigation settlement and other litigation costs</link:label>
    <link:label id="lab_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts_label_en-US" xlink:label="lab_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement And Other Litigation Costs</link:label>
    <link:label id="lab_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts_documentation_en-US" xlink:label="lab_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement And Other Litigation Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts" xlink:href="sgry-20220331.xsd#sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts" xlink:to="lab_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_737b6511-9d36-4f3c-ae31-855d9af7ab6b_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_cb075646-5422-472e-83be-45378c1437f6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Comprehensive income attributable to non-controlling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_39d64d2d-9561-4614-8ddd-85096b73d75e_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_a197e9bd-5d0b-462a-b7df-eb5503c5e20a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_40907d17-b8ea-44a2-b40a-1a12ced50933_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from disposals of facilities and other assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_14405146-d840-48fe-a750-ba222c90c5da_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5e2af51a-20b0-4e7c-ac8d-d68dbdfa5424_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_d0ab90bd-8a27-480a-8863-fdd2c80f82b5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_1806b27f-b929-44f1-ad11-cb5b11f97451_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7f84541c-81eb-4a9a-8afd-216f64e6a6db_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_9b0c1a7f-8891-43ea-af5f-0152a166352f_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity offering</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e72dfa2c-2047-4f1a-8175-8abd0dbac799_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_5a805c68-df86-43a6-94d2-f1614a1b6278_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_fe71c3d2-ff08-4553-854d-903474b73a91_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4d82310d-fcac-4350-9d44-75465c16073d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_a8d789ac-2cc6-4f9f-aa1f-96fe8b5b25f3_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_fd2171a7-1b1a-44f7-8b79-9e2756243480_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of non-controlling interests</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_976b40b7-92be-4376-9bb8-3565fb3591d6_negatedTerseLabel_en-US" xlink:label="lab_sgry_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in operating lease assets</link:label>
    <link:label id="lab_sgry_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_sgry_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease, Right-Of-Use Assets</link:label>
    <link:label id="lab_sgry_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_sgry_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease, Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:href="sgry-20220331.xsd#sgry_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:to="lab_sgry_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_255af84e-6735-4168-bbee-575256eeec88_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation on property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SurgicalFacilitiesMember_a218d543-9b7b-40dc-896b-7cb9fe8865e5_terseLabel_en-US" xlink:label="lab_sgry_SurgicalFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facilities</link:label>
    <link:label id="lab_sgry_SurgicalFacilitiesMember_label_en-US" xlink:label="lab_sgry_SurgicalFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facilities [Member]</link:label>
    <link:label id="lab_sgry_SurgicalFacilitiesMember_documentation_en-US" xlink:label="lab_sgry_SurgicalFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilitiesMember" xlink:href="sgry-20220331.xsd#sgry_SurgicalFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SurgicalFacilitiesMember" xlink:to="lab_sgry_SurgicalFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_c2e38349-72b3-4a6e-a2ee-99817f32cdfb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_143b1590-49b0-48b1-a603-8db7ad2b1539_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of equity offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_659e70d0-f54b-4d04-aac8-3fc2ca1b54d6_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity offering (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_d38934ab-ad54-4ef9-a0f0-00386a898bae_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_6a7c50cb-10a1-486e-99ef-bd5d9f7d4056_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests&#8212;redeemable</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_730a2d37-5d03-4507-baec-cc1975459560_periodStartLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_d11e5dc9-3a2e-4b7e-9ea2-c3893310cc4c_periodEndLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_921c3942-7e39-4a42-8676-f17492fee5dc_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_33cd222b-8d73-46a3-8e4b-277f8812e519_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_53e0380d-5321-43db-9a58-0253d1aa1489_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_c3e4641c-bf59-4643-82b9-a06a920737b0_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, including post acquisition adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d19e5ea0-b3c7-4e13-9b05-71d31a82adf5_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_a8afdb68-cfb6-4997-b75f-a8ef8095eb8c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_f68f5ce0-a789-4146-8a28-8a48a743bbf1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_51eae334-3fe6-481f-ba2a-11c3b5881221_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rollforward of Noncontrolling Interest - Redeemable</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b3cf6dc8-c230-4fcd-9ac7-f74fd664bc2e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_69d6e760-15bc-4243-81bb-bfb404a5c736_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_15d4ee05-9895-4ce9-bc5e-8ccfafa2d68b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of leased assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedAtFairValue_ce35e931-30e1-4c49-9436-4e537e0d31ee_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of investments</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedAtFairValue_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedAtFairValue" xlink:to="lab_us-gaap_InvestmentOwnedAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_b8e6ef0a-6713-4478-83bf-3bf1cc91b7f8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and Disposals</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_3d986bc8-ba1b-4a2f-9996-65b12194e2c9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted shares</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_7df4f153-f537-4ff6-863c-b22ed0dac923_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effect of Interest Rate Swaps</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Rate Derivatives [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_c56eef3d-97e7-4de5-a5cf-4994563bf699_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_6b4f576e-866d-4202-92c3-958104241d99_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Source</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_4d9ad7b3-dcbe-474a-b9b1-ff6aa813a8fe_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_8830c8fb-d2ee-48cf-9182-8f244e05b600_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ReceiveFixedSwapTwoMember_63741038-64c8-4d7d-94ae-f842491ccaa8_terseLabel_en-US" xlink:label="lab_sgry_ReceiveFixedSwapTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receive-fixed swap</link:label>
    <link:label id="lab_sgry_ReceiveFixedSwapTwoMember_label_en-US" xlink:label="lab_sgry_ReceiveFixedSwapTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receive-fixed Swap Two [Member]</link:label>
    <link:label id="lab_sgry_ReceiveFixedSwapTwoMember_documentation_en-US" xlink:label="lab_sgry_ReceiveFixedSwapTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receive-fixed Swap Two Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ReceiveFixedSwapTwoMember" xlink:href="sgry-20220331.xsd#sgry_ReceiveFixedSwapTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ReceiveFixedSwapTwoMember" xlink:to="lab_sgry_ReceiveFixedSwapTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_70bc1358-5349-473f-884f-39a4b1b6d4ca_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_1dfe77a1-5910-4ac1-89b8-01671f76eb50_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_35897325-9340-4218-9799-e0d86ec29e92_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of accumulated OCI related</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets_bb149752-6a57-41b7-ae47-edf00ba9b37e_terseLabel_en-US" xlink:label="lab_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use operating lease assets</link:label>
    <link:label id="lab_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets_label_en-US" xlink:label="lab_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Right Of Use Assets</link:label>
    <link:label id="lab_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets_documentation_en-US" xlink:label="lab_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets" xlink:href="sgry-20220331.xsd#sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets" xlink:to="lab_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_5e589c1e-3bda-4cfe-841a-4d5a331c848d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_feac97c9-e39d-489a-8056-e6e391fb2126_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred dividends</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_87ef9af3-f390-4f30-814c-6aa715c383a5_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3de8d57d-169c-4744-b4af-5d9c8c771e03_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_3d9520f6-e0d7-44cd-9484-886a285d39b1_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_ff3ddb99-c646-4714-a957-50151dacd709_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyNatureDomain_af6aa600-9a22-4480-a242-0dec073629b1_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyNatureDomain_label_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:to="lab_us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_147d6bbe-a4ea-429f-9dd8-ab84afe4b7e7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_5bd181b2-aa08-4aa4-ad12-21988b7800de_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_8b1b571e-92a7-443e-96ae-68dd2392d09f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e66e75c9-91d1-4e2f-8b58-8d6f3107e0e2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfessionalFees_3afa1d34-6412-4d86-9d9b-596eec73ad0c_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional and medical fees</link:label>
    <link:label id="lab_us-gaap_ProfessionalFees_label_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e2318ddd-bfca-4f62-883c-cd5894ee921d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_cfb5abed-607b-4a10-8474-afa999ed74d5_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_c9df2d9a-de41-4bbe-9ac1-9754c5f2dce1_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Including Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments_af9c3b4f-16d0-45ae-b903-721c25bdb182_terseLabel_en-US" xlink:label="lab_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated payments</link:label>
    <link:label id="lab_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments_label_en-US" xlink:label="lab_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Accelerated Payments</link:label>
    <link:label id="lab_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments_documentation_en-US" xlink:label="lab_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Accelerated Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments" xlink:href="sgry-20220331.xsd#sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments" xlink:to="lab_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_ba1cb384-682e-4496-bdfa-aaad1e528682_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a057d5c-0b59-4574-947c-4971cf408afe_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_89c128c3-3aa6-4bcd-b7da-c3170ad40edd_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_9a075340-4a27-4e9e-b9db-75927bbf6587_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_e4ba5321-1323-49bd-95b4-63a91576b0ff_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenues</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_67cc671e-d0ba-41de-b482-e04eda44d82e_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4444832f-a144-4995-a067-2befb949e0e8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1d72cceb-3e21-4371-8363-c35fc2e5e36f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_OperatingAndFinanceLeaseExpense_b8a29780-ef2d-400e-ad50-0077a1605e62_terseLabel_en-US" xlink:label="lab_sgry_OperatingAndFinanceLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease expense</link:label>
    <link:label id="lab_sgry_OperatingAndFinanceLeaseExpense_label_en-US" xlink:label="lab_sgry_OperatingAndFinanceLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Expense</link:label>
    <link:label id="lab_sgry_OperatingAndFinanceLeaseExpense_documentation_en-US" xlink:label="lab_sgry_OperatingAndFinanceLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OperatingAndFinanceLeaseExpense" xlink:href="sgry-20220331.xsd#sgry_OperatingAndFinanceLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_OperatingAndFinanceLeaseExpense" xlink:to="lab_sgry_OperatingAndFinanceLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_5a8486e2-c980-4882-adf6-d8b4bfb7c095_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_5426b8d7-0577-4ce7-9c93-781faefebcd6_negatedTerseLabel_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to non-controlling interest&#8212;redeemable holders</link:label>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders</link:label>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_documentation_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="sgry-20220331.xsd#sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_eb25d00b-f9e0-41d4-ab5b-101183b10931_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_a67647e7-50c2-49e5-955a-37ac52e79c74_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_ee674c7e-e023-4373-8b7b-0d591d231fac_negatedLabel_en-US" xlink:label="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposals and deconsolidations, net</link:label>
    <link:label id="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_848976b7-1332-42d1-8fda-4f98e4b358b8_negatedTerseLabel_en-US" xlink:label="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposals and deconsolidations, net</link:label>
    <link:label id="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_label_en-US" xlink:label="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition Of Assets And Deconsolidation</link:label>
    <link:label id="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_documentation_en-US" xlink:label="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition of Assets And Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" xlink:href="sgry-20220331.xsd#sgry_GainLossOnDispositionOfAssetsAndDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" xlink:to="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_018ee9c1-4a49-441b-9e3b-898f0b616801_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investing activities</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_VariableInterestEntityNumberOfFacilities_435511e7-8b99-4931-8d7c-4c3fa7f8fcb0_terseLabel_en-US" xlink:label="lab_sgry_VariableInterestEntityNumberOfFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of facilities included in VIE</link:label>
    <link:label id="lab_sgry_VariableInterestEntityNumberOfFacilities_label_en-US" xlink:label="lab_sgry_VariableInterestEntityNumberOfFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Number Of Facilities</link:label>
    <link:label id="lab_sgry_VariableInterestEntityNumberOfFacilities_documentation_en-US" xlink:label="lab_sgry_VariableInterestEntityNumberOfFacilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Number of Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_VariableInterestEntityNumberOfFacilities" xlink:href="sgry-20220331.xsd#sgry_VariableInterestEntityNumberOfFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_VariableInterestEntityNumberOfFacilities" xlink:to="lab_sgry_VariableInterestEntityNumberOfFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0862b640-a5a8-4691-b83d-b78894dc8bfc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c9da1530-7b68-44b9-9d20-86b6367d0ba2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_94b232c9-dbb0-46ba-9600-ee2fa28694ca_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_e5369875-63a4-4d79-8765-f2028ca376d5_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_f8be29f5-89b0-4f34-b64c-f23c82882380_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_OtherServicesMember_9553e9c9-65b2-45ef-a6e0-ef4e7f4c45ab_verboseLabel_en-US" xlink:label="lab_sgry_OtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other service revenues</link:label>
    <link:label id="lab_sgry_OtherServicesMember_label_en-US" xlink:label="lab_sgry_OtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Services [Member]</link:label>
    <link:label id="lab_sgry_OtherServicesMember_documentation_en-US" xlink:label="lab_sgry_OtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherServicesMember" xlink:href="sgry-20220331.xsd#sgry_OtherServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_OtherServicesMember" xlink:to="lab_sgry_OtherServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_AssetsAndLiabilitiesLesseeTableTextBlock_08d519bd-7d9d-4633-8499-43c2217eb7df_terseLabel_en-US" xlink:label="lab_sgry_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Right-of-use Assets and Liabilities Related to Leases</link:label>
    <link:label id="lab_sgry_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_sgry_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_sgry_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_sgry_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="sgry-20220331.xsd#sgry_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_sgry_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestRollForward_5c136c08-31d3-4bae-b6ee-448e6b68de34_terseLabel_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Controlling Interests - Redeemable [Roll Forward]</link:label>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestRollForward_label_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestRollForward_documentation_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemableNoncontrollingInterestRollForward" xlink:href="sgry-20220331.xsd#sgry_RedeemableNoncontrollingInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_RedeemableNoncontrollingInterestRollForward" xlink:to="lab_sgry_RedeemableNoncontrollingInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ThreePayFixedInterestRateSwapsMember_cd23d03f-d2ce-44d9-a31f-dc99b6aa7ff1_terseLabel_en-US" xlink:label="lab_sgry_ThreePayFixedInterestRateSwapsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Pay-fixed Interest Rate Swaps</link:label>
    <link:label id="lab_sgry_ThreePayFixedInterestRateSwapsMember_label_en-US" xlink:label="lab_sgry_ThreePayFixedInterestRateSwapsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Pay-fixed Interest Rate Swaps [Member]</link:label>
    <link:label id="lab_sgry_ThreePayFixedInterestRateSwapsMember_documentation_en-US" xlink:label="lab_sgry_ThreePayFixedInterestRateSwapsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Pay-fixed Interest Rate Swaps Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ThreePayFixedInterestRateSwapsMember" xlink:href="sgry-20220331.xsd#sgry_ThreePayFixedInterestRateSwapsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ThreePayFixedInterestRateSwapsMember" xlink:to="lab_sgry_ThreePayFixedInterestRateSwapsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_4b17d287-0772-4265-b98a-3fab0da0e3f3_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ReceiveFixedSwapOneMember_e647f773-2f71-423d-a184-ff08a00742a4_terseLabel_en-US" xlink:label="lab_sgry_ReceiveFixedSwapOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receive-fixed swap</link:label>
    <link:label id="lab_sgry_ReceiveFixedSwapOneMember_label_en-US" xlink:label="lab_sgry_ReceiveFixedSwapOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receive-fixed Swap One [Member]</link:label>
    <link:label id="lab_sgry_ReceiveFixedSwapOneMember_documentation_en-US" xlink:label="lab_sgry_ReceiveFixedSwapOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receive-fixed Swap One Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ReceiveFixedSwapOneMember" xlink:href="sgry-20220331.xsd#sgry_ReceiveFixedSwapOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ReceiveFixedSwapOneMember" xlink:to="lab_sgry_ReceiveFixedSwapOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGuaranteeObligationsTable_6d1b7cdd-e976-493c-afb7-f8fb3457bf71_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Guarantor Obligations [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGuaranteeObligationsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Guarantor Obligations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGuaranteeObligationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:to="lab_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments_6cf7b23c-9b76-456c-84ac-d5eecd2d1aa5_terseLabel_en-US" xlink:label="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of grants received</link:label>
    <link:label id="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments_label_en-US" xlink:label="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Repayments</link:label>
    <link:label id="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments_documentation_en-US" xlink:label="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Repayments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments" xlink:href="sgry-20220331.xsd#sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments" xlink:to="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_10efab76-f987-4070-8ec6-9a59663bd95d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_f09ec7e9-7ab7-44eb-8775-0323799c195f_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_b89a644b-d47a-44ef-8854-e012df8745f1_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Surgery Partners, Inc. stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0a3673ef-cf26-487b-a7d2-debce4e2ca37_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_6042869f-eae1-4421-a1e7-db5ceab5c44b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_abb051cc-a5ea-479f-bafc-b87403654353_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants_5cc82c15-5242-4e73-af29-8975e5cf1c68_terseLabel_en-US" xlink:label="lab_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare accelerated payments and deferred governmental grants</link:label>
    <link:label id="lab_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants_label_en-US" xlink:label="lab_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Medicare Accelerated Payments And Deferred Governmental Grants</link:label>
    <link:label id="lab_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants_documentation_en-US" xlink:label="lab_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Medicare Accelerated Payments And Deferred Governmental Grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" xlink:href="sgry-20220331.xsd#sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" xlink:to="lab_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsMember_39c74b88-c1b6-4502-a72a-fe2059eb0033_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsMember" xlink:to="lab_us-gaap_EquityMethodInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_6ba0919c-360d-40e7-9d32-95d628b4a43e_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives in cash flow hedging relationships</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_b01210b3-2aa1-4ee7-8481-02b0089240f8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7952453f-919b-461e-9856-4cf7237f366e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrentAndNoncurrent_756d3522-041d-40fc-8219-643b6ecbdcba_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term tax receivable agreement liability</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_406fe52e-9fb5-4e88-acc9-5b7797b506d5_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_0036c94d-232f-4016-8d17-8aa124cb3e0c_negatedLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax loss on disposals and deconsolidations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_16ac3016-bd99-4056-90b0-aed91f14eb79_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_78e63793-dfe8-441a-b472-8d2baa8bf0a6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9e4c8ff5-8d7b-4c7f-a029-701e11073b94_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated_33d58afc-b525-4a5d-bfc2-814924d39b80_terseLabel_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of surgical facilities owned, consolidated</link:label>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated_label_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Surgical Facilities Owned, Consolidated</link:label>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated_documentation_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Surgical Facilities Owned, Consolidated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated" xlink:href="sgry-20220331.xsd#sgry_NumberOfSurgicalFacilitiesOwnedConsolidated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated" xlink:to="lab_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_90fdcaeb-fa3c-4011-8665-1978eb7b0654_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate acquisition date fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_34ab2949-4470-43fc-9906-1b766a3432c9_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate acquisition date fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_NotMateriallyMoreRestrictiveMember_2898517f-91c8-49d9-9d8c-fb802c51075e_terseLabel_en-US" xlink:label="lab_sgry_NotMateriallyMoreRestrictiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Materially More Restrictive</link:label>
    <link:label id="lab_sgry_NotMateriallyMoreRestrictiveMember_label_en-US" xlink:label="lab_sgry_NotMateriallyMoreRestrictiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Materially More Restrictive [Member]</link:label>
    <link:label id="lab_sgry_NotMateriallyMoreRestrictiveMember_documentation_en-US" xlink:label="lab_sgry_NotMateriallyMoreRestrictiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Materially More Restrictive [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NotMateriallyMoreRestrictiveMember" xlink:href="sgry-20220331.xsd#sgry_NotMateriallyMoreRestrictiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_NotMateriallyMoreRestrictiveMember" xlink:to="lab_sgry_NotMateriallyMoreRestrictiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_df87a85c-c6d1-4faf-bac1-ffc2a3cebc14_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_aba42670-136e-4c26-9561-77d050747caa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_4bd93107-4ce7-44c6-b6ac-cb7a7581454a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_45ca93f7-d762-4f5e-878d-6b97584e7ef8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_99aa3300-b8d0-4239-b2c2-50be3d03de71_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_4f605974-6b76-4985-99c2-2ce89fb5326e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_f7b8c2a6-415f-4acb-9cae-7fd61edddb29_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DisposalGroupOneMember_3f7322b2-d845-4c69-bf16-85fee453bcea_terseLabel_en-US" xlink:label="lab_sgry_DisposalGroupOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group One</link:label>
    <link:label id="lab_sgry_DisposalGroupOneMember_label_en-US" xlink:label="lab_sgry_DisposalGroupOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group One [Member]</link:label>
    <link:label id="lab_sgry_DisposalGroupOneMember_documentation_en-US" xlink:label="lab_sgry_DisposalGroupOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupOneMember" xlink:href="sgry-20220331.xsd#sgry_DisposalGroupOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DisposalGroupOneMember" xlink:to="lab_sgry_DisposalGroupOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_87343201-29e6-4b8d-a32a-4265a11f9b4c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_062543b5-0a3c-4f55-a235-abc9972af197_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_714ba637-b49a-4800-b7b3-1341bcd2a814_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_db1dea8e-378f-4fd1-98f1-2de5c0d674b2_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_abb5d723-4529-4622-a406-8a3851fbbc29_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_848f9ca1-dc1f-4a26-a10d-2aa3db4e7951_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestPolicyTextBlock_caefb850-a810-4232-87ce-199572e0eee4_terseLabel_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Controlling Interests&#8212;Redeemable</link:label>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestPolicyTextBlock_label_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Policy Text Block]</link:label>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestPolicyTextBlock_documentation_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:href="sgry-20220331.xsd#sgry_RedeemableNoncontrollingInterestPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:to="lab_sgry_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_a88ab686-6cc7-4f23-9233-b3139d625a86_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_49aa102d-cfd8-4737-9ccb-0ea1a07264e0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_291ad015-e1fb-41ef-af54-76b4add2a405_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_053e7267-681e-495b-9843-78337a85dd61_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_07b55f06-dc76-49fb-84a5-1221c68c32db_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9b86804b-71bf-41b4-b45e-a34ae202718e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_36bd0895-4d28-4974-86f0-8af3e989bb47_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_54b26d08-5c0d-4404-bfff-8c9e1bfaf0b7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_cae64411-f753-4cc6-a67d-bb0c9b5b6883_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e0590ee1-a6ea-4ac2-ba51-3075e7a9cec7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7e329cce-8a02-4c7f-a521-b4fb14ce36f4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_f03cec95-55bf-4cbd-bb08-1114f29b796b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_26bccffa-6904-4371-804f-68854b4f7b01_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ProceedsFromGovernmentAssistance_f267ca85-f4d6-4d9f-8312-1f6d97e60841_terseLabel_en-US" xlink:label="lab_sgry_ProceedsFromGovernmentAssistance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from grants received</link:label>
    <link:label id="lab_sgry_ProceedsFromGovernmentAssistance_label_en-US" xlink:label="lab_sgry_ProceedsFromGovernmentAssistance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Government Assistance</link:label>
    <link:label id="lab_sgry_ProceedsFromGovernmentAssistance_documentation_en-US" xlink:label="lab_sgry_ProceedsFromGovernmentAssistance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Government Assistance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ProceedsFromGovernmentAssistance" xlink:href="sgry-20220331.xsd#sgry_ProceedsFromGovernmentAssistance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ProceedsFromGovernmentAssistance" xlink:to="lab_sgry_ProceedsFromGovernmentAssistance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_e8af0082-e27f-45f2-83aa-4bedb9240512_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_6c0ec492-3061-40b6-9287-ddc2bfbabfad_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_097983fc-726c-4af3-8125-93ce40f7e47b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_71bd33da-ad4e-4f73-81ca-787c13fc8b66_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_0a46f387-eed5-4d88-8591-4bad41a97171_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Information by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1fa3577b-b8e4-4b1b-b4dd-07709671fd19_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefits attributable to non-recurring earnings' impact on the valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_32256a6b-6c56-4657-a17c-a38f22b58de4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_66bfa883-2ace-4df6-82b2-818d15ce3e90_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_e5cb9437-298b-4778-a3a0-af7b1011139f_negatedLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Amounts attributable to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_LeaseRightOfUseAsset_bd647393-0b1d-4b55-b0ef-88827806812f_totalLabel_en-US" xlink:label="lab_sgry_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total leased assets</link:label>
    <link:label id="lab_sgry_LeaseRightOfUseAsset_label_en-US" xlink:label="lab_sgry_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_sgry_LeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_sgry_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LeaseRightOfUseAsset" xlink:href="sgry-20220331.xsd#sgry_LeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_LeaseRightOfUseAsset" xlink:to="lab_sgry_LeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_98cb70be-8e41-41e0-8dde-d243db4a156c_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_ff047470-4dc9-4c20-b32a-3b6224acbeaa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_82cc63c1-701a-4544-a604-81ce8598f585_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SelfPayRevenueMember_4357cc05-ceca-474b-a51e-e2ab72b7ac5e_terseLabel_en-US" xlink:label="lab_sgry_SelfPayRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-pay</link:label>
    <link:label id="lab_sgry_SelfPayRevenueMember_label_en-US" xlink:label="lab_sgry_SelfPayRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-Pay Revenue [Member]</link:label>
    <link:label id="lab_sgry_SelfPayRevenueMember_documentation_en-US" xlink:label="lab_sgry_SelfPayRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-Pay Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SelfPayRevenueMember" xlink:href="sgry-20220331.xsd#sgry_SelfPayRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SelfPayRevenueMember" xlink:to="lab_sgry_SelfPayRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_OtherPatientServiceRevenueSourcesMember_e28fa1fd-f394-485d-8d8b-f4318f032eba_terseLabel_en-US" xlink:label="lab_sgry_OtherPatientServiceRevenueSourcesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_sgry_OtherPatientServiceRevenueSourcesMember_label_en-US" xlink:label="lab_sgry_OtherPatientServiceRevenueSourcesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Patient Service Revenue Sources [Member]</link:label>
    <link:label id="lab_sgry_OtherPatientServiceRevenueSourcesMember_documentation_en-US" xlink:label="lab_sgry_OtherPatientServiceRevenueSourcesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Patient Service Revenue Sources [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherPatientServiceRevenueSourcesMember" xlink:href="sgry-20220331.xsd#sgry_OtherPatientServiceRevenueSourcesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_OtherPatientServiceRevenueSourcesMember" xlink:to="lab_sgry_OtherPatientServiceRevenueSourcesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_35229934-514f-4395-8753-7f9224e05441_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_MateriallyMoreRestrictiveMember_a9dc206c-34ba-4329-b209-90087683a50c_terseLabel_en-US" xlink:label="lab_sgry_MateriallyMoreRestrictiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Materially More Restrictive</link:label>
    <link:label id="lab_sgry_MateriallyMoreRestrictiveMember_label_en-US" xlink:label="lab_sgry_MateriallyMoreRestrictiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Materially More Restrictive [Member]</link:label>
    <link:label id="lab_sgry_MateriallyMoreRestrictiveMember_documentation_en-US" xlink:label="lab_sgry_MateriallyMoreRestrictiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Materially More Restrictive [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_MateriallyMoreRestrictiveMember" xlink:href="sgry-20220331.xsd#sgry_MateriallyMoreRestrictiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_MateriallyMoreRestrictiveMember" xlink:to="lab_sgry_MateriallyMoreRestrictiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_5ea0ba5a-459c-4b2a-a48c-c9e8e2b2b725_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwned_e802921b-0a06-4864-9171-7380b376f8b5_terseLabel_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of surgical facilities owned</link:label>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwned_label_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Surgical Facilities Owned</link:label>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwned_documentation_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Surgical Facilities Owned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwned" xlink:href="sgry-20220331.xsd#sgry_NumberOfSurgicalFacilitiesOwned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_NumberOfSurgicalFacilitiesOwned" xlink:to="lab_sgry_NumberOfSurgicalFacilitiesOwned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_fda64a1e-8526-4f23-b5ff-6f01ccec7e8d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_47b0fbbb-954f-4ef0-b22c-9ac96face686_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_dc5dedda-4ac7-4ed6-974d-ad19bdd7912e_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_d3465f32-7e40-4446-ad7f-557d06a3d0a8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b8bc4eba-013e-4a4b-ad2f-7fc92bf6b7bc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $294.6 and $272.3, respectively</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_66b35f9a-b46d-492c-a923-91634cd42701_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_2b46b91d-d2ef-4c14-a352-10d3142ce0fe_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SurgicalFacilityServicesMember_33679b41-fab1-493f-97e6-2737abd2cdac_terseLabel_en-US" xlink:label="lab_sgry_SurgicalFacilityServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facility Services</link:label>
    <link:label id="lab_sgry_SurgicalFacilityServicesMember_label_en-US" xlink:label="lab_sgry_SurgicalFacilityServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facility Services [Member]</link:label>
    <link:label id="lab_sgry_SurgicalFacilityServicesMember_documentation_en-US" xlink:label="lab_sgry_SurgicalFacilityServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facility Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityServicesMember" xlink:href="sgry-20220331.xsd#sgry_SurgicalFacilityServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SurgicalFacilityServicesMember" xlink:to="lab_sgry_SurgicalFacilityServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a4f2d24e-5c96-42dc-8403-231ee4db4b17_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_d837d1a6-f92f-400d-839f-454243122090_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_f6b43a86-f0b4-4840-bcf9-7da10afae845_negatedTerseLabel_en-US" xlink:label="lab_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use operating lease liabilities</link:label>
    <link:label id="lab_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_label_en-US" xlink:label="lab_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease, Liability</link:label>
    <link:label id="lab_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_documentation_en-US" xlink:label="lab_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:href="sgry-20220331.xsd#sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:to="lab_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_65942068-8a60-46c3-9ec4-c04edb954d84_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Amounts and Fair Values of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_b9145439-cd74-4a4e-a4b2-4b3524595da1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_InterestRateCapTwoMember_f1d07386-d7c6-4674-bfb5-e7d3246abbb8_terseLabel_en-US" xlink:label="lab_sgry_InterestRateCapTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate cap</link:label>
    <link:label id="lab_sgry_InterestRateCapTwoMember_label_en-US" xlink:label="lab_sgry_InterestRateCapTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cap Two [Member]</link:label>
    <link:label id="lab_sgry_InterestRateCapTwoMember_documentation_en-US" xlink:label="lab_sgry_InterestRateCapTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cap Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_InterestRateCapTwoMember" xlink:href="sgry-20220331.xsd#sgry_InterestRateCapTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_InterestRateCapTwoMember" xlink:to="lab_sgry_InterestRateCapTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SeniorUnsecuredNotesDue2025Member_10eb1090-23b5-4122-a2ee-cc0955724584_verboseLabel_en-US" xlink:label="lab_sgry_SeniorUnsecuredNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.750% senior unsecured notes due 2025</link:label>
    <link:label id="lab_sgry_SeniorUnsecuredNotesDue2025Member_label_en-US" xlink:label="lab_sgry_SeniorUnsecuredNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2025 [Member]</link:label>
    <link:label id="lab_sgry_SeniorUnsecuredNotesDue2025Member_documentation_en-US" xlink:label="lab_sgry_SeniorUnsecuredNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2025Member" xlink:href="sgry-20220331.xsd#sgry_SeniorUnsecuredNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SeniorUnsecuredNotesDue2025Member" xlink:to="lab_sgry_SeniorUnsecuredNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_2346ada1-e0b6-42c0-bb04-f214148ac955_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_c44716a2-e2ae-4f70-bf74-93de8bab1cbe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeVariableInterestRate_5da18afb-3075-48b9-8c86-5bdda4eb9999_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeVariableInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable interest rate of derivative instrument (percent)</link:label>
    <link:label id="lab_us-gaap_DerivativeVariableInterestRate_label_en-US" xlink:label="lab_us-gaap_DerivativeVariableInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Variable Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeVariableInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeVariableInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeVariableInterestRate" xlink:to="lab_us-gaap_DerivativeVariableInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_AncillaryServicesMember_c86bbbbe-7be9-477b-bb95-9302e2f4a024_terseLabel_en-US" xlink:label="lab_sgry_AncillaryServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ancillary Services</link:label>
    <link:label id="lab_sgry_AncillaryServicesMember_label_en-US" xlink:label="lab_sgry_AncillaryServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ancillary Services [Member]</link:label>
    <link:label id="lab_sgry_AncillaryServicesMember_documentation_en-US" xlink:label="lab_sgry_AncillaryServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ancillary Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AncillaryServicesMember" xlink:href="sgry-20220331.xsd#sgry_AncillaryServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_AncillaryServicesMember" xlink:to="lab_sgry_AncillaryServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityAbstract_1a1f9a14-8c23-45a2-8db6-ac2ad5280391_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities:</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_8d1cfcb9-1768-4d9e-a74b-4a5034e04e2f_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_ef476d8b-ea2e-41c9-973c-84fa376320c5_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4f2a1046-8bae-4127-8be6-32cf1d01f3fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_1d9af8a3-8974-42e4-9f90-6a60558f4421_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_618e1077-cb9b-4015-9458-0589a56e9e17_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a13fa032-5d01-4dfb-b07e-3bd61c380f3c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5908948-8769-4b4c-81fe-4fe66fa928b4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_cd5e17d4-1e03-4eea-b450-fdc5249da993_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_025f2b72-60eb-416a-8d57-7ef4601c63f4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount estimated to be reclassified as a reduction to interest expense over next 12 months</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:to="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_95d8b175-a7f7-42e8-8e98-1fe650fa13fb_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_cefcd1be-3497-4daa-b9f4-2ae4ce135a92_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_b91bb828-fc6a-4205-b614-40851a7a85da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_d71d111b-4a28-46f1-955d-5e80da78280d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from equity offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_0dbb9ae9-7530-4f91-b5a3-c090668c4da1_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_aa936dfa-2c71-4938-b5c3-4fa0084f8ff9_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_3f2ade87-26ca-411b-ac04-aad09f0d5ab6_verboseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_d06e95dc-d354-4b83-aba0-2ecc4219f2da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_469e48ce-ef91-44fe-a0b1-c317e86d7098_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_16459102-46ea-43fd-a7b6-2e4c76310e99_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Payments) receipts related to ownership transactions with non-controlling interest holders</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_7fc19786-5206-4cca-a803-8580fb388272_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_NoncashInterestIncomeExpenseNet_5353c9f4-35b4-4ef0-a835-17dc24b89001_negatedTerseLabel_en-US" xlink:label="lab_sgry_NoncashInterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense, net</link:label>
    <link:label id="lab_sgry_NoncashInterestIncomeExpenseNet_label_en-US" xlink:label="lab_sgry_NoncashInterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Interest Income (Expense), Net</link:label>
    <link:label id="lab_sgry_NoncashInterestIncomeExpenseNet_documentation_en-US" xlink:label="lab_sgry_NoncashInterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NoncashInterestIncomeExpenseNet" xlink:href="sgry-20220331.xsd#sgry_NoncashInterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_NoncashInterestIncomeExpenseNet" xlink:to="lab_sgry_NoncashInterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_35f80ca9-ccd4-4703-a62a-b6a5460f6969_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_FacilitiesAmbulatorySurgeryCentersMember_03b79f70-68cc-4804-b881-5435683d20f7_terseLabel_en-US" xlink:label="lab_sgry_FacilitiesAmbulatorySurgeryCentersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities, Ambulatory Surgery Centers</link:label>
    <link:label id="lab_sgry_FacilitiesAmbulatorySurgeryCentersMember_label_en-US" xlink:label="lab_sgry_FacilitiesAmbulatorySurgeryCentersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities, Ambulatory Surgery Centers [Member]</link:label>
    <link:label id="lab_sgry_FacilitiesAmbulatorySurgeryCentersMember_documentation_en-US" xlink:label="lab_sgry_FacilitiesAmbulatorySurgeryCentersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities, Ambulatory Surgery Centers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FacilitiesAmbulatorySurgeryCentersMember" xlink:href="sgry-20220331.xsd#sgry_FacilitiesAmbulatorySurgeryCentersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_FacilitiesAmbulatorySurgeryCentersMember" xlink:to="lab_sgry_FacilitiesAmbulatorySurgeryCentersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b34721d3-3ce1-4575-aafb-d929ac47ea36_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6099c403-29a3-45af-9158-2a7d07603f79_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b3f90d30-cfae-42cd-885d-d00600d792a7_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_efc91087-846d-4a85-ac27-fe32a824efa0_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_1b8218ed-0091-4e90-a59e-f5c75136ed95_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Controlling Interests&#8212; Non-Redeemable</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsLineItems_92b2db53-f92a-4226-8889-1aa51fabdec4_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations [Line Items]</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsLineItems_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems" xlink:to="lab_us-gaap_GuaranteeObligationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_fbfe957a-5c24-4119-8842-aaa332dea9b5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_8f87c32d-fd24-4721-8e94-0da29ba1cce4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_0773af5f-d751-407f-b789-8f3e439dc789_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_98315111-57ca-49dc-a2b4-f999b7bab2be_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net income attributable to non-controlling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b7a48682-3df5-4e93-a8e7-6fd1edcb65d4_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to non-controlling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_a8f92396-12bd-4020-ada5-b29ee2204e64_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DerivativeLiabilityNotionalAmountFinancingComponent_40f5cd1c-36a9-4ae9-b65b-e22eaeafada0_terseLabel_en-US" xlink:label="lab_sgry_DerivativeLiabilityNotionalAmountFinancingComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, notional amount, financing component</link:label>
    <link:label id="lab_sgry_DerivativeLiabilityNotionalAmountFinancingComponent_label_en-US" xlink:label="lab_sgry_DerivativeLiabilityNotionalAmountFinancingComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount, Financing Component</link:label>
    <link:label id="lab_sgry_DerivativeLiabilityNotionalAmountFinancingComponent_documentation_en-US" xlink:label="lab_sgry_DerivativeLiabilityNotionalAmountFinancingComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount, Financing Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DerivativeLiabilityNotionalAmountFinancingComponent" xlink:href="sgry-20220331.xsd#sgry_DerivativeLiabilityNotionalAmountFinancingComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DerivativeLiabilityNotionalAmountFinancingComponent" xlink:to="lab_sgry_DerivativeLiabilityNotionalAmountFinancingComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6b7021b-cd55-44eb-9187-3659c1ecb0b5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_95a49ce5-27f0-4ba0-b2a6-41dac04ce0dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_020cc711-2da6-45c1-a1ff-86cd1f399453_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_21287d9b-506d-4d1b-a28a-eed9e8e44c90_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_2f4339b2-0886-4629-82b0-61e09126ecf4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Expense and Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_23d05a6d-bc5f-42e6-ba64-7a513f149129_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_cc8d1090-efeb-452f-8ff0-e77a3b91d1c0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired_371bd029-4ed0-483f-b6db-b95ec7efa5ca_terseLabel_en-US" xlink:label="lab_sgry_NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of non-controlling interests in surgical facilities acquired</link:label>
    <link:label id="lab_sgry_NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired_label_en-US" xlink:label="lab_sgry_NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Non-Controlling Interests In Surgical Facilities Acquired</link:label>
    <link:label id="lab_sgry_NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired_documentation_en-US" xlink:label="lab_sgry_NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Non-Controlling Interests In Surgical Facilities Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired" xlink:href="sgry-20220331.xsd#sgry_NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired" xlink:to="lab_sgry_NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_422636c3-ff15-4bd5-a1fb-5037381390c6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3583ce4d-5f61-432c-b1a9-4490508ec583_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding- basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_bf81d26f-ed7b-400a-a273-4a928135a407_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_5affe14a-47db-4a9e-bc3d-cc8507aece81_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_CostReportLiabilitiesCurrent_671260cd-ffc0-42b9-8c8c-ea12a66fe266_terseLabel_en-US" xlink:label="lab_sgry_CostReportLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost report liabilities</link:label>
    <link:label id="lab_sgry_CostReportLiabilitiesCurrent_label_en-US" xlink:label="lab_sgry_CostReportLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Report Liabilities, Current</link:label>
    <link:label id="lab_sgry_CostReportLiabilitiesCurrent_documentation_en-US" xlink:label="lab_sgry_CostReportLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Report Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CostReportLiabilitiesCurrent" xlink:href="sgry-20220331.xsd#sgry_CostReportLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_CostReportLiabilitiesCurrent" xlink:to="lab_sgry_CostReportLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_A2017TermLoanMaturing2024Member_b6acc505-c027-4aa8-a987-811a8b76ef4e_verboseLabel_en-US" xlink:label="lab_sgry_A2017TermLoanMaturing2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured term loan</link:label>
    <link:label id="lab_sgry_A2017TermLoanMaturing2024Member_label_en-US" xlink:label="lab_sgry_A2017TermLoanMaturing2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Term Loan, Maturing 2024 [Member]</link:label>
    <link:label id="lab_sgry_A2017TermLoanMaturing2024Member_documentation_en-US" xlink:label="lab_sgry_A2017TermLoanMaturing2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Term Loan, Maturing 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017TermLoanMaturing2024Member" xlink:href="sgry-20220331.xsd#sgry_A2017TermLoanMaturing2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_A2017TermLoanMaturing2024Member" xlink:to="lab_sgry_A2017TermLoanMaturing2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_1af6a3c6-0c99-42bd-a88f-555af578a7fd_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to non-controlling interests&#8212;redeemable</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Redeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_51a94f62-14f9-4f33-9fa9-62cd974760d1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and advances to affiliates</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_a1e5c7b2-3607-474f-8307-17d027266728_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_2ed54046-f98d-4511-a7db-348ea4f8d264_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ThreeReceiveFixedInterestRateSwapsMember_2b88ffc2-f55a-4113-a2e6-19359962803a_terseLabel_en-US" xlink:label="lab_sgry_ThreeReceiveFixedInterestRateSwapsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Receive-fixed Interest Rate Swaps</link:label>
    <link:label id="lab_sgry_ThreeReceiveFixedInterestRateSwapsMember_label_en-US" xlink:label="lab_sgry_ThreeReceiveFixedInterestRateSwapsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Receive-fixed Interest Rate Swaps [Member]</link:label>
    <link:label id="lab_sgry_ThreeReceiveFixedInterestRateSwapsMember_documentation_en-US" xlink:label="lab_sgry_ThreeReceiveFixedInterestRateSwapsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Receive-fixed Interest Rate Swaps Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ThreeReceiveFixedInterestRateSwapsMember" xlink:href="sgry-20220331.xsd#sgry_ThreeReceiveFixedInterestRateSwapsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ThreeReceiveFixedInterestRateSwapsMember" xlink:to="lab_sgry_ThreeReceiveFixedInterestRateSwapsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsMinorityInterest_1b33e4ee-d76c-4200-9725-ce8ef1cfed2d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to non-controlling interest holders</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsMinorityInterest_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsMinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:to="lab_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_193f2bb9-7791-4c70-baac-70ed96cdcc2e_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to Surgery Partners, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_684fcb8b-0137-4e2f-988e-41aeeb4f75f6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_33f7bbcb-0bb6-4479-b5d5-74c75b44c834_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4c249332-9ebe-417a-998c-7703ba89c696_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_a2c81fd5-3c88-4031-b6d0-e02c7d2e4563_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_251d462f-398c-4429-9d38-3482e6ef0239_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in earnings of unconsolidated affiliates</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_f42bf9fd-bab3-4e36-98c5-33b788450639_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_6493c9a3-9a99-4130-a858-4e397f4846ba_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_cec48f01-ee34-49e3-9cf7-2e4888066163_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating expenses</link:label>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_label_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Cost and Expense, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCostAndExpenseOperating" xlink:to="lab_us-gaap_OtherCostAndExpenseOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_IncreaseDecreaseInFinanceLeaseLiability_8c8d1355-7678-4633-9e7f-a0dbf735df3c_terseLabel_en-US" xlink:label="lab_sgry_IncreaseDecreaseInFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in finance lease liabilities</link:label>
    <link:label id="lab_sgry_IncreaseDecreaseInFinanceLeaseLiability_label_en-US" xlink:label="lab_sgry_IncreaseDecreaseInFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Finance Lease Liability</link:label>
    <link:label id="lab_sgry_IncreaseDecreaseInFinanceLeaseLiability_documentation_en-US" xlink:label="lab_sgry_IncreaseDecreaseInFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_IncreaseDecreaseInFinanceLeaseLiability" xlink:href="sgry-20220331.xsd#sgry_IncreaseDecreaseInFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_IncreaseDecreaseInFinanceLeaseLiability" xlink:to="lab_sgry_IncreaseDecreaseInFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_4c9ea0b8-b1ff-41d0-940f-7173b76a5925_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_74cb129e-25be-4570-8a4f-f88961152a48_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_5e4182a2-2830-4681-9017-baf72f9b6155_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_fe738d20-fc8f-4c26-b7bc-bda0bb069dcb_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_a9f019d4-8915-47d3-bbfc-cd0ae73b5a44_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_34e941b0-2d39-4d37-af30-d6e3359c14c0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d971ef56-5e26-491e-9534-033db6510dcf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6d4f6f8a-bbe8-4358-acfb-a231eafe4eec_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, stockholders' equity (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_81cb0d4e-ce98-4d85-9bd6-db4d9bbddaaf_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, stockholders' equity (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyByNatureAxis_239746d5-221a-46d2-a76c-c53ed25ce02d_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty, Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyByNatureAxis_label_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty, Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyByNatureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:to="lab_us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SurgicalFacilitiesExistingMarketsMember_71f18278-69f5-4b1d-b2f4-8713ac42527c_terseLabel_en-US" xlink:label="lab_sgry_SurgicalFacilitiesExistingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facilities, Existing Markets</link:label>
    <link:label id="lab_sgry_SurgicalFacilitiesExistingMarketsMember_label_en-US" xlink:label="lab_sgry_SurgicalFacilitiesExistingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facilities, Existing Markets [Member]</link:label>
    <link:label id="lab_sgry_SurgicalFacilitiesExistingMarketsMember_documentation_en-US" xlink:label="lab_sgry_SurgicalFacilitiesExistingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facilities, Existing Markets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilitiesExistingMarketsMember" xlink:href="sgry-20220331.xsd#sgry_SurgicalFacilitiesExistingMarketsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SurgicalFacilitiesExistingMarketsMember" xlink:to="lab_sgry_SurgicalFacilitiesExistingMarketsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_a24b8bad-433e-473c-97e4-6be3f440176c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7cc8afa6-c139-4e52-b061-3400e4fa7bf4_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_CashFlowLesseeAbstract_5d70f528-63f6-44c9-b519-c30ec860a2ca_terseLabel_en-US" xlink:label="lab_sgry_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_sgry_CashFlowLesseeAbstract_label_en-US" xlink:label="lab_sgry_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:label id="lab_sgry_CashFlowLesseeAbstract_documentation_en-US" xlink:label="lab_sgry_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CashFlowLesseeAbstract" xlink:href="sgry-20220331.xsd#sgry_CashFlowLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_CashFlowLesseeAbstract" xlink:to="lab_sgry_CashFlowLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_791520f6-6ee1-4a59-92df-fd9fffe68f54_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_548a710b-375f-481b-804c-1a9badce14aa_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateCapMember_289b76c2-0a38-4b3f-9058-8f5bda332499_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateCapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cap</link:label>
    <link:label id="lab_us-gaap_InterestRateCapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateCapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateCapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateCapMember" xlink:to="lab_us-gaap_InterestRateCapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_PayFixedSwapOneMember_985dde85-250e-42a6-9520-e013c177897e_terseLabel_en-US" xlink:label="lab_sgry_PayFixedSwapOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed swap</link:label>
    <link:label id="lab_sgry_PayFixedSwapOneMember_label_en-US" xlink:label="lab_sgry_PayFixedSwapOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap One [Member]</link:label>
    <link:label id="lab_sgry_PayFixedSwapOneMember_documentation_en-US" xlink:label="lab_sgry_PayFixedSwapOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap One Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapOneMember" xlink:href="sgry-20220331.xsd#sgry_PayFixedSwapOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_PayFixedSwapOneMember" xlink:to="lab_sgry_PayFixedSwapOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_704d533d-3848-479c-b85e-91e2c5b3d8a1_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_a4e6cd06-1470-4cc3-b43c-7f62daf92a7b_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b96caa6f-e426-4f8d-8a31-2584f8479d07_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_2980a5ad-2c03-4b03-8059-85e5ee40a118_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_dc55716a-ddea-41d2-82c4-386b2e379d73_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired_49101626-bba0-45ca-9dc3-2c1bf34d5a92_terseLabel_en-US" xlink:label="lab_sgry_NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of non-controlling interests in in-development de novo surgical facilities acquired</link:label>
    <link:label id="lab_sgry_NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired_label_en-US" xlink:label="lab_sgry_NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Non-Controlling Interests In In-Development De Novo Surgical Facilities Acquired</link:label>
    <link:label id="lab_sgry_NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired_documentation_en-US" xlink:label="lab_sgry_NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Non-Controlling Interests In In-Development De Novo Surgical Facilities Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired" xlink:href="sgry-20220331.xsd#sgry_NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired" xlink:to="lab_sgry_NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_e861add0-3249-48fd-a5df-578872d3b1e9_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_bb216c52-92be-459b-97a7-ff324931308b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeMember_844f751f-3eb1-4f4f-901b-38ee230c7c34_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherIncomeMember_label_en-US" xlink:label="lab_us-gaap_OtherIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeMember" xlink:to="lab_us-gaap_OtherIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_63aeae73-7984-495c-a8d7-5ef56cddef50_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_adb505a2-ed28-4d3f-a86d-e7a0345d482c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ecc5b163-cdc4-4073-976b-695a1fb5379c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b6ddd218-a305-49c1-b691-d55db3142c9b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_IncreaseDecreaseInFinanceLeaseRightOfUseAssets_8a28da10-66ae-4273-8c99-2cfafb65c039_terseLabel_en-US" xlink:label="lab_sgry_IncreaseDecreaseInFinanceLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in finance lease assets</link:label>
    <link:label id="lab_sgry_IncreaseDecreaseInFinanceLeaseRightOfUseAssets_label_en-US" xlink:label="lab_sgry_IncreaseDecreaseInFinanceLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Finance Lease, Right-Of-Use Assets</link:label>
    <link:label id="lab_sgry_IncreaseDecreaseInFinanceLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_sgry_IncreaseDecreaseInFinanceLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Finance Lease, Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_IncreaseDecreaseInFinanceLeaseRightOfUseAssets" xlink:href="sgry-20220331.xsd#sgry_IncreaseDecreaseInFinanceLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_IncreaseDecreaseInFinanceLeaseRightOfUseAssets" xlink:to="lab_sgry_IncreaseDecreaseInFinanceLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet_f3540623-2acd-4991-9bcc-1ba2d8f3c01e_terseLabel_en-US" xlink:label="lab_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition and disposal of shares of non-controlling interests, net</link:label>
    <link:label id="lab_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet_label_en-US" xlink:label="lab_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Controlling Interest, Acquisitions And Disposals Of Interests Held By Non-Controlling Interest Holders, Net</link:label>
    <link:label id="lab_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet_documentation_en-US" xlink:label="lab_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Controlling Interest, Acquisitions And Disposals Of Interests Held By Non-Controlling Interest Holders, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" xlink:href="sgry-20220331.xsd#sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" xlink:to="lab_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_PayFixedSwapTwoMember_715a8461-0072-457e-8073-b2fb9995ca3a_terseLabel_en-US" xlink:label="lab_sgry_PayFixedSwapTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed swap</link:label>
    <link:label id="lab_sgry_PayFixedSwapTwoMember_label_en-US" xlink:label="lab_sgry_PayFixedSwapTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap Two [Member]</link:label>
    <link:label id="lab_sgry_PayFixedSwapTwoMember_documentation_en-US" xlink:label="lab_sgry_PayFixedSwapTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap Two Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapTwoMember" xlink:href="sgry-20220331.xsd#sgry_PayFixedSwapTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_PayFixedSwapTwoMember" xlink:to="lab_sgry_PayFixedSwapTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_5d868891-2720-494e-bc9a-cc8617e72b27_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_42dfb003-d112-40e7-8085-f9c2700192e7_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentContractMember_222faa58-aecc-473d-b554-d18a72ffdb8c_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government</link:label>
    <link:label id="lab_us-gaap_GovernmentContractMember_label_en-US" xlink:label="lab_us-gaap_GovernmentContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GovernmentContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentContractMember" xlink:to="lab_us-gaap_GovernmentContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_PayablesToCustomers_1fa358b9-a43d-420e-8f8b-f211d9021b1e_terseLabel_en-US" xlink:label="lab_srt_PayablesToCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due to patients and payors</link:label>
    <link:label id="lab_srt_PayablesToCustomers_label_en-US" xlink:label="lab_srt_PayablesToCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broker-Dealer, Payable to Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PayablesToCustomers" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_PayablesToCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_PayablesToCustomers" xlink:to="lab_srt_PayablesToCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_2d86d8f2-660f-42be-92d9-9dad700c578b_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and other intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_c7677406-bb23-4ac6-9c31-7e0caf012532_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_f5dabff6-7734-45ca-9625-0279973926dd_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_288d96ee-7dd5-447c-8f61-0b97c3286e61_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_2bc612ba-23ab-4d87-91a1-bbf262c8f0fc_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ef4f6958-b634-45e7-bbf5-fe042ab01364_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_5b952acd-4c78-454b-9f9b-2cb29f1af127_terseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and benefits</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_34d1d4c6-ca36-4e11-8851-ba7361c172bc_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_56e3f592-3e1a-4941-9a10-548817b4fc5e_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_98dad4d5-89b5-409e-93bf-727cd6441031_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_278da9b3-d4ab-48e4-b2cd-d9007ca484d8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_309644b7-dcc8-425d-9644-7e64f3fc6635_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Rate Swaps and Interest Rate Caps Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_2bb7c7c7-961a-47ff-a90e-0c2a129f7e00_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_33cb075c-f9a3-4b9b-bd3f-ff1086d9f093_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f05e47c1-eefe-4336-9211-2178fcf72a75_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_80aa0775-5087-46d1-8777-0bcc3a337f97_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_e383f725-08ed-4770-b851-6f28aa24a3e8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other financing activities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_HealthcareOrganizationPatientServiceMember_cd02a067-032c-4011-854c-2b08e59eb59d_verboseLabel_en-US" xlink:label="lab_sgry_HealthcareOrganizationPatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent service revenues</link:label>
    <link:label id="lab_sgry_HealthcareOrganizationPatientServiceMember_f52e2f4f-21e6-440f-bcf5-263c3cb13ae6_terseLabel_en-US" xlink:label="lab_sgry_HealthcareOrganizationPatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient service revenues</link:label>
    <link:label id="lab_sgry_HealthcareOrganizationPatientServiceMember_label_en-US" xlink:label="lab_sgry_HealthcareOrganizationPatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Organization, Patient Service [Member]</link:label>
    <link:label id="lab_sgry_HealthcareOrganizationPatientServiceMember_documentation_en-US" xlink:label="lab_sgry_HealthcareOrganizationPatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Organization, Patient Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_HealthcareOrganizationPatientServiceMember" xlink:href="sgry-20220331.xsd#sgry_HealthcareOrganizationPatientServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember" xlink:to="lab_sgry_HealthcareOrganizationPatientServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_85812176-be9a-4d1f-b009-24870b7db5e1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_29c71a3c-933d-48c7-a245-bb477d2f5e0a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_90d210dd-7ae1-49bc-b7c0-f196a2abfd68_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_3bbb181e-6bf8-4b0f-87a8-ae8baaeee095_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_d6e9d16c-5cfc-456b-9386-35202c4d9c75_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_3eaf6aef-b430-46e1-99dc-8f6a6bc19f6a_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_06764c12-fda8-4a50-811d-f71f2b44ed1a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_607e5fe5-abbd-445e-9b90-7106caeb5e3c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_94a61af2-5ef5-4a08-9554-517cbedb512c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2ffc8b92-266c-4660-9017-823e1eac8be0_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding- diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_6f973a70-768c-4858-96ef-7d7312ebabd3_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_5b9b041f-b5d0-45df-a303-98f6708a24fd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_PayFixedSwapThreeMember_46acb422-144b-4c08-9c94-4871af513db5_terseLabel_en-US" xlink:label="lab_sgry_PayFixedSwapThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed swap</link:label>
    <link:label id="lab_sgry_PayFixedSwapThreeMember_label_en-US" xlink:label="lab_sgry_PayFixedSwapThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap Three [Member]</link:label>
    <link:label id="lab_sgry_PayFixedSwapThreeMember_documentation_en-US" xlink:label="lab_sgry_PayFixedSwapThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap Three Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapThreeMember" xlink:href="sgry-20220331.xsd#sgry_PayFixedSwapThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_PayFixedSwapThreeMember" xlink:to="lab_sgry_PayFixedSwapThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_FinanceLeaseCost_03421504-3b10-41e8-9eba-13bb3839cfad_totalLabel_en-US" xlink:label="lab_sgry_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease costs</link:label>
    <link:label id="lab_sgry_FinanceLeaseCost_label_en-US" xlink:label="lab_sgry_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:label id="lab_sgry_FinanceLeaseCost_documentation_en-US" xlink:label="lab_sgry_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FinanceLeaseCost" xlink:href="sgry-20220331.xsd#sgry_FinanceLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_FinanceLeaseCost" xlink:to="lab_sgry_FinanceLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_bfc402ba-aa35-4640-9de7-e12c041ee8f1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest payable</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_063ad141-f5c1-442f-9306-383a810dd195_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5c72ac96-671a-42d6-910d-cd894a608baa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, basis spread on variable rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_3be03a46-e382-4d12-936a-5f16922ac248_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_5bce270a-8a4a-48ee-b195-2dddf42a0101_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ProductsAndServicesLineItems_3333433e-561c-4080-83b4-d10bc1d3e14c_terseLabel_en-US" xlink:label="lab_sgry_ProductsAndServicesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products And Services [Line Items]</link:label>
    <link:label id="lab_sgry_ProductsAndServicesLineItems_label_en-US" xlink:label="lab_sgry_ProductsAndServicesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products And Services [Line Items]</link:label>
    <link:label id="lab_sgry_ProductsAndServicesLineItems_documentation_en-US" xlink:label="lab_sgry_ProductsAndServicesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products And Services [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ProductsAndServicesLineItems" xlink:href="sgry-20220331.xsd#sgry_ProductsAndServicesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ProductsAndServicesLineItems" xlink:to="lab_sgry_ProductsAndServicesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_a783fadd-46af-4fbf-9494-5c9a7c2b411e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_f21f5be2-c204-4ae6-be6c-4f519a43f335_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_b4ee2743-8a12-4510-9211-a871d14e1f9c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire equity method investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_8d39846e-3151-436f-8b6e-29b3513273c6_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_b956d279-29b2-4e7c-a3c1-a2121c3f2eda_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7626f326-4090-4548-b38d-107d869d707c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_57c43ae6-5351-4495-890a-1d80beb5d41a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_58a70b3c-7b7d-4d38-a178-8f5a473d8d95_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Revenue and Operating Income</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_941ea3e7-9701-4353-87e8-8189f3b6955e_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1e4a9d70-412a-4705-b5cf-5af8f5c8ea52_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_d38a1712-64ef-4193-aef8-fbd71ab9738e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:to="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_727a8f94-0d64-4fa2-9a0b-b1b5d96fc409_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_PayFixedSwapFourMember_8b9f2cea-7919-4a4e-b8e2-deb122093a5e_terseLabel_en-US" xlink:label="lab_sgry_PayFixedSwapFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed swap</link:label>
    <link:label id="lab_sgry_PayFixedSwapFourMember_label_en-US" xlink:label="lab_sgry_PayFixedSwapFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap Four [Member]</link:label>
    <link:label id="lab_sgry_PayFixedSwapFourMember_documentation_en-US" xlink:label="lab_sgry_PayFixedSwapFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay-fixed Swap Four Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapFourMember" xlink:href="sgry-20220331.xsd#sgry_PayFixedSwapFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_PayFixedSwapFourMember" xlink:to="lab_sgry_PayFixedSwapFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_5aca4d16-63ba-4916-852b-8d641147da9a_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_cb09385e-0bcf-4e4b-8802-cae6271f0948_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6f88cce2-438a-4502-bb27-8af28c35fede_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm_deb4c9be-466f-4788-9ebc-6069e6536d37_terseLabel_en-US" xlink:label="lab_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected tax savings period</link:label>
    <link:label id="lab_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm_label_en-US" xlink:label="lab_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Tax Agreement, Projected Tax Savings, Term</link:label>
    <link:label id="lab_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm_documentation_en-US" xlink:label="lab_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Tax Agreement, Projected Tax Savings, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm" xlink:href="sgry-20220331.xsd#sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm" xlink:to="lab_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_b1b15c3d-36a3-459a-9d8b-206c23646070_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_cec7922c-5182-4e7c-a3ad-d832c5d7b5f1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of preferred dividends</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Preferred Stock and Preference Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:to="lab_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_eed0038d-58d8-4399-aae6-5f5c8da146f3_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_d6b8070c-ccc8-4e2c-b113-197cd25aa162_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash outflows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e926eb33-8c7a-47ba-88e9-748c6122a2fd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d591ff08-4f05-4a4c-bce3-2dde468c27b7_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_a506e938-2f79-4b6a-ad60-39faa6fbcdd8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_d93b3fce-a617-4de1-b261-0bda31045d96_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_02680afb-f267-4dad-89c1-7461e209255f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: unamortized debt issuance costs and discounts</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_c440155c-e090-4de8-9f75-5ebee282d7dd_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_71c92186-7202-4d37-8bb2-bc75af67f5ca_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_d9bb833c-2c70-434a-85ba-677a57d5773a_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Funds Rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_5de0cea7-2418-4bdd-9adc-8c5d41930d85_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_f1934b95-f44f-43b8-b2df-8fa52e2804aa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent_b09d0462-88a1-47da-944f-a7fdb6a8a439_terseLabel_en-US" xlink:label="lab_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare accelerated payments and deferred governmental grants</link:label>
    <link:label id="lab_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent_label_en-US" xlink:label="lab_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Accelerated Payments And Deferred Governmental Grants, Current</link:label>
    <link:label id="lab_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent_documentation_en-US" xlink:label="lab_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Accelerated Payments And Deferred Governmental Grants, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent" xlink:href="sgry-20220331.xsd#sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent" xlink:to="lab_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_0c06d5fa-308f-4015-a290-4ae6582b1878_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_142527be-814a-4bd4-9473-385ffe3e8f8c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized fair value discount (premium)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_4ec0771f-3dcf-4c40-b128-d4d6a5bb848a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_021c5252-33b4-44fb-ba7e-448215737c2d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_e600238f-56b2-45b1-82b2-bdb2bdcbaaf2_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_597d6776-4152-4c0b-8453-68de09a611b6_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_2984ebc1-da86-44bb-a610-98f37f17654c_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_60703319-962f-4204-9f98-b4c58fd9731e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss recognized in income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_a523eef8-a85e-42ef-a861-748e41910713_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests&#8212;non-redeemable</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_VariableAndShortTermLeaseCost_42ed3ffc-f9d8-4654-87a6-8920a7055d70_terseLabel_en-US" xlink:label="lab_sgry_VariableAndShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable and short-term lease costs</link:label>
    <link:label id="lab_sgry_VariableAndShortTermLeaseCost_label_en-US" xlink:label="lab_sgry_VariableAndShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable And Short-Term Lease, Cost</link:label>
    <link:label id="lab_sgry_VariableAndShortTermLeaseCost_documentation_en-US" xlink:label="lab_sgry_VariableAndShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable And Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_VariableAndShortTermLeaseCost" xlink:href="sgry-20220331.xsd#sgry_VariableAndShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_VariableAndShortTermLeaseCost" xlink:to="lab_sgry_VariableAndShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_InterestRateCapOneMember_638a9a64-e2ae-466f-831e-305b40a22457_terseLabel_en-US" xlink:label="lab_sgry_InterestRateCapOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate cap</link:label>
    <link:label id="lab_sgry_InterestRateCapOneMember_label_en-US" xlink:label="lab_sgry_InterestRateCapOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cap One [Member]</link:label>
    <link:label id="lab_sgry_InterestRateCapOneMember_documentation_en-US" xlink:label="lab_sgry_InterestRateCapOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cap One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_InterestRateCapOneMember" xlink:href="sgry-20220331.xsd#sgry_InterestRateCapOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_InterestRateCapOneMember" xlink:to="lab_sgry_InterestRateCapOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelfInsuranceReserve_61a4041f-31ea-488f-8bfe-5c5494248fe3_terseLabel_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional, general and workers' compensation insurance reserve</link:label>
    <link:label id="lab_us-gaap_SelfInsuranceReserve_label_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Insurance Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SelfInsuranceReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfInsuranceReserve" xlink:to="lab_us-gaap_SelfInsuranceReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_e1f31ceb-8b21-4f7d-8e21-ea7fc7cf4726_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rollforward of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration_bd91f63c-b229-4510-a297-55805d721db3_terseLabel_en-US" xlink:label="lab_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of surgical facilities contributed as non-cash consideration</link:label>
    <link:label id="lab_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration_label_en-US" xlink:label="lab_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Number Of Surgical Facilities Contributed As Non-Cash Consideration</link:label>
    <link:label id="lab_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration_documentation_en-US" xlink:label="lab_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Number Of Surgical Facilities Contributed As Non-Cash Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration" xlink:href="sgry-20220331.xsd#sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration" xlink:to="lab_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_9a839b77-667e-43d0-904c-d4ab998e67ee_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_c662f7a0-03f3-4a8d-b0cf-5c37899b620b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value; shares authorized - 300,000,000; shares issued and outstanding - 89,904,913 and 89,332,557, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_b0dd0a01-bbbf-4a26-98c5-4fa06ac8b3fd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DeferredEmployeeRelatedLiabilitiesCurrent_6e5633ec-e099-4291-aace-539d688e3837_terseLabel_en-US" xlink:label="lab_sgry_DeferredEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred accrued payroll and benefits</link:label>
    <link:label id="lab_sgry_DeferredEmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_sgry_DeferredEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Employee-related Liabilities, Current</link:label>
    <link:label id="lab_sgry_DeferredEmployeeRelatedLiabilitiesCurrent_documentation_en-US" xlink:label="lab_sgry_DeferredEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredEmployeeRelatedLiabilitiesCurrent" xlink:href="sgry-20220331.xsd#sgry_DeferredEmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DeferredEmployeeRelatedLiabilitiesCurrent" xlink:to="lab_sgry_DeferredEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate_70a2e5d2-3c98-49f3-bcab-9ce4dbfd629f_terseLabel_en-US" xlink:label="lab_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative tax agreement, basis spread on variable rate (percent)</link:label>
    <link:label id="lab_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate_label_en-US" xlink:label="lab_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Tax Agreement, Interest Rate, Basis Spread on Variable Rate</link:label>
    <link:label id="lab_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate_documentation_en-US" xlink:label="lab_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Tax Agreement, Interest Rate, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate" xlink:href="sgry-20220331.xsd#sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate" xlink:to="lab_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_98941ac1-68b3-429f-a801-478135548e72_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_0ddd4a04-3505-48f4-a67c-d55b9523c43f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in earnings of unconsolidated affiliates, net of distributions received</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_36280aa8-b2ed-4faa-895a-2ba6fd20cf50_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_345f498d-be81-4bd0-9e6a-52f1211f8eb7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments_2844324a-700d-4d70-b134-cc461c14d81f_terseLabel_en-US" xlink:label="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred accelerated payments</link:label>
    <link:label id="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments_label_en-US" xlink:label="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grants, Deferred Accelerated Payments</link:label>
    <link:label id="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments_documentation_en-US" xlink:label="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grants, Deferred Accelerated Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments" xlink:href="sgry-20220331.xsd#sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments" xlink:to="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_929beb14-7717-4cfa-abc3-934cfba2c765_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7e41af55-53eb-4f04-8cab-2a36d094236b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>sgry-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b4dabe6f-88db-4fc2-b66b-139c1a2f1a72,g:e82a3438-fa59-433e-866a-e64d4d57702b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.surgerypartners.com/role/Cover" xlink:type="simple" xlink:href="sgry-20220331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8c177005-deee-4b41-863c-f7fd52683ad3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_DocumentType_8c177005-deee-4b41-863c-f7fd52683ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_0639c6ea-cc4a-4ac5-bedb-9b43510efe74" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_DocumentQuarterlyReport_0639c6ea-cc4a-4ac5-bedb-9b43510efe74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ebf6bd5b-5b63-4642-9bbb-7c737fad75b9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_DocumentPeriodEndDate_ebf6bd5b-5b63-4642-9bbb-7c737fad75b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_91852065-dac1-42fb-b0ca-ea5353f6920f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_DocumentTransitionReport_91852065-dac1-42fb-b0ca-ea5353f6920f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9afb0a63-f7bf-4de6-a986-5627b606c26c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_EntityFileNumber_9afb0a63-f7bf-4de6-a986-5627b606c26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a2efb684-1428-4986-87d5-ad25a23b0fe3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_EntityRegistrantName_a2efb684-1428-4986-87d5-ad25a23b0fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6dfff0f5-332c-4df6-b266-f9fa7d9c883b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6dfff0f5-332c-4df6-b266-f9fa7d9c883b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6f111bb5-ebb0-4029-8d6e-add6ba215ad7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_EntityTaxIdentificationNumber_6f111bb5-ebb0-4029-8d6e-add6ba215ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_34db3ed5-9839-4845-b378-232434a4601e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_EntityAddressAddressLine1_34db3ed5-9839-4845-b378-232434a4601e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1c2df315-a881-4c26-a84a-def4624d00ad" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_EntityAddressCityOrTown_1c2df315-a881-4c26-a84a-def4624d00ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1c3d8082-afdd-44cf-9060-1dda3f173794" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_EntityAddressStateOrProvince_1c3d8082-afdd-44cf-9060-1dda3f173794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c6e22eec-c6d3-41d5-bb84-034612447786" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_EntityAddressPostalZipCode_c6e22eec-c6d3-41d5-bb84-034612447786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0e2e9dfb-3d5f-4957-9a72-47ca887cb848" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_CityAreaCode_0e2e9dfb-3d5f-4957-9a72-47ca887cb848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c7ab3c48-5d44-43b5-bbaa-f713ae537518" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_LocalPhoneNumber_c7ab3c48-5d44-43b5-bbaa-f713ae537518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_17fecbfc-d54d-4d6d-8a00-558712c99684" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_Security12bTitle_17fecbfc-d54d-4d6d-8a00-558712c99684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c4e11904-c566-471d-ae51-4b4efe986af0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_TradingSymbol_c4e11904-c566-471d-ae51-4b4efe986af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e6dfd6e9-74cc-47c6-a7f8-b4c61c60b49e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_SecurityExchangeName_e6dfd6e9-74cc-47c6-a7f8-b4c61c60b49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_b63db613-6ff5-4dea-a293-8def0fad3d11" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_EntityCurrentReportingStatus_b63db613-6ff5-4dea-a293-8def0fad3d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ef7f04dd-3156-4f4b-ab31-8afbe0c5cdd2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_EntityInteractiveDataCurrent_ef7f04dd-3156-4f4b-ab31-8afbe0c5cdd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_8d7f5b15-dc7f-4375-b0fe-329a8cb03bc7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_EntityFilerCategory_8d7f5b15-dc7f-4375-b0fe-329a8cb03bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_aafc531c-9d0d-48f3-abea-f77d08f21997" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_EntitySmallBusiness_aafc531c-9d0d-48f3-abea-f77d08f21997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_50a4949c-4414-482b-8334-cecf9dcb0e1c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_EntityEmergingGrowthCompany_50a4949c-4414-482b-8334-cecf9dcb0e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_41b222f8-4785-4de5-8292-e8a900a04d3d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_EntityShellCompany_41b222f8-4785-4de5-8292-e8a900a04d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_daf95b51-7768-4f6a-84ed-a04bfee5e4f6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_daf95b51-7768-4f6a-84ed-a04bfee5e4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bebcc7df-995a-4084-b930-e48e9e8db702" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_EntityCentralIndexKey_bebcc7df-995a-4084-b930-e48e9e8db702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_32762c30-8888-4567-8e56-aeb26e7dc9a4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_CurrentFiscalYearEndDate_32762c30-8888-4567-8e56-aeb26e7dc9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_be4caa68-9880-41a4-8dce-b6c5b3dea1bd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_DocumentFiscalYearFocus_be4caa68-9880-41a4-8dce-b6c5b3dea1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_f508a406-1ec3-4657-bca0-902b29b34248" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_f508a406-1ec3-4657-bca0-902b29b34248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_24d54b25-28ca-40ff-aa5b-d01d6d751efa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba863d6-84f9-4363-a1d3-64869375ee5f" xlink:to="loc_dei_AmendmentFlag_24d54b25-28ca-40ff-aa5b-d01d6d751efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sgry-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_643c8dd9-f064-426a-af98-3d33ebbae35c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_efb73595-7e1b-4308-8924-5b9d566ad853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_643c8dd9-f064-426a-af98-3d33ebbae35c" xlink:to="loc_us-gaap_AssetsAbstract_efb73595-7e1b-4308-8924-5b9d566ad853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_8c395a59-38c1-45a9-bba2-93bdf456594f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_efb73595-7e1b-4308-8924-5b9d566ad853" xlink:to="loc_us-gaap_AssetsCurrentAbstract_8c395a59-38c1-45a9-bba2-93bdf456594f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2c43768d-fbc9-4f08-a541-95d7c2722289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8c395a59-38c1-45a9-bba2-93bdf456594f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2c43768d-fbc9-4f08-a541-95d7c2722289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4f0051ac-4052-4adb-9314-c23ae15e10f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8c395a59-38c1-45a9-bba2-93bdf456594f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4f0051ac-4052-4adb-9314-c23ae15e10f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e80c50bc-dd03-43e4-ba4a-f8148dad1de4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8c395a59-38c1-45a9-bba2-93bdf456594f" xlink:to="loc_us-gaap_InventoryNet_e80c50bc-dd03-43e4-ba4a-f8148dad1de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_55a5526a-7be6-49fe-af57-fa05c80c6f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8c395a59-38c1-45a9-bba2-93bdf456594f" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_55a5526a-7be6-49fe-af57-fa05c80c6f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_d0c42f5f-e32f-40c7-827d-70519817dbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8c395a59-38c1-45a9-bba2-93bdf456594f" xlink:to="loc_us-gaap_OtherAssetsCurrent_d0c42f5f-e32f-40c7-827d-70519817dbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_286ac80b-3e4f-494e-91fb-d233494edeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8c395a59-38c1-45a9-bba2-93bdf456594f" xlink:to="loc_us-gaap_AssetsCurrent_286ac80b-3e4f-494e-91fb-d233494edeb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_ef83b511-037a-4cff-b7c0-74925bd05ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_efb73595-7e1b-4308-8924-5b9d566ad853" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_ef83b511-037a-4cff-b7c0-74925bd05ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_be52ad63-56d8-42b7-8cc2-e43d28dc2bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_efb73595-7e1b-4308-8924-5b9d566ad853" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_be52ad63-56d8-42b7-8cc2-e43d28dc2bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_40f0c733-8212-443f-8e4c-01100bd71d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_efb73595-7e1b-4308-8924-5b9d566ad853" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_40f0c733-8212-443f-8e4c-01100bd71d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b59ea890-4f4d-47bd-a497-e6aef3f92cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_efb73595-7e1b-4308-8924-5b9d566ad853" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b59ea890-4f4d-47bd-a497-e6aef3f92cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_7af3e95a-00fc-4ad2-993b-a48ae604a58a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_efb73595-7e1b-4308-8924-5b9d566ad853" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_7af3e95a-00fc-4ad2-993b-a48ae604a58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8707e164-0bfc-4994-b38e-a5fd4fd6c5be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_efb73595-7e1b-4308-8924-5b9d566ad853" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8707e164-0bfc-4994-b38e-a5fd4fd6c5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_fb590138-1486-4299-9b7d-18ff75379de8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_efb73595-7e1b-4308-8924-5b9d566ad853" xlink:to="loc_us-gaap_Assets_fb590138-1486-4299-9b7d-18ff75379de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4919ba3e-45ca-4a6f-a865-3147caee2cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_643c8dd9-f064-426a-af98-3d33ebbae35c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4919ba3e-45ca-4a6f-a865-3147caee2cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_49094af3-5d1a-4af9-9eb5-9be4de095ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4919ba3e-45ca-4a6f-a865-3147caee2cc0" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_49094af3-5d1a-4af9-9eb5-9be4de095ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_612eb381-59e5-412c-bbac-678aafa2dc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49094af3-5d1a-4af9-9eb5-9be4de095ae9" xlink:to="loc_us-gaap_AccountsPayableCurrent_612eb381-59e5-412c-bbac-678aafa2dc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b7e36b48-9d27-4c40-b9da-509cec8275a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49094af3-5d1a-4af9-9eb5-9be4de095ae9" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b7e36b48-9d27-4c40-b9da-509cec8275a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent_46e12654-536d-4d78-90bb-5d6376c97d4a" xlink:href="sgry-20220331.xsd#sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49094af3-5d1a-4af9-9eb5-9be4de095ae9" xlink:to="loc_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent_46e12654-536d-4d78-90bb-5d6376c97d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3e185bdc-7453-4c9a-983d-32963cf2ec63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49094af3-5d1a-4af9-9eb5-9be4de095ae9" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_3e185bdc-7453-4c9a-983d-32963cf2ec63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_5e86ebfc-43c3-4d48-838f-9acc51fbec6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49094af3-5d1a-4af9-9eb5-9be4de095ae9" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_5e86ebfc-43c3-4d48-838f-9acc51fbec6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a04d8e8a-a5f4-482f-99bd-f9796f6a916a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49094af3-5d1a-4af9-9eb5-9be4de095ae9" xlink:to="loc_us-gaap_LiabilitiesCurrent_a04d8e8a-a5f4-482f-99bd-f9796f6a916a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_ec302077-4d88-4c3e-84c3-c2a634505fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4919ba3e-45ca-4a6f-a865-3147caee2cc0" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_ec302077-4d88-4c3e-84c3-c2a634505fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e67d3ae7-1be7-4a5d-9da2-03a0357a93cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4919ba3e-45ca-4a6f-a865-3147caee2cc0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e67d3ae7-1be7-4a5d-9da2-03a0357a93cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ea71e596-3478-4dbd-90e6-46b642cbfaa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4919ba3e-45ca-4a6f-a865-3147caee2cc0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ea71e596-3478-4dbd-90e6-46b642cbfaa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_c95e5252-6ec3-40a5-9a48-c05a4e6961c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4919ba3e-45ca-4a6f-a865-3147caee2cc0" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_c95e5252-6ec3-40a5-9a48-c05a4e6961c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_42a58d9e-9c1f-4abe-9177-0608709087bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4919ba3e-45ca-4a6f-a865-3147caee2cc0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_42a58d9e-9c1f-4abe-9177-0608709087bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_caf1e2a4-03c6-4ad2-812a-c8e137f35257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_42a58d9e-9c1f-4abe-9177-0608709087bd" xlink:to="loc_us-gaap_PreferredStockValue_caf1e2a4-03c6-4ad2-812a-c8e137f35257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_03a20692-6aad-4926-a355-6407655de00d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_42a58d9e-9c1f-4abe-9177-0608709087bd" xlink:to="loc_us-gaap_CommonStockValueOutstanding_03a20692-6aad-4926-a355-6407655de00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_b27100b6-073c-4fff-93d5-cab7379cfde0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_42a58d9e-9c1f-4abe-9177-0608709087bd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_b27100b6-073c-4fff-93d5-cab7379cfde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8fa33826-012e-4cde-be09-f169e0154e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_42a58d9e-9c1f-4abe-9177-0608709087bd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8fa33826-012e-4cde-be09-f169e0154e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_30e04e4c-0086-47fa-bb30-ce3a3a23eab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_42a58d9e-9c1f-4abe-9177-0608709087bd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_30e04e4c-0086-47fa-bb30-ce3a3a23eab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8887c753-cb12-45d1-bbb4-948e476e4d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_42a58d9e-9c1f-4abe-9177-0608709087bd" xlink:to="loc_us-gaap_StockholdersEquity_8887c753-cb12-45d1-bbb4-948e476e4d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_549c37ff-85ce-437a-8bb6-92603021c277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_42a58d9e-9c1f-4abe-9177-0608709087bd" xlink:to="loc_us-gaap_MinorityInterest_549c37ff-85ce-437a-8bb6-92603021c277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50e504fd-5a98-4ac2-90b0-8bbc000b626c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_42a58d9e-9c1f-4abe-9177-0608709087bd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50e504fd-5a98-4ac2-90b0-8bbc000b626c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4a866d4e-0c82-4555-9560-752be9b2df26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4919ba3e-45ca-4a6f-a865-3147caee2cc0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_4a866d4e-0c82-4555-9560-752be9b2df26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="sgry-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_95181d08-58e6-4323-aed2-d3b94e08cb21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_821a6f56-b658-46eb-b610-f6cc5bce53c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_95181d08-58e6-4323-aed2-d3b94e08cb21" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_821a6f56-b658-46eb-b610-f6cc5bce53c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6f80499f-8fbc-4a49-b38b-6291997315a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_95181d08-58e6-4323-aed2-d3b94e08cb21" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6f80499f-8fbc-4a49-b38b-6291997315a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f2206c29-08c8-4ddb-b7b8-53b2af9c3e42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_95181d08-58e6-4323-aed2-d3b94e08cb21" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f2206c29-08c8-4ddb-b7b8-53b2af9c3e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_e6623873-8a61-4605-bc00-66acf410d50f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_95181d08-58e6-4323-aed2-d3b94e08cb21" xlink:to="loc_us-gaap_PreferredStockSharesIssued_e6623873-8a61-4605-bc00-66acf410d50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2f6ae746-2571-4ace-a91e-d7a31f440338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_95181d08-58e6-4323-aed2-d3b94e08cb21" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2f6ae746-2571-4ace-a91e-d7a31f440338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b0747631-ecef-4a73-8b4d-b46407d1b2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_95181d08-58e6-4323-aed2-d3b94e08cb21" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b0747631-ecef-4a73-8b4d-b46407d1b2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_325e4fa8-d28d-45a3-9f11-d91b50f0144d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_95181d08-58e6-4323-aed2-d3b94e08cb21" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_325e4fa8-d28d-45a3-9f11-d91b50f0144d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ae824bdd-8049-4d26-bbe1-abb6cabbbf1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_95181d08-58e6-4323-aed2-d3b94e08cb21" xlink:to="loc_us-gaap_CommonStockSharesIssued_ae824bdd-8049-4d26-bbe1-abb6cabbbf1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_eac8cf9e-4245-46c6-876d-066f1fc05253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_95181d08-58e6-4323-aed2-d3b94e08cb21" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_eac8cf9e-4245-46c6-876d-066f1fc05253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sgry-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_2c6faeec-2f38-4325-a241-04c1eac35842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_be253932-b9d4-4e21-8a9e-6d6a3d3d118a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2c6faeec-2f38-4325-a241-04c1eac35842" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_be253932-b9d4-4e21-8a9e-6d6a3d3d118a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d130f90a-b0ce-46c0-b106-e5e70c0aa10b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2c6faeec-2f38-4325-a241-04c1eac35842" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d130f90a-b0ce-46c0-b106-e5e70c0aa10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_71a92088-6a22-4ff4-b0fd-e9daee868b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d130f90a-b0ce-46c0-b106-e5e70c0aa10b" xlink:to="loc_us-gaap_LaborAndRelatedExpense_71a92088-6a22-4ff4-b0fd-e9daee868b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_f64c8695-f4e0-43bd-84d7-025732d1c690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d130f90a-b0ce-46c0-b106-e5e70c0aa10b" xlink:to="loc_us-gaap_SuppliesExpense_f64c8695-f4e0-43bd-84d7-025732d1c690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_ed7ca6e3-d21a-42bd-adc8-943ab6b9eafa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d130f90a-b0ce-46c0-b106-e5e70c0aa10b" xlink:to="loc_us-gaap_ProfessionalFees_ed7ca6e3-d21a-42bd-adc8-943ab6b9eafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OperatingAndFinanceLeaseExpense_3e678b9e-6b06-4601-ad41-4c7fb302efff" xlink:href="sgry-20220331.xsd#sgry_OperatingAndFinanceLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d130f90a-b0ce-46c0-b106-e5e70c0aa10b" xlink:to="loc_sgry_OperatingAndFinanceLeaseExpense_3e678b9e-6b06-4601-ad41-4c7fb302efff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_5939fe50-3b13-4eeb-9d36-0269852f0f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d130f90a-b0ce-46c0-b106-e5e70c0aa10b" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_5939fe50-3b13-4eeb-9d36-0269852f0f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_ad199658-0649-492a-a2b0-0d57475cfe36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d130f90a-b0ce-46c0-b106-e5e70c0aa10b" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_ad199658-0649-492a-a2b0-0d57475cfe36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_243a7202-385d-429b-a4a3-c0db988f13b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d130f90a-b0ce-46c0-b106-e5e70c0aa10b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_243a7202-385d-429b-a4a3-c0db988f13b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6c804357-5e3b-49d9-9b72-01d6d74a98d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d130f90a-b0ce-46c0-b106-e5e70c0aa10b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6c804357-5e3b-49d9-9b72-01d6d74a98d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_9548a2b6-0db8-444d-abc3-41b559f3a818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d130f90a-b0ce-46c0-b106-e5e70c0aa10b" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_9548a2b6-0db8-444d-abc3-41b559f3a818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GrantRevenue_9774c3a7-ac65-45e9-88d0-56a425e22cac" xlink:href="sgry-20220331.xsd#sgry_GrantRevenue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d130f90a-b0ce-46c0-b106-e5e70c0aa10b" xlink:to="loc_sgry_GrantRevenue_9774c3a7-ac65-45e9-88d0-56a425e22cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_9b422e7d-e89d-4b83-8b09-126c7b1c8dff" xlink:href="sgry-20220331.xsd#sgry_GainLossOnDispositionOfAssetsAndDeconsolidation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d130f90a-b0ce-46c0-b106-e5e70c0aa10b" xlink:to="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_9b422e7d-e89d-4b83-8b09-126c7b1c8dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2d3ce5b6-5d94-496c-93f0-da58e02946f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d130f90a-b0ce-46c0-b106-e5e70c0aa10b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2d3ce5b6-5d94-496c-93f0-da58e02946f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_bed4ee7d-a36c-4ae8-a48d-e4bbb497ca50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d130f90a-b0ce-46c0-b106-e5e70c0aa10b" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_bed4ee7d-a36c-4ae8-a48d-e4bbb497ca50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonrecurringIncomeExpense_0b4772a1-cd0f-462a-b366-ca3c3caff67c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonrecurringIncomeExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d130f90a-b0ce-46c0-b106-e5e70c0aa10b" xlink:to="loc_us-gaap_OtherNonrecurringIncomeExpense_0b4772a1-cd0f-462a-b366-ca3c3caff67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3c74cf49-dbfe-45af-9423-c51db350ec4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d130f90a-b0ce-46c0-b106-e5e70c0aa10b" xlink:to="loc_us-gaap_OperatingExpenses_3c74cf49-dbfe-45af-9423-c51db350ec4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4c88957b-a860-41d1-9da4-42cfa5377382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2c6faeec-2f38-4325-a241-04c1eac35842" xlink:to="loc_us-gaap_OperatingIncomeLoss_4c88957b-a860-41d1-9da4-42cfa5377382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_0bb26d57-82f7-43bb-a3d7-8b893f59ac21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2c6faeec-2f38-4325-a241-04c1eac35842" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_0bb26d57-82f7-43bb-a3d7-8b893f59ac21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_b599ffe6-688c-438d-a908-228e62238253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2c6faeec-2f38-4325-a241-04c1eac35842" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_b599ffe6-688c-438d-a908-228e62238253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d7675945-ffb3-4532-b1dd-068944851622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2c6faeec-2f38-4325-a241-04c1eac35842" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d7675945-ffb3-4532-b1dd-068944851622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_dea15af0-2609-48ff-8641-7aec71eed7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2c6faeec-2f38-4325-a241-04c1eac35842" xlink:to="loc_us-gaap_ProfitLoss_dea15af0-2609-48ff-8641-7aec71eed7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_424d7bf5-51fb-49d7-91c6-26350b0e88d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2c6faeec-2f38-4325-a241-04c1eac35842" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_424d7bf5-51fb-49d7-91c6-26350b0e88d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b1e27f31-7bf9-41ed-a361-0d905c864920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2c6faeec-2f38-4325-a241-04c1eac35842" xlink:to="loc_us-gaap_NetIncomeLoss_b1e27f31-7bf9-41ed-a361-0d905c864920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_1a5dc2ca-db7a-43b8-915e-3f9296ff29cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2c6faeec-2f38-4325-a241-04c1eac35842" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_1a5dc2ca-db7a-43b8-915e-3f9296ff29cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_12d32683-4c5c-4809-8e05-20a492f6d3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2c6faeec-2f38-4325-a241-04c1eac35842" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_12d32683-4c5c-4809-8e05-20a492f6d3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_65193a60-6173-4cf2-9e6f-ef682d75a8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2c6faeec-2f38-4325-a241-04c1eac35842" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_65193a60-6173-4cf2-9e6f-ef682d75a8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_0ff2ca2f-debb-4ef5-b977-1cab6be27f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_65193a60-6173-4cf2-9e6f-ef682d75a8ca" xlink:to="loc_us-gaap_EarningsPerShareBasic_0ff2ca2f-debb-4ef5-b977-1cab6be27f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_68058a82-17ce-40eb-a69f-927aad6ccb08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_65193a60-6173-4cf2-9e6f-ef682d75a8ca" xlink:to="loc_us-gaap_EarningsPerShareDiluted_68058a82-17ce-40eb-a69f-927aad6ccb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c6d184fe-efa3-459e-b14f-4bc83483ae4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2c6faeec-2f38-4325-a241-04c1eac35842" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c6d184fe-efa3-459e-b14f-4bc83483ae4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b522f1a1-4671-4872-8cf1-eb34e37b8ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c6d184fe-efa3-459e-b14f-4bc83483ae4a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b522f1a1-4671-4872-8cf1-eb34e37b8ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cfcd9dc9-8784-4e30-9b7b-dd3acf4765ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c6d184fe-efa3-459e-b14f-4bc83483ae4a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cfcd9dc9-8784-4e30-9b7b-dd3acf4765ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="sgry-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_19efb26e-5ca9-4496-85e2-222e65b30bae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7ad0112f-7339-404c-bde5-4f6ff011bc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_19efb26e-5ca9-4496-85e2-222e65b30bae" xlink:to="loc_us-gaap_ProfitLoss_7ad0112f-7339-404c-bde5-4f6ff011bc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_fc43a5d2-91af-4475-9cbd-be43e6c52cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_19efb26e-5ca9-4496-85e2-222e65b30bae" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_fc43a5d2-91af-4475-9cbd-be43e6c52cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_6de16e7f-1a93-4a8b-85b7-599d3b950981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_fc43a5d2-91af-4475-9cbd-be43e6c52cc3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_6de16e7f-1a93-4a8b-85b7-599d3b950981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d62f518b-2bf2-4cc8-91b1-82101c53dcf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_19efb26e-5ca9-4496-85e2-222e65b30bae" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d62f518b-2bf2-4cc8-91b1-82101c53dcf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_bd562a46-5a17-40ce-968f-8bafeb2736d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_19efb26e-5ca9-4496-85e2-222e65b30bae" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_bd562a46-5a17-40ce-968f-8bafeb2736d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ebcf9ea7-e59f-4c52-ba26-be017523de43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_19efb26e-5ca9-4496-85e2-222e65b30bae" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_ebcf9ea7-e59f-4c52-ba26-be017523de43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgry-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e20682ae-9202-49c1-86e1-cc3afa6e1bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e8a16465-c78c-41bf-a3d3-ce99d794d91a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e20682ae-9202-49c1-86e1-cc3afa6e1bcb" xlink:to="loc_us-gaap_StatementTable_e8a16465-c78c-41bf-a3d3-ce99d794d91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9dccb1e2-0fff-49fb-9712-b43a47eabc0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e8a16465-c78c-41bf-a3d3-ce99d794d91a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9dccb1e2-0fff-49fb-9712-b43a47eabc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fc00720f-65b0-4425-8177-312fe1df9034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9dccb1e2-0fff-49fb-9712-b43a47eabc0d" xlink:to="loc_us-gaap_EquityComponentDomain_fc00720f-65b0-4425-8177-312fe1df9034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9ae62a2d-8c85-41de-880d-00a3757adb83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fc00720f-65b0-4425-8177-312fe1df9034" xlink:to="loc_us-gaap_CommonStockMember_9ae62a2d-8c85-41de-880d-00a3757adb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b7e9456b-4786-47fd-98e7-768645b19e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fc00720f-65b0-4425-8177-312fe1df9034" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b7e9456b-4786-47fd-98e7-768645b19e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dccb7ef5-f582-48f8-aa09-b43c2b04a31d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fc00720f-65b0-4425-8177-312fe1df9034" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dccb7ef5-f582-48f8-aa09-b43c2b04a31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6c3b8937-f793-4fbb-8d56-f7e594af9b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fc00720f-65b0-4425-8177-312fe1df9034" xlink:to="loc_us-gaap_RetainedEarningsMember_6c3b8937-f793-4fbb-8d56-f7e594af9b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_7f766a27-9389-4c7c-bae4-2d9c9e439453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fc00720f-65b0-4425-8177-312fe1df9034" xlink:to="loc_us-gaap_NoncontrollingInterestMember_7f766a27-9389-4c7c-bae4-2d9c9e439453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4bc5ea55-add7-483d-8d4d-79f9c66f9415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e8a16465-c78c-41bf-a3d3-ce99d794d91a" xlink:to="loc_us-gaap_StatementLineItems_4bc5ea55-add7-483d-8d4d-79f9c66f9415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4bc5ea55-add7-483d-8d4d-79f9c66f9415" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_75fc5641-eb51-41ee-b926-07b98e938eba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_75fc5641-eb51-41ee-b926-07b98e938eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_29281de7-a06c-4f58-970c-567630dd2a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_29281de7-a06c-4f58-970c-567630dd2a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_53aa47b2-fb49-4034-a437-aa47776183fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_53aa47b2-fb49-4034-a437-aa47776183fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0015301b-b98e-45eb-aa5b-9197cd225e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0015301b-b98e-45eb-aa5b-9197cd225e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_81478d61-84c5-4197-8090-0dd46f6b4889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_81478d61-84c5-4197-8090-0dd46f6b4889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_40f78aa4-8356-4974-b903-b10051d8d99d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_40f78aa4-8356-4974-b903-b10051d8d99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1ce92358-0827-43c7-9d56-13f2adf6ba4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1ce92358-0827-43c7-9d56-13f2adf6ba4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ab652f4-f6f5-4ded-88e4-e500946dc597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ab652f4-f6f5-4ded-88e4-e500946dc597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_3b1dbc1e-aa2a-48d9-9e06-72cb6c87fe67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_3b1dbc1e-aa2a-48d9-9e06-72cb6c87fe67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet_b5b7b475-bfa9-43c0-8ef2-17f07043678e" xlink:href="sgry-20220331.xsd#sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet_b5b7b475-bfa9-43c0-8ef2-17f07043678e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_66ccd204-cb2e-4548-9385-e14b3bdc2e36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_66ccd204-cb2e-4548-9385-e14b3bdc2e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9755606f-d763-44b4-aa32-69cf332dcbcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9755606f-d763-44b4-aa32-69cf332dcbcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_530106d2-ec4b-4185-bb8f-5a5eeacd4c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b5ca1667-b47a-4fa3-ab9c-127232689392" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_530106d2-ec4b-4185-bb8f-5a5eeacd4c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sgry-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_e57649b4-06d0-4bf6-8e1c-fad49445a20e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b8f0233c-0081-4daf-93da-b285b0154fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e57649b4-06d0-4bf6-8e1c-fad49445a20e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b8f0233c-0081-4daf-93da-b285b0154fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_435a3159-0c9f-4a26-b059-f078b49ca277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b8f0233c-0081-4daf-93da-b285b0154fe0" xlink:to="loc_us-gaap_ProfitLoss_435a3159-0c9f-4a26-b059-f078b49ca277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1e60538-146c-4442-bffb-5e9ad7a5ae16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b8f0233c-0081-4daf-93da-b285b0154fe0" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1e60538-146c-4442-bffb-5e9ad7a5ae16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8cab7abf-4042-4dd3-90c7-dfce020633c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1e60538-146c-4442-bffb-5e9ad7a5ae16" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8cab7abf-4042-4dd3-90c7-dfce020633c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NoncashInterestIncomeExpenseNet_f1870264-e5fa-49fd-a131-00fa7b94a57c" xlink:href="sgry-20220331.xsd#sgry_NoncashInterestIncomeExpenseNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1e60538-146c-4442-bffb-5e9ad7a5ae16" xlink:to="loc_sgry_NoncashInterestIncomeExpenseNet_f1870264-e5fa-49fd-a131-00fa7b94a57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c90e725f-76bd-41f2-90f1-bf8d02249548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1e60538-146c-4442-bffb-5e9ad7a5ae16" xlink:to="loc_us-gaap_ShareBasedCompensation_c90e725f-76bd-41f2-90f1-bf8d02249548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_9cc1e89c-d9df-45d5-92e6-22e000bdc855" xlink:href="sgry-20220331.xsd#sgry_GainLossOnDispositionOfAssetsAndDeconsolidation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1e60538-146c-4442-bffb-5e9ad7a5ae16" xlink:to="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_9cc1e89c-d9df-45d5-92e6-22e000bdc855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7bf2189e-8578-46c0-9f95-b472030bedbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1e60538-146c-4442-bffb-5e9ad7a5ae16" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7bf2189e-8578-46c0-9f95-b472030bedbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_1793cd98-4a28-4af4-975f-ad81429f197f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1e60538-146c-4442-bffb-5e9ad7a5ae16" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_1793cd98-4a28-4af4-975f-ad81429f197f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_44e8b436-df9f-41fb-b4c2-55fa62443eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1e60538-146c-4442-bffb-5e9ad7a5ae16" xlink:to="loc_us-gaap_OperatingLeaseExpense_44e8b436-df9f-41fb-b4c2-55fa62443eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dacbb1fa-037f-4dd9-8942-75f753644e76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1e60538-146c-4442-bffb-5e9ad7a5ae16" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dacbb1fa-037f-4dd9-8942-75f753644e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_85c02de8-a886-40c5-b126-f491a91a7515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dacbb1fa-037f-4dd9-8942-75f753644e76" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_85c02de8-a886-40c5-b126-f491a91a7515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants_a65c6c70-c412-4e95-934b-e86d5d137a87" xlink:href="sgry-20220331.xsd#sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dacbb1fa-037f-4dd9-8942-75f753644e76" xlink:to="loc_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants_a65c6c70-c412-4e95-934b-e86d5d137a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_365f040f-ccb2-4f76-9159-444e6da7e572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dacbb1fa-037f-4dd9-8942-75f753644e76" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_365f040f-ccb2-4f76-9159-444e6da7e572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a6b4510-5994-4a02-a5d8-bfb9954b9aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b8f0233c-0081-4daf-93da-b285b0154fe0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a6b4510-5994-4a02-a5d8-bfb9954b9aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_27b64f4e-0806-4b36-baa8-7c22ee4daf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e57649b4-06d0-4bf6-8e1c-fad49445a20e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_27b64f4e-0806-4b36-baa8-7c22ee4daf2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c7e663d3-0e47-4dd9-bdc0-aa6cc48c0bab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_27b64f4e-0806-4b36-baa8-7c22ee4daf2e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c7e663d3-0e47-4dd9-bdc0-aa6cc48c0bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_be073e4a-1ebb-4209-bea2-077cc4983c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_27b64f4e-0806-4b36-baa8-7c22ee4daf2e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_be073e4a-1ebb-4209-bea2-077cc4983c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_ad958302-14da-4fef-8f0a-c1fb65b5dc85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_27b64f4e-0806-4b36-baa8-7c22ee4daf2e" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_ad958302-14da-4fef-8f0a-c1fb65b5dc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_01da9ff9-dde8-42df-b8f8-ddcef5368171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_27b64f4e-0806-4b36-baa8-7c22ee4daf2e" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_01da9ff9-dde8-42df-b8f8-ddcef5368171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7ed33257-e80c-4828-a540-82c567a6bd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_27b64f4e-0806-4b36-baa8-7c22ee4daf2e" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7ed33257-e80c-4828-a540-82c567a6bd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_51f4a6e1-2a9a-45dd-a5d7-4dfca893ff19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_27b64f4e-0806-4b36-baa8-7c22ee4daf2e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_51f4a6e1-2a9a-45dd-a5d7-4dfca893ff19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_04554dcc-c318-4fe4-b913-d2f6f4f62760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e57649b4-06d0-4bf6-8e1c-fad49445a20e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_04554dcc-c318-4fe4-b913-d2f6f4f62760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_60c817d3-a9f7-436a-8e7b-82f2c3491ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_04554dcc-c318-4fe4-b913-d2f6f4f62760" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_60c817d3-a9f7-436a-8e7b-82f2c3491ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_cc9b8be4-3066-4358-a080-8e2208c002da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_04554dcc-c318-4fe4-b913-d2f6f4f62760" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_cc9b8be4-3066-4358-a080-8e2208c002da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_c09e8675-842a-4501-ad12-1a6d869bc109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_04554dcc-c318-4fe4-b913-d2f6f4f62760" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_c09e8675-842a-4501-ad12-1a6d869bc109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6d8fcfac-cddc-44aa-aa29-444bc4bf1548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_04554dcc-c318-4fe4-b913-d2f6f4f62760" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6d8fcfac-cddc-44aa-aa29-444bc4bf1548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_65be7cbd-7368-4019-8608-c63a61cb2cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_04554dcc-c318-4fe4-b913-d2f6f4f62760" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_65be7cbd-7368-4019-8608-c63a61cb2cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_e8ae8f91-1e9e-41e6-8323-4921b20f1a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_04554dcc-c318-4fe4-b913-d2f6f4f62760" xlink:to="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_e8ae8f91-1e9e-41e6-8323-4921b20f1a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsMinorityInterest_8e60a68c-803b-4836-8ec5-0fdcad5610b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsMinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_04554dcc-c318-4fe4-b913-d2f6f4f62760" xlink:to="loc_us-gaap_PaymentsOfDividendsMinorityInterest_8e60a68c-803b-4836-8ec5-0fdcad5610b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_9035038d-2c52-48b0-a561-d06126dec5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_04554dcc-c318-4fe4-b913-d2f6f4f62760" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_9035038d-2c52-48b0-a561-d06126dec5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_7525194d-1ba6-4209-953b-7da54c45dc07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_04554dcc-c318-4fe4-b913-d2f6f4f62760" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_7525194d-1ba6-4209-953b-7da54c45dc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_ff298e05-1cb0-4f14-828a-89084430336f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_04554dcc-c318-4fe4-b913-d2f6f4f62760" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_ff298e05-1cb0-4f14-828a-89084430336f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c3589eb7-0496-410c-a9e7-566f264203f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_04554dcc-c318-4fe4-b913-d2f6f4f62760" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c3589eb7-0496-410c-a9e7-566f264203f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e490ddaf-9cd9-458e-93a0-c35e0d053e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e57649b4-06d0-4bf6-8e1c-fad49445a20e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e490ddaf-9cd9-458e-93a0-c35e0d053e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3b8ebb59-2c17-4382-bb1e-cb57cca481d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e57649b4-06d0-4bf6-8e1c-fad49445a20e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3b8ebb59-2c17-4382-bb1e-cb57cca481d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f099cc4f-20d9-4876-b602-e33cbf028863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e57649b4-06d0-4bf6-8e1c-fad49445a20e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f099cc4f-20d9-4876-b602-e33cbf028863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies" xlink:type="simple" xlink:href="sgry-20220331.xsd#OrganizationandSummaryofAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e3062999-8434-4378-929e-ac896e1b274d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_a45804b4-a309-4bee-a877-4ededdcc3c13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e3062999-8434-4378-929e-ac896e1b274d" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_a45804b4-a309-4bee-a877-4ededdcc3c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies" xlink:type="simple" xlink:href="sgry-20220331.xsd#OrganizationandSummaryofAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81f0a2cb-d79c-41d6-8106-f73fdcc6fa8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7cba4a32-0981-404f-a6bf-62970c56bc79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81f0a2cb-d79c-41d6-8106-f73fdcc6fa8c" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7cba4a32-0981-404f-a6bf-62970c56bc79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_ac3b8b0e-fe75-4651-8093-8a0664cef709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81f0a2cb-d79c-41d6-8106-f73fdcc6fa8c" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_ac3b8b0e-fe75-4651-8093-8a0664cef709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_4305de89-0ea1-4e3d-b1a2-3775c30cad17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81f0a2cb-d79c-41d6-8106-f73fdcc6fa8c" xlink:to="loc_us-gaap_UseOfEstimates_4305de89-0ea1-4e3d-b1a2-3775c30cad17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_0f5a4eac-3448-436b-be7d-d97d2f58d3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81f0a2cb-d79c-41d6-8106-f73fdcc6fa8c" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_0f5a4eac-3448-436b-be7d-d97d2f58d3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_98bffc25-d823-4067-a0de-a67ee37af6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81f0a2cb-d79c-41d6-8106-f73fdcc6fa8c" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_98bffc25-d823-4067-a0de-a67ee37af6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ad192da7-affc-4355-9f94-f29bb39850e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81f0a2cb-d79c-41d6-8106-f73fdcc6fa8c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ad192da7-affc-4355-9f94-f29bb39850e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_24510e94-7b81-4bdf-a098-0eafca322ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81f0a2cb-d79c-41d6-8106-f73fdcc6fa8c" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_24510e94-7b81-4bdf-a098-0eafca322ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_26b3445f-0573-4e18-b691-3349151c43b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81f0a2cb-d79c-41d6-8106-f73fdcc6fa8c" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_26b3445f-0573-4e18-b691-3349151c43b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_215f8538-f910-4c7b-bcec-086fe3004642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81f0a2cb-d79c-41d6-8106-f73fdcc6fa8c" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_215f8538-f910-4c7b-bcec-086fe3004642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_0eb401bb-832c-4f8a-b225-3e38e6617ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81f0a2cb-d79c-41d6-8106-f73fdcc6fa8c" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_0eb401bb-832c-4f8a-b225-3e38e6617ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemableNoncontrollingInterestPolicyTextBlock_4f9f5fc6-39ca-4c5b-9f7f-ca485d63e11d" xlink:href="sgry-20220331.xsd#sgry_RedeemableNoncontrollingInterestPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81f0a2cb-d79c-41d6-8106-f73fdcc6fa8c" xlink:to="loc_sgry_RedeemableNoncontrollingInterestPolicyTextBlock_4f9f5fc6-39ca-4c5b-9f7f-ca485d63e11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_493567fe-6426-48dd-ba0a-bc4055d96585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81f0a2cb-d79c-41d6-8106-f73fdcc6fa8c" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_493567fe-6426-48dd-ba0a-bc4055d96585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables" xlink:type="simple" xlink:href="sgry-20220331.xsd#OrganizationandSummaryofAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83ae0a77-a9d0-4304-9c58-0b41ba565e28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_f4ec100f-7499-4bb1-ade2-66d64be29414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83ae0a77-a9d0-4304-9c58-0b41ba565e28" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_f4ec100f-7499-4bb1-ade2-66d64be29414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_5ba352e4-8302-4206-b9cf-6a7c8beabaea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83ae0a77-a9d0-4304-9c58-0b41ba565e28" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_5ba352e4-8302-4206-b9cf-6a7c8beabaea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_b0c1c730-9069-4bc0-848c-714cc64b6d57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83ae0a77-a9d0-4304-9c58-0b41ba565e28" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_b0c1c730-9069-4bc0-848c-714cc64b6d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_6b3842c6-ba5a-4d20-a2ff-c1a7543d16bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83ae0a77-a9d0-4304-9c58-0b41ba565e28" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_6b3842c6-ba5a-4d20-a2ff-c1a7543d16bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#OrganizationandSummaryofAccountingPoliciesOrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c21b6ed5-2740-4287-99d8-7df602712775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_24f98bb4-fa7f-4302-b693-2796d1cebce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AirlineProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c21b6ed5-2740-4287-99d8-7df602712775" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_24f98bb4-fa7f-4302-b693-2796d1cebce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0ba4af17-e0c7-4f6b-a03d-e9cffa6c9eea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_24f98bb4-fa7f-4302-b693-2796d1cebce0" xlink:to="loc_srt_ProductOrServiceAxis_0ba4af17-e0c7-4f6b-a03d-e9cffa6c9eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3894eaa5-816b-4a6a-9f0c-0aa9bc6a20fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0ba4af17-e0c7-4f6b-a03d-e9cffa6c9eea" xlink:to="loc_srt_ProductsAndServicesDomain_3894eaa5-816b-4a6a-9f0c-0aa9bc6a20fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FacilitiesAmbulatorySurgeryCentersMember_9ffb3a6b-3e66-44f2-8082-6d254b4046ee" xlink:href="sgry-20220331.xsd#sgry_FacilitiesAmbulatorySurgeryCentersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3894eaa5-816b-4a6a-9f0c-0aa9bc6a20fd" xlink:to="loc_sgry_FacilitiesAmbulatorySurgeryCentersMember_9ffb3a6b-3e66-44f2-8082-6d254b4046ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FacilitiesSurgicalHospitalsMember_742c691c-945c-48f8-a3c6-4f331afb1b46" xlink:href="sgry-20220331.xsd#sgry_FacilitiesSurgicalHospitalsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3894eaa5-816b-4a6a-9f0c-0aa9bc6a20fd" xlink:to="loc_sgry_FacilitiesSurgicalHospitalsMember_742c691c-945c-48f8-a3c6-4f331afb1b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ProductsAndServicesLineItems_808d8fe4-f5a6-4994-a976-0b34ada2525c" xlink:href="sgry-20220331.xsd#sgry_ProductsAndServicesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_24f98bb4-fa7f-4302-b693-2796d1cebce0" xlink:to="loc_sgry_ProductsAndServicesLineItems_808d8fe4-f5a6-4994-a976-0b34ada2525c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwned_34ee3d64-f51d-446c-b991-3f3def73519c" xlink:href="sgry-20220331.xsd#sgry_NumberOfSurgicalFacilitiesOwned"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_ProductsAndServicesLineItems_808d8fe4-f5a6-4994-a976-0b34ada2525c" xlink:to="loc_sgry_NumberOfSurgicalFacilitiesOwned_34ee3d64-f51d-446c-b991-3f3def73519c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_a912ef41-1759-4683-b260-880634d52d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_ProductsAndServicesLineItems_808d8fe4-f5a6-4994-a976-0b34ada2525c" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_a912ef41-1759-4683-b260-880634d52d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest_5907b616-670c-4650-bff2-67baa8a24c5f" xlink:href="sgry-20220331.xsd#sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_ProductsAndServicesLineItems_808d8fe4-f5a6-4994-a976-0b34ada2525c" xlink:to="loc_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest_5907b616-670c-4650-bff2-67baa8a24c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated_bf0bf986-bc88-414f-8387-a1d2f90bfdee" xlink:href="sgry-20220331.xsd#sgry_NumberOfSurgicalFacilitiesOwnedConsolidated"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_ProductsAndServicesLineItems_808d8fe4-f5a6-4994-a976-0b34ada2525c" xlink:to="loc_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated_bf0bf986-bc88-414f-8387-a1d2f90bfdee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#OrganizationandSummaryofAccountingPoliciesCARESACTDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8ee0a356-55ea-4dbc-bedd-6dbeef2d6e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ProceedsFromGovernmentAssistance_5cab0c28-d373-4dd6-b9e7-3891c660f8ba" xlink:href="sgry-20220331.xsd#sgry_ProceedsFromGovernmentAssistance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8ee0a356-55ea-4dbc-bedd-6dbeef2d6e8b" xlink:to="loc_sgry_ProceedsFromGovernmentAssistance_5cab0c28-d373-4dd6-b9e7-3891c660f8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GrantRevenue_0232dcf0-7498-410f-b3b3-b196a92a2c84" xlink:href="sgry-20220331.xsd#sgry_GrantRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8ee0a356-55ea-4dbc-bedd-6dbeef2d6e8b" xlink:to="loc_sgry_GrantRevenue_0232dcf0-7498-410f-b3b3-b196a92a2c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments_e518e01c-1634-4625-80b5-d7f811730505" xlink:href="sgry-20220331.xsd#sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8ee0a356-55ea-4dbc-bedd-6dbeef2d6e8b" xlink:to="loc_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments_e518e01c-1634-4625-80b5-d7f811730505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments_3a49c247-68b7-42be-b337-54aa7e6d7a57" xlink:href="sgry-20220331.xsd#sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8ee0a356-55ea-4dbc-bedd-6dbeef2d6e8b" xlink:to="loc_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments_3a49c247-68b7-42be-b337-54aa7e6d7a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments_2d421618-f5b7-4619-9b18-28f5d48a3a35" xlink:href="sgry-20220331.xsd#sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8ee0a356-55ea-4dbc-bedd-6dbeef2d6e8b" xlink:to="loc_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments_2d421618-f5b7-4619-9b18-28f5d48a3a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredEmployeeRelatedLiabilitiesCurrent_9a101c7e-8fa5-4730-88ae-2dfe5866b9f9" xlink:href="sgry-20220331.xsd#sgry_DeferredEmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8ee0a356-55ea-4dbc-bedd-6dbeef2d6e8b" xlink:to="loc_sgry_DeferredEmployeeRelatedLiabilitiesCurrent_9a101c7e-8fa5-4730-88ae-2dfe5866b9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7a6450d8-3ee9-4802-b36c-33a5dc9c6813" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_b46a581b-fd97-4f40-86e5-8793c82f3c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7a6450d8-3ee9-4802-b36c-33a5dc9c6813" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_b46a581b-fd97-4f40-86e5-8793c82f3c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_13e691c0-d50f-474a-baa4-310298084996" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_b46a581b-fd97-4f40-86e5-8793c82f3c2b" xlink:to="loc_srt_ConsolidatedEntitiesAxis_13e691c0-d50f-474a-baa4-310298084996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_f4349483-c0c6-4c1b-800c-ba469a39d26b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_13e691c0-d50f-474a-baa4-310298084996" xlink:to="loc_srt_ConsolidatedEntitiesDomain_f4349483-c0c6-4c1b-800c-ba469a39d26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_038bd7e8-a556-4f88-a4ce-4792cd24126d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_f4349483-c0c6-4c1b-800c-ba469a39d26b" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_038bd7e8-a556-4f88-a4ce-4792cd24126d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_5d88d6a5-b234-433b-a50d-6f23f3a439cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_b46a581b-fd97-4f40-86e5-8793c82f3c2b" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_5d88d6a5-b234-433b-a50d-6f23f3a439cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_VariableInterestEntityNumberOfFacilities_80dc61b5-3902-464f-a0e2-7b879853b5fa" xlink:href="sgry-20220331.xsd#sgry_VariableInterestEntityNumberOfFacilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5d88d6a5-b234-433b-a50d-6f23f3a439cb" xlink:to="loc_sgry_VariableInterestEntityNumberOfFacilities_80dc61b5-3902-464f-a0e2-7b879853b5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6b2cb2ad-9b62-466d-badf-cd6e47e81034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5d88d6a5-b234-433b-a50d-6f23f3a439cb" xlink:to="loc_us-gaap_Assets_6b2cb2ad-9b62-466d-badf-cd6e47e81034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1a6174b7-8312-46c0-8783-f7ce08435766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_5d88d6a5-b234-433b-a50d-6f23f3a439cb" xlink:to="loc_us-gaap_Liabilities_1a6174b7-8312-46c0-8783-f7ce08435766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e9538f61-12f1-445f-a9a2-1e436ecd2e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_54595a90-93ea-4077-8b75-e242e74f000f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e9538f61-12f1-445f-a9a2-1e436ecd2e02" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_54595a90-93ea-4077-8b75-e242e74f000f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_33adc033-3c4e-444a-a31a-90fc6c1c1aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_54595a90-93ea-4077-8b75-e242e74f000f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_33adc033-3c4e-444a-a31a-90fc6c1c1aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fbce8cca-980c-45ec-b62b-4d4b7ddb4932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_33adc033-3c4e-444a-a31a-90fc6c1c1aa0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fbce8cca-980c-45ec-b62b-4d4b7ddb4932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_b0db5373-7f80-485d-a7b3-1f75a2f21ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fbce8cca-980c-45ec-b62b-4d4b7ddb4932" xlink:to="loc_us-gaap_SecuredDebtMember_b0db5373-7f80-485d-a7b3-1f75a2f21ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_3a7bb8e5-671e-46be-8b18-a6143aec69da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fbce8cca-980c-45ec-b62b-4d4b7ddb4932" xlink:to="loc_us-gaap_SeniorNotesMember_3a7bb8e5-671e-46be-8b18-a6143aec69da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_eb103983-372b-4f53-bd73-57e4e31fad07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_54595a90-93ea-4077-8b75-e242e74f000f" xlink:to="loc_us-gaap_DebtInstrumentAxis_eb103983-372b-4f53-bd73-57e4e31fad07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4a565ce0-6240-404f-8855-71b63e00f36f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_eb103983-372b-4f53-bd73-57e4e31fad07" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4a565ce0-6240-404f-8855-71b63e00f36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017TermLoanMaturing2024Member_9c6d4359-fb90-4883-ad9d-5347d10d9b0d" xlink:href="sgry-20220331.xsd#sgry_A2017TermLoanMaturing2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4a565ce0-6240-404f-8855-71b63e00f36f" xlink:to="loc_sgry_A2017TermLoanMaturing2024Member_9c6d4359-fb90-4883-ad9d-5347d10d9b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2025Member_69ea635c-2c7e-4412-b4c2-b1c0f6d2d781" xlink:href="sgry-20220331.xsd#sgry_SeniorUnsecuredNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4a565ce0-6240-404f-8855-71b63e00f36f" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2025Member_69ea635c-2c7e-4412-b4c2-b1c0f6d2d781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2027Member_b571a381-c67c-47fd-8d24-b5947c8df91f" xlink:href="sgry-20220331.xsd#sgry_SeniorUnsecuredNotesDue2027Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4a565ce0-6240-404f-8855-71b63e00f36f" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2027Member_b571a381-c67c-47fd-8d24-b5947c8df91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_05444761-b897-4088-8bba-9573428f0a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_54595a90-93ea-4077-8b75-e242e74f000f" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_05444761-b897-4088-8bba-9573428f0a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_5d7ca12f-15c9-4c59-9de0-e6139dbf43e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_05444761-b897-4088-8bba-9573428f0a4a" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_5d7ca12f-15c9-4c59-9de0-e6139dbf43e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4b633c6e-d253-4f6e-98f3-f466c70fc2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_5d7ca12f-15c9-4c59-9de0-e6139dbf43e0" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4b633c6e-d253-4f6e-98f3-f466c70fc2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_e83323fb-3866-41cb-b28a-193c3c2db8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4b633c6e-d253-4f6e-98f3-f466c70fc2a1" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_e83323fb-3866-41cb-b28a-193c3c2db8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9a451c4f-9a22-488d-b94b-857c4804ef1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4b633c6e-d253-4f6e-98f3-f466c70fc2a1" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9a451c4f-9a22-488d-b94b-857c4804ef1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_199dd1c5-9a95-4727-b382-39808be2ec25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_54595a90-93ea-4077-8b75-e242e74f000f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_199dd1c5-9a95-4727-b382-39808be2ec25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9141b8b8-2fc5-4b65-88a1-f70d3b5eb36f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_199dd1c5-9a95-4727-b382-39808be2ec25" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9141b8b8-2fc5-4b65-88a1-f70d3b5eb36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e0a4634e-44db-48d7-905a-0954789966ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9141b8b8-2fc5-4b65-88a1-f70d3b5eb36f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e0a4634e-44db-48d7-905a-0954789966ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_47d16f46-f109-4bd2-a77b-3da44e44b5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_54595a90-93ea-4077-8b75-e242e74f000f" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_47d16f46-f109-4bd2-a77b-3da44e44b5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5c82f5e1-753d-4eb5-b437-c7ed84ff444a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_47d16f46-f109-4bd2-a77b-3da44e44b5ed" xlink:to="loc_us-gaap_LongTermDebt_5c82f5e1-753d-4eb5-b437-c7ed84ff444a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c9044201-0384-454c-a362-533a2e21153d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_47d16f46-f109-4bd2-a77b-3da44e44b5ed" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c9044201-0384-454c-a362-533a2e21153d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7bfb9344-079f-4b84-aec7-b44f516c8102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_178fd11b-68f1-4ec7-9ade-09371948a18c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7bfb9344-079f-4b84-aec7-b44f516c8102" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_178fd11b-68f1-4ec7-9ade-09371948a18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_89e69f4f-e6cd-4c61-8321-ab901b15245a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_178fd11b-68f1-4ec7-9ade-09371948a18c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_89e69f4f-e6cd-4c61-8321-ab901b15245a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_85e89f20-3991-4fed-9ce3-ce96e88ff6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_89e69f4f-e6cd-4c61-8321-ab901b15245a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_85e89f20-3991-4fed-9ce3-ce96e88ff6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_e5e8cd7b-4b9f-4fa5-b3b9-95d22db7e1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_85e89f20-3991-4fed-9ce3-ce96e88ff6b1" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_e5e8cd7b-4b9f-4fa5-b3b9-95d22db7e1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_62d61912-ae4f-456d-b67f-fa0f0ff45007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_178fd11b-68f1-4ec7-9ade-09371948a18c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_62d61912-ae4f-456d-b67f-fa0f0ff45007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e078c0e2-6d8b-4b17-bf09-0bbca5eeb776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_62d61912-ae4f-456d-b67f-fa0f0ff45007" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e078c0e2-6d8b-4b17-bf09-0bbca5eeb776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_b1a14502-095d-43bd-abee-6663e5ec8e57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e078c0e2-6d8b-4b17-bf09-0bbca5eeb776" xlink:to="loc_us-gaap_SalesRevenueNetMember_b1a14502-095d-43bd-abee-6663e5ec8e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bc9c7579-a92f-4a09-8adc-1e2c50bee859" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_178fd11b-68f1-4ec7-9ade-09371948a18c" xlink:to="loc_srt_ProductOrServiceAxis_bc9c7579-a92f-4a09-8adc-1e2c50bee859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3b2d699f-9e1b-423a-80b5-e44e867f2230" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_bc9c7579-a92f-4a09-8adc-1e2c50bee859" xlink:to="loc_srt_ProductsAndServicesDomain_3b2d699f-9e1b-423a-80b5-e44e867f2230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_HealthcareOrganizationPatientServiceMember_5ac84122-0607-447f-8a54-ccf2a4292e31" xlink:href="sgry-20220331.xsd#sgry_HealthcareOrganizationPatientServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3b2d699f-9e1b-423a-80b5-e44e867f2230" xlink:to="loc_sgry_HealthcareOrganizationPatientServiceMember_5ac84122-0607-447f-8a54-ccf2a4292e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityServicesMember_f03d6e0f-c8f5-4656-b05c-b6941a10837d" xlink:href="sgry-20220331.xsd#sgry_SurgicalFacilityServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_5ac84122-0607-447f-8a54-ccf2a4292e31" xlink:to="loc_sgry_SurgicalFacilityServicesMember_f03d6e0f-c8f5-4656-b05c-b6941a10837d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AncillaryServicesMember_90fe8106-037b-4a6b-bb8d-365b1206dc9e" xlink:href="sgry-20220331.xsd#sgry_AncillaryServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_5ac84122-0607-447f-8a54-ccf2a4292e31" xlink:to="loc_sgry_AncillaryServicesMember_90fe8106-037b-4a6b-bb8d-365b1206dc9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherServicesMember_58eb1579-0b2a-4ac2-98cc-7947adad4a1b" xlink:href="sgry-20220331.xsd#sgry_OtherServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3b2d699f-9e1b-423a-80b5-e44e867f2230" xlink:to="loc_sgry_OtherServicesMember_58eb1579-0b2a-4ac2-98cc-7947adad4a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_84adeff4-df00-40e2-8d35-7d1828b6eb75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_178fd11b-68f1-4ec7-9ade-09371948a18c" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_84adeff4-df00-40e2-8d35-7d1828b6eb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_d6c7aa6c-c057-41cc-8678-8c7ba0b55a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_84adeff4-df00-40e2-8d35-7d1828b6eb75" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_d6c7aa6c-c057-41cc-8678-8c7ba0b55a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_803d4d3e-65b2-4324-8de4-d2d55f5607f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ecba8d96-cc71-4765-bd42-12d29a35af68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_803d4d3e-65b2-4324-8de4-d2d55f5607f7" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ecba8d96-cc71-4765-bd42-12d29a35af68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e96db0d2-b8b6-4402-961b-bb3debf1bb25" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ecba8d96-cc71-4765-bd42-12d29a35af68" xlink:to="loc_srt_ProductOrServiceAxis_e96db0d2-b8b6-4402-961b-bb3debf1bb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_14e5298e-5e59-4130-91cc-3b77f8359255" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e96db0d2-b8b6-4402-961b-bb3debf1bb25" xlink:to="loc_srt_ProductsAndServicesDomain_14e5298e-5e59-4130-91cc-3b77f8359255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_HealthcareOrganizationPatientServiceMember_3cb24157-0b85-438d-89cc-970919639627" xlink:href="sgry-20220331.xsd#sgry_HealthcareOrganizationPatientServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_14e5298e-5e59-4130-91cc-3b77f8359255" xlink:to="loc_sgry_HealthcareOrganizationPatientServiceMember_3cb24157-0b85-438d-89cc-970919639627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PrivateInsuranceMember_fbdfacc8-5537-4dac-85b3-741d49e4dff5" xlink:href="sgry-20220331.xsd#sgry_PrivateInsuranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_3cb24157-0b85-438d-89cc-970919639627" xlink:to="loc_sgry_PrivateInsuranceMember_fbdfacc8-5537-4dac-85b3-741d49e4dff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractMember_f90fea3a-e24c-4f5d-8027-08e91d1406e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GovernmentContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_3cb24157-0b85-438d-89cc-970919639627" xlink:to="loc_us-gaap_GovernmentContractMember_f90fea3a-e24c-4f5d-8027-08e91d1406e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SelfPayRevenueMember_7f639d29-f685-484f-b5d8-fd3c69f9faa9" xlink:href="sgry-20220331.xsd#sgry_SelfPayRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_3cb24157-0b85-438d-89cc-970919639627" xlink:to="loc_sgry_SelfPayRevenueMember_7f639d29-f685-484f-b5d8-fd3c69f9faa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherPatientServiceRevenueSourcesMember_b80969f9-dfff-4bae-8e87-eb6d9f5ec056" xlink:href="sgry-20220331.xsd#sgry_OtherPatientServiceRevenueSourcesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_3cb24157-0b85-438d-89cc-970919639627" xlink:to="loc_sgry_OtherPatientServiceRevenueSourcesMember_b80969f9-dfff-4bae-8e87-eb6d9f5ec056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherServicesMember_fdad563f-f5f0-44ff-81e9-1dbb0ad84a26" xlink:href="sgry-20220331.xsd#sgry_OtherServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_14e5298e-5e59-4130-91cc-3b77f8359255" xlink:to="loc_sgry_OtherServicesMember_fdad563f-f5f0-44ff-81e9-1dbb0ad84a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_853203e4-e32f-4397-949f-b306aff2c967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ecba8d96-cc71-4765-bd42-12d29a35af68" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_853203e4-e32f-4397-949f-b306aff2c967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4df4b04f-9bd6-4233-b151-4fae196d8369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_853203e4-e32f-4397-949f-b306aff2c967" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4df4b04f-9bd6-4233-b151-4fae196d8369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e987d29b-4a7f-4787-bc1a-39c2733dd3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4df4b04f-9bd6-4233-b151-4fae196d8369" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e987d29b-4a7f-4787-bc1a-39c2733dd3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6ce0983c-3bec-46b9-937a-8eb33e19b842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ecba8d96-cc71-4765-bd42-12d29a35af68" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6ce0983c-3bec-46b9-937a-8eb33e19b842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52d28467-e76a-411c-9550-71b1c4f36e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6ce0983c-3bec-46b9-937a-8eb33e19b842" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52d28467-e76a-411c-9550-71b1c4f36e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_a56d156e-0111-40dc-9fa5-a5a191162e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_52d28467-e76a-411c-9550-71b1c4f36e01" xlink:to="loc_us-gaap_SalesRevenueNetMember_a56d156e-0111-40dc-9fa5-a5a191162e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8bfd4ab2-4a16-4312-b1bb-7aa154ad8add" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ecba8d96-cc71-4765-bd42-12d29a35af68" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_8bfd4ab2-4a16-4312-b1bb-7aa154ad8add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_64438b05-f4bf-47cf-b147-d2276f6b87e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8bfd4ab2-4a16-4312-b1bb-7aa154ad8add" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_64438b05-f4bf-47cf-b147-d2276f6b87e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e113364f-1ca6-462a-9524-6b147ef2445b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8bfd4ab2-4a16-4312-b1bb-7aa154ad8add" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e113364f-1ca6-462a-9524-6b147ef2445b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRollforwardofGoodwillDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#OrganizationandSummaryofAccountingPoliciesRollforwardofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRollforwardofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eef263b7-f475-444a-9ed7-e4bd0b048788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_66e3f595-22b2-4475-ba14-85774de713ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eef263b7-f475-444a-9ed7-e4bd0b048788" xlink:to="loc_us-gaap_GoodwillRollForward_66e3f595-22b2-4475-ba14-85774de713ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7805af05-d216-4f08-a7d5-140bba5b5252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_66e3f595-22b2-4475-ba14-85774de713ec" xlink:to="loc_us-gaap_Goodwill_7805af05-d216-4f08-a7d5-140bba5b5252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_55ad327f-cd6c-4471-874a-d6419628a88f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_66e3f595-22b2-4475-ba14-85774de713ec" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_55ad327f-cd6c-4471-874a-d6419628a88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidation_30a69ebf-9baa-43c3-a036-42eb9d7780ef" xlink:href="sgry-20220331.xsd#sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_66e3f595-22b2-4475-ba14-85774de713ec" xlink:to="loc_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidation_30a69ebf-9baa-43c3-a036-42eb9d7780ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_37fdf2bf-d975-463d-b441-8b7ba233a27f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_66e3f595-22b2-4475-ba14-85774de713ec" xlink:to="loc_us-gaap_Goodwill_37fdf2bf-d975-463d-b441-8b7ba233a27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dacf09aa-bfb3-4922-a2f4-cae581c77bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemableNoncontrollingInterestRollForward_1ad6a803-bc79-41f2-9d5e-eca89b8d4faf" xlink:href="sgry-20220331.xsd#sgry_RedeemableNoncontrollingInterestRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dacf09aa-bfb3-4922-a2f4-cae581c77bb9" xlink:to="loc_sgry_RedeemableNoncontrollingInterestRollForward_1ad6a803-bc79-41f2-9d5e-eca89b8d4faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_e1c95bbf-5237-48c3-a8a5-b53da7e24cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_RedeemableNoncontrollingInterestRollForward_1ad6a803-bc79-41f2-9d5e-eca89b8d4faf" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_e1c95bbf-5237-48c3-a8a5-b53da7e24cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_245cc906-0dab-4e5b-9262-dd6659612522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_RedeemableNoncontrollingInterestRollForward_1ad6a803-bc79-41f2-9d5e-eca89b8d4faf" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_245cc906-0dab-4e5b-9262-dd6659612522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests_d53b55ac-1e1b-4f2f-aad0-b1fe6aabecbf" xlink:href="sgry-20220331.xsd#sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_RedeemableNoncontrollingInterestRollForward_1ad6a803-bc79-41f2-9d5e-eca89b8d4faf" xlink:to="loc_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests_d53b55ac-1e1b-4f2f-aad0-b1fe6aabecbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_02653217-e464-445c-8bc5-faab6c1c97c9" xlink:href="sgry-20220331.xsd#sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_RedeemableNoncontrollingInterestRollForward_1ad6a803-bc79-41f2-9d5e-eca89b8d4faf" xlink:to="loc_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_02653217-e464-445c-8bc5-faab6c1c97c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_1c718134-e3a5-4f77-8dda-fec01e01e924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_RedeemableNoncontrollingInterestRollForward_1ad6a803-bc79-41f2-9d5e-eca89b8d4faf" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_1c718134-e3a5-4f77-8dda-fec01e01e924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_16ba12c3-fd8e-4e12-97d8-792721164a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d2746ed5-4e30-4cf0-9417-94cdd4d6fcb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_16ba12c3-fd8e-4e12-97d8-792721164a0b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d2746ed5-4e30-4cf0-9417-94cdd4d6fcb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_10d84cf1-0fe5-4bc4-ab45-94962fd5423a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_16ba12c3-fd8e-4e12-97d8-792721164a0b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_10d84cf1-0fe5-4bc4-ab45-94962fd5423a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_31adbe3c-f109-4f7f-a3d1-73ca2f5a6ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_16ba12c3-fd8e-4e12-97d8-792721164a0b" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_31adbe3c-f109-4f7f-a3d1-73ca2f5a6ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_ca6a9569-d193-4179-aef7-4dd713be09f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_16ba12c3-fd8e-4e12-97d8-792721164a0b" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_ca6a9569-d193-4179-aef7-4dd713be09f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposals" xlink:type="simple" xlink:href="sgry-20220331.xsd#AcquisitionsandDisposals"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0d4cff0d-e485-4a7f-82ad-636b18da02a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_a2066f29-b659-46d9-820e-e1327d5ab29b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0d4cff0d-e485-4a7f-82ad-636b18da02a3" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_a2066f29-b659-46d9-820e-e1327d5ab29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsTables" xlink:type="simple" xlink:href="sgry-20220331.xsd#AcquisitionsandDisposalsTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_824038db-8855-45f4-b41b-9bf0b6131520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_cad49067-f6f4-416e-a33e-5e47098e62b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_824038db-8855-45f4-b41b-9bf0b6131520" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_cad49067-f6f4-416e-a33e-5e47098e62b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#AcquisitionsandDisposalsAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_07db7134-62ec-4119-a5d8-6f8603feceff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8450ad82-f832-4332-83a3-b46b76c23fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_07db7134-62ec-4119-a5d8-6f8603feceff" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8450ad82-f832-4332-83a3-b46b76c23fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c83d1d76-0214-4a05-a2a1-7cb4b7236a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8450ad82-f832-4332-83a3-b46b76c23fbe" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c83d1d76-0214-4a05-a2a1-7cb4b7236a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_584b0297-a2c0-49fa-a05f-8a1b20f92192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c83d1d76-0214-4a05-a2a1-7cb4b7236a3a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_584b0297-a2c0-49fa-a05f-8a1b20f92192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilitiesMember_6613d70c-46a4-4253-9629-66675bf8e87b" xlink:href="sgry-20220331.xsd#sgry_SurgicalFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_584b0297-a2c0-49fa-a05f-8a1b20f92192" xlink:to="loc_sgry_SurgicalFacilitiesMember_6613d70c-46a4-4253-9629-66675bf8e87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilitiesExistingMarketsMember_c3fa1c9d-a11c-4e55-a2b9-84d67b972e1d" xlink:href="sgry-20220331.xsd#sgry_SurgicalFacilitiesExistingMarketsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_SurgicalFacilitiesMember_6613d70c-46a4-4253-9629-66675bf8e87b" xlink:to="loc_sgry_SurgicalFacilitiesExistingMarketsMember_c3fa1c9d-a11c-4e55-a2b9-84d67b972e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_9e43fa83-f335-44ae-9513-3b7b68473750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_584b0297-a2c0-49fa-a05f-8a1b20f92192" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_9e43fa83-f335-44ae-9513-3b7b68473750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_82207176-32c9-4456-9a43-4bb21c7a731f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8450ad82-f832-4332-83a3-b46b76c23fbe" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_82207176-32c9-4456-9a43-4bb21c7a731f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_2dadb167-ec5f-4554-a55b-33bacd891939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82207176-32c9-4456-9a43-4bb21c7a731f" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_2dadb167-ec5f-4554-a55b-33bacd891939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e501401c-8e4f-4b57-897b-04ed8d3fe726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82207176-32c9-4456-9a43-4bb21c7a731f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e501401c-8e4f-4b57-897b-04ed8d3fe726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_438a6439-13d3-4a81-9bbf-1968d69a184c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82207176-32c9-4456-9a43-4bb21c7a731f" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_438a6439-13d3-4a81-9bbf-1968d69a184c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#AcquisitionsandDisposalsSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_51a64b48-4b7f-4d8e-8375-284590ef45ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0ed9f496-d39b-416b-89ae-126c437b28b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_51a64b48-4b7f-4d8e-8375-284590ef45ac" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0ed9f496-d39b-416b-89ae-126c437b28b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d6cfae92-0710-453e-adef-b8fec6d1e2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0ed9f496-d39b-416b-89ae-126c437b28b3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d6cfae92-0710-453e-adef-b8fec6d1e2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0ea6e6f-ba4e-4d65-a38e-55796bddfde4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d6cfae92-0710-453e-adef-b8fec6d1e2b9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0ea6e6f-ba4e-4d65-a38e-55796bddfde4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilitiesMember_7659a899-6dd5-413a-ad18-55097126a3b6" xlink:href="sgry-20220331.xsd#sgry_SurgicalFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0ea6e6f-ba4e-4d65-a38e-55796bddfde4" xlink:to="loc_sgry_SurgicalFacilitiesMember_7659a899-6dd5-413a-ad18-55097126a3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_088ed97a-1e19-4563-9d71-07c943ca606e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0ed9f496-d39b-416b-89ae-126c437b28b3" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_088ed97a-1e19-4563-9d71-07c943ca606e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6619399f-00a3-4a54-b067-ecf1fe07eac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_088ed97a-1e19-4563-9d71-07c943ca606e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6619399f-00a3-4a54-b067-ecf1fe07eac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_ac76a010-13b3-4241-8cf0-0397d70683fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_088ed97a-1e19-4563-9d71-07c943ca606e" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_ac76a010-13b3-4241-8cf0-0397d70683fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2f1ae67c-c134-4b51-a510-812f1afb10af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_088ed97a-1e19-4563-9d71-07c943ca606e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2f1ae67c-c134-4b51-a510-812f1afb10af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_2866480f-132b-4df9-bffd-1308dd640e49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_088ed97a-1e19-4563-9d71-07c943ca606e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_2866480f-132b-4df9-bffd-1308dd640e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_55ea0b99-3566-4d35-9e51-155ff8966d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_2866480f-132b-4df9-bffd-1308dd640e49" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_55ea0b99-3566-4d35-9e51-155ff8966d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a44b54e0-cfa3-4185-a27c-90c5838e0801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_2866480f-132b-4df9-bffd-1308dd640e49" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a44b54e0-cfa3-4185-a27c-90c5838e0801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3c4dc056-5da7-49cf-a3b1-8193601f1c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_2866480f-132b-4df9-bffd-1308dd640e49" xlink:to="loc_us-gaap_Goodwill_3c4dc056-5da7-49cf-a3b1-8193601f1c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets_fbcfe00b-3422-4cdf-9f28-75b55901197b" xlink:href="sgry-20220331.xsd#sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_2866480f-132b-4df9-bffd-1308dd640e49" xlink:to="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets_fbcfe00b-3422-4cdf-9f28-75b55901197b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_3a98e8c9-f9c1-40a8-87eb-eb93d4757d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_2866480f-132b-4df9-bffd-1308dd640e49" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_3a98e8c9-f9c1-40a8-87eb-eb93d4757d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_9d3c008e-f0f4-4b2b-b585-40cb556fb3bc" xlink:href="sgry-20220331.xsd#sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_2866480f-132b-4df9-bffd-1308dd640e49" xlink:to="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_9d3c008e-f0f4-4b2b-b585-40cb556fb3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_25aa17c7-9a80-480d-8ab4-03fa3704a02b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_2866480f-132b-4df9-bffd-1308dd640e49" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_25aa17c7-9a80-480d-8ab4-03fa3704a02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e6d9969e-b92e-4125-a2b2-21f44de31f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9b4703dc-03a7-4432-baa4-bb72f2bb4145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e6d9969e-b92e-4125-a2b2-21f44de31f57" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9b4703dc-03a7-4432-baa4-bb72f2bb4145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ab88909f-f4a0-48e4-80bf-4316276e8e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9b4703dc-03a7-4432-baa4-bb72f2bb4145" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ab88909f-f4a0-48e4-80bf-4316276e8e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_97ded168-14be-4c3d-b73b-3d77694eb5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ab88909f-f4a0-48e4-80bf-4316276e8e38" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_97ded168-14be-4c3d-b73b-3d77694eb5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupOneMember_bcd10894-8704-419b-bfce-baf7f56417da" xlink:href="sgry-20220331.xsd#sgry_DisposalGroupOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_97ded168-14be-4c3d-b73b-3d77694eb5d7" xlink:to="loc_sgry_DisposalGroupOneMember_bcd10894-8704-419b-bfce-baf7f56417da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_1b6fdb97-8cf3-4946-b58a-25b5d5c79253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9b4703dc-03a7-4432-baa4-bb72f2bb4145" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_1b6fdb97-8cf3-4946-b58a-25b5d5c79253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_f2acdf4b-0538-47d7-a230-72f7b415b25a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_1b6fdb97-8cf3-4946-b58a-25b5d5c79253" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_f2acdf4b-0538-47d7-a230-72f7b415b25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_0638d35c-0958-4eb2-a609-00886ed637f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_f2acdf4b-0538-47d7-a230-72f7b415b25a" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_0638d35c-0958-4eb2-a609-00886ed637f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d0d890d2-2f22-4cb3-9348-2d15fca6e30b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9b4703dc-03a7-4432-baa4-bb72f2bb4145" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d0d890d2-2f22-4cb3-9348-2d15fca6e30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cfdbce3a-5d87-4c8d-b521-06f0d53536e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d0d890d2-2f22-4cb3-9348-2d15fca6e30b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cfdbce3a-5d87-4c8d-b521-06f0d53536e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_0c3368f1-774c-492e-8ef2-073444e97797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cfdbce3a-5d87-4c8d-b521-06f0d53536e9" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_0c3368f1-774c-492e-8ef2-073444e97797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87fdedac-efb1-464b-880f-5ec98ee7f328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9b4703dc-03a7-4432-baa4-bb72f2bb4145" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87fdedac-efb1-464b-880f-5ec98ee7f328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_5d3e2d4f-6de6-446a-b0cc-85a95c4b42e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87fdedac-efb1-464b-880f-5ec98ee7f328" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_5d3e2d4f-6de6-446a-b0cc-85a95c4b42e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_ffdc6033-3144-4456-94e9-6f32fc88b8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87fdedac-efb1-464b-880f-5ec98ee7f328" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_ffdc6033-3144-4456-94e9-6f32fc88b8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration_c58cc24b-0d45-471c-8882-91ccca4db798" xlink:href="sgry-20220331.xsd#sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87fdedac-efb1-464b-880f-5ec98ee7f328" xlink:to="loc_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration_c58cc24b-0d45-471c-8882-91ccca4db798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_764b075c-6999-4c4d-8ad5-75821fca5fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87fdedac-efb1-464b-880f-5ec98ee7f328" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_764b075c-6999-4c4d-8ad5-75821fca5fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtFairValue_10619425-a2dc-48f2-96a3-82e174918093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedAtFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87fdedac-efb1-464b-880f-5ec98ee7f328" xlink:to="loc_us-gaap_InvestmentOwnedAtFairValue_10619425-a2dc-48f2-96a3-82e174918093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebt" xlink:type="simple" xlink:href="sgry-20220331.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_002a9a1a-68e3-4f45-a818-d6ad84aebf98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_8dc22340-895e-48f3-8c6d-d90943c15d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_002a9a1a-68e3-4f45-a818-d6ad84aebf98" xlink:to="loc_us-gaap_LongTermDebtTextBlock_8dc22340-895e-48f3-8c6d-d90943c15d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtTables" xlink:type="simple" xlink:href="sgry-20220331.xsd#LongTermDebtTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6f01bff8-bc58-44db-87cf-522567db8a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_4a431dc3-cc42-4b39-8569-46e4fee4eb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6f01bff8-bc58-44db-87cf-522567db8a3b" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_4a431dc3-cc42-4b39-8569-46e4fee4eb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#LongTermDebtSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_90571d32-6910-4dd4-8564-00d4dc47f42e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_51518315-20a5-4648-ba7c-6e60dfe273dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_90571d32-6910-4dd4-8564-00d4dc47f42e" xlink:to="loc_us-gaap_DebtInstrumentTable_51518315-20a5-4648-ba7c-6e60dfe273dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_74f56eff-9c0f-41aa-8b03-f763e5b420d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_51518315-20a5-4648-ba7c-6e60dfe273dd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_74f56eff-9c0f-41aa-8b03-f763e5b420d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_81ddca47-1d89-4a38-afab-9c42b181147c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_74f56eff-9c0f-41aa-8b03-f763e5b420d1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_81ddca47-1d89-4a38-afab-9c42b181147c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_8dbbe609-f08e-4bda-802b-9405e52bf0db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_81ddca47-1d89-4a38-afab-9c42b181147c" xlink:to="loc_us-gaap_SecuredDebtMember_8dbbe609-f08e-4bda-802b-9405e52bf0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_58dc2c2d-b34e-4816-976e-ffa28170e36c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_81ddca47-1d89-4a38-afab-9c42b181147c" xlink:to="loc_us-gaap_SeniorNotesMember_58dc2c2d-b34e-4816-976e-ffa28170e36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NotesPayableAndSecuredLoansMember_0139273f-93f7-4841-a87f-810af44cf6fa" xlink:href="sgry-20220331.xsd#sgry_NotesPayableAndSecuredLoansMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_81ddca47-1d89-4a38-afab-9c42b181147c" xlink:to="loc_sgry_NotesPayableAndSecuredLoansMember_0139273f-93f7-4841-a87f-810af44cf6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6660870c-21fa-4d1e-8b94-3148bbc5c4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_51518315-20a5-4648-ba7c-6e60dfe273dd" xlink:to="loc_us-gaap_DebtInstrumentAxis_6660870c-21fa-4d1e-8b94-3148bbc5c4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7cee8b19-cda5-42b0-8d06-204cf6bea102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6660870c-21fa-4d1e-8b94-3148bbc5c4ed" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7cee8b19-cda5-42b0-8d06-204cf6bea102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017TermLoanMaturing2024Member_e4d14de1-6680-4c9a-bb29-2088394d14b5" xlink:href="sgry-20220331.xsd#sgry_A2017TermLoanMaturing2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7cee8b19-cda5-42b0-8d06-204cf6bea102" xlink:to="loc_sgry_A2017TermLoanMaturing2024Member_e4d14de1-6680-4c9a-bb29-2088394d14b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2025Member_5c8f9fde-2402-49d7-8e47-47c863cf7518" xlink:href="sgry-20220331.xsd#sgry_SeniorUnsecuredNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7cee8b19-cda5-42b0-8d06-204cf6bea102" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2025Member_5c8f9fde-2402-49d7-8e47-47c863cf7518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2027Member_7f55416d-680b-4860-94fb-646184637943" xlink:href="sgry-20220331.xsd#sgry_SeniorUnsecuredNotesDue2027Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7cee8b19-cda5-42b0-8d06-204cf6bea102" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2027Member_7f55416d-680b-4860-94fb-646184637943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_900f1c87-2ab5-4e26-85d2-2e7dad7677ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_51518315-20a5-4648-ba7c-6e60dfe273dd" xlink:to="loc_us-gaap_DebtInstrumentLineItems_900f1c87-2ab5-4e26-85d2-2e7dad7677ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c02ff227-184b-476f-a0f9-fcd74f04f2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900f1c87-2ab5-4e26-85d2-2e7dad7677ba" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c02ff227-184b-476f-a0f9-fcd74f04f2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_8819830c-31d5-4413-bc7a-e111b2f08abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900f1c87-2ab5-4e26-85d2-2e7dad7677ba" xlink:to="loc_us-gaap_FinanceLeaseLiability_8819830c-31d5-4413-bc7a-e111b2f08abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ec1a7c2c-3cdb-4d3d-99e9-42370fb71718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900f1c87-2ab5-4e26-85d2-2e7dad7677ba" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ec1a7c2c-3cdb-4d3d-99e9-42370fb71718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_8dd281cc-d47a-49cc-a9ba-704b8edcfe91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900f1c87-2ab5-4e26-85d2-2e7dad7677ba" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_8dd281cc-d47a-49cc-a9ba-704b8edcfe91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_f2abcbfe-bacc-49cc-afc5-42219ad36807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900f1c87-2ab5-4e26-85d2-2e7dad7677ba" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_f2abcbfe-bacc-49cc-afc5-42219ad36807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_ce9b5d9b-c89e-4d06-9924-d34e77399500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900f1c87-2ab5-4e26-85d2-2e7dad7677ba" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_ce9b5d9b-c89e-4d06-9924-d34e77399500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_736afaf4-9ac2-4172-92e5-edc675da46e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900f1c87-2ab5-4e26-85d2-2e7dad7677ba" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_736afaf4-9ac2-4172-92e5-edc675da46e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_c2d1c5a4-bde9-4111-89c0-05cbf77fe485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900f1c87-2ab5-4e26-85d2-2e7dad7677ba" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_c2d1c5a4-bde9-4111-89c0-05cbf77fe485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryDetails_1" xlink:type="simple" xlink:href="sgry-20220331.xsd#LongTermDebtSummaryDetails_1"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtSummaryDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#LongTermDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3ad81f38-c035-4b80-b7be-2590d3013f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4f8b6993-fe15-4a4f-a410-23e644023217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3ad81f38-c035-4b80-b7be-2590d3013f33" xlink:to="loc_us-gaap_DebtInstrumentTable_4f8b6993-fe15-4a4f-a410-23e644023217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_3ef36f77-e0d3-43c9-9c82-089b0f2d5fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4f8b6993-fe15-4a4f-a410-23e644023217" xlink:to="loc_us-gaap_CreditFacilityAxis_3ef36f77-e0d3-43c9-9c82-089b0f2d5fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4e030d07-1ead-4403-b020-8ae64e132d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_3ef36f77-e0d3-43c9-9c82-089b0f2d5fd9" xlink:to="loc_us-gaap_CreditFacilityDomain_4e030d07-1ead-4403-b020-8ae64e132d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_6ed27743-9de0-4051-8502-be4f7a0bb8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_4e030d07-1ead-4403-b020-8ae64e132d0e" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_6ed27743-9de0-4051-8502-be4f7a0bb8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_b1933873-b8cc-412f-b0bd-b003b74ccef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_4e030d07-1ead-4403-b020-8ae64e132d0e" xlink:to="loc_us-gaap_LetterOfCreditMember_b1933873-b8cc-412f-b0bd-b003b74ccef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3423f2d4-221b-40fa-a65e-4f97887432d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4f8b6993-fe15-4a4f-a410-23e644023217" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3423f2d4-221b-40fa-a65e-4f97887432d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ff3f805c-dc27-44ae-8dab-3825c865bc73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3423f2d4-221b-40fa-a65e-4f97887432d4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ff3f805c-dc27-44ae-8dab-3825c865bc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_304ea41a-d730-4d45-8e5f-a5a6083ebb29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ff3f805c-dc27-44ae-8dab-3825c865bc73" xlink:to="loc_us-gaap_SecuredDebtMember_304ea41a-d730-4d45-8e5f-a5a6083ebb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_aece87e5-d4eb-4ae4-96e8-9a867c7985e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4f8b6993-fe15-4a4f-a410-23e644023217" xlink:to="loc_us-gaap_DebtInstrumentAxis_aece87e5-d4eb-4ae4-96e8-9a867c7985e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fae4f4fa-72fc-401e-b697-92cb8ff2666f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_aece87e5-d4eb-4ae4-96e8-9a867c7985e3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fae4f4fa-72fc-401e-b697-92cb8ff2666f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017SeniorSecuredCreditFacilityMember_39eaa6fe-4cca-44dd-8d05-196f127a65b3" xlink:href="sgry-20220331.xsd#sgry_A2017SeniorSecuredCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fae4f4fa-72fc-401e-b697-92cb8ff2666f" xlink:to="loc_sgry_A2017SeniorSecuredCreditFacilityMember_39eaa6fe-4cca-44dd-8d05-196f127a65b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6918afb8-5b23-425e-8ce7-d105ee3b87c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4f8b6993-fe15-4a4f-a410-23e644023217" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6918afb8-5b23-425e-8ce7-d105ee3b87c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_13f52435-929c-4d44-ac1c-9e8146ee331f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6918afb8-5b23-425e-8ce7-d105ee3b87c2" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_13f52435-929c-4d44-ac1c-9e8146ee331f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_7e076777-64fb-42ba-9d6e-54f4d3e8a6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6918afb8-5b23-425e-8ce7-d105ee3b87c2" xlink:to="loc_us-gaap_LineOfCredit_7e076777-64fb-42ba-9d6e-54f4d3e8a6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/Leases" xlink:type="simple" xlink:href="sgry-20220331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c5224907-a77c-484c-b4a5-0a74532a89ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_deeaf6e1-25c0-4eb9-a76e-7f3d98146414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c5224907-a77c-484c-b4a5-0a74532a89ae" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_deeaf6e1-25c0-4eb9-a76e-7f3d98146414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_314a2d50-dc6d-4175-8fc3-9f0d13ac4d61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c5224907-a77c-484c-b4a5-0a74532a89ae" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_314a2d50-dc6d-4175-8fc3-9f0d13ac4d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesTables" xlink:type="simple" xlink:href="sgry-20220331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9ae32295-7f01-4ad9-842e-20095075e550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AssetsAndLiabilitiesLesseeTableTextBlock_b6e544d8-d152-49ba-9a8d-4aafce1b7085" xlink:href="sgry-20220331.xsd#sgry_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9ae32295-7f01-4ad9-842e-20095075e550" xlink:to="loc_sgry_AssetsAndLiabilitiesLesseeTableTextBlock_b6e544d8-d152-49ba-9a8d-4aafce1b7085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_2cf245a4-b3e6-49f2-adb9-486425feb6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9ae32295-7f01-4ad9-842e-20095075e550" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_2cf245a4-b3e6-49f2-adb9-486425feb6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b6e03bc7-02da-4781-a08c-ea133303e050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_82c80486-9f91-495c-b4e2-66c2c718a527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b6e03bc7-02da-4781-a08c-ea133303e050" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_82c80486-9f91-495c-b4e2-66c2c718a527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_27c234cd-cff5-4870-88de-78a35c0c12cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b6e03bc7-02da-4781-a08c-ea133303e050" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_27c234cd-cff5-4870-88de-78a35c0c12cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_2b828aeb-22e8-4206-bc0a-6916a5da629a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b6e03bc7-02da-4781-a08c-ea133303e050" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_2b828aeb-22e8-4206-bc0a-6916a5da629a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_da7f276b-2ea7-4ca0-8aff-7dde08e3fd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b6e03bc7-02da-4781-a08c-ea133303e050" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_da7f276b-2ea7-4ca0-8aff-7dde08e3fd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_56083384-a5cc-4e4e-a2b9-c95638cdb154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b6e03bc7-02da-4781-a08c-ea133303e050" xlink:to="loc_us-gaap_AssetsAbstract_56083384-a5cc-4e4e-a2b9-c95638cdb154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba2f0311-6768-4aff-a8c5-059039468f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_56083384-a5cc-4e4e-a2b9-c95638cdb154" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba2f0311-6768-4aff-a8c5-059039468f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_1a91bbf8-7579-4b8c-8d9b-9feca156aa6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_56083384-a5cc-4e4e-a2b9-c95638cdb154" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_1a91bbf8-7579-4b8c-8d9b-9feca156aa6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LeaseRightOfUseAsset_73931dad-a057-43d9-9e3f-742938a44e5e" xlink:href="sgry-20220331.xsd#sgry_LeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_56083384-a5cc-4e4e-a2b9-c95638cdb154" xlink:to="loc_sgry_LeaseRightOfUseAsset_73931dad-a057-43d9-9e3f-742938a44e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_f1aefb02-13ce-40ec-a95d-c954025290ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b6e03bc7-02da-4781-a08c-ea133303e050" xlink:to="loc_us-gaap_LiabilitiesAbstract_f1aefb02-13ce-40ec-a95d-c954025290ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_7c1cad62-f778-4da3-9802-649656a65558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_f1aefb02-13ce-40ec-a95d-c954025290ec" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_7c1cad62-f778-4da3-9802-649656a65558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ce2685b5-ee77-410b-8903-11364e08ce2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_7c1cad62-f778-4da3-9802-649656a65558" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ce2685b5-ee77-410b-8903-11364e08ce2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6744d288-31c0-4717-9b70-320d47f38cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_7c1cad62-f778-4da3-9802-649656a65558" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6744d288-31c0-4717-9b70-320d47f38cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8d5b1c64-a129-4655-81a1-5fa2fe942cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_7c1cad62-f778-4da3-9802-649656a65558" xlink:to="loc_us-gaap_OperatingLeaseLiability_8d5b1c64-a129-4655-81a1-5fa2fe942cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityAbstract_2bc342c7-510f-467d-b7df-7bb8bcf7a3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_f1aefb02-13ce-40ec-a95d-c954025290ec" xlink:to="loc_us-gaap_FinanceLeaseLiabilityAbstract_2bc342c7-510f-467d-b7df-7bb8bcf7a3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_95c8a0af-84c2-4d70-861e-0d7c98724fba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_2bc342c7-510f-467d-b7df-7bb8bcf7a3aa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_95c8a0af-84c2-4d70-861e-0d7c98724fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_2071e594-24bf-41c9-a4d0-1aad879f9266" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_2bc342c7-510f-467d-b7df-7bb8bcf7a3aa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_2071e594-24bf-41c9-a4d0-1aad879f9266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_fd52c15d-b364-424b-bd40-7407c62ba0be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_2bc342c7-510f-467d-b7df-7bb8bcf7a3aa" xlink:to="loc_us-gaap_FinanceLeaseLiability_fd52c15d-b364-424b-bd40-7407c62ba0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LeaseLiability_0e7b4adf-67a9-45c8-bc0b-46265905541a" xlink:href="sgry-20220331.xsd#sgry_LeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b6e03bc7-02da-4781-a08c-ea133303e050" xlink:to="loc_sgry_LeaseLiability_0e7b4adf-67a9-45c8-bc0b-46265905541a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ab15f9f5-672c-4ade-98d7-92e740787183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_IncreaseDecreaseInFinanceLeaseLiability_8311752b-ecd2-4ab1-b92d-1b6a1900166c" xlink:href="sgry-20220331.xsd#sgry_IncreaseDecreaseInFinanceLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ab15f9f5-672c-4ade-98d7-92e740787183" xlink:to="loc_sgry_IncreaseDecreaseInFinanceLeaseLiability_8311752b-ecd2-4ab1-b92d-1b6a1900166c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_IncreaseDecreaseInFinanceLeaseRightOfUseAssets_593af46c-133d-461a-85ab-b8fe8336ede6" xlink:href="sgry-20220331.xsd#sgry_IncreaseDecreaseInFinanceLeaseRightOfUseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ab15f9f5-672c-4ade-98d7-92e740787183" xlink:to="loc_sgry_IncreaseDecreaseInFinanceLeaseRightOfUseAssets_593af46c-133d-461a-85ab-b8fe8336ede6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c9ffee0c-af42-48de-a571-847f5572aad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ab15f9f5-672c-4ade-98d7-92e740787183" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c9ffee0c-af42-48de-a571-847f5572aad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_deb1b45c-dd83-405d-b3b9-260e053f7272" xlink:href="sgry-20220331.xsd#sgry_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ab15f9f5-672c-4ade-98d7-92e740787183" xlink:to="loc_sgry_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_deb1b45c-dd83-405d-b3b9-260e053f7272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#LeasesLeaseExpenseandCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_14c8a8ca-3181-44c0-b240-b1ad8abe7967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_892638c0-1eea-4b8b-8fac-a4ffea65624c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_14c8a8ca-3181-44c0-b240-b1ad8abe7967" xlink:to="loc_us-gaap_OperatingLeaseCost_892638c0-1eea-4b8b-8fac-a4ffea65624c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FinanceLeaseCost1Abstract_8d4c67a6-b973-4e5e-be3d-c87194183963" xlink:href="sgry-20220331.xsd#sgry_FinanceLeaseCost1Abstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_14c8a8ca-3181-44c0-b240-b1ad8abe7967" xlink:to="loc_sgry_FinanceLeaseCost1Abstract_8d4c67a6-b973-4e5e-be3d-c87194183963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ae012198-e323-4046-93de-049e23f4cea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_FinanceLeaseCost1Abstract_8d4c67a6-b973-4e5e-be3d-c87194183963" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ae012198-e323-4046-93de-049e23f4cea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_e3bd73f2-19c8-4b44-8459-8e0151961300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_FinanceLeaseCost1Abstract_8d4c67a6-b973-4e5e-be3d-c87194183963" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_e3bd73f2-19c8-4b44-8459-8e0151961300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FinanceLeaseCost_6b71431a-e92a-4f76-983b-68531f9043df" xlink:href="sgry-20220331.xsd#sgry_FinanceLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_FinanceLeaseCost1Abstract_8d4c67a6-b973-4e5e-be3d-c87194183963" xlink:to="loc_sgry_FinanceLeaseCost_6b71431a-e92a-4f76-983b-68531f9043df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_VariableAndShortTermLeaseCost_8ff910f3-a3d0-45f5-956a-ce904ab7b056" xlink:href="sgry-20220331.xsd#sgry_VariableAndShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_14c8a8ca-3181-44c0-b240-b1ad8abe7967" xlink:to="loc_sgry_VariableAndShortTermLeaseCost_8ff910f3-a3d0-45f5-956a-ce904ab7b056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_1cba5364-f0ce-4a4e-8ddd-edfd1588d022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_14c8a8ca-3181-44c0-b240-b1ad8abe7967" xlink:to="loc_us-gaap_LeaseCost_1cba5364-f0ce-4a4e-8ddd-edfd1588d022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CashFlowLesseeAbstract_60da41cc-7f28-4c99-92cc-dd0be4b31f11" xlink:href="sgry-20220331.xsd#sgry_CashFlowLesseeAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_14c8a8ca-3181-44c0-b240-b1ad8abe7967" xlink:to="loc_sgry_CashFlowLesseeAbstract_60da41cc-7f28-4c99-92cc-dd0be4b31f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_4faca927-b8d6-45c1-a568-aee57f5ce233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_CashFlowLesseeAbstract_60da41cc-7f28-4c99-92cc-dd0be4b31f11" xlink:to="loc_us-gaap_OperatingLeasePayments_4faca927-b8d6-45c1-a568-aee57f5ce233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_6feba4f7-9af0-4f34-903c-8ce2b649a113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_CashFlowLesseeAbstract_60da41cc-7f28-4c99-92cc-dd0be4b31f11" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_6feba4f7-9af0-4f34-903c-8ce2b649a113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_1ff9b169-f674-4334-bc4c-04de246ca1da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_CashFlowLesseeAbstract_60da41cc-7f28-4c99-92cc-dd0be4b31f11" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_1ff9b169-f674-4334-bc4c-04de246ca1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_92852aee-b65a-4c56-8780-3bd67f361255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_14c8a8ca-3181-44c0-b240-b1ad8abe7967" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_92852aee-b65a-4c56-8780-3bd67f361255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_2d9dd1fb-bf17-459e-9731-adbefc5b5a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_14c8a8ca-3181-44c0-b240-b1ad8abe7967" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_2d9dd1fb-bf17-459e-9731-adbefc5b5a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivities" xlink:type="simple" xlink:href="sgry-20220331.xsd#DerivativesandHedgingActivities"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5d8ebce1-3ed2-4525-a031-292f804cf577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1f82b89e-5880-43f1-abba-d4f7100b8f60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5d8ebce1-3ed2-4525-a031-292f804cf577" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1f82b89e-5880-43f1-abba-d4f7100b8f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables" xlink:type="simple" xlink:href="sgry-20220331.xsd#DerivativesandHedgingActivitiesTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8419535b-b384-4d42-b824-ad799b4a2c12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_77c4e700-82b6-426d-8b99-3160652a212a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8419535b-b384-4d42-b824-ad799b4a2c12" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_77c4e700-82b6-426d-8b99-3160652a212a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1ddb3952-f4a9-4379-8e0d-184a8ced97ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8419535b-b384-4d42-b824-ad799b4a2c12" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1ddb3952-f4a9-4379-8e0d-184a8ced97ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_55dee5d6-834a-4741-982c-d55ad40b3b64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8419535b-b384-4d42-b824-ad799b4a2c12" xlink:to="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_55dee5d6-834a-4741-982c-d55ad40b3b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#DerivativesandHedgingActivitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_98e97c09-a625-406e-a015-6b79a5a9d23e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_db217f5f-0b37-4288-a01e-714d1352b8df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_98e97c09-a625-406e-a015-6b79a5a9d23e" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_db217f5f-0b37-4288-a01e-714d1352b8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d5aa5b8c-2554-4b83-ab7f-c725be3e9aec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_db217f5f-0b37-4288-a01e-714d1352b8df" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d5aa5b8c-2554-4b83-ab7f-c725be3e9aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_588e2e11-a00d-4466-b3d7-d363af619a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d5aa5b8c-2554-4b83-ab7f-c725be3e9aec" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_588e2e11-a00d-4466-b3d7-d363af619a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_eb0f908c-976d-482c-bde1-b146bb55c946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_588e2e11-a00d-4466-b3d7-d363af619a2d" xlink:to="loc_us-gaap_InterestRateSwapMember_eb0f908c-976d-482c-bde1-b146bb55c946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_41a3d26b-359d-4002-8bbe-99cd41d3ded2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateCapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_588e2e11-a00d-4466-b3d7-d363af619a2d" xlink:to="loc_us-gaap_InterestRateCapMember_41a3d26b-359d-4002-8bbe-99cd41d3ded2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ThreePayFixedInterestRateSwapsMember_d5de179b-bdd8-49d8-9125-cf6ddf0b2f86" xlink:href="sgry-20220331.xsd#sgry_ThreePayFixedInterestRateSwapsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_588e2e11-a00d-4466-b3d7-d363af619a2d" xlink:to="loc_sgry_ThreePayFixedInterestRateSwapsMember_d5de179b-bdd8-49d8-9125-cf6ddf0b2f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ThreeReceiveFixedInterestRateSwapsMember_a93d66f1-0160-44f7-81e9-ab3350d37ff6" xlink:href="sgry-20220331.xsd#sgry_ThreeReceiveFixedInterestRateSwapsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_588e2e11-a00d-4466-b3d7-d363af619a2d" xlink:to="loc_sgry_ThreeReceiveFixedInterestRateSwapsMember_a93d66f1-0160-44f7-81e9-ab3350d37ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_2e692df8-e1b5-4af0-a86c-e116eb84f09f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_db217f5f-0b37-4288-a01e-714d1352b8df" xlink:to="loc_us-gaap_HedgingDesignationAxis_2e692df8-e1b5-4af0-a86c-e116eb84f09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2704769c-1fb8-438a-b9f3-7af14fa518d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_2e692df8-e1b5-4af0-a86c-e116eb84f09f" xlink:to="loc_us-gaap_HedgingDesignationDomain_2704769c-1fb8-438a-b9f3-7af14fa518d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9c84eca9-e731-4fd5-b8e1-92495e4b9343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_2704769c-1fb8-438a-b9f3-7af14fa518d8" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9c84eca9-e731-4fd5-b8e1-92495e4b9343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_8e42741b-f364-4af3-a138-696b08c74582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_2704769c-1fb8-438a-b9f3-7af14fa518d8" xlink:to="loc_us-gaap_NondesignatedMember_8e42741b-f364-4af3-a138-696b08c74582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_3a0710c2-ac56-4de6-88cc-a06f3fc40d36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_db217f5f-0b37-4288-a01e-714d1352b8df" xlink:to="loc_us-gaap_VariableRateAxis_3a0710c2-ac56-4de6-88cc-a06f3fc40d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_fdbfff41-0e8e-4add-b85d-2cd9341d7a77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_3a0710c2-ac56-4de6-88cc-a06f3fc40d36" xlink:to="loc_us-gaap_VariableRateDomain_fdbfff41-0e8e-4add-b85d-2cd9341d7a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_7186c85c-6f87-45ec-a89d-1672fa71e4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_fdbfff41-0e8e-4add-b85d-2cd9341d7a77" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_7186c85c-6f87-45ec-a89d-1672fa71e4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e7928737-75a8-4421-8567-0ab13f6a0987" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_db217f5f-0b37-4288-a01e-714d1352b8df" xlink:to="loc_srt_RangeAxis_e7928737-75a8-4421-8567-0ab13f6a0987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f6e068d9-fa77-4016-ac8b-79989f2ed90a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e7928737-75a8-4421-8567-0ab13f6a0987" xlink:to="loc_srt_RangeMember_f6e068d9-fa77-4016-ac8b-79989f2ed90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ca1dd3d5-e770-41c3-98d9-faa401f34028" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f6e068d9-fa77-4016-ac8b-79989f2ed90a" xlink:to="loc_srt_MinimumMember_ca1dd3d5-e770-41c3-98d9-faa401f34028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c3527002-9b49-4b0e-8b71-2379fc6f2cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_db217f5f-0b37-4288-a01e-714d1352b8df" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c3527002-9b49-4b0e-8b71-2379fc6f2cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_5acac37e-342d-415d-9b0b-28a70b29e830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c3527002-9b49-4b0e-8b71-2379fc6f2cc3" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_5acac37e-342d-415d-9b0b-28a70b29e830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_fdc9f3e9-7e94-4c77-a2de-7b35ad025eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c3527002-9b49-4b0e-8b71-2379fc6f2cc3" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_fdc9f3e9-7e94-4c77-a2de-7b35ad025eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_b04f22f0-28e6-4444-ae35-c45b7574d1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c3527002-9b49-4b0e-8b71-2379fc6f2cc3" xlink:to="loc_us-gaap_DerivativeNotionalAmount_b04f22f0-28e6-4444-ae35-c45b7574d1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeVariableInterestRate_b50d196c-afc9-4ac8-9929-aab1fd65cb49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeVariableInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c3527002-9b49-4b0e-8b71-2379fc6f2cc3" xlink:to="loc_us-gaap_DerivativeVariableInterestRate_b50d196c-afc9-4ac8-9929-aab1fd65cb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_36fd78f9-96f7-4e3b-8ed9-ffbd49438492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_391186ca-d8b2-411e-801d-df57ab139dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_36fd78f9-96f7-4e3b-8ed9-ffbd49438492" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_391186ca-d8b2-411e-801d-df57ab139dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_edcdda16-0c9d-4413-99f3-10ef910742c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_391186ca-d8b2-411e-801d-df57ab139dc5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_edcdda16-0c9d-4413-99f3-10ef910742c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_edcdda16-0c9d-4413-99f3-10ef910742c0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapOneMember_f4894ceb-2792-4c0d-8633-fd8e0fe0f9f5" xlink:href="sgry-20220331.xsd#sgry_PayFixedSwapOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:to="loc_sgry_PayFixedSwapOneMember_f4894ceb-2792-4c0d-8633-fd8e0fe0f9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapTwoMember_8500900e-dd0e-46f7-9658-155426859623" xlink:href="sgry-20220331.xsd#sgry_PayFixedSwapTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:to="loc_sgry_PayFixedSwapTwoMember_8500900e-dd0e-46f7-9658-155426859623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapThreeMember_6df78b15-606e-4da5-86ba-490f44e15c11" xlink:href="sgry-20220331.xsd#sgry_PayFixedSwapThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:to="loc_sgry_PayFixedSwapThreeMember_6df78b15-606e-4da5-86ba-490f44e15c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_InterestRateCapOneMember_e9531de0-e9e2-41aa-94b3-f0903fc7ef25" xlink:href="sgry-20220331.xsd#sgry_InterestRateCapOneMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:to="loc_sgry_InterestRateCapOneMember_e9531de0-e9e2-41aa-94b3-f0903fc7ef25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_InterestRateCapTwoMember_8b672262-1e4c-4172-95a0-74d168932ada" xlink:href="sgry-20220331.xsd#sgry_InterestRateCapTwoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:to="loc_sgry_InterestRateCapTwoMember_8b672262-1e4c-4172-95a0-74d168932ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapFourMember_21896aa5-8ec5-40ae-8ae9-b3e8af65ceda" xlink:href="sgry-20220331.xsd#sgry_PayFixedSwapFourMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:to="loc_sgry_PayFixedSwapFourMember_21896aa5-8ec5-40ae-8ae9-b3e8af65ceda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapFiveMember_f0ac9d6e-46d0-4b8e-bc6c-151e6f9cd5d1" xlink:href="sgry-20220331.xsd#sgry_PayFixedSwapFiveMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:to="loc_sgry_PayFixedSwapFiveMember_f0ac9d6e-46d0-4b8e-bc6c-151e6f9cd5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PayFixedSwapSixMember_8cfe8a6d-1aef-483b-b518-8f3b61e239cc" xlink:href="sgry-20220331.xsd#sgry_PayFixedSwapSixMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:to="loc_sgry_PayFixedSwapSixMember_8cfe8a6d-1aef-483b-b518-8f3b61e239cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ReceiveFixedSwapOneMember_b94be124-4886-4d55-a459-4317a30ca289" xlink:href="sgry-20220331.xsd#sgry_ReceiveFixedSwapOneMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:to="loc_sgry_ReceiveFixedSwapOneMember_b94be124-4886-4d55-a459-4317a30ca289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ReceiveFixedSwapTwoMember_bc0dbdfa-fd05-4a50-8bcd-ce8f38d78b2e" xlink:href="sgry-20220331.xsd#sgry_ReceiveFixedSwapTwoMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:to="loc_sgry_ReceiveFixedSwapTwoMember_bc0dbdfa-fd05-4a50-8bcd-ce8f38d78b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ReceiveFixedSwapThreeMember_93ab8cf8-b376-4050-a83f-e769d4cb1890" xlink:href="sgry-20220331.xsd#sgry_ReceiveFixedSwapThreeMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a86a6355-7bbd-410b-b110-66bf063de862" xlink:to="loc_sgry_ReceiveFixedSwapThreeMember_93ab8cf8-b376-4050-a83f-e769d4cb1890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_42cddfb8-497f-4b3c-a56f-d57c6f2931d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_391186ca-d8b2-411e-801d-df57ab139dc5" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_42cddfb8-497f-4b3c-a56f-d57c6f2931d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_01569dde-e34f-4407-8fd4-57b89f0d4996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_42cddfb8-497f-4b3c-a56f-d57c6f2931d7" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_01569dde-e34f-4407-8fd4-57b89f0d4996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_709ed5ce-2e60-4609-b6a0-25d2e540ddb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_42cddfb8-497f-4b3c-a56f-d57c6f2931d7" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_709ed5ce-2e60-4609-b6a0-25d2e540ddb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_4ffe67bc-4957-4368-87fd-dc802866ea7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_42cddfb8-497f-4b3c-a56f-d57c6f2931d7" xlink:to="loc_us-gaap_DerivativeNotionalAmount_4ffe67bc-4957-4368-87fd-dc802866ea7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8fe8137c-948b-408e-9b1d-a3650a90363e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b4c8a633-952f-48ac-8541-ae41c155d6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8fe8137c-948b-408e-9b1d-a3650a90363e" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b4c8a633-952f-48ac-8541-ae41c155d6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ece185fe-bcbf-4080-9626-cf7cf458180d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b4c8a633-952f-48ac-8541-ae41c155d6ba" xlink:to="loc_us-gaap_HedgingDesignationAxis_ece185fe-bcbf-4080-9626-cf7cf458180d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_16ff9492-b32a-4d6a-90e6-03d226f6385e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_ece185fe-bcbf-4080-9626-cf7cf458180d" xlink:to="loc_us-gaap_HedgingDesignationDomain_16ff9492-b32a-4d6a-90e6-03d226f6385e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_63d0aa1d-077d-43d9-823b-af078912b297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_16ff9492-b32a-4d6a-90e6-03d226f6385e" xlink:to="loc_us-gaap_NondesignatedMember_63d0aa1d-077d-43d9-823b-af078912b297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b71e0117-1b6f-4fd8-80e8-22ca555de893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_16ff9492-b32a-4d6a-90e6-03d226f6385e" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b71e0117-1b6f-4fd8-80e8-22ca555de893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_86b6a6ac-e6e6-48da-8bbe-c05ca724aa2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b4c8a633-952f-48ac-8541-ae41c155d6ba" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_86b6a6ac-e6e6-48da-8bbe-c05ca724aa2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_615127e7-d4db-4407-b5f1-b37d67edee43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_86b6a6ac-e6e6-48da-8bbe-c05ca724aa2a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_615127e7-d4db-4407-b5f1-b37d67edee43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_be53b3e9-f05b-4a93-9b2d-476d6732a946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_615127e7-d4db-4407-b5f1-b37d67edee43" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_be53b3e9-f05b-4a93-9b2d-476d6732a946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0bba5976-1832-4803-9fcd-ae7984c1ce44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_615127e7-d4db-4407-b5f1-b37d67edee43" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0bba5976-1832-4803-9fcd-ae7984c1ce44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d49bf9e0-e2c8-42ac-b9ee-5a14e5d2a7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b4c8a633-952f-48ac-8541-ae41c155d6ba" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d49bf9e0-e2c8-42ac-b9ee-5a14e5d2a7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_297d7d78-377d-4c2a-9185-00c96db7cd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d49bf9e0-e2c8-42ac-b9ee-5a14e5d2a7b8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_297d7d78-377d-4c2a-9185-00c96db7cd0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_842a3d57-5ad3-421d-90a2-0c0c910cfe1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_297d7d78-377d-4c2a-9185-00c96db7cd0a" xlink:to="loc_us-gaap_InterestRateSwapMember_842a3d57-5ad3-421d-90a2-0c0c910cfe1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_2f06fc0d-f1d1-4907-812d-e7d532a43ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateCapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_297d7d78-377d-4c2a-9185-00c96db7cd0a" xlink:to="loc_us-gaap_InterestRateCapMember_2f06fc0d-f1d1-4907-812d-e7d532a43ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_4624217e-6e6a-4911-a478-cb8db3330684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b4c8a633-952f-48ac-8541-ae41c155d6ba" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_4624217e-6e6a-4911-a478-cb8db3330684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_92d3850c-a863-45ab-b8c2-80eebc061062" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_4624217e-6e6a-4911-a478-cb8db3330684" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_92d3850c-a863-45ab-b8c2-80eebc061062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_fe8f60b3-09d4-4b34-a083-331f24b5e2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_4624217e-6e6a-4911-a478-cb8db3330684" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_fe8f60b3-09d4-4b34-a083-331f24b5e2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DerivativeLiabilityNotionalAmountFinancingComponent_9ae41c74-5327-48ff-843b-3c507978e5d3" xlink:href="sgry-20220331.xsd#sgry_DerivativeLiabilityNotionalAmountFinancingComponent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_4624217e-6e6a-4911-a478-cb8db3330684" xlink:to="loc_sgry_DerivativeLiabilityNotionalAmountFinancingComponent_9ae41c74-5327-48ff-843b-3c507978e5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bc9bb0d6-8d16-43d4-8912-d062e77d18d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_c91c191b-d04e-4746-98db-05215f39d844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bc9bb0d6-8d16-43d4-8912-d062e77d18d6" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_c91c191b-d04e-4746-98db-05215f39d844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7063fcbc-41d9-4a68-b88e-b3184461bc90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_c91c191b-d04e-4746-98db-05215f39d844" xlink:to="loc_us-gaap_HedgingDesignationAxis_7063fcbc-41d9-4a68-b88e-b3184461bc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_156df1b4-48a8-4f2f-bdd1-a4aa0c3a0587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_7063fcbc-41d9-4a68-b88e-b3184461bc90" xlink:to="loc_us-gaap_HedgingDesignationDomain_156df1b4-48a8-4f2f-bdd1-a4aa0c3a0587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_1c3591c7-e792-4dca-b204-c28f1168e8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_156df1b4-48a8-4f2f-bdd1-a4aa0c3a0587" xlink:to="loc_us-gaap_NondesignatedMember_1c3591c7-e792-4dca-b204-c28f1168e8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_41d93ac6-1d26-4b29-87e7-d2fc502f78fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_156df1b4-48a8-4f2f-bdd1-a4aa0c3a0587" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_41d93ac6-1d26-4b29-87e7-d2fc502f78fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ef82aca8-326a-4984-b03c-22b1bc2a3013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_c91c191b-d04e-4746-98db-05215f39d844" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ef82aca8-326a-4984-b03c-22b1bc2a3013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a6e0e681-4b61-4872-9581-714c3cdfab7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ef82aca8-326a-4984-b03c-22b1bc2a3013" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a6e0e681-4b61-4872-9581-714c3cdfab7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember_82eb71f9-9ee8-4413-a47c-c88b4bf75b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a6e0e681-4b61-4872-9581-714c3cdfab7b" xlink:to="loc_us-gaap_OtherIncomeMember_82eb71f9-9ee8-4413-a47c-c88b4bf75b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_1608e9ed-7087-47b0-8a86-70567d7c6f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a6e0e681-4b61-4872-9581-714c3cdfab7b" xlink:to="loc_us-gaap_InterestExpenseMember_1608e9ed-7087-47b0-8a86-70567d7c6f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_59717cea-e028-4528-961b-6a23f01ced43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_c91c191b-d04e-4746-98db-05215f39d844" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_59717cea-e028-4528-961b-6a23f01ced43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_1e65c045-1ad3-402f-8f3f-9ff150fb7639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_59717cea-e028-4528-961b-6a23f01ced43" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_1e65c045-1ad3-402f-8f3f-9ff150fb7639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_6a4dbaf2-91e7-4e43-bd7c-d5153fa0e334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_59717cea-e028-4528-961b-6a23f01ced43" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_6a4dbaf2-91e7-4e43-bd7c-d5153fa0e334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_08a16fb9-f985-4ad7-a1e5-857828c7094f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_59717cea-e028-4528-961b-6a23f01ced43" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax_08a16fb9-f985-4ad7-a1e5-857828c7094f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EarningsPerShare" xlink:type="simple" xlink:href="sgry-20220331.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ea7357d0-f6f1-4b54-a04d-6873856fce93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_85bc7793-57e7-49cc-903b-e7573d886631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ea7357d0-f6f1-4b54-a04d-6873856fce93" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_85bc7793-57e7-49cc-903b-e7573d886631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="sgry-20220331.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_32f0daee-b1fd-4a66-8859-34ddc782b88a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_913008bd-3d2f-425f-b010-0d28c1f75c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_32f0daee-b1fd-4a66-8859-34ddc782b88a" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_913008bd-3d2f-425f-b010-0d28c1f75c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#EarningsPerShareSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a2caa965-cca3-4df4-af7e-f636692bedef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_41fdf6cd-63b7-490f-a5e7-d86586dce12a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a2caa965-cca3-4df4-af7e-f636692bedef" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_41fdf6cd-63b7-490f-a5e7-d86586dce12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_78a25dc7-c865-4226-8313-bc07b541498e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_41fdf6cd-63b7-490f-a5e7-d86586dce12a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_78a25dc7-c865-4226-8313-bc07b541498e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a355ff4-fd04-4ad6-92d6-959d8de56631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_78a25dc7-c865-4226-8313-bc07b541498e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a355ff4-fd04-4ad6-92d6-959d8de56631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_36defcd3-8dc0-4205-9498-e1eed8222390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a355ff4-fd04-4ad6-92d6-959d8de56631" xlink:to="loc_us-gaap_EmployeeStockOptionMember_36defcd3-8dc0-4205-9498-e1eed8222390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_a113a308-cc31-4ec3-9f30-b7a19527855a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1a355ff4-fd04-4ad6-92d6-959d8de56631" xlink:to="loc_us-gaap_RestrictedStockMember_a113a308-cc31-4ec3-9f30-b7a19527855a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_736911fb-c1e3-4630-b86e-23d72249a1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_41fdf6cd-63b7-490f-a5e7-d86586dce12a" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_736911fb-c1e3-4630-b86e-23d72249a1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_7c3a0464-2424-4a50-85e1-671a3d99f35f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_736911fb-c1e3-4630-b86e-23d72249a1a0" xlink:to="loc_us-gaap_NetIncomeLossAbstract_7c3a0464-2424-4a50-85e1-671a3d99f35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dbffe00e-dbbd-4150-abc8-164a8de28059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_7c3a0464-2424-4a50-85e1-671a3d99f35f" xlink:to="loc_us-gaap_NetIncomeLoss_dbffe00e-dbbd-4150-abc8-164a8de28059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_e51bfe12-92d1-4d1c-a050-0a795b412d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_7c3a0464-2424-4a50-85e1-671a3d99f35f" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_e51bfe12-92d1-4d1c-a050-0a795b412d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_24aa5469-b152-4865-a1c5-2ace49668a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_7c3a0464-2424-4a50-85e1-671a3d99f35f" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_24aa5469-b152-4865-a1c5-2ace49668a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ebc15ae2-0697-4741-b473-a4f0b923a275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_736911fb-c1e3-4630-b86e-23d72249a1a0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ebc15ae2-0697-4741-b473-a4f0b923a275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bf0ab9b6-685b-4bd6-8e2a-c057d56269e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ebc15ae2-0697-4741-b473-a4f0b923a275" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bf0ab9b6-685b-4bd6-8e2a-c057d56269e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fa91eb05-09f7-4363-aed0-836da0d85acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ebc15ae2-0697-4741-b473-a4f0b923a275" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fa91eb05-09f7-4363-aed0-836da0d85acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a0741e24-4387-4dda-bb27-60ad4404b726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_736911fb-c1e3-4630-b86e-23d72249a1a0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a0741e24-4387-4dda-bb27-60ad4404b726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6f0f0a41-d524-438e-9bae-0a90da05c78f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a0741e24-4387-4dda-bb27-60ad4404b726" xlink:to="loc_us-gaap_EarningsPerShareBasic_6f0f0a41-d524-438e-9bae-0a90da05c78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_044af1b6-de33-472b-9575-a07157099257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a0741e24-4387-4dda-bb27-60ad4404b726" xlink:to="loc_us-gaap_EarningsPerShareDiluted_044af1b6-de33-472b-9575-a07157099257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f112d335-544e-46b0-b088-5fed5f91279b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_736911fb-c1e3-4630-b86e-23d72249a1a0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f112d335-544e-46b0-b088-5fed5f91279b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilities" xlink:type="simple" xlink:href="sgry-20220331.xsd#OtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_585a8d2f-3658-44d2-a3e9-031b58f26008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_23eaf181-ba20-4ab8-ad0e-e75576a8a534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_585a8d2f-3658-44d2-a3e9-031b58f26008" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_23eaf181-ba20-4ab8-ad0e-e75576a8a534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="sgry-20220331.xsd#OtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_4e2773e3-77b4-4b3a-ac61-aa59becb62c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_bffb8e66-2375-41dd-8717-b7c38b504b89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_4e2773e3-77b4-4b3a-ac61-aa59becb62c2" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_bffb8e66-2375-41dd-8717-b7c38b504b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#OtherCurrentLiabilitiesSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_8d6239ce-0ec2-48c0-9606-75199069f6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8b1042b0-69ac-430b-af3b-66b8528c7568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_8d6239ce-0ec2-48c0-9606-75199069f6e9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8b1042b0-69ac-430b-af3b-66b8528c7568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_cfd0e033-4150-4288-9bcc-08fd2f83c9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_8d6239ce-0ec2-48c0-9606-75199069f6e9" xlink:to="loc_us-gaap_InterestPayableCurrent_cfd0e033-4150-4288-9bcc-08fd2f83c9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PayablesToCustomers_13877cfa-a1b4-4d73-94d4-a7965bf5a196" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_PayablesToCustomers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_8d6239ce-0ec2-48c0-9606-75199069f6e9" xlink:to="loc_srt_PayablesToCustomers_13877cfa-a1b4-4d73-94d4-a7965bf5a196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CostReportLiabilitiesCurrent_b6e6140e-9cca-4924-bfb4-6e0bb57f76a1" xlink:href="sgry-20220331.xsd#sgry_CostReportLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_8d6239ce-0ec2-48c0-9606-75199069f6e9" xlink:to="loc_sgry_CostReportLiabilitiesCurrent_b6e6140e-9cca-4924-bfb4-6e0bb57f76a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TaxReceivableAgreementLiabilityCurrent_b8046ad6-36e1-4477-9263-3429ecfa76ec" xlink:href="sgry-20220331.xsd#sgry_TaxReceivableAgreementLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_8d6239ce-0ec2-48c0-9606-75199069f6e9" xlink:to="loc_sgry_TaxReceivableAgreementLiabilityCurrent_b8046ad6-36e1-4477-9263-3429ecfa76ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_96fb33f7-6e04-4524-9ed4-a4f07a384355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_8d6239ce-0ec2-48c0-9606-75199069f6e9" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_96fb33f7-6e04-4524-9ed4-a4f07a384355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_60cca6bb-5107-4b6c-881d-0b77b9fad3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_8d6239ce-0ec2-48c0-9606-75199069f6e9" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_60cca6bb-5107-4b6c-881d-0b77b9fad3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="sgry-20220331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ab4b1302-0789-4286-89f9-72e35b98b69c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b4ae5fab-c519-49fd-b48b-e92d4bf1732d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ab4b1302-0789-4286-89f9-72e35b98b69c" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b4ae5fab-c519-49fd-b48b-e92d4bf1732d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_919403db-d979-4321-b336-04217281b4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_367b9085-ffae-48a3-a1de-b15db4ebb900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGuaranteeObligationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_919403db-d979-4321-b336-04217281b4c8" xlink:to="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_367b9085-ffae-48a3-a1de-b15db4ebb900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_363753e5-f10b-46cd-81c5-736a99eb36f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_367b9085-ffae-48a3-a1de-b15db4ebb900" xlink:to="loc_us-gaap_VariableRateAxis_363753e5-f10b-46cd-81c5-736a99eb36f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b8e1a86e-69ba-40fd-92bc-ec25d79e1d46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_363753e5-f10b-46cd-81c5-736a99eb36f9" xlink:to="loc_us-gaap_VariableRateDomain_b8e1a86e-69ba-40fd-92bc-ec25d79e1d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_c9daf3e9-4922-4c65-8a17-b30bb4943a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_b8e1a86e-69ba-40fd-92bc-ec25d79e1d46" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_c9daf3e9-4922-4c65-8a17-b30bb4943a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_41da6d8c-221f-4e2d-8aa8-61acb633585f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_b8e1a86e-69ba-40fd-92bc-ec25d79e1d46" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_41da6d8c-221f-4e2d-8aa8-61acb633585f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyByNatureAxis_136bb0a4-ac57-4bd4-8514-f37f6ed7aca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyByNatureAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_367b9085-ffae-48a3-a1de-b15db4ebb900" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyByNatureAxis_136bb0a4-ac57-4bd4-8514-f37f6ed7aca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain_257c62d7-b9c5-4d2b-bb16-b9015b74c68d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyByNatureAxis_136bb0a4-ac57-4bd4-8514-f37f6ed7aca2" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain_257c62d7-b9c5-4d2b-bb16-b9015b74c68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_MateriallyMoreRestrictiveMember_1194bdaa-3410-42a8-b70a-08ea7d0f32a5" xlink:href="sgry-20220331.xsd#sgry_MateriallyMoreRestrictiveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain_257c62d7-b9c5-4d2b-bb16-b9015b74c68d" xlink:to="loc_sgry_MateriallyMoreRestrictiveMember_1194bdaa-3410-42a8-b70a-08ea7d0f32a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NotMateriallyMoreRestrictiveMember_d20e0728-8c45-49e3-8a18-2b6b99b3adca" xlink:href="sgry-20220331.xsd#sgry_NotMateriallyMoreRestrictiveMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain_257c62d7-b9c5-4d2b-bb16-b9015b74c68d" xlink:to="loc_sgry_NotMateriallyMoreRestrictiveMember_d20e0728-8c45-49e3-8a18-2b6b99b3adca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsLineItems_a1d8281e-b243-4869-80ff-3a4d1134e3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_367b9085-ffae-48a3-a1de-b15db4ebb900" xlink:to="loc_us-gaap_GuaranteeObligationsLineItems_a1d8281e-b243-4869-80ff-3a4d1134e3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserve_794c20cd-ae07-48c6-81f6-333a57cd7aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SelfInsuranceReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_a1d8281e-b243-4869-80ff-3a4d1134e3c7" xlink:to="loc_us-gaap_SelfInsuranceReserve_794c20cd-ae07-48c6-81f6-333a57cd7aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimatedInsuranceRecoveries_e6c54a55-66bb-4cfd-8d18-afd8fad7adac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimatedInsuranceRecoveries"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_a1d8281e-b243-4869-80ff-3a4d1134e3c7" xlink:to="loc_us-gaap_EstimatedInsuranceRecoveries_e6c54a55-66bb-4cfd-8d18-afd8fad7adac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_f0b0de3b-de4b-4db3-9c99-6bcd21f9b43a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_a1d8281e-b243-4869-80ff-3a4d1134e3c7" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_f0b0de3b-de4b-4db3-9c99-6bcd21f9b43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b9640611-0967-438c-82bd-44497c506e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_a1d8281e-b243-4869-80ff-3a4d1134e3c7" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b9640611-0967-438c-82bd-44497c506e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm_290928ae-62aa-4fba-88f6-fc43679d8cc2" xlink:href="sgry-20220331.xsd#sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_a1d8281e-b243-4869-80ff-3a4d1134e3c7" xlink:to="loc_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm_290928ae-62aa-4fba-88f6-fc43679d8cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6c2e946f-5513-4091-a2ad-3b1444f81452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_a1d8281e-b243-4869-80ff-3a4d1134e3c7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6c2e946f-5513-4091-a2ad-3b1444f81452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate_3d507ca6-131e-440a-a563-1ddddc59beac" xlink:href="sgry-20220331.xsd#sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_a1d8281e-b243-4869-80ff-3a4d1134e3c7" xlink:to="loc_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate_3d507ca6-131e-440a-a563-1ddddc59beac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrentAndNoncurrent_e5814bd4-7d03-4c76-9eab-8a0f716dd0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_a1d8281e-b243-4869-80ff-3a4d1134e3c7" xlink:to="loc_us-gaap_TaxesPayableCurrentAndNoncurrent_e5814bd4-7d03-4c76-9eab-8a0f716dd0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount_1e9511d5-8329-4f95-b035-4b76efdb1808" xlink:href="sgry-20220331.xsd#sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_a1d8281e-b243-4869-80ff-3a4d1134e3c7" xlink:to="loc_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount_1e9511d5-8329-4f95-b035-4b76efdb1808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReporting" xlink:type="simple" xlink:href="sgry-20220331.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3f2ed1f0-e8b4-4eaa-9423-ead737f08ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_83eb2b98-809a-4d68-a992-f1720461b318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3f2ed1f0-e8b4-4eaa-9423-ead737f08ca4" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_83eb2b98-809a-4d68-a992-f1720461b318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="sgry-20220331.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7e1fcf14-0a1b-4709-9532-929f00ad44c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_b7c6117f-9018-4f4c-84e2-69ecbce5e354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7e1fcf14-0a1b-4709-9532-929f00ad44c8" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_b7c6117f-9018-4f4c-84e2-69ecbce5e354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_9bef9d2e-e823-45b8-97e9-11458643232c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7e1fcf14-0a1b-4709-9532-929f00ad44c8" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_9bef9d2e-e823-45b8-97e9-11458643232c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_993f2c19-bdca-468a-8b4d-48923c4cb9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7e1fcf14-0a1b-4709-9532-929f00ad44c8" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_993f2c19-bdca-468a-8b4d-48923c4cb9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5da18a8a-5acd-47d4-b696-6b43af8197ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_701bc629-6922-4390-a4ee-2733783ad683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5da18a8a-5acd-47d4-b696-6b43af8197ca" xlink:to="loc_us-gaap_NumberOfOperatingSegments_701bc629-6922-4390-a4ee-2733783ad683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8e80c872-a9e4-48d5-8420-e0dad523af01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5da18a8a-5acd-47d4-b696-6b43af8197ca" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8e80c872-a9e4-48d5-8420-e0dad523af01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_a8b7f75f-d535-468f-819f-0ad4be5cc8d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8e80c872-a9e4-48d5-8420-e0dad523af01" xlink:to="loc_srt_ConsolidationItemsAxis_a8b7f75f-d535-468f-819f-0ad4be5cc8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_015c7dda-01a7-43da-b70e-e23a73290b15" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_a8b7f75f-d535-468f-819f-0ad4be5cc8d7" xlink:to="loc_srt_ConsolidationItemsDomain_015c7dda-01a7-43da-b70e-e23a73290b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_d66af5b2-de8e-4c6c-8455-5093a920c3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_015c7dda-01a7-43da-b70e-e23a73290b15" xlink:to="loc_us-gaap_OperatingSegmentsMember_d66af5b2-de8e-4c6c-8455-5093a920c3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_8cd6a9cf-d10a-443d-a7b4-ff1dff29e692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_015c7dda-01a7-43da-b70e-e23a73290b15" xlink:to="loc_us-gaap_CorporateNonSegmentMember_8cd6a9cf-d10a-443d-a7b4-ff1dff29e692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e8329fee-9827-49b7-a2d9-44d118fac942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8e80c872-a9e4-48d5-8420-e0dad523af01" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e8329fee-9827-49b7-a2d9-44d118fac942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_30c93935-57dc-4bb6-a51f-bef9a1438c44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e8329fee-9827-49b7-a2d9-44d118fac942" xlink:to="loc_us-gaap_SegmentDomain_30c93935-57dc-4bb6-a51f-bef9a1438c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityServicesMember_bb04b840-2351-49ed-b0c7-357de7394fe1" xlink:href="sgry-20220331.xsd#sgry_SurgicalFacilityServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_30c93935-57dc-4bb6-a51f-bef9a1438c44" xlink:to="loc_sgry_SurgicalFacilityServicesMember_bb04b840-2351-49ed-b0c7-357de7394fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AncillaryServicesMember_a9fb144a-c644-4749-ab0f-40c4d4cc7117" xlink:href="sgry-20220331.xsd#sgry_AncillaryServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_30c93935-57dc-4bb6-a51f-bef9a1438c44" xlink:to="loc_sgry_AncillaryServicesMember_a9fb144a-c644-4749-ab0f-40c4d4cc7117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_502ad5bb-0a58-4f50-b5f2-f30a62e1aed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8e80c872-a9e4-48d5-8420-e0dad523af01" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_502ad5bb-0a58-4f50-b5f2-f30a62e1aed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_04fc7ec1-45b1-4e7d-ab04-c38d1bdbc2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_502ad5bb-0a58-4f50-b5f2-f30a62e1aed5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_04fc7ec1-45b1-4e7d-ab04-c38d1bdbc2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_ec6244a5-d110-420c-8f54-e1796b955d95" xlink:href="sgry-20220331.xsd#sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_502ad5bb-0a58-4f50-b5f2-f30a62e1aed5" xlink:to="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_ec6244a5-d110-420c-8f54-e1796b955d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_502ad5bb-0a58-4f50-b5f2-f30a62e1aed5" xlink:to="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_96182594-812c-45f9-8924-85b607622211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_96182594-812c-45f9-8924-85b607622211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_47f0393d-cd6d-4616-8090-5804179df996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_47f0393d-cd6d-4616-8090-5804179df996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3a24fb74-4069-49d3-8499-48ef78d5e647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3a24fb74-4069-49d3-8499-48ef78d5e647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_50b023f2-91f6-497a-bebd-0c7300f7301b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_50b023f2-91f6-497a-bebd-0c7300f7301b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_95cdf2e0-750b-4b90-afbb-809868509355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_us-gaap_ShareBasedCompensation_95cdf2e0-750b-4b90-afbb-809868509355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts_2504b30c-1dbd-40c3-a2e5-c1e5fa28dff7" xlink:href="sgry-20220331.xsd#sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts_2504b30c-1dbd-40c3-a2e5-c1e5fa28dff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_3bf62bd5-a4d5-4e91-b4f7-13c91953362d" xlink:href="sgry-20220331.xsd#sgry_GainLossOnDispositionOfAssetsAndDeconsolidation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_3bf62bd5-a4d5-4e91-b4f7-13c91953362d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts_64b73d45-d6fe-4264-a88a-a3b6d3f9a3ea" xlink:href="sgry-20220331.xsd#sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts_64b73d45-d6fe-4264-a88a-a3b6d3f9a3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_60b08c1b-4d85-4d71-88d9-316fa6b97fac" xlink:href="sgry-20220331.xsd#sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_60b08c1b-4d85-4d71-88d9-316fa6b97fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_a125c683-854e-4e86-832d-6d363cbb4eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_a125c683-854e-4e86-832d-6d363cbb4eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_212543ee-c231-4445-95d3-b16ec207895d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_212543ee-c231-4445-95d3-b16ec207895d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_dc0b1b16-366a-4745-80ec-ba6e8df0d952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_us-gaap_LitigationSettlementExpense_dc0b1b16-366a-4745-80ec-ba6e8df0d952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_b27ddc1c-03c6-4250-b997-4cabc1153feb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_bdc77c3d-72db-4951-b8a0-cc3e95bbdd59" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_b27ddc1c-03c6-4250-b997-4cabc1153feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c7af3f33-4ea2-4f76-8937-359ebfad7d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9c4700f8-87f9-4db3-ab53-2364bcee60b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c7af3f33-4ea2-4f76-8937-359ebfad7d67" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9c4700f8-87f9-4db3-ab53-2364bcee60b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_0153fb9c-31ac-458c-89e0-17eead0c565e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9c4700f8-87f9-4db3-ab53-2364bcee60b1" xlink:to="loc_srt_ConsolidationItemsAxis_0153fb9c-31ac-458c-89e0-17eead0c565e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_00662626-afb9-407b-bea8-5a32e11ca2ea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_0153fb9c-31ac-458c-89e0-17eead0c565e" xlink:to="loc_srt_ConsolidationItemsDomain_00662626-afb9-407b-bea8-5a32e11ca2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_1f06d9a5-c790-4303-900f-ef175364aa7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_00662626-afb9-407b-bea8-5a32e11ca2ea" xlink:to="loc_us-gaap_OperatingSegmentsMember_1f06d9a5-c790-4303-900f-ef175364aa7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_4c8dd543-94a9-463e-9223-70cc204081bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_00662626-afb9-407b-bea8-5a32e11ca2ea" xlink:to="loc_us-gaap_CorporateNonSegmentMember_4c8dd543-94a9-463e-9223-70cc204081bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_53c618da-0b7b-4d16-90e8-28ae482708c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9c4700f8-87f9-4db3-ab53-2364bcee60b1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_53c618da-0b7b-4d16-90e8-28ae482708c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d076f652-0c09-4d49-b707-9b971701eb54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_53c618da-0b7b-4d16-90e8-28ae482708c9" xlink:to="loc_us-gaap_SegmentDomain_d076f652-0c09-4d49-b707-9b971701eb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityServicesMember_532a9c23-9d13-48bb-8bc7-9822b6eee009" xlink:href="sgry-20220331.xsd#sgry_SurgicalFacilityServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d076f652-0c09-4d49-b707-9b971701eb54" xlink:to="loc_sgry_SurgicalFacilityServicesMember_532a9c23-9d13-48bb-8bc7-9822b6eee009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AncillaryServicesMember_d696bb31-9f0c-44f7-aa24-1c3a4aea0223" xlink:href="sgry-20220331.xsd#sgry_AncillaryServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d076f652-0c09-4d49-b707-9b971701eb54" xlink:to="loc_sgry_AncillaryServicesMember_d696bb31-9f0c-44f7-aa24-1c3a4aea0223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_75aad57b-b855-4bba-82c5-343a473010dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9c4700f8-87f9-4db3-ab53-2364bcee60b1" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_75aad57b-b855-4bba-82c5-343a473010dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f200ab18-9036-456b-8a26-6e26d2c5e19c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_75aad57b-b855-4bba-82c5-343a473010dd" xlink:to="loc_us-gaap_Assets_f200ab18-9036-456b-8a26-6e26d2c5e19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f91365d4-fe02-4f84-a274-9686580adc8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_75aad57b-b855-4bba-82c5-343a473010dd" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f91365d4-fe02-4f84-a274-9686580adc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SubsequentEvents" xlink:type="simple" xlink:href="sgry-20220331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_624a26da-23ab-406f-bd3f-0ed4b6d1e852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_c1ae8fe2-cbd7-4a38-9c73-15df0ef2d737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_624a26da-23ab-406f-bd3f-0ed4b6d1e852" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_c1ae8fe2-cbd7-4a38-9c73-15df0ef2d737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="sgry-20220331.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_fc94b3fd-c801-427a-b6bd-a532d58458e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_e2898aa7-eb57-429c-9502-1ad05ce5d8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_fc94b3fd-c801-427a-b6bd-a532d58458e1" xlink:to="loc_us-gaap_SubsequentEventTable_e2898aa7-eb57-429c-9502-1ad05ce5d8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_195692c9-2926-4f9b-9602-8033ffc4cc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e2898aa7-eb57-429c-9502-1ad05ce5d8fe" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_195692c9-2926-4f9b-9602-8033ffc4cc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0aecf960-d62b-40a0-9db6-3c325e8ff1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_195692c9-2926-4f9b-9602-8033ffc4cc3b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0aecf960-d62b-40a0-9db6-3c325e8ff1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_1f09e637-5c2d-4798-85e1-76e8e3750fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0aecf960-d62b-40a0-9db6-3c325e8ff1e3" xlink:to="loc_us-gaap_SubsequentEventMember_1f09e637-5c2d-4798-85e1-76e8e3750fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_445c0956-f1bd-45b5-9008-2a2589ac3827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e2898aa7-eb57-429c-9502-1ad05ce5d8fe" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_445c0956-f1bd-45b5-9008-2a2589ac3827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4d215a2f-e7a1-4454-a06e-2af05a628c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_445c0956-f1bd-45b5-9008-2a2589ac3827" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4d215a2f-e7a1-4454-a06e-2af05a628c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember_43d476c9-19c9-43a9-9afb-fdb3ca48fb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4d215a2f-e7a1-4454-a06e-2af05a628c09" xlink:to="loc_us-gaap_EquityMethodInvestmentsMember_43d476c9-19c9-43a9-9afb-fdb3ca48fb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_56f42b35-9501-4b6e-bb6c-5b759554c5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e2898aa7-eb57-429c-9502-1ad05ce5d8fe" xlink:to="loc_us-gaap_SubsequentEventLineItems_56f42b35-9501-4b6e-bb6c-5b759554c5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired_6b45509e-35ea-47ee-b3c9-0a3ab487cd64" xlink:href="sgry-20220331.xsd#sgry_NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_56f42b35-9501-4b6e-bb6c-5b759554c5d1" xlink:to="loc_sgry_NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired_6b45509e-35ea-47ee-b3c9-0a3ab487cd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired_9dd86cac-bb19-402b-a545-4b0b3eac21a2" xlink:href="sgry-20220331.xsd#sgry_NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_56f42b35-9501-4b6e-bb6c-5b759554c5d1" xlink:to="loc_sgry_NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired_9dd86cac-bb19-402b-a545-4b0b3eac21a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_597605c7-2613-4f8c-a8b4-f0caea0b1961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_56f42b35-9501-4b6e-bb6c-5b759554c5d1" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_597605c7-2613-4f8c-a8b4-f0caea0b1961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331706270648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 26, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Surgery Partners, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3620923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">310 Seven Springs Way, Suite&#160;500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brentwood<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">234-5900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SGRY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,904,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001638833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331705270184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 378.9<span></span>
</td>
<td class="nump">$ 389.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">412.4<span></span>
</td>
<td class="nump">430.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">62.9<span></span>
</td>
<td class="nump">61.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">32.2<span></span>
</td>
<td class="nump">25.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">50.6<span></span>
</td>
<td class="nump">39.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">937.0<span></span>
</td>
<td class="nump">946.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net of accumulated depreciation of $294.6 and $272.3, respectively</a></td>
<td class="nump">778.9<span></span>
</td>
<td class="nump">629.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and other intangible assets, net</a></td>
<td class="nump">3,967.8<span></span>
</td>
<td class="nump">3,955.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in and advances to affiliates</a></td>
<td class="nump">94.5<span></span>
</td>
<td class="nump">88.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use operating lease assets</a></td>
<td class="nump">277.4<span></span>
</td>
<td class="nump">324.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Long-term deferred tax assets</a></td>
<td class="nump">113.9<span></span>
</td>
<td class="nump">114.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">120.0<span></span>
</td>
<td class="nump">59.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">6,289.5<span></span>
</td>
<td class="nump">6,117.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">122.9<span></span>
</td>
<td class="nump">124.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and benefits</a></td>
<td class="nump">83.8<span></span>
</td>
<td class="nump">77.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent', window );">Medicare accelerated payments and deferred governmental grants</a></td>
<td class="nump">46.5<span></span>
</td>
<td class="nump">64.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">221.1<span></span>
</td>
<td class="nump">210.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current maturities of long-term debt</a></td>
<td class="nump">68.0<span></span>
</td>
<td class="nump">60.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">542.3<span></span>
</td>
<td class="nump">536.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt, less current maturities</a></td>
<td class="nump">3,025.2<span></span>
</td>
<td class="nump">2,878.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Right-of-use operating lease liabilities</a></td>
<td class="nump">272.1<span></span>
</td>
<td class="nump">315.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">95.8<span></span>
</td>
<td class="nump">87.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Non-controlling interests&#8212;redeemable</a></td>
<td class="nump">341.5<span></span>
</td>
<td class="nump">330.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value; shares authorized - 20,310,000; shares issued or outstanding - none</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.01 par value; shares authorized - 300,000,000; shares issued and outstanding - 89,904,913 and 89,332,557, respectively</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,625.2<span></span>
</td>
<td class="nump">1,622.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">25.3<span></span>
</td>
<td class="num">(31.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained deficit</a></td>
<td class="num">(490.5)<span></span>
</td>
<td class="num">(502.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Surgery Partners, Inc. stockholders' equity</a></td>
<td class="nump">1,160.9<span></span>
</td>
<td class="nump">1,089.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests&#8212;non-redeemable</a></td>
<td class="nump">851.7<span></span>
</td>
<td class="nump">880.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">2,012.6<span></span>
</td>
<td class="nump">1,969.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 6,289.5<span></span>
</td>
<td class="nump">$ 6,117.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medicare Accelerated Payments And Deferred Governmental Grants, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331705255592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Accumulated depreciation on property and equipment</a></td>
<td class="nump">$ 294.6<span></span>
</td>
<td class="nump">$ 272.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (shares)</a></td>
<td class="nump">20,310,000<span></span>
</td>
<td class="nump">20,310,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (shares)</a></td>
<td class="nump">89,904,913<span></span>
</td>
<td class="nump">89,332,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (shares)</a></td>
<td class="nump">89,904,913<span></span>
</td>
<td class="nump">89,332,557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331703918520">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 596.2<span></span>
</td>
<td class="nump">$ 512.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">178.9<span></span>
</td>
<td class="nump">151.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supplies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">171.6<span></span>
</td>
<td class="nump">147.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional and medical fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">63.6<span></span>
</td>
<td class="nump">55.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_OperatingAndFinanceLeaseExpense', window );">Lease expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">22.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37.3<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Cost of revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">471.4<span></span>
</td>
<td class="nump">408.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29.5<span></span>
</td>
<td class="nump">26.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27.4<span></span>
</td>
<td class="nump">25.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Transaction and integration costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7.1<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_GrantRevenue', window );">Grant funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(15.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation', window );">Gain on disposals and deconsolidations, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of unconsolidated affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3.1)<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation settlement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(32.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonrecurringIncomeExpense', window );">Other income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">495.8<span></span>
</td>
<td class="nump">448.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100.4<span></span>
</td>
<td class="nump">64.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(56.3)<span></span>
</td>
<td class="num">(53.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Income before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44.1<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1.3)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42.8<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net income attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(30.6)<span></span>
</td>
<td class="num">(31.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Surgery Partners, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12.2<span></span>
</td>
<td class="num">(21.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Less: Amounts attributable to participating securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(10.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to common stockholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 12.2<span></span>
</td>
<td class="num">$ (31.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net income (loss) per share attributable to common stockholders</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in USD per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in USD per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average common shares outstanding</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">87,995<span></span>
</td>
<td class="nump">54,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">90,272<span></span>
</td>
<td class="nump">54,773<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The impact of potentially dilutive securities for the three months ended March 31, 2021 was not considered because the effect would be anti-dilutive.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Disposition of Assets And Deconsolidation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_GainLossOnDispositionOfAssetsAndDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_GrantRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_GrantRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_OperatingAndFinanceLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_OperatingAndFinanceLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonrecurringIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) that is infrequent in occurrence or unusual in nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=114868883&amp;loc=SL114871943-224233<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonrecurringIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2793-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331705257464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 42.8<span></span>
</td>
<td class="nump">$ 10.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Derivative activity</a></td>
<td class="nump">56.8<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">99.6<span></span>
</td>
<td class="nump">17.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Comprehensive income attributable to non-controlling interests</a></td>
<td class="num">(30.6)<span></span>
</td>
<td class="num">(31.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to Surgery Partners, Inc.</a></td>
<td class="nump">$ 69.0<span></span>
</td>
<td class="num">$ (14.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331701395496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Retained Deficit</div></th>
<th class="th"><div>Non-Controlling Interests&#8212; Non-Redeemable</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, stockholders' equity (shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,462,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance, stockholders' equity at Dec. 31, 2020</a></td>
<td class="nump">$ 882.1<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 607.9<span></span>
</td>
<td class="num">$ (61.0)<span></span>
</td>
<td class="num">$ (431.8)<span></span>
</td>
<td class="nump">$ 766.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net (loss) income</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21.0)<span></span>
</td>
<td class="nump">21.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Equity-based compensation (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">812,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="num">(2.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings', window );">Preferred dividends</a></td>
<td class="num">(10.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Equity offering (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Equity offering</a></td>
<td class="nump">248.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">248.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Other comprehensive income</a></td>
<td class="nump">6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet', window );">Acquisition and disposal of shares of non-controlling interests, net</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions to non-controlling interests&#8212;non-redeemable holders</a></td>
<td class="num">(20.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20.8)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, stockholders' equity (shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,899,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance, stockholders' equity at Mar. 31, 2021</a></td>
<td class="nump">$ 1,105.3<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">843.3<span></span>
</td>
<td class="num">(54.6)<span></span>
</td>
<td class="num">(452.8)<span></span>
</td>
<td class="nump">768.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, stockholders' equity (shares) at Dec. 31, 2021</a></td>
<td class="nump">89,332,557<span></span>
</td>
<td class="nump">89,333,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance, stockholders' equity at Dec. 31, 2021</a></td>
<td class="nump">$ 1,969.6<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">1,622.3<span></span>
</td>
<td class="num">(31.5)<span></span>
</td>
<td class="num">(502.7)<span></span>
</td>
<td class="nump">880.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net (loss) income</a></td>
<td class="nump">32.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Equity-based compensation (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">572,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Other comprehensive income</a></td>
<td class="nump">56.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet', window );">Acquisition and disposal of shares of non-controlling interests, net</a></td>
<td class="num">(29.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions to non-controlling interests&#8212;non-redeemable holders</a></td>
<td class="num">$ (24.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24.6)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, stockholders' equity (shares) at Mar. 31, 2022</a></td>
<td class="nump">89,904,913<span></span>
</td>
<td class="nump">89,905,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance, stockholders' equity at Mar. 31, 2022</a></td>
<td class="nump">$ 2,012.6<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 1,625.2<span></span>
</td>
<td class="nump">$ 25.3<span></span>
</td>
<td class="num">$ (490.5)<span></span>
</td>
<td class="nump">$ 851.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Controlling Interest, Acquisitions And Disposals Of Interests Held By Non-Controlling Interest Holders, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331706330232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 42.8<span></span>
</td>
<td class="nump">$ 10.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">27.4<span></span>
</td>
<td class="nump">25.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_NoncashInterestIncomeExpenseNet', window );">Non-cash interest expense, net</a></td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation', window );">Gain on disposals and deconsolidations, net</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Equity in earnings of unconsolidated affiliates, net of distributions received</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">8.6<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants', window );">Medicare accelerated payments and deferred governmental grants</a></td>
<td class="num">(18.0)<span></span>
</td>
<td class="num">(7.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other operating assets and liabilities</a></td>
<td class="nump">7.2<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">79.8<span></span>
</td>
<td class="nump">50.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(18.2)<span></span>
</td>
<td class="num">(14.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments for acquisitions, net of cash acquired</a></td>
<td class="num">(31.1)<span></span>
</td>
<td class="num">(2.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from disposals of facilities and other assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sales of equity investments</a></td>
<td class="nump">11.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities</a></td>
<td class="num">(9.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(47.1)<span></span>
</td>
<td class="num">(14.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments on long-term debt</a></td>
<td class="num">(17.0)<span></span>
</td>
<td class="num">(16.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Borrowings of long-term debt</a></td>
<td class="nump">11.9<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from equity offering</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">260.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of equity offering costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(12.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock', window );">Payment of preferred dividends</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsMinorityInterest', window );">Distributions to non-controlling interest holders</a></td>
<td class="num">(36.2)<span></span>
</td>
<td class="num">(31.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">(Payments) receipts related to ownership transactions with non-controlling interest holders</a></td>
<td class="num">(3.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">(Payments) receipts related to ownership transactions with non-controlling interest holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(43.7)<span></span>
</td>
<td class="nump">187.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(11.0)<span></span>
</td>
<td class="nump">223.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">389.9<span></span>
</td>
<td class="nump">318.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 378.9<span></span>
</td>
<td class="nump">$ 541.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Disposition of Assets And Deconsolidation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_GainLossOnDispositionOfAssetsAndDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Medicare Accelerated Payments And Deferred Governmental Grants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_NoncashInterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Interest Income (Expense), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_NoncashInterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsMinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsMinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331706701976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Accounting Policies</a></td>
<td class="text">Organization and Summary of Accounting Policies<div style="margin-bottom:6pt;margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Surgery Partners, Inc., a Delaware corporation, acting through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. The surgical facilities, which include ambulatory surgery centers ("ASCs") and surgical hospitals, primarily provide non-emergency surgical procedures across many specialties, including, among others, gastroenterology, general surgery, ophthalmology, orthopedics and pain management. The Company's surgical hospitals also provide services such as diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy and wound care. Ancillary services are comprised of multi-specialty physician practices, urgent care facilities and anesthesia services. Unless the context otherwise indicates, Surgery Partners, Inc. and its subsidiaries are referred to herein as "Surgery Partners," "we," "us," "our" or the "Company."</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company owned or operated a portfolio of 127 surgical facilities, comprised of 109 ASCs and 18 surgical hospitals in 31 states. The Company owns these facilities in partnership with physicians and, in some cases, health care systems in the markets and communities it serves.&#160;The Company owned a majority interest in 85 of the surgical facilities and consolidated 108 of the facilities for financial reporting purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation of the Company's financial position and results of operations have been included. The Company&#8217;s fiscal year ends on December&#160;31 and interim results are not necessarily indicative of results for a full year or any other interim period. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company&#8217;s consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021 (the "2021 Annual Report on Form 10-K").</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. Actual results could differ from those estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The COVID-19 pandemic has significantly affected the Company's facilities, employees, patients, communities, business operations and financial performance, as well as the United States economy and financial markets. The impact of the COVID-19 pandemic on the Company's surgical facilities varies based on the market in which the facility operates, the type of surgical facility and the procedures that are typically performed. The Company cannot provide any certainty regarding the length and severity of the impact of the COVID-19 pandemic on its business operations and financial performance. As a result of the COVID-19 pandemic, the Company has implemented new clinical safety measures to provide a safe environment for its patients, surgeons and employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CARES Act </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the &#8220;CARES Act&#8221;) was signed into law to provide stimulus funding for the United States economy. As part of the CARES Act, the United States government announced that it would offer relief to eligible health care providers, including distribution of direct grants to hospitals, ASCs and other health care providers based on how much they bill Medicare. Payments received from these grants are not required to be repaid provided the recipients attest to and comply with certain terms and conditions, including limitations on balance billing and not using funds received from the grants to reimburse expenses or losses that other sources are obligated to reimburse. The Company has received approximately $87&#160;million of the grant funds distributed under the CARES Act and other governmental assistance programs, including approximately $1&#160;million during the three months ended March&#160;31, 2022. The recognition of amounts received is conditioned upon attestation with terms and conditions that funds will be used for COVID-19 related healthcare expenses or lost revenues.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company&#8217;s assessment of whether the terms and conditions for amounts received are reasonably assured of having been met considers, among other things, the CARES Act, the COVID-19 Economic Relief Bill, enacted on December 27, 2020, and all frequently asked questions and other interpretive guidance issued by the United States Department of Health and Human Services ("HHS"), including in the Provider Relief Fund Reporting Portal and associated user guides. This guidance sets forth the allowable methods for quantifying </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">eligible healthcare related expenses and lost revenues. Only healthcare related expenses attributable to COVID-19 that another source has not reimbursed and is not obligated to reimburse are eligible to be claimed. Based on guidance, the Company estimates approximately $1.2 million and $15.1 million of grant funds received qualified for recognition as a reduction in operating expenses for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amounts received, but not recognized as a reduction to operating expenses, are reflected as a component of Medicare accelerated payments and deferred governmental grants in the condensed consolidated balance sheets as of both March&#160;31, 2022 and December 31, 2021. Any unrecognized amounts may be recognized as a reduction in operating expenses in subsequent periods if the underlying conditions for recognition are met. Additional guidance or new and amended interpretations of existing guidance on the terms and conditions of such payments may result in the Company&#8217;s inability to recognize certain payments, changes in the estimate of amounts recognized, or the derecognition of amounts previously recognized, which may be material.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As a way to increase cash flow to Medicare providers impacted by the COVID-19 pandemic, the CARES Act expanded the Medicare Accelerated and Advance Payment Program, which allowed for most providers and suppliers, including the Company&#8217;s surgical hospitals and ASCs to request an advance payment of anticipated Medicare revenues. The Company received approximately $120&#160;million of accelerated payments during the year ended December 31, 2020. The payments received were deferred and included in the condensed consolidated balance sheets. During the three months ended March 31, 2022, approximately $18&#160;million has been repaid in accordance with the terms of the program. These repayments are included as a component of the change in Medicare accelerated payments and deferred government grants in the condensed consolidated statements of cash flows. Under these terms, repayment started one year after the initial funding by offsetting 25% of new claims paid by CMS. After 11 months of repayment at this level, the repayments will increase to 50% of new claims paid by CMS for a period of six months. Any outstanding amounts due at the end of the repayment period are subject to interest at a rate of 4%. As of March 31, 2022 and December 31, 2021, the remaining deferred accelerated payments was approximately $42&#160;million and $60&#160;million, respectively, which was included as a component of Medicare accelerated payments and deferred governmental grants in the condensed consolidated balance sheets. The Company does not expect to receive additional Medicare accelerated payments. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The CARES Act also provided for the deferral of the Company's portion of social security payroll taxes during 2020. Under the CARES Act, half of the deferred amount was paid in December 2021 and the remaining portion will be paid in December 2022. As of both March&#160;31, 2022 and December 31, 2021, the Company had deferred approximately $8.5&#160;million, which was included as a component of accrued payroll and benefits in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is continuing to closely monitor legislative actions and regulatory guidance at the federal, state and local levels with respect to the CARES Act as other governmental assistance might become available to the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification 810, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">". The Company has the power to direct the activities that most significantly impact a VIE's economic performance. Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur. As of March&#160;31, 2022, the Company's consolidated VIEs include six surgical facilities and five physician practices.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The total assets (excluding goodwill and intangible assets, net) of the consolidated VIEs included in the accompanying condensed consolidated balance sheets as of March&#160;31, 2022 and December&#160;31, 2021 were $71.4 million and $48.1 million, respectively, and the total liabilities of the consolidated VIEs were $46.7 million and $20.1 million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on inputs classified into the following hierarchy:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These may include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, depending on the nature of the item being valued.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, restricted invested assets and accounts payable approximate their fair values under Level 3 calculations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of the carrying amounts and estimated fair values of the Company's long-term debt follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior secured term loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,527.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,530.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,504.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,530.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.750% senior unsecured notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">367.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.000% senior unsecured notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values in the table above were based on Level 2 inputs using quoted prices for identical liabilities in inactive markets. The carrying amounts related to the Company's other long-term debt obligations, including finance lease obligations, approximate their fair values based on Level 3 inputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's revenues generally relate to contracts with patients in which the performance obligations are to provide health care services. The Company recognizes revenues in the period in which its obligations to provide health care services are satisfied and reports the amount that reflects the consideration the Company expects to be entitled to receive. The contractual relationships with patients, in most cases, also involve a third-party payor (e.g., Medicare, Medicaid and private insurance organizations, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by or negotiated with the third-party payors. The payment arrangements with third-party payors for the services provided to the related patients typically specify payments at amounts less than the Company's standard charges. The Company continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of revenues by service type as a percentage of total revenues follows:</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Surgical facilities revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Ancillary services revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total patient service revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other service revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Patient service revenues.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This revenue is related to charging facility fees in exchange for providing patient care. The fee charged for health care procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications. The fee does not normally include professional fees charged by the patient&#8217;s surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patient service revenues are recognized as performance obligations are satisfied. Performance obligations are based on the nature of services provided. Typically, the Company recognizes revenue at a point in time in which services are rendered and the Company has no obligation to provide further patient services. As the Company primarily performs outpatient procedures, performance obligations are generally satisfied same day and revenue is recognized on the date of service.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments and discounts from third-party payors. The Company estimates its contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. Changes in estimated contractual adjustments and discounts are recorded in the period of change. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other service revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other service revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets. These agreements typically require the Company to provide recurring management services over a multi-year period, which are billed and collected on a monthly basis. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which management services are rendered and billed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in millions):</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.238%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.887%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Private insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Self-pay</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total patient service revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">587.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other service revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Other is comprised of anesthesia service agreements, automobile liability, letters of protection and other payor types. </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company maintains its cash and cash equivalent balances at high credit quality financial institutions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable from third-party payors are recorded net of estimated implicit price concessions, which are estimated based on the historical trend of the Company's surgical hospitals&#8217; cash collections and contractual write-offs, and for the Company's surgical facilities in general, established fee schedules, relationships with payors and procedure statistics. While changes in estimated reimbursement from third-party payors remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on its financial condition or results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), private insurance organizations, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. Amounts are classified outside of self-pay if the Company has an agreement with the third-party payor or has verified a patient&#8217;s coverage prior to services rendered. The Company's policy is to collect co-payments and deductibles prior to providing medical services. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of its surgical facilities to ensure the proper collection and aged category. Collection efforts include direct contact with third-party payors or patients, written correspondence and the use of legal or collection agency assistance, as required. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill represents the fair value of the consideration provided in an acquisition over the fair value of net assets acquired and is not amortized. Additions to goodwill include amounts resulting from new business combinations and incremental ownership purchases in the Company's subsidiaries. A summary of the Company's acquisitions and dispositions for the three months ended March&#160;31, 2022 is included in Note 2. "Acquisitions and Disposals."</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of activity related to goodwill for the three months ended March&#160;31, 2022 is as follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,911.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions, including post acquisition adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Disposals and deconsolidations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,925.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A detailed evaluation of potential impairment indicators was performed as of March 31, 2022, which specifically considered the ongoing impact of the COVID-19 pandemic. On the basis of available evidence as of March 31, 2022, no indicators of impairment were identified. Future estimates of fair value could be adversely affected if the actual outcome of one or more of the Company's assumptions changes materially in the future, including a material decline in the Company&#8217;s stock price and the fair value of its long-term debt, lower than expected surgical case volumes, higher market interest rates or increased operating costs. Such changes impacting the calculation of fair value, the risks of which are amplified by the COVID-19 pandemic, could result in a material impairment charge in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records all derivatives on the balance sheet at fair value and any financing elements treated as debt instruments are recorded at amortized cost. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain of its risk, even though hedge accounting does not apply or the Company elects not to apply hedge accounting.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-Controlling Interests&#8212;Redeemable</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively.&#160;In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners&#8217; or physician minority members&#8217;, as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility.&#160;The non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">redeemable are reported outside of stockholders' equity in the condensed consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of activity related to non-controlling interests&#8212;redeemable is as follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at&#160;beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests&#8212;redeemable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of shares of non-controlling interests, net&#8212;redeemable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to non-controlling interest&#8212;redeemable holders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at&#160;end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a carryforward exists, the Company makes a determination as to whether the carryforward will be utilized in the future. A valuation allowance is established for certain carryforwards when their recoverability is deemed to be uncertain. The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions. If our expectations for future operating results on a consolidated basis or at the state jurisdiction level vary from actual results due to changes in health care regulations, general economic conditions, or other factors, we may need to adjust the valuation allowance, for </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">all or a portion of our deferred tax assets. Our income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on our future earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company and certain of its subsidiaries file a consolidated federal income tax return. The partnerships, limited liability companies, and certain non-consolidated physician practice corporations also file separate income tax returns. The Company's allocable portion of each partnership's and limited liability company's income or loss is included in taxable income of the Company. The remaining income or loss of each partnership and limited liability company is allocated to the other owners.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company's effective tax rate was 2.9% for the three months ended March&#160;31, 2022 compared to 1.8% for the three months ended March&#160;31, 2021. For the three months ended March&#160;31, 2022, the effective tax rate differed from 21% primarily due to earnings attributable to non-controlling interests, an increase in the Company&#8217;s valuation allowance attributable to interest expense limitations, and discrete tax benefits of (a) $4.6&#160;million related to the vesting of restricted stock awards, (b) $1.8&#160;million attributable to non-recurring earnings&#8217; impact on the Company&#8217;s valuation allowance, and (c) $1.0&#160;million related to entity divestitures. For the three months ended March&#160;31, 2021, the effective tax rate differed from 21% due to tax benefits of $2.2&#160;million related to the vesting of restricted stock awards. Based upon the application of interim accounting guidance, the tax rate as a percentage of net income after income attributable to non-controlling interests will vary based upon the relative net income from period to period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331706699640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Disposals<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions and Disposals</a></td>
<td class="text">Acquisitions and Disposals<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, the Company acquired a controlling interest in two surgical facilities, one of which was merged into an existing surgical facility, for aggregate cash consideration of $31.1&#160;million, net of cash acquired, and non-cash consideration of $2.6&#160;million. The cash consideration was funded through available resources and the non-cash consideration consisted of a non-controlling interest in one of the Company's existing surgical facilities. The total consideration was allocated to the assets acquired and liabilities assumed based upon the respective acquisition date fair values. The aggregate amounts preliminarily recognized for each major class of assets acquired and liabilities assumed for the acquisitions are as follows (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.955%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aggregate acquisition date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aggregate acquisition date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values assigned to certain assets acquired and liabilities assumed by the Company have been estimated on a preliminary basis and are subject to change as new facts and circumstances emerge that were present at the date of acquisition. During the three months ended March&#160;31, 2022, no significant changes were made to the purchase price allocation of assets and liabilities, existing at the date of acquisition, related to individual acquisitions completed in 2021. The goodwill acquired was allocated to the Company's Surgical Facility services reportable segment. The results of operations of the acquisitions were included in the Company&#8217;s results of operations beginning on the dates of acquisition and were not considered significant for the three months ended March&#160;31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Disposals and Deconsolidations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, the Company sold its interests in a surgical facility, which was previously accounted for as an equity method investment, for net cash proceeds of $11.5&#160;million, and recognized a pre-tax loss of $0.4&#160;million included in loss on disposals and deconsolidations, net in the condensed consolidated statements of operations for the three months ended March 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, the Company contributed its interests in two surgical facilities as non-cash consideration for non-controlling interests in two new separate entities. As a result of these transactions, the Company lost control of the previously controlled surgical facilities but retains a non-controlling interest in each, resulting in the deconsolidation of the previously consolidated entities. The remaining non-controlling interests were accounted for as equity method investments, and initially measured and recorded at fair value as of the dates of the transactions. The fair value measurement utilizes Level 3 inputs, which includes unobservable data, to measure the fair value of the retained non-controlling interests. The fair value determination was based on a combination of multiple valuation methods, which included discounted cash flow and market value approach, which incorporates estimates of future earnings and market valuation multiples for certain guideline companies. The preliminary fair value of the investments of $9.8&#160;million was recorded as a component of investments in and advances to affiliates in the accompanying condensed consolidated balance sheets. Further, </span></div>based on the preliminary valuation, the transactions resulted in a pretax net loss on deconsolidations of $5.6&#160;million, which is included in gain on disposals and deconsolidations, net, in the accompanying condensed consolidated statement of operations for the three months ended March&#160;31, 2022. The gains were determined based on the difference between the fair value of the Company's retained interests in the entities and the carrying values of both the tangible and intangible assets of the entities immediately prior to the transactions.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331706651464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt</a></td>
<td class="text">Long-Term Debt<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of long-term debt follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior secured term loan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,527.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,530.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.750% senior unsecured notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.000% senior unsecured notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable and other secured loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs and discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,093.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,938.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current maturities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,025.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,878.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:4pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Includes unamortized fair value discount of $2.8 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and $3.0&#160;million as of March&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">December&#160;31, 2021, respectively. </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The increase in finance lease obligations is a result of the modification of certain existing facility real estate leases that were previously classified as operating leases. See Note 4. "Leases" for further discussion.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revolving Credit Facility</span></div>As of March 31, 2022, the Company's availability on its revolving credit facility (the "Revolver") was $203.0 million (including outstanding letters of credit of $7.0 million). There were no outstanding borrowings under the Revolver as of both March 31, 2022 and December 31, 2021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331706608696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the consolidated balance sheets (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.941%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNC0yLTEtMS00NjQ2Ng_0f2dda77-9e14-4a9d-bd4c-1fca9c544334"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNC0yLTEtMS00NjQ2Ng_32523eef-34e6-4b2a-913b-0c4967f1b23d">Property and equipment, net of accumulated depreciation</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">745.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">653.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfOS0yLTEtMS00NjQ2OA_4491f22a-c2d0-4ffb-9a7d-8129b50d1a26"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfOS0yLTEtMS00NjQ2OA_e2b110e3-da5b-424a-8c7d-d3e258e86a47">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">272.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">315.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">355.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTMtMi0xLTEtNDY0NzI_4d4afb66-9139-4863-9c1e-c7148377256b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTMtMi0xLTEtNDY0NzI_822c6ee1-f967-42b7-8426-35b31d91efae">Current maturities of long-term debt</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTQtMi0xLTEtNDY0Nzc_9fb4ebe5-aa6a-445d-86cd-135374660488"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTQtMi0xLTEtNDY0Nzc_f854c062-dd64-4d2b-a477-9bd1f49a42d6">Long-term debt, less current maturities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">484.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">815.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">720.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, the Company extended certain existing facility real estate leases, resulting in the reclassification of the leases from operating to finance. The modifications resulted in an increase to finance lease liabilities and assets of $146.5&#160;million and $145.0&#160;million, respectively, including the reclassification of existing operating lease liabilities and assets of $60.8&#160;million and $59.3&#160;million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's lease expense and their classification in the condensed consolidated statement of operations (in millions):</span></div><div style="margin-bottom:12pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable and short-term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information (dollars in millions):</span></div><div style="margin-bottom:12pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from operating leases </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing cash outflows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the consolidated balance sheets (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.941%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNC0yLTEtMS00NjQ2Ng_0f2dda77-9e14-4a9d-bd4c-1fca9c544334"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNC0yLTEtMS00NjQ2Ng_32523eef-34e6-4b2a-913b-0c4967f1b23d">Property and equipment, net of accumulated depreciation</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">745.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">653.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfOS0yLTEtMS00NjQ2OA_4491f22a-c2d0-4ffb-9a7d-8129b50d1a26"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfOS0yLTEtMS00NjQ2OA_e2b110e3-da5b-424a-8c7d-d3e258e86a47">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">272.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">315.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">355.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTMtMi0xLTEtNDY0NzI_4d4afb66-9139-4863-9c1e-c7148377256b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTMtMi0xLTEtNDY0NzI_822c6ee1-f967-42b7-8426-35b31d91efae">Current maturities of long-term debt</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTQtMi0xLTEtNDY0Nzc_9fb4ebe5-aa6a-445d-86cd-135374660488"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTQtMi0xLTEtNDY0Nzc_f854c062-dd64-4d2b-a477-9bd1f49a42d6">Long-term debt, less current maturities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">484.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">815.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">720.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, the Company extended certain existing facility real estate leases, resulting in the reclassification of the leases from operating to finance. The modifications resulted in an increase to finance lease liabilities and assets of $146.5&#160;million and $145.0&#160;million, respectively, including the reclassification of existing operating lease liabilities and assets of $60.8&#160;million and $59.3&#160;million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's lease expense and their classification in the condensed consolidated statement of operations (in millions):</span></div><div style="margin-bottom:12pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable and short-term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information (dollars in millions):</span></div><div style="margin-bottom:12pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from operating leases </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing cash outflows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331706650344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Hedging Activities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivatives and Hedging Activities</a></td>
<td class="text">Derivatives and Hedging Activities<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps and interest rate caps as part of its interest rate risk management strategy. During 2022 and 2021, such derivatives have been used to hedge the variable cash flows associated with existing variable-rate debt.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income ("OCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings, as documented at hedge inception in accordance with the Company&#8217;s accounting policy election. Amounts reported in accumulated OCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company&#8217;s variable-rate debt. Over the next 12 months, the Company estimates that an additional $12.0 million will be reclassified as an increase to interest expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company had nine interest rate swaps with a total net hedged notional amount of $1.2&#160;billion and two interest rate caps with a total hedged notional amount of $329.8&#160;million. Of the nine interest rate swaps, three are pay-fixed, receive 1-Month LIBOR (subject to a minimum of 0.75%) interest rate swaps designated in cash flow hedging relationships with a total notional amount of $1.2&#160;billion and a termination date of March 31, 2025. The remaining six interest rate swaps are undesignated and consist of three pay-fixed, receive 1-Month LIBOR (subject to a minimum of 1.00%) interest rate swaps and three pay 1-Month LIBOR (subject to a minimum of 1.00%), receive-fixed interest rate swaps with a termination date of November 30, 2023. The pay-floating, receive-fixed swaps are designed to economically offset the undesignated pay-fixed, receive-floating swaps. The interest rate caps each have a termination date of March&#160;31, 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The pay-fixed, receive floating interest rate swaps did not meet the requirements to be considered derivatives in their entirety as a result of the financing component. Accordingly, the swaps are considered hybrid instruments, consisting of a financing element treated as a debt instrument and an embedded at-market derivative that was designated as a cash flow hedge. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Within the Company&#8217;s condensed consolidated balance sheets, the financing elements treated as debt instruments described above are carried at amortized cost and the embedded at-market derivatives and the undesignated swaps are recorded at fair value. The cash flows related to the portion treated as debt are classified as financing activities in the condensed consolidated statements of cash flows while the portion treated as an at-market derivative are classified as operating activities. Cash settlements related to the undesignated swaps will offset and are classified as operating activities in the condensed consolidated cash flows. Within the Company&#8217;s condensed consolidated balance sheets, the interest rate caps are recorded at fair value. The cash flows related to the interest rate caps are classified as operating activities in the condensed consolidated statements of cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The key terms of interest rate swaps and interest rate caps outstanding are presented below:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.352%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.743%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 7, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 7, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 7, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate cap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate cap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 28, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receive-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(165.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(165.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receive-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(120.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(120.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receive-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,529.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,533.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our interest rate swap agreements, excluding the portion treated as debt, are recognized at fair value in the condensed consolidated balance sheets and are valued using pricing models that rely on market observable inputs such as yield curve data, which are classified as Level 2 inputs within the fair value hierarchy. The fair value of the interest rate caps are determined using the market standard methodology of discounting the future expected cash receipts that would occur if variable interest rates rise above the strike rate of the caps. The variable interest rates used in the calculation of projected receipts on the caps are based on an expectation of future interest rates derived from observable market interest rate curves and volatilities. The interest rate caps are classified using Level 2 inputs within the fair value hierarchy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the fair values of our derivatives and their location on the condensed consolidated balance sheets (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.989%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate caps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">The balance as of March&#160;31, 2022 and December 31, 2021 is related to the financing component of the pay-fixed, receive floating interest rate swaps.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the pre-tax effect of the interest rate swaps and caps on the Company's accumulated OCI and condensed consolidated statement of operations (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.542%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss recognized in income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain recognized in OCI (effective portion)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss reclassified from accumulated OCI into income (effective portion) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Includes amortization of accumulated OCI related to de-designated and terminated interest rate swaps of $5.3 million for the three months ended March&#160;31, 2022 with no related amortization for the three months ended March&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331706541768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic and diluted earnings per share are calculated based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities exist and have a dilutive effect on earnings per share. The Company computes basic and diluted earnings per share using the two-class method. The two-class method of computing earnings per share is an earnings allocation method that determines earnings per share for common shares and participating securities according to their participation rights in dividends and undistributed earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator of basic and diluted earnings per share follows (dollars in millions, except per share amounts; shares in thousands): </span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.304%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) attributable to Surgery Partners, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: amounts allocated to participating securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding- basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding- diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income (loss) per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dilutive securities outstanding not included in the computation of income (loss) per share as their effect is antidilutive:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Includes dividends accrued for the Series A Preferred Stock for the three months ended March 31, 2021. The Series A Preferred Stock did  not participate in undistributed losses and was converted to common stock during the second quarter of 2021. There were no participating securities for the three months ended March 31, 2022.</span></div><div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">The impact of potentially dilutive securities for the three months ended March 31, 2021, was not considered because the effect would be anti-dilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331710523208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Current Liabilities</a></td>
<td class="text">Other Current Liabilities<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of other current liabilities is as follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts due to patients and payors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost report liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax receivable agreement liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331706649224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Professional, General and Workers' Compensation Liability Risks</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is subject to claims and legal actions in the ordinary course of business, including claims relating to patient treatment, employment practices and personal injuries. The Company maintains professional, general and workers' compensation liability insurance in excess of self-insured retentions through third party commercial insurance carriers. Although management believes the coverage is sufficient for the Company's operations, some claims may potentially exceed the scope of coverage in effect. Plaintiffs in these matters may </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">request punitive or other damages that may not be covered by insurance. The Company is not aware of any such proceedings that are reasonably possible to have a material adverse effect on the Company's business, financial position, results of operations or liquidity. Total professional, general and workers' compensation claim liabilities as of March&#160;31, 2022 and December&#160;31, 2021 were $18.9 million and $19.8 million, respectively. Expected insurance recoveries of $8.7 million as of both March&#160;31, 2022 and December&#160;31, 2021, are included as a component of other current assets and other long-term assets in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Laws and Regulations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Laws and regulations governing the Company's business, including those relating to the Medicare and Medicaid programs, are complex and subject to interpretation. These laws and regulations govern every aspect of how the Company's surgical facilities conduct their operations, from licensing requirements to how and whether the Company's facilities may receive payments pursuant to the Medicare and Medicaid programs. Compliance with such laws and regulations can be subject to future government agency review and interpretation as well as legislative changes to such laws. Noncompliance with such laws and regulations may subject the Company to significant regulatory sanctions including fines, penalties, and exclusion from the Medicare, Medicaid and other federal health care programs. From time to time, governmental regulatory agencies will conduct inquiries of the Company's practices, including, but not limited to, the Company's compliance with federal and state fraud and abuse laws, billing practices and relationships with physicians.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stockholder Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On December 4, 2017, a purported Company stockholder filed an action in the Delaware Court of Chancery (the "Delaware Action"). That action is captioned Witmer v. H.I.G. Capital, L.L.C., et al., C.A. No. 2017-0862. The plaintiff in the Delaware Action asserted claims against (i) certain current and former members of the Company&#8217;s Board of Directors (together, the "Directors"); (ii) H.I.G. Capital, LLC and certain of its affiliates (collectively, "H.I.G."); and (iii) Bain Capital Private Equity, L.P. and certain of its affiliates (collectively, "Bain Capital" and, together with the Directors and H.I.G., the "Defendants"). The parties to the Delaware Action negotiated a final stipulation of settlement (the &#8220;Settlement Stipulation&#8221;), which governs the terms of the settlement of the Delaware Action, and which they filed with the Court of Chancery on November 22, 2021. On February 11, 2022, the Court of Chancery approved the settlement of the Delaware Action as memorialized in the Settlement Stipulation. That decision became final and non-appealable on March 14, 2022. The case is now closed. Pursuant to the settlement, the Company received $32.8&#160;million in March 2022, which was included in litigation settlement in the condensed consolidated statements of operations for the three months ended March 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Acquired Facilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company, through its wholly-owned subsidiaries or controlled partnerships and limited liability companies, has acquired and will continue to acquire surgical facilities with prior operating histories. Such facilities may have unknown or contingent liabilities, including liabilities for failure to comply with health care laws and regulations, such as billing and reimbursement laws and regulations, the Stark Law, the Anti-Kickback Statute, the FCA, and similar fraud and abuse laws. Although the Company attempts to assure that no such liabilities exist, obtain indemnification from prospective sellers covering such matters and institute policies designed to conform centers to its standards following completion of acquisitions, there can be no assurance that the Company will not become liable for past activities that may later be asserted to be improper by private plaintiffs or government agencies. There can be no assurance that any such matter will be covered by indemnification or, if covered, that the liability sustained will not exceed contractual limits or the financial capacity of the indemnifying party.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company cannot predict whether federal or state statutory or regulatory provisions will be enacted that would prohibit or otherwise regulate relationships which the Company has established or may establish with other health care providers or have materially adverse effects on its business or revenues arising from such future actions. Management believes, however, that it will be able to adjust the Company's operations so as to be in compliance with any statutory or regulatory provision as may be applicable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Potential Physician Investor Liability</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A majority of the physician investors in the partnerships and limited liability companies which operate the Company's surgical facilities carry general and professional liability insurance on a claims-made basis. Each partnership or limited liability company may, however, be liable for damages to persons or property arising from occurrences at the surgical facilities. Although the various physician investors and other surgeons generally are required to obtain general and professional liability insurance with tail coverage that extends beyond the period of any claims-made policies, such individuals may not be able to obtain coverage in amounts sufficient to cover all potential liability. Since most insurance policies contain exclusions, the physician investors will not be insured against all possible occurrences. In the event of an uninsured or underinsured loss, the value of an investment in the partnership interests or limited liability company membership units and the amount of distributions could be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Tax Receivable Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On May 9, 2017, the Company entered into an agreement to amend that certain Income Tax Receivable Agreement, dated September 30, 2015 (as amended, the "TRA"), by and between the Company, and the other parties referred to therein, which amendment became effective on August 31, 2017. Pursuant to the amendment to the TRA, the Company agreed to make payments to H.I.G., the Company's former controlling shareholder, in its capacity as the stockholders representative pursuant to a fixed payment schedule. The amounts payable under the TRA are calculated as the product of (i) an annual base amount and (ii) the maximum corporate federal income tax rate for the applicable year plus three percent. The amounts payable under the TRA are related to the Company&#8217;s projected realized tax savings </span></div>over the next five years and are not dependent on the Company&#8217;s actual tax savings over such period. The calculation of amounts payable pursuant to the TRA is thus dependent on the maximum corporate federal income tax rate. To the extent that the Company is unable to make payments under the TRA, such payments will be deferred and will accrue interest at a rate of the LIBOR plus 500 basis points until paid. If the terms of credit agreements and other debt documents cause the Company to be unable to make payments under the TRA and such terms are not materially more restrictive than those existing as of September 30, 2015, such payments will be deferred and will accrue interest at a rate of LIBOR plus 300 basis points until paid.Assuming the Company's tax rate is 24%, calculated as the maximum corporate federal tax rate plus three percent, throughout the remaining term of the TRA, the Company estimates the total remaining amounts payable under the TRA was approximately $22.0 million as of both March&#160;31, 2022 and December&#160;31, 2021. As a result of the amendment to the TRA, the Company was required to value the liability under the TRA by discounting the fixed payment schedule using the Company&#8217;s incremental borrowing rate. The carrying value of the liability under the TRA, reflecting the discount, was $20.2 million and $19.7 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively, and is included as a component of other current liabilities in the condensed consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331706696776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company currently operates in&#160;two&#160;major lines of business that are also the Company's reportable operating segments - the operation of surgical facilities and the operation of ancillary services. The Surgical Facility Services segment consists of the operation of ASCs, surgical hospitals and anesthesia services. The Ancillary Services segment consists of multi-specialty physician practices. The "All other" line item primarily consists of the Company's corporate general and administrative functions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables present financial information for each reportable segment (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">578.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reconciliation of Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction, integration and acquisition costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on disposals and deconsolidations, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on litigation settlement and other litigation costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount includes transaction and integration costs of $7.1 million and $5.3 million for the three months ended March&#160;31, 2022 and 2021, respectively. This amount further includes start-up costs related to a de novo surgical hospital of $4.1 million for the three months ended March 31, 2021. </span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount includes other litigation costs of $2.0 million and $1.0 million for the three months ended March&#160;31, 2022 and 2021, respectively. This amount also includes gain on litigation settlement of $32.8 million for the three months ended March&#160;31, 2022, with no comparable activity in the 2021 period.</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,651.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,552.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">593.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,289.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,117.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash purchases of property and equipment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331706650904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2022, the Company acquired non-controlling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interests in three surgical facilities and four in-development de novo surgical facilities for a combined purchase price of $48.6&#160;million. The non-controlling interests will be accounted for as equity method investments.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331706315256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation of the Company's financial position and results of operations have been included. The Company&#8217;s fiscal year ends on December&#160;31 and interim results are not necessarily indicative of results for a full year or any other interim period. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company&#8217;s consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021 (the "2021 Annual Report on Form 10-K").</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text">Variable Interest Entities<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification 810, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span>". The Company has the power to direct the activities that most significantly impact a VIE's economic performance. Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on inputs classified into the following hierarchy:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These may include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, depending on the nature of the item being valued.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, restricted invested assets and accounts payable approximate their fair values under Level 3 calculations.</span></div>The fair values in the table above were based on Level 2 inputs using quoted prices for identical liabilities in inactive markets. The carrying amounts related to the Company's other long-term debt obligations, including finance lease obligations, approximate their fair values based on Level 3 inputs.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenues</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's revenues generally relate to contracts with patients in which the performance obligations are to provide health care services. The Company recognizes revenues in the period in which its obligations to provide health care services are satisfied and reports the amount that reflects the consideration the Company expects to be entitled to receive. The contractual relationships with patients, in most cases, also involve a third-party payor (e.g., Medicare, Medicaid and private insurance organizations, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by or negotiated with the third-party payors. The payment arrangements with third-party payors for the services provided to the related patients typically specify payments at amounts less than the Company's standard charges. The Company continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.</span></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Patient service revenues.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This revenue is related to charging facility fees in exchange for providing patient care. The fee charged for health care procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications. The fee does not normally include professional fees charged by the patient&#8217;s surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patient service revenues are recognized as performance obligations are satisfied. Performance obligations are based on the nature of services provided. Typically, the Company recognizes revenue at a point in time in which services are rendered and the Company has no obligation to provide further patient services. As the Company primarily performs outpatient procedures, performance obligations are generally satisfied same day and revenue is recognized on the date of service.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments and discounts from third-party payors. The Company estimates its contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. Changes in estimated contractual adjustments and discounts are recorded in the period of change. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other service revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other service revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets. These agreements typically require the Company to provide recurring management services over a multi-year period, which are billed and collected on a monthly basis. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which management services are rendered and billed.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company maintains its cash and cash equivalent balances at high credit quality financial institutions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable from third-party payors are recorded net of estimated implicit price concessions, which are estimated based on the historical trend of the Company's surgical hospitals&#8217; cash collections and contractual write-offs, and for the Company's surgical facilities in general, established fee schedules, relationships with payors and procedure statistics. While changes in estimated reimbursement from third-party payors remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on its financial condition or results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), private insurance organizations, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. Amounts are classified outside of self-pay if the Company has an agreement with the third-party payor or has verified a patient&#8217;s coverage prior to services rendered. The Company's policy is to collect co-payments and deductibles prior to providing medical services. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients.</span></div>The Company's collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of its surgical facilities to ensure the proper collection and aged category. Collection efforts include direct contact with third-party payors or patients, written correspondence and the use of legal or collection agency assistance, as required.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text">GoodwillGoodwill represents the fair value of the consideration provided in an acquisition over the fair value of net assets acquired and is not amortized. Additions to goodwill include amounts resulting from new business combinations and incremental ownership purchases in the Company's subsidiaries.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Instruments and Hedging Activities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records all derivatives on the balance sheet at fair value and any financing elements treated as debt instruments are recorded at amortized cost. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain of its risk, even though hedge accounting does not apply or the Company elects not to apply hedge accounting.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.</span></div>For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income ("OCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings, as documented at hedge inception in accordance with the Company&#8217;s accounting policy election. Amounts reported in accumulated OCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company&#8217;s variable-rate debt.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_RedeemableNoncontrollingInterestPolicyTextBlock', window );">Non-Controlling Interests&#8212;Redeemable</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-Controlling Interests&#8212;Redeemable</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively.&#160;In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners&#8217; or physician minority members&#8217;, as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility.&#160;The non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">redeemable are reported outside of stockholders' equity in the condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a carryforward exists, the Company makes a determination as to whether the carryforward will be utilized in the future. A valuation allowance is established for certain carryforwards when their recoverability is deemed to be uncertain. The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions. If our expectations for future operating results on a consolidated basis or at the state jurisdiction level vary from actual results due to changes in health care regulations, general economic conditions, or other factors, we may need to adjust the valuation allowance, for </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">all or a portion of our deferred tax assets. Our income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on our future earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company and certain of its subsidiaries file a consolidated federal income tax return. The partnerships, limited liability companies, and certain non-consolidated physician practice corporations also file separate income tax returns. The Company's allocable portion of each partnership's and limited liability company's income or loss is included in taxable income of the Company. The remaining income or loss of each partnership and limited liability company is allocated to the other owners.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_RedeemableNoncontrollingInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable Noncontrolling Interest [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_RedeemableNoncontrollingInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331709649272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Carrying Amounts and Fair Values of Long-Term Debt</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of the carrying amounts and estimated fair values of the Company's long-term debt follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior secured term loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,527.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,530.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,504.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,530.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.750% senior unsecured notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">367.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.000% senior unsecured notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Revenues</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of revenues by service type as a percentage of total revenues follows:</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Surgical facilities revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Ancillary services revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total patient service revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other service revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in millions):</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.238%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.887%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Private insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Self-pay</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total patient service revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">587.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">505.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other service revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div>(1)Other is comprised of anesthesia service agreements, automobile liability, letters of protection and other payor types.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Rollforward of Goodwill</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of activity related to goodwill for the three months ended March&#160;31, 2022 is as follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,911.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions, including post acquisition adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Disposals and deconsolidations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,925.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestTableTextBlock', window );">Schedule of Rollforward of Noncontrolling Interest - Redeemable</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of activity related to non-controlling interests&#8212;redeemable is as follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at&#160;beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests&#8212;redeemable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of shares of non-controlling interests, net&#8212;redeemable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to non-controlling interest&#8212;redeemable holders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at&#160;end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331706699640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Disposals (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Assets Acquired and Liabilities Assumed</a></td>
<td class="text">The aggregate amounts preliminarily recognized for each major class of assets acquired and liabilities assumed for the acquisitions are as follows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.955%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aggregate acquisition date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aggregate acquisition date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331706637848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Long-term Debt</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of long-term debt follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior secured term loan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,527.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,530.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.750% senior unsecured notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.000% senior unsecured notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable and other secured loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs and discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,093.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,938.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current maturities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,025.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,878.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Includes unamortized fair value discount of $2.8 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and $3.0&#160;million as of March&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span>December&#160;31, 2021, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331706473192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Components of Right-of-use Assets and Liabilities Related to Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the consolidated balance sheets (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.941%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNC0yLTEtMS00NjQ2Ng_0f2dda77-9e14-4a9d-bd4c-1fca9c544334"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNC0yLTEtMS00NjQ2Ng_32523eef-34e6-4b2a-913b-0c4967f1b23d">Property and equipment, net of accumulated depreciation</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">745.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">653.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfOS0yLTEtMS00NjQ2OA_4491f22a-c2d0-4ffb-9a7d-8129b50d1a26"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfOS0yLTEtMS00NjQ2OA_e2b110e3-da5b-424a-8c7d-d3e258e86a47">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">272.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">315.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">355.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTMtMi0xLTEtNDY0NzI_4d4afb66-9139-4863-9c1e-c7148377256b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTMtMi0xLTEtNDY0NzI_822c6ee1-f967-42b7-8426-35b31d91efae">Current maturities of long-term debt</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTQtMi0xLTEtNDY0Nzc_9fb4ebe5-aa6a-445d-86cd-135374660488"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTQtMi0xLTEtNDY0Nzc_f854c062-dd64-4d2b-a477-9bd1f49a42d6">Long-term debt, less current maturities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">484.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">815.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">720.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Expense and Cash Flow Information</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's lease expense and their classification in the condensed consolidated statement of operations (in millions):</span></div><div style="margin-bottom:12pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable and short-term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information (dollars in millions):</span></div><div style="margin-bottom:12pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from operating leases </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing cash outflows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331701331736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Hedging Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of Interest Rate Swaps and Interest Rate Caps Outstanding</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The key terms of interest rate swaps and interest rate caps outstanding are presented below:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.352%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.743%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 7, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 7, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 7, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate cap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate cap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pay-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 28, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receive-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(165.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(165.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receive-fixed swap</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(120.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(120.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receive-fixed swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,529.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,533.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the fair values of our derivatives and their location on the condensed consolidated balance sheets (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.989%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate caps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">The balance as of March&#160;31, 2022 and December 31, 2021 is related to the financing component of the pay-fixed, receive floating interest rate swaps.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock', window );">Schedule of Effect of Interest Rate Swaps</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the pre-tax effect of the interest rate swaps and caps on the Company's accumulated OCI and condensed consolidated statement of operations (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.542%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss recognized in income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain recognized in OCI (effective portion)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss reclassified from accumulated OCI into income (effective portion) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Includes amortization of accumulated OCI related to de-designated and terminated interest rate swaps of $5.3 million for the three months ended March&#160;31, 2022 with no related amortization for the three months ended March&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331706544216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator of basic and diluted earnings per share follows (dollars in millions, except per share amounts; shares in thousands): </span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.304%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) attributable to Surgery Partners, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: amounts allocated to participating securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding- basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding- diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income (loss) per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dilutive securities outstanding not included in the computation of income (loss) per share as their effect is antidilutive:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Includes dividends accrued for the Series A Preferred Stock for the three months ended March 31, 2021. The Series A Preferred Stock did  not participate in undistributed losses and was converted to common stock during the second quarter of 2021. There were no participating securities for the three months ended March 31, 2022.</span></div><div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">The impact of potentially dilutive securities for the three months ended March 31, 2021, was not considered because the effect would be anti-dilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331706549192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Summary of Other Current Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of other current liabilities is as follows (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts due to patients and payors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost report liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax receivable agreement liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331706085096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of Segment Revenue and Operating Income</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables present financial information for each reportable segment (in millions):</span></div><div style="margin-bottom:9pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.411%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">578.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reconciliation of Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction, integration and acquisition costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on disposals and deconsolidations, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on litigation settlement and other litigation costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount includes transaction and integration costs of $7.1 million and $5.3 million for the three months ended March&#160;31, 2022 and 2021, respectively. This amount further includes start-up costs related to a de novo surgical hospital of $4.1 million for the three months ended March 31, 2021. </span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount includes other litigation costs of $2.0 million and $1.0 million for the three months ended March&#160;31, 2022 and 2021, respectively. This amount also includes gain on litigation settlement of $32.8 million for the three months ended March&#160;31, 2022, with no comparable activity in the 2021 period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock', window );">Schedule of Reconciliation of Assets from Segment to Consolidated</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,651.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,552.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">593.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,289.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,117.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Financial Information by Reportable Segment</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash purchases of property and equipment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331701399768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Organization (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>surgical_facility </div>
<div>state</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_ProductsAndServicesLineItems', window );"><strong>Products And Services [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_NumberOfSurgicalFacilitiesOwned', window );">Number of surgical facilities owned</a></td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which entity operates | state</a></td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest', window );">Number of surgical facilities owned, majority interest</a></td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated', window );">Number of surgical facilities owned, consolidated</a></td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_FacilitiesAmbulatorySurgeryCentersMember', window );">Facilities, Ambulatory Surgery Centers</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_ProductsAndServicesLineItems', window );"><strong>Products And Services [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_NumberOfSurgicalFacilitiesOwned', window );">Number of surgical facilities owned</a></td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_FacilitiesSurgicalHospitalsMember', window );">Facilities, Surgical Hospitals</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_ProductsAndServicesLineItems', window );"><strong>Products And Services [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_NumberOfSurgicalFacilitiesOwned', window );">Number of surgical facilities owned</a></td>
<td class="nump">18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_NumberOfSurgicalFacilitiesOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Surgical Facilities Owned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_NumberOfSurgicalFacilitiesOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Surgical Facilities Owned, Consolidated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_NumberOfSurgicalFacilitiesOwnedConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Surgical Facilities Owned, Majority Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_ProductsAndServicesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Products And Services [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_ProductsAndServicesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_FacilitiesAmbulatorySurgeryCentersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_FacilitiesAmbulatorySurgeryCentersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_FacilitiesSurgicalHospitalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_FacilitiesSurgicalHospitalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331706279288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - CARES ACT (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_ProceedsFromGovernmentAssistance', window );">Proceeds from grants received</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_GrantRevenue', window );">Grant funds</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">$ 15.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments', window );">Accelerated payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments', window );">Repayments of grants received</a></td>
<td class="nump">18.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments', window );">Deferred accelerated payments</a></td>
<td class="nump">42.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.0<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DeferredEmployeeRelatedLiabilitiesCurrent', window );">Deferred accrued payroll and benefits</a></td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Repayments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grants, Deferred Accelerated Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Accelerated Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DeferredEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Employee-related Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DeferredEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_GrantRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_GrantRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_ProceedsFromGovernmentAssistance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Government Assistance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_ProceedsFromGovernmentAssistance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331701060456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Variable Interest Entities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>surgical_facility</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>physician_practice</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_VariableInterestEntityNumberOfFacilities', window );">Number of facilities included in VIE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">$ 6,289.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,117.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">71.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="nump">$ 46.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_VariableInterestEntityNumberOfFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable Interest Entity, Number of Facilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_VariableInterestEntityNumberOfFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331710460824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Carrying Amount and Fair Value of Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Senior secured term loan | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,527.0<span></span>
</td>
<td class="nump">$ 1,530.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Senior secured term loan | Fair Value | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,504.1<span></span>
</td>
<td class="nump">1,530.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.750% senior unsecured notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.750% senior unsecured notes due 2025 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 370.0<span></span>
</td>
<td class="nump">370.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.750% senior unsecured notes due 2025 | Fair Value | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 367.2<span></span>
</td>
<td class="nump">371.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 10.000% senior unsecured notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 10.000% senior unsecured notes due 2027 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 545.0<span></span>
</td>
<td class="nump">545.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 10.000% senior unsecured notes due 2027 | Fair Value | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 570.2<span></span>
</td>
<td class="nump">$ 577.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_A2017TermLoanMaturing2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_A2017TermLoanMaturing2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331701539256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details) - Revenue Source - Revenue<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a proportion of total revenues (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Patent service revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a proportion of total revenues (as a percent)</a></td>
<td class="nump">98.60%<span></span>
</td>
<td class="nump">98.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Surgical Facility Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a proportion of total revenues (as a percent)</a></td>
<td class="nump">95.70%<span></span>
</td>
<td class="nump">95.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Ancillary Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a proportion of total revenues (as a percent)</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Other service revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a proportion of total revenues (as a percent)</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_HealthcareOrganizationPatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_HealthcareOrganizationPatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_SurgicalFacilityServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_SurgicalFacilityServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_AncillaryServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_AncillaryServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_OtherServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_OtherServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331701283928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Schedule of Revenues by Sources (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 596.2<span></span>
</td>
<td class="nump">$ 512.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_HealthcareOrganizationPatientServiceMember', window );">Patient service revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 587.7<span></span>
</td>
<td class="nump">$ 505.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_HealthcareOrganizationPatientServiceMember', window );">Patient service revenues | Customer | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a proportion of total revenues (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_PrivateInsuranceMember', window );">Private insurance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 300.2<span></span>
</td>
<td class="nump">$ 246.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_PrivateInsuranceMember', window );">Private insurance | Customer | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a proportion of total revenues (as a percent)</a></td>
<td class="nump">51.10%<span></span>
</td>
<td class="nump">48.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember', window );">Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 249.0<span></span>
</td>
<td class="nump">$ 226.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember', window );">Government | Customer | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a proportion of total revenues (as a percent)</a></td>
<td class="nump">42.40%<span></span>
</td>
<td class="nump">44.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_SelfPayRevenueMember', window );">Self-pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 16.8<span></span>
</td>
<td class="nump">$ 13.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_SelfPayRevenueMember', window );">Self-pay | Customer | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a proportion of total revenues (as a percent)</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_OtherPatientServiceRevenueSourcesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 21.7<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_OtherPatientServiceRevenueSourcesMember', window );">Other | Customer | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a proportion of total revenues (as a percent)</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_OtherServicesMember', window );">Other service revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="nump">$ 6.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_HealthcareOrganizationPatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_HealthcareOrganizationPatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_PrivateInsuranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_PrivateInsuranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_SelfPayRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_SelfPayRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_OtherPatientServiceRevenueSourcesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_OtherPatientServiceRevenueSourcesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_OtherServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_OtherServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331706794040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Rollforward of Goodwill (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">$ 3,911.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions, including post acquisition adjustments</a></td>
<td class="nump">43.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidation', window );">Disposals and deconsolidations</a></td>
<td class="num">(29.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">$ 3,925.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Written off Related to Sale of Business Unit and Deconsolidation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331706163592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Schedule of Non-Controlling Interests - Redeemable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_RedeemableNoncontrollingInterestRollForward', window );"><strong>Non-Controlling Interests - Redeemable [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Balance at beginning of period</a></td>
<td class="nump">$ 330.2<span></span>
</td>
<td class="nump">$ 306.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Net income attributable to non-controlling interests&#8212;redeemable</a></td>
<td class="nump">10.6<span></span>
</td>
<td class="nump">10.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests', window );">Acquisition of shares of non-controlling interests, net&#8212;redeemable</a></td>
<td class="nump">12.3<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions to non-controlling interest&#8212;redeemable holders</a></td>
<td class="num">(11.6)<span></span>
</td>
<td class="num">(10.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Balance at end of period</a></td>
<td class="nump">$ 341.5<span></span>
</td>
<td class="nump">$ 308.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable Noncontrolling Interest, Increase (Decrease) from Redemptions or Purchase of Interests</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_RedeemableNoncontrollingInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable Noncontrolling Interest [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_RedeemableNoncontrollingInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331709635560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate (percent)</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Tax benefits related to vesting of restricted stock awards</a></td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Tax benefits attributable to non-recurring earnings' impact on the valuation allowance</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationDispositionOfBusiness', window );">Tax benefits related to the sale of partnership interests</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331701435960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Disposals - Acquisitions (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>surgical_facility </div>
<div>business_entity</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments for acquisitions, net of cash acquired</a></td>
<td class="nump">$ 31.1<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesMember', window );">Surgical Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of facilities acquired | surgical_facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments for acquisitions, net of cash acquired</a></td>
<td class="nump">31.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Noncash consideration</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesExistingMarketsMember', window );">Surgical Facilities, Existing Markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of facilities acquired | surgical_facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of Individually Immaterial Business Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of facilities acquired | business_entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesExistingMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesExistingMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331703857400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Disposals - Summary (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Net assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 3,925.8<span></span>
</td>
<td class="nump">$ 3,911.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesMember', window );">Surgical Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total consideration</a></td>
<td class="nump">34.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Fair value of non-controlling interests</a></td>
<td class="nump">10.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Aggregate acquisition date fair value</a></td>
<td class="nump">45.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Net assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets', window );">Current assets</a></td>
<td class="nump">5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">42.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets', window );">Right-of-use operating lease assets</a></td>
<td class="nump">20.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(5.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability', window );">Right-of-use operating lease liabilities</a></td>
<td class="num">(19.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Aggregate acquisition date fair value</a></td>
<td class="nump">$ 45.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331701425912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Disposals - Disposals and Deconsolidations (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>surgical_facility</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>business_entity</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from disposals of facilities and other assets</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Fair value of investments</a></td>
<td class="nump">9.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of Individually Immaterial Business Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of businesses acquired | business_entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_DisposalGroupOneMember', window );">Disposal Group One | Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from disposals of facilities and other assets</a></td>
<td class="nump">11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Pre-tax loss on disposals and deconsolidations</a></td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration', window );">Number of surgical facilities contributed as non-cash consideration | surgical_facility</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Number Of Surgical Facilities Contributed As Non-Cash Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 5D<br> -Subparagraph (SX 210.12-13D(Column C))<br> -URI http://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=SL120429264-123010<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -URI http://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_DisposalGroupOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_DisposalGroupOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331701025320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Summary (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease obligations</a></td>
<td class="nump">$ 507.7<span></span>
</td>
<td class="nump">$ 364.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized debt issuance costs and discounts</a></td>
<td class="num">(15.8)<span></span>
</td>
<td class="num">(16.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities', window );">Total debt</a></td>
<td class="nump">3,093.2<span></span>
</td>
<td class="nump">2,938.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Less: Current maturities</a></td>
<td class="nump">68.0<span></span>
</td>
<td class="nump">60.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Total long-term debt</a></td>
<td class="nump">3,025.2<span></span>
</td>
<td class="nump">2,878.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Senior secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">1,527.0<span></span>
</td>
<td class="nump">1,530.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Unamortized fair value discount (premium)</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 6.750% senior unsecured notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 370.0<span></span>
</td>
<td class="nump">370.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 10.000% senior unsecured notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 545.0<span></span>
</td>
<td class="nump">545.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sgry_NotesPayableAndSecuredLoansMember', window );">Notes payable and other secured loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 159.3<span></span>
</td>
<td class="nump">$ 145.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28567-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, including portion classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_A2017TermLoanMaturing2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_A2017TermLoanMaturing2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sgry_NotesPayableAndSecuredLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sgry_NotesPayableAndSecuredLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331706163816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Narrative (Details) - Secured Debt - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Availability on line of credit instrument</a></td>
<td class="nump">$ 203,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | The Revolver</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount of line of credit outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Availability on line of credit instrument</a></td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_A2017SeniorSecuredCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_A2017SeniorSecuredCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331703891240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Components of Right-of-us Assets and Liabilities Related to Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Property and equipment, net of accumulated depreciation of $294.6 and $272.3, respectively<span></span>
</td>
<td class="text">Property and equipment, net of accumulated depreciation of $294.6 and $272.3, respectively<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Less: Current maturities<span></span>
</td>
<td class="text">Less: Current maturities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Long-term debt, less current maturities<span></span>
</td>
<td class="text">Long-term debt, less current maturities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 277.4<span></span>
</td>
<td class="nump">$ 324.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease assets</a></td>
<td class="nump">467.6<span></span>
</td>
<td class="nump">329.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_LeaseRightOfUseAsset', window );">Total leased assets</a></td>
<td class="nump">745.0<span></span>
</td>
<td class="nump">653.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current</a></td>
<td class="nump">35.2<span></span>
</td>
<td class="nump">40.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term</a></td>
<td class="nump">272.1<span></span>
</td>
<td class="nump">315.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">307.3<span></span>
</td>
<td class="nump">355.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityAbstract', window );"><strong>Finance lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current</a></td>
<td class="nump">22.9<span></span>
</td>
<td class="nump">19.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term</a></td>
<td class="nump">484.8<span></span>
</td>
<td class="nump">345.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease obligations</a></td>
<td class="nump">507.7<span></span>
</td>
<td class="nump">364.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_LeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 815.0<span></span>
</td>
<td class="nump">$ 720.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_LeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_LeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331701410712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_IncreaseDecreaseInFinanceLeaseLiability', window );">Increase in finance lease liabilities</a></td>
<td class="nump">$ 146.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_IncreaseDecreaseInFinanceLeaseRightOfUseAssets', window );">Increase in finance lease assets</a></td>
<td class="nump">145.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Decrease in operating lease liabilities</a></td>
<td class="nump">60.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_IncreaseDecreaseInOperatingLeaseRightOfUseAssets', window );">Decrease in operating lease assets</a></td>
<td class="nump">$ 59.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_IncreaseDecreaseInFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Finance Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_IncreaseDecreaseInFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_IncreaseDecreaseInFinanceLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Finance Lease, Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_IncreaseDecreaseInFinanceLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_IncreaseDecreaseInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Operating Lease, Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_IncreaseDecreaseInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331701315032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Expense and Cash Flow Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 16.1<span></span>
</td>
<td class="nump">$ 18.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_FinanceLeaseCost1Abstract', window );"><strong>Finance lease costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of leased assets</a></td>
<td class="nump">9.2<span></span>
</td>
<td class="nump">7.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">9.9<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_FinanceLeaseCost', window );">Total finance lease costs</a></td>
<td class="nump">19.1<span></span>
</td>
<td class="nump">13.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_VariableAndShortTermLeaseCost', window );">Variable and short-term lease costs</a></td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">39.6<span></span>
</td>
<td class="nump">37.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_CashFlowLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash outflows from operating leases</a></td>
<td class="nump">15.6<span></span>
</td>
<td class="nump">18.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash outflows from finance leases</a></td>
<td class="nump">9.8<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash outflows from finance leases</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease obligations</a></td>
<td class="nump">22.0<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for finance lease obligations</a></td>
<td class="nump">$ 89.3<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_CashFlowLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_CashFlowLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_FinanceLeaseCost1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Cost1 [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_FinanceLeaseCost1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_VariableAndShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable And Short-Term Lease, Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_VariableAndShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331701274728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Hedging Activities - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>interest_rate_swap</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths', window );">Amount estimated to be reclassified as a reduction to interest expense over next 12 months</a></td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative notional amount</a></td>
<td class="nump">$ 1,529.8<span></span>
</td>
<td class="nump">$ 1,533.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of interest rate swaps | interest_rate_swap</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Derivatives in cash flow hedging relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative notional amount</a></td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember', window );">Interest Rate Cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of interest rate swaps | interest_rate_swap</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember', window );">Interest Rate Cap | Derivatives in cash flow hedging relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative notional amount</a></td>
<td class="nump">$ 329.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ThreePayFixedInterestRateSwapsMember', window );">Three Pay-fixed Interest Rate Swaps | LIBOR | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeVariableInterestRate', window );">Variable interest rate of derivative instrument (percent)</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ThreePayFixedInterestRateSwapsMember', window );">Three Pay-fixed Interest Rate Swaps | Derivatives not designated as hedging instruments | LIBOR | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeVariableInterestRate', window );">Variable interest rate of derivative instrument (percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ThreeReceiveFixedInterestRateSwapsMember', window );">Three Receive-fixed Interest Rate Swaps | Derivatives not designated as hedging instruments | LIBOR | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeVariableInterestRate', window );">Variable interest rate of derivative instrument (percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable interest rate in effect as of the balance sheet date related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfInterestRateDerivativesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of interest rate derivative instruments held by the entity at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfInterestRateDerivativesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ThreePayFixedInterestRateSwapsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_ThreePayFixedInterestRateSwapsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ThreeReceiveFixedInterestRateSwapsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_ThreeReceiveFixedInterestRateSwapsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331701455128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivatives and Hedging Activities - Interest Rate Swaps and Interest Rate Caps Outstanding (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">$ 67.2<span></span>
</td>
<td class="nump">$ 23.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="num">(47.0)<span></span>
</td>
<td class="num">(58.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative notional amount</a></td>
<td class="nump">1,529.8<span></span>
</td>
<td class="nump">1,533.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapOneMember', window );">Pay-fixed swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">435.0<span></span>
</td>
<td class="nump">435.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapTwoMember', window );">Pay-fixed swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">330.0<span></span>
</td>
<td class="nump">330.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapThreeMember', window );">Pay-fixed swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">435.0<span></span>
</td>
<td class="nump">435.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_InterestRateCapOneMember', window );">Interest rate cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">164.9<span></span>
</td>
<td class="nump">166.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_InterestRateCapTwoMember', window );">Interest rate cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">164.9<span></span>
</td>
<td class="nump">166.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapFourMember', window );">Pay-fixed swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">165.0<span></span>
</td>
<td class="nump">165.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapFiveMember', window );">Pay-fixed swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">120.0<span></span>
</td>
<td class="nump">120.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapSixMember', window );">Pay-fixed swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">150.0<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ReceiveFixedSwapOneMember', window );">Receive-fixed swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="num">(165.0)<span></span>
</td>
<td class="num">(165.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ReceiveFixedSwapTwoMember', window );">Receive-fixed swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="num">(120.0)<span></span>
</td>
<td class="num">(120.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ReceiveFixedSwapThreeMember', window );">Receive-fixed swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="num">$ (150.0)<span></span>
</td>
<td class="num">$ (150.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_InterestRateCapOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_InterestRateCapOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_InterestRateCapTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_InterestRateCapTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_PayFixedSwapSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ReceiveFixedSwapOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_ReceiveFixedSwapOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ReceiveFixedSwapTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_ReceiveFixedSwapTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sgry_ReceiveFixedSwapThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sgry_ReceiveFixedSwapThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331701166392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivatives and Hedging Activities - Derivatives Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">$ 67.2<span></span>
</td>
<td class="nump">$ 23.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">47.0<span></span>
</td>
<td class="nump">58.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DerivativeLiabilityNotionalAmountFinancingComponent', window );">Derivative liability, notional amount, financing component</a></td>
<td class="nump">42.4<span></span>
</td>
<td class="nump">45.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments | Other long-term assets | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments | Other long-term liabilities | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">12.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives in cash flow hedging relationships | Other long-term assets | Interest Rate Cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">11.1<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives in cash flow hedging relationships | Other long-term liabilities | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Derivative asset, notional amount</a></td>
<td class="nump">$ 51.4<span></span>
</td>
<td class="nump">$ 8.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DerivativeLiabilityNotionalAmountFinancingComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative Liability, Notional Amount, Financing Component</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DerivativeLiabilityNotionalAmountFinancingComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331701034184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Hedging Activities - Pre-tax Effect of Derivatives on AOCI and Statement of Operations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax', window );">Amortization of accumulated OCI related</a></td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedging instruments | Other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Loss recognized in income</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives in cash flow hedging relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Gain recognized in OCI (effective portion)</a></td>
<td class="num">(50.4)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives in cash flow hedging relationships | Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Loss recognized in income</a></td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from discontinuance of cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331710473880">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Summary (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Surgery Partners, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 12.2<span></span>
</td>
<td class="num">$ (21.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Less: Amounts attributable to participating securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(10.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to common stockholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 12.2<span></span>
</td>
<td class="num">$ (31.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding- basic (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">87,995<span></span>
</td>
<td class="nump">54,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding- diluted (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">90,272<span></span>
</td>
<td class="nump">54,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Income (loss) per share:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in USD per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in USD per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Income (loss) per share:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities outstanding not included in the computation of income (loss) per share as their effect is antidilutive (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,634<span></span>
</td>
<td class="nump">1,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Income (loss) per share:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities outstanding not included in the computation of income (loss) per share as their effect is antidilutive (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">643<span></span>
</td>
<td class="nump">1,410<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The impact of potentially dilutive securities for the three months ended March 31, 2021 was not considered because the effect would be anti-dilutive.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2793-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331701032328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Current Liabilities - Summary (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Right-of-use operating lease liabilities</a></td>
<td class="nump">$ 35.2<span></span>
</td>
<td class="nump">$ 40.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">36.0<span></span>
</td>
<td class="nump">29.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_PayablesToCustomers', window );">Amounts due to patients and payors</a></td>
<td class="nump">32.7<span></span>
</td>
<td class="nump">26.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_CostReportLiabilitiesCurrent', window );">Cost report liabilities</a></td>
<td class="nump">22.5<span></span>
</td>
<td class="nump">26.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_TaxReceivableAgreementLiabilityCurrent', window );">Tax receivable agreement liability</a></td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">74.5<span></span>
</td>
<td class="nump">68.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 221.1<span></span>
</td>
<td class="nump">$ 210.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_CostReportLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost Report Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_CostReportLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_TaxReceivableAgreementLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Receivable Agreement Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_TaxReceivableAgreementLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PayablesToCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount payable to customer by broker-dealer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Rule 15c3-1<br> -Number 240<br> -Section 15c3-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PayablesToCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331704773240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Professional, general and workers' compensation insurance reserve</a></td>
<td class="nump">$ 18.9<span></span>
</td>
<td class="nump">$ 18.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EstimatedInsuranceRecoveries', window );">Expected insurance recoveries</a></td>
<td class="nump">8.7<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation settlement</a></td>
<td class="nump">32.8<span></span>
</td>
<td class="nump">$ 32.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm', window );">Projected tax savings period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal effective tax rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrentAndNoncurrent', window );">Long-term tax receivable agreement liability</a></td>
<td class="nump">22.0<span></span>
</td>
<td class="nump">$ 22.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount', window );">Net long-term tax receivable agreement liability</a></td>
<td class="nump">$ 20.2<span></span>
</td>
<td class="nump">$ 20.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember', window );">Federal Funds Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate', window );">Collaborative tax agreement, basis spread on variable rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">LIBOR | Materially More Restrictive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">LIBOR | Not Materially More Restrictive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Tax Agreement, Interest Rate, Basis Spread on Variable Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Tax Agreement, Projected Tax Savings, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Income Tax Liabilities, Net Of Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EstimatedInsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EstimatedInsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelfInsuranceReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelfInsuranceReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualRiskOrUncertaintyByNatureAxis=sgry_MateriallyMoreRestrictiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualRiskOrUncertaintyByNatureAxis=sgry_MateriallyMoreRestrictiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualRiskOrUncertaintyByNatureAxis=sgry_NotMateriallyMoreRestrictiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualRiskOrUncertaintyByNatureAxis=sgry_NotMateriallyMoreRestrictiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331705146712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Revenues and Operating Income by Reportable Segment (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 596.2<span></span>
</td>
<td class="nump">$ 512.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.1<span></span>
</td>
<td class="nump">72.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Reconciliation of Adjusted EBITDA:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Income before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.1<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30.6)<span></span>
</td>
<td class="num">(31.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.4<span></span>
</td>
<td class="nump">25.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.3<span></span>
</td>
<td class="nump">53.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts', window );">Transaction, integration and acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.1<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation', window );">Gain on disposals and deconsolidations, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts', window );">(Gain) loss on litigation settlement and other litigation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30.8)<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.1<span></span>
</td>
<td class="nump">72.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Transaction and integration costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.1<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Start-up costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Other litigation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation settlement</a></td>
<td class="num">$ (32.8)<span></span>
</td>
<td class="num">(32.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Surgical Facility Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">578.8<span></span>
</td>
<td class="nump">495.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.0<span></span>
</td>
<td class="nump">95.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Reconciliation of Adjusted EBITDA:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.0<span></span>
</td>
<td class="nump">95.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Ancillary Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.4<span></span>
</td>
<td class="nump">16.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Reconciliation of Adjusted EBITDA:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">All other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24.0)<span></span>
</td>
<td class="num">(21.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Reconciliation of Adjusted EBITDA:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (24.0)<span></span>
</td>
<td class="num">$ (21.2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Integration Related Costs, And Merger Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Before Interest Taxes Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Disposition of Assets And Deconsolidation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_GainLossOnDispositionOfAssetsAndDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) Related to Litigation Settlement And Other Litigation Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sgry_SurgicalFacilityServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sgry_SurgicalFacilityServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sgry_AncillaryServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sgry_AncillaryServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331703881000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 6,289.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,117.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Total cash purchases of property and equipment</a></td>
<td class="nump">18.2<span></span>
</td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Surgical Facility Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">5,651.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,552.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Total cash purchases of property and equipment</a></td>
<td class="nump">17.7<span></span>
</td>
<td class="nump">14.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Ancillary Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">44.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Total cash purchases of property and equipment</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">All other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">593.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 517.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Total cash purchases of property and equipment</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sgry_SurgicalFacilityServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sgry_SurgicalFacilityServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sgry_AncillaryServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sgry_AncillaryServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140331701366152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($) </div>
<div>non-controlling_interest</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire equity method investments | $</a></td>
<td class="nump">$ 48.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired', window );">Number of non-controlling interests in surgical facilities acquired</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired', window );">Number of non-controlling interests in in-development de novo surgical facilities acquired</a></td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Non-Controlling Interests In In-Development De Novo Surgical Facilities Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Non-Controlling Interests In Surgical Facilities Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>sgry-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sgry="http://www.surgerypartners.com/20220331"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sgry-20220331.xsd" xlink:type="simple"/>
    <context id="i51617289ac834d6ba852340071fb7b89_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i650656e76ffc4d5eaefdd127e9d68ab3_I20220426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <instant>2022-04-26</instant>
        </period>
    </context>
    <context id="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i46ce349a7375461fa1b7f757dc08d081_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i65d685057ae641c3b746cf6377dd430f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i48d044e479254b2f8935070ff1a00ac4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i02439221d0d244d9bcd5569225a9eceb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i61d245da91744ed8b196945289f8015a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2faf06f152e04dfaac19ae85d0f6df18_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i64de719b0ad14503b4dba6762866534b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4a8fc7979812433d8763ce3c5642dc80_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0a837d715cbc4966875dc62f6e78cbd7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idf10b9430f6847b490ed2cf648c93e32_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1aeda0f667e349c086a29bab4acce588_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib0cfdca28efe4489bed9689a67756a3c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i253dec092e2d41f28b85f643ccdd68cd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i44d8b197c09347a5bfe50b624fa0d5b3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0a8cdfe2cc68416e866d30dbf21372d9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1114172ce5094c68bedb86e8b7d44cb7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib49a1cb0982e43ec901c64053a39f745_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia510a69b8e64403eb11f83898b8a08ec_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic00c0198779b477e9adb83fad573131e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id5cf9408c2ea45248462023da0418e49_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i07efbfabca9b4e33acccafb2fe2d7c82_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8070a501ab2c40589c94526f6bda6ebe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i25ae47e0aa9a4921a427c583c4ff6645_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2930feb3f5944505ad4c3d63f26d5f4f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i635f7b61fc044f528748645b77893543_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifeb7edc101bf4e3ca14bd0a2df3bec5f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iacb41fa48e0c4c0280b70a8b8b967a6c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib052d4f8c5ef41118d1450786f139047_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if23681243e73450cb3fa31d9cffac2b7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i58b12b437d5442cbbfda520a3f432240_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia2e53044aa4142028b8b7d9863d3accb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id4c0aada0e14421286ede0517722bf59_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i10d1f1007efc4b109adc6675a736352c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i01ae3c8148ba4c25b35336360e5e7dc2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:FacilitiesAmbulatorySurgeryCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib0b5bb8fa6d646029f554028ebaa467d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:FacilitiesSurgicalHospitalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i88ed6b4d58e5453984121369f4f11efc_D20200327-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <startDate>2020-03-27</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if6defdbda29a4879a3bd483aed3cec04_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i637e4d2ab4e8411490e75163721ebd0f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaf52a3e1a85b4de2af6a8274e5c65a76_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i506df12890674df3996c010a349ca7c0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2db8fa84c09d480799b76b68681936d9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8ad5676bd3f84e0d8244dd53d99a6a10_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9ed8c6b6471245ee8d17d81941bd3725_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idcfcf6c0b474488abf86dd8a19ab641d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib8e675c069904c2e8d2f8233b2f7c50c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idfcab3d9997245d19b06ae33b0d19589_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13642547953b42fdb47054b1218975af_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i966e8ae61ccd4f959e269cc4f8b50a26_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia4c64a5508684384921c71fc65d53263_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibc4246d5efcb4678b5c651d7a3105ea2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia76476dcbd9b4daa8c5d611fe63a4b6f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifdeef4374f4d4416b5733b872ca3567b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iccee81bad7154b409425f6d227df3575_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc7c7055d90440d89c4a9125446ce784_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id4d0a1269abf4dceb2f3b53070b65c94_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifa35c00cc5c94cc98aa5fc428cac0a9a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i60c5087599d24a0695f4e51d9b7328cd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5fdee6a1e69f430b9fc7afc764249da1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8c305d408ef046519c734c40b5368141_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib886d75d98b64a8ba3306ec5ed447ea9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i69bd64deadca4e6987ccdd1fe1a5acd1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i959b5b49ffbc4125a8ae719a2e147008_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2a4abce686244862adef8618f10a35ed_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib2581fac27134361aaf1f3ca3c3db4de_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i32fa0d6361714af289d98b250659260a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib355fe300c3849b69133727cc10b4d92_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i27472f8f1c174b2aa18b1c47df6601f6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3b35f441d1234c148a0c51b5feb19edd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic27723e5b1494789a14c6e03c6cef1d1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia93d7f09a5db46538ab762616820eb2b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i319afcfd65824c03b4113efb64fc3b29_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GovernmentContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6669ea6cc07c457ab9a998a810a31b86_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iccb4e1634f8c4cbf9f988a392008a061_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1a3ac13dcce1497ea3da4a85c473c3c3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4ad6e3e1169d4e76ac6ee8f514dd661a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8520c7f7026a4db4b18532d86207d82e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i47646e2fdd1a4fe7a52ba359cf577a71_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if2c5800e21be4fe29d33c18b7bcf1f2a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0024968fe06e453fbbb57a1a738a5ea7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i094886c1cfb34257a319635071262fdd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibc8bc1d058e74796a84a897fcabea948_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iccfe7b6d79b74feb8e7a7078913f412a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6bffa160d95c4aa38530da4f45398c33_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i23a8281e1b3a4519bcf1d6d34c3cddf9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i13eb2c0495f34e2bbb3d47dd7920135f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie823b906c9164e118eff58dafb9c18ce_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id6de0b52340d4ee0be44beb83074a915_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesExistingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idc9abc5f15644909ae180fa28f65f13e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib803580ff3fd404097fe48426bec1d0b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i97af3ba9bf154ce48824c269e037ff4f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:DisposalGroupOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i64cc0a22695c41e39895df392aa6ef14_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:DisposalGroupOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i23157d624d184f359c7bfa4ba8b5e305_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iabc81fe53c8740a5835ce19d18a21d80_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1c6502e60a4b4f40b2ab3906a1e7320a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6f81ce56efe4167827c87bda7c7d7ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic09d86ac1f06413595ed16720d86db9a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6efe1dcecbea4bcbbe13edfdc24585b8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sgry:NotesPayableAndSecuredLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4d53ad311174404c83910a5b4a784afd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sgry:NotesPayableAndSecuredLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d81a2e35ef544709f6c3c5a6ec09d33_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib597d64d1a7b476fa1d8e9c70fa2d9c6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6ed7fc212be442dab6bdeb5bf9fc9902_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic6f105cec2c74bac8f0818b041444a8f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i83e7577cfc3e485fa204871cd2bebed9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia5195b743fe34283b9ca5fca00063c24_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia71c20142f984a65b73126b2fc598e6b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibfefa22461da4d3d8abc5576226480fb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iae1b34f8d424499badf3a4c4c1482bff_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ThreePayFixedInterestRateSwapsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie0cd5769098e47f6a43dac3d7b1801fc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ThreePayFixedInterestRateSwapsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i35f44859d11f47c1b1e53d1b04378a95_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ThreeReceiveFixedInterestRateSwapsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i612b998bf6814f52b34921481a7fed42_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6feaa769eee6494280e04ca4428e2d1e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id325fcdc0f7c47528506f54fa3611300_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib8b44c0e1c7740bd90f41c1945029459_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia15782f2cb274cddb56795539491873a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id9d8edabf0d9426fb79d750950a72128_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i110b4a998ba9459cb22bd9c1786eb35f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:InterestRateCapOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i36389bf37a7143988be57524833186e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:InterestRateCapOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if939f474cbd9448a890aaa8ad9497a6c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:InterestRateCapTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i470b3213c5384e66a7ea1d5fe3c19aec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:InterestRateCapTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i482b7170e0e44958a6bccac3fb8b4bb1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifc2a066e204b487d9b869bbac4264ca0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b59666e5a6445af800a6e82b2247fa6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i72dbce711df14aa19565cfda8712ae96_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i279c0b5c9ef6400db373978fe16df294_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8205810c50914fc8b2ee5716cdd1e3ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:PayFixedSwapSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5179e2adfc75478a8bceb8a842e8343d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i06b61d1351f642c39e07376db16278bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1c751ca3945547ff89766e783b1692c2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifec07c218a224559988b65a85dca34bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75a4d54131d04ec7a9ad66d50af16a7e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i746cdb6a8857465b8789529fa778ae72_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sgry:ReceiveFixedSwapThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i052e333e8fbc4c8d828f8652b2a87288_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie234fc584e43432db473ff2d1b925b9b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5395316d4cc4c4cb5531fc9710de0ef_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4ed5590de58f45ffa296c26e82b8cb5d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3dd7a0c476e3425a9cd8fdf81d246d59_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i290ced8dda3d48ff99a0576554a33576_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i86d66d0402e1453c9f1b3777c6d974bd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5ff93bdfad7b424a8bf0ec3d14822809_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i774a5b342a17415398ee546db06a900e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i393e1260928244db91312ff5bdb20b39_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i187ebd1016734402ac3d28311bd88d06_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id1b3debb3c6a4868aa2e70b6925bc311_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie6066679117046deaa28e14ca575fd6b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i79f21a0125dd44b3a07effa007c432cf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2d0118a56e5349658c4a7dc1533913ce_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i67c06ab0cc1645feb07263a0b462f478_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i06587c3ef400423ab6d0e0c77f4b8182_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i17ca4d1cea4549488f03f41d62feb261_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i39d94629b8b54e53a9a62a201b44250b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i49e70dcd4ab4442e93dc776b77191c75_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icf580ac915f4455f888d4bffc00ceccd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i62d2751322cd45d690eae0422a55f102_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">sgry:MateriallyMoreRestrictiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2ae955700f5a407192e0f30ca8c9cef7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">sgry:NotMateriallyMoreRestrictiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i06f4c1e12ebf42428954114c64170b8b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i95c194ebfbd94fa8a271308daec9afbb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id484bee12a474b8bbcedacad3a0e452e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia230717bfdb149e5b55ed8b1922373c3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i37cfe03bc9ed4713b3b1e61e87a612c2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id144f2f56936461e8128c2d94933dc55_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if2df432d764946c98419eddd4b217200_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i30d11e9517014207867a3d78c850cb1c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i241a5e9cb633484a83e8b37dd0d53c59_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i405edebb54534016a7214669c2bd5d18_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67f8f1225fb34764b0261414fc217735_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1a3f22cbbd5f47d4955fd2c0473366ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95727e44b2eb479d8bbcd65296068f83_D20220401-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="iea161d59c161497f8a5bb07b4bdb04b9_D20220401-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="surgical_facility">
        <measure>sgry:surgical_facility</measure>
    </unit>
    <unit id="state">
        <measure>sgry:state</measure>
    </unit>
    <unit id="physician_practice">
        <measure>sgry:physician_practice</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="business_entity">
        <measure>sgry:business_entity</measure>
    </unit>
    <unit id="interest_rate_swap">
        <measure>sgry:interest_rate_swap</measure>
    </unit>
    <unit id="segment">
        <measure>sgry:segment</measure>
    </unit>
    <unit id="non-controlling_interest">
        <measure>sgry:non-controlling_interest</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180L2ZyYWc6ZDZiOGQzMjQ4NTlkNDMyZmFkMGQwMzUyNzBiOTRiMWEvdGFibGU6ODhjNTZkM2E4YjA1NGRjYzhiMDNiOTFhZmNmOWE0YmYvdGFibGVyYW5nZTo4OGM1NmQzYThiMDU0ZGNjOGIwM2I5MWFmY2Y5YTRiZl80LTEtMS0xLTM5OTM2_ea5404c5-5e3c-4553-aa2c-8553d7335f06">0001638833</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180L2ZyYWc6ZDZiOGQzMjQ4NTlkNDMyZmFkMGQwMzUyNzBiOTRiMWEvdGFibGU6ODhjNTZkM2E4YjA1NGRjYzhiMDNiOTFhZmNmOWE0YmYvdGFibGVyYW5nZTo4OGM1NmQzYThiMDU0ZGNjOGIwM2I5MWFmY2Y5YTRiZl81LTEtMS0xLTM5OTM2_206b70ea-2ed7-4a14-a1fa-21bc93354d25">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180L2ZyYWc6ZDZiOGQzMjQ4NTlkNDMyZmFkMGQwMzUyNzBiOTRiMWEvdGFibGU6ODhjNTZkM2E4YjA1NGRjYzhiMDNiOTFhZmNmOWE0YmYvdGFibGVyYW5nZTo4OGM1NmQzYThiMDU0ZGNjOGIwM2I5MWFmY2Y5YTRiZl85LTEtMS0xLTM5OTM2_e663c5f0-d96e-4f1e-8691-6a09e9162262">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180L2ZyYWc6ZDZiOGQzMjQ4NTlkNDMyZmFkMGQwMzUyNzBiOTRiMWEvdGFibGU6ODhjNTZkM2E4YjA1NGRjYzhiMDNiOTFhZmNmOWE0YmYvdGFibGVyYW5nZTo4OGM1NmQzYThiMDU0ZGNjOGIwM2I5MWFmY2Y5YTRiZl8xMC0xLTEtMS0zOTkzNg_95b052af-51de-48ee-a71a-c2da7861d98e">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180L2ZyYWc6ZDZiOGQzMjQ4NTlkNDMyZmFkMGQwMzUyNzBiOTRiMWEvdGFibGU6ODhjNTZkM2E4YjA1NGRjYzhiMDNiOTFhZmNmOWE0YmYvdGFibGVyYW5nZTo4OGM1NmQzYThiMDU0ZGNjOGIwM2I5MWFmY2Y5YTRiZl8xMS0xLTEtMS0zOTkzNg_52bac0e9-743b-4dfc-a8da-2421da67c2ab">false</dei:AmendmentFlag>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNC0yLTEtMS00NjQ2Ng_0f2dda77-9e14-4a9d-bd4c-1fca9c544334">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNC0yLTEtMS00NjQ2Ng_32523eef-34e6-4b2a-913b-0c4967f1b23d">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfOS0yLTEtMS00NjQ2OA_4491f22a-c2d0-4ffb-9a7d-8129b50d1a26">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfOS0yLTEtMS00NjQ2OA_e2b110e3-da5b-424a-8c7d-d3e258e86a47">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTMtMi0xLTEtNDY0NzI_4d4afb66-9139-4863-9c1e-c7148377256b">http://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligationsCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTMtMi0xLTEtNDY0NzI_822c6ee1-f967-42b7-8426-35b31d91efae">http://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligationsCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTQtMi0xLTEtNDY0Nzc_9fb4ebe5-aa6a-445d-86cd-135374660488">http://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTQtMi0xLTEtNDY0Nzc_f854c062-dd64-4d2b-a477-9bd1f49a42d6">http://fasb.org/us-gaap/2021-01-31#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzM3_12a76239-81db-4f5e-96b4-e272f4bae61c">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzQx_da939a36-8510-4488-9b1f-84710acd95c2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yOTg_6be44b66-2886-4b1a-a3c6-4ee7dfa7d7e3">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzUy_fd65bf6f-bfc9-4e22-8c33-54d26ae7dc2e">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzM4_24a7b917-a5ea-458f-b576-2c2f4c37855d">001-37576</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzQ3_f104a784-081b-4949-b955-0b050a30978c">Surgery Partners, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGFibGU6NTZhNDg4MGJjNjM2NGUwOTgyYjRkMjI0Y2M3MThkZmMvdGFibGVyYW5nZTo1NmE0ODgwYmM2MzY0ZTA5ODJiNGQyMjRjYzcxOGRmY18wLTAtMS0xLTM5OTM2_f7894b43-d092-42ed-8e31-09e84aef5f85">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGFibGU6NTZhNDg4MGJjNjM2NGUwOTgyYjRkMjI0Y2M3MThkZmMvdGFibGVyYW5nZTo1NmE0ODgwYmM2MzY0ZTA5ODJiNGQyMjRjYzcxOGRmY18wLTItMS0xLTM5OTM2_3f674c14-fc68-4bf6-90b9-3ea8e9141498">47-3620923</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzUz_2705d7f5-9808-4bca-8577-aadbb3e316f5">310 Seven Springs Way, Suite&#160;500</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzQ5_f86982b4-7430-402e-bb76-0c9d074a55e7">Brentwood</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzQz_2bd5a531-924a-46ea-9df3-48fbf7866b37">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzQw_cb5ab6e8-f87a-47f6-99dd-c09e01706044">37027</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzQ0_0a927710-4df0-462d-b7a1-e808675abcbb">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzQ1_36d53f02-673d-4ee0-ba99-49775b0b3993">234-5900</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGFibGU6YTE3NjljMzI4ZjA4NDZiNWIxOTgwNmEzNzBmZWFjNjgvdGFibGVyYW5nZTphMTc2OWMzMjhmMDg0NmI1YjE5ODA2YTM3MGZlYWM2OF8xLTAtMS0xLTM5OTM2_b4b088cf-b18f-4400-a8a1-f7a72b218234">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGFibGU6YTE3NjljMzI4ZjA4NDZiNWIxOTgwNmEzNzBmZWFjNjgvdGFibGVyYW5nZTphMTc2OWMzMjhmMDg0NmI1YjE5ODA2YTM3MGZlYWM2OF8xLTItMS0xLTM5OTM2_ba375e4a-e093-4bda-8b15-5ce8671f5393">SGRY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGFibGU6YTE3NjljMzI4ZjA4NDZiNWIxOTgwNmEzNzBmZWFjNjgvdGFibGVyYW5nZTphMTc2OWMzMjhmMDg0NmI1YjE5ODA2YTM3MGZlYWM2OF8xLTQtMS0xLTM5OTM2_6535126d-7d3e-474a-8bbb-1a80105a20e7">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzU0_c64a9d94-9690-4dab-98a0-1791e97661b8">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzUw_bef0f763-5c81-4227-8299-ff4a5385b5c4">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGFibGU6MzdlOTgwM2YwZTI4NDdmNzlmMmVmMDQ4NzMyNWU2YTQvdGFibGVyYW5nZTozN2U5ODAzZjBlMjg0N2Y3OWYyZWYwNDg3MzI1ZTZhNF8wLTAtMS0xLTQxNDY4L3RleHRyZWdpb246YzM1N2YzYmZkYTk5NDllNGExNjY4ZmZiZmQyYTBkNWZfMTA5OTUxMTYyNzgyOQ_483ddcb6-6e0b-4cae-8442-2973e16d4c0c">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGFibGU6MzdlOTgwM2YwZTI4NDdmNzlmMmVmMDQ4NzMyNWU2YTQvdGFibGVyYW5nZTozN2U5ODAzZjBlMjg0N2Y3OWYyZWYwNDg3MzI1ZTZhNF8xLTItMS0xLTM5OTM2L3RleHRyZWdpb246M2U1YzBkNDUwYmM1NDE2NDgxMTIzY2U4MDNhNTlhZDRfMzA_f789d5fb-1519-45f2-aa30-e201aabbace7">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGFibGU6MzdlOTgwM2YwZTI4NDdmNzlmMmVmMDQ4NzMyNWU2YTQvdGFibGVyYW5nZTozN2U5ODAzZjBlMjg0N2Y3OWYyZWYwNDg3MzI1ZTZhNF8yLTItMS0xLTM5OTM2L3RleHRyZWdpb246YTJjNDFiYmE5MzY0NDE1MGFhYTJlN2FmZDlmMWM4NDlfMjg_b3bed20c-7488-4889-8ad5-8480155c6d22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMzUx_38aaff93-6a42-4043-9fba-2049215e5c1c">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i650656e76ffc4d5eaefdd127e9d68ab3_I20220426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xL2ZyYWc6NGUzNDhjOWEyNTQwNDQ5NWI1MGI4Njg0ZWNiY2VjYzEvdGV4dHJlZ2lvbjo0ZTM0OGM5YTI1NDA0NDk1YjUwYjg2ODRlY2JjZWNjMV8yMjgx_05910138-5342-49eb-b149-5ad56c1f22e4"
      unitRef="shares">89904299</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNC0yLTEtMS0zOTkzNg_ee43879a-75bd-49de-bf25-f4a2f3c01c3e"
      unitRef="usd">378900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNC00LTEtMS0zOTkzNg_d0da05c9-7a01-4227-82fd-70d91090561b"
      unitRef="usd">389900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNS0yLTEtMS0zOTkzNg_4cce10aa-f0fa-499b-b5a1-c498dd3f216a"
      unitRef="usd">412400000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNS00LTEtMS0zOTkzNg_9be79f8b-0dae-4bf9-ba71-1711ac490a3f"
      unitRef="usd">430200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNi0yLTEtMS0zOTkzNg_75cd2f04-651c-4195-b36e-71f7c8ce0782"
      unitRef="usd">62900000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNi00LTEtMS0zOTkzNg_a1180807-09ef-45fc-adc3-6c088709e3b2"
      unitRef="usd">61100000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNy0yLTEtMS0zOTkzNg_11f0c24b-c5f5-4170-9412-64e26ef66b7d"
      unitRef="usd">32200000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNy00LTEtMS0zOTkzNg_1b4a0c7a-8eb0-4261-b42f-d6f66abd93ee"
      unitRef="usd">25600000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfOC0yLTEtMS0zOTkzNg_04fac9aa-07e6-47e3-b298-f9994d678c99"
      unitRef="usd">50600000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfOC00LTEtMS0zOTkzNg_7132435c-0995-457a-8470-1b781c4f5f11"
      unitRef="usd">39300000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfOS0yLTEtMS0zOTkzNg_e934d6a4-d514-496e-8b59-9c6c9459d090"
      unitRef="usd">937000000.0</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfOS00LTEtMS0zOTkzNg_89947f46-5b2c-41d0-9407-790dcdfc47a6"
      unitRef="usd">946100000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTAtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjphYmE3YzI5NDYwMjI0YTg2YjdiZjE3MzA1OTVjZTI2YV82Mw_9c39f2fe-0bed-4166-87d7-c41b7d99f85f"
      unitRef="usd">294600000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTAtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjphYmE3YzI5NDYwMjI0YTg2YjdiZjE3MzA1OTVjZTI2YV83MA_0ee34bce-1836-4d11-8488-a9aae0c0697e"
      unitRef="usd">272300000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTAtMi0xLTEtMzk5MzY_020dff01-ccfa-4056-8c92-e5624700f940"
      unitRef="usd">778900000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTAtNC0xLTEtMzk5MzY_b30bdc30-3a64-4223-b271-c30505097576"
      unitRef="usd">629700000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTEtMi0xLTEtMzk5MzY_fc09bed6-fe22-4325-9bd9-f9119293d849"
      unitRef="usd">3967800000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTEtNC0xLTEtMzk5MzY_64308782-3a3b-4b1b-b771-0c218a6eb986"
      unitRef="usd">3955500000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTItMi0xLTEtMzk5MzY_eb1b3c9e-be53-4848-9dfe-451bdb691fee"
      unitRef="usd">94500000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTItNC0xLTEtMzk5MzY_4e345461-8ee2-4a12-9dba-3a9e2f78400f"
      unitRef="usd">88700000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTMtMi0xLTEtMzk5MzY_5b607240-8a12-41ed-bea5-0aa04ae905d9"
      unitRef="usd">277400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTMtNC0xLTEtMzk5MzY_78518414-ae32-4876-bcd1-18463ba223a8"
      unitRef="usd">324100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTQtMi0xLTEtMzk5MzY_3937a5d6-1c91-4e79-991b-1c44bdbb3a4c"
      unitRef="usd">113900000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTQtNC0xLTEtMzk5MzY_1fbfb0e8-285f-49af-8247-2d3c53f6f041"
      unitRef="usd">114400000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTUtMi0xLTEtMzk5MzY_541d4bf4-1abb-47b6-b125-e5a1676244f0"
      unitRef="usd">120000000.0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTUtNC0xLTEtMzk5MzY_8bbea040-9e0e-4117-b7de-16de7262194d"
      unitRef="usd">59100000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTYtMi0xLTEtMzk5MzY_a91e7878-1769-49ef-a182-2c2bc9cb8c06"
      unitRef="usd">6289500000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMTYtNC0xLTEtMzk5MzY_ca224ff3-15b7-45cb-860b-120b9e0a2318"
      unitRef="usd">6117600000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjAtMi0xLTEtMzk5MzY_cab37492-67f8-4122-8810-7032bc1add53"
      unitRef="usd">122900000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjAtNC0xLTEtMzk5MzY_f40dcdf9-21b5-41bf-b19d-53e056234495"
      unitRef="usd">124900000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjEtMi0xLTEtMzk5MzY_9f04466c-2189-4faa-a777-8c13c9ff400b"
      unitRef="usd">83800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjEtNC0xLTEtMzk5MzY_72161e07-2e5f-4607-9a99-acafcb1ec6bd"
      unitRef="usd">77100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <sgry:MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjItMi0xLTEtMzk5MzY_f134591f-3154-42d0-b08f-256e3f7ad2c4"
      unitRef="usd">46500000</sgry:MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent>
    <sgry:MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjItNC0xLTEtMzk5MzY_c23acc3e-f5d8-4c1d-93b6-8268ce2d8414"
      unitRef="usd">64400000</sgry:MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjMtMi0xLTEtMzk5MzY_2fd247db-9bdf-4a74-9c95-11f741e188de"
      unitRef="usd">221100000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjMtNC0xLTEtMzk5MzY_b29bd614-1f12-4fe0-87da-c9640c6bb53e"
      unitRef="usd">210000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjQtMi0xLTEtMzk5MzY_533e7844-c41d-4269-afb7-d1ecffbe43a5"
      unitRef="usd">68000000.0</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjQtNC0xLTEtMzk5MzY_d6f6e91b-084a-40e1-af95-3bde3f3461ae"
      unitRef="usd">60400000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjUtMi0xLTEtMzk5MzY_564d93ae-a5eb-44a2-9aae-38477761dc33"
      unitRef="usd">542300000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjUtNC0xLTEtMzk5MzY_87ad4a4b-ea52-418d-aac5-d26e93162cf1"
      unitRef="usd">536800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjYtMi0xLTEtMzk5MzY_6a396544-6861-4e6b-a7b8-e789fec5b92c"
      unitRef="usd">3025200000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjYtNC0xLTEtMzk5MzY_1afb652f-1fb0-4444-a6be-1e9e8dae9363"
      unitRef="usd">2878400000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjctMi0xLTEtMzk5MzY_29d32512-14e8-49d0-ae81-6abd67c6b618"
      unitRef="usd">272100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjctNC0xLTEtMzk5MzY_36614f0a-c8dc-471f-a31a-842df71f10d0"
      unitRef="usd">315600000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjgtMi0xLTEtMzk5MzY_6a546438-edc7-4103-9a81-cdc6b59687e0"
      unitRef="usd">95800000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMjgtNC0xLTEtMzk5MzY_e2c81be7-46fe-415d-8e30-66cc2baa3002"
      unitRef="usd">87000000.0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzAtMi0xLTEtMzk5MzY_d61b21d7-a77c-46ff-924f-dd99d285a59a"
      unitRef="usd">341500000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzAtNC0xLTEtMzk5MzY_2df9367e-5bf0-469e-b6b6-7bea28b6cfb9"
      unitRef="usd">330200000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzQtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjoxYzY3MTRiZWQ0ZmU0OTgwYjM3ZDcyNTc0ODU1MTg5Nl8yMQ_97fbe686-42ed-440b-a7cc-8236733fcf92"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzQtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjoxYzY3MTRiZWQ0ZmU0OTgwYjM3ZDcyNTc0ODU1MTg5Nl8yMQ_d0c3e131-a179-4135-a764-e9447cf519cb"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzQtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjoxYzY3MTRiZWQ0ZmU0OTgwYjM3ZDcyNTc0ODU1MTg5Nl81NQ_37f7f87c-49cf-44de-aed1-561443dea855"
      unitRef="shares">20310000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzQtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjoxYzY3MTRiZWQ0ZmU0OTgwYjM3ZDcyNTc0ODU1MTg5Nl81NQ_64bfd1c6-6545-4973-97c6-68bf143547ce"
      unitRef="shares">20310000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzQtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjoxYzY3MTRiZWQ0ZmU0OTgwYjM3ZDcyNTc0ODU1MTg5Nl85MA_22d7c400-77d1-47f8-8a5b-be5db7f13ecb"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzQtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjoxYzY3MTRiZWQ0ZmU0OTgwYjM3ZDcyNTc0ODU1MTg5Nl85MA_790972b5-ba16-44d7-8cf8-ea20b7b26668"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzQtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjoxYzY3MTRiZWQ0ZmU0OTgwYjM3ZDcyNTc0ODU1MTg5Nl85MA_b6ac732b-8d29-490a-97d1-4600b3ce3e04"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzQtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjoxYzY3MTRiZWQ0ZmU0OTgwYjM3ZDcyNTc0ODU1MTg5Nl85MA_c6e5f5c6-6c79-48a6-b155-3e4cb32f786a"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzQtMi0xLTEtMzk5MzY_7a9708a7-8891-4683-b4ca-ed0db75c34d4"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzQtNC0xLTEtMzk5MzY_d0206a27-8938-4060-8068-57f5f25f99b3"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzUtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjo5MWQ2ZjBjNTc4Njc0MDBmYjQ3NTM2ZDY5MGIyNDdjZl8xOA_1fb8236e-9ec5-41a3-912f-8635aea23694"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzUtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjo5MWQ2ZjBjNTc4Njc0MDBmYjQ3NTM2ZDY5MGIyNDdjZl8xOA_e9ec46b7-0644-4676-b750-229535b4a83e"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzUtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjo5MWQ2ZjBjNTc4Njc0MDBmYjQ3NTM2ZDY5MGIyNDdjZl81Mg_89502ce1-df92-4c39-8ab1-b8f517405d8b"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzUtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjo5MWQ2ZjBjNTc4Njc0MDBmYjQ3NTM2ZDY5MGIyNDdjZl81Mg_fd766783-9082-41ce-996f-d2d9ad7d69ee"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzUtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjo5MWQ2ZjBjNTc4Njc0MDBmYjQ3NTM2ZDY5MGIyNDdjZl84OA_1bba6c7f-dd20-4383-85f2-266602f3abd2"
      unitRef="shares">89904913</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzUtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjo5MWQ2ZjBjNTc4Njc0MDBmYjQ3NTM2ZDY5MGIyNDdjZl84OA_7a4dd198-e940-41a9-a046-563828eaaedb"
      unitRef="shares">89904913</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzUtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjo5MWQ2ZjBjNTc4Njc0MDBmYjQ3NTM2ZDY5MGIyNDdjZl85NQ_573fba06-cf88-43e8-8a8a-7481ea534822"
      unitRef="shares">89332557</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzUtMC0xLTEtMzk5MzYvdGV4dHJlZ2lvbjo5MWQ2ZjBjNTc4Njc0MDBmYjQ3NTM2ZDY5MGIyNDdjZl85NQ_6c3c7ed0-352c-4ce0-82f4-bc8e63776af4"
      unitRef="shares">89332557</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzUtMi0xLTEtMzk5MzY_0456cd0e-ec13-484a-8b00-2add76b4dc27"
      unitRef="usd">900000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzUtNC0xLTEtMzk5MzY_b72591ff-4de9-4b15-85ab-b412919beda8"
      unitRef="usd">900000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzYtMi0xLTEtMzk5MzY_6383324b-73ba-470c-8b5e-87fd0e0d03ce"
      unitRef="usd">1625200000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzYtNC0xLTEtMzk5MzY_968c9c1b-3e8b-440a-8f9b-13eb88125c2d"
      unitRef="usd">1622300000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzctMi0xLTEtMzk5MzY_addb573e-7c9a-43da-9d14-203aac414c2a"
      unitRef="usd">25300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzctNC0xLTEtMzk5MzY_a1b34ee2-5ad8-4275-802f-b62131354258"
      unitRef="usd">-31500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzgtMi0xLTEtMzk5MzY_28b99a02-f06f-463d-830c-783b66a30716"
      unitRef="usd">-490500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzgtNC0xLTEtMzk5MzY_54172555-9f28-463a-b314-13376669c85a"
      unitRef="usd">-502700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzktMi0xLTEtMzk5MzY_3e6b087f-b4f0-4542-948a-7dd99739acb1"
      unitRef="usd">1160900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfMzktNC0xLTEtMzk5MzY_c59d65c2-f653-40ad-8b0e-89e53075c4b2"
      unitRef="usd">1089000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNDAtMi0xLTEtMzk5MzY_ab1e7d57-f5f7-46f5-83e1-bba9a9816211"
      unitRef="usd">851700000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNDAtNC0xLTEtMzk5MzY_ff5960f1-0446-4bd1-bf93-7cbe557c50f5"
      unitRef="usd">880600000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNDEtMi0xLTEtMzk5MzY_1e3ccd80-1d10-4917-80ae-cc54b4b45d3d"
      unitRef="usd">2012600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNDEtNC0xLTEtMzk5MzY_35ea28e5-1748-44de-94f6-6bedc0e75e76"
      unitRef="usd">1969600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNDItMi0xLTEtMzk5MzY_e0a88f01-6fbe-4c2c-9a0f-eb82799a98b3"
      unitRef="usd">6289500000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xMy9mcmFnOmYzNGU4NTVjYjBkODQzZmY5MWQzYTQyNmUwYjYxMjFjL3RhYmxlOjY2NzQ4MmNhNjM4YjRjMjU4MTVkODI1ZDJiMjllZmU4L3RhYmxlcmFuZ2U6NjY3NDgyY2E2MzhiNGMyNTgxNWQ4MjVkMmIyOWVmZThfNDItNC0xLTEtMzk5MzY_68c34d70-b431-4683-9dc7-e4ae1257e01f"
      unitRef="usd">6117600000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMy0yLTEtMS0zOTkzNg_3d40a682-fc54-4c3c-bade-5962f09eef0b"
      unitRef="usd">596200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMy00LTEtMS0zOTkzNg_9bccfd8d-c814-4191-a303-d69474e0d145"
      unitRef="usd">512400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfNS0yLTEtMS0zOTkzNg_a3cdf6b0-940d-44c9-8de2-342f9de9e6e0"
      unitRef="usd">178900000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfNS00LTEtMS0zOTkzNg_1af48e6a-5f56-4b0a-a637-0a6d17d5d2af"
      unitRef="usd">151700000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:SuppliesExpense
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfNi0yLTEtMS0zOTkzNg_f5f0ef51-64ea-429e-a181-e29ceef4dbb2"
      unitRef="usd">171600000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfNi00LTEtMS0zOTkzNg_a72ab08a-b410-4f59-b392-ed96b3852e66"
      unitRef="usd">147300000</us-gaap:SuppliesExpense>
    <us-gaap:ProfessionalFees
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfNy0yLTEtMS0zOTkzNg_575592e9-9f89-44f8-ae68-18bf036d330c"
      unitRef="usd">63600000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfNy00LTEtMS0zOTkzNg_44252d69-3460-4443-8a6f-b7d50f00c05b"
      unitRef="usd">55500000</us-gaap:ProfessionalFees>
    <sgry:OperatingAndFinanceLeaseExpense
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfOC0yLTEtMS0zOTkzNg_fee238f0-df84-4d95-8fce-e89e01145905"
      unitRef="usd">20000000.0</sgry:OperatingAndFinanceLeaseExpense>
    <sgry:OperatingAndFinanceLeaseExpense
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfOC00LTEtMS0zOTkzNg_4a3a1abc-e0ee-4f7b-8c9d-20e527154e98"
      unitRef="usd">22800000</sgry:OperatingAndFinanceLeaseExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfOS0yLTEtMS0zOTkzNg_6e46291a-56a8-4bb9-8538-c78ec57b7025"
      unitRef="usd">37300000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfOS00LTEtMS0zOTkzNg_0d3d633e-3358-494c-a955-025009ba33aa"
      unitRef="usd">31600000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTAtMi0xLTEtMzk5MzY_5be87a48-5a46-4e07-93da-085cc9fd5bbd"
      unitRef="usd">471400000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTAtNC0xLTEtMzk5MzY_dd87dfbc-cf79-443c-a861-609a90d82648"
      unitRef="usd">408900000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTEtMi0xLTEtMzk5MzY_7383a8ef-8ec8-4165-be55-2dbefae6a9ac"
      unitRef="usd">29500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTEtNC0xLTEtMzk5MzY_2b6aa91e-ecb0-4ca5-b5be-74084b291e30"
      unitRef="usd">26800000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTItMi0xLTEtMzk5MzY_ffd327f2-bd5b-4802-ae36-d9d3f9590e30"
      unitRef="usd">27400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTItNC0xLTEtMzk5MzY_f7c36219-1805-4efd-8043-d7680d57018e"
      unitRef="usd">25700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTMtMi0xLTEtNDU5NDI_52ac4cd4-1979-4620-886d-a06ebef56133"
      unitRef="usd">7100000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTMtNC0xLTEtNDU5NDI_268af92e-c3f4-480b-870c-ec3f226f598b"
      unitRef="usd">5300000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <sgry:GrantRevenue
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTMtMi0xLTEtMzk5MzY_78a06e46-ea8d-489d-8eb0-dce36bc8a439"
      unitRef="usd">1200000</sgry:GrantRevenue>
    <sgry:GrantRevenue
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTMtNC0xLTEtMzk5MzY_820462a0-9010-4a23-9758-8e39ba9f4819"
      unitRef="usd">15100000</sgry:GrantRevenue>
    <sgry:GainLossOnDispositionOfAssetsAndDeconsolidation
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTQtMi0xLTEtMzk5MzY_96ec6285-1c17-482f-9047-7c1b4dcda0fb"
      unitRef="usd">100000</sgry:GainLossOnDispositionOfAssetsAndDeconsolidation>
    <sgry:GainLossOnDispositionOfAssetsAndDeconsolidation
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTQtNC0xLTEtMzk5MzY_60c8f1bf-b64f-4025-9f17-eff928d0f49d"
      unitRef="usd">900000</sgry:GainLossOnDispositionOfAssetsAndDeconsolidation>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTUtMi0xLTEtMzk5MzY_96ff62f1-aa8e-490a-a346-aa99f120028f"
      unitRef="usd">3100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTUtNC0xLTEtMzk5MzY_662786bb-17ba-499d-93db-08ded00fc725"
      unitRef="usd">2600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTktMi0xLTEtMzk5MzY_29f12a66-c5d5-495e-bae9-cc72eae83022"
      unitRef="usd">32800000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMTktNC0xLTEtMzk5MzY_10c0ffea-175b-4e8a-a460-800a19d0b5ff"
      unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:OtherNonrecurringIncomeExpense
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjAtMi0xLTEtMzk5MzY_f4a2d72a-b13d-4238-84d0-4f7c4c6f3fbd"
      unitRef="usd">-2400000</us-gaap:OtherNonrecurringIncomeExpense>
    <us-gaap:OtherNonrecurringIncomeExpense
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjAtNC0xLTEtMzk5MzY_983dbb5e-04d1-4542-bf61-fb2727651a3f"
      unitRef="usd">0</us-gaap:OtherNonrecurringIncomeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjEtMi0xLTEtMzk5MzY_b6b1c966-84c3-43f3-a21e-2e168a205e50"
      unitRef="usd">495800000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjEtNC0xLTEtMzk5MzY_7fbd6484-9069-4729-abee-95e17fbfb535"
      unitRef="usd">448100000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjItMi0xLTEtMzk5MzY_a9ef279b-5b6b-45e4-a826-96b1bde9bef0"
      unitRef="usd">100400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjItNC0xLTEtMzk5MzY_9dcd0272-d83b-4db3-b3c7-d3e580f73b7a"
      unitRef="usd">64300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjMtMi0xLTEtMzk5MzY_5d202a14-6c9c-493f-ad98-b28d884a1605"
      unitRef="usd">-56300000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjMtNC0xLTEtMzk5MzY_d0e29818-5068-4950-badd-7c1404a5e825"
      unitRef="usd">-53300000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjQtMi0xLTEtMzk5MzY_049d1494-e8b1-4af0-8760-9659e626bb52"
      unitRef="usd">44100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjQtNC0xLTEtMzk5MzY_b4937285-ab0c-4ed6-9390-989cb21419a9"
      unitRef="usd">11000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjUtMi0xLTEtMzk5MzY_0baa17cc-1059-4c14-a52f-27fb1fbb90cf"
      unitRef="usd">1300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjUtNC0xLTEtMzk5MzY_b7ca889d-d8fd-45c6-94d6-74f5cfb0700a"
      unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjYtMi0xLTEtMzk5MzY_df555325-d808-46a3-a506-df7eea36e675"
      unitRef="usd">42800000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjYtNC0xLTEtMzk5MzY_c0d055a6-d538-4fec-ac51-ddf6db2c0932"
      unitRef="usd">10800000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjctMi0xLTEtMzk5MzY_6685bfaf-1f58-4c28-9626-d50aee385fa7"
      unitRef="usd">30600000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjctNC0xLTEtMzk5MzY_1207415d-2588-41ad-9758-e72bddc49a5c"
      unitRef="usd">31800000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjgtMi0xLTEtMzk5MzY_021d40ac-326a-4613-9348-957adbe20857"
      unitRef="usd">12200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjgtNC0xLTEtMzk5MzY_f564e7f8-459e-4b47-a968-80f0d162def9"
      unitRef="usd">-21000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjktMi0xLTEtMzk5MzY_7db3f465-ab87-461d-b2ce-8afbfaa3227e"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMjktNC0xLTEtMzk5MzY_8d8c1d79-f95d-4599-9afc-e07f501d5f7f"
      unitRef="usd">10300000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzAtMi0xLTEtMzk5MzY_8262f76b-0891-4af7-8ab5-b9d516a1e4f8"
      unitRef="usd">12200000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzAtNC0xLTEtMzk5MzY_971af0c0-9dcb-4cbf-995d-a6222446414c"
      unitRef="usd">-31300000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzMtMi0xLTEtMzk5MzY_a5dc84c9-7ed4-4db3-86c4-3bad89c0b62a"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzMtNC0xLTEtMzk5MzY_217963fe-d3ee-4e63-ad6c-65d6503d56ba"
      unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzQtMi0xLTEtMzk5MzY_f316c610-a8bf-4296-81dd-e5befb731d9e"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzQtNC0xLTEtMzk5MzY_5b797168-8f73-4ca9-8faa-caa680e32762"
      unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzYtMi0xLTEtMzk5MzY_eb7a87c7-0dde-4a2e-9a13-6d22507a886e"
      unitRef="shares">87995000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzYtNC0xLTEtMzk5MzY_8fee75fc-a378-4f03-9b06-2717fa85ee0b"
      unitRef="shares">54773000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzctMi0xLTEtMzk5MzY_3aaf1ab2-cdc3-4241-9f41-41b592762a11"
      unitRef="shares">90272000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzctNC0xLTEtMzk5MzY_e0983b0a-cd91-4e3f-af96-ff0084a35973"
      unitRef="shares">54773000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xOS9mcmFnOjhhNDY5ZDVmMzExOTQ3YWE5MjM5ZTQ2YmZiOWM3ODg5L3RhYmxlOmE4YTQwZTU1ZTgxMzRiNmViYmQ3OWY1NDhjMmM1ZjE1L3RhYmxlcmFuZ2U6YThhNDBlNTVlODEzNGI2ZWJiZDc5ZjU0OGMyYzVmMTVfMy0yLTEtMS0zOTkzNg_df555325-d808-46a3-a506-df7eea36e675"
      unitRef="usd">42800000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xOS9mcmFnOjhhNDY5ZDVmMzExOTQ3YWE5MjM5ZTQ2YmZiOWM3ODg5L3RhYmxlOmE4YTQwZTU1ZTgxMzRiNmViYmQ3OWY1NDhjMmM1ZjE1L3RhYmxlcmFuZ2U6YThhNDBlNTVlODEzNGI2ZWJiZDc5ZjU0OGMyYzVmMTVfMy00LTEtMS0zOTkzNg_c0d055a6-d538-4fec-ac51-ddf6db2c0932"
      unitRef="usd">10800000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xOS9mcmFnOjhhNDY5ZDVmMzExOTQ3YWE5MjM5ZTQ2YmZiOWM3ODg5L3RhYmxlOmE4YTQwZTU1ZTgxMzRiNmViYmQ3OWY1NDhjMmM1ZjE1L3RhYmxlcmFuZ2U6YThhNDBlNTVlODEzNGI2ZWJiZDc5ZjU0OGMyYzVmMTVfNS0yLTEtMS0zOTkzNg_e0273c9b-dc90-465c-ba21-23491268c0b3"
      unitRef="usd">56800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xOS9mcmFnOjhhNDY5ZDVmMzExOTQ3YWE5MjM5ZTQ2YmZiOWM3ODg5L3RhYmxlOmE4YTQwZTU1ZTgxMzRiNmViYmQ3OWY1NDhjMmM1ZjE1L3RhYmxlcmFuZ2U6YThhNDBlNTVlODEzNGI2ZWJiZDc5ZjU0OGMyYzVmMTVfNS00LTEtMS0zOTkzNg_3a872617-fdb2-46f9-9032-db2ace817f37"
      unitRef="usd">6400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xOS9mcmFnOjhhNDY5ZDVmMzExOTQ3YWE5MjM5ZTQ2YmZiOWM3ODg5L3RhYmxlOmE4YTQwZTU1ZTgxMzRiNmViYmQ3OWY1NDhjMmM1ZjE1L3RhYmxlcmFuZ2U6YThhNDBlNTVlODEzNGI2ZWJiZDc5ZjU0OGMyYzVmMTVfNi0yLTEtMS0zOTkzNg_9b8699a6-fb64-49eb-aac7-d2d7397df577"
      unitRef="usd">99600000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xOS9mcmFnOjhhNDY5ZDVmMzExOTQ3YWE5MjM5ZTQ2YmZiOWM3ODg5L3RhYmxlOmE4YTQwZTU1ZTgxMzRiNmViYmQ3OWY1NDhjMmM1ZjE1L3RhYmxlcmFuZ2U6YThhNDBlNTVlODEzNGI2ZWJiZDc5ZjU0OGMyYzVmMTVfNi00LTEtMS0zOTkzNg_3fc465df-7ca9-4ef4-95c9-0aac003240ea"
      unitRef="usd">17200000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xOS9mcmFnOjhhNDY5ZDVmMzExOTQ3YWE5MjM5ZTQ2YmZiOWM3ODg5L3RhYmxlOmE4YTQwZTU1ZTgxMzRiNmViYmQ3OWY1NDhjMmM1ZjE1L3RhYmxlcmFuZ2U6YThhNDBlNTVlODEzNGI2ZWJiZDc5ZjU0OGMyYzVmMTVfNy0yLTEtMS0zOTkzNg_5c9f24b9-69aa-4ade-8e32-5ea61a6e424d"
      unitRef="usd">30600000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xOS9mcmFnOjhhNDY5ZDVmMzExOTQ3YWE5MjM5ZTQ2YmZiOWM3ODg5L3RhYmxlOmE4YTQwZTU1ZTgxMzRiNmViYmQ3OWY1NDhjMmM1ZjE1L3RhYmxlcmFuZ2U6YThhNDBlNTVlODEzNGI2ZWJiZDc5ZjU0OGMyYzVmMTVfNy00LTEtMS0zOTkzNg_04e5e458-9b9f-4a64-b8c1-23c4e5025a77"
      unitRef="usd">31800000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xOS9mcmFnOjhhNDY5ZDVmMzExOTQ3YWE5MjM5ZTQ2YmZiOWM3ODg5L3RhYmxlOmE4YTQwZTU1ZTgxMzRiNmViYmQ3OWY1NDhjMmM1ZjE1L3RhYmxlcmFuZ2U6YThhNDBlNTVlODEzNGI2ZWJiZDc5ZjU0OGMyYzVmMTVfOC0yLTEtMS0zOTkzNg_eb022e9a-7e26-4220-ab9b-95e66f6c2a89"
      unitRef="usd">69000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xOS9mcmFnOjhhNDY5ZDVmMzExOTQ3YWE5MjM5ZTQ2YmZiOWM3ODg5L3RhYmxlOmE4YTQwZTU1ZTgxMzRiNmViYmQ3OWY1NDhjMmM1ZjE1L3RhYmxlcmFuZ2U6YThhNDBlNTVlODEzNGI2ZWJiZDc5ZjU0OGMyYzVmMTVfOC00LTEtMS0zOTkzNg_27fc56ef-0b69-4261-85d3-52fb18ebab3d"
      unitRef="usd">-14600000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i65d685057ae641c3b746cf6377dd430f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMy0xLTEtMS0zOTkzNg_c873e142-ebf2-4542-b923-f5574659b65f"
      unitRef="shares">50462000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i65d685057ae641c3b746cf6377dd430f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMy0zLTEtMS0zOTkzNg_944730b2-78fc-48d7-98b2-707c0b312957"
      unitRef="usd">500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i48d044e479254b2f8935070ff1a00ac4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMy01LTEtMS0zOTkzNg_5724e23a-f03c-40bb-9f6c-807e4b2852a8"
      unitRef="usd">607900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i02439221d0d244d9bcd5569225a9eceb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMy03LTEtMS0zOTkzNg_ef34228d-8209-43b4-8145-7becabb3bce6"
      unitRef="usd">-61000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i61d245da91744ed8b196945289f8015a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMy05LTEtMS0zOTkzNg_c96a9fad-84f1-4ce5-aa11-2f9600077790"
      unitRef="usd">-431800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2faf06f152e04dfaac19ae85d0f6df18_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMy0xMS0xLTEtMzk5MzY_a13331a5-d295-4e00-9068-03ad6632ffaf"
      unitRef="usd">766500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i64de719b0ad14503b4dba6762866534b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMy0xMy0xLTEtMzk5MzY_7207f622-dee0-454e-acc1-a9758b642751"
      unitRef="usd">882100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i4a8fc7979812433d8763ce3c5642dc80_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNC05LTEtMS0zOTkzNg_de5fc144-cd1e-4362-83eb-5fc09d911dde"
      unitRef="usd">-21000000.0</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i0a837d715cbc4966875dc62f6e78cbd7_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNC0xMS0xLTEtMzk5MzY_38231e11-81cb-4ef7-a265-694cb3cf9c95"
      unitRef="usd">21100000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNC0xMy0xLTEtMzk5MzY_63fd0910-53f8-4ab4-94f6-b3274c16f44e"
      unitRef="usd">100000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="idf10b9430f6847b490ed2cf648c93e32_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNS0xLTEtMS0zOTkzNg_c7fe206e-4f65-4673-84c6-da2b4dd67446"
      unitRef="shares">812000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1aeda0f667e349c086a29bab4acce588_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNS01LTEtMS0zOTkzNg_d5386f91-85e9-4e8d-9900-47f8b258d322"
      unitRef="usd">-2800000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNS0xMy0xLTEtMzk5MzY_3625771e-2eae-4b86-91c5-e4cdbfbc58df"
      unitRef="usd">-2800000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="i1aeda0f667e349c086a29bab4acce588_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNi01LTEtMS0zOTkzNg_c6483415-f04b-4f2d-9135-0fb0b4b071fb"
      unitRef="usd">10300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNi0xMy0xLTEtMzk5MzY_5edd0c0e-6a80-471c-9086-1e0c55768db3"
      unitRef="usd">10300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="idf10b9430f6847b490ed2cf648c93e32_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNy0xLTEtMS0zOTkzNg_8f4148fb-41f2-4985-98d1-6ac99e33af57"
      unitRef="shares">8625000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="idf10b9430f6847b490ed2cf648c93e32_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNy0zLTEtMS0zOTkzNg_781507fd-bcb2-464a-87f1-e2cb3083f17c"
      unitRef="usd">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1aeda0f667e349c086a29bab4acce588_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNy01LTEtMS0zOTkzNg_72d59c02-c186-4b7a-8b54-f201d24d0b69"
      unitRef="usd">248200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfNy0xMy0xLTEtMzk5MzY_8a60cd17-dfba-4667-b88d-ce990026d7bf"
      unitRef="usd">248300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ib0cfdca28efe4489bed9689a67756a3c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfOC03LTEtMS0zOTkzNg_04f17634-edd7-49c0-a885-87d7b0a95e96"
      unitRef="usd">6400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfOC0xMy0xLTEtMzk5MzY_5866a825-cdd3-4a98-b747-9ae113ed62d1"
      unitRef="usd">6400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet
      contextRef="i1aeda0f667e349c086a29bab4acce588_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfOS01LTEtMS0zOTkzNg_08a4d030-da0a-4638-ae8b-e27270d83bfa"
      unitRef="usd">300000</sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet>
    <sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet
      contextRef="i0a837d715cbc4966875dc62f6e78cbd7_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfOS0xMS0xLTEtMzk5MzY_69971cba-32fc-4599-8cfa-aafb39d1a2fb"
      unitRef="usd">2000000.0</sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet>
    <sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfOS0xMy0xLTEtMzk5MzY_60f9ffba-ca15-46c2-9d99-667340f05336"
      unitRef="usd">2300000</sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i0a837d715cbc4966875dc62f6e78cbd7_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMTAtMTEtMS0xLTM5OTM2_ff7f5307-bd7f-4344-b44f-e8ce7c32348d"
      unitRef="usd">20800000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMTAtMTMtMS0xLTM5OTM2_c86dd2ee-2bef-4bbc-ae76-9ae3ddecc272"
      unitRef="usd">20800000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i253dec092e2d41f28b85f643ccdd68cd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMTEtMS0xLTEtMzk5MzY_fc1e9419-be73-45d5-b35d-3bb0c1febf51"
      unitRef="shares">59899000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i253dec092e2d41f28b85f643ccdd68cd_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMTEtMy0xLTEtMzk5MzY_6906331b-6ae2-4789-a510-7400dfebc1c4"
      unitRef="usd">600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i44d8b197c09347a5bfe50b624fa0d5b3_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMTEtNS0xLTEtMzk5MzY_1b15e8ae-fdd7-4f12-9aad-812e60807581"
      unitRef="usd">843300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0a8cdfe2cc68416e866d30dbf21372d9_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMTEtNy0xLTEtMzk5MzY_c74cefe9-349e-420b-84f3-aca6e786afb5"
      unitRef="usd">-54600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1114172ce5094c68bedb86e8b7d44cb7_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMTEtOS0xLTEtMzk5MzY_9f1bd171-d099-4a8f-ba2d-1f63e05b8b7a"
      unitRef="usd">-452800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib49a1cb0982e43ec901c64053a39f745_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMTEtMTEtMS0xLTM5OTM2_b78583c4-9e4c-4a57-9a13-7a5375f4ded6"
      unitRef="usd">768800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia510a69b8e64403eb11f83898b8a08ec_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjExYzFjNWE0NDIzYTRhZWJiODYzM2Y2ODUzY2M4YmJkL3RhYmxlcmFuZ2U6MTFjMWM1YTQ0MjNhNGFlYmI4NjMzZjY4NTNjYzhiYmRfMTEtMTMtMS0xLTM5OTM2_16aaa2d0-3048-460c-975c-fd578ddbc6b0"
      unitRef="usd">1105300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic00c0198779b477e9adb83fad573131e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMC0xLTEtMS00MTU2NQ_24801cb4-7e91-4d3b-bf15-cef3daa66364"
      unitRef="shares">89333000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic00c0198779b477e9adb83fad573131e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMC0zLTEtMS00MTU3MQ_a67d080a-3184-46c7-a052-d7846e93c532"
      unitRef="usd">900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id5cf9408c2ea45248462023da0418e49_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMC01LTEtMS00MTU3Nw_85650362-6fa6-4793-b87f-029c228ac225"
      unitRef="usd">1622300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i07efbfabca9b4e33acccafb2fe2d7c82_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMC03LTEtMS00MTU4Mw_8a9e9a4d-a574-4166-b5cf-af1a00e39733"
      unitRef="usd">-31500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8070a501ab2c40589c94526f6bda6ebe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMC05LTEtMS00MTU4OQ_f16591e3-f1f1-483e-bb08-c300a4962f31"
      unitRef="usd">-502700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i25ae47e0aa9a4921a427c583c4ff6645_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMC0xMS0xLTEtNDE1OTU_ce9bfc81-b037-4556-b653-835761d33e1b"
      unitRef="usd">880600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMC0xMy0xLTEtNDI0ODE_41b4e581-90ff-4be3-b9e3-49fcba397a95"
      unitRef="usd">1969600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i2930feb3f5944505ad4c3d63f26d5f4f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMS05LTEtMS00MTU4OQ_ab4d7157-72be-4fe7-b4ca-212dff528b93"
      unitRef="usd">12200000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i635f7b61fc044f528748645b77893543_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMS0xMS0xLTEtNDE1OTU_0c09cd46-4297-4406-9445-eecbc11e9a69"
      unitRef="usd">20000000.0</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMS0xMy0xLTEtNDI0ODk_a240044f-61c1-4f94-9157-508f446e4584"
      unitRef="usd">32200000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ifeb7edc101bf4e3ca14bd0a2df3bec5f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMi0xLTEtMS00MTU2NQ_0307388e-d13b-4080-ba4e-c49d341e046b"
      unitRef="shares">572000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iacb41fa48e0c4c0280b70a8b8b967a6c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMi01LTEtMS00MTU3Nw_f6b6eb06-de0f-4dc5-ba9d-d34f13e08310"
      unitRef="usd">7700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMi0xMy0xLTEtNDI0ODk_1a37c89e-3280-4444-b86c-5bf3f0164dfa"
      unitRef="usd">7700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ib052d4f8c5ef41118d1450786f139047_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMy03LTEtMS00MTU4Mw_fb9e265e-8335-4ec4-9b4d-f867fb195e93"
      unitRef="usd">56800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfMy0xMy0xLTEtNDI0ODc_6abb5ade-90f9-470f-8709-1a56b5d6a8d7"
      unitRef="usd">56800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet
      contextRef="iacb41fa48e0c4c0280b70a8b8b967a6c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNC01LTEtMS00MTU3Nw_563520b5-be38-4a38-ad8f-451d8dc854f0"
      unitRef="usd">-4800000</sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet>
    <sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet
      contextRef="i635f7b61fc044f528748645b77893543_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNC0xMS0xLTEtNDE1OTU_a269a8d4-122c-43f1-b09b-ebf03abbdb73"
      unitRef="usd">-24300000</sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet>
    <sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNC0xMy0xLTEtNDI0ODc_9b4585a2-b83d-49de-aca2-de2d27cb8b86"
      unitRef="usd">-29100000</sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i635f7b61fc044f528748645b77893543_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNS0xMS0xLTEtNDE1OTU_61b85dc2-a716-43bd-9511-d3c70ec292aa"
      unitRef="usd">24600000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNS0xMy0xLTEtNDI0ODc_6ad9599f-ec09-4dfc-9d6f-12028380139e"
      unitRef="usd">24600000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if23681243e73450cb3fa31d9cffac2b7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNi0xLTEtMS00MjQ4NQ_6d9f5417-a880-4a91-a7aa-abe47a80c1d9"
      unitRef="shares">89905000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if23681243e73450cb3fa31d9cffac2b7_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNi0zLTEtMS00MjQ4NQ_11b105a3-8c5e-438f-9b29-fe5d7a4a8f73"
      unitRef="usd">900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i58b12b437d5442cbbfda520a3f432240_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNi01LTEtMS00MjQ4NQ_f8f22fe1-6d71-41bc-92f0-8b17d70a2649"
      unitRef="usd">1625200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2e53044aa4142028b8b7d9863d3accb_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNi03LTEtMS00MjQ4NQ_c6a3db2b-ef5b-440a-a3d1-0ba6d19a6cc1"
      unitRef="usd">25300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id4c0aada0e14421286ede0517722bf59_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNi05LTEtMS00MjQ4NQ_b926f863-3ce6-4fbf-9f08-ee1a04fe039a"
      unitRef="usd">-490500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i10d1f1007efc4b109adc6675a736352c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNi0xMS0xLTEtNDI0ODU_94cbf63a-df5c-4acb-8427-c818ed411791"
      unitRef="usd">851700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yMi9mcmFnOjAwNGFkMWM5NjM4MjQwZmFiZDk2MmE4ZTgyYjEwYmEwL3RhYmxlOjMzMDVjM2U2YTk1NDRmM2U5MjFmODgyYWE5YjNhYWQyL3RhYmxlcmFuZ2U6MzMwNWMzZTZhOTU0NGYzZTkyMWY4ODJhYTliM2FhZDJfNi0xMy0xLTEtNDI0ODU_963f9db6-cf77-4264-befe-a40a35b1fccf"
      unitRef="usd">2012600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMy0yLTEtMS0zOTkzNg_72b6cf0c-dcd5-4e65-9075-9f267c932a01"
      unitRef="usd">42800000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMy00LTEtMS0zOTkzNg_a5e6d5df-c8cc-414f-abff-7f38c2842372"
      unitRef="usd">10800000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfNS0yLTEtMS0zOTkzNg_08a69bfe-a757-404e-bd96-326d48b4963f"
      unitRef="usd">27400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfNS00LTEtMS0zOTkzNg_3fd10c8c-b872-4183-9042-97632c20bb03"
      unitRef="usd">25700000</us-gaap:DepreciationDepletionAndAmortization>
    <sgry:NoncashInterestIncomeExpenseNet
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfNi0yLTEtMS0zOTkzNg_9f7a6ad7-4107-4c6d-8ed0-6ef97a4edf44"
      unitRef="usd">-6100000</sgry:NoncashInterestIncomeExpenseNet>
    <sgry:NoncashInterestIncomeExpenseNet
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfNi00LTEtMS0zOTkzNg_bd881e9d-142b-4f0c-83ca-6ecea2cfdbec"
      unitRef="usd">-1600000</sgry:NoncashInterestIncomeExpenseNet>
    <us-gaap:ShareBasedCompensation
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfNy0yLTEtMS0zOTkzNg_7f026ed2-96f4-43b6-b462-1c657187f98f"
      unitRef="usd">3700000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfNy00LTEtMS0zOTkzNg_54ba043e-6db8-4dee-8eee-10459e142d19"
      unitRef="usd">5200000</us-gaap:ShareBasedCompensation>
    <sgry:GainLossOnDispositionOfAssetsAndDeconsolidation
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfOC0yLTEtMS0zOTkzNg_f45a0f4d-0cdd-405c-9188-d3bf653276ac"
      unitRef="usd">100000</sgry:GainLossOnDispositionOfAssetsAndDeconsolidation>
    <sgry:GainLossOnDispositionOfAssetsAndDeconsolidation
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfOC00LTEtMS0zOTkzNg_e4073728-42d1-4424-85d8-fd8d4c6154a6"
      unitRef="usd">900000</sgry:GainLossOnDispositionOfAssetsAndDeconsolidation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTEtMi0xLTEtMzk5MzY_634a5982-8168-4ef0-bc94-c9ba28eab594"
      unitRef="usd">1000000.0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTEtNC0xLTEtMzk5MzY_032c1825-8545-4d4d-9820-d6b2cc4c6086"
      unitRef="usd">-100000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTItMi0xLTEtMzk5MzY_d5c6bce3-c243-4af5-958f-5450a8d22324"
      unitRef="usd">900000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTItNC0xLTEtMzk5MzY_8fb548c6-99ca-472f-9c1b-0da62255e24e"
      unitRef="usd">200000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:OperatingLeaseExpense
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTMtMi0xLTEtMzk5MzY_16c42b82-f628-4f9a-a157-e90d78573c40"
      unitRef="usd">8600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTMtNC0xLTEtMzk5MzY_4b9af0fd-d8ed-4d61-a8f4-e320794ca44c"
      unitRef="usd">9800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTUtMi0xLTEtMzk5MzY_72ea8f9e-6477-4e58-80ba-052dd159d04a"
      unitRef="usd">-2000000.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTUtNC0xLTEtMzk5MzY_08d97622-60f1-4239-b2a7-e7d7ca5ee5af"
      unitRef="usd">-3900000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <sgry:IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTYtMi0xLTEtMzk5MzY_2db65d67-b5fe-4ee5-aeb9-f480f5a90db2"
      unitRef="usd">-18000000.0</sgry:IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants>
    <sgry:IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTYtNC0xLTEtMzk5MzY_20296328-1112-45af-8341-258526ef5a01"
      unitRef="usd">-7200000</sgry:IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTgtMi0xLTEtMzk5MzY_8818806d-74d3-42b8-bd41-2276956fef7f"
      unitRef="usd">-7200000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTgtNC0xLTEtMzk5MzY_674461f3-3485-4a34-b2c3-02767f18bc83"
      unitRef="usd">-1600000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTktMi0xLTEtMzk5MzY_236da617-568d-466b-9b49-8a46d80c1b56"
      unitRef="usd">79800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMTktNC0xLTEtMzk5MzY_324a23bb-1e2a-4958-a7e7-f6749a7fcfa6"
      unitRef="usd">50200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjItMi0xLTEtMzk5MzY_e04c6dbc-5a2a-4b27-8331-564a80755655"
      unitRef="usd">18200000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjItNC0xLTEtMzk5MzY_7706b541-9d1b-420a-ac34-e7c99544f3c5"
      unitRef="usd">14500000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjMtMi0xLTEtMzk5MzY_89b87a8c-bd54-4a48-969c-5a6b338bc6ef"
      unitRef="usd">31100000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjMtNC0xLTEtMzk5MzY_5207fdb2-2bf0-475b-b03f-91d61115a7a8"
      unitRef="usd">2100000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjQtMi0xLTEtMzk5MzY_90e6e611-54cf-4fbd-a2c2-f88a27c43106"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjQtNC0xLTEtMzk5MzY_cbb68f0c-983b-4c54-ae35-a26df75c43fa"
      unitRef="usd">2300000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjUtMi0xLTEtNDQ2NjI_002466a2-2bc8-4859-8d62-0a8c1ef44edf"
      unitRef="usd">11500000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjUtNC0xLTEtNDQ2NjI_7bc1f003-ae04-4d39-a393-2e9582acfa06"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjUtMi0xLTEtMzk5MzY_e2ca5b0f-56f8-4d2a-8b54-6b1236675948"
      unitRef="usd">9300000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjUtNC0xLTEtMzk5MzY_896e41ca-863c-4f6e-9c66-757615573ef6"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjYtMi0xLTEtMzk5MzY_28efdb5e-20f9-48a0-a936-75893e6f6596"
      unitRef="usd">-47100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjYtNC0xLTEtMzk5MzY_f2d4bcf7-f9d8-4643-8c5c-591200fdeb2c"
      unitRef="usd">-14300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjktMi0xLTEtMzk5MzY_bf9f8444-5582-4055-ba90-abf27285cbae"
      unitRef="usd">17000000.0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMjktNC0xLTEtMzk5MzY_390f2cf4-4348-404a-8862-2cad0068e3c1"
      unitRef="usd">16600000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzAtMi0xLTEtMzk5MzY_f0f7972b-63a3-490f-936c-4c865b0c9514"
      unitRef="usd">11900000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzAtNC0xLTEtMzk5MzY_9d447cbe-6c7e-4711-9975-269fe22daa09"
      unitRef="usd">600000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzEtMi0xLTEtMzk5MzY_495c4559-ad7e-4c2b-b51c-ccfc261ed4d4"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzEtNC0xLTEtMzk5MzY_5e73a3c6-9032-4abb-a1a0-941c1589941f"
      unitRef="usd">1100000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzItMi0xLTEtMzk5MzY_4a15fd6d-9aaf-42ba-bb39-d48edb34f539"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzItNC0xLTEtMzk5MzY_d2221f47-23be-46a7-83e9-f5880e5cc144"
      unitRef="usd">260900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzMtMi0xLTEtMzk5MzY_c34b3ca0-add9-4ceb-82c1-fcb13bd22c6f"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzMtNC0xLTEtMzk5MzY_799d2480-da9b-42de-a7af-8ef52c0c848a"
      unitRef="usd">12600000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzQtMi0xLTEtMzk5MzY_9b98f44e-a50d-481f-a897-3604bd9152eb"
      unitRef="usd">0</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzQtNC0xLTEtMzk5MzY_b7c9fe0c-cceb-4b53-90c1-a44b80ae86fd"
      unitRef="usd">5100000</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsOfDividendsMinorityInterest
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzUtMi0xLTEtMzk5MzY_61201db4-e50b-400e-8b11-7be7c0107052"
      unitRef="usd">36200000</us-gaap:PaymentsOfDividendsMinorityInterest>
    <us-gaap:PaymentsOfDividendsMinorityInterest
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzUtNC0xLTEtMzk5MzY_02ed5d6b-0b81-401d-a56b-01d4a5d5614e"
      unitRef="usd">31300000</us-gaap:PaymentsOfDividendsMinorityInterest>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzYtMi0xLTEtMzk5MzY_3933f4a8-420d-49ad-a989-32e24ea9f437"
      unitRef="usd">3100000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzYtNC0xLTEtMzk5MzY_2961f516-f53e-463a-804f-48cec675dc66"
      unitRef="usd">1000000.0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzctMi0xLTEtMzk5MzY_3527f158-2977-4107-ab56-1e7d632d25ed"
      unitRef="usd">700000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzctNC0xLTEtMzk5MzY_0fd57005-b08c-47eb-952f-fb112b33fbb3"
      unitRef="usd">-8000000.0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzgtMi0xLTEtMzk5MzY_6c4c11c1-65b6-406a-a0f6-93c2656b37b4"
      unitRef="usd">-43700000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzgtNC0xLTEtMzk5MzY_2019150a-6a26-4eba-8b1d-7d03d1a4624e"
      unitRef="usd">187800000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzktMi0xLTEtMzk5MzY_71b737d5-2d71-4de1-b48c-c220f821e1ae"
      unitRef="usd">-11000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfMzktNC0xLTEtMzk5MzY_52c600d4-c7fc-447d-9fa2-cd64c2f10777"
      unitRef="usd">223700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfNDAtMi0xLTEtMzk5MzY_f22bd252-b8ae-45d4-b581-4e8a0484e969"
      unitRef="usd">389900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i64de719b0ad14503b4dba6762866534b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfNDAtNC0xLTEtMzk5MzY_811d4048-223e-4ea3-a46f-dfdd3266b89b"
      unitRef="usd">318200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfNDEtMi0xLTEtMzk5MzY_d10afdd1-0e45-4ef9-905e-26c829b4cd8a"
      unitRef="usd">378900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia510a69b8e64403eb11f83898b8a08ec_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18yNS9mcmFnOjJjZmU5ODBiMjg0ZTQyZWJiMGFmMDZkYWJkMDYzYzdiL3RhYmxlOjEyOWIyMWVmMzRiMTQ3NWZhNzRmMTIzZTgzNGUyM2QyL3RhYmxlcmFuZ2U6MTI5YjIxZWYzNGIxNDc1ZmE3NGYxMjNlODM0ZTIzZDJfNDEtNC0xLTEtMzk5MzY_9fdfc806-73d7-4ac8-b65b-3ae25f0d49ea"
      unitRef="usd">541900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgzMTc_59ece22b-8b17-496f-ba65-18145e260dc7">Organization and Summary of Accounting Policies&lt;div style="margin-bottom:6pt;margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Surgery Partners, Inc., a Delaware corporation, acting through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. The surgical facilities, which include ambulatory surgery centers ("ASCs") and surgical hospitals, primarily provide non-emergency surgical procedures across many specialties, including, among others, gastroenterology, general surgery, ophthalmology, orthopedics and pain management. The Company's surgical hospitals also provide services such as diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy and wound care. Ancillary services are comprised of multi-specialty physician practices, urgent care facilities and anesthesia services. Unless the context otherwise indicates, Surgery Partners, Inc. and its subsidiaries are referred to herein as "Surgery Partners," "we," "us," "our" or the "Company."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the Company owned or operated a portfolio of 127 surgical facilities, comprised of 109 ASCs and 18 surgical hospitals in 31 states. The Company owns these facilities in partnership with physicians and, in some cases, health care systems in the markets and communities it serves.&#160;The Company owned a majority interest in 85 of the surgical facilities and consolidated 108 of the facilities for financial reporting purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation of the Company's financial position and results of operations have been included. The Company&#x2019;s fiscal year ends on December&#160;31 and interim results are not necessarily indicative of results for a full year or any other interim period. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021 (the "2021 Annual Report on Form 10-K").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;COVID-19 Pandemic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The COVID-19 pandemic has significantly affected the Company's facilities, employees, patients, communities, business operations and financial performance, as well as the United States economy and financial markets. The impact of the COVID-19 pandemic on the Company's surgical facilities varies based on the market in which the facility operates, the type of surgical facility and the procedures that are typically performed. The Company cannot provide any certainty regarding the length and severity of the impact of the COVID-19 pandemic on its business operations and financial performance. As a result of the COVID-19 pandemic, the Company has implemented new clinical safety measures to provide a safe environment for its patients, surgeons and employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CARES Act &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the &#x201c;CARES Act&#x201d;) was signed into law to provide stimulus funding for the United States economy. As part of the CARES Act, the United States government announced that it would offer relief to eligible health care providers, including distribution of direct grants to hospitals, ASCs and other health care providers based on how much they bill Medicare. Payments received from these grants are not required to be repaid provided the recipients attest to and comply with certain terms and conditions, including limitations on balance billing and not using funds received from the grants to reimburse expenses or losses that other sources are obligated to reimburse. The Company has received approximately $87&#160;million of the grant funds distributed under the CARES Act and other governmental assistance programs, including approximately $1&#160;million during the three months ended March&#160;31, 2022. The recognition of amounts received is conditioned upon attestation with terms and conditions that funds will be used for COVID-19 related healthcare expenses or lost revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s assessment of whether the terms and conditions for amounts received are reasonably assured of having been met considers, among other things, the CARES Act, the COVID-19 Economic Relief Bill, enacted on December 27, 2020, and all frequently asked questions and other interpretive guidance issued by the United States Department of Health and Human Services ("HHS"), including in the Provider Relief Fund Reporting Portal and associated user guides. This guidance sets forth the allowable methods for quantifying &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;eligible healthcare related expenses and lost revenues. Only healthcare related expenses attributable to COVID-19 that another source has not reimbursed and is not obligated to reimburse are eligible to be claimed. Based on guidance, the Company estimates approximately $1.2 million and $15.1 million of grant funds received qualified for recognition as a reduction in operating expenses for the three months ended March&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Amounts received, but not recognized as a reduction to operating expenses, are reflected as a component of Medicare accelerated payments and deferred governmental grants in the condensed consolidated balance sheets as of both March&#160;31, 2022 and December 31, 2021. Any unrecognized amounts may be recognized as a reduction in operating expenses in subsequent periods if the underlying conditions for recognition are met. Additional guidance or new and amended interpretations of existing guidance on the terms and conditions of such payments may result in the Company&#x2019;s inability to recognize certain payments, changes in the estimate of amounts recognized, or the derecognition of amounts previously recognized, which may be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;As a way to increase cash flow to Medicare providers impacted by the COVID-19 pandemic, the CARES Act expanded the Medicare Accelerated and Advance Payment Program, which allowed for most providers and suppliers, including the Company&#x2019;s surgical hospitals and ASCs to request an advance payment of anticipated Medicare revenues. The Company received approximately $120&#160;million of accelerated payments during the year ended December 31, 2020. The payments received were deferred and included in the condensed consolidated balance sheets. During the three months ended March 31, 2022, approximately $18&#160;million has been repaid in accordance with the terms of the program. These repayments are included as a component of the change in Medicare accelerated payments and deferred government grants in the condensed consolidated statements of cash flows. Under these terms, repayment started one year after the initial funding by offsetting 25% of new claims paid by CMS. After 11 months of repayment at this level, the repayments will increase to 50% of new claims paid by CMS for a period of six months. Any outstanding amounts due at the end of the repayment period are subject to interest at a rate of 4%. As of March 31, 2022 and December 31, 2021, the remaining deferred accelerated payments was approximately $42&#160;million and $60&#160;million, respectively, which was included as a component of Medicare accelerated payments and deferred governmental grants in the condensed consolidated balance sheets. The Company does not expect to receive additional Medicare accelerated payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The CARES Act also provided for the deferral of the Company's portion of social security payroll taxes during 2020. Under the CARES Act, half of the deferred amount was paid in December 2021 and the remaining portion will be paid in December 2022. As of both March&#160;31, 2022 and December 31, 2021, the Company had deferred approximately $8.5&#160;million, which was included as a component of accrued payroll and benefits in the condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company is continuing to closely monitor legislative actions and regulatory guidance at the federal, state and local levels with respect to the CARES Act as other governmental assistance might become available to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification 810, "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;". The Company has the power to direct the activities that most significantly impact a VIE's economic performance. Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur. As of March&#160;31, 2022, the Company's consolidated VIEs include six surgical facilities and five physician practices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The total assets (excluding goodwill and intangible assets, net) of the consolidated VIEs included in the accompanying condensed consolidated balance sheets as of March&#160;31, 2022 and December&#160;31, 2021 were $71.4 million and $48.1 million, respectively, and the total liabilities of the consolidated VIEs were $46.7 million and $20.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on inputs classified into the following hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt"&gt;Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt"&gt;Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These may include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt"&gt;Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, depending on the nature of the item being valued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, restricted invested assets and accounts payable approximate their fair values under Level 3 calculations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of the carrying amounts and estimated fair values of the Company's long-term debt follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior secured term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,527.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,530.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,504.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,530.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.750% senior unsecured notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;370.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;370.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;367.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;371.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.000% senior unsecured notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;545.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;545.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;570.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;577.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair values in the table above were based on Level 2 inputs using quoted prices for identical liabilities in inactive markets. The carrying amounts related to the Company's other long-term debt obligations, including finance lease obligations, approximate their fair values based on Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's revenues generally relate to contracts with patients in which the performance obligations are to provide health care services. The Company recognizes revenues in the period in which its obligations to provide health care services are satisfied and reports the amount that reflects the consideration the Company expects to be entitled to receive. The contractual relationships with patients, in most cases, also involve a third-party payor (e.g., Medicare, Medicaid and private insurance organizations, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by or negotiated with the third-party payors. The payment arrangements with third-party payors for the services provided to the related patients typically specify payments at amounts less than the Company's standard charges. The Company continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of revenues by service type as a percentage of total revenues follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Surgical facilities revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Ancillary services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total patient service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patient service revenues.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;This revenue is related to charging facility fees in exchange for providing patient care. The fee charged for health care procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications. The fee does not normally include professional fees charged by the patient&#x2019;s surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patient service revenues are recognized as performance obligations are satisfied. Performance obligations are based on the nature of services provided. Typically, the Company recognizes revenue at a point in time in which services are rendered and the Company has no obligation to provide further patient services. As the Company primarily performs outpatient procedures, performance obligations are generally satisfied same day and revenue is recognized on the date of service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments and discounts from third-party payors. The Company estimates its contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. Changes in estimated contractual adjustments and discounts are recorded in the period of change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other service revenues.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Other service revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets. These agreements typically require the Company to provide recurring management services over a multi-year period, which are billed and collected on a monthly basis. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which management services are rendered and billed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.238%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Private insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;246.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;249.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Self-pay&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total patient service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;587.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;505.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;596.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;512.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;Other is comprised of anesthesia service agreements, automobile liability, letters of protection and other payor types. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company maintains its cash and cash equivalent balances at high credit quality financial institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts receivable from third-party payors are recorded net of estimated implicit price concessions, which are estimated based on the historical trend of the Company's surgical hospitals&#x2019; cash collections and contractual write-offs, and for the Company's surgical facilities in general, established fee schedules, relationships with payors and procedure statistics. While changes in estimated reimbursement from third-party payors remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on its financial condition or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), private insurance organizations, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. Amounts are classified outside of self-pay if the Company has an agreement with the third-party payor or has verified a patient&#x2019;s coverage prior to services rendered. The Company's policy is to collect co-payments and deductibles prior to providing medical services. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of its surgical facilities to ensure the proper collection and aged category. Collection efforts include direct contact with third-party payors or patients, written correspondence and the use of legal or collection agency assistance, as required. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill represents the fair value of the consideration provided in an acquisition over the fair value of net assets acquired and is not amortized. Additions to goodwill include amounts resulting from new business combinations and incremental ownership purchases in the Company's subsidiaries. A summary of the Company's acquisitions and dispositions for the three months ended March&#160;31, 2022 is included in Note 2. "Acquisitions and Disposals."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of activity related to goodwill for the three months ended March&#160;31, 2022 is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,911.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisitions, including post acquisition adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Disposals and deconsolidations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,925.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A detailed evaluation of potential impairment indicators was performed as of March 31, 2022, which specifically considered the ongoing impact of the COVID-19 pandemic. On the basis of available evidence as of March 31, 2022, no indicators of impairment were identified. Future estimates of fair value could be adversely affected if the actual outcome of one or more of the Company's assumptions changes materially in the future, including a material decline in the Company&#x2019;s stock price and the fair value of its long-term debt, lower than expected surgical case volumes, higher market interest rates or increased operating costs. Such changes impacting the calculation of fair value, the risks of which are amplified by the COVID-19 pandemic, could result in a material impairment charge in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company records all derivatives on the balance sheet at fair value and any financing elements treated as debt instruments are recorded at amortized cost. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain of its risk, even though hedge accounting does not apply or the Company elects not to apply hedge accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-Controlling Interests&#x2014;Redeemable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively.&#160;In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners&#x2019; or physician minority members&#x2019;, as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility.&#160;The non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;redeemable are reported outside of stockholders' equity in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of activity related to non-controlling interests&#x2014;redeemable is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at&#160;beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&#x2014;redeemable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisition of shares of non-controlling interests, net&#x2014;redeemable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions to non-controlling interest&#x2014;redeemable holders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at&#160;end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;308.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a carryforward exists, the Company makes a determination as to whether the carryforward will be utilized in the future. A valuation allowance is established for certain carryforwards when their recoverability is deemed to be uncertain. The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions. If our expectations for future operating results on a consolidated basis or at the state jurisdiction level vary from actual results due to changes in health care regulations, general economic conditions, or other factors, we may need to adjust the valuation allowance, for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;all or a portion of our deferred tax assets. Our income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on our future earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company and certain of its subsidiaries file a consolidated federal income tax return. The partnerships, limited liability companies, and certain non-consolidated physician practice corporations also file separate income tax returns. The Company's allocable portion of each partnership's and limited liability company's income or loss is included in taxable income of the Company. The remaining income or loss of each partnership and limited liability company is allocated to the other owners.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The Company's effective tax rate was 2.9% for the three months ended March&#160;31, 2022 compared to 1.8% for the three months ended March&#160;31, 2021. For the three months ended March&#160;31, 2022, the effective tax rate differed from 21% primarily due to earnings attributable to non-controlling interests, an increase in the Company&#x2019;s valuation allowance attributable to interest expense limitations, and discrete tax benefits of (a) $4.6&#160;million related to the vesting of restricted stock awards, (b) $1.8&#160;million attributable to non-recurring earnings&#x2019; impact on the Company&#x2019;s valuation allowance, and (c) $1.0&#160;million related to entity divestitures. For the three months ended March&#160;31, 2021, the effective tax rate differed from 21% due to tax benefits of $2.2&#160;million related to the vesting of restricted stock awards. Based upon the application of interim accounting guidance, the tax rate as a percentage of net income after income attributable to non-controlling interests will vary based upon the relative net income from period to period.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <sgry:NumberOfSurgicalFacilitiesOwned
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTAyMQ_7ddbb0cc-47c0-4ac9-aeba-b7d98fdd06f3"
      unitRef="surgical_facility">127</sgry:NumberOfSurgicalFacilitiesOwned>
    <sgry:NumberOfSurgicalFacilitiesOwned
      contextRef="i01ae3c8148ba4c25b35336360e5e7dc2_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA1OA_ca9b4aee-0a90-4e06-ad3b-41487632313f"
      unitRef="surgical_facility">109</sgry:NumberOfSurgicalFacilitiesOwned>
    <sgry:NumberOfSurgicalFacilitiesOwned
      contextRef="ib0b5bb8fa6d646029f554028ebaa467d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA3MA_7e1850cf-305b-4ba8-b81a-004874320e42"
      unitRef="surgical_facility">18</sgry:NumberOfSurgicalFacilitiesOwned>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5NQ_10710396-841e-4ed2-ab84-817a6df7651c"
      unitRef="state">31</us-gaap:NumberOfStatesInWhichEntityOperates>
    <sgry:NumberOfSurgicalFacilitiesOwnedMajorityInterest
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTI5NA_814dfafe-c57a-4564-a030-8574bdee552d"
      unitRef="surgical_facility">85</sgry:NumberOfSurgicalFacilitiesOwnedMajorityInterest>
    <sgry:NumberOfSurgicalFacilitiesOwnedConsolidated
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTM0MQ_692f36d7-50d6-44da-90e8-0957f07de14d"
      unitRef="surgical_facility">108</sgry:NumberOfSurgicalFacilitiesOwnedConsolidated>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyNzY_ea1f9972-b381-463a-a285-9c54b27ccbd0">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation of the Company's financial position and results of operations have been included. The Company&#x2019;s fiscal year ends on December&#160;31 and interim results are not necessarily indicative of results for a full year or any other interim period. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021 (the "2021 Annual Report on Form 10-K").&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyMjI_4d6549fd-40ca-4081-bfa9-80e708cce523">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyNTQ_10fafa56-2b64-4106-98b3-8c010d4107cd">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <sgry:ProceedsFromGovernmentAssistance
      contextRef="i88ed6b4d58e5453984121369f4f11efc_D20200327-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY4NDE1Mw_399ea590-987d-4039-ab1b-ac8ec41f8285"
      unitRef="usd">87000000</sgry:ProceedsFromGovernmentAssistance>
    <sgry:ProceedsFromGovernmentAssistance
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY4NDg0Nw_9981516b-c3a1-4f79-a4d6-09e3e6f923a3"
      unitRef="usd">1000000</sgry:ProceedsFromGovernmentAssistance>
    <sgry:GrantRevenue
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY4NDg1OQ_78a06e46-ea8d-489d-8eb0-dce36bc8a439"
      unitRef="usd">1200000</sgry:GrantRevenue>
    <sgry:GrantRevenue
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfODI0NjMzNzI2ODg0OQ_820462a0-9010-4a23-9758-8e39ba9f4819"
      unitRef="usd">15100000</sgry:GrantRevenue>
    <sgry:CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments
      contextRef="if6defdbda29a4879a3bd483aed3cec04_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfNzc2NQ_5df7b2d9-5470-466e-a7b9-a11f95285ff8"
      unitRef="usd">120000000</sgry:CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments>
    <sgry:CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY4NDE5OA_b381a5e5-b56a-4af2-8e98-dab5e3a481f5"
      unitRef="usd">18000000</sgry:CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments>
    <sgry:CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY4NDI0MA_56b54cee-ef7b-4050-9e5d-c0a2d4f1f03a"
      unitRef="usd">42000000</sgry:CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments>
    <sgry:CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY2OTc3MA_ba9b12a6-c025-43f2-891f-d53224057c6d"
      unitRef="usd">60000000</sgry:CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments>
    <sgry:DeferredEmployeeRelatedLiabilitiesCurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY3MjUyNA_0db62248-7e6c-4ac9-96c2-a8586e8ad2b8"
      unitRef="usd">8500000</sgry:DeferredEmployeeRelatedLiabilitiesCurrent>
    <sgry:DeferredEmployeeRelatedLiabilitiesCurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY3MjUyNA_92613c2a-ea06-4673-80d3-e8ad82c0a3bb"
      unitRef="usd">8500000</sgry:DeferredEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyMDQ_5ba61939-2e80-4c30-b52e-95ed5bb783ae">Variable Interest Entities&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification 810, "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;". The Company has the power to direct the activities that most significantly impact a VIE's economic performance. Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur.</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <sgry:VariableInterestEntityNumberOfFacilities
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA0NjE_88a624f8-0ccd-47c5-8b83-f8f942133b1d"
      unitRef="surgical_facility">6</sgry:VariableInterestEntityNumberOfFacilities>
    <sgry:VariableInterestEntityNumberOfFacilities
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA0ODg_feaf302a-ae2b-4dcd-bc02-8095ab6868f8"
      unitRef="physician_practice">5</sgry:VariableInterestEntityNumberOfFacilities>
    <us-gaap:Assets
      contextRef="i637e4d2ab4e8411490e75163721ebd0f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA2OTE_f8f6b74c-0a59-4d64-8c53-ac093b42363f"
      unitRef="usd">71400000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iaf52a3e1a85b4de2af6a8274e5c65a76_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA2OTg_52c8a8d4-372b-4e13-9726-5bdcb4a97d69"
      unitRef="usd">48100000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="i637e4d2ab4e8411490e75163721ebd0f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA3NzI_fce4cdc1-50e1-4b52-8e94-78bbdc2b98bc"
      unitRef="usd">46700000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="iaf52a3e1a85b4de2af6a8274e5c65a76_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA3Nzk_eec53c43-1877-42c3-a041-86c99b60c1e3"
      unitRef="usd">20100000</us-gaap:Liabilities>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyMDU_d5c14006-8221-4660-9835-c738e942b6a0">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on inputs classified into the following hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt"&gt;Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt"&gt;Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These may include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt"&gt;Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, depending on the nature of the item being valued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, restricted invested assets and accounts payable approximate their fair values under Level 3 calculations.&lt;/span&gt;&lt;/div&gt;The fair values in the table above were based on Level 2 inputs using quoted prices for identical liabilities in inactive markets. The carrying amounts related to the Company's other long-term debt obligations, including finance lease obligations, approximate their fair values based on Level 3 inputs.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyODI_742351c2-26d8-43b0-8f7b-1d8a5c252403">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of the carrying amounts and estimated fair values of the Company's long-term debt follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior secured term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,527.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,530.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,504.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,530.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.750% senior unsecured notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;370.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;370.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;367.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;371.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.000% senior unsecured notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;545.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;545.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;570.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;577.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:LongTermDebt
      contextRef="i506df12890674df3996c010a349ca7c0_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfMy0yLTEtMS0zOTkzNg_fe410891-4877-4a0f-b1b5-fd5a860f89e5"
      unitRef="usd">1527000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i2db8fa84c09d480799b76b68681936d9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfMy00LTEtMS0zOTkzNg_eb73a5c8-fd30-4a19-9e8d-9355e2027345"
      unitRef="usd">1530700000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i8ad5676bd3f84e0d8244dd53d99a6a10_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfMy02LTEtMS0zOTkzNg_c1be8d59-97a4-49bb-936a-250c4b6bb7be"
      unitRef="usd">1504100000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i9ed8c6b6471245ee8d17d81941bd3725_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfMy04LTEtMS0zOTkzNg_c72150f8-bcdd-450c-a573-c481a57c2ffe"
      unitRef="usd">1530700000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idcfcf6c0b474488abf86dd8a19ab641d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfNC0wLTEtMS0zOTkzNi90ZXh0cmVnaW9uOjM2NjdjNWYwMGJiNzQ5ZmE4MDZiY2ZiMDhlMzM2YzFkXzQ_54be529a-b9d8-481b-86a9-1ec69c02da58"
      unitRef="number">0.06750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ib8e675c069904c2e8d2f8233b2f7c50c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfNC0yLTEtMS0zOTkzNg_e65c7c3d-da3f-4ac6-8feb-082ff133a4e0"
      unitRef="usd">370000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="idfcab3d9997245d19b06ae33b0d19589_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfNC00LTEtMS0zOTkzNg_db857ab2-263d-441d-8d61-e13037ae7bb6"
      unitRef="usd">370000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i13642547953b42fdb47054b1218975af_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfNC02LTEtMS0zOTkzNg_b5c89680-255f-4b15-838d-d7e7edddd5ff"
      unitRef="usd">367200000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i966e8ae61ccd4f959e269cc4f8b50a26_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfNC04LTEtMS0zOTkzNg_80c79baa-133f-4817-bf80-28f070bc7978"
      unitRef="usd">371900000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia4c64a5508684384921c71fc65d53263_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfNS0wLTEtMS0zOTkzNi90ZXh0cmVnaW9uOjcwYzBhY2VkMDc5OTQ4YWE4OGFkZDVkMWY5NDBkNDMyXzQ_8ae946db-f983-4a17-a62c-9a316fe34c11"
      unitRef="number">0.10000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ibc4246d5efcb4678b5c651d7a3105ea2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfNS0yLTEtMS0zOTkzNg_41c45907-9c34-4188-b029-33a192066b78"
      unitRef="usd">545000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ia76476dcbd9b4daa8c5d611fe63a4b6f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfNS00LTEtMS0zOTkzNg_8dbcf7eb-d5c9-433c-895c-8cb215a3cba3"
      unitRef="usd">545000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ifdeef4374f4d4416b5733b872ca3567b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfNS02LTEtMS0zOTkzNg_6c212d74-fc97-4483-8b3e-962c4e86cb24"
      unitRef="usd">570200000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iccee81bad7154b409425f6d227df3575_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmU2YWQzMjQxZjU4NDQ3NDI4YWZjZTNjOWI0MDBiM2JjL3RhYmxlcmFuZ2U6ZTZhZDMyNDFmNTg0NDc0MjhhZmNlM2M5YjQwMGIzYmNfNS04LTEtMS0zOTkzNg_f096eadd-59d3-4a6a-80e4-ad43c63a226e"
      unitRef="usd">577000000.0</us-gaap:LongTermDebt>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyNDk_c31dcaa5-fd23-4699-9a2c-7496286627b2">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's revenues generally relate to contracts with patients in which the performance obligations are to provide health care services. The Company recognizes revenues in the period in which its obligations to provide health care services are satisfied and reports the amount that reflects the consideration the Company expects to be entitled to receive. The contractual relationships with patients, in most cases, also involve a third-party payor (e.g., Medicare, Medicaid and private insurance organizations, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by or negotiated with the third-party payors. The payment arrangements with third-party payors for the services provided to the related patients typically specify payments at amounts less than the Company's standard charges. The Company continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patient service revenues.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;This revenue is related to charging facility fees in exchange for providing patient care. The fee charged for health care procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications. The fee does not normally include professional fees charged by the patient&#x2019;s surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patient service revenues are recognized as performance obligations are satisfied. Performance obligations are based on the nature of services provided. Typically, the Company recognizes revenue at a point in time in which services are rendered and the Company has no obligation to provide further patient services. As the Company primarily performs outpatient procedures, performance obligations are generally satisfied same day and revenue is recognized on the date of service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments and discounts from third-party payors. The Company estimates its contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. Changes in estimated contractual adjustments and discounts are recorded in the period of change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other service revenues.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Other service revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets. These agreements typically require the Company to provide recurring management services over a multi-year period, which are billed and collected on a monthly basis. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which management services are rendered and billed.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyMzk_c6ffbff8-98cb-4723-b98b-37041cd06dae">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of revenues by service type as a percentage of total revenues follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Surgical facilities revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Ancillary services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total patient service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.238%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.815%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Private insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;246.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;249.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;226.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Self-pay&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total patient service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;587.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;505.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;596.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;512.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)Other is comprised of anesthesia service agreements, automobile liability, letters of protection and other payor types.</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibc7c7055d90440d89c4a9125446ce784_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjFkNWE1NWJiNGVhNTQ0YjVhNjQ2ZTkzYmQ0NGQzZThiL3RhYmxlcmFuZ2U6MWQ1YTU1YmI0ZWE1NDRiNWE2NDZlOTNiZDQ0ZDNlOGJfMy0yLTEtMS0zOTkzNg_e2dbbd47-94e2-4617-8be5-9bbedab19a41"
      unitRef="number">0.957</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id4d0a1269abf4dceb2f3b53070b65c94_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjFkNWE1NWJiNGVhNTQ0YjVhNjQ2ZTkzYmQ0NGQzZThiL3RhYmxlcmFuZ2U6MWQ1YTU1YmI0ZWE1NDRiNWE2NDZlOTNiZDQ0ZDNlOGJfMy00LTEtMS0zOTkzNg_c03cf99f-e979-4924-b460-34004d6841cd"
      unitRef="number">0.955</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifa35c00cc5c94cc98aa5fc428cac0a9a_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjFkNWE1NWJiNGVhNTQ0YjVhNjQ2ZTkzYmQ0NGQzZThiL3RhYmxlcmFuZ2U6MWQ1YTU1YmI0ZWE1NDRiNWE2NDZlOTNiZDQ0ZDNlOGJfNC0yLTEtMS0zOTkzNg_4c8f6b9f-b2f0-4f30-b520-6679e84a7632"
      unitRef="number">0.029</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i60c5087599d24a0695f4e51d9b7328cd_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjFkNWE1NWJiNGVhNTQ0YjVhNjQ2ZTkzYmQ0NGQzZThiL3RhYmxlcmFuZ2U6MWQ1YTU1YmI0ZWE1NDRiNWE2NDZlOTNiZDQ0ZDNlOGJfNC00LTEtMS0zOTkzNg_c4199153-890b-4bf1-a53b-6ba433d1b8fb"
      unitRef="number">0.032</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5fdee6a1e69f430b9fc7afc764249da1_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjFkNWE1NWJiNGVhNTQ0YjVhNjQ2ZTkzYmQ0NGQzZThiL3RhYmxlcmFuZ2U6MWQ1YTU1YmI0ZWE1NDRiNWE2NDZlOTNiZDQ0ZDNlOGJfNS0yLTEtMS0zOTkzNg_09cda3db-81e0-4d30-aea0-c36b09c8bff2"
      unitRef="number">0.986</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8c305d408ef046519c734c40b5368141_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjFkNWE1NWJiNGVhNTQ0YjVhNjQ2ZTkzYmQ0NGQzZThiL3RhYmxlcmFuZ2U6MWQ1YTU1YmI0ZWE1NDRiNWE2NDZlOTNiZDQ0ZDNlOGJfNS00LTEtMS0zOTkzNg_368b7593-ce8d-4a51-a839-a486456513e5"
      unitRef="number">0.987</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib886d75d98b64a8ba3306ec5ed447ea9_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjFkNWE1NWJiNGVhNTQ0YjVhNjQ2ZTkzYmQ0NGQzZThiL3RhYmxlcmFuZ2U6MWQ1YTU1YmI0ZWE1NDRiNWE2NDZlOTNiZDQ0ZDNlOGJfNi0yLTEtMS0zOTkzNg_4b99a37f-2ca7-418c-92c4-b65b7106f909"
      unitRef="number">0.014</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i69bd64deadca4e6987ccdd1fe1a5acd1_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjFkNWE1NWJiNGVhNTQ0YjVhNjQ2ZTkzYmQ0NGQzZThiL3RhYmxlcmFuZ2U6MWQ1YTU1YmI0ZWE1NDRiNWE2NDZlOTNiZDQ0ZDNlOGJfNi00LTEtMS0zOTkzNg_f6d7666f-599a-4ea0-99ad-bf13b5b5402d"
      unitRef="number">0.013</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i959b5b49ffbc4125a8ae719a2e147008_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjFkNWE1NWJiNGVhNTQ0YjVhNjQ2ZTkzYmQ0NGQzZThiL3RhYmxlcmFuZ2U6MWQ1YTU1YmI0ZWE1NDRiNWE2NDZlOTNiZDQ0ZDNlOGJfNy0yLTEtMS0zOTkzNg_4f9e29bd-0c9c-4323-8e15-c6c1413fe00d"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2a4abce686244862adef8618f10a35ed_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjFkNWE1NWJiNGVhNTQ0YjVhNjQ2ZTkzYmQ0NGQzZThiL3RhYmxlcmFuZ2U6MWQ1YTU1YmI0ZWE1NDRiNWE2NDZlOTNiZDQ0ZDNlOGJfNy00LTEtMS0zOTkzNg_7909f959-c54e-4c07-a8ee-e2b34339b494"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib2581fac27134361aaf1f3ca3c3db4de_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNC0yLTEtMS0zOTkzNg_7688d336-3b9c-45ad-92c5-87feb498bfc6"
      unitRef="usd">300200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i32fa0d6361714af289d98b250659260a_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNC00LTEtMS0zOTkzNg_37602c38-15bd-4b72-8982-70e83f57e1c1"
      unitRef="number">0.511</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib355fe300c3849b69133727cc10b4d92_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNC02LTEtMS0zOTkzNg_538d6615-153c-48cc-bcce-4324e47c5205"
      unitRef="usd">246100000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i27472f8f1c174b2aa18b1c47df6601f6_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNC04LTEtMS0zOTkzNg_cd0694a0-7fc8-43e6-b60e-46ce850bf764"
      unitRef="number">0.487</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3b35f441d1234c148a0c51b5feb19edd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNS0yLTEtMS0zOTkzNg_30ec11d0-382a-45d3-baa5-c1c9a438ce1c"
      unitRef="usd">249000000.0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic27723e5b1494789a14c6e03c6cef1d1_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNS00LTEtMS0zOTkzNg_66d4a26a-3cf4-4455-a462-1c9a22a27d82"
      unitRef="number">0.424</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia93d7f09a5db46538ab762616820eb2b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNS02LTEtMS0zOTkzNg_d1abb1dd-4395-4ae8-9b97-e3722ac8c786"
      unitRef="usd">226400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i319afcfd65824c03b4113efb64fc3b29_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNS04LTEtMS0zOTkzNg_a4181b71-74dc-4b95-9165-f2732c2edda2"
      unitRef="number">0.448</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6669ea6cc07c457ab9a998a810a31b86_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNi0yLTEtMS0zOTkzNg_c784dbb0-a569-4f71-9012-40c4b7895986"
      unitRef="usd">16800000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iccb4e1634f8c4cbf9f988a392008a061_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNi00LTEtMS0zOTkzNg_4b494b30-57be-4d93-881f-29296b9de794"
      unitRef="number">0.029</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1a3ac13dcce1497ea3da4a85c473c3c3_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNi02LTEtMS0zOTkzNg_8fb10bb0-b5c8-4fa6-a680-0d9800536ace"
      unitRef="usd">13200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4ad6e3e1169d4e76ac6ee8f514dd661a_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNi04LTEtMS0zOTkzNg_8bf3107a-cf5c-4613-8424-d1055b7480cc"
      unitRef="number">0.026</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8520c7f7026a4db4b18532d86207d82e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNy0yLTEtMS0zOTkzNg_ac2a398e-dd90-4723-bb2a-dfa4de11763a"
      unitRef="usd">21700000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i47646e2fdd1a4fe7a52ba359cf577a71_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNy00LTEtMS0zOTkzNg_e0c69f39-7184-430d-9f44-7629f883f9c6"
      unitRef="number">0.036</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if2c5800e21be4fe29d33c18b7bcf1f2a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNy02LTEtMS0zOTkzNg_c785457a-7128-43b2-b83b-0cea5c49580a"
      unitRef="usd">20000000.0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0024968fe06e453fbbb57a1a738a5ea7_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfNy04LTEtMS0zOTkzNg_36b585da-ce0b-4b4b-b4c3-e2ab83e28c29"
      unitRef="number">0.039</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i094886c1cfb34257a319635071262fdd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfOC0yLTEtMS0zOTkzNg_2c7c28ad-ce73-49f8-a317-759c80b8971e"
      unitRef="usd">587700000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibc8bc1d058e74796a84a897fcabea948_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfOC00LTEtMS0zOTkzNg_e83a178a-d12b-4612-9296-f124bd1c345f"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iccfe7b6d79b74feb8e7a7078913f412a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfOC02LTEtMS0zOTkzNg_2d51c18c-7242-4868-b9bd-27918d939b8e"
      unitRef="usd">505700000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6bffa160d95c4aa38530da4f45398c33_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfOC04LTEtMS0zOTkzNg_f69091f7-1e52-4b00-9173-e469fb9817f6"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i23a8281e1b3a4519bcf1d6d34c3cddf9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfOS0yLTEtMS0zOTkzNg_b2e52599-3c1f-47b3-9d13-84674821f025"
      unitRef="usd">8500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i13eb2c0495f34e2bbb3d47dd7920135f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfOS02LTEtMS0zOTkzNg_b0ede8ce-a1a4-4fe0-8b25-19a6e119665a"
      unitRef="usd">6700000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfMTAtMi0xLTEtMzk5MzY_580bbc89-cea0-4ff9-9501-e8ca5ec8c67c"
      unitRef="usd">596200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjA5ZmI0ZTdlNDkwYTQyODI5ZDgwNjRiM2Y2ODEzZDZjL3RhYmxlcmFuZ2U6MDlmYjRlN2U0OTBhNDI4MjlkODA2NGIzZjY4MTNkNmNfMTAtNi0xLTEtMzk5MzY_2aa9424e-fdbb-48df-b15c-ab34825c53ff"
      unitRef="usd">512400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyNjc_f753b548-6ba0-4097-8ba4-9f9cfa09e606">&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company maintains its cash and cash equivalent balances at high credit quality financial institutions.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyOTE_02b5a57b-ea7d-4c67-af73-ede59986963d">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts receivable from third-party payors are recorded net of estimated implicit price concessions, which are estimated based on the historical trend of the Company's surgical hospitals&#x2019; cash collections and contractual write-offs, and for the Company's surgical facilities in general, established fee schedules, relationships with payors and procedure statistics. While changes in estimated reimbursement from third-party payors remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on its financial condition or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), private insurance organizations, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. Amounts are classified outside of self-pay if the Company has an agreement with the third-party payor or has verified a patient&#x2019;s coverage prior to services rendered. The Company's policy is to collect co-payments and deductibles prior to providing medical services. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients.&lt;/span&gt;&lt;/div&gt;The Company's collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of its surgical facilities to ensure the proper collection and aged category. Collection efforts include direct contact with third-party payors or patients, written correspondence and the use of legal or collection agency assistance, as required.</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyODQ_337d9282-fbdf-49b6-8329-166513084188">GoodwillGoodwill represents the fair value of the consideration provided in an acquisition over the fair value of net assets acquired and is not amortized. Additions to goodwill include amounts resulting from new business combinations and incremental ownership purchases in the Company's subsidiaries.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyMzA_98f4376f-7614-4519-aab3-e74249502b2e">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of activity related to goodwill for the three months ended March&#160;31, 2022 is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,911.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisitions, including post acquisition adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Disposals and deconsolidations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,925.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmIyMTlkM2I2NmIxNjQ2OTRiNzMyZmYwNDVmOTU1NDIxL3RhYmxlcmFuZ2U6YjIxOWQzYjY2YjE2NDY5NGI3MzJmZjA0NWY5NTU0MjFfMC0yLTEtMS0zOTkzNg_b416c8d4-0660-47f6-82c2-6a7609a2a7e0"
      unitRef="usd">3911800000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmIyMTlkM2I2NmIxNjQ2OTRiNzMyZmYwNDVmOTU1NDIxL3RhYmxlcmFuZ2U6YjIxOWQzYjY2YjE2NDY5NGI3MzJmZjA0NWY5NTU0MjFfMS0yLTEtMS0zOTkzNg_32995c4e-2ccf-47dc-88c5-e1e5703647f5"
      unitRef="usd">43400000</us-gaap:GoodwillAcquiredDuringPeriod>
    <sgry:GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidation
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmIyMTlkM2I2NmIxNjQ2OTRiNzMyZmYwNDVmOTU1NDIxL3RhYmxlcmFuZ2U6YjIxOWQzYjY2YjE2NDY5NGI3MzJmZjA0NWY5NTU0MjFfMi0yLTEtMS0zOTkzNg_83b24e56-b420-408c-a094-08118facf237"
      unitRef="usd">29400000</sgry:GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidation>
    <us-gaap:Goodwill
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOmIyMTlkM2I2NmIxNjQ2OTRiNzMyZmYwNDVmOTU1NDIxL3RhYmxlcmFuZ2U6YjIxOWQzYjY2YjE2NDY5NGI3MzJmZjA0NWY5NTU0MjFfMy0yLTEtMS0zOTkzNg_1a169744-a8c7-43ed-9fc4-27a7fa618f6a"
      unitRef="usd">3925800000</us-gaap:Goodwill>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyNzI_3eea38f7-11ba-4e35-981a-cfe7cf009104">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company records all derivatives on the balance sheet at fair value and any financing elements treated as debt instruments are recorded at amortized cost. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain of its risk, even though hedge accounting does not apply or the Company elects not to apply hedge accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.&lt;/span&gt;&lt;/div&gt;For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income ("OCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings, as documented at hedge inception in accordance with the Company&#x2019;s accounting policy election. Amounts reported in accumulated OCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company&#x2019;s variable-rate debt.</us-gaap:DerivativesPolicyTextBlock>
    <sgry:RedeemableNoncontrollingInterestPolicyTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyMjE_dbaba9a9-0463-4db9-8a07-6af47c61c8ef">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-Controlling Interests&#x2014;Redeemable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively.&#160;In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners&#x2019; or physician minority members&#x2019;, as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility.&#160;The non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;redeemable are reported outside of stockholders' equity in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</sgry:RedeemableNoncontrollingInterestPolicyTextBlock>
    <us-gaap:RedeemableNoncontrollingInterestTableTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyMTY_4f49dfe0-bbfd-48a1-9fb9-15cd0bcc4f3b">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of activity related to non-controlling interests&#x2014;redeemable is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at&#160;beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&#x2014;redeemable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisition of shares of non-controlling interests, net&#x2014;redeemable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions to non-controlling interest&#x2014;redeemable holders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at&#160;end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;308.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RedeemableNoncontrollingInterestTableTextBlock>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjZiMGM1MDdmNTJjYTQxZGE4NGFhMGJlNjNiMjAyZmJlL3RhYmxlcmFuZ2U6NmIwYzUwN2Y1MmNhNDFkYTg0YWEwYmU2M2IyMDJmYmVfMi0yLTEtMS0zOTkzNg_ab0054b4-d985-433e-b77c-f4a173ac3092"
      unitRef="usd">330200000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i64de719b0ad14503b4dba6762866534b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjZiMGM1MDdmNTJjYTQxZGE4NGFhMGJlNjNiMjAyZmJlL3RhYmxlcmFuZ2U6NmIwYzUwN2Y1MmNhNDFkYTg0YWEwYmU2M2IyMDJmYmVfMi00LTEtMS0zOTkzNg_a1394354-ebee-421d-924d-d55a07a9229d"
      unitRef="usd">306800000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjZiMGM1MDdmNTJjYTQxZGE4NGFhMGJlNjNiMjAyZmJlL3RhYmxlcmFuZ2U6NmIwYzUwN2Y1MmNhNDFkYTg0YWEwYmU2M2IyMDJmYmVfMy0yLTEtMS0zOTkzNg_480aa369-5293-4fa7-b544-ea1389c33387"
      unitRef="usd">10600000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjZiMGM1MDdmNTJjYTQxZGE4NGFhMGJlNjNiMjAyZmJlL3RhYmxlcmFuZ2U6NmIwYzUwN2Y1MmNhNDFkYTg0YWEwYmU2M2IyMDJmYmVfMy00LTEtMS0zOTkzNg_423aa092-f10f-4f67-8f7e-c34f425f405a"
      unitRef="usd">10700000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <sgry:RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjZiMGM1MDdmNTJjYTQxZGE4NGFhMGJlNjNiMjAyZmJlL3RhYmxlcmFuZ2U6NmIwYzUwN2Y1MmNhNDFkYTg0YWEwYmU2M2IyMDJmYmVfNC0yLTEtMS0zOTkzNg_a1ea0243-3eb2-4473-9d16-5c0b1c392467"
      unitRef="usd">12300000</sgry:RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests>
    <sgry:RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjZiMGM1MDdmNTJjYTQxZGE4NGFhMGJlNjNiMjAyZmJlL3RhYmxlcmFuZ2U6NmIwYzUwN2Y1MmNhNDFkYTg0YWEwYmU2M2IyMDJmYmVfNC00LTEtMS0zOTkzNg_5d43d290-9650-492c-a702-9e351def60ca"
      unitRef="usd">1200000</sgry:RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests>
    <sgry:RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjZiMGM1MDdmNTJjYTQxZGE4NGFhMGJlNjNiMjAyZmJlL3RhYmxlcmFuZ2U6NmIwYzUwN2Y1MmNhNDFkYTg0YWEwYmU2M2IyMDJmYmVfNS0yLTEtMS0zOTkzNg_f719c5fb-33d5-4040-940a-3bac8b0cab22"
      unitRef="usd">11600000</sgry:RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <sgry:RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjZiMGM1MDdmNTJjYTQxZGE4NGFhMGJlNjNiMjAyZmJlL3RhYmxlcmFuZ2U6NmIwYzUwN2Y1MmNhNDFkYTg0YWEwYmU2M2IyMDJmYmVfNS00LTEtMS0zOTkzNg_9692a73f-a729-4715-b40f-e2a457c537d8"
      unitRef="usd">10500000</sgry:RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjZiMGM1MDdmNTJjYTQxZGE4NGFhMGJlNjNiMjAyZmJlL3RhYmxlcmFuZ2U6NmIwYzUwN2Y1MmNhNDFkYTg0YWEwYmU2M2IyMDJmYmVfNi0yLTEtMS0zOTkzNg_04515f70-0dfa-42e0-8659-10726eceef95"
      unitRef="usd">341500000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="ia510a69b8e64403eb11f83898b8a08ec_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RhYmxlOjZiMGM1MDdmNTJjYTQxZGE4NGFhMGJlNjNiMjAyZmJlL3RhYmxlcmFuZ2U6NmIwYzUwN2Y1MmNhNDFkYTg0YWEwYmU2M2IyMDJmYmVfNi00LTEtMS0zOTkzNg_bd6bfa5c-ed5a-4753-8170-5f219276809e"
      unitRef="usd">308200000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjgyNzM_266dc554-e4d6-46da-9c75-755e681dfa47">&lt;div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a carryforward exists, the Company makes a determination as to whether the carryforward will be utilized in the future. A valuation allowance is established for certain carryforwards when their recoverability is deemed to be uncertain. The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions. If our expectations for future operating results on a consolidated basis or at the state jurisdiction level vary from actual results due to changes in health care regulations, general economic conditions, or other factors, we may need to adjust the valuation allowance, for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;all or a portion of our deferred tax assets. Our income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on our future earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company and certain of its subsidiaries file a consolidated federal income tax return. The partnerships, limited liability companies, and certain non-consolidated physician practice corporations also file separate income tax returns. The Company's allocable portion of each partnership's and limited liability company's income or loss is included in taxable income of the Company. The remaining income or loss of each partnership and limited liability company is allocated to the other owners.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjYwMDE_79963895-67e1-457d-b234-8a028b8e6523"
      unitRef="number">0.029</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMjYwNDM_759325a3-aa36-4008-b2f4-f8184f27846e"
      unitRef="number">0.018</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY4NzY0Ng_50fdfc2b-e68c-475f-9463-878e428602b4"
      unitRef="usd">-4600000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY4NzcwMw_3f417347-202a-48ec-85f8-701c4539789a"
      unitRef="usd">-1800000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationDispositionOfBusiness
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY4ODAzNQ_6fb7b064-a7ea-4c26-a13f-3d0f15df5247"
      unitRef="usd">-1000000</us-gaap:IncomeTaxReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zMS9mcmFnOjViNmI3YjJiYTUxMzQ2NTQ4NjY4Mzc1ODhhZDUxZDFkL3RleHRyZWdpb246NWI2YjdiMmJhNTEzNDY1NDg2NjgzNzU4OGFkNTFkMWRfMTA5OTUxMTY4MTQ3Nw_5d6bbbf3-f701-4a69-a2bb-fd312dd3bb17"
      unitRef="usd">-2200000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfMTQyMg_a30570ec-8529-4ace-aa25-2f9dee9abc65">Acquisitions and Disposals&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022, the Company acquired a controlling interest in two surgical facilities, one of which was merged into an existing surgical facility, for aggregate cash consideration of $31.1&#160;million, net of cash acquired, and non-cash consideration of $2.6&#160;million. The cash consideration was funded through available resources and the non-cash consideration consisted of a non-controlling interest in one of the Company's existing surgical facilities. The total consideration was allocated to the assets acquired and liabilities assumed based upon the respective acquisition date fair values. The aggregate amounts preliminarily recognized for each major class of assets acquired and liabilities assumed for the acquisitions are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Aggregate acquisition date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Aggregate acquisition date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair values assigned to certain assets acquired and liabilities assumed by the Company have been estimated on a preliminary basis and are subject to change as new facts and circumstances emerge that were present at the date of acquisition. During the three months ended March&#160;31, 2022, no significant changes were made to the purchase price allocation of assets and liabilities, existing at the date of acquisition, related to individual acquisitions completed in 2021. The goodwill acquired was allocated to the Company's Surgical Facility services reportable segment. The results of operations of the acquisitions were included in the Company&#x2019;s results of operations beginning on the dates of acquisition and were not considered significant for the three months ended March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disposals and Deconsolidations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, the Company sold its interests in a surgical facility, which was previously accounted for as an equity method investment, for net cash proceeds of $11.5&#160;million, and recognized a pre-tax loss of $0.4&#160;million included in loss on disposals and deconsolidations, net in the condensed consolidated statements of operations for the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022, the Company contributed its interests in two surgical facilities as non-cash consideration for non-controlling interests in two new separate entities. As a result of these transactions, the Company lost control of the previously controlled surgical facilities but retains a non-controlling interest in each, resulting in the deconsolidation of the previously consolidated entities. The remaining non-controlling interests were accounted for as equity method investments, and initially measured and recorded at fair value as of the dates of the transactions. The fair value measurement utilizes Level 3 inputs, which includes unobservable data, to measure the fair value of the retained non-controlling interests. The fair value determination was based on a combination of multiple valuation methods, which included discounted cash flow and market value approach, which incorporates estimates of future earnings and market valuation multiples for certain guideline companies. The preliminary fair value of the investments of $9.8&#160;million was recorded as a component of investments in and advances to affiliates in the accompanying condensed consolidated balance sheets. Further, &lt;/span&gt;&lt;/div&gt;based on the preliminary valuation, the transactions resulted in a pretax net loss on deconsolidations of $5.6&#160;million, which is included in gain on disposals and deconsolidations, net, in the accompanying condensed consolidated statement of operations for the three months ended March&#160;31, 2022. The gains were determined based on the difference between the fair value of the Company's retained interests in the entities and the carrying values of both the tangible and intangible assets of the entities immediately prior to the transactions.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="ie823b906c9164e118eff58dafb9c18ce_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfMzI5ODUzNDg5MDczMg_e9127bd7-aea5-460f-bee9-4ff5a7ec329f"
      unitRef="surgical_facility">2</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="id6de0b52340d4ee0be44beb83074a915_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfMzI5ODUzNDg5MDc0MA_dc3a29b9-ff74-45bd-95c3-85ff3d56056f"
      unitRef="surgical_facility">1</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="idc9abc5f15644909ae180fa28f65f13e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfMjYy_db4c7293-a0ec-4247-9242-0a06bc121d05"
      unitRef="usd">31100000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="idc9abc5f15644909ae180fa28f65f13e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfODI0NjMzNzIxNDg2Ng_888d53d3-0d56-4aa8-b294-dca254be095e"
      unitRef="usd">2600000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfMTQyOQ_9127ee51-b527-473f-9bf6-af34bd518d0d">The aggregate amounts preliminarily recognized for each major class of assets acquired and liabilities assumed for the acquisitions are as follows (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Aggregate acquisition date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Aggregate acquisition date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="idc9abc5f15644909ae180fa28f65f13e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RhYmxlOjRhYTZmNjY4NDQzZDRkMTFiNGQ1MWMxOGNiYWQ5MWZkL3RhYmxlcmFuZ2U6NGFhNmY2Njg0NDNkNGQxMWI0ZDUxYzE4Y2JhZDkxZmRfMS0yLTEtMS0zOTkzNg_aea7acb0-f0f3-468d-b768-681fb7aea6e1"
      unitRef="usd">34700000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="ib803580ff3fd404097fe48426bec1d0b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RhYmxlOjRhYTZmNjY4NDQzZDRkMTFiNGQ1MWMxOGNiYWQ5MWZkL3RhYmxlcmFuZ2U6NGFhNmY2Njg0NDNkNGQxMWI0ZDUxYzE4Y2JhZDkxZmRfMi0yLTEtMS0zOTkzNg_7a43af39-c6a1-4292-885c-9682da283c0e"
      unitRef="usd">10600000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ib803580ff3fd404097fe48426bec1d0b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RhYmxlOjRhYTZmNjY4NDQzZDRkMTFiNGQ1MWMxOGNiYWQ5MWZkL3RhYmxlcmFuZ2U6NGFhNmY2Njg0NDNkNGQxMWI0ZDUxYzE4Y2JhZDkxZmRfMy0yLTEtMS0zOTkzNg_bcf9deac-7288-4ca6-ba87-323b51833afd"
      unitRef="usd">45300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
      contextRef="ib803580ff3fd404097fe48426bec1d0b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RhYmxlOjRhYTZmNjY4NDQzZDRkMTFiNGQ1MWMxOGNiYWQ5MWZkL3RhYmxlcmFuZ2U6NGFhNmY2Njg0NDNkNGQxMWI0ZDUxYzE4Y2JhZDkxZmRfNS0yLTEtMS0zOTkzNg_9940c2fa-668e-4e08-aab8-bfec7d10a824"
      unitRef="usd">5300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="ib803580ff3fd404097fe48426bec1d0b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RhYmxlOjRhYTZmNjY4NDQzZDRkMTFiNGQ1MWMxOGNiYWQ5MWZkL3RhYmxlcmFuZ2U6NGFhNmY2Njg0NDNkNGQxMWI0ZDUxYzE4Y2JhZDkxZmRfNi0yLTEtMS0zOTkzNg_08c6631b-8ced-4514-97c8-03ae3f4e3ed7"
      unitRef="usd">1900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:Goodwill
      contextRef="ib803580ff3fd404097fe48426bec1d0b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RhYmxlOjRhYTZmNjY4NDQzZDRkMTFiNGQ1MWMxOGNiYWQ5MWZkL3RhYmxlcmFuZ2U6NGFhNmY2Njg0NDNkNGQxMWI0ZDUxYzE4Y2JhZDkxZmRfNy0yLTEtMS0zOTkzNg_41676fa1-89fd-49bd-bf50-8f9344a12410"
      unitRef="usd">42700000</us-gaap:Goodwill>
    <sgry:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets
      contextRef="ib803580ff3fd404097fe48426bec1d0b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RhYmxlOjRhYTZmNjY4NDQzZDRkMTFiNGQ1MWMxOGNiYWQ5MWZkL3RhYmxlcmFuZ2U6NGFhNmY2Njg0NDNkNGQxMWI0ZDUxYzE4Y2JhZDkxZmRfOC0yLTEtMS0zOTkzNg_13a2882b-cac6-4afe-9197-40c3a9f18847"
      unitRef="usd">20700000</sgry:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="ib803580ff3fd404097fe48426bec1d0b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RhYmxlOjRhYTZmNjY4NDQzZDRkMTFiNGQ1MWMxOGNiYWQ5MWZkL3RhYmxlcmFuZ2U6NGFhNmY2Njg0NDNkNGQxMWI0ZDUxYzE4Y2JhZDkxZmRfMTAtMi0xLTEtMzk5MzY_b46c1634-64bf-4387-90f7-a9d035776563"
      unitRef="usd">5500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <sgry:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability
      contextRef="ib803580ff3fd404097fe48426bec1d0b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RhYmxlOjRhYTZmNjY4NDQzZDRkMTFiNGQ1MWMxOGNiYWQ5MWZkL3RhYmxlcmFuZ2U6NGFhNmY2Njg0NDNkNGQxMWI0ZDUxYzE4Y2JhZDkxZmRfMTItMi0xLTEtMzk5MzY_5b6100ee-9204-4abd-84da-a01d48db8d00"
      unitRef="usd">19800000</sgry:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ib803580ff3fd404097fe48426bec1d0b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RhYmxlOjRhYTZmNjY4NDQzZDRkMTFiNGQ1MWMxOGNiYWQ5MWZkL3RhYmxlcmFuZ2U6NGFhNmY2Njg0NDNkNGQxMWI0ZDUxYzE4Y2JhZDkxZmRfMTMtMi0xLTEtMzk5MzY_4ea94c1b-bb36-44af-8d3b-c3c6b1b89b84"
      unitRef="usd">45300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i97af3ba9bf154ce48824c269e037ff4f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfODI0NjMzNzIxNTMxOA_bb975e60-79e9-4e77-a502-918647e33978"
      unitRef="usd">11500000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i64cc0a22695c41e39895df392aa6ef14_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfODI0NjMzNzIxNTM1Nw_c3cef8d7-a922-4013-9d21-3f139b081592"
      unitRef="usd">-400000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <sgry:DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration
      contextRef="i97af3ba9bf154ce48824c269e037ff4f_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfMTY0OTI2NzQ0OTA4NA_59e7ce6d-2b09-43d2-9ea4-9f25c18c938b"
      unitRef="surgical_facility">2</sgry:DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="i23157d624d184f359c7bfa4ba8b5e305_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfMTY0OTI2NzQ0OTE1Ng_22f4695a-3415-4d5d-a171-0644dda9f08b"
      unitRef="business_entity">2</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfMTA5OTUxMTYzMzY5MA_01c29b16-ee51-430c-9493-b2a2b200b1f7"
      unitRef="usd">9800000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i97af3ba9bf154ce48824c269e037ff4f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNC9mcmFnOmEyYmQ3ZDM5MDNmYzQzMmViY2QzMjIwMTkzNDA4NDFjL3RleHRyZWdpb246YTJiZDdkMzkwM2ZjNDMyZWJjZDMyMjAxOTM0MDg0MWNfMTA5OTUxMTYzMzczNw_59331d41-d3b1-420d-b0ca-3a663a97ac03"
      unitRef="usd">-5600000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:LongTermDebtTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RleHRyZWdpb246OTVmMGMwZTU0NGYwNDY0NTk0OGU4ZDFmZDc3M2RkMTFfMzExMQ_f4d4d8b6-c365-4c87-974e-fed4e726ffc0">Long-Term Debt&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of long-term debt follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior secured term loan &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,527.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,530.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.750% senior unsecured notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;370.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;370.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.000% senior unsecured notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;545.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;545.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Notes payable and other secured loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;507.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;364.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: unamortized debt issuance costs and discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,093.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,938.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current maturities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,025.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,878.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:4pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;Includes unamortized fair value discount of $2.8 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;and $3.0&#160;million as of March&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The increase in finance lease obligations is a result of the modification of certain existing facility real estate leases that were previously classified as operating leases. See Note 4. "Leases" for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revolving Credit Facility&lt;/span&gt;&lt;/div&gt;As of March 31, 2022, the Company's availability on its revolving credit facility (the "Revolver") was $203.0 million (including outstanding letters of credit of $7.0 million). There were no outstanding borrowings under the Revolver as of both March 31, 2022 and December 31, 2021</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RleHRyZWdpb246OTVmMGMwZTU0NGYwNDY0NTk0OGU4ZDFmZDc3M2RkMTFfMzExNg_162ddf48-5392-4711-a7c5-697a7bf0bd82">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of long-term debt follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior secured term loan &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,527.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,530.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.750% senior unsecured notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;370.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;370.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.000% senior unsecured notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;545.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;545.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Notes payable and other secured loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;507.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;364.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: unamortized debt issuance costs and discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,093.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,938.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current maturities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,025.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,878.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;Includes unamortized fair value discount of $2.8 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;and $3.0&#160;million as of March&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;December&#160;31, 2021, respectively.</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iabc81fe53c8740a5835ce19d18a21d80_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfMi0yLTEtMS0zOTkzNg_9ba99db7-e864-41f4-a461-a8544b9d88a2"
      unitRef="usd">1527000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1c6502e60a4b4f40b2ab3906a1e7320a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfMi00LTEtMS0zOTkzNg_d7026d9d-3103-466f-b0a2-b3c24e3b6b27"
      unitRef="usd">1530700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idcfcf6c0b474488abf86dd8a19ab641d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfMy0wLTEtMS0zOTkzNi90ZXh0cmVnaW9uOmQ4ZjEwZTlkODkxZjQ2ZWE5NDdiNzFjZDdlZGM2ZTE4XzQ_54be529a-b9d8-481b-86a9-1ec69c02da58"
      unitRef="number">0.06750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="idcfcf6c0b474488abf86dd8a19ab641d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfMy0yLTEtMS0zOTkzNg_35f759f1-ee4d-4e94-a9fd-ac9e212ec9fa"
      unitRef="usd">370000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia6f81ce56efe4167827c87bda7c7d7ae_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfMy00LTEtMS0zOTkzNg_e95873af-6780-4ea3-8984-949ec8aeb922"
      unitRef="usd">370000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia4c64a5508684384921c71fc65d53263_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfNC0wLTEtMS0zOTkzNi90ZXh0cmVnaW9uOjdiMDZhODFmNmQ2NDRiMDg5MWRkNjJlNDE3YjEyODBhXzQ_8ae946db-f983-4a17-a62c-9a316fe34c11"
      unitRef="number">0.10000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia4c64a5508684384921c71fc65d53263_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfNC0yLTEtMS0zOTkzNg_60291b9c-80c9-4309-8c18-3beca4d23511"
      unitRef="usd">545000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic09d86ac1f06413595ed16720d86db9a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfNC00LTEtMS0zOTkzNg_e2ec2267-9598-4461-aa97-24b362f11020"
      unitRef="usd">545000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6efe1dcecbea4bcbbe13edfdc24585b8_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfNS0yLTEtMS0zOTkzNg_252a026d-c0df-473b-94cc-c1f801cfb18c"
      unitRef="usd">159300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4d53ad311174404c83910a5b4a784afd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfNS00LTEtMS0zOTkzNg_64ffa869-136c-4d94-a86c-5103edf047ac"
      unitRef="usd">145000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfNi0yLTEtMS0zOTkzNg_3804d54e-05f5-4781-b3e2-239a7afcc618"
      unitRef="usd">507700000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfNi00LTEtMS0zOTkzNg_0fb80184-45a7-44e5-9344-9057a02a9ab0"
      unitRef="usd">364600000</us-gaap:FinanceLeaseLiability>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfNy0yLTEtMS0zOTkzNg_90a3f4ef-b0cc-4500-ae55-a774a8db0af2"
      unitRef="usd">15800000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfNy00LTEtMS0zOTkzNg_0f963e8b-ed34-427e-9b04-ce20ebda59c5"
      unitRef="usd">16500000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfOC0yLTEtMS0zOTkzNg_3dba12b8-d9e5-4b2b-9a6a-d411eb265a0a"
      unitRef="usd">3093200000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfOC00LTEtMS0zOTkzNg_14a7adf0-cf13-4a01-acd7-7ce10164890f"
      unitRef="usd">2938800000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfOS0yLTEtMS0zOTkzNg_533e7844-c41d-4269-afb7-d1ecffbe43a5"
      unitRef="usd">68000000.0</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfOS00LTEtMS0zOTkzNg_d6f6e91b-084a-40e1-af95-3bde3f3461ae"
      unitRef="usd">60400000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfMTAtMi0xLTEtMzk5MzY_ebdc011f-3591-4eda-b001-feec4a9716b5"
      unitRef="usd">3025200000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RhYmxlOjhhNmVkMDNjZTU0MDRiMDJhOWUxZTc5NDdhZDgxMWU3L3RhYmxlcmFuZ2U6OGE2ZWQwM2NlNTQwNGIwMmE5ZTFlNzk0N2FkODExZTdfMTAtNC0xLTEtMzk5MzY_502b6bc5-a117-4382-a453-77bc2c319bbb"
      unitRef="usd">2878400000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="iabc81fe53c8740a5835ce19d18a21d80_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RleHRyZWdpb246OTVmMGMwZTU0NGYwNDY0NTk0OGU4ZDFmZDc3M2RkMTFfMTIy_859cf0ef-6f03-48a6-8619-1599df533193"
      unitRef="usd">2800000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="i1c6502e60a4b4f40b2ab3906a1e7320a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RleHRyZWdpb246OTVmMGMwZTU0NGYwNDY0NTk0OGU4ZDFmZDc3M2RkMTFfMTA5OTUxMTYzMDkxNg_27a1d1cc-a913-4add-bde1-4fe06c148cc4"
      unitRef="usd">3000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i6d81a2e35ef544709f6c3c5a6ec09d33_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RleHRyZWdpb246OTVmMGMwZTU0NGYwNDY0NTk0OGU4ZDFmZDc3M2RkMTFfNzU3_2d4b1ac2-c8e5-4d5e-85bf-b84faf22cab8"
      unitRef="usd">203000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="ib597d64d1a7b476fa1d8e9c70fa2d9c6_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RleHRyZWdpb246OTVmMGMwZTU0NGYwNDY0NTk0OGU4ZDFmZDc3M2RkMTFfODA0_17e5578d-1340-4183-a5c1-53321a2a013e"
      unitRef="usd">7000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i6ed7fc212be442dab6bdeb5bf9fc9902_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RleHRyZWdpb246OTVmMGMwZTU0NGYwNDY0NTk0OGU4ZDFmZDc3M2RkMTFfODIw_de5cb57a-7424-4e2c-8bfa-773c2e6c1772"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="ic6f105cec2c74bac8f0818b041444a8f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18zNy9mcmFnOjk1ZjBjMGU1NDRmMDQ2NDU5NDhlOGQxZmQ3NzNkZDExL3RleHRyZWdpb246OTVmMGMwZTU0NGYwNDY0NTk0OGU4ZDFmZDc3M2RkMTFfODIw_f214c01e-805d-4bbc-a768-b435af07a164"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RleHRyZWdpb246MWE1ODhhMGQ1M2JhNGVkYjlmOWVhZmJkNDQzZTYxOGFfNTQ1_1fa7930e-36af-461c-8c5e-d93cd0245f33">Leases&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the consolidated balance sheets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification in Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;277.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNC0yLTEtMS00NjQ2Ng_0f2dda77-9e14-4a9d-bd4c-1fca9c544334"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNC0yLTEtMS00NjQ2Ng_32523eef-34e6-4b2a-913b-0c4967f1b23d"&gt;Property and equipment, net of accumulated depreciation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;467.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;745.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;653.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfOS0yLTEtMS00NjQ2OA_4491f22a-c2d0-4ffb-9a7d-8129b50d1a26"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfOS0yLTEtMS00NjQ2OA_e2b110e3-da5b-424a-8c7d-d3e258e86a47"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;272.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;315.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;307.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;355.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTMtMi0xLTEtNDY0NzI_4d4afb66-9139-4863-9c1e-c7148377256b"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTMtMi0xLTEtNDY0NzI_822c6ee1-f967-42b7-8426-35b31d91efae"&gt;Current maturities of long-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTQtMi0xLTEtNDY0Nzc_9fb4ebe5-aa6a-445d-86cd-135374660488"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTQtMi0xLTEtNDY0Nzc_f854c062-dd64-4d2b-a477-9bd1f49a42d6"&gt;Long-term debt, less current maturities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;484.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;345.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;507.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;364.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;815.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;720.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, the Company extended certain existing facility real estate leases, resulting in the reclassification of the leases from operating to finance. The modifications resulted in an increase to finance lease liabilities and assets of $146.5&#160;million and $145.0&#160;million, respectively, including the reclassification of existing operating lease liabilities and assets of $60.8&#160;million and $59.3&#160;million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the Company's lease expense and their classification in the condensed consolidated statement of operations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable and short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental cash flow information (dollars in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from operating leases &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RleHRyZWdpb246MWE1ODhhMGQ1M2JhNGVkYjlmOWVhZmJkNDQzZTYxOGFfNTQ1_6f53aa97-c188-4f59-b18b-a44676115a10">Leases&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the consolidated balance sheets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification in Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;277.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNC0yLTEtMS00NjQ2Ng_0f2dda77-9e14-4a9d-bd4c-1fca9c544334"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNC0yLTEtMS00NjQ2Ng_32523eef-34e6-4b2a-913b-0c4967f1b23d"&gt;Property and equipment, net of accumulated depreciation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;467.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;745.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;653.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfOS0yLTEtMS00NjQ2OA_4491f22a-c2d0-4ffb-9a7d-8129b50d1a26"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfOS0yLTEtMS00NjQ2OA_e2b110e3-da5b-424a-8c7d-d3e258e86a47"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;272.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;315.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;307.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;355.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTMtMi0xLTEtNDY0NzI_4d4afb66-9139-4863-9c1e-c7148377256b"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTMtMi0xLTEtNDY0NzI_822c6ee1-f967-42b7-8426-35b31d91efae"&gt;Current maturities of long-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTQtMi0xLTEtNDY0Nzc_9fb4ebe5-aa6a-445d-86cd-135374660488"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTQtMi0xLTEtNDY0Nzc_f854c062-dd64-4d2b-a477-9bd1f49a42d6"&gt;Long-term debt, less current maturities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;484.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;345.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;507.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;364.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;815.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;720.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, the Company extended certain existing facility real estate leases, resulting in the reclassification of the leases from operating to finance. The modifications resulted in an increase to finance lease liabilities and assets of $146.5&#160;million and $145.0&#160;million, respectively, including the reclassification of existing operating lease liabilities and assets of $60.8&#160;million and $59.3&#160;million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the Company's lease expense and their classification in the condensed consolidated statement of operations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable and short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental cash flow information (dollars in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from operating leases &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <sgry:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RleHRyZWdpb246MWE1ODhhMGQ1M2JhNGVkYjlmOWVhZmJkNDQzZTYxOGFfMzI5ODUzNDg4NTk3Nw_5fe61bec-63f8-4ecf-873d-14e37348394e">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the consolidated balance sheets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification in Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;277.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNC0yLTEtMS00NjQ2Ng_0f2dda77-9e14-4a9d-bd4c-1fca9c544334"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNC0yLTEtMS00NjQ2Ng_32523eef-34e6-4b2a-913b-0c4967f1b23d"&gt;Property and equipment, net of accumulated depreciation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;467.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;745.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;653.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfOS0yLTEtMS00NjQ2OA_4491f22a-c2d0-4ffb-9a7d-8129b50d1a26"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfOS0yLTEtMS00NjQ2OA_e2b110e3-da5b-424a-8c7d-d3e258e86a47"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;272.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;315.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;307.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;355.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTMtMi0xLTEtNDY0NzI_4d4afb66-9139-4863-9c1e-c7148377256b"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTMtMi0xLTEtNDY0NzI_822c6ee1-f967-42b7-8426-35b31d91efae"&gt;Current maturities of long-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTQtMi0xLTEtNDY0Nzc_9fb4ebe5-aa6a-445d-86cd-135374660488"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTQtMi0xLTEtNDY0Nzc_f854c062-dd64-4d2b-a477-9bd1f49a42d6"&gt;Long-term debt, less current maturities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;484.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;345.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;507.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;364.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;815.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;720.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sgry:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMy00LTEtMS00NTQwNw_ec983d65-c4f5-4917-b367-365bcfc928a0"
      unitRef="usd">277400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMy02LTEtMS00NTQwNw_07a53df0-3e60-4c65-9ab4-b8160628bee4"
      unitRef="usd">324100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNC00LTEtMS00NTQwNw_28195c66-e827-45e5-b65f-3876ac8d8ade"
      unitRef="usd">467600000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNC02LTEtMS00NTQwNw_95591a3c-2952-436b-a216-fcceada0aa48"
      unitRef="usd">329600000</us-gaap:FinanceLeaseRightOfUseAsset>
    <sgry:LeaseRightOfUseAsset
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNS00LTEtMS00NjQ2Mw_5e5d1011-fb75-4a5f-9fc5-d8608f5a1d83"
      unitRef="usd">745000000.0</sgry:LeaseRightOfUseAsset>
    <sgry:LeaseRightOfUseAsset
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfNS02LTEtMS00NjQ2Mw_dbcf7e90-2145-4802-bd93-2d32720d2d36"
      unitRef="usd">653700000</sgry:LeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfOS00LTEtMS00NTQwNw_445d8979-d865-44e8-8195-4050411b0d8e"
      unitRef="usd">35200000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfOS02LTEtMS00NTQwNw_26d20620-d18e-4d28-9a5f-eb2c0d6f83c4"
      unitRef="usd">40100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTAtNC0xLTEtNDU0MDc_d80b636b-c834-4ef2-a238-22daf79287d7"
      unitRef="usd">272100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTAtNi0xLTEtNDU0MDc_4bd03f47-8c0c-4e67-83ed-a53db1288314"
      unitRef="usd">315600000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTEtNC0xLTEtNDY0NjM_78db5665-6a4f-4af7-9e2b-8d3b52e7f01c"
      unitRef="usd">307300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTEtNi0xLTEtNDY0NjM_c9f679fd-8f4d-46bf-a6c2-75faa6393bc5"
      unitRef="usd">355700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTMtNC0xLTEtNDU0MDc_320de23a-9743-4231-891f-4ab6c9c4cc3d"
      unitRef="usd">22900000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTMtNi0xLTEtNDU0MDc_4ceb7782-66cd-4e71-8d4e-5fcb84def651"
      unitRef="usd">19000000.0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTQtNC0xLTEtNDU0MDc_f4cded43-21f2-43b8-a61a-a62dfc6e698c"
      unitRef="usd">484800000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTQtNi0xLTEtNDU0MDc_907006fb-ec90-41f5-abf4-6e9ea70aed6d"
      unitRef="usd">345600000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTUtNC0xLTEtNDY0NjM_16a9bfd8-4e5e-4045-b724-74e321312792"
      unitRef="usd">507700000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTUtNi0xLTEtNDY0NjM_702d309c-859d-4686-9f72-0a404b66e249"
      unitRef="usd">364600000</us-gaap:FinanceLeaseLiability>
    <sgry:LeaseLiability
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTYtNC0xLTEtNDY0NjM_aa81219c-7622-49fc-a030-d81dc51fc5cd"
      unitRef="usd">815000000.0</sgry:LeaseLiability>
    <sgry:LeaseLiability
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjIyYzNjZWU1ZmNiMTQ4NmQ5YTQ2YTY4YjJhYTUzMGU3L3RhYmxlcmFuZ2U6MjJjM2NlZTVmY2IxNDg2ZDlhNDZhNjhiMmFhNTMwZTdfMTYtNi0xLTEtNDY0NjM_21433c6f-8776-4e0d-ac50-439ef907c027"
      unitRef="usd">720300000</sgry:LeaseLiability>
    <sgry:IncreaseDecreaseInFinanceLeaseLiability
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RleHRyZWdpb246MWE1ODhhMGQ1M2JhNGVkYjlmOWVhZmJkNDQzZTYxOGFfODI0NjMzNzIxMDI4OA_f6269c5b-2765-45b6-a2be-0d146fc934b8"
      unitRef="usd">146500000</sgry:IncreaseDecreaseInFinanceLeaseLiability>
    <sgry:IncreaseDecreaseInFinanceLeaseRightOfUseAssets
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RleHRyZWdpb246MWE1ODhhMGQ1M2JhNGVkYjlmOWVhZmJkNDQzZTYxOGFfODI0NjMzNzIxMDM0OQ_4f58bd8a-dd24-4898-9155-9228653e4511"
      unitRef="usd">145000000</sgry:IncreaseDecreaseInFinanceLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RleHRyZWdpb246MWE1ODhhMGQ1M2JhNGVkYjlmOWVhZmJkNDQzZTYxOGFfODI0NjMzNzIxMDM5Mw_4880422f-a73e-4d92-95d9-510d37ce4bb1"
      unitRef="usd">-60800000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <sgry:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RleHRyZWdpb246MWE1ODhhMGQ1M2JhNGVkYjlmOWVhZmJkNDQzZTYxOGFfODI0NjMzNzIxMDQwMQ_8efec604-32a5-42b7-b57a-7c4c1a5b4e50"
      unitRef="usd">-59300000</sgry:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RleHRyZWdpb246MWE1ODhhMGQ1M2JhNGVkYjlmOWVhZmJkNDQzZTYxOGFfNTU2_e8ccde82-bd36-4132-820d-766da785fda5">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the Company's lease expense and their classification in the condensed consolidated statement of operations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable and short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental cash flow information (dollars in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from operating leases &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfMi0yLTEtMS0zOTkzNg_e2d4d348-28a0-4157-bda4-cc9188109952"
      unitRef="usd">16100000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfMi00LTEtMS0zOTkzNg_29e5feb9-eb46-43bd-a307-af74a314b0ae"
      unitRef="usd">18600000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfNC0yLTEtMS0zOTkzNg_ac303573-4fc2-4969-90ef-8fcb94ffeff5"
      unitRef="usd">9200000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfNC00LTEtMS0zOTkzNg_888cf9b4-7f66-4db2-8798-adfe3851677f"
      unitRef="usd">7100000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfNS0yLTEtMS0zOTkzNg_3126dd07-dbb8-42ef-a2d6-7be0cbc36839"
      unitRef="usd">9900000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfNS00LTEtMS0zOTkzNg_4c2e8f82-35d6-4959-a0a5-dd59fe6a2a91"
      unitRef="usd">6300000</us-gaap:FinanceLeaseInterestExpense>
    <sgry:FinanceLeaseCost
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfNi0yLTEtMS0zOTkzNg_b1233ca4-4f29-49fc-b5b6-3e6c2601ca57"
      unitRef="usd">19100000</sgry:FinanceLeaseCost>
    <sgry:FinanceLeaseCost
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfNi00LTEtMS0zOTkzNg_627dbdd0-fd88-4405-9dc5-79410c5872dd"
      unitRef="usd">13400000</sgry:FinanceLeaseCost>
    <sgry:VariableAndShortTermLeaseCost
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfNy0yLTEtMS0zOTkzNg_39efdea6-102f-4e29-a102-4004d2a56b03"
      unitRef="usd">4400000</sgry:VariableAndShortTermLeaseCost>
    <sgry:VariableAndShortTermLeaseCost
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfNy00LTEtMS0zOTkzNg_ebca1856-d81c-4307-a923-3470eb504842"
      unitRef="usd">5200000</sgry:VariableAndShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfOC0yLTEtMS0zOTkzNg_dd51f891-f4cd-4976-a139-f7da2cbcb59c"
      unitRef="usd">39600000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOmY4ZjgwYjdhMGY2YTQ0MTk4ZjYwYzI5MWMwZTM3YTc2L3RhYmxlcmFuZ2U6ZjhmODBiN2EwZjZhNDQxOThmNjBjMjkxYzBlMzdhNzZfOC00LTEtMS0zOTkzNg_5b484333-abed-4a26-a4fd-2a8a85a806cc"
      unitRef="usd">37200000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjdkZGNkYTY1NmQ5ZjRkMTJiY2E5YjI0ODYwY2RkMzQ2L3RhYmxlcmFuZ2U6N2RkY2RhNjU2ZDlmNGQxMmJjYTliMjQ4NjBjZGQzNDZfMy0xLTEtMS0zOTkzNg_4525ce75-c7bf-45d3-b435-48b3732fbd83"
      unitRef="usd">15600000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjdkZGNkYTY1NmQ5ZjRkMTJiY2E5YjI0ODYwY2RkMzQ2L3RhYmxlcmFuZ2U6N2RkY2RhNjU2ZDlmNGQxMmJjYTliMjQ4NjBjZGQzNDZfMy0zLTEtMS0zOTkzNg_63cdbecc-c856-4e48-8dd1-283a8a3762e0"
      unitRef="usd">18200000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjdkZGNkYTY1NmQ5ZjRkMTJiY2E5YjI0ODYwY2RkMzQ2L3RhYmxlcmFuZ2U6N2RkY2RhNjU2ZDlmNGQxMmJjYTliMjQ4NjBjZGQzNDZfNC0xLTEtMS0zOTkzNg_165937c1-fc23-4ae2-9f00-7fdb10a70d47"
      unitRef="usd">9800000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjdkZGNkYTY1NmQ5ZjRkMTJiY2E5YjI0ODYwY2RkMzQ2L3RhYmxlcmFuZ2U6N2RkY2RhNjU2ZDlmNGQxMmJjYTliMjQ4NjBjZGQzNDZfNC0zLTEtMS0zOTkzNg_345bf7e6-dfdc-4277-aca5-a06231546c76"
      unitRef="usd">5700000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjdkZGNkYTY1NmQ5ZjRkMTJiY2E5YjI0ODYwY2RkMzQ2L3RhYmxlcmFuZ2U6N2RkY2RhNjU2ZDlmNGQxMmJjYTliMjQ4NjBjZGQzNDZfNS0xLTEtMS0zOTkzNg_570077e2-ce7c-49b8-9d63-d97555854323"
      unitRef="usd">6000000.0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjdkZGNkYTY1NmQ5ZjRkMTJiY2E5YjI0ODYwY2RkMzQ2L3RhYmxlcmFuZ2U6N2RkY2RhNjU2ZDlmNGQxMmJjYTliMjQ4NjBjZGQzNDZfNS0zLTEtMS0zOTkzNg_94d08d8e-3448-4dc6-a479-43946d88b5ef"
      unitRef="usd">5000000.0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjdkZGNkYTY1NmQ5ZjRkMTJiY2E5YjI0ODYwY2RkMzQ2L3RhYmxlcmFuZ2U6N2RkY2RhNjU2ZDlmNGQxMmJjYTliMjQ4NjBjZGQzNDZfOC0xLTEtMS0zOTkzNg_d9a6944a-f70a-4f74-a9d9-2a268784b4fc"
      unitRef="usd">22000000.0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjdkZGNkYTY1NmQ5ZjRkMTJiY2E5YjI0ODYwY2RkMzQ2L3RhYmxlcmFuZ2U6N2RkY2RhNjU2ZDlmNGQxMmJjYTliMjQ4NjBjZGQzNDZfOC0zLTEtMS0zOTkzNg_881efa0a-366e-4807-b3fd-7c59e1cfe262"
      unitRef="usd">6300000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjdkZGNkYTY1NmQ5ZjRkMTJiY2E5YjI0ODYwY2RkMzQ2L3RhYmxlcmFuZ2U6N2RkY2RhNjU2ZDlmNGQxMmJjYTliMjQ4NjBjZGQzNDZfOS0xLTEtMS0zOTkzNg_40e2ecca-c29a-4e63-bccb-7fe000d59639"
      unitRef="usd">89300000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180MC9mcmFnOjFhNTg4YTBkNTNiYTRlZGI5ZjllYWZiZDQ0M2U2MThhL3RhYmxlOjdkZGNkYTY1NmQ5ZjRkMTJiY2E5YjI0ODYwY2RkMzQ2L3RhYmxlcmFuZ2U6N2RkY2RhNjU2ZDlmNGQxMmJjYTliMjQ4NjBjZGQzNDZfOS0zLTEtMS0zOTkzNg_68a8bbe4-ab29-42ff-b655-747ee24ea35f"
      unitRef="usd">1400000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfNjI0NA_6237b0ca-7263-446f-b14d-ebf88171d160">Derivatives and Hedging Activities&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps and interest rate caps as part of its interest rate risk management strategy. During 2022 and 2021, such derivatives have been used to hedge the variable cash flows associated with existing variable-rate debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income ("OCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings, as documented at hedge inception in accordance with the Company&#x2019;s accounting policy election. Amounts reported in accumulated OCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company&#x2019;s variable-rate debt. Over the next 12 months, the Company estimates that an additional $12.0 million will be reclassified as an increase to interest expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the Company had nine interest rate swaps with a total net hedged notional amount of $1.2&#160;billion and two interest rate caps with a total hedged notional amount of $329.8&#160;million. Of the nine interest rate swaps, three are pay-fixed, receive 1-Month LIBOR (subject to a minimum of 0.75%) interest rate swaps designated in cash flow hedging relationships with a total notional amount of $1.2&#160;billion and a termination date of March 31, 2025. The remaining six interest rate swaps are undesignated and consist of three pay-fixed, receive 1-Month LIBOR (subject to a minimum of 1.00%) interest rate swaps and three pay 1-Month LIBOR (subject to a minimum of 1.00%), receive-fixed interest rate swaps with a termination date of November 30, 2023. The pay-floating, receive-fixed swaps are designed to economically offset the undesignated pay-fixed, receive-floating swaps. The interest rate caps each have a termination date of March&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The pay-fixed, receive floating interest rate swaps did not meet the requirements to be considered derivatives in their entirety as a result of the financing component. Accordingly, the swaps are considered hybrid instruments, consisting of a financing element treated as a debt instrument and an embedded at-market derivative that was designated as a cash flow hedge. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Within the Company&#x2019;s condensed consolidated balance sheets, the financing elements treated as debt instruments described above are carried at amortized cost and the embedded at-market derivatives and the undesignated swaps are recorded at fair value. The cash flows related to the portion treated as debt are classified as financing activities in the condensed consolidated statements of cash flows while the portion treated as an at-market derivative are classified as operating activities. Cash settlements related to the undesignated swaps will offset and are classified as operating activities in the condensed consolidated cash flows. Within the Company&#x2019;s condensed consolidated balance sheets, the interest rate caps are recorded at fair value. The cash flows related to the interest rate caps are classified as operating activities in the condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The key terms of interest rate swaps and interest rate caps outstanding are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 7, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 7, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 7, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate cap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate cap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 28, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receive-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(165.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(165.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receive-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(120.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(120.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receive-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(150.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(150.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,529.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,533.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Our interest rate swap agreements, excluding the portion treated as debt, are recognized at fair value in the condensed consolidated balance sheets and are valued using pricing models that rely on market observable inputs such as yield curve data, which are classified as Level 2 inputs within the fair value hierarchy. The fair value of the interest rate caps are determined using the market standard methodology of discounting the future expected cash receipts that would occur if variable interest rates rise above the strike rate of the caps. The variable interest rates used in the calculation of projected receipts on the caps are based on an expectation of future interest rates derived from observable market interest rate curves and volatilities. The interest rate caps are classified using Level 2 inputs within the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the fair values of our derivatives and their location on the condensed consolidated balance sheets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.989%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives in cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate caps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;The balance as of March&#160;31, 2022 and December 31, 2021 is related to the financing component of the pay-fixed, receive floating interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the pre-tax effect of the interest rate swaps and caps on the Company's accumulated OCI and condensed consolidated statement of operations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss recognized in income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives in cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain recognized in OCI (effective portion)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss reclassified from accumulated OCI into income (effective portion) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;Includes amortization of accumulated OCI related to de-designated and terminated interest rate swaps of $5.3 million for the three months ended March&#160;31, 2022 with no related amortization for the three months ended March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfMTEyNg_bcb3b782-e8bd-4ff8-8a8f-21ebde94df39"
      unitRef="usd">-12000000</us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="i83e7577cfc3e485fa204871cd2bebed9_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfMTM4Mg_f7b6888d-c23c-454f-b7ad-3badd0d3d00f"
      unitRef="interest_rate_swap">9</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia5195b743fe34283b9ca5fca00063c24_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfMTQ0OA_5b9beb48-76ee-4895-8568-fbb485038538"
      unitRef="usd">1200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="ia71c20142f984a65b73126b2fc598e6b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfMzI5ODUzNDg5MzExMg_d0979c38-c8b7-45dc-a2de-9ef6da393c2d"
      unitRef="interest_rate_swap">2</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ibfefa22461da4d3d8abc5576226480fb_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfOTM0NTg0ODg0NTg2Mw_95e6b85e-b768-43ad-adf8-aab3cbe21b17"
      unitRef="usd">329800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="i83e7577cfc3e485fa204871cd2bebed9_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfMTQ1OQ_86cd00ec-5e6d-4457-a14e-5eded8eaa42c"
      unitRef="interest_rate_swap">9</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeVariableInterestRate
      contextRef="iae1b34f8d424499badf3a4c4c1482bff_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfMTU0OA_53dff8d9-b01e-4ab2-9ba2-f53a43fec338"
      unitRef="number">0.0075</us-gaap:DerivativeVariableInterestRate>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia5195b743fe34283b9ca5fca00063c24_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfMTY1MA_09a4af2b-092d-4d42-a89a-111e107dfbb6"
      unitRef="usd">1200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeVariableInterestRate
      contextRef="ie0cd5769098e47f6a43dac3d7b1801fc_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfMTgxMw_2aca3d3d-6df4-42e2-a558-e2c74f54ccce"
      unitRef="number">0.0100</us-gaap:DerivativeVariableInterestRate>
    <us-gaap:DerivativeVariableInterestRate
      contextRef="i35f44859d11f47c1b1e53d1b04378a95_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfMTg4Nw_22e91a32-517c-47ff-a5b4-d11ed1390599"
      unitRef="number">0.0100</us-gaap:DerivativeVariableInterestRate>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfNjI0MA_e4cf527f-fef5-4d26-b801-40b5985fa385">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The key terms of interest rate swaps and interest rate caps outstanding are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 7, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 7, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 7, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;435.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate cap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate cap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pay-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 28, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receive-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(165.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(165.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receive-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(120.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(120.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receive-fixed swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(150.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(150.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,529.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,533.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i612b998bf6814f52b34921481a7fed42_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMi00LTEtMS0zOTkzNg_413e6c52-cce5-4ab6-8203-49c02d58a9da"
      unitRef="usd">435000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i6feaa769eee6494280e04ca4428e2d1e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMi04LTEtMS0zOTkzNg_9f5f8a2b-4e4e-4038-b370-ef17e6535fb9"
      unitRef="usd">435000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="id325fcdc0f7c47528506f54fa3611300_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMy00LTEtMS0zOTkzNg_6e7e1539-856f-4627-b4bb-8cb521ad30f3"
      unitRef="usd">330000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="ib8b44c0e1c7740bd90f41c1945029459_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMy04LTEtMS0zOTkzNg_c8b80777-6786-48af-a7d0-ea14ae41d017"
      unitRef="usd">330000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="ia15782f2cb274cddb56795539491873a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfNC00LTEtMS0zOTkzNg_bfc7b9fd-3f9b-45ec-b65a-c6fe38078948"
      unitRef="usd">435000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="id9d8edabf0d9426fb79d750950a72128_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfNC04LTEtMS0zOTkzNg_fd5cef67-730d-4f79-8c10-466bd5697a50"
      unitRef="usd">435000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i110b4a998ba9459cb22bd9c1786eb35f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfNS00LTEtMS0zOTkzNg_bc7300c4-f6d9-4e40-adb9-535e726e42c5"
      unitRef="usd">164900000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i36389bf37a7143988be57524833186e1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfNS04LTEtMS0zOTkzNg_df5d9b65-24c4-4584-a541-047275e70920"
      unitRef="usd">166800000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="if939f474cbd9448a890aaa8ad9497a6c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfNi00LTEtMS0zOTkzNg_ffd02e0b-cc7b-45eb-8f06-1af353ec13df"
      unitRef="usd">164900000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i470b3213c5384e66a7ea1d5fe3c19aec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfNi04LTEtMS0zOTkzNg_537f8237-cb67-43f3-80b9-003fb258e641"
      unitRef="usd">166800000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i482b7170e0e44958a6bccac3fb8b4bb1_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfNy00LTEtMS0zOTkzNg_2fe9834e-cec1-41f7-90a1-9d6673b2a3e1"
      unitRef="usd">165000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="ifc2a066e204b487d9b869bbac4264ca0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfNy04LTEtMS0zOTkzNg_c47a4149-8547-4a46-a14d-212a476ddbfd"
      unitRef="usd">165000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i1b59666e5a6445af800a6e82b2247fa6_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfOC00LTEtMS0zOTkzNg_a7fe934f-2e0a-41c1-b16b-219c5db687a7"
      unitRef="usd">120000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i72dbce711df14aa19565cfda8712ae96_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfOC04LTEtMS0zOTkzNg_4f770d2c-4065-47be-96cc-2ecb5ae238eb"
      unitRef="usd">120000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i279c0b5c9ef6400db373978fe16df294_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfOS00LTEtMS0zOTkzNg_5d80ca50-1262-4acf-83a2-195cf4e5544d"
      unitRef="usd">150000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i8205810c50914fc8b2ee5716cdd1e3ef_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfOS04LTEtMS0zOTkzNg_3d8bba95-d714-4009-b014-ea2843d02196"
      unitRef="usd">150000000.0</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i5179e2adfc75478a8bceb8a842e8343d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMTAtNC0xLTEtMzk5MzY_3dd107be-b8d3-4a78-bdc3-347b4c97d7db"
      unitRef="usd">165000000.0</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i06b61d1351f642c39e07376db16278bf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMTAtOC0xLTEtMzk5MzY_6cffbd89-8fd2-48d4-8d2f-d2fbe037e63d"
      unitRef="usd">165000000.0</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i1c751ca3945547ff89766e783b1692c2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMTEtNC0xLTEtMzk5MzY_24b6d07a-5085-4994-ae30-836793ce01a9"
      unitRef="usd">120000000.0</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ifec07c218a224559988b65a85dca34bd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMTEtOC0xLTEtMzk5MzY_b23143be-3865-4458-9fb4-39bf3bbd4eb4"
      unitRef="usd">120000000.0</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i75a4d54131d04ec7a9ad66d50af16a7e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMTItNC0xLTEtMzk5MzY_347a50f7-a326-490b-9abb-370769569410"
      unitRef="usd">150000000.0</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i746cdb6a8857465b8789529fa778ae72_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMTItOC0xLTEtMzk5MzY_64de3d2b-d2df-4c69-93ac-04cec99d4423"
      unitRef="usd">150000000.0</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMTctNC0xLTEtMzk5MzY_d19d88c8-8682-4c65-aa3e-1048ef7f1bf1"
      unitRef="usd">1529800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjkwMWFjNWE4NGRjZTRlNzU5YTcyYzEzMzUzNWM0N2RjL3RhYmxlcmFuZ2U6OTAxYWM1YTg0ZGNlNGU3NTlhNzJjMTMzNTM1YzQ3ZGNfMTctOC0xLTEtMzk5MzY_ceefc1ad-94e5-4ca7-bd5d-8e47aef4ea68"
      unitRef="usd">1533600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfNjI0Mw_e9569218-9c46-4752-ae78-5152bec0a01f">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the fair values of our derivatives and their location on the condensed consolidated balance sheets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.989%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives in cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate caps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;The balance as of March&#160;31, 2022 and December 31, 2021 is related to the financing component of the pay-fixed, receive floating interest rate swaps.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i052e333e8fbc4c8d828f8652b2a87288_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfMy00LTEtMS0zOTkzNg_c20762a6-f398-4b25-8ade-e6d904b9de87"
      unitRef="usd">4700000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="ie234fc584e43432db473ff2d1b925b9b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfMy04LTEtMS0zOTkzNg_e27e631c-6a46-4236-8bcd-7f6131bf4e76"
      unitRef="usd">12500000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ib5395316d4cc4c4cb5531fc9710de0ef_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfNC02LTEtMS0zOTkzNg_117c5a1f-e0d5-41bc-9d74-bf2a992cc4aa"
      unitRef="usd">4600000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i4ed5590de58f45ffa296c26e82b8cb5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfNC0xMC0xLTEtMzk5MzY_bbad4e5e-3332-47e2-ad3f-88c265437282"
      unitRef="usd">12400000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i3dd7a0c476e3425a9cd8fdf81d246d59_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfNy00LTEtMS00MjIzOA_16af8b25-6a64-4153-9f2d-ded5731e1f25"
      unitRef="usd">11100000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i290ced8dda3d48ff99a0576554a33576_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfNy04LTEtMS00MjIzNA_2eb559fe-9505-42cd-aaa3-656a20a4f9ea"
      unitRef="usd">2900000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i86d66d0402e1453c9f1b3777c6d974bd_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfNy00LTEtMS0zOTkzNg_6c224026-ed28-4a48-9647-ecddc3e1006f"
      unitRef="usd">51400000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i5ff93bdfad7b424a8bf0ec3d14822809_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfNy04LTEtMS0zOTkzNg_ac1d1c46-8525-41b0-a4fd-fdc31cb13129"
      unitRef="usd">8200000</us-gaap:DerivativeAssetNotionalAmount>
    <sgry:DerivativeLiabilityNotionalAmountFinancingComponent
      contextRef="i83e7577cfc3e485fa204871cd2bebed9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfOC02LTEtMS0zOTkzNg_9c7ef40a-3fcc-4fdf-af6f-851d3e6d252e"
      unitRef="usd">42400000</sgry:DerivativeLiabilityNotionalAmountFinancingComponent>
    <sgry:DerivativeLiabilityNotionalAmountFinancingComponent
      contextRef="i774a5b342a17415398ee546db06a900e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfOC0xMC0xLTEtMzk5MzY_2e635120-06d2-46db-a68a-e9435e274cdc"
      unitRef="usd">45800000</sgry:DerivativeLiabilityNotionalAmountFinancingComponent>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfOS00LTEtMS0zOTkzNg_2d8db358-bb67-4a5c-9d9d-208321a5fc80"
      unitRef="usd">67200000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfOS02LTEtMS0zOTkzNg_26cf3ccc-163f-4d54-b280-7414b89086ab"
      unitRef="usd">47000000.0</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeAssetNotionalAmount
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfOS04LTEtMS0zOTkzNg_873d9986-3349-46d6-848f-b8d922968be5"
      unitRef="usd">23600000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOjcwMjQ5YjY2OTI5NzRkYWE4MDgwM2YxOGJjZjdkNTA4L3RhYmxlcmFuZ2U6NzAyNDliNjY5Mjk3NGRhYTgwODAzZjE4YmNmN2Q1MDhfOS0xMC0xLTEtMzk5MzY_136a544b-f1b0-432e-b888-fcfa8a5739fb"
      unitRef="usd">58200000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfNjI0MQ_10581483-5c1b-4e1b-be6e-6d3d67f7fe97">&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the pre-tax effect of the interest rate swaps and caps on the Company's accumulated OCI and condensed consolidated statement of operations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss recognized in income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives in cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain recognized in OCI (effective portion)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss reclassified from accumulated OCI into income (effective portion) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;Includes amortization of accumulated OCI related to de-designated and terminated interest rate swaps of $5.3 million for the three months ended March&#160;31, 2022 with no related amortization for the three months ended March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i393e1260928244db91312ff5bdb20b39_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOmEyZWVkYTFmNDU0ZjQxZDM4ZDY3ZGVjYWI5OWQ2YWY5L3RhYmxlcmFuZ2U6YTJlZWRhMWY0NTRmNDFkMzhkNjdkZWNhYjk5ZDZhZjlfMy0zLTEtMS0zOTkzNg_d98d02dc-8f52-440d-a813-449681d0c6ef"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i187ebd1016734402ac3d28311bd88d06_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOmEyZWVkYTFmNDU0ZjQxZDM4ZDY3ZGVjYWI5OWQ2YWY5L3RhYmxlcmFuZ2U6YTJlZWRhMWY0NTRmNDFkMzhkNjdkZWNhYjk5ZDZhZjlfMy01LTEtMS0zOTkzNg_a586be91-efde-462d-a8ab-d55e242ce63d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="id1b3debb3c6a4868aa2e70b6925bc311_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOmEyZWVkYTFmNDU0ZjQxZDM4ZDY3ZGVjYWI5OWQ2YWY5L3RhYmxlcmFuZ2U6YTJlZWRhMWY0NTRmNDFkMzhkNjdkZWNhYjk5ZDZhZjlfNi0zLTEtMS0zOTkzNg_e915ce34-aed6-477a-95d4-447b3478c9da"
      unitRef="usd">-50400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie6066679117046deaa28e14ca575fd6b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOmEyZWVkYTFmNDU0ZjQxZDM4ZDY3ZGVjYWI5OWQ2YWY5L3RhYmxlcmFuZ2U6YTJlZWRhMWY0NTRmNDFkMzhkNjdkZWNhYjk5ZDZhZjlfNi01LTEtMS0zOTkzNg_1ac9309a-a6e3-4127-88cb-357cd30adc07"
      unitRef="usd">-900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i79f21a0125dd44b3a07effa007c432cf_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOmEyZWVkYTFmNDU0ZjQxZDM4ZDY3ZGVjYWI5OWQ2YWY5L3RhYmxlcmFuZ2U6YTJlZWRhMWY0NTRmNDFkMzhkNjdkZWNhYjk5ZDZhZjlfNy0zLTEtMS0zOTkzNg_a6488f87-7968-464f-aea9-0117db35c025"
      unitRef="usd">6400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i2d0118a56e5349658c4a7dc1533913ce_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RhYmxlOmEyZWVkYTFmNDU0ZjQxZDM4ZDY3ZGVjYWI5OWQ2YWY5L3RhYmxlcmFuZ2U6YTJlZWRhMWY0NTRmNDFkMzhkNjdkZWNhYjk5ZDZhZjlfNy01LTEtMS0zOTkzNg_dfdbd5b2-8ea2-4cae-8903-090056a415a9"
      unitRef="usd">5500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfNjE4Mg_32dc6ce0-2e64-4719-8be4-484d5ce3c17d"
      unitRef="usd">5300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180Ni9mcmFnOjUwMWRjZmIzZDJmODQ1NDU5MTlhZTFlNTM4MTMyZWEzL3RleHRyZWdpb246NTAxZGNmYjNkMmY4NDU0NTkxOWFlMWU1MzgxMzJlYTNfMTY0OTI2NzQ1MTExNg_50ef4891-f603-4725-92ef-117bd6c30d87"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RleHRyZWdpb246NGIxY2MxMDVkYjRiNDFkYjg1OThhOGZkMjk3YWE3MzVfMjA5NQ_0a539e2a-7bd3-4c9e-bea2-ba1289d503c4">Earnings Per Share&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic and diluted earnings per share are calculated based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities exist and have a dilutive effect on earnings per share. The Company computes basic and diluted earnings per share using the two-class method. The two-class method of computing earnings per share is an earnings allocation method that determines earnings per share for common shares and participating securities according to their participation rights in dividends and undistributed earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A reconciliation of the numerator and denominator of basic and diluted earnings per share follows (dollars in millions, except per share amounts; shares in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to Surgery Partners, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: amounts allocated to participating securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding- basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding- diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Income (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Dilutive securities outstanding not included in the computation of income (loss) per share as their effect is antidilutive:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;Includes dividends accrued for the Series A Preferred Stock for the three months ended March 31, 2021. The Series A Preferred Stock did  not participate in undistributed losses and was converted to common stock during the second quarter of 2021. There were no participating securities for the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;The impact of potentially dilutive securities for the three months ended March 31, 2021, was not considered because the effect would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RleHRyZWdpb246NGIxY2MxMDVkYjRiNDFkYjg1OThhOGZkMjk3YWE3MzVfMjA4OA_d3950163-b5e4-4ef2-a37e-a66ca120b388">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A reconciliation of the numerator and denominator of basic and diluted earnings per share follows (dollars in millions, except per share amounts; shares in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to Surgery Partners, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: amounts allocated to participating securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding- basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding- diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Income (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Dilutive securities outstanding not included in the computation of income (loss) per share as their effect is antidilutive:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;Includes dividends accrued for the Series A Preferred Stock for the three months ended March 31, 2021. The Series A Preferred Stock did  not participate in undistributed losses and was converted to common stock during the second quarter of 2021. There were no participating securities for the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;The impact of potentially dilutive securities for the three months ended March 31, 2021, was not considered because the effect would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfMy0xLTEtMS0zOTkzNg_021d40ac-326a-4613-9348-957adbe20857"
      unitRef="usd">12200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfMy0zLTEtMS0zOTkzNg_f564e7f8-459e-4b47-a968-80f0d162def9"
      unitRef="usd">-21000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfNC0xLTEtMS0zOTkzNg_5d7d9d8d-7ae4-4224-b410-e3616ab0ef6a"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfNC0zLTEtMS0zOTkzNg_d442ff81-613e-421c-a6c8-e3089b58b463"
      unitRef="usd">10300000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfNS0xLTEtMS0zOTkzNg_4ba73752-290e-4054-98fb-97bd49ec948b"
      unitRef="usd">12200000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfNS0zLTEtMS0zOTkzNg_198893c3-d802-43f2-9b21-41f6698d378a"
      unitRef="usd">-31300000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfOC0xLTEtMS0zOTkzNg_5d0914fb-0493-441d-9079-28598465eacd"
      unitRef="shares">87995000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfOC0zLTEtMS0zOTkzNg_7bd06b61-561e-4b55-95a8-e2c5e7ed9b02"
      unitRef="shares">54773000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfOS0xLTEtMS00NTE5OQ_19167194-0235-42ec-8b5c-51a5c1cb029c"
      unitRef="shares">90272000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfOS0zLTEtMS00NjUyMw_31cb36f3-e489-48fe-a9cd-1517c6757671"
      unitRef="shares">54773000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfMTEtMS0xLTEtMzk5MzY_368e382a-e9c3-42a8-aee0-76f832f3a854"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfMTEtMy0xLTEtMzk5MzY_747bf581-3537-4241-898e-b83d431f2851"
      unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfMTMtMS0xLTEtNDUyMDE_650b7a44-16e6-4a20-926d-815a6c759ccc"
      unitRef="usdPerShare">0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfMTMtMy0xLTEtNDY1MjY_c9e7695f-111d-4850-8ac8-6d409a0b8848"
      unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i67c06ab0cc1645feb07263a0b462f478_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfMTQtMS0xLTEtMzk5MzY_3d6597ee-5826-4c20-a226-05cfcb5042ba"
      unitRef="shares">1634000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i06587c3ef400423ab6d0e0c77f4b8182_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfMTQtMy0xLTEtMzk5MzY_0105615b-1297-4d81-aad2-705710d06a49"
      unitRef="shares">1728000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i17ca4d1cea4549488f03f41d62feb261_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfMTUtMS0xLTEtMzk5MzY_29296d3e-68c7-4a3d-a943-9d83827cd79d"
      unitRef="shares">643000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i39d94629b8b54e53a9a62a201b44250b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RhYmxlOmM1OTA5YjJlNzFlMTRmYjI4OGY5NzNhN2MxODlhNTc2L3RhYmxlcmFuZ2U6YzU5MDliMmU3MWUxNGZiMjg4Zjk3M2E3YzE4OWE1NzZfMTUtMy0xLTEtMzk5MzY_35d6cba0-62e4-444a-8d11-3484e55a9613"
      unitRef="shares">1410000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN180OS9mcmFnOjRiMWNjMTA1ZGI0YjQxZGI4NTk4YThmZDI5N2FhNzM1L3RleHRyZWdpb246NGIxY2MxMDVkYjRiNDFkYjg1OThhOGZkMjk3YWE3MzVfMTY0OTI2NzQ0NDk2Nw_a2269af5-8f9f-4e20-b9ba-7c7ed52cad35"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RleHRyZWdpb246YzI1OGE5Mjg3NzE5NDVmY2EyODRmYzQ1NjJlYmJiN2NfMTc1_dee698fc-b116-4230-9bf9-0f984d29d832">Other Current Liabilities&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of other current liabilities is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amounts due to patients and payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost report liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax receivable agreement liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RleHRyZWdpb246YzI1OGE5Mjg3NzE5NDVmY2EyODRmYzQ1NjJlYmJiN2NfMTc5_c33022d5-31ef-4840-a43f-76367f79f112">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of other current liabilities is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amounts due to patients and payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost report liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax receivable agreement liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfMi0yLTEtMS0zOTkzNg_239e961d-3ee5-484a-97f2-c37f1182bb5a"
      unitRef="usd">35200000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfMi00LTEtMS0zOTkzNg_f9469821-0c73-4ece-b5b9-82e92860c53c"
      unitRef="usd">40100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfMy0yLTEtMS0zOTkzNg_9ad9db2f-bcc4-4573-b11c-81d52d27f78a"
      unitRef="usd">36000000.0</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfMy00LTEtMS0zOTkzNg_a8a19f09-7e44-4df7-9b53-a8b9a5bd287e"
      unitRef="usd">29200000</us-gaap:InterestPayableCurrent>
    <srt:PayablesToCustomers
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfNC0yLTEtMS00NTc0NA_380153b8-94cd-440c-bb5f-ce5c6c5eaa4d"
      unitRef="usd">32700000</srt:PayablesToCustomers>
    <srt:PayablesToCustomers
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfNC00LTEtMS00NTc0NA_9ca9813f-f883-4913-9d2a-37f6b0f8fdd3"
      unitRef="usd">26000000.0</srt:PayablesToCustomers>
    <sgry:CostReportLiabilitiesCurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfNC0yLTEtMS0zOTkzNg_0f34180f-94da-4ec6-b5bc-a511e9394dac"
      unitRef="usd">22500000</sgry:CostReportLiabilitiesCurrent>
    <sgry:CostReportLiabilitiesCurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfNC00LTEtMS0zOTkzNg_27aacb11-5ac6-4d48-ab70-7c9857e9b09b"
      unitRef="usd">26400000</sgry:CostReportLiabilitiesCurrent>
    <sgry:TaxReceivableAgreementLiabilityCurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfNi0yLTEtMS0zOTkzNg_e8dcbff9-a1d2-4507-8dc2-55359829b15f"
      unitRef="usd">20200000</sgry:TaxReceivableAgreementLiabilityCurrent>
    <sgry:TaxReceivableAgreementLiabilityCurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfNi00LTEtMS0zOTkzNg_a2545559-dec9-499c-91d5-f172e87f74be"
      unitRef="usd">19700000</sgry:TaxReceivableAgreementLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfOC0yLTEtMS0zOTkzNg_afa34a5c-20b3-4f49-ad3b-4fced20180a9"
      unitRef="usd">74500000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfOC00LTEtMS0zOTkzNg_d40b3707-ba0c-4537-a06c-0d636259b143"
      unitRef="usd">68600000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfOS0yLTEtMS0zOTkzNg_d05b0a5a-9457-4746-a8f7-1f8c15fb2dc0"
      unitRef="usd">221100000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181Mi9mcmFnOmMyNThhOTI4NzcxOTQ1ZmNhMjg0ZmM0NTYyZWJiYjdjL3RhYmxlOmQyOWU2NDMwOWY4OTRjMTM5OTM0Y2FjZmNiMWY5YmFkL3RhYmxlcmFuZ2U6ZDI5ZTY0MzA5Zjg5NGMxMzk5MzRjYWNmY2IxZjliYWRfOS00LTEtMS0zOTkzNg_0f10c6c4-bed4-4496-b15e-51e3c99c04bd"
      unitRef="usd">210000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTE1ODA_e82254f2-8e02-475e-8f19-44f6b6a0f2f2">Commitments and Contingencies&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Professional, General and Workers' Compensation Liability Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company is subject to claims and legal actions in the ordinary course of business, including claims relating to patient treatment, employment practices and personal injuries. The Company maintains professional, general and workers' compensation liability insurance in excess of self-insured retentions through third party commercial insurance carriers. Although management believes the coverage is sufficient for the Company's operations, some claims may potentially exceed the scope of coverage in effect. Plaintiffs in these matters may &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;request punitive or other damages that may not be covered by insurance. The Company is not aware of any such proceedings that are reasonably possible to have a material adverse effect on the Company's business, financial position, results of operations or liquidity. Total professional, general and workers' compensation claim liabilities as of March&#160;31, 2022 and December&#160;31, 2021 were $18.9 million and $19.8 million, respectively. Expected insurance recoveries of $8.7 million as of both March&#160;31, 2022 and December&#160;31, 2021, are included as a component of other current assets and other long-term assets in the condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Laws and Regulations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Laws and regulations governing the Company's business, including those relating to the Medicare and Medicaid programs, are complex and subject to interpretation. These laws and regulations govern every aspect of how the Company's surgical facilities conduct their operations, from licensing requirements to how and whether the Company's facilities may receive payments pursuant to the Medicare and Medicaid programs. Compliance with such laws and regulations can be subject to future government agency review and interpretation as well as legislative changes to such laws. Noncompliance with such laws and regulations may subject the Company to significant regulatory sanctions including fines, penalties, and exclusion from the Medicare, Medicaid and other federal health care programs. From time to time, governmental regulatory agencies will conduct inquiries of the Company's practices, including, but not limited to, the Company's compliance with federal and state fraud and abuse laws, billing practices and relationships with physicians.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stockholder Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On December 4, 2017, a purported Company stockholder filed an action in the Delaware Court of Chancery (the "Delaware Action"). That action is captioned Witmer v. H.I.G. Capital, L.L.C., et al., C.A. No. 2017-0862. The plaintiff in the Delaware Action asserted claims against (i) certain current and former members of the Company&#x2019;s Board of Directors (together, the "Directors"); (ii) H.I.G. Capital, LLC and certain of its affiliates (collectively, "H.I.G."); and (iii) Bain Capital Private Equity, L.P. and certain of its affiliates (collectively, "Bain Capital" and, together with the Directors and H.I.G., the "Defendants"). The parties to the Delaware Action negotiated a final stipulation of settlement (the &#x201c;Settlement Stipulation&#x201d;), which governs the terms of the settlement of the Delaware Action, and which they filed with the Court of Chancery on November 22, 2021. On February 11, 2022, the Court of Chancery approved the settlement of the Delaware Action as memorialized in the Settlement Stipulation. That decision became final and non-appealable on March 14, 2022. The case is now closed. Pursuant to the settlement, the Company received $32.8&#160;million in March 2022, which was included in litigation settlement in the condensed consolidated statements of operations for the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquired Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company, through its wholly-owned subsidiaries or controlled partnerships and limited liability companies, has acquired and will continue to acquire surgical facilities with prior operating histories. Such facilities may have unknown or contingent liabilities, including liabilities for failure to comply with health care laws and regulations, such as billing and reimbursement laws and regulations, the Stark Law, the Anti-Kickback Statute, the FCA, and similar fraud and abuse laws. Although the Company attempts to assure that no such liabilities exist, obtain indemnification from prospective sellers covering such matters and institute policies designed to conform centers to its standards following completion of acquisitions, there can be no assurance that the Company will not become liable for past activities that may later be asserted to be improper by private plaintiffs or government agencies. There can be no assurance that any such matter will be covered by indemnification or, if covered, that the liability sustained will not exceed contractual limits or the financial capacity of the indemnifying party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company cannot predict whether federal or state statutory or regulatory provisions will be enacted that would prohibit or otherwise regulate relationships which the Company has established or may establish with other health care providers or have materially adverse effects on its business or revenues arising from such future actions. Management believes, however, that it will be able to adjust the Company's operations so as to be in compliance with any statutory or regulatory provision as may be applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Potential Physician Investor Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A majority of the physician investors in the partnerships and limited liability companies which operate the Company's surgical facilities carry general and professional liability insurance on a claims-made basis. Each partnership or limited liability company may, however, be liable for damages to persons or property arising from occurrences at the surgical facilities. Although the various physician investors and other surgeons generally are required to obtain general and professional liability insurance with tail coverage that extends beyond the period of any claims-made policies, such individuals may not be able to obtain coverage in amounts sufficient to cover all potential liability. Since most insurance policies contain exclusions, the physician investors will not be insured against all possible occurrences. In the event of an uninsured or underinsured loss, the value of an investment in the partnership interests or limited liability company membership units and the amount of distributions could be adversely affected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Tax Receivable Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On May 9, 2017, the Company entered into an agreement to amend that certain Income Tax Receivable Agreement, dated September 30, 2015 (as amended, the "TRA"), by and between the Company, and the other parties referred to therein, which amendment became effective on August 31, 2017. Pursuant to the amendment to the TRA, the Company agreed to make payments to H.I.G., the Company's former controlling shareholder, in its capacity as the stockholders representative pursuant to a fixed payment schedule. The amounts payable under the TRA are calculated as the product of (i) an annual base amount and (ii) the maximum corporate federal income tax rate for the applicable year plus three percent. The amounts payable under the TRA are related to the Company&#x2019;s projected realized tax savings &lt;/span&gt;&lt;/div&gt;over the next five years and are not dependent on the Company&#x2019;s actual tax savings over such period. The calculation of amounts payable pursuant to the TRA is thus dependent on the maximum corporate federal income tax rate. To the extent that the Company is unable to make payments under the TRA, such payments will be deferred and will accrue interest at a rate of the LIBOR plus 500 basis points until paid. If the terms of credit agreements and other debt documents cause the Company to be unable to make payments under the TRA and such terms are not materially more restrictive than those existing as of September 30, 2015, such payments will be deferred and will accrue interest at a rate of LIBOR plus 300 basis points until paid.Assuming the Company's tax rate is 24%, calculated as the maximum corporate federal tax rate plus three percent, throughout the remaining term of the TRA, the Company estimates the total remaining amounts payable under the TRA was approximately $22.0 million as of both March&#160;31, 2022 and December&#160;31, 2021. As a result of the amendment to the TRA, the Company was required to value the liability under the TRA by discounting the fixed payment schedule using the Company&#x2019;s incremental borrowing rate. The carrying value of the liability under the TRA, reflecting the discount, was $20.2 million and $19.7 million as of March&#160;31, 2022 and December&#160;31, 2021, respectively, and is included as a component of other current liabilities in the condensed consolidated balance sheets.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SelfInsuranceReserve
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTA5OTUxMTY3NDMxOQ_b28a7d8a-048f-4534-ab2a-d2e4c77511ad"
      unitRef="usd">18900000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTA5OTUxMTY3NDMyMw_aeee8c94-94d6-43f4-8b92-12bb96f999fd"
      unitRef="usd">19800000</us-gaap:SelfInsuranceReserve>
    <us-gaap:EstimatedInsuranceRecoveries
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTA5OTUxMTY3NDMzNQ_21a68e21-3344-4401-a4e2-9eb510b73dcf"
      unitRef="usd">8700000</us-gaap:EstimatedInsuranceRecoveries>
    <us-gaap:EstimatedInsuranceRecoveries
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTA5OTUxMTY3NDMzNQ_c8df912c-fdf9-4038-93be-ba33b214c8c7"
      unitRef="usd">8700000</us-gaap:EstimatedInsuranceRecoveries>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i49e70dcd4ab4442e93dc776b77191c75_D20220301-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfOTM0NTg0ODg4NDc0Nw_c09135a7-80a8-42c7-a5a4-9f01a4347784"
      unitRef="usd">32800000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="icf580ac915f4455f888d4bffc00ceccd_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfOTg2OA_c7f3e0e0-a712-4cd7-973d-b5709897f308"
      unitRef="number">0.03</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <sgry:CollaborativeTaxAgreementProjectedTaxSavingsTerm
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfOTk4OA_e58629d9-970a-4218-8f30-318a82ae288a">P5Y</sgry:CollaborativeTaxAgreementProjectedTaxSavingsTerm>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i62d2751322cd45d690eae0422a55f102_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTAzNDc_6da378be-ed95-4ad4-a1a4-cc18c2c52f85"
      unitRef="number">0.0500</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i2ae955700f5a407192e0f30ca8c9cef7_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTA2NzM_9dbd329b-ce46-46c5-9279-632380741d60"
      unitRef="number">0.0300</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTA3MzY_f2222f84-6f89-47a0-95d4-9f1524414d67"
      unitRef="number">0.24</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <sgry:CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate
      contextRef="icf580ac915f4455f888d4bffc00ceccd_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTA3OTg_a6e4e082-76b5-4183-b762-696c29b6e9dd"
      unitRef="number">0.03</sgry:CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate>
    <us-gaap:TaxesPayableCurrentAndNoncurrent
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTA5OTUxMTY3NDM4NA_3adf0fe4-7290-4730-bb8a-ab76e3d7bc3e"
      unitRef="usd">22000000</us-gaap:TaxesPayableCurrentAndNoncurrent>
    <us-gaap:TaxesPayableCurrentAndNoncurrent
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTA5OTUxMTY3NDM4NA_659ed8cc-1152-4f72-bd19-ea6bbd31cd8f"
      unitRef="usd">22000000</us-gaap:TaxesPayableCurrentAndNoncurrent>
    <sgry:DeferredIncomeTaxLiabilitiesNetOfDiscount
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTA5OTUxMTY3NDM5Mg_3316d2c8-ece5-4f9b-9f1b-5e0a7084de9c"
      unitRef="usd">20200000</sgry:DeferredIncomeTaxLiabilitiesNetOfDiscount>
    <sgry:DeferredIncomeTaxLiabilitiesNetOfDiscount
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181NS9mcmFnOmRhZWRhMTIxOGQ4OTQyYmJiYjAwMDE3OTQzMDk2OGI1L3RleHRyZWdpb246ZGFlZGExMjE4ZDg5NDJiYmJiMDAwMTc5NDMwOTY4YjVfMTA5OTUxMTY3NDM5Ng_10c12ca1-6469-4bf0-9059-75370e57ab0f"
      unitRef="usd">19700000</sgry:DeferredIncomeTaxLiabilitiesNetOfDiscount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfMjA0OQ_34a3a653-236d-444b-ba49-03e2f065817f">Segment Reporting&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company currently operates in&#160;two&#160;major lines of business that are also the Company's reportable operating segments - the operation of surgical facilities and the operation of ancillary services. The Surgical Facility Services segment consists of the operation of ASCs, surgical hospitals and anesthesia services. The Ancillary Services segment consists of multi-specialty physician practices. The "All other" line item primarily consists of the Company's corporate general and administrative functions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables present financial information for each reportable segment (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;578.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;596.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;512.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Adjusted EBITDA:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Reconciliation of Adjusted EBITDA:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transaction, integration and acquisition costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain on disposals and deconsolidations, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Gain) loss on litigation settlement and other litigation costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;This amount includes transaction and integration costs of $7.1 million and $5.3 million for the three months ended March&#160;31, 2022 and 2021, respectively. This amount further includes start-up costs related to a de novo surgical hospital of $4.1 million for the three months ended March 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;This amount includes other litigation costs of $2.0 million and $1.0 million for the three months ended March&#160;31, 2022 and 2021, respectively. This amount also includes gain on litigation settlement of $32.8 million for the three months ended March&#160;31, 2022, with no comparable activity in the 2021 period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,651.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,552.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;593.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;517.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,289.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,117.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash purchases of property and equipment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash purchases of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfNjI_cf3a1e90-212f-4fa0-a522-4a55d428ebac"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfMjAzOQ_4d00c862-e0cb-4947-8f4f-748144d68b56">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables present financial information for each reportable segment (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;578.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;596.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;512.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Adjusted EBITDA:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Reconciliation of Adjusted EBITDA:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transaction, integration and acquisition costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain on disposals and deconsolidations, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Gain) loss on litigation settlement and other litigation costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;This amount includes transaction and integration costs of $7.1 million and $5.3 million for the three months ended March&#160;31, 2022 and 2021, respectively. This amount further includes start-up costs related to a de novo surgical hospital of $4.1 million for the three months ended March 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;This amount includes other litigation costs of $2.0 million and $1.0 million for the three months ended March&#160;31, 2022 and 2021, respectively. This amount also includes gain on litigation settlement of $32.8 million for the three months ended March&#160;31, 2022, with no comparable activity in the 2021 period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i06f4c1e12ebf42428954114c64170b8b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMy0yLTEtMS0zOTkzNg_41115043-4453-4372-83d7-70a4f4168d7e"
      unitRef="usd">578800000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i95c194ebfbd94fa8a271308daec9afbb_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMy00LTEtMS0zOTkzNg_ed6155c8-2763-4547-9dae-a056b9497bfb"
      unitRef="usd">495800000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id484bee12a474b8bbcedacad3a0e452e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfNC0yLTEtMS0zOTkzNg_67df8930-f8fc-4ebd-b2f0-54167570a649"
      unitRef="usd">17400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia230717bfdb149e5b55ed8b1922373c3_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfNC00LTEtMS0zOTkzNg_cabe2302-37fd-4d54-b942-063b3bdacb3e"
      unitRef="usd">16600000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfNi0yLTEtMS0zOTkzNg_a6fc1d94-c23d-4cfa-ba49-11fc66b6934c"
      unitRef="usd">596200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfNi00LTEtMS0zOTkzNg_4410a06e-9ef0-4059-be1c-5777ace8334e"
      unitRef="usd">512400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i06f4c1e12ebf42428954114c64170b8b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfOS0yLTEtMS0zOTkzNg_2e6c6d4d-3a75-4e28-832d-80d64af6c31c"
      unitRef="usd">101000000.0</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i95c194ebfbd94fa8a271308daec9afbb_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfOS00LTEtMS0zOTkzNg_8416b4e3-9793-4472-add3-589c0982ae16"
      unitRef="usd">95000000.0</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="id484bee12a474b8bbcedacad3a0e452e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTAtMi0xLTEtMzk5MzY_ac1dec48-23c1-446c-9854-c7bd25ff7dfc"
      unitRef="usd">100000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ia230717bfdb149e5b55ed8b1922373c3_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTAtNC0xLTEtMzk5MzY_4c6b1301-07c3-4a68-8e50-22e3345abbb2"
      unitRef="usd">-900000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i37cfe03bc9ed4713b3b1e61e87a612c2_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTItMi0xLTEtMzk5MzY_a03bf046-a334-47e9-b967-8d9d643cb264"
      unitRef="usd">-24000000.0</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="id144f2f56936461e8128c2d94933dc55_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTItNC0xLTEtMzk5MzY_02a18595-6118-43e5-a70d-5769a62b4735"
      unitRef="usd">-21200000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTMtMi0xLTEtMzk5MzY_9f8a955d-88a9-4f14-a240-5a211e75c821"
      unitRef="usd">77100000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTMtNC0xLTEtMzk5MzY_f9e59bc9-f299-42a0-a574-ce7aabf4ae18"
      unitRef="usd">72900000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTYtMi0xLTEtMzk5MzY_f5b39e2b-307b-436b-9cec-0672e68440ec"
      unitRef="usd">44100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTYtNC0xLTEtMzk5MzY_b3f9af87-e968-4d4c-acbc-e45d616ae200"
      unitRef="usd">11000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTgtMi0xLTEtMzk5MzY_87485d51-fa51-440f-b4b0-0fda72afc15a"
      unitRef="usd">30600000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTgtNC0xLTEtMzk5MzY_7e4f2746-0610-45b0-8df9-bb2c26c641d8"
      unitRef="usd">31800000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTktMi0xLTEtMzk5MzY_e56eb0c0-ae25-4b31-aa51-e1e915e531e6"
      unitRef="usd">27400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMTktNC0xLTEtMzk5MzY_b554a520-1ae0-41a5-b0d2-2d5acbee98c0"
      unitRef="usd">25700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjAtMi0xLTEtMzk5MzY_ddc2eb9b-469b-41d8-b326-ffbf56a33b71"
      unitRef="usd">-56300000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjAtNC0xLTEtMzk5MzY_5f9f6ea3-9642-4998-ad27-6e5685821cd3"
      unitRef="usd">-53300000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:ShareBasedCompensation
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjEtMi0xLTEtMzk5MzY_910a3749-356e-4ae9-8d27-c32f4ce8d04c"
      unitRef="usd">3700000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjEtNC0xLTEtMzk5MzY_3525a103-5bbc-448d-83d2-d0b6f4d2cdd7"
      unitRef="usd">5200000</us-gaap:ShareBasedCompensation>
    <sgry:BusinessCombinationIntegrationRelatedCostsAndMergerCosts
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjItMi0xLTEtMzk5MzY_9aaa879f-70b6-4fab-8852-381b105f2831"
      unitRef="usd">7100000</sgry:BusinessCombinationIntegrationRelatedCostsAndMergerCosts>
    <sgry:BusinessCombinationIntegrationRelatedCostsAndMergerCosts
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjItNC0xLTEtMzk5MzY_e7a92ac9-f458-4d97-b4a1-9bf1651309ed"
      unitRef="usd">9400000</sgry:BusinessCombinationIntegrationRelatedCostsAndMergerCosts>
    <sgry:GainLossOnDispositionOfAssetsAndDeconsolidation
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjQtMi0xLTEtMzk5MzY_452672f5-4a25-4a39-a763-ede31cd47604"
      unitRef="usd">100000</sgry:GainLossOnDispositionOfAssetsAndDeconsolidation>
    <sgry:GainLossOnDispositionOfAssetsAndDeconsolidation
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjQtNC0xLTEtMzk5MzY_26ce70d3-5d29-4bf4-b19f-02c41e18bd2f"
      unitRef="usd">900000</sgry:GainLossOnDispositionOfAssetsAndDeconsolidation>
    <sgry:GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjUtMi0xLTEtMzk5MzY_bc98a9ef-47b5-4e43-a0c2-a0af2e237c10"
      unitRef="usd">30800000</sgry:GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts>
    <sgry:GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjUtNC0xLTEtMzk5MzY_dd790fd5-0b5b-41cb-a6ba-c1fcf46c14a1"
      unitRef="usd">-1000000.0</sgry:GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjktMi0xLTEtMzk5MzY_e0f239be-3f8f-476b-97d3-ec9282c5f736"
      unitRef="usd">77100000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjJhNjc3OTc2YzBmNTQ1NThiNjc5OGRkYmI0OTFmZDNjL3RhYmxlcmFuZ2U6MmE2Nzc5NzZjMGY1NDU1OGI2Nzk4ZGRiYjQ5MWZkM2NfMjktNC0xLTEtMzk5MzY_2df6281b-b0f1-40b4-a521-629e76ab7d4c"
      unitRef="usd">72900000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfOTgx_8c7e2850-0b58-466a-86b1-30816aa08351"
      unitRef="usd">7100000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfOTg4_a4a535b0-c5fd-4bf7-abcc-31d16df45152"
      unitRef="usd">5300000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfMTEyNg_082166d8-168a-44fe-88cb-8a9c849abdf8"
      unitRef="usd">4100000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:LitigationSettlementExpense
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfMTQ4Mg_84db0156-b1f5-4334-b173-c07877cfab7f"
      unitRef="usd">2000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfMTQ4OQ_9362bcc7-8359-482f-a8f1-d8a5126897ed"
      unitRef="usd">1000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfMTA5OTUxMTYzMTE5Nw_a6d2358f-29c1-4476-ac53-ff2b657ef40e"
      unitRef="usd">32800000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfMTY0OTI2NzQ0NTI0NA_18221a30-4f69-4a2b-8cf7-92a2cb5a57dd"
      unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfMjAyMw_ce3b590c-ca09-4f1c-9061-48bac304bb9e">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,651.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,552.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;593.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;517.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,289.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,117.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock>
    <us-gaap:Assets
      contextRef="if2df432d764946c98419eddd4b217200_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOmJmYTEzMmYyZDhhNDQ0N2Y5MWM2NmMwNDIzZjdlYTA3L3RhYmxlcmFuZ2U6YmZhMTMyZjJkOGE0NDQ3ZjkxYzY2YzA0MjNmN2VhMDdfMi0yLTEtMS0zOTkzNg_b7af0f55-89d0-4280-93af-bb4ffdc708eb"
      unitRef="usd">5651400000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i30d11e9517014207867a3d78c850cb1c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOmJmYTEzMmYyZDhhNDQ0N2Y5MWM2NmMwNDIzZjdlYTA3L3RhYmxlcmFuZ2U6YmZhMTMyZjJkOGE0NDQ3ZjkxYzY2YzA0MjNmN2VhMDdfMi00LTEtMS0zOTkzNg_968afb0d-17f3-49d7-a7ec-cb1cc0ad6548"
      unitRef="usd">5552800000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i241a5e9cb633484a83e8b37dd0d53c59_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOmJmYTEzMmYyZDhhNDQ0N2Y5MWM2NmMwNDIzZjdlYTA3L3RhYmxlcmFuZ2U6YmZhMTMyZjJkOGE0NDQ3ZjkxYzY2YzA0MjNmN2VhMDdfMy0yLTEtMS0zOTkzNg_0ca8ca53-a6a3-4a98-938c-62987b3d3752"
      unitRef="usd">44600000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i405edebb54534016a7214669c2bd5d18_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOmJmYTEzMmYyZDhhNDQ0N2Y5MWM2NmMwNDIzZjdlYTA3L3RhYmxlcmFuZ2U6YmZhMTMyZjJkOGE0NDQ3ZjkxYzY2YzA0MjNmN2VhMDdfMy00LTEtMS0zOTkzNg_928fb058-c8fd-4d74-9b9d-94c5e87be250"
      unitRef="usd">47500000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i67f8f1225fb34764b0261414fc217735_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOmJmYTEzMmYyZDhhNDQ0N2Y5MWM2NmMwNDIzZjdlYTA3L3RhYmxlcmFuZ2U6YmZhMTMyZjJkOGE0NDQ3ZjkxYzY2YzA0MjNmN2VhMDdfNC0yLTEtMS0zOTkzNg_351a13c5-9bc9-4ade-8ec1-f494c2fb3431"
      unitRef="usd">593500000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i1a3f22cbbd5f47d4955fd2c0473366ea_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOmJmYTEzMmYyZDhhNDQ0N2Y5MWM2NmMwNDIzZjdlYTA3L3RhYmxlcmFuZ2U6YmZhMTMyZjJkOGE0NDQ3ZjkxYzY2YzA0MjNmN2VhMDdfNC00LTEtMS0zOTkzNg_6bf4e9b5-3812-4de3-80b2-04dbeb058cee"
      unitRef="usd">517300000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2f2c73a27bad4276adf8541dd20dfb2d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOmJmYTEzMmYyZDhhNDQ0N2Y5MWM2NmMwNDIzZjdlYTA3L3RhYmxlcmFuZ2U6YmZhMTMyZjJkOGE0NDQ3ZjkxYzY2YzA0MjNmN2VhMDdfNS0yLTEtMS0zOTkzNg_af1000d8-3340-4678-850c-50be5ee19e3a"
      unitRef="usd">6289500000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i46ce349a7375461fa1b7f757dc08d081_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOmJmYTEzMmYyZDhhNDQ0N2Y5MWM2NmMwNDIzZjdlYTA3L3RhYmxlcmFuZ2U6YmZhMTMyZjJkOGE0NDQ3ZjkxYzY2YzA0MjNmN2VhMDdfNS00LTEtMS0zOTkzNg_e3f38f6b-7266-4449-8bff-f3286e8a67f3"
      unitRef="usd">6117600000</us-gaap:Assets>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RleHRyZWdpb246ZmIxNGQ4M2FkZDg4NDBmNDhkOGNiNzhkN2NkOTZkYmZfMjAzNg_c60daae7-aa2d-4d45-8bfd-9f672ec781d3">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash purchases of property and equipment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash purchases of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i06f4c1e12ebf42428954114c64170b8b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjU4ZDEwZmVlZTdiNDRmY2RhZWRlMjZhYjRmZGQ4ODE2L3RhYmxlcmFuZ2U6NThkMTBmZWVlN2I0NGZjZGFlZGUyNmFiNGZkZDg4MTZfMy0yLTEtMS0zOTkzNg_20dd5cac-390f-49fa-9570-506290214c0d"
      unitRef="usd">17700000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i95c194ebfbd94fa8a271308daec9afbb_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjU4ZDEwZmVlZTdiNDRmY2RhZWRlMjZhYjRmZGQ4ODE2L3RhYmxlcmFuZ2U6NThkMTBmZWVlN2I0NGZjZGFlZGUyNmFiNGZkZDg4MTZfMy00LTEtMS0zOTkzNg_56f0e970-b8cd-49ab-b392-8f4556c9cf40"
      unitRef="usd">14200000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id484bee12a474b8bbcedacad3a0e452e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjU4ZDEwZmVlZTdiNDRmY2RhZWRlMjZhYjRmZGQ4ODE2L3RhYmxlcmFuZ2U6NThkMTBmZWVlN2I0NGZjZGFlZGUyNmFiNGZkZDg4MTZfNC0yLTEtMS0zOTkzNg_0bd117d4-20d2-4e1c-aaf8-7a25f0980085"
      unitRef="usd">200000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia230717bfdb149e5b55ed8b1922373c3_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjU4ZDEwZmVlZTdiNDRmY2RhZWRlMjZhYjRmZGQ4ODE2L3RhYmxlcmFuZ2U6NThkMTBmZWVlN2I0NGZjZGFlZGUyNmFiNGZkZDg4MTZfNC00LTEtMS0zOTkzNg_36f3da20-4851-47ba-a7ba-29f786ddceb1"
      unitRef="usd">100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i37cfe03bc9ed4713b3b1e61e87a612c2_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjU4ZDEwZmVlZTdiNDRmY2RhZWRlMjZhYjRmZGQ4ODE2L3RhYmxlcmFuZ2U6NThkMTBmZWVlN2I0NGZjZGFlZGUyNmFiNGZkZDg4MTZfNi0yLTEtMS0zOTkzNg_ad7a5bed-10dd-4d5a-bfbd-7fc0169f3ac0"
      unitRef="usd">300000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id144f2f56936461e8128c2d94933dc55_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjU4ZDEwZmVlZTdiNDRmY2RhZWRlMjZhYjRmZGQ4ODE2L3RhYmxlcmFuZ2U6NThkMTBmZWVlN2I0NGZjZGFlZGUyNmFiNGZkZDg4MTZfNi00LTEtMS0zOTkzNg_1b1739f1-7e10-4ea5-8b49-791687e7d838"
      unitRef="usd">200000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjU4ZDEwZmVlZTdiNDRmY2RhZWRlMjZhYjRmZGQ4ODE2L3RhYmxlcmFuZ2U6NThkMTBmZWVlN2I0NGZjZGFlZGUyNmFiNGZkZDg4MTZfNy0yLTEtMS0zOTkzNg_a37bc63a-1fad-4a9d-a4da-212c99d98314"
      unitRef="usd">18200000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2609484f5dea4364b46ba6dee6f14e62_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN181OC9mcmFnOmZiMTRkODNhZGQ4ODQwZjQ4ZDhjYjc4ZDdjZDk2ZGJmL3RhYmxlOjU4ZDEwZmVlZTdiNDRmY2RhZWRlMjZhYjRmZGQ4ODE2L3RhYmxlcmFuZ2U6NThkMTBmZWVlN2I0NGZjZGFlZGUyNmFiNGZkZDg4MTZfNy00LTEtMS0zOTkzNg_dd263da4-4593-49c7-b4f4-4121df33d18b"
      unitRef="usd">14500000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i51617289ac834d6ba852340071fb7b89_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN182MS9mcmFnOjUwN2U1MTllYmQ1ZTQxYTI5Y2YxYzUxMTFmZTRiMzc5L3RleHRyZWdpb246NTA3ZTUxOWViZDVlNDFhMjljZjFjNTExMWZlNGIzNzlfMjA5_8d89d024-4cb7-4c4b-bab2-ccb6bf479a40">Subsequent Events&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In April 2022, the Company acquired non-controlling &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;interests in three surgical facilities and four in-development de novo surgical facilities for a combined purchase price of $48.6&#160;million. The non-controlling interests will be accounted for as equity method investments.&lt;/span&gt;</us-gaap:SubsequentEventsTextBlock>
    <sgry:NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired
      contextRef="i95727e44b2eb479d8bbcd65296068f83_D20220401-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN182MS9mcmFnOjUwN2U1MTllYmQ1ZTQxYTI5Y2YxYzUxMTFmZTRiMzc5L3RleHRyZWdpb246NTA3ZTUxOWViZDVlNDFhMjljZjFjNTExMWZlNGIzNzlfMTY0OTI2NzQ0MjY3MQ_05b9c783-2119-482d-a1f1-a9a0ed090ebe"
      unitRef="non-controlling_interest">3</sgry:NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired>
    <sgry:NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired
      contextRef="i95727e44b2eb479d8bbcd65296068f83_D20220401-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN182MS9mcmFnOjUwN2U1MTllYmQ1ZTQxYTI5Y2YxYzUxMTFmZTRiMzc5L3RleHRyZWdpb246NTA3ZTUxOWViZDVlNDFhMjljZjFjNTExMWZlNGIzNzlfMTY0OTI2NzQ0MjY3OQ_514a19fa-1238-4985-9c27-46dfeb50e576"
      unitRef="non-controlling_interest">4</sgry:NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="iea161d59c161497f8a5bb07b4bdb04b9_D20220401-20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN182MS9mcmFnOjUwN2U1MTllYmQ1ZTQxYTI5Y2YxYzUxMTFmZTRiMzc5L3RleHRyZWdpb246NTA3ZTUxOWViZDVlNDFhMjljZjFjNTExMWZlNGIzNzlfODI0NjMzNzIwOTMwNQ_32915316-2c3d-4ff9-a0e2-d5b1787fc4de"
      unitRef="usd">48600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzctNC0xLTEtMzk5MzY_e0983b0a-cd91-4e3f-af96-ff0084a35973"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzctNC0xLTEtMzk5MzY_e0983b0a-cd91-4e3f-af96-ff0084a35973"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzctMi0xLTEtMzk5MzY_3aaf1ab2-cdc3-4241-9f41-41b592762a11"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzctMi0xLTEtMzk5MzY_3aaf1ab2-cdc3-4241-9f41-41b592762a11"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzQtNC0xLTEtMzk5MzY_5b797168-8f73-4ca9-8faa-caa680e32762"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzQtNC0xLTEtMzk5MzY_5b797168-8f73-4ca9-8faa-caa680e32762"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzQtMi0xLTEtMzk5MzY_f316c610-a8bf-4296-81dd-e5befb731d9e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzQtMi0xLTEtMzk5MzY_f316c610-a8bf-4296-81dd-e5befb731d9e"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RleHRyZWdpb246ODQ3MGZiMGI3NjY4NDQ4MGFhNGEyM2Q5ODVlNGUyNzNfMzky_e44d5c8e-2e66-4df1-a1e1-4d01aa20ae69" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RleHRyZWdpb246ODQ3MGZiMGI3NjY4NDQ4MGFhNGEyM2Q5ODVlNGUyNzNfMzky_e44d5c8e-2e66-4df1-a1e1-4d01aa20ae69" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The impact of potentially dilutive securities for the three months ended March 31, 2021 was not considered because the effect would be anti-dilutive.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzctNC0xLTEtMzk5MzY_e0983b0a-cd91-4e3f-af96-ff0084a35973"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RleHRyZWdpb246ODQ3MGZiMGI3NjY4NDQ4MGFhNGEyM2Q5ODVlNGUyNzNfMzky_e44d5c8e-2e66-4df1-a1e1-4d01aa20ae69"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzctMi0xLTEtMzk5MzY_3aaf1ab2-cdc3-4241-9f41-41b592762a11"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RleHRyZWdpb246ODQ3MGZiMGI3NjY4NDQ4MGFhNGEyM2Q5ODVlNGUyNzNfMzky_e44d5c8e-2e66-4df1-a1e1-4d01aa20ae69"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzQtNC0xLTEtMzk5MzY_5b797168-8f73-4ca9-8faa-caa680e32762"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RleHRyZWdpb246ODQ3MGZiMGI3NjY4NDQ4MGFhNGEyM2Q5ODVlNGUyNzNfMzky_e44d5c8e-2e66-4df1-a1e1-4d01aa20ae69"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RhYmxlOmFmNjk5MGM5YzI3NjQxNjBhYmEwZDZmMjZiYzQyOWI4L3RhYmxlcmFuZ2U6YWY2OTkwYzljMjc2NDE2MGFiYTBkNmYyNmJjNDI5YjhfMzQtMi0xLTEtMzk5MzY_f316c610-a8bf-4296-81dd-e5befb731d9e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjhkMjRlZGM1OWEzODRlZjA4NzQ4MjIzZGUyNDdiNmE3L3NlYzo4ZDI0ZWRjNTlhMzg0ZWYwODc0ODIyM2RlMjQ3YjZhN18xNi9mcmFnOjg0NzBmYjBiNzY2ODQ0ODBhYTRhMjNkOTg1ZTRlMjczL3RleHRyZWdpb246ODQ3MGZiMGI3NjY4NDQ4MGFhNGEyM2Q5ODVlNGUyNzNfMzky_e44d5c8e-2e66-4df1-a1e1-4d01aa20ae69"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>67
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MY0_>.A29_C)1J/HO>FEMPPG*#DJ+LFT,"LJ\:OZS[^U$#!K@Q4@#TC8@;VU
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MLM.<:+&O/XX\"ZU%61_N. /9Q@#N;X30/T[,]Y;N^]KM_P!02P,$%     @
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M8X'5!LC;IYQ%A3$PB((X?W>_%H6H&6"]PX 4!N2Y!GIAH+<,B-UA8!0&1LO
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M4=AZHP+IJ-FI,FT[LXC4<,6U0?P-"K?F'ZS%0E!''HIA!Q\@]65P9Q@&.BZ
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M/E"MN5JZ[W8:N9.@[ M/\;3X-GCCOH@=/+_%%]/L"U^Y3?;!\8$I\(I&"5_
MEI"Q$#@J^X:7W1BY<9_!YM(8N7:7*\Z@#ED!^'TAI=G=V!<47U*O_P502P,$
M%     @ $(JC5/".&Z0)(P  [&X  !@   !X;"]W;W)K<VAE971S+W-H965T
M."YX;6R]/6ESVT:6?P7%M3=6%4V+E&3+SE$E.\[$M9N)UTHR6[6U'T"@22(&
MT1PT()KSZ_>=?8"@+.WU(3%% =VOWWVVOMO;]K/;&--E7[9UX[Z?;+IN]^;%
M"U=LS#9W,[LS#?QF9=MMWL&/[?J%V[4F+^FE;?UB<7[^\L4VKYK)#]_1=Q_;
M'[ZS?5=7C?G89J[?;O/V\-;4=O_]9#[1+SY5ZTV'7[SXX;M=OC:WIOM]][&%
MGU[X5<IJ:QI7V29KS>K[R<W\S=M+?)X>^*,R>Q=]SO D2VL_XP\?RN\GYPB0
MJ4W1X0HY_'-GWIFZQH4 C+_+FA._);X8?];5?Z*SPUF6N3/O;/VWJNPVWT^N
M)UEI5GE?=Y_L_F<CY[G"]0I;._I_MI=GSR=9T;O.;N5E@&!;-?QO_D7P\) 7
M%O+"@N#FC0C*'_,N_^&[UNZS%I^&U? #'97>!N"J!HERV[7PVPK>ZW[XM5WG
M3?6/G%'4E-DM4R>SJ^RF*&S?=%6SSC[:NBHJX[Y[T<&F^.J+0C9XRQLL3FQP
MD?UBFV[CLO=-:<KT_1< K(=XH1"_7=R[X"]Y.\LNYM-L<;Y8W+/>A<? !:UW
M\0 ,3+-WMG%PUC(@Y&-KG&DZ_@*P\E/5Y$U1Y75V"U\:8-#.9?]QLW1="RSV
MG_= =.DANB2(+O_O:/*_ND&6/'_;MVL#SW[,VZXQK9MF'YIB-LWR[$=3Y_N\
M-5EAVYUM!:,H=[!8MVEMO]YD%6#+]4M7E57>PN+3S.X;1U" IH&78+\\:^AE
MP'%C.A1KA,S!QE4!WZWRHJJK#B'#UY :=8W@.]/>585QL^RWC1E[?IKM-U4!
M0#1%W9<FR[?+OLX[B^_*L0J@)YPJ>S:YN7WG)F>TA5]J8]VNZO(:5MJU%>"L
MJ@_PR=Y5L%ICF^? #[!.4QS"._#KPI1]B^ 6K74.Y+>!W^\,<A&#Q0 !G@!?
M6POHLMV&<+O.@:\LP61KNS[ -P:P#LL*P("_W:;;Y/56?F_;;@.8+*N"T;,#
MS8P[@HI%7F7<O+/;'0#QC1LY6@;_67\HQ2D\"(C+709T6S?6=561 0+6!'.=
M+Y'>EL !23!="]O#YZ80J':;''1H09\.CC;$$^:[ P&Y!YXKLP*89Y;='-$S
M8Z;: LJ=*9$7MJ!TJ^>*PH,L6N4-P(T,5R!2$4%-1ZL>\XQQL+^K\HAI?F]J
M ]2![V$SP/B7CLFPAUV!0H!1Y,[I"0F@=8?<39"#G3%M"X!W-H/E#- #\#@Y
M6F:23?8&_]_39]NW$Z FP3,1@LTFV8U#!( 6!'*H&IS20_(,"A1BJ56!@N-F
M((_="N39XLOSQ:MQZ4AP/#]_G:$,T,'FUV.< B>YF&<.]:!+&(N%&C&<H!Z>
MW\EI-]4.3%VW":2CC5 4,F>W0 *PM0#2Q@"!-TQ$=P#6VM(R>%X0O\^F8_@
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M@IUBWF6U\1@9<!O;UT!WU+4YK0'O_-DW[/E[]APBY.L+!^;"8QA@:46Q*J%
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M+NT.JL'3D9V/)M8DI"!8?XK^*#D&XV_'58Q&%0P^*]RBSBOR8=ZJ:E?,I(Y
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M3*D%>YX.]QD*4^,U"<K5;%FEPSU.ZZ";M;$U5CB^T=+PX^;[OAJFG 14X(S
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MP,S@ _![O'I>?\ -_!^X^^&_ %!+ P04    "  0BJ-41'\,V=P&  "N$@
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MDA0G-8W>,/)*:Q(AT@#=T70Z.MF.9PJR0_JA3X\]OV?*1+H_FHP6C?A.'J,
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M:_I(43N#W#E$+@X3=\#X-:__ E!+ P04    "  0BJ-4]A><^IP%  #I&
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MP)"1<).S#(0[E^_K%,Q<&_93(5\ZF147J;_J>:%JIS84=P"4RWX!ZVO=)OI
M9]RFSEN)OPZ<H<]PW* ;N9SZ"""ET7'>O?'D%?*TP.^V4?\HW\RW/X?H^P-S
MA%JY9A8\IL<DY^6:?$B"KVHEQ3K4]K.KS=_"4;@'43_O]A4O'(+A*NKAR(@Z
M;4?4Z4^.J$?Y3B/J:40]C:BG$?4THIY&U-.(>AI13R/J:43]X1%UV/G\7)!>
M^X_LN!1<)L*7Z':W_8Y_'3Y?;\G#/P&0X+4H';0SL(X&<TRM.GQ8#PNK*O\Q
M>Z6L585_S8FGI!T!SC.E[&;A%+3_W;CZ%U!+ P04    "  0BJ-4J@K;>^8)
M   3(   &0   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6R]6FUSV[@1_BL8
MU6WM&5O6BV4[.<<S3GSMN9-<,DFN]Z'3#Q )23B3A * EM5??\\N2(JD*,7V
MW?2+(Y# [K/OBV6N5L;>NX527CRF2>;>]!;>+U^?GKIHH5+I^F:I,KR9&9M*
MCZ6=G[JE53+F0VER.AH,SD]3J;/>]14_^V2OKTSN$YVI3U:X/$VE7;]5B5F]
MZ0U[Y8//>K[P].#T^FHIY^J+\K\L/UFL3BLJL4Y5YK3)A%6S-[V;X>NW9[2?
M-_Q;JY6K_18DR=28>UK<Q6]Z P*D$A5YHB#QSX-ZIY*$" '&MX)FKV))!^N_
M2^K_8-DARU0Z]<XDO^K8+][T+GLB5C.9)_ZS6?VD"GDF1"\RB>._8A7VGF-S
ME#MOTN(P$*0Z"__*QT(/M0.7@QT'1L6!$>,.C!CEK?3R^LJ:E;"T&]3H!XO*
MIP%.9V24+][BK<8Y?WVKK'Z0I!DG9!:+GU0\U]E<W)"VM-?*79UZ\*'=IU%!
M\VV@.=I!<RP^F,POG/@QBU7</'\*?!7(40GR[6@OP0_2]L5X>"Q&@]%H#[UQ
M)?28Z8V_*[2XRYRW.;S,[Y)?W&H7)<;E5HG_W$RQ'9[TWSTHSBH49XSB[$]5
M_1^E*;XNE'AGTJ7,UG_[R^5H>/&#$V;ZFXK"*9V)W-$1G7EEE?/"2J_@Z#7"
MT(0W0L:Q<%Y.=:+]FAY4)]0C<H93C #/4YDAOH6&BO$F:+*^G1FDYD&Q&?KB
M*VA'$2 FVBV$7^@:P&.L*_QB:352B4[6P,S8ZQ3=2BZ#%IK/(W[LQ%):+\R,
M<35W6.WN"]0$29#-O9JO^^(VMZ0;\D.FC!]P2Y='BX:&%A*N-56*=*E8!PL8
M0C'V!P"6TX1P0+H9LB*A<2;2X!$C_/T":M+.$Z-R\TEAA*GO"V2C!K-8.3W/
M^# K?"&]^);+1,_6)&;%)F!P+/*6N$&O<V1Q ?)P=^S+^-F&E8 AK(J,1523
MG\!(>9HGS-E@JQ5D-*L6E+-I>X:U$H>]C^_N>D<,SN53I[[E4"IL!EH))-<S
MS?2Z/$@'#$Z"SA) 3'SHCD0<K+!:Z&C![UDRB&YEYF21[F<S> P\3MH,F]TQ
MZ2(V$<<ZJ<H7-@%*M>0C022()_$H&,)W! OMR3,VS](D.EJ+LL;TQ4U*KTA-
M2V/]MIJ@";P+OR%OW8PKG23PF:96.J.JYJY+N2YR%V(JE;$JK=8&W>5('Q]@
M,MJ<J4<OAB/$(*7M9HB!"V+, R [ELPH[C5)*Q-Q,!SU!RA+24+ZZY1 4@B2
MDM$R.-4E$+3&3HDL#W.6:;Z)8B%C 3.JSA!G2TF0]H"4*5^Z0V8*F)*M0CP.
MAOV1F!9X.5I6[404;9'<0VX\>M6_+!4 C<Z"/G<@)9FL4FPL6.YDIA]5?$SZ
M4A0OPQ.NF^+]W=N/G\4A8H62'J=:*OTZS5-B.NA?3/YZU*F)6BJ XS4CG_R5
M70](W4)OZ>T)RL)>98&$:8B8^+;M-NES@;&*&D)BZ?1C=UZ&#O*LE;LB0$/F
M(ZI!4R_7TK _&.S04LB2!?GGT:M@!%1[W;%#53]3D9LBZL8#UM8X:(NE3(RD
MG-+FL-%6T%5("LC"F4EU)!/D43.;.7@]>5Y#H]O*J[@$LH%[A_LK"8MR$7NZ
MR3M,57'K]%7-(25256"W* S:AB: 9$0F87] DH0P]509JH*V EMQPG.=DR#@
MT(L'YP%S@,XBXDY5R638BTS#^1T/DW5(,!OUUG@MUE.KR;A5;WA<NB;1 P-9
M(X_LSUV"1X;S1<;C#%LC$,(G$V3]..;R<X+.Y1ZBU^HK9]B5;)9THM:JX7WQ
M*WQ,=V=Z (TIK89H0H&*F<Y4)ES6^*I0Y/@M&5Q=B)8(C"JR>DIOI^8AI+%(
M6JM#.47BL%[_CQD[7T29VB^RJ[8U/'=CE:K? (.9A,D?9)*KX'&U!JI64XD8
M%5_RU[8TC+A1FS8JD)L6N=#L#DVBY_6%MN )-1#H1Q*UBS\5SBZ;;T/"A=N&
ML-E ZHMWQ =A[DM+M43NT!_7XR(YL/\]B=5WI-_(^V=Y85=W_F++[R#VA\7>
M9?2 YUZM.4]V--=[;R$F]R"<Q0R%F@*\#^WIE,8EKUL]D;A%8@WU(SP9X@G%
M9.A??^26EYSJECC\7%;TT)2*0TA8="KHH;] H-P];=,'_+5TR6.ZG\I$S[+A
MY5I<%&@.Q-EX@H[P)L!H+9M58Q^=\7BP.=98/)U&@_4^''=MNX@ON! TZO10
M#,_/^J]* L/S<W1]_P]J+?E:_</P$H=K@C466[W&$XB-:IIN++Y+[%\Y6M[1
M)1-Z)8:3.J')7D*?M]H=<8-[?;+1UB'+=522:"U?1I&$JU%L+%]&<=*D.-E/
M\4 ,CR=\>>!?XW'_7'S,;4?R$'*.5K7H0M1CE.2<+O:4N>,J?\XSKL>-#/J=
M1-?,T%7=X*-Q,1J"Z%PR4Q.KI+@8(@^OZ?)95#B#>[Y]X#F'SI9(<V%( H1K
MK1+PS"WT I;RN+C';Z?I]^I!)6)4$EAMJDU-FH5&+D?,K$,FKKTI^L =%2%6
MH;&MA**]!7C.R=+&Z$W]PL0F,7/JLM&RNNKJSS!R3[,LNL=&56WDYG?I"[6L
M3 YI3121;6>;X4\#E:,1C"JZ*NY*O=7W*B NQ(BJ?GT7#1XUE<:5292'NQX1
M6%KS6X!8H3-919;U0:/M6/!%KQ"H.EV(V6+'/0R.S*Q)Z^8N=-A2.YD[>-.#
M(5Q)T=;LN("TG"%8Z$7^8!(44C88HRLJK&L=X\)M<MO5FFJ:AT6%-IX3.XU:
M^H1:_K[D<N,<G7^OPW"5NI..1_59+UVDFI>&\LI?;^#O.CJ3CSRX2TPV/Z&
MH%$D,4+I[E_@+S=THQ\H2XWZD]J#I]!*:FC+<V=(=.5OD#QKB/&$H<56?=TI
MPG#8'U:L1JBWSX%>T)@,@; \=]D?O5C\P^'11@6C&M&S"6K 5Q[!'(CS"["
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M'0O0_LH24=T+&]C>WL__ 5!+ P04    "  0BJ-4=ZJ6T+D"  #M!0  &0
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M7LI)KL!(2$C;-7)8& \Z2T1D-L?35=FXCI#6:)3+!0DKT,2985([R #PH4F
MQH4XDJ>O;)1)99I/ISE!KO-W:7E4AT098)=N+QV?YZ@C^\X02DR0$DA,6@'L
M*=OA(AWRLB_W0+N9@8TT71[C9A;&:'3LLCRGP?OP!>=-#2?MH*%S<AJBE;1*
M1]5 $EXONCPUXH1-%DGYD5R),R3A\3_EC?C 6)OM=;X"RF4&_R"DO1,_EBG
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M3&40Q9>03+3R<1'^99]#H3V"5@II1!WG>$)$._J:]K NV1PYL");I8(ES 3
M$HLZID6N5ZQ$J#TLLL$^;IL03YD39_3CEG KUSV2_0A(]%[G@HQ"(UD\?F?#
MC!"_5MYS0?N5.30"F8K;*2+86H6U8"1\P EH(YC];"HMSI"G.E*+['6CV9:C
M'CCAIV>V:B]Y=$L!]E8R(G%F?.%F(8;AJ EBH:UC[7HRS?TYQ\<_GPQE[XBN
M[:>3VI<]60:)>Q!$_'JH^+UN^6@N8\\@2&E+YT@H:HAZ5*AQ=08MN$5K5FH
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M)RH[J0W)K7PJI%(@S8X=9#0@QQU-MW['X_ZX=QCBE?OPO'_6^[^4_]7&86>
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M8TIS8AH0UW0R)4.7_VM9B*8D_*'>->,:'IF@K.TENBH8I"2@NV^O?Y"1S_[
M.)OG&G!-Y*U>*O;H8'[4J#=^2AKPKMI1TI_V@_B\G3_/YNT4)X\;3E<@<$U0
MJI\\ -U.QG9CU=9/HY6R--O\LJ*?"6IG0-_7B@JAVS@'_>]I^0=02P,$%
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M2B)]$:M9V@9K7C/,TDL"?R!P1Y>JT'@BZ&ZHN S72!5Q1VSX(<%(X8Z8&<P
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M":.<K-$(>!X:3;Y/-MHH/-'^KE'4*15UG*+.#44K)1. 5)-,R9QL%;41%"2
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M?5!^KO$+(_?N'MY(@[>Z>]SA* C*.N#[3$IS6M@ Y7 Y_@]02P,$%     @
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M,*<5-S=R]18:03W+ETFNW2]9-;%10+)*&UDT8*R@8*+^I_?-06P!D&<W(&D
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MLE2P_3"CEHK:':#]5"F[G3@'=9,>_@502P,$%     @ $(JC5+38M<$P P
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M[MZHTI0O$!2&%Z+KTLZK5%OO9(GG^3L4__2I5V!4<^_((7N[6N<%]4(3::@
ML0F/Z(I&&69L@R;00FA8@A,X)%"M]+L:Z+5.)_VN7'GU]>HSZ6L?D$+X]J>7
MWJT\^"F1"]L'*;@]&=?YNUG.EKW6K>TPWLT/30]F&XF=F[R!@ZQ?4'CV&8G!
M9;/1!3XR[XGR@19+VU;,A88FQ7XFT$<2:3; >BR$W@X,0-F9#OX"4$L#!!0
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M254]6C4P\NC:G"=IL&ERCP?L:T'9!?A^+Z4Y#ZQ TRFO_P502P,$%     @
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M<VAE970T,BYX;6R=E-]OFS 0Q_\5"_6AE38@$*"K"%+2;%JE98I:=7N8]N#
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MEFY.=R=:;.VHNQ8:!F>[K.#;ADAC /=+(?3KB7E ^[6T^@]02P,$%     @
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M*E]CZRZ\DCK&D%W4,W6,^[J=[?<"=>K>6U\X+: J7^.];K/Y%ML.KK<=0;-
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M6C$KPUHRR^93K;9$.S1Z<Q=E;DIKC(9+)^.]U?B4HYV=+T'S#7.I-(3)A'R
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M#7)"':,O$ES9;[+)9+O]!HE62HLD!Z,'"4NS7_J4+T0%@'KJ 6$."(\%M')
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M%E#W[QB3AQ.]0/UM9OXO4$L#!!0    ( !"*HU2M&PLF@P,   H-   9
M>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;+U7VX[:,!#]%2OJ0U=JDS@7 BM
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M2@^V]C+3'RM8& -]?\&YVBQ,@/KS9_@'4$L#!!0    ( !"*HU3ZYN#\G0(
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M/NO^R4\^ 5!+ 0(4 Q0    ( !"*HU0'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ $(JC5%D$JH7N
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ $(JC5)E<G",0!@  G"<  !,              ( !S $  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  0BJ-44=8PK40%  !S%0
M&               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ $(JC5$^:'O;W!@  :QL  !@              ("!APT  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( !"*HU2-@]LS* ,
M 'D*   8              " @;04  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    "  0BJ-4/,@8Y.H&   M&P  &               @($2
M&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ $(JC5+3W
M/W@J P  AP@  !@              ("!,A\  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( !"*HU1S S<T  8  /(9   8
M  " @9(B  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  0
MBJ-4<1H6T"@'  !5'0  &               @('(*   >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ $(JC5/".&Z0)(P  [&X  !@
M         ("!)C   'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( !"*HU1$?PS9W 8  *X2   8              " @653  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  0BJ-4JZ$51YT#  "F!P
M&0              @(%W6@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( !"*HU3V%YSZG 4  .D8   9              " @4M>  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ $(JC5*H*VWOF
M"0  $R   !D              ("!'F0  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    "  0BJ-4.^ZS0<$$  #)"P  &0
M@($[;@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( !"*
MHU1WJI;0N0(  .T%   9              " @3-S  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ $(JC5#"LP]/5#   ]2   !D
M         ("!(W8  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    "  0BJ-42$I:(GP%  "=#0  &0              @($O@P  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( !"*HU1QR JU:@(  &$%
M   9              " @>*(  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ $(JC5!$@O(LK%0  %D(  !D              ("!@XL
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  0BJ-4C\.?
M=H<%  #O#@  &0              @('EH   >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( !"*HU2*40O2#0,  *L&   9
M  " @:.F  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
M$(JC5/12YD@M P  J@8  !D              ("!YZD  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    "  0BJ-4C/-@Z+,$  ![#   &0
M            @(%+K0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( !"*HU1XTIX<DP4  /$0   9              " @36R  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ $(JC5(T3W7PB!
M@0D  !D              ("!_[<  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    "  0BJ-4Y/)W4L<"  #G!0  &0              @(%8
MO   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( !"*HU0[
M-QYW)04  "T-   9              " @5:_  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ $(JC5(ZTG67% @  A @  !D
M     ("!LL0  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !"*HU16_?[F=00  ($6   9              "
M@:W5  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ $(JC
M5)0 85"7 @  -@8  !D              ("!6=H  'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    "  0BJ-4V=PZ8A8#  ":"   &0
M        @($GW0  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( !"*HU2S'U>C#P,  + '   9              " @73@  !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ $(JC5+38M<$P P  I0H
M !D              ("!NN,  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    "  0BJ-4"G[?-78#   U"P  &0              @($AYP
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( !"*HU163$L'
MK0,  '@+   9              " @<[J  !X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ $(JC5.M&FA\*!   Q@X  !D
M ("!LNX  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  0
MBJ-4NK+5YX\"  !Z!P  &0              @('S\@  >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( !"*HU0+<G-%- 0  *@0   9
M          " @;GU  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#
M%     @ $(JC5+9(3#]8 @  _ 4  !D              ("!)/H  'AL+W=O
M<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  0BJ-4DNY_/]T#   Y
M#0  &0              @(&S_   >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM
M;%!+ 0(4 Q0    ( !"*HU0CO)MY. 0  ,<2   9              " @<<
M 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ $(JC5-BE
M&^XR!   .Q@  !D              ("!-@4! 'AL+W=O<FMS:&5E=',O<VAE
M970T-2YX;6Q02P$"% ,4    "  0BJ-4LZ"_A:,#  !N#P  &0
M    @(&?"0$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M !"*HU1W&#WC=@,  #<+   9              " @7D- 0!X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ $(JC5,#&[RF(!   T@\  !D
M             ("!)A$! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    "  0BJ-41Y5)(/P"  !R"   &0              @('E%0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( !"*HU0GI7NL/@0
M 'D0   9              " @1@9 0!X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ $(JC5+2&"JB]!0  IQD  !D              ("!
MC1T! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    "  0BJ-4
MK1L+)H,#   *#0  &0              @(&!(P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    ( !"*HU3ZYN#\G0(  , &   9
M      " @3LG 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ $(JC5(#K=S\6 P  9A$   T              ( !#RH! 'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    "  0BJ-4EXJ[',     3 @  "P
M@ %0+0$ 7W)E;',O+G)E;'-02P$"% ,4    "  0BJ-4J\\F8S4$  !V(P
M#P              @ $Y+@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M$(JC5'Q^Z1O4 0  QA\  !H              ( !FS(! 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ $(JC5"IDTJ;* 0  FQ\  !,
M             ( !IS0! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #T
,/0"B$   HC8!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>172</ContextCount>
  <ElementCount>281</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>70</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies</Role>
      <ShortName>Organization and Summary of Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2113102 - Disclosure - Acquisitions and Disposals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/AcquisitionsandDisposals</Role>
      <ShortName>Acquisitions and Disposals</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2118103 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2122104 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2127105 - Disclosure - Derivatives and Hedging Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/DerivativesandHedgingActivities</Role>
      <ShortName>Derivatives and Hedging Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2133106 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2136107 - Disclosure - Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OtherCurrentLiabilities</Role>
      <ShortName>Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2139108 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2141109 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2145110 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Organization and Summary of Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2314302 - Disclosure - Acquisitions and Disposals (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/AcquisitionsandDisposalsTables</Role>
      <ShortName>Acquisitions and Disposals (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/AcquisitionsandDisposals</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2319303 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/LongTermDebt</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2323304 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/Leases</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2328305 - Disclosure - Derivatives and Hedging Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables</Role>
      <ShortName>Derivatives and Hedging Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/DerivativesandHedgingActivities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2334306 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/EarningsPerShare</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2337307 - Disclosure - Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables</Role>
      <ShortName>Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/OtherCurrentLiabilities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2342308 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/SegmentReporting</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Organization and Summary of Accounting Policies - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Organization and Summary of Accounting Policies - CARES ACT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - CARES ACT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Organization and Summary of Accounting Policies - Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Organization and Summary of Accounting Policies - Carrying Amount and Fair Value of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Carrying Amount and Fair Value of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2409406 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Revenues by Sources (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Schedule of Revenues by Sources (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2410407 - Disclosure - Organization and Summary of Accounting Policies - Rollforward of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRollforwardofGoodwillDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Rollforward of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2411408 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Non-Controlling Interests - Redeemable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Schedule of Non-Controlling Interests - Redeemable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2412409 - Disclosure - Organization and Summary of Accounting Policies - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2415410 - Disclosure - Acquisitions and Disposals - Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails</Role>
      <ShortName>Acquisitions and Disposals - Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2416411 - Disclosure - Acquisitions and Disposals - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails</Role>
      <ShortName>Acquisitions and Disposals - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2417412 - Disclosure - Acquisitions and Disposals - Disposals and Deconsolidations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails</Role>
      <ShortName>Acquisitions and Disposals - Disposals and Deconsolidations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2420413 - Disclosure - Long-Term Debt - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LongTermDebtSummaryDetails</Role>
      <ShortName>Long-Term Debt - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2421414 - Disclosure - Long-Term Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails</Role>
      <ShortName>Long-Term Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2424415 - Disclosure - Leases - Components of Right-of-us Assets and Liabilities Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Components of Right-of-us Assets and Liabilities Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2425416 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2426417 - Disclosure - Leases - Lease Expense and Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails</Role>
      <ShortName>Leases - Lease Expense and Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2429418 - Disclosure - Derivatives and Hedging Activities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails</Role>
      <ShortName>Derivatives and Hedging Activities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2430419 - Disclosure - Derivatives and Hedging Activities - Interest Rate Swaps and Interest Rate Caps Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails</Role>
      <ShortName>Derivatives and Hedging Activities - Interest Rate Swaps and Interest Rate Caps Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2431420 - Disclosure - Derivatives and Hedging Activities - Derivatives Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails</Role>
      <ShortName>Derivatives and Hedging Activities - Derivatives Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2432421 - Disclosure - Derivatives and Hedging Activities - Pre-tax Effect of Derivatives on AOCI and Statement of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails</Role>
      <ShortName>Derivatives and Hedging Activities - Pre-tax Effect of Derivatives on AOCI and Statement of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2435422 - Disclosure - Earnings Per Share - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails</Role>
      <ShortName>Earnings Per Share - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2438423 - Disclosure - Other Current Liabilities - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails</Role>
      <ShortName>Other Current Liabilities - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2440424 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/CommitmentsandContingencies</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2443425 - Disclosure - Segment Reporting - Revenues and Operating Income by Reportable Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails</Role>
      <ShortName>Segment Reporting - Revenues and Operating Income by Reportable Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2444426 - Disclosure - Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails</Role>
      <ShortName>Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sgry-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/SubsequentEvents</ParentRole>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="sgry-20220331.htm">sgry-20220331.htm</File>
    <File>a2022q1exhibit101.htm</File>
    <File>a2022q1exhibit102.htm</File>
    <File>a2022q1exhibit103.htm</File>
    <File>a2022q1exhibit311.htm</File>
    <File>a2022q1exhibit312.htm</File>
    <File>a2022q1exhibit321.htm</File>
    <File>sgry-20220331.xsd</File>
    <File>sgry-20220331_cal.xml</File>
    <File>sgry-20220331_def.xml</File>
    <File>sgry-20220331_lab.xml</File>
    <File>sgry-20220331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="576">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>72
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sgry-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 25,
   "contextCount": 172,
   "dts": {
    "calculationLink": {
     "local": [
      "sgry-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sgry-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sgry-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sgry-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sgry-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sgry-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 471,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 8,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 13
   },
   "keyCustom": 42,
   "keyStandard": 239,
   "memberCustom": 32,
   "memberStandard": 36,
   "nsprefix": "sgry",
   "nsuri": "http://www.surgerypartners.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.surgerypartners.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118103 - Disclosure - Long-Term Debt",
     "role": "http://www.surgerypartners.com/role/LongTermDebt",
     "shortName": "Long-Term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122104 - Disclosure - Leases",
     "role": "http://www.surgerypartners.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127105 - Disclosure - Derivatives and Hedging Activities",
     "role": "http://www.surgerypartners.com/role/DerivativesandHedgingActivities",
     "shortName": "Derivatives and Hedging Activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133106 - Disclosure - Earnings Per Share",
     "role": "http://www.surgerypartners.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136107 - Disclosure - Other Current Liabilities",
     "role": "http://www.surgerypartners.com/role/OtherCurrentLiabilities",
     "shortName": "Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139108 - Disclosure - Commitments and Contingencies",
     "role": "http://www.surgerypartners.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141109 - Disclosure - Segment Reporting",
     "role": "http://www.surgerypartners.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145110 - Disclosure - Subsequent Events",
     "role": "http://www.surgerypartners.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Accounting Policies (Policies)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Organization and Summary of Accounting Policies (Tables)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables",
     "shortName": "Organization and Summary of Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i2f2c73a27bad4276adf8541dd20dfb2d_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i2f2c73a27bad4276adf8541dd20dfb2d_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314302 - Disclosure - Acquisitions and Disposals (Tables)",
     "role": "http://www.surgerypartners.com/role/AcquisitionsandDisposalsTables",
     "shortName": "Acquisitions and Disposals (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319303 - Disclosure - Long-Term Debt (Tables)",
     "role": "http://www.surgerypartners.com/role/LongTermDebtTables",
     "shortName": "Long-Term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgry:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323304 - Disclosure - Leases (Tables)",
     "role": "http://www.surgerypartners.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgry:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328305 - Disclosure - Derivatives and Hedging Activities (Tables)",
     "role": "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables",
     "shortName": "Derivatives and Hedging Activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334306 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.surgerypartners.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337307 - Disclosure - Other Current Liabilities (Tables)",
     "role": "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables",
     "shortName": "Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2342308 - Disclosure - Segment Reporting (Tables)",
     "role": "http://www.surgerypartners.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i2f2c73a27bad4276adf8541dd20dfb2d_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sgry:NumberOfSurgicalFacilitiesOwned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "surgical_facility",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Organization and Summary of Accounting Policies - Organization (Details)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails",
     "shortName": "Organization and Summary of Accounting Policies - Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i2f2c73a27bad4276adf8541dd20dfb2d_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sgry:NumberOfSurgicalFacilitiesOwned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "surgical_facility",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "sgry:ProceedsFromGovernmentAssistance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Organization and Summary of Accounting Policies - CARES ACT (Details)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails",
     "shortName": "Organization and Summary of Accounting Policies - CARES ACT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "sgry:ProceedsFromGovernmentAssistance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i2f2c73a27bad4276adf8541dd20dfb2d_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sgry:VariableInterestEntityNumberOfFacilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "surgical_facility",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Organization and Summary of Accounting Policies - Variable Interest Entities (Details)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails",
     "shortName": "Organization and Summary of Accounting Policies - Variable Interest Entities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i2f2c73a27bad4276adf8541dd20dfb2d_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sgry:VariableInterestEntityNumberOfFacilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "surgical_facility",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i2f2c73a27bad4276adf8541dd20dfb2d_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i2f2c73a27bad4276adf8541dd20dfb2d_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i506df12890674df3996c010a349ca7c0_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Organization and Summary of Accounting Policies - Carrying Amount and Fair Value of Long-Term Debt (Details)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails",
     "shortName": "Organization and Summary of Accounting Policies - Carrying Amount and Fair Value of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i506df12890674df3996c010a349ca7c0_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i959b5b49ffbc4125a8ae719a2e147008_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408405 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
     "shortName": "Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i959b5b49ffbc4125a8ae719a2e147008_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409406 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Revenues by Sources (Details)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails",
     "shortName": "Organization and Summary of Accounting Policies - Schedule of Revenues by Sources (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i094886c1cfb34257a319635071262fdd_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i46ce349a7375461fa1b7f757dc08d081_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410407 - Disclosure - Organization and Summary of Accounting Policies - Rollforward of Goodwill (Details)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRollforwardofGoodwillDetails",
     "shortName": "Organization and Summary of Accounting Policies - Rollforward of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i46ce349a7375461fa1b7f757dc08d081_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411408 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Non-Controlling Interests - Redeemable (Details)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails",
     "shortName": "Organization and Summary of Accounting Policies - Schedule of Non-Controlling Interests - Redeemable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i64de719b0ad14503b4dba6762866534b_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412409 - Disclosure - Organization and Summary of Accounting Policies - Income Taxes (Details)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails",
     "shortName": "Organization and Summary of Accounting Policies - Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415410 - Disclosure - Acquisitions and Disposals - Acquisitions (Details)",
     "role": "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
     "shortName": "Acquisitions and Disposals - Acquisitions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "ie823b906c9164e118eff58dafb9c18ce_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:NumberOfBusinessesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "surgical_facility",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i2f2c73a27bad4276adf8541dd20dfb2d_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416411 - Disclosure - Acquisitions and Disposals - Summary (Details)",
     "role": "http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails",
     "shortName": "Acquisitions and Disposals - Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "idc9abc5f15644909ae180fa28f65f13e_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfProductiveAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417412 - Disclosure - Acquisitions and Disposals - Disposals and Deconsolidations (Details)",
     "role": "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails",
     "shortName": "Acquisitions and Disposals - Disposals and Deconsolidations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i2f2c73a27bad4276adf8541dd20dfb2d_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InvestmentOwnedAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i2f2c73a27bad4276adf8541dd20dfb2d_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420413 - Disclosure - Long-Term Debt - Summary (Details)",
     "role": "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails",
     "shortName": "Long-Term Debt - Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i2f2c73a27bad4276adf8541dd20dfb2d_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LaborAndRelatedExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i6d81a2e35ef544709f6c3c5a6ec09d33_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421414 - Disclosure - Long-Term Debt - Narrative (Details)",
     "role": "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails",
     "shortName": "Long-Term Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i6d81a2e35ef544709f6c3c5a6ec09d33_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sgry:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i2f2c73a27bad4276adf8541dd20dfb2d_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424415 - Disclosure - Leases - Components of Right-of-us Assets and Liabilities Related to Leases (Details)",
     "role": "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails",
     "shortName": "Leases - Components of Right-of-us Assets and Liabilities Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sgry:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i2f2c73a27bad4276adf8541dd20dfb2d_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "sgry:IncreaseDecreaseInFinanceLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425416 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.surgerypartners.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "sgry:IncreaseDecreaseInFinanceLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426417 - Disclosure - Leases - Lease Expense and Cash Flow Information (Details)",
     "role": "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails",
     "shortName": "Leases - Lease Expense and Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429418 - Disclosure - Derivatives and Hedging Activities - Narrative (Details)",
     "role": "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
     "shortName": "Derivatives and Hedging Activities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i2f2c73a27bad4276adf8541dd20dfb2d_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetNotionalAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430419 - Disclosure - Derivatives and Hedging Activities - Interest Rate Swaps and Interest Rate Caps Outstanding (Details)",
     "role": "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails",
     "shortName": "Derivatives and Hedging Activities - Interest Rate Swaps and Interest Rate Caps Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i612b998bf6814f52b34921481a7fed42_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i2f2c73a27bad4276adf8541dd20dfb2d_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetNotionalAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431420 - Disclosure - Derivatives and Hedging Activities - Derivatives Assets and Liabilities (Details)",
     "role": "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails",
     "shortName": "Derivatives and Hedging Activities - Derivatives Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i83e7577cfc3e485fa204871cd2bebed9_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "sgry:DerivativeLiabilityNotionalAmountFinancingComponent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432421 - Disclosure - Derivatives and Hedging Activities - Pre-tax Effect of Derivatives on AOCI and Statement of Operations (Details)",
     "role": "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails",
     "shortName": "Derivatives and Hedging Activities - Pre-tax Effect of Derivatives on AOCI and Statement of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435422 - Disclosure - Earnings Per Share - Summary (Details)",
     "role": "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails",
     "shortName": "Earnings Per Share - Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i67c06ab0cc1645feb07263a0b462f478_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i2f2c73a27bad4276adf8541dd20dfb2d_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438423 - Disclosure - Other Current Liabilities - Summary (Details)",
     "role": "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails",
     "shortName": "Other Current Liabilities - Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i2f2c73a27bad4276adf8541dd20dfb2d_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InterestPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "role": "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i2f2c73a27bad4276adf8541dd20dfb2d_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SelfInsuranceReserve",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440424 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i46ce349a7375461fa1b7f757dc08d081_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:SelfInsuranceReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443425 - Disclosure - Segment Reporting - Revenues and Operating Income by Reportable Segment (Details)",
     "role": "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails",
     "shortName": "Segment Reporting - Revenues and Operating Income by Reportable Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i2f2c73a27bad4276adf8541dd20dfb2d_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444426 - Disclosure - Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details)",
     "role": "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
     "shortName": "Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "if2df432d764946c98419eddd4b217200_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "iea161d59c161497f8a5bb07b4bdb04b9_D20220401-20220430",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.surgerypartners.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "iea161d59c161497f8a5bb07b4bdb04b9_D20220401-20220430",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i65d685057ae641c3b746cf6377dd430f_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i65d685057ae641c3b746cf6377dd430f_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "sgry:NoncashInterestIncomeExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Accounting Policies",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies",
     "shortName": "Organization and Summary of Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113102 - Disclosure - Acquisitions and Disposals",
     "role": "http://www.surgerypartners.com/role/AcquisitionsandDisposals",
     "shortName": "Acquisitions and Disposals",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20220331.htm",
      "contextRef": "i51617289ac834d6ba852340071fb7b89_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 70,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sgry_A2017SeniorSecuredCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Senior Secured Credit Facility [Member]",
        "label": "2017 Senior Secured Credit Facility [Member]",
        "terseLabel": "The Revolver"
       }
      }
     },
     "localname": "A2017SeniorSecuredCreditFacilityMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_A2017TermLoanMaturing2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Term Loan, Maturing 2024 [Member]",
        "label": "2017 Term Loan, Maturing 2024 [Member]",
        "verboseLabel": "Senior secured term loan"
       }
      }
     },
     "localname": "A2017TermLoanMaturing2024Member",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_AncillaryServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ancillary Services [Member]",
        "label": "Ancillary Services [Member]",
        "terseLabel": "Ancillary Services"
       }
      }
     },
     "localname": "AncillaryServicesMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of Components of Right-of-use Assets and Liabilities Related to Leases"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Integration Related Costs, And Merger Costs",
        "label": "Business Combination, Integration Related Costs, And Merger Costs",
        "terseLabel": "Transaction, integration and acquisition costs"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCostsAndMergerCosts",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease, Liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease, Liability",
        "negatedTerseLabel": "Right-of-use operating lease liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Right Of Use Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Right Of Use Assets",
        "terseLabel": "Right-of-use operating lease assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingRightOfUseAssets",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_CashFlowLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow, Lessee",
        "label": "Cash Flow, Lessee [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashFlowLesseeAbstract",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Tax Agreement, Interest Rate, Basis Spread on Variable Rate",
        "label": "Collaborative Tax Agreement, Interest Rate, Basis Spread on Variable Rate",
        "terseLabel": "Collaborative tax agreement, basis spread on variable rate (percent)"
       }
      }
     },
     "localname": "CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Tax Agreement, Projected Tax Savings, Term",
        "label": "Collaborative Tax Agreement, Projected Tax Savings, Term",
        "terseLabel": "Projected tax savings period"
       }
      }
     },
     "localname": "CollaborativeTaxAgreementProjectedTaxSavingsTerm",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Repayments",
        "label": "Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Repayments",
        "terseLabel": "Repayments of grants received"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grants, Deferred Accelerated Payments",
        "label": "Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grants, Deferred Accelerated Payments",
        "terseLabel": "Deferred accelerated payments"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantsDeferredAcceleratedPayments",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Accelerated Payments",
        "label": "Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Accelerated Payments",
        "terseLabel": "Accelerated payments"
       }
      }
     },
     "localname": "CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_CostReportLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Report Liabilities, Current",
        "label": "Cost Report Liabilities, Current",
        "terseLabel": "Cost report liabilities"
       }
      }
     },
     "localname": "CostReportLiabilitiesCurrent",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_DeferredEmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Employee-related Liabilities, Current",
        "label": "Deferred Employee-related Liabilities, Current",
        "terseLabel": "Deferred accrued payroll and benefits"
       }
      }
     },
     "localname": "DeferredEmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Income Tax Liabilities, Net Of Discount",
        "label": "Deferred Income Tax Liabilities, Net Of Discount",
        "terseLabel": "Net long-term tax receivable agreement liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNetOfDiscount",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_DerivativeLiabilityNotionalAmountFinancingComponent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Liability, Notional Amount, Financing Component",
        "label": "Derivative Liability, Notional Amount, Financing Component",
        "terseLabel": "Derivative liability, notional amount, financing component"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmountFinancingComponent",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Number Of Surgical Facilities Contributed As Non-Cash Consideration",
        "label": "Disposal Group, Number Of Surgical Facilities Contributed As Non-Cash Consideration",
        "terseLabel": "Number of surgical facilities contributed as non-cash consideration"
       }
      }
     },
     "localname": "DisposalGroupNumberOfSurgicalFacilitiesContributedAsNonCashConsideration",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgry_DisposalGroupOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group One [Member]",
        "label": "Disposal Group One [Member]",
        "terseLabel": "Disposal Group One"
       }
      }
     },
     "localname": "DisposalGroupOneMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Before Interest Taxes Depreciation And Amortization",
        "label": "Earnings Before Interest Taxes Depreciation And Amortization",
        "terseLabel": "Adjusted EBITDA"
       }
      }
     },
     "localname": "EarningsBeforeInterestTaxesDepreciationAndAmortization",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_FacilitiesAmbulatorySurgeryCentersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facilities, Ambulatory Surgery Centers [Member]",
        "label": "Facilities, Ambulatory Surgery Centers [Member]",
        "terseLabel": "Facilities, Ambulatory Surgery Centers"
       }
      }
     },
     "localname": "FacilitiesAmbulatorySurgeryCentersMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_FacilitiesSurgicalHospitalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facilities, Surgical Hospitals [Member]",
        "label": "Facilities, Surgical Hospitals [Member]",
        "terseLabel": "Facilities, Surgical Hospitals"
       }
      }
     },
     "localname": "FacilitiesSurgicalHospitalsMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_FinanceLeaseCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Cost",
        "label": "Finance Lease, Cost",
        "totalLabel": "Total finance lease costs"
       }
      }
     },
     "localname": "FinanceLeaseCost",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_FinanceLeaseCost1Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Cost1 [Abstract]",
        "label": "Finance Lease, Cost1 [Abstract]",
        "terseLabel": "Finance lease costs:"
       }
      }
     },
     "localname": "FinanceLeaseCost1Abstract",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sgry_GainLossOnDispositionOfAssetsAndDeconsolidation": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Disposition of Assets And Deconsolidation",
        "label": "Gain (Loss) On Disposition Of Assets And Deconsolidation",
        "negatedLabel": "Gain on disposals and deconsolidations, net",
        "negatedTerseLabel": "Gain on disposals and deconsolidations, net"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssetsAndDeconsolidation",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) Related to Litigation Settlement And Other Litigation Costs",
        "label": "Gain (Loss) Related to Litigation Settlement And Other Litigation Costs",
        "negatedTerseLabel": "(Gain) loss on litigation settlement and other litigation costs"
       }
      }
     },
     "localname": "GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill, Written off Related to Sale of Business Unit and Deconsolidation",
        "label": "Goodwill, Written off Related to Sale of Business Unit and Deconsolidation",
        "negatedTerseLabel": "Disposals and deconsolidations"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidation",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRollforwardofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_GrantRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Revenue",
        "label": "Grant Revenue",
        "negatedTerseLabel": "Grant funds",
        "terseLabel": "Grant funds"
       }
      }
     },
     "localname": "GrantRevenue",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_HealthcareOrganizationPatientServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Healthcare Organization, Patient Service [Member]",
        "label": "Healthcare Organization, Patient Service [Member]",
        "terseLabel": "Patient service revenues",
        "verboseLabel": "Patent service revenues"
       }
      }
     },
     "localname": "HealthcareOrganizationPatientServiceMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_IncreaseDecreaseInFinanceLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Finance Lease Liability",
        "label": "Increase (Decrease) in Finance Lease Liability",
        "terseLabel": "Increase in finance lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInFinanceLeaseLiability",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_IncreaseDecreaseInFinanceLeaseRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Finance Lease, Right-Of-Use Assets",
        "label": "Increase (Decrease) in Finance Lease, Right-Of-Use Assets",
        "terseLabel": "Increase in finance lease assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInFinanceLeaseRightOfUseAssets",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Medicare Accelerated Payments And Deferred Governmental Grants",
        "label": "Increase (Decrease) In Medicare Accelerated Payments And Deferred Governmental Grants",
        "terseLabel": "Medicare accelerated payments and deferred governmental grants"
       }
      }
     },
     "localname": "IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Operating Lease, Right-Of-Use Assets",
        "label": "Increase (Decrease) in Operating Lease, Right-Of-Use Assets",
        "negatedTerseLabel": "Decrease in operating lease assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_InterestRateCapOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Cap One",
        "label": "Interest Rate Cap One [Member]",
        "terseLabel": "Interest rate cap"
       }
      }
     },
     "localname": "InterestRateCapOneMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_InterestRateCapTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Cap Two",
        "label": "Interest Rate Cap Two [Member]",
        "terseLabel": "Interest rate cap"
       }
      }
     },
     "localname": "InterestRateCapTwoMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_LeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_LeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Right-of-Use Asset",
        "label": "Lease, Right-Of-Use Asset",
        "totalLabel": "Total leased assets"
       }
      }
     },
     "localname": "LeaseRightOfUseAsset",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_MateriallyMoreRestrictiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Materially More Restrictive [Member]",
        "label": "Materially More Restrictive [Member]",
        "terseLabel": "Materially More Restrictive"
       }
      }
     },
     "localname": "MateriallyMoreRestrictiveMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Accelerated Payments And Deferred Governmental Grants, Current",
        "label": "Medicare Accelerated Payments And Deferred Governmental Grants, Current",
        "terseLabel": "Medicare accelerated payments and deferred governmental grants"
       }
      }
     },
     "localname": "MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Controlling Interest, Acquisitions And Disposals Of Interests Held By Non-Controlling Interest Holders, Net",
        "label": "Non-Controlling Interest, Acquisitions And Disposals Of Interests Held By Non-Controlling Interest Holders, Net",
        "terseLabel": "Acquisition and disposal of shares of non-controlling interests, net"
       }
      }
     },
     "localname": "NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_NoncashInterestIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Interest Income (Expense), Net",
        "label": "Noncash Interest Income (Expense), Net",
        "negatedTerseLabel": "Non-cash interest expense, net"
       }
      }
     },
     "localname": "NoncashInterestIncomeExpenseNet",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_NotMateriallyMoreRestrictiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Not Materially More Restrictive [Member]",
        "label": "Not Materially More Restrictive [Member]",
        "terseLabel": "Not Materially More Restrictive"
       }
      }
     },
     "localname": "NotMateriallyMoreRestrictiveMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_NotesPayableAndSecuredLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable and Secured Loans [Member]",
        "label": "Notes Payable and Secured Loans [Member]",
        "terseLabel": "Notes payable and other secured loans"
       }
      }
     },
     "localname": "NotesPayableAndSecuredLoansMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Non-Controlling Interests In In-Development De Novo Surgical Facilities Acquired",
        "label": "Number Of Non-Controlling Interests In In-Development De Novo Surgical Facilities Acquired",
        "terseLabel": "Number of non-controlling interests in in-development de novo surgical facilities acquired"
       }
      }
     },
     "localname": "NumberOfNonControllingInterestsInInDevelopmentDeNovoSurgicalFacilitiesAcquired",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgry_NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Non-Controlling Interests In Surgical Facilities Acquired",
        "label": "Number Of Non-Controlling Interests In Surgical Facilities Acquired",
        "terseLabel": "Number of non-controlling interests in surgical facilities acquired"
       }
      }
     },
     "localname": "NumberOfNonControllingInterestsInSurgicalFacilitiesAcquired",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgry_NumberOfSurgicalFacilitiesOwned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Surgical Facilities Owned",
        "label": "Number of Surgical Facilities Owned",
        "terseLabel": "Number of surgical facilities owned"
       }
      }
     },
     "localname": "NumberOfSurgicalFacilitiesOwned",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgry_NumberOfSurgicalFacilitiesOwnedConsolidated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Surgical Facilities Owned, Consolidated",
        "label": "Number Of Surgical Facilities Owned, Consolidated",
        "terseLabel": "Number of surgical facilities owned, consolidated"
       }
      }
     },
     "localname": "NumberOfSurgicalFacilitiesOwnedConsolidated",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Surgical Facilities Owned, Majority Interest",
        "label": "Number Of Surgical Facilities Owned, Majority Interest",
        "terseLabel": "Number of surgical facilities owned, majority interest"
       }
      }
     },
     "localname": "NumberOfSurgicalFacilitiesOwnedMajorityInterest",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgry_OperatingAndFinanceLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease, Expense",
        "label": "Operating And Finance Lease, Expense",
        "terseLabel": "Lease expense"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseExpense",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_OtherPatientServiceRevenueSourcesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Patient Service Revenue Sources [Member]",
        "label": "Other Patient Service Revenue Sources [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPatientServiceRevenueSourcesMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_OtherServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Services [Member]",
        "label": "Other Services [Member]",
        "verboseLabel": "Other service revenues"
       }
      }
     },
     "localname": "OtherServicesMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_PayFixedSwapFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pay-fixed Swap Five Member",
        "label": "Pay-fixed Swap Five [Member]",
        "terseLabel": "Pay-fixed swap"
       }
      }
     },
     "localname": "PayFixedSwapFiveMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_PayFixedSwapFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pay-fixed Swap Four Member",
        "label": "Pay-fixed Swap Four [Member]",
        "terseLabel": "Pay-fixed swap"
       }
      }
     },
     "localname": "PayFixedSwapFourMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_PayFixedSwapOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pay-fixed Swap One Member",
        "label": "Pay-fixed Swap One [Member]",
        "terseLabel": "Pay-fixed swap"
       }
      }
     },
     "localname": "PayFixedSwapOneMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_PayFixedSwapSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pay-fixed Swap Six Member",
        "label": "Pay-fixed Swap Six [Member]",
        "terseLabel": "Pay-fixed swap"
       }
      }
     },
     "localname": "PayFixedSwapSixMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_PayFixedSwapThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pay-fixed Swap Three Member",
        "label": "Pay-fixed Swap Three [Member]",
        "terseLabel": "Pay-fixed swap"
       }
      }
     },
     "localname": "PayFixedSwapThreeMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_PayFixedSwapTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pay-fixed Swap Two Member",
        "label": "Pay-fixed Swap Two [Member]",
        "terseLabel": "Pay-fixed swap"
       }
      }
     },
     "localname": "PayFixedSwapTwoMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_PrivateInsuranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Insurance [Member]",
        "label": "Private Insurance [Member]",
        "terseLabel": "Private insurance"
       }
      }
     },
     "localname": "PrivateInsuranceMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_ProceedsFromGovernmentAssistance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Government Assistance",
        "label": "Proceeds From Government Assistance",
        "terseLabel": "Proceeds from grants received"
       }
      }
     },
     "localname": "ProceedsFromGovernmentAssistance",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_ProductsAndServicesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products And Services [Line Items]",
        "label": "Products And Services [Line Items]",
        "terseLabel": "Products And Services [Line Items]"
       }
      }
     },
     "localname": "ProductsAndServicesLineItems",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sgry_ReceiveFixedSwapOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receive-fixed Swap One Member",
        "label": "Receive-fixed Swap One [Member]",
        "terseLabel": "Receive-fixed swap"
       }
      }
     },
     "localname": "ReceiveFixedSwapOneMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_ReceiveFixedSwapThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receive-fixed Swap Three Member",
        "label": "Receive-fixed Swap Three [Member]",
        "terseLabel": "Receive-fixed swap"
       }
      }
     },
     "localname": "ReceiveFixedSwapThreeMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_ReceiveFixedSwapTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receive-fixed Swap Two Member",
        "label": "Receive-fixed Swap Two [Member]",
        "terseLabel": "Receive-fixed swap"
       }
      }
     },
     "localname": "ReceiveFixedSwapTwoMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "label": "Redeemable Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders",
        "negatedTerseLabel": "Distributions to non-controlling interest\u2014redeemable holders"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest, Increase (Decrease) from Redemptions or Purchase of Interests",
        "label": "Redeemable Noncontrolling Interest, Increase (Decrease) From Redemptions Or Purchase Of Interests",
        "terseLabel": "Acquisition of shares of non-controlling interests, net\u2014redeemable"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_RedeemableNoncontrollingInterestPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest [Policy Text Block]",
        "label": "Redeemable Noncontrolling Interest [Policy Text Block]",
        "terseLabel": "Non-Controlling Interests\u2014Redeemable"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestPolicyTextBlock",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sgry_RedeemableNoncontrollingInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest [Roll Forward]",
        "label": "Redeemable Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Non-Controlling Interests - Redeemable [Roll Forward]"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestRollForward",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sgry_SelfPayRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Self-Pay Revenue [Member]",
        "label": "Self-Pay Revenue [Member]",
        "terseLabel": "Self-pay"
       }
      }
     },
     "localname": "SelfPayRevenueMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_SeniorUnsecuredNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due 2025",
        "label": "Senior Unsecured Notes Due 2025 [Member]",
        "verboseLabel": "6.750% senior unsecured notes due 2025"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDue2025Member",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_SeniorUnsecuredNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes, Due 2027",
        "label": "Senior Unsecured Notes, Due 2027 [Member]",
        "terseLabel": "10.000% senior unsecured notes due 2027"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDue2027Member",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_SurgicalFacilitiesExistingMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgical Facilities, Existing Markets",
        "label": "Surgical Facilities, Existing Markets [Member]",
        "terseLabel": "Surgical Facilities, Existing Markets"
       }
      }
     },
     "localname": "SurgicalFacilitiesExistingMarketsMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_SurgicalFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgical Facilities",
        "label": "Surgical Facilities [Member]",
        "terseLabel": "Surgical Facilities"
       }
      }
     },
     "localname": "SurgicalFacilitiesMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_SurgicalFacilityServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgical Facility Services [Member]",
        "label": "Surgical Facility Services [Member]",
        "terseLabel": "Surgical Facility Services"
       }
      }
     },
     "localname": "SurgicalFacilityServicesMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_TaxReceivableAgreementLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivable Agreement Liability, Current",
        "label": "Tax Receivable Agreement Liability, Current",
        "terseLabel": "Tax receivable agreement liability"
       }
      }
     },
     "localname": "TaxReceivableAgreementLiabilityCurrent",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_ThreePayFixedInterestRateSwapsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Pay-fixed Interest Rate Swaps Member",
        "label": "Three Pay-fixed Interest Rate Swaps [Member]",
        "terseLabel": "Three Pay-fixed Interest Rate Swaps"
       }
      }
     },
     "localname": "ThreePayFixedInterestRateSwapsMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_ThreeReceiveFixedInterestRateSwapsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Receive-fixed Interest Rate Swaps Member",
        "label": "Three Receive-fixed Interest Rate Swaps [Member]",
        "terseLabel": "Three Receive-fixed Interest Rate Swaps"
       }
      }
     },
     "localname": "ThreeReceiveFixedInterestRateSwapsMember",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_VariableAndShortTermLeaseCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable And Short-Term Lease, Cost",
        "label": "Variable And Short-Term Lease, Cost",
        "terseLabel": "Variable and short-term lease costs"
       }
      }
     },
     "localname": "VariableAndShortTermLeaseCost",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_VariableInterestEntityNumberOfFacilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entity, Number of Facilities",
        "label": "Variable Interest Entity, Number Of Facilities",
        "terseLabel": "Number of facilities included in VIE"
       }
      }
     },
     "localname": "VariableInterestEntityNumberOfFacilities",
     "nsuri": "http://www.surgerypartners.com/20220331",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r118",
      "r239",
      "r244",
      "r252",
      "r366",
      "r367",
      "r374",
      "r375",
      "r464",
      "r532",
      "r541",
      "r542",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by consolidated entity or group of entities.",
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r118",
      "r239",
      "r244",
      "r252",
      "r366",
      "r367",
      "r374",
      "r375",
      "r464",
      "r532",
      "r541",
      "r542",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity or group of entities consolidated into reporting entity.",
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r118",
      "r171",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r191",
      "r195",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r249",
      "r251",
      "r252",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r118",
      "r171",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r191",
      "r195",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r249",
      "r251",
      "r252",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r257",
      "r286",
      "r321",
      "r323",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r515",
      "r517",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_PayablesToCustomers": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount payable to customer by broker-dealer.",
        "label": "Broker-Dealer, Payable to Customer",
        "terseLabel": "Amounts due to patients and payors"
       }
      }
     },
     "localname": "PayablesToCustomers",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r198",
      "r302",
      "r303",
      "r481",
      "r514",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r198",
      "r302",
      "r303",
      "r481",
      "r514",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r257",
      "r286",
      "r311",
      "r321",
      "r323",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r515",
      "r517",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r257",
      "r286",
      "r311",
      "r321",
      "r323",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r515",
      "r517",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r42",
      "r467"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r17",
      "r32",
      "r203",
      "r204"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r35",
      "r60",
      "r61",
      "r62",
      "r503",
      "r522",
      "r523"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r59",
      "r62",
      "r70",
      "r71",
      "r72",
      "r120",
      "r121",
      "r122",
      "r372",
      "r518",
      "r519",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r33",
      "r330",
      "r467"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r327",
      "r328",
      "r329",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings": {
     "auth_ref": [
      "r287",
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance.",
        "label": "Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings",
        "negatedTerseLabel": "Preferred dividends"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AirlineProductsAndServicesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of each product and service or each group of similar products and services of an entity by various financial or nonfinancial attributes.",
        "label": "Products and Services [Table]",
        "terseLabel": "Products and Services [Table]"
       }
      }
     },
     "localname": "AirlineProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Dilutive securities outstanding not included in the computation of income (loss) per share as their effect is antidilutive (shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r112",
      "r179",
      "r186",
      "r193",
      "r212",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r250",
      "r252",
      "r253",
      "r366",
      "r374",
      "r433",
      "r465",
      "r467",
      "r484",
      "r500"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets",
        "totalLabel": "Total assets",
        "verboseLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails",
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r19",
      "r21",
      "r55",
      "r112",
      "r212",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r250",
      "r252",
      "r253",
      "r366",
      "r374",
      "r433",
      "r465",
      "r467"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r393",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r320",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails",
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r320",
      "r322",
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails",
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.",
        "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value",
        "terseLabel": "Fair value of non-controlling interests"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Start-up costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions and Disposals"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposals"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "terseLabel": "Transaction and integration costs"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": {
     "auth_ref": [
      "r356"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "auth_ref": [
      "r356"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "negatedTerseLabel": "Current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]",
        "terseLabel": "Net assets acquired:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r355",
      "r356"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r356"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "terseLabel": "Aggregate acquisition date fair value",
        "totalLabel": "Aggregate acquisition date fair value"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r15",
      "r39",
      "r103"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r26",
      "r104",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r98",
      "r103",
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r98",
      "r434"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months",
        "negatedTerseLabel": "Amount estimated to be reclassified as a reduction to interest expense over next 12 months"
       }
      }
     },
     "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r236",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r120",
      "r121",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r31",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending Balance, stockholders' equity (shares)",
        "periodStartLabel": "Beginning Balance, stockholders' equity (shares)",
        "terseLabel": "Common stock, shares outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, $0.01 par value; shares authorized - 300,000,000; shares issued and outstanding - 89,904,913 and 89,332,557, respectively"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r65",
      "r67",
      "r68",
      "r77",
      "r494",
      "r511"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss) attributable to Surgery Partners, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r65",
      "r67",
      "r76",
      "r364",
      "r365",
      "r385",
      "r493",
      "r510"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Less: Comprehensive income attributable to non-controlling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r65",
      "r67",
      "r75",
      "r363",
      "r385",
      "r492",
      "r509"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r160",
      "r161",
      "r201",
      "r430",
      "r431",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r160",
      "r161",
      "r201",
      "r430",
      "r431",
      "r524",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r160",
      "r161",
      "r201",
      "r430",
      "r431",
      "r524",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r160",
      "r161",
      "r201",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Revenue by service type as a proportion of total revenues (as a percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r160",
      "r161",
      "r201",
      "r430",
      "r431",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r109",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r373",
      "r377",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r195",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "verboseLabel": "All other"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r158",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r111",
      "r118",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r275",
      "r276",
      "r277",
      "r278",
      "r446",
      "r485",
      "r487",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument, basis spread on variable rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r29",
      "r272",
      "r487",
      "r499"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r48",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r49",
      "r111",
      "r118",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r275",
      "r276",
      "r277",
      "r278",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r49",
      "r111",
      "r118",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r275",
      "r276",
      "r277",
      "r278",
      "r288",
      "r289",
      "r290",
      "r291",
      "r442",
      "r443",
      "r446",
      "r447",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r261",
      "r273",
      "r275",
      "r276",
      "r444"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Less: unamortized debt issuance costs and discounts"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "auth_ref": [
      "r261",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount (premium).",
        "label": "Debt Instrument, Unamortized Discount (Premium), Net",
        "terseLabel": "Unamortized fair value discount (premium)"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Long-term deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r101",
      "r113",
      "r341",
      "r346",
      "r347",
      "r348"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r101",
      "r174"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotionalAmount": {
     "auth_ref": [
      "r387",
      "r388",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative asset.",
        "label": "Derivative Asset, Notional Amount",
        "terseLabel": "Derivative asset, notional amount"
       }
      }
     },
     "localname": "DerivativeAssetNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r57",
      "r394",
      "r396",
      "r402",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r414",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivatives and Hedging Activities"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r387",
      "r388",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "negatedTerseLabel": "Derivative liability, notional amount",
        "terseLabel": "Derivative liability, notional amount"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r388",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeVariableInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable interest rate in effect as of the balance sheet date related to the interest rate derivative.",
        "label": "Derivative, Variable Interest Rate",
        "terseLabel": "Variable interest rate of derivative instrument (percent)"
       }
      }
     },
     "localname": "DerivativeVariableInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r117",
      "r386",
      "r389",
      "r391",
      "r392",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Instruments and Hedging Activities"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives in cash flow hedging relationships"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r221",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposed of by Sale"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "auth_ref": [
      "r101",
      "r221",
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "negatedLabel": "Pre-tax loss on disposals and deconsolidations"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r320",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r78",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r133",
      "r136",
      "r141",
      "r144",
      "r145",
      "r149",
      "r150",
      "r416",
      "r417",
      "r495",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net income (loss) per share attributable to common stockholders",
        "verboseLabel": "Income (loss) per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r78",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r136",
      "r141",
      "r144",
      "r145",
      "r149",
      "r150",
      "r416",
      "r417",
      "r495",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r115",
      "r337",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal effective tax rate (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r331",
      "r337"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount",
        "negatedTerseLabel": "Tax benefits related to vesting of restricted stock awards"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r70",
      "r71",
      "r72",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r132",
      "r152",
      "r213",
      "r287",
      "r292",
      "r327",
      "r328",
      "r329",
      "r343",
      "r344",
      "r415",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r518",
      "r519",
      "r520",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentsMember": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in the stock of an investee which is adjusted for the investor's share of the earnings or losses of the investee after the date of acquisition.",
        "label": "Equity Method Investments [Member]",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r263",
      "r275",
      "r276",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimatedInsuranceRecoveries": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts.",
        "label": "Estimated Insurance Recoveries",
        "terseLabel": "Expected insurance recoveries"
       }
      }
     },
     "localname": "EstimatedInsuranceRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r419",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r419",
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r263",
      "r275",
      "r276",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r420",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r263",
      "r275",
      "r276",
      "r419",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r263",
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r263",
      "r275",
      "r276",
      "r312",
      "r313",
      "r318",
      "r319",
      "r420",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r263",
      "r275",
      "r276",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r424",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "terseLabel": "Federal Funds Rate"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r451",
      "r456",
      "r462"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails": {
       "order": 2.0,
       "parentTag": "sgry_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r454",
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash outflows from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r449",
      "r461"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 1.0,
       "parentTag": "sgry_LeaseLiability",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance lease obligations",
        "totalLabel": "Finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Liability [Abstract]",
        "terseLabel": "Finance lease liabilities:"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r449"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r449"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r453",
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "terseLabel": "Financing cash outflows from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 2.0,
       "parentTag": "sgry_LeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r451",
      "r456",
      "r462"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails": {
       "order": 1.0,
       "parentTag": "sgry_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of leased assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r235"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 8.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedTerseLabel": "Litigation settlement",
        "verboseLabel": "Litigation settlement"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r216",
      "r217",
      "r467",
      "r483"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, end of period",
        "periodStartLabel": "Goodwill, beginning of period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRollforwardofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Acquisitions, including post acquisition adjustments"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRollforwardofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRollforwardofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GovernmentContractMember": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Formal agreement with government or its agency.",
        "label": "Government Contract [Member]",
        "terseLabel": "Government"
       }
      }
     },
     "localname": "GovernmentContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GuaranteeObligationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Guarantor Obligations [Line Items]",
        "terseLabel": "Guarantor Obligations [Line Items]"
       }
      }
     },
     "localname": "GuaranteeObligationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r391",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r114",
      "r349"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Income before income taxes",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r73",
      "r101",
      "r176",
      "r211",
      "r490",
      "r507"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Equity in earnings of unconsolidated affiliates"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.",
        "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions",
        "negatedTerseLabel": "Equity in earnings of unconsolidated affiliates, net of distributions received"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r320",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r2",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r12",
      "r13",
      "r14",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r225",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r131",
      "r132",
      "r177",
      "r336",
      "r345",
      "r351",
      "r513"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r69",
      "r332",
      "r333",
      "r338",
      "r339",
      "r340",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r337"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "negatedTerseLabel": "Tax benefits attributable to non-recurring earnings' impact on the valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationDispositionOfBusiness": {
     "auth_ref": [
      "r337"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Amount",
        "negatedTerseLabel": "Tax benefits related to the sale of partnership interests"
       }
      }
     },
     "localname": "IncomeTaxReconciliationDispositionOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r100",
      "r458"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "negatedTerseLabel": "Decrease in operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedTerseLabel": "Other operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Goodwill and other intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "negatedTerseLabel": "Interest expense, net",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r24",
      "r25",
      "r45"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateCapMember": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract in which the cap writer, in return for a premium, agrees to limit, or cap, the cap holder's risk associated with an increase in interest rates. If rates go above a specified interest-rate-level (the strike price or the cap rate), the cap holder is entitled to receive cash payments equal to the excess of the market rate over the strike price multiplied by the notional principal amount.",
        "label": "Interest Rate Cap [Member]",
        "terseLabel": "Interest Rate Cap"
       }
      }
     },
     "localname": "InterestRateCapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r16",
      "r53",
      "r467"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedAtFairValue": {
     "auth_ref": [
      "r525",
      "r528",
      "r529"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.",
        "label": "Investment Owned, at Fair Value",
        "terseLabel": "Fair value of investments"
       }
      }
     },
     "localname": "InvestmentOwnedAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Investments in and advances to affiliates"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LaborAndRelatedExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.",
        "label": "Labor and Related Expense",
        "terseLabel": "Salaries and benefits"
       }
      }
     },
     "localname": "LaborAndRelatedExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r460",
      "r462"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Expense and Cash Flow Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r44",
      "r112",
      "r187",
      "r212",
      "r239",
      "r240",
      "r241",
      "r244",
      "r245",
      "r246",
      "r248",
      "r250",
      "r252",
      "r253",
      "r367",
      "r374",
      "r375",
      "r433",
      "r465",
      "r466"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r38",
      "r112",
      "r212",
      "r433",
      "r467",
      "r489",
      "r506"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r47",
      "r112",
      "r212",
      "r239",
      "r240",
      "r241",
      "r244",
      "r245",
      "r246",
      "r248",
      "r250",
      "r252",
      "r253",
      "r367",
      "r374",
      "r375",
      "r433",
      "r465",
      "r466",
      "r467"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r29",
      "r487",
      "r499"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Amount of line of credit outstanding"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Availability on line of credit instrument"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Other litigation costs"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r29",
      "r262",
      "r274",
      "r275",
      "r276",
      "r487",
      "r502"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-term Debt and Lease Obligation",
        "terseLabel": "Long-term debt, less current maturities",
        "verboseLabel": "Total long-term debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-term Debt and Lease Obligation, Current",
        "terseLabel": "Less: Current maturities",
        "verboseLabel": "Current maturities of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, including portion classified as current.",
        "label": "Long-term Debt and Lease Obligation, Including Current Maturities",
        "totalLabel": "Total debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r49",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r52",
      "r112",
      "r212",
      "r239",
      "r244",
      "r245",
      "r246",
      "r252",
      "r253",
      "r433",
      "r488",
      "r505"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interests\u2014non-redeemable"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Distributions to non-controlling interests\u2014non-redeemable holders"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r98",
      "r99",
      "r102"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r14",
      "r64",
      "r66",
      "r72",
      "r74",
      "r102",
      "r112",
      "r123",
      "r125",
      "r126",
      "r127",
      "r128",
      "r131",
      "r132",
      "r138",
      "r179",
      "r185",
      "r189",
      "r192",
      "r195",
      "r212",
      "r239",
      "r240",
      "r241",
      "r244",
      "r245",
      "r246",
      "r248",
      "r250",
      "r252",
      "r253",
      "r417",
      "r433",
      "r491",
      "r508"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss) attributable to Surgery Partners, Inc.",
        "totalLabel": "Net income (loss) attributable to Surgery Partners, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r64",
      "r66",
      "r72",
      "r131",
      "r132",
      "r370",
      "r384"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net income attributable to non-controlling interests",
        "negatedTerseLabel": "Less: Net income attributable to non-controlling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest",
        "terseLabel": "Net income attributable to non-controlling interests\u2014redeemable"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r133",
      "r134",
      "r140",
      "r145",
      "r179",
      "r185",
      "r189",
      "r192",
      "r195"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net income (loss) attributable to common stockholders",
        "totalLabel": "Net income (loss) attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": {
     "auth_ref": [
      "r282",
      "r370",
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.",
        "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest",
        "terseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": {
     "auth_ref": [
      "r105",
      "r106",
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.",
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)",
        "terseLabel": "Noncash consideration"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r292",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-Controlling Interests\u2014 Non-Redeemable"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives not designated as hedging instruments"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfBusinessesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of businesses acquired by the entity during the period.",
        "label": "Number of Businesses Acquired",
        "terseLabel": "Number of facilities acquired",
        "verboseLabel": "Number of businesses acquired"
       }
      }
     },
     "localname": "NumberOfBusinessesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfInterestRateDerivativesHeld": {
     "auth_ref": [
      "r388",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.",
        "label": "Number of Interest Rate Derivatives Held",
        "terseLabel": "Number of interest rate swaps"
       }
      }
     },
     "localname": "NumberOfInterestRateDerivativesHeld",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of states the entity operates in as of the balance sheet date.",
        "label": "Number of States in which Entity Operates",
        "terseLabel": "Number of states in which entity operates"
       }
      }
     },
     "localname": "NumberOfStatesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.",
        "label": "Operating Costs and Expenses",
        "totalLabel": "Cost of revenues"
       }
      }
     },
     "localname": "OperatingCostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r179",
      "r185",
      "r189",
      "r192",
      "r195"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r457",
      "r462"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r452"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r449"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 2.0,
       "parentTag": "sgry_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Operating lease liabilities:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r449"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current",
        "verboseLabel": "Right-of-use operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails",
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r449"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Right-of-use operating lease liabilities",
        "verboseLabel": "Long-term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r455",
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash outflows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 1.0,
       "parentTag": "sgry_LeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets",
        "verboseLabel": "Right-of-use operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r45"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r54",
      "r467"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r58",
      "r60"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Derivative activity",
        "verboseLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r58",
      "r60",
      "r395",
      "r399",
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Gain recognized in OCI (effective portion)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r60",
      "r63",
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Loss recognized in income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax": {
     "auth_ref": [
      "r401"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from discontinuance of cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax",
        "terseLabel": "Amortization of accumulated OCI related"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income, net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Cost and Expense, Operating",
        "terseLabel": "Other operating expenses"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]",
        "terseLabel": "Summary of Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherIncomeMember": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other revenue.",
        "label": "Other Income [Member]",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r22",
      "r23",
      "r45",
      "r467"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other liabilities.",
        "label": "Other Liabilities Disclosure [Text Block]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonrecurringIncomeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 9.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense (income) that is infrequent in occurrence or unusual in nature.",
        "label": "Other Nonrecurring (Income) Expense",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonrecurringIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r86",
      "r89"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other investing activities"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Payments of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsMinorityInterest": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests.",
        "label": "Payments of Ordinary Dividends, Noncontrolling Interest",
        "negatedTerseLabel": "Distributions to non-controlling interest holders"
       }
      }
     },
     "localname": "PaymentsOfDividendsMinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Preferred Stock and Preference Stock",
        "negatedTerseLabel": "Payment of preferred dividends"
       }
      }
     },
     "localname": "PaymentsOfDividendsPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payments of equity offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r87",
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Total consideration"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Payments for acquisitions, net of cash acquired",
        "terseLabel": "Payments for acquisitions, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "terseLabel": "Payments to acquire equity method investments"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment",
        "terseLabel": "Total cash purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "(Payments) receipts related to ownership transactions with non-controlling interest holders"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r30",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r30",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r30",
      "r467"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.01 par value; shares authorized - 20,310,000; shares issued or outstanding - none"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r18",
      "r20",
      "r214",
      "r215"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from equity offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Borrowings of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "(Payments) receipts related to ownership transactions with non-controlling interest holders"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r92",
      "r96"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing activities"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Proceeds from Sale of Equity Method Investments",
        "terseLabel": "Proceeds from sales of equity investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from disposals of facilities and other assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails",
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Revenue Source"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r526",
      "r527"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Professional and medical fees"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r14",
      "r64",
      "r66",
      "r72",
      "r97",
      "r112",
      "r123",
      "r131",
      "r132",
      "r179",
      "r185",
      "r189",
      "r192",
      "r195",
      "r212",
      "r239",
      "r240",
      "r241",
      "r244",
      "r245",
      "r246",
      "r248",
      "r250",
      "r252",
      "r253",
      "r363",
      "r369",
      "r371",
      "r384",
      "r385",
      "r417",
      "r433",
      "r497"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r222",
      "r451",
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "terseLabel": "Accumulated depreciation on property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r56",
      "r223",
      "r456"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, net of accumulated depreciation of $294.6 and $272.3, respectively"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r205",
      "r207",
      "r208",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDerivativesAssetsandLiabilitiesDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesInterestRateSwapsandInterestRateCapsOutstandingDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesPretaxEffectofDerivativesonAOCIandStatementofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": {
     "auth_ref": [
      "r186",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Assets from Segment to Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r185",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of Segment Revenue and Operating Income"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "auth_ref": [
      "r280",
      "r281",
      "r283",
      "r284"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "terseLabel": "Non-controlling interests\u2014redeemable"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.",
        "label": "Redeemable Noncontrolling Interest [Table Text Block]",
        "terseLabel": "Schedule of Rollforward of Noncontrolling Interest - Redeemable"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Principal payments on long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted shares"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r34",
      "r292",
      "r330",
      "r467",
      "r504",
      "r521",
      "r523"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r132",
      "r213",
      "r327",
      "r328",
      "r329",
      "r343",
      "r344",
      "r415",
      "r518",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r170",
      "r171",
      "r184",
      "r190",
      "r191",
      "r198",
      "r199",
      "r201",
      "r301",
      "r302",
      "r481"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r110",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r459",
      "r462"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for finance lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r459",
      "r462"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r160",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Carrying Amounts and Fair Values of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Summary of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r386",
      "r389",
      "r390",
      "r391",
      "r392",
      "r398",
      "r402",
      "r408",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "terseLabel": "Schedule of Interest Rate Swaps and Interest Rate Caps Outstanding"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r136",
      "r137",
      "r141",
      "r145",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r219",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Rollforward of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGuaranteeObligationsTable": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the type or nature of guarantees, for example performance, indemnification, payment and other guarantees, and related information such as term, origin and purpose, triggering event, maximum exposure, and carrying value. Represents the guarantor's disclosures which include the information about each guarantee, or each group of similar guarantees, even if the likelihood of the guarantor's need to make any payments under the guarantee is remote. This excludes disclosures for product warranties.",
        "label": "Schedule of Guarantor Obligations [Table]",
        "terseLabel": "Schedule of Guarantor Obligations [Table]"
       }
      }
     },
     "localname": "ScheduleOfGuaranteeObligationsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.",
        "label": "Schedule of Interest Rate Derivatives [Table Text Block]",
        "terseLabel": "Schedule of Effect of Interest Rate Swaps"
       }
      }
     },
     "localname": "ScheduleOfInterestRateDerivativesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r179",
      "r182",
      "r188",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r179",
      "r182",
      "r188",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Financial Information by Reportable Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r366",
      "r367",
      "r374",
      "r375",
      "r376",
      "r378",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r157",
      "r160",
      "r161",
      "r162",
      "r430",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Revenues"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtNarrativeDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r166",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r195",
      "r201",
      "r230",
      "r231",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r166",
      "r168",
      "r169",
      "r179",
      "r183",
      "r189",
      "r193",
      "r194",
      "r195",
      "r196",
      "r198",
      "r200",
      "r201",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Significant Reconciling Item, Consolidated [Abstract]",
        "terseLabel": "Reconciliation of Adjusted EBITDA:"
       }
      }
     },
     "localname": "SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SelfInsuranceReserve": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.",
        "label": "Self Insurance Reserve",
        "terseLabel": "Professional, general and workers' compensation insurance reserve"
       }
      }
     },
     "localname": "SelfInsuranceReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCarryingAmountandFairValueofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.",
        "label": "Series of Individually Immaterial Business Acquisitions [Member]",
        "terseLabel": "Series of Individually Immaterial Business Acquisitions"
       }
      }
     },
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsandDeconsolidationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Equity-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r3",
      "r166",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r195",
      "r201",
      "r219",
      "r226",
      "r230",
      "r231",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r51",
      "r70",
      "r71",
      "r72",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r132",
      "r152",
      "r213",
      "r287",
      "r292",
      "r327",
      "r328",
      "r329",
      "r343",
      "r344",
      "r415",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r518",
      "r519",
      "r520",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r152",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r30",
      "r31",
      "r287",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Equity offering (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r30",
      "r31",
      "r287",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Equity-based compensation (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r30",
      "r31",
      "r287",
      "r292"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Equity offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r30",
      "r31",
      "r292",
      "r324",
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r31",
      "r36",
      "r37",
      "r112",
      "r206",
      "r212",
      "r433",
      "r467"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Surgery Partners, Inc. stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r71",
      "r112",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r212",
      "r213",
      "r292",
      "r327",
      "r328",
      "r329",
      "r343",
      "r344",
      "r361",
      "r362",
      "r383",
      "r415",
      "r433",
      "r435",
      "r436",
      "r440",
      "r519",
      "r520",
      "r554"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance, stockholders' equity",
        "periodStartLabel": "Beginning Balance, stockholders' equity",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r441",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r441",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r441",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r441",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r468",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SuppliesExpense": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense associated with supplies that were used during the current accounting period.",
        "label": "Supplies Expense",
        "terseLabel": "Supplies"
       }
      }
     },
     "localname": "SuppliesExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r28",
      "r486",
      "r501"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.",
        "label": "Taxes Payable",
        "terseLabel": "Long-term tax receivable agreement liability"
       }
      }
     },
     "localname": "TaxesPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "auth_ref": [
      "r139",
      "r142",
      "r143"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic",
        "negatedLabel": "Less: Amounts attributable to participating securities"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnusualRiskOrUncertaintyByNatureAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nature of risk and uncertainty, for example, but not limited to, threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.",
        "label": "Unusual Risk or Uncertainty, Nature [Axis]",
        "terseLabel": "Unusual Risk or Uncertainty, Nature [Axis]"
       }
      }
     },
     "localname": "UnusualRiskOrUncertaintyByNatureAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualRiskOrUncertaintyNatureDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of the unusual risk or uncertainty, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.",
        "label": "Unusual Risk or Uncertainty, Nature [Domain]",
        "terseLabel": "Unusual Risk or Uncertainty, Nature [Domain]"
       }
      }
     },
     "localname": "UnusualRiskOrUncertaintyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r156",
      "r163",
      "r164",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r366",
      "r367",
      "r374",
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails",
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r135",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (shares)",
        "verboseLabel": "Weighted average shares outstanding- diluted (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r133",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (shares)",
        "verboseLabel": "Weighted average shares outstanding- basic (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.surgerypartners.com/role/EarningsPerShareSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted average common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "65",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2793-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "66",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2814-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=123583895&loc=d3e30768-111565"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(3)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "14",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "15",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r535": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r536": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r537": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r538": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r539": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r541": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r542": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "01"
  },
  "r543": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "02"
  },
  "r544": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(ii)",
   "Subsection": "01"
  },
  "r545": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)",
   "Subsection": "01"
  },
  "r546": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(A)",
   "Subsection": "01"
  },
  "r547": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(A)",
   "Subsection": "02"
  },
  "r548": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(B)",
   "Subsection": "01"
  },
  "r549": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(B)",
   "Subsection": "02"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(C)",
   "Subsection": "02"
  },
  "r551": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "01"
  },
  "r552": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "02"
  },
  "r553": {
   "Name": "Rule 15c3-1",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15c3-1"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>73
<FILENAME>0001638833-22-000096-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001638833-22-000096-xbrl.zip
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M*5C"YI'K !M[3]N"1&8CV;0>:OEIFR+B!0"A'F7KAYC2PYYQP[%TDBS4E("
M^LL5AV3 #;I0QC-M)8.6I-;E@9#[B;@.I?<U=9.P?5SM4IC ([E\O-BC8(_:
M@E4\/G][.=A'5->[2DY[<1U_4/WI'0E4GO?FG!A+C"LD(Y<KIE-DY<3=V!OH
M*)JW#=3VCM"V!OR4-GXX[4$#.DTH+;>]"]UU^0UVA!A>/YFZLW"S3M-$4*%'
M.?E2Q1+\F$+]N>5I(AFXCMZ&'LEH-Y:(0@U8P>*=2#;H[I2BI>W:GG*AEXK8
M<SO,[;-22S0ME8H%FE*1\0:=N^R:AF,0RU+&'LHSR%T6&(0FXB6#.-7_//.1
MH(V$;.GVBE@E:87IG\ID@<S3,B'$:(:;KI2QW.D@+%JP1:6RJ98VG9<8HV0+
M(0P$_;=#^!,M==/+G9$(Z*LP3W@0*#1D#<2  YU.H[15'>O^^'BR"F^E2;>*
M.R8)D5<$%38;#ERK>)YK%/6\R _L%Z#(1Y1RM%AED>(@X52P(BBQ?E9&"S3?
M*BR<3D9:V/0$ U&HC7^L%/U*]M:046 JDC4L( RF^Z+XPDY]S.1-5(;_1AB,
M 7\@8'A.&<X\G"B&"U:2+ZFLH9II)==9Y'#CBA=+"EZ #PXJ#;YMT6ALLTS6
MUK,%KP QPTDH_2TE8ND&UKE[SSI0/1M[6#I6<VD/^_;Q<9SB55^=P?=R!G_[
M1)S!O7']DI:ZB?.Y6C>7#FIQ/E-U2M]P@N )(TMSJSE4P><<71/R% @W,&O4
M5=" A*%Y<41XM1Q)EA=PM8":BY!QD:U BHS>TX&\W,PHQBXRE<R4*>2J-D\-
MAGR3UE$68K8BGH$;8H?.TZSS6^[0P*N\AV'.&Q^Y:EP@!"HSU"KFQ)D/T0K8
M;@G[B'%DR& KXH"4:B)7)W Y'/!R348@4X$6B\W TJX$1@%95HU&DII%@V(:
MZEXV+@W;#HJ<.%/32J[W$\T[2L=02:T*+N^C(^5:\@>955BC$C2O->?XPQ*C
M@;FJU5(4V:FB<AF;QTBR3H'[4Z.JAM%R(LB[R[-(*UHRX+58 &\&?V8(5"J2
MTK3N&*74ZFEM=]W6=TO44M-RN_8K>^!<.1R:UE!K4,N$C6-%?P&[">II$F%
M0DW7*T:@XS9C^#W[3(NREC2?%6GCT5(YG^E*1AO62O3_JIC6=L]H($D1KVSD
M'5[&(%92U-Y2RE_A3NX':C$IDK6@NC5EG4U;A$%[: @S[M 3Q(&%E<6FNRO3
M^Z+3[Y276FZ=:,UQ\7*0J$P+FL=9ZW=E< '[ :(X*\C%V9866=9B5$H2FBLQ
M@]OMA:L$A3Z%OW659"10O#@RI<0870]7)I>2-^C_CFG*Y(!:APZ:7O-%\JZG
M?/*K&OH56!D&R+BC69AP#+]+<4ZD&IO[(-M[]\#$/E*YD3V%EF&<"EX-1J=3
M*;PC&$>YY+A1U&M<8MEPRA/#%4AO4OP3-MHF;U >GDK(^<Q+4&.![BA16M5!
M*]'4JAP<->@]L7>X+R*;Z#Z,WR'-AMPHS17+(V;.FICE-T&'ID@>D87^1"^3
M>&Z"&J#9(E.< 2=7)P5'X]I8O'EJA8+E9Y$ TP%+6[*C\R8M,L-\8)H<B7BT
MSW%4V@-;.S G<N!!!,^,0:U25&4),T2BVVJ5.L^3/*U0U^ ST7!#X+6O(1[)
M4X [0U"]8>, Z@V5K?,2958Y],LAZU',ZH2W/61K\ZY$*MWRF-:)+;:(AX4,
M/X;UYP$>R;ZZ;K4BU0.7[>:R0NY-!K(OB6E&5245&RZ^)9WI/*$["(N>8005
M/UH*#V7NC-*+\;0EP!53TFE);E$E:>O 8,* PI(7$U#O@<T@""R'TK-:AA?Q
M^A9'JB7QZYPL!^-:VQHP\M@4/SO@G%MLA,P'\P($*;@(C/<JTC5F SBPZ:K2
MLJ5^T&1W44-Z_OB73%]1?42>WB9]VR(G]?UHW4]+_?;)&%8W2W!/!@:DOV0
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M,O92;4_2%A8'$X;N'<ZM;]IY38&*^]G-FJD66PRFN\)B5)]8S!TRWEO,T[E
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M3-X-3X:7S$HOKX)3X)G(+I#'"J?@)Y$=TIUM.P/>/3H!3HY#L/SV$S,09K;
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MN58SVT!KNJ)UNSTY?NUIR:32+96L_WRKU_W$AO\;P/_N^L]7 ^+]#(@O^VA
MW+0\VQ>U)^K"_8AX1'9O"@/XB%;Q\W>^74^4/@K\-IFAQ$2[<NT=# )BQWS7
M::V5;$9_DIJU?4L::LGC+??X^O+GX>4G"N@X&UZ.PV!T=OR,QN[\_]LU7-/?
M];1@&/+I%S]V_1=#0^F_P2_/@F&9QL'P!H:PZ87'5/EPE0/ZGS?4_A,0#WH#
MW-8#CM;OY&2/-.M!'*ME+?&4Q&T2/B'NP>GI:7%.A0(9%ATB;Z,L*>+/FT]2
M/P],<_S_&B=_)%)"1)PGR%U?$@D='M(_1R^.CNXB$K,I]SGH7X513QA]M448
M?8YP3O#/O%YD/_U_4$L#!!0    ( !"*HU0N$-W;($@  'N< 0 5    83(P
M,C)Q,65X:&EB:70Q,#(N:'1M[7U9<]M(EN[[_168ZF6D&Y!MR:Z]IR)HB;;9
M(TL:4BJ/GVZ 1))$&0386"2S?_T]6VX 2$GNJA:D<,>,2R2!7$^>/.MW_O8?
M)^?'EQ\OAL&R6J7!Q=7KT]%Q\,W!\^<?7AX_?WYR>1*\NWQ_&KQZ]N(PN"RB
MK$RJ),^B]/GSX=DWP3?+JEK_]/SYS<W-LYN7S_)B\?QR_!R;>O4\S?-2/8NK
M^)M?_H;?P+\JBG_Y/W_[CX.#X"2?U2N55<&L4%&EXJ NDVP1?(A5^2DX.)"G
MCO/UID@6RRHX>G%T%'S(BT_)=<2_5TF5JE]T.W][SI__]IPZ^=LTCS>__"U.
MKH,D_J]ODL/H\(?YT=&+%]_]^.VK5]/#'U[^J%Y,5?3C]#!Z^=UWT?\[A$$^
MA\?YG;+:I.J_OEDEV<%28?\_?7^TKGZ^2>)J^=/ABQ=_^<9[KE*?JX,H31;9
M3S1:^'6>9Q6,HH!6^<]6X[_G2_KG69[FQ4]_>D'_^QE_.9A'JR3=_/2?E\E*
ME<&9N@G&^2K*_C,L82\/2E4D<WZP3/ZI?CH\A&G2QQN9-[23)IG2Z\"3'WY>
M)M.D"@Y?/#ORQ]I>PZA8P#).\ZK*5S\=XC*NHSB&S3Y(U1P:_,'YIN ^\"MG
MIC/87U7P-TD6PZ>?#EY^M_[C)_^J8_(\C%C-\B+"D_!3#2,J\*EO?AF\'YZ=
M#$^"P=E),!Y.+@>7\&'X_N+T_"/\<AD,WHZ'0_QKZ_YVK):S$+_5997,-]Y*
M/-A"?//+Y;O1)+CSG(.]:IF4P5__] .<PY_U"O1L Q>%4LQ.'FIXW_Q"*W3X
M\WX J[54A9IN CH P"23K,H#-9^K695<JR J@WP>O(^*V3+X(60>":NL]"(/
MS9,GP&-UNV$P5=6-4EDPJ8N%*C;!1514F2K*,!AELV=>$_W<I^-\M8ZR32]V
M*<KB8)!5RSS;!!^>!9?1.BKR8*_7ZS?\K&8U$D8?5O!9W[GAT9VF<_CL ??:
MNU*/OM<+M67W5^LTWSPTFWL6!)? 9^0H!^4R2M- T= "0Y\A'2_S4?/#:#93
MZZH,9M!+DM7 &9694W"35,N@LDV'0;W.,_H&N.BJI";AS9@DV3(H517,\P)>
M2O IX+KF&L#OZ<4US#&/@7$"/68HJ$*#S'</#SL8;S]//:P'3&K&,\,;H0^G
MGW9#9;$L*B[B)>Q2DM'P:9@A7G3K(K].8MAIW!+8J G>;/# JT>P\/; !1=$
M2'U8>#A_3X/Q'CT:QGN1L_9,-'\"'$V5#\J!G\;^[T7[O2& HV??XSJ<U 7R
M,V1,K;,?.M<97WK0,0OS]H=?DYD*+@I5)KBZ87"\3-0\>%OD-W!-G<_G\',1
M%&H-UQ9UE/.%-SR'4]UL?AGAGS7<5= >W(0EJ.YI@L07!C$1(=%C5(,,6\CW
M^,5- B\7"LF77\=Q0L>EN17UW8U/)W =3^HI##B)"FP3GAG 0-,$.'B)L\,W
M7N=1$:/2<I(4P,#S@C08MZW^<W.:0Q\X>+"*-L&\R%=!!<T3$>!_8UI:CQ!H
M*V-UG5<@0H& ,U5EA7HDD ]LM@+=;V'(0!,'?8*'__JG5]__#')7,*^AD2G:
MZ5194E=A4'["ENF]J@)*1>8FQ&B>I%_G\RAI;W87X3#Q,>F"V 5C7'G#<$BV
M2<^F:YP>=.6^QO,"81!DAPC6"#@9G:RJ &YV@^(?_*;'G":?% LF>-02/+RP
M:QDN@A8(ZV*=EPI[B>+K*)OI\ZZ;4#3971/U=BB:?<KRFU3%"YS&,JKN/&<Y
MIO^H8=O;^T448;9"MIRW!(5<Z2O>P:] YJ8FRZ70498#[62+:*%H+6%V>87]
MV0U'FP.L-;( 8C[XC/D55JZL<2VHYP0M&W.0ZEEL-PN"-'X(G>Z<.AW*IL@.
MG4;0W Q67E6)D+]H!/[F.)0(>W&65_A<644LC.*OL%IJD<.G-M.>DE*P2BHT
M7@/=R>F*8)11F6?1-(4/J[S.B!)I&X2@8 ?PA;UD7X1:[$UX*_P0X@SH(TO$
MB_Q:%:1S3)'QX,C#8 8+/&-%9@G$5%%W>;&(LN2?Q+#D&.TEV(LJ<$1INH'E
MOH:S@8WAKT#3T0(_Z"?H6^99\B@N:8G[#-,"]0Q6I^*)R-8#@UP+CPR#M=B1
MELD:)\%D@5RAVOSU3]_^^#.L/^YXH"*X3691"0PDSZ K.;; <G$#B2Z(K'B+
MA)QPPV-5SHID2I:P8)9&->XD+B3TAE/%TPUB3!+7-%LD!2"=X&:9I]!7G!/M
M[@WVS7DA7>(Z3V%;35>*Y@''?LTJ" S#;G["*@JMG-#;_%X+P5UZ1,]SIQX:
MW35/ :J_1/1$)'NO][GIFP0XT762I[PY&Z:K4EKSS\=3$?JF?1+Z7ASA0KR!
M/9%[H6PO?$B$VFO)QKV=>B#@!"L%C31/5^M X7F&U;Y9)C,^2R6<'A9D[;/Y
MC3Z/=/B D95X-VE&#[R;^&!^@Q=*'J@41"C@'*OH-Y2)#2^::ODUMO*K[L)E
MU/$&+R'@P17;G9#]XUNJLK:-D 85!].-;ZWBIIE]5<LBKQ=+8)/$JU9P'X$L
M[DO9R 9@R';^6NA ]L=L%*];1Q@76XK+Q;1L[UP;O295,YL^T"E= 9H<+=$R
M6?#=BIO!#_@;C/>5?$)C9I&G*8D;^@/3!SS(L@Y(-2MH3'[EZ\-T_418^\M'
M8\_!@Z:R,C(VG=>@2LWAL'VUZCQ%JXYUI[+I_^A[-OV'._6GL$.<FX+L&Y11
M&A7:\9%D& @#WY(^_^=7AR]"F"#R]3^_^I;_7J,6FV7U"N7+#4G\_M7!8OJB
MAF;A3Q#5T]2([]$,"#@&/56U_"-F5 LT!("4#ZTCZX%K N5ANA124OFCSZ*)
M,6>+UNLTF=% L$T0LG'-M )?3W_#.Q1F4*CK!':%E,X8R8Q=*RW#A<Q&;$36
MQ&2.&#HP4.$B8;U0P';[;RTR8^[!147Z4: 2VCW6O^ S"@=Q HJ5HD7> Y5I
ME<?)/$%G2W.3PJ#W*_X:C]&$#E<?UORI\.,>*EPCX&LQNW'OS(.M^8:$II2M
M-U;C9Z,6/.$;B"SKYBL>9>A%$:W8&,ZR-_N@5<NX1/8H8:X@YRG8WF2*!@F'
M1Y(-@'X@,R4Q2]\,(28+YNC"__#\SM(Z)I$1C2MHWT@38#@TK5",6&F:W\ C
M?_W3MS_\O)4:W4#'M3BJ?BI4&N&J;0U]%.)]85^)IF6>UE7[E:WQC>Z_RT*W
MO ;5Y& *E^*G@V@.:M-/47H3;<IO[A6A>4N?]XA3Q*/7Y^.9].=XOGKVW8^X
M$"L5@WB0PM&$Q<'_LDT*I(EDSD9$N';$+H\"2UV@?$+>_J1T#HQQ_<,Y$<U_
MRTEC*R.T?!^>^[BVN4?[?/B,5\+E6\@-KZ,9LRP2'+8(G^L\1<]*FU>6'9(A
M2BTD?-_K,MVRL;W8Q?YLX^$/SUZ\Q*7PKQLQ=*O/"?L+)IO5E XOA8B6-<C^
M=!>!OF#OUC&(D'Q%!1=IE)&5&L5+O+JNHU2[9]"=#&I%B?92>HSM& %P\V15
MK\B>$E0W.:H\&/P=[!W]!;V=%5RR2&!*=_A49*M9;ZCA;A$,[H%E>:I0R6I:
M%R!Y6VK K>+?C$<LKZN#?'ZPSF>?5 7[B+J=0@5U5A<%V[I<%Z80X2RGEH$L
MQ"&,0[NK?[332<@"&_L)X>&RZ@H<-#*?X56&#W7P*'H;>]<271%=JS3DV.TJ
M2C+JV&K/UBDKJ]"2!YO#\"3 9G<V&(0N5DF+,1XL"N#0/3WK,$EPF@V)PAOM
M1S6;:F(A6X.V+BEV#D]5<Q9&_#2R.K",HDY52?(H>46RO-&7.-6D%Z&QB)=^
MQ]@[&Q&109KR7-95])G(<J.B@F4'LGR3*]#X;LU4M>!.*[%UF40/(:\%LKPX
M*JA]ZSR7>3![O5?;MP\>W;W;WM8;M(IBQ9H"J#MX-*(L.%$SM9K"IY>'^D;V
M1V^WL?T;#,MZ'_1"WT3.N:9));'V+ESS&M].<W!H<: .2:4)'(+8>(+4YQD,
M?R',QL8BL);V5.Z'N$_W0TOWUB?=,;R$S>"CJ;(D3@=UIBCL)2.3)G"$:9[5
M) R6R6>0(\W-_]V+O^QKBO0Z,-PZFE78@#VP="LAO^,VIPJI5KO>K,.M:6=D
M,]T=3&0AV6]C':X<S9:)NC8L1ZXHDG87>926%#4Q39-R">_P;$&IN640&+=@
MS*O/@F! 043.2FD3L'.]Z9#HET O9M7QV"%_=<XZ6Z]?'OXA-/7]L\-O[T15
M+1-#E:]_.GCY[ =\_5JA+!JE<AYQO=FX5SYHSD*3"Z82 H8?A$L6#BODG8*=
M@9^ \)X*-U)]XD;LF>FP[CG<IF'=PZW9DOIV].+PV^!\E24@Z. W:".$5E&9
M(<-XM,)XV$Z[>/]=$4.X.8&UXF3Z8!@G_KD[(8?,G$FF \Y(9E"INHY0DKY!
MSAD9D;[.R$F% G$R1]X!3);"U6(G2*J5X?-LUT7%,@4Q7<5KMR@B%+XUTP5M
MQZ[I,R 8F %VS!I2!:=:8?_NRZ:7/W_'?CU/[ >>7^2@*9L;CZZ'/1J'CM#^
MIXHI#L#SA+%KAVX]O'THX'K'E4<7FBJ!NRC5ON">3&K(WKP_K.J5F%D&J995
M["4..^_GN#&!&6;F4HB-]HT]MVO#&0Q[.)J[*M<"Q6842A*\DDI,FK.AA.SP
M8[-=27HQ*0GH0C")5B]^'&BR'*%.BXV.0?#):NPT5KM_Q"/,YQ<=U-*/488I
M*&N-U <+X(R4AEG9%=F;84P,.>'QE/6:W;H+UP=^&P:>BI1&-Z*)4N0;:V 4
M0J]5Q"[+B2O8NQ'DKD4(TQ*JZ)-).K'QT#.[[U&<KZOV$WB_\D D8T0W.@6N
M#/3$Q)DI-!]B] 3&ZJ'G0#FYH!CZG2:^N;F3*!WWF4?F<';>Y3?P8.&;NN)<
ML3XJ::@Z](^NED(!_9:BQ<+=1,S>Q#*;];6T'''\L;X/,**Y,7!W3,U,6,,;
MC,%++JQ\BL:FIH4LO\G08(#)"LG,&*L6>!W $M(VK#"%HRCOP?Q?K.^&6O)P
MKL5NZ!0&%'F@.^G@Z.!QN#_[>ZV_>C01@DXJ\]>8P*<7$WC'K4?1S')N/WFR
M!Q ,[90OM,GS!:/CU16#*'38WDF+X&G2K?(VAP;&=*63RARK.:L@*LUO]OG&
M SVFKMPG,48@@I?A5]"ZHW4TH\C^SM?)1(\RQE39X37#Z .Y=TE'QVOQ&).%
M;AD0/?-4SDH/X[5Z+:X[U-@#:5V.'R83&/)$\KXI4.VG#(!2#,[.F=P5W_7H
M(U_Z0\\ZP,G=&/49Q?]RYP:%E%$$/"L!121.@'.9E#]75M?RKD[/#SL2]RG$
MNHJJNFRYK2E^RCBJ(S?"QH=_X5@,,Z!"Q?5L>PHBC"&OBQGG\MOVQ0G2:IP\
MDD^7&'M$C3H,JW,KDZX[V_&C!=;$R=X*-EIJ_QLH(>Q:?L([V9^M-*%8V[82
M3UJJKA79A\7'#>?Q.DI2R0!GLSC'2CI\1R(&EA$'$'B- J?*Q- @<5C"2 YN
M,$G0/NOD>]C@3+0> "<#6D)[>U+5)(PI*^TR6$EGI.;3):KK/M&4O:R0A&X4
M9KNOH)%ER9%VQQQ!D6""#><5NF(RNV#VO;O+9"MULI<99JG.ZVRF@WW:D!5$
M9O <_T0&.-/XS SG#DWGDGR$UW"S17>4,R>/*#01Q6&P=.U\)J A]RSG<]!&
M4I-/#*.$*SXO!&^D/49, RXILJ4U<9N.7, (D?U*:-N"D7T:L;!^ N\.=!T6
M%M$R.56_WSX][3/:GR-J]",$#TGSF;$9>+30)9.MBV2%5.2@'YKWT5=D/W%0
M0E)R"CE=!-^^"&!B2N*M[]>X2'TQ2I'L@&0Q(2^>+KWT2DY@GNX<=3058\A3
MBVHL[F4+DN+^HEU[?QX(>QJ3G0@[)ID'>Y_W'?,:<$',7?2]1QBAB) 0<"O(
M/?CC"Z#>#0A/\TI<^0E[[SGD'7498M<SBF"D3W,'E:94;L0"GR[L&9[3(#4:
M-D?[MF)5@9S&@4%1F7#F6$=N,#JZYNPY<FUI-*Q2_*A1Y6'2P'#CDN/JT!I'
M+;OO:N>KP9B017CI+0(%Y:TK$R[,\PEU--P<1D^=S.I"25QVIB_, J:7)GCS
M(=Z.Z,"R()YWN^4MU*/'VTLW3MW;UBEH=.-N,L?\I1N9,#&KG) [#K]M[JL"
MT31A6 _:38KI340@QC3 V,SXY8L#>)G'()"O=F8;\UAC?@W'^Q.Q'_8O)Z'7
MYD-KMNZ#]1#D][HTPKMK3&SR#@QFTC$H$KHJL;6.8=SSX1,&22R2]'0C/U+H
MZW)38N05191P;E!BEH5%; 1?RXC-;K-M,0:92*7E-ML8AL0&DF (K#%R72V1
M#"2!Z9:$Y--V#Q!@CBOV$%B=EU("W 4TWASY4QPL:E"K$\Q52N@: ,TA*CEO
MP2:W4) .#H+7V\1?A9(!YT!U@D[!:;R95=]AW9>*D140?A-_<YPAV)_<1C',
M?H*,R,,3:F@!Q32I"K'PU)D=IHNO",^!DB>X;]/$0V&FH$E)\*CRI\+5>AA)
MWVNV1BZQ'G(T1EE".MTFH3FQVACR4Y5?W2/_9O=(IW;B,%QOMSHC@;=H+#8A
M'"XSXLA  LS;.L&//5!.+=<)*.>>:,;9=CWH:_B2&[[T\I&$+]WE]#Z0\@IB
M [$D7?3B\TP!,;]BS65?9Q!*'HFK$C7/DY^.0M888^NQ)T&2K3R-V*B;#5U&
MJSB-GIZV*;!'+B#CS>MRP#IP[S=Y\8F0+[$DU&>,W%:8)V#=/%WO&QY8"W)U
M.LN7>=KE!+*)OF[ZLFLY)T6":*71FHF2G5'(S9<9M.&G*F)%85U/TV2&Z0F+
M(F*K#/P-JU&S"QODEBQ?P1/+J%CM:T1,FZ*19/.TUO)!DJ9J@=I'42^>N(&[
MEY[--ED*]7@;@[>R$D<)ITQ+] M0_3H%(MBWKA04%^H94YOFA/\^>GOB)-0?
M)XFQ><O5!WLZ3V#C$U1QXQKM"XLB!X:5J05A^\],=/V\3H-54FI":0$U? '!
M/.UM[\^N&R5YMBSR#"'OIV@_4BHIT4Q%@HXQ9<2H(U#D TG]VEB"^H&37859
MG%60PF4(NX_F%VQQ1D A)--K0+@DUK#-\] %JL+LN32ENU'@&+"5&Z4^B6KQ
MQ&FC5Y<*LX3VI6+$5W1:U(7'"@HUKTOXB?)>#-M/-SNJC=QFI?PCU=(O5A;T
MU/\X)4%Z>.H$WR.*_W:K=J!W&TD T\@V&AQ\TX@JL7$J6^\Z><1L.R9D$OX"
MO01D/E- =@PDOZK315?\O;1.=&+:WLBQ*3)&P_"#U!PL2^UX("Q+<35@<UM'
MPN88UHV XCXI^I S8GJ=(>/F1[Z>UJ<?J-&G$WO45'Q( M'Y^S'E]<\8%F_&
M%4UA-:N:D;R"N4IS1RQEYQ _#BI(67(()Q:P$8J95R2L+',X(BRLS(NH1IR$
M""'![R'L6LZ1%%I<QN'/8+OSE>+*%X0#F"BW#(:Q')CSMDS6Y5/Q'_4/^V30
M[RSX5G!I'YQ)MZH,E.RVPY<4-J\/OX25 6B 2]%/XF8<OFN&\,OK%$YF6N;!
M/VH@]_F&RU7)?MHX6%WN@][3<V #UR5>2L^"L5H\@_<.O_O^Y\-GV-/!R[UD
M?^_;_:].KW^ST^M*UYI&<"B20>8D.KC%V<( ^.<"HXZ!$ ME0>Q(7LG*/$UT
M?(4;N/^EK;0L'AJA"M&KN#P-AK#!]TH"NSBU8(8*%!=. OEHA=$6((X0(+,$
M6PE\PY?.;8YXH*;@GENVJ1D'3='26)7.J=EDT .I\)[&JTV5R6%R:C3=9/X,
M;'28LTTTFZH BF"@BM -ECW\BQ[5[C'#,M<IW=Y^S:I_;09/7FCKD<AF7#!T
ME TBD^@W(/S,/B'FCN2T1*QN*=A %YI2T,W)X6OJ\'FB%S46<=(.GW)X7ON*
MV9^2LHCEVBB<R@116:JJ?58LPZ (<$?W<BV87R&>_C"(IR\!!7A@% !?.?%8
MDP4 <,UB3DY )[ZRDWT?6FC6P@;,<;D*BN!F7KQ(#%LTI:"3?1.AS%=.0[-M
MWFMLC+4KW $T8  $L*.L)LA;9+2VCZ]A('<* WGU2,) >A/TT:!="W*H\SK1
M(4'.#7%5&\5A;[I_)U)WZ?RIZ-N+_G!W=D7=O1X@L;7'" #TN 3'_A"(5@%'
M+)&U877@BG0 :Z@0.H'$=661-G%U[@*8T[9<TP7;J'6EL;?=^]Q%!- U9ZW]
M>>ZQ&AL^+J'F;N-6!"T%IYM@!4(O 1=';;+7&4K7EXV;]LB0#.EK0K,0Y!_7
MQ.(DIJ?1S1.F]1X1NU:2[DCL#>^0062Z&\D^65(- J^&G8;P)4-?>VFB&N@V
MJ@3<&-9PKA(6M$E<+_6LZNQ:E0[PL*DSW:ICWW %6&7Q*1^B_IPB$Q;W9:?(
MPRTC2G6WN)$$&G*V4:,ZBQ-LK_-6"6K;"I^+_;WK?09+N[6,HBGK@"#>UXKJ
MN?G'R3>F=\/Y3LRK%]%&H]=*L9C!/GG,N-:#0K,YS81!+?8.C_8=9(OVI8HK
M<,#I(I6&O?&*2FA YFV5=*<*:#]STHBU?NJ[;5TU_T37E/Q7*O#29A*;PJJL
MIOR=E'UYO:_1;R/7V 2+,D<3K.%?G3O\$M4+;+YC$7VOQAIG53+2K VO=7++
M'71V4R8SI6KHE9B[5D@.I2_R$)Z4&Z)%9FCVB^)'/=O.6G][Q_N";.X6Q?":
MUSNE)^5D!G/J+QG3+%^F0@Y[_M3Q^EAC'>.\+M$ 'B7Q?LA!8KBU05JOUG"T
M5GJF7!H (Z3I3A'88B$I:8"PBQL[>=+6]"@7#P._>6,I^!%^KHJ$\AK)'BE@
M^$N5-M@\HW_Y401W830T]*3TN 5,Z8 +G^#M0L>WLB4/D$<>O*:?QY.!Q9P&
ML@>:**A5_9ZLN?^*GJM^B,,H,MB G3$1=YB-J0H9[ WOMKYN#1=>8 PA::PR
M]=Q8Z2\:'Z\V6MZFBI'CL/P)G5(8GZPOEQ!AITJI?8#N!@SY@8O)57FGU7>>
M_[<L_9OVTM^^UH( ST?6J5%%A=?A7W<OU!?N!6,G\!8P?D1S'Y"=V-4*_9WW
MJY"YM2%X"AK?>UZCT":"F5= R)HA>7=Y,.P=GBHI'M-JUS3A+N *KOJZ()*R
MDK&PN=;,0?I\@U%4=;'.2V6S[=R[WUS*Q& [P"D[;N,ON'=7Z#/#2!*SFQ:
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MVD/1(@Z0U_=HJ;>I$*:N+Q:2]D+EVF_QM6#]BW0_?R;@<[D\^8DL=_<&J";
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MKH)*U<&T*.&E%)\"CFNN /R>7ES"'(L$F";08XY",33(//?PL(/I]O/4PWK
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MJE$O!$D&-EV!+C<SY*")A#ZY+TU7T-@$[7RJJJC+,*@^80_T7ET#&2+#PO'
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M2S5[%F!B]M<_'3[#G@Y>[J7[>]_N?_46_8N]1=>ZFBZF1R(99$JB@UNJ*@R
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MLXX(.M81(Z4C1WY;@)B6YGK&H8,OH\@G!NG#-]H<2OYZNATTSMW*<2YXSB(
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MY,[>4ATM[?76V6AS"!6GB/=4+5A3SAEO,ILB1HS\_XV>0[_:!:41E%(HG$4
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MX+9E!\BSD !.2.;E33SF^4BRM^"-SV4*B:C+&]'A@7SIIT:'(ER%2T7-3AX
M1_H9D<L*#@,NR):]%TK6%DJP$/EY&YV0H*+J.Y&O:D36<-)I-SO[@K#JWH;:
M.9WUZ5CPX.6>$)8'_.4N6%Y("X.1)E]N[L=0G2IAS$N[_Q0J24,)/%0KA2*G
M2P,%()F)LIZZ("5SKX>ZSB7IK1*GD2GW *NJW!(D]8I4:5"! &&+U:D2_J1I
MRZ%50G&CR $5:K&G\IPTE9;JH]^/UA=33W0XRL(@G#']I *-F8K+E!,_PRUO
MQ++.8D:HVJO-!KX-)0F"0C%?BKLI<Q-C*V>&[PYRPSTAMS>I;"!O?SK:&X
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MR@/>YZ]]AA^<^)^^G/T74$L#!!0    ( !"*HU306T0>"@4  /47   5
M83(P,C)Q,65X:&EB:70S,C$N:'1M[5AM;]LV$/Z^7W%UL#8%K%<[B2.[!ES;
M05.D<1:KZ_IIH"7*XBJ)*DG'T7[]CI3MO#9K@+;NA@2!8/O(XW/W'!^>V'LV
MF@S#CV=C2%6>P=G[UR?'0VA8CO.A-72<43B"-^&[$VC;K@>A((5DBO&"9(XS
M/FU (U6J#!QGN5S:RY;-Q=P)SQWMJNUDG$MJQRIN]'OZ%WQ2$O=_Z3VS+!CQ
M:)'30D$D*%$TAH5DQ1P^Q%1^ LM:C1KRLA)LGBKP7=^'#UQ\8A>DMBNF,MI?
M^^DY]?>>8Q;IS7A<]7LQNP 6OVHPO]WQ?7)($J]#VMY>/&MWO)GOQ^W]EN?2
M&?G30Y .#J_G2%5E]%4C9X654KU^T/;M@[U2=9<L5FG@N>ZO#3.TWTMXH7 ]
M@?/KC[6;.\X4O506R=B\"$Q(C7KJVASQC(M@QS5_76VQ$I*SK I>A"RG$D[I
M$LYY3HH738DT6)(*EM0#)?N;!H>(SGQ;UH@/T$W&"KJ.P/,UYO%ERF9,0<NW
MO9N [X<:86ZIV [6X?@\/#XZ'@["X\DIEN;Y]/W@-(1P C\[<J\#[^VI/;1A
M.AX:]%YKSVW^]+@'4QB,)F?A>/2?2O<ZR8?N/DR.('PSANG@_/7@=#RU)G^<
MC#_"8!AJB^^Z_J.#N6=SWS_KKX54+*FZYB=6Q.@D\#KE=]_I[7N3<EQ Q(N"
M1EJO8<E4"BJE\'E!!,:652!HR84"GL!T(>945'"&IH(*V83C(K)A5X]_OH/*
MZ7:'/"])49EO7O<EH,LC+G+P7.LW2+@PODL$RF.@&'H,[XB(TN<[WK[;;7E-
M(^!-(!(2EJ%U@V=*HX7 ,P7C)D4,X\LH)<6<HO3G.9-28\=_/3+&<P)2*B@B
MO@[MW,2Q1M8$2J)41Z6'+!"*D$@.+AE1@?3@0DTH%T(N"%*B.%S;JQ2#KC<J
MXB0Q+_7!='WL=)5-76BK%:9$S$A!I36YS&@%@\AD5!=:$^T$<>UUNM^@>AZN
MPI+$,9Z?5D83%;3VL4#^Q;.UO<+<]5[697'W&6)":SHA6618HQ&67:9K8U,O
M@GY>,$'UF2]-[=:42"1NEV!="O#V=N.7&WJNRFM36BN.O,-6&]DY[)K"^SZI
M_1^QYC_(&BM0!')B=@?*CB),;SE6[]PUI81IW2D%E9J]IC:3+ .<AI!(AMS*
M$NF433,K804I(OT[.HQ-VVF8PE&+K":?H^*0FOX5WRN=NB5)<KTH8E):0EAA
M;Y]QK^.::8K,,KH>,>,")<M"5C-22AJL/W1C)LN,5 $K##EF4C<G8HY-ZHPK
MQ?- -Z@76N4BDJW@&IBU>=6[MMRVO;=:&)&J>+WRJK6U:YNCXKM&O^Z"OV1^
M<.[#C@\.OMZS8W"+]8A5F;;\.B84>IY)+()7C5;C5MX#O[P$[R:AFHH[6>/E
M#]]EYI7B=77SO%CEXEM%M'EA^:%AU=AB&O%ZLP;F5-:C&OWG.^V#KC1/@+<V
MC 6+8'R!2]W90ULA9#N0C,. *>0N^@J0PY31!,\W/.L4NZ P21*&W<ZM%]+-
MUG&,=MSWOGM#33KW"M]V3I\1'A%F9P#VE=6JJZR;RJ_4\2>Q?1+;)[&])K8C
M<L%B"&T8<>R(5/5SZ.W64#U2<J_$]G>46CC#]I+I7M!TJ+4>'VWZUR<]?FPX
MW^K.Y<?XN75'7/+ZDCP0-".Z1N[<&E^=/R85[M44,I,\6Z@O3WG$+=6-9WTA
M;J[F^_\ 4$L#!!0    ( !"*HU1/\%;Y7*X! '?Q$@ 1    <V=R>2TR,#(R
M,#,S,2YH=&WLO6E7&\FR+OS]_@J][/.>W;V6"^<\N'MS%P;LIH\E;)#M([YX
MY0B%-= E"2-^_8TL2=@,ML$6:'#U7AM+JJRLK(R()X;,C/CS_YYWVK6S4/3S
M7O<_:W@=K=7^[\:?_U^6_>_S_5>U[9X;=D)W4-LJ@AD$7_N4#XYK[WWH?ZS%
MHM>IO>\5'_,SDV7E/5N]TU&1'QT/:@01<NUB\<PR;VP0,5/*VXQ%1S(KA,TP
MU0X;$K&1Y,G1LZ"(H8RJ+!JN,T9IR)00)@N">>:YE(C8)_Z9\H0%[[@V5+$0
MD9),$4)]($Q:861Z[/$ W@[>L-M_EI\/_K-V/!B</GOZ]-.G3^OGMFBO]XJC
MIWFWG7=#>MVG@\)T^[%7=,P IN,IO 3*$,DP69MTXD-^V4G903^X]:/>V5.X
MD)KC?]BT:=[O,8+E[<\D"-&GDQ;3&\[[^97&G^BT*7[ZO_57!^XX=$R6=_L#
MTW7A\B[H,O_60ZZUS\^_UAC3+Z9BVKQ??)ZU:/JV; L_EB^;(9Q1?-GTJ!A=
MZ;L_+(Y",3HUQ: +#+;N>IUT&T'T\TW#?G9DS.G-9TPNW/(<(&0&TW[U41,R
M?(N6F&=(?=%/>G5_C9R3:1-/QQ<OFT*O'V\C#M9:/RVO3II^O5%BQ6E_-[J[
M2K-TV9K^F&;/VJ9[])^UT,W>'JP!1P?C-_[LA(&II?NS\,\P/_O/VE:O.P Y
MS9JC4[C-C;_]9VT0S@=/RR<_W?@__^?__#G(!^VPD2B532GQY]/QCW\^'7=M
M>WZT\:?/SVK]P:@=_K/F\_YIVXR>=7O=  /(SY^EAJ$8?\R]#]WR(UQO %@4
MN1L__WRP'^)_UG*.!99$:>,495Y8HSBA#"&)HY56Z0_;Y5 P$/DS=W1-)STZ
MY,]VNC"^T1:\3F':NUT?SO\GC-9JN8>N/7TWLMN]LU=D_ZQ%ZT-_LG-V^%*?
M[)T<?ZR?[+</7];QWON=B[UM^'RRR1H7;UC]9/?B\.7;46/;YXW.#GU%&^W6
M18\=;N^BP_?[)XUF^[A^<02?6Y_VMAW:V]X=U<E^NW[RAK9.#H\;6*%7Y'#4
M>N_$X?9AOO?RS05<8W#?Q\9V?738>?&Q_O+-I_H%/./B>;[7W,_K[W?._,L7
MN7WY5NQM'\,S#C_6R0YKG6SBQLO]D];%<5[?;D#;%\>'G48'QHQ:G=;DGG?P
M+-X];/;8'KQ/H_/FHM5,[=^BPY>-D[V7NY_J9)?7W[_HM$B+M^!YAVT88W-G
M4#] YZ^:=;[7K),/P7"&F.,9#]1EC'.:&4-<IN"3EY3RB,3:!@*X$50I2O]\
M>H6H#TGCK6%1 (%?Y'UGVJU@BIVNWP9]LU8;"S \X7SPS,,O60<>>YQY4['
M=UD WV !@H25*)B,!"\S9C#+#([P%5NG@0.8)WQM Y.G"18>C?I3(^,S^5_
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MHIMWC_I+0A\2342@N#D)B/EHC,/:!,4]BL)'K%:&/BE" B]>]-K@T![MPA2
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M((S!'^-#5 *KF%(.@-)? I2LF&M1D<L2KG#*BBHQ951@8R*.U!GJJ$^Y2)8
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M(,!<>D&8QXK%M$5"VFB8-<KR0-%*V+*?4VT7H![WXF[7YV>Y'YIV>[3;28G
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MUZ$X.#9%>#ZZO8.K++'3.6WW1@$XI^<^[IVFKE81;A @C'0T1(80(]18X5%
M3LK(K,**+!'<K"A;S 4ML'2&>>R"89QIIE1$-#+L 2N")6*9O))'88M]4!Y%
M[D"5E8RQBDA!M=>@*[15EC,P3HPV@AC@ <L8X6B9G)D59(FYH 3302+O/#/
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M?S#NHO]EM=EA<90[4'Z3,DP'H3C+W<_OWDA)K[=ZW7ZOG?O2.-V%H5RS._>
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M;.X<7.6>!1SMP<[6V_W=YN[.06VSL5W;^=^MOS9!M&M;>_7Z[L'![EYCCJ^
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MUAG34G*;JH5JNK8!LYIQO4@VYQV1ZO.RW7__2Q$L_^C7!J$=3A/1)POK3VJ
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M*:EQJFWG3>'[M71,+_=?VYE-?S._WQJ^J=7N&P>MPH_W##_VCT.[/66FVF_
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MC)+X3(-^YPXIYBSB"GN0'R(BK1*($APPR^<TR NYB)+X)1^IMB!>E 0I('X
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MNP?_;&\V]W8;.Z_AJ>VW[S?_@M=M_;.9KVMG>[/QV]\[N[O_KL'U51_XLC6
M+_,WN.+?/HSI_44C=-MMV^LW6IT&?'4[]UF<_XINP:##@V3G9%X=Q_-Y+,?]
M^'+\RQ^AU3]NV].7K4YU%=6;_KBZ',\(Z57?-WSZ@J56\9"I1A':T3>/GEZM
MGIIP0X;/*9#+A%S[-%Z][7."\UN]\V>#)625X^N?KN%@;S:@7\36Y\A0^.5+
MS=1+9P1FAK?QPT1F?LEBE<'W*J6\/53*FU>5\A4W^P&G\E(8;8ZCU/6>YQR0
MODD*QTTN^+E-')EU(TZX >8GA]\?\=Y\[*]\!DEU=VPY5X[M/9EC>Z5'WI58
MX,[N.!9X>-C<V!>?-OXYVC[;_+&S!Z_YN"FVOVR+3WOOZ/[1I];.QVVVLW$@
M+C8(-OG^WKOOG_8^D$][!S^VS][#./YI[1^]8SL?]TESX_#+]M$V^?1EDTQM
M$.SE[_NSW=S[I[VSL7G6?+-%/WW\;^O3AA>?OGS .V^V3_?/8"Q[_Z3M4WQ:
M;0[LXK.=O:]GS8,';)%7OUW PC9/DFV>0]N^)6$;/,$V#]>U;XD/ S\"NG8&
MA[&7ST<<]^)A[/3S1L]0Y;UH=&*U&32P/UZ6VD$/53N(KM*:GY/8@'=]JW9_
M&AFAWUJ#TU+[?YDT=(7Y5Y<A?U$C\97M'[YN=[__%<-!?&-;G:IP8MYU>A]]
MV_;[K00SF(>\W@E[]D=9%^=8%YN[4RH\8JJ8-PX%;S"H<.&1LQ0LR;@A5&J/
M7<[2D;5:%PO":ZY;"\(?#^&3RI=9K2@P.$J@<P'AR2"#&47PE_51$Y686EF3
MJW6JQ;70DY_U5S2O9LC?QSX'^L0:O#VFWIE!A,TXV$E ;O!7^R1/Y=MNKZ*\
M96IRNQ2$V)J2/,9I:8R5*#G)$3?1(6N]0H$&Q8P*22@@1&-F]*E^VH7Q"ST\
MBE@J]/"H]#"EEY('-R@DI'(I%1X31T9X@S"0! ;AQ'&T*VM$+4_?C&>P.3QL
M&3E+1TU5)@>#H4NP@9<-<5,:2"ZVOM0CJJI"DXNFR>GM6Z#$1+DS2!IK$;<A
M(AW!K1312F)EY)2'E36&9ZBH1RFL6@"]8$ _I XJ@%X\H"=U#^911"XT,LXD
M #3X1D[[' GV\ RFPF:WB)$9D>!EKI2\S#&BZWI&[I[T#F+OM)&[J79BK_^B
M 7!:O8^(T@VU[<71N,E>.J79VJ+FI]8+2TV%8EDSYE@S=EY-[QXZL$ T%JE(
M)>)@#62=<> P1RF3]-1JL[(FS2I>K*^\ +S4O(QR(<Y"G/5I8UDH=&$4.BF[
MJ4I>R)@0=M( A4J"M @,"9H<T=%9Q\"/)OQ.?G1MV//GU57J>@*_5$BHMWUN
M6"&!+:)" J6E0D*ID% J),Q;(6%W;^?5__?7SM\;<%W_K['Y[L/6WGX-+FRQ
MI1%>C$O\PV.#P^X)?'<H]1*N/,?)*I%TX<4"Q"J^ERH,BMRN7,+3&:LRM[/6
MPX]5K]);WEEE7G\^KX:P)1EKGE<U3\V0"1%-]%T*#-2N.,@OA==X;R&WI]G-
MS=IOL$MPDX-,O>[WR7W2I9J2=1AK5J'@GU6+\5O;"@A6]5?V.(N%G\W23R[]
M2<^8]R=')^W*N1V>ZKNZ9;4UVK+*Z?Y3D8LR?VOOX\#"@Z&Q$5/+MP9EBJ9+
M@'0[Z-6EU*WQUG__?_^E*:%_-(98S2]['T.,1UG?EGF<+@;5G:2P:Q9#L9AJ
M.\M0I>AF,S>L(5X*/-UF?3CJGG1^RFH_N['NM1K44I1X*E]9OO*Y5@C[Y0;,
MJ(%BVW9\SO@&#>5C;OXP+@2.K^6=)<OCO-E,S->'0XH@M<!"V2@Y\<PI+GV2
M3*D0.,/I\U:>04)_U7YCZ$967N1R]MHXW3XOJ[_^O?GF]=?MC]NB^64;/OO=
M]T]'KUN?-K[2[:--_FGOX'3_R^;W_:/-[^=[R%\V?^R?O?[2_+B)FQM;9[D$
M?]X'WMG8/]NFN33_A[-]NLWWC_[[=7(/>7OO]1?X+K*_]PYO?VD>PG>W]X^V
M.'SWV:=<FG^O^67_[+"U?_0^%[?Y,5G<1BL6":<HND01%_";,Y2A) 284A@G
M15I9$_@%ET^PI<Z=X5LW'EO*8EIW)*;I;)9;LM)4^E_%1X?=-JR7_<W_.VD-
M3I?Y5-VR4-39Y*%;SA7#CB*EDT=<!X6,SG]BE4N,$&J$JKJ4%WXJ_+04_ 3W
M,.8\<F6HX(XF;9C "J=$+,;6\\)/=>8G,GF<35$>*;,H80;\A)U#)DF/-%81
MK*L%M7IE36*U:@I#%89ZO$N;)R$84\X,I23@0#D/QOD@A(1'A#7@(+OK*>J:
M/.#"58_!56SRU$5BG%(=D*;8(,X<1YIP@53N;.8<<SY*X"HRX]3%,A^]+2SU
M-%E*$F G$:PA"O14T(X8:;B@VB2-B;"%I9:"I<1D4,I(:Y(%EN*)(.ZC0-82
M@F@R$NX]I93!*VN\/@>*"TT].YJ:YW!5L@G+1 2-F(=DK2?&1BT"3C(DHHN[
M5V=R^@'$=*4[M26,,6(%"M0(Q"/&R&"I$68V2,EH G.OK"DI2T2J4-224)3D
M(2IB'+8!W $,?D%P5BI)M92"\9^X>X6BZD!1IU<I2E&LDJ04A1AQWM6+R'I/
MD#5*:"<Y58*LK&E-5TF-*&J195G4JGJTJBPW0V=N2C8JPO*+LKTWJ*FY?'D&
MH[S+V]5RJ%$UAF*E8J5BI6*E8J6G8:5YPH_<ZN254483RAD+6DGF(_,"%%;P
M&M^^:@J(@XNV%[^4T+WS$PM%3]]93S=?3<4C0Q3)$\Z1#R0BSB1%FD6'X%%L
M@B$DA+BR1N^V:U* 7EOO&%O-5%!$>.>YD5(K$;RD24:EO0MJ[GJE!=Z/">^I
MB![3E)%("-+$NURW72%+I4#2<.^83\8;4>'[SMYR 7EM0;[PHL0%Y(\+\HF8
MF&0I8$,P$BQIQ*WCR/ DD6-4<4]DXCSF--(Z87R1[3GK'Q$;!HR1L\.*9T?'
ML=.OZCF5$SC7G\ )B6!G<E:[U%PY;G ,U"?)M3<LLE_2UM11G"J$O]7OG\2P
M<=++C 57T0W#8SG5SS^S@5Y=LD\YA#,/-^U.'\)1*5(LP;5(H#JX5 QI[B4*
MECH>@E2<RY4U<#)K%*Q?T'[BTX;R[4(^Q4KU#?D0&X,%KI4J,FX\UM)2XT!,
M6+A\H?7M0S[7\.X_MGT2?T&[11+>B'8G$_>#8%HFDZOFQMRN2P=D#,:(JZ0=
M%3JP7+&3/K$DLZ>-Y<*XQ4K%2L5*S\=*]2CS7]3+O3N-DP$M)JE0BD1$HP77
MT6F)#/$"1>Z#2\Z#@$DUDB_/*[OK;2^FV.O%T BM;ZT0.^'ZTE]/,O)>LAV*
ME8J5EC) <75E7P]?3OJ#JLG(7O>BMFVN:KO5&=6TW1ASW%9G\X>/_?Y.&M<D
MW;2]#LQVORSW\RSWK:E@A9=<,TX$2I@[Q!,-L-HS@7!RV'%7];A;62-XE94<
ME*4!=J'?8J5BI6*EYV.E1VT37J3,HTB9J<B%B"%@CR.25N?M%N*1 :&*2,1>
M""5U<*Q.6N8YIN$TNBG%',@KR3=U2;Z!*ZR>ZI>*N MCI^F*N#IQPG4"'XOD
MBKA&"V1T(,!5WIC(F$VYW*1^(>D3/-[_3,$]K3WNBNS9)^.OV2"Y!.RB+.;!
M[F2I6*6)P"H%Y+P#[$IND5:)H$B]8UBS1)1?2(YO06YMD;OP &A![CT@=S*\
MJ6@08"R*/ %'@#L%R'6"HT1QKO$6<HOSE37*]6I)@ETR[)8TDF*E8J5BI>=C
MI<>,<1:U<A\Q@LD(IK82^T 4"LE9<#2D0DYKN'-CSB"G,BB7AG)E.H19"FP]
M# J'G63]E4ZRI=)6V1@K5BI6*E9ZRE::0W\Y[%/PENJ8(N?:N!B,U,9*I82T
MS,^MOZI5YTK[\HLB$*]L__!UN_O]KQ@.XAO;ZN0'U],@]MY'W[;]?BO!#%;E
M(3IAS_XH,FT.F;;S:JK;!>:)*,DXBB$HE(.!R&HMD%:@S[ U(IK<[6*5UZCD
M0P%XH>%BI6*E.BZ6"P]6E,7R\1;+Z:PL+:755" ? D/<&HV<X@H9&PEA,4@:
M2-U6R^>5F;7N_^^DU:^R%ANVDX^6]8^[?=MN=%-CF)^4?P/+H$L%Q!JM406Q
M_HM&)PZ>5SI7B9<7*Q4K+6\.1O^@=_JRV>V\FBZ(>(D,^Z  -D9<V-])XU?T
M_XKM\.?I[+?_-6Q2THRELN)<PF&ZC [6E@?,, *3Y[T0II&-VJ%(%54X:.:2
MS4E7==H)*8 OM%RL5*Q4Q\5S8=7&R^)9O\5SJO:X-$81[RQB-'G$A3%(^V21
MM<DQ$XBE^5PWG=%:H"#^J2!^87&U@O@Z(GZR$#E.)N6T(6])KO;K*3(!8 _>
M$N,X8<&8S(BODUY^7IE# (YA=?X,EL:@>WU(;22^\O,7!?P;HP:8)<VH[/84
M*Q4K%2L5*Q4K%2L5*RVF+LS"V[%MMSK=7M6K?"CK-J+O1=N/KWO=HRM:\+J&
MY2/OJ+A&\_0MWUL?; ]W$L ]VA8[>]OT<THJ"885 C,FQ!GGR'&>4-0^*L\H
MXSJ ;X3O5-2V8+N^V%YXBE'!]J-A>_LJMKV6(= 8$741L.V<1S8JF?.+6  3
M>JIHG;"]H-RB.@<Z_K1MV_&Q80>-;=OSAPU&7C0RKNZ2)>2Z/0 ,&E[72P:S
M'[HG.2R2+V?\[*![_#(;IM]MM\+PF>4CMOF*15'!X"['AD8:<FTA[;1(DC/O
M0Y#:A\];-ZL1]:I[=-3M5.<\AW6A=DX&_8'MY,DKE:$61V%C:7(1N4V>1,.)
M02XJAK@( CDF F+.84]2=$F0E35A7FAC%A2\7028'GF;Y]'XHFYL^S^/8?PY
MC%XG!IVA#&]'G[,/R(\B],-2A[_LS5O:\2Z 2R=WP0R68"N'I(T4<:4-LH)@
MI.!&"4"EGGB>L\9D(=)"I(5(%TBDG ?MB%' I8PK*UR* CM)>;(X",<*D=::
M2)L3HI0X(J*V$:7JD&LB%#QJ&Y F-$JLL1(:1*GF;&$)!85*"Y4^82J=<RO"
M@UJAWDO-B8Q:RL!P<(D2IF@PUW/IS_KH%5)]<%*=4*=><1]3-(AQ$Q&GV"'-
M$T/6V[S+)&UR CQ]/D.>SMU<K]!IH=-"I\-S8X1PHJ@'06HX4*J+P6E@5:<"
MY]ZI0J?+0:<[$QK5).("400%; SB5B?D+ V(),DB%@X,;%?6N%A(L]+"IX5/
MGS"?SE/<BAM+O,-&T\A9] 83+SD6S#*3%!?%TZ\UBTYEQSBEA6:>(Q.Y!QH5
MN3@'84A9P91(/,0@5]:4U#-HM+CZA4L+E]Z>2_/FA)7&Z2@YQRPZ0I)FVFBG
M+=;1/S27WF2?OQ#M38EV(E6)2&M!GV+$,->(2^R14<*C%(32(3@O'5Y9(R\(
M%D\BJEJE.OU>W7'P;VA]6_L/_!@/^<CV#EJ=2R/[8_3(:#27ORPW6&RET^%#
MK4Z(G<%+4_'Q<#9<[_>U\YF9_*)+G^-COM/A;=6@SB=O. LP<6U[W(\OQ[_\
MD2LAM>WIRU:G GGUIC^NCCN?.9N8A.K[AD__\;T5!H>9%E;QD!I&F5^C;QX]
MO5H]-6'2X7.<K!))KWT:KY)KG_O9QXI53*Y_Y\\^]>?/*7+]=SZ/L2IS.VL]
M_%CU*KWEG57F]>?S:@A;DK'F>54W^M3GE;>Z$7T\<K&WD-35IYZ"ZC'VF!BM
ME'%<J6AL<)HE"[*&$4;B4,026E)0?RY-M\^V-_[YLDT_T/V]KZ2Y\?X(?A?;
M7UX?[6S ZS]NBGV0G?L?WYU.2=.S[>_-CR!#]SX=[NQ]P,TW^_#[U]/MC_M\
M9^._A_M[[=8V?7WX:>._:?O5>7-2O+WW@3;??:9<8^(=1V [@GA@#KE$!/(Q
ML6"ME$SRE35M7C!6I_(!#^3*/WV7_$FZUK=DI1*FK 5%G5VB*+;][K.5*F"-
M+6)$\US>1"&+!45!:2ZC85XPFA,[%Y4A7_BI\-,]]X(6/AF.M:?1<@%+,)=
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M>&6/<T>@4KUC7I8[F!(R6A.ML0Q(\<!0WH9$+F26HTH:(5-,*LUFN1*L>2I
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MK2]4%QZ0+5!=$%2GJI 8G*A/'''&P:O W"*M)474VX"QU)%Y E"5,VJPE7.
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MWB\^3.I_O/Q^6[\N:>3E@[!' 8WW;&?,K4F0D<ZZ@'$?PTRF3#A#6*3!R8C
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MZ%V$"L*W 9BFC8%8X^QTO-T:)B)F#?*^Q<HGGZ,)QO7XW(,5)B",'8!;R)/
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M (W ZP-5W2N&9["?8/>#^0)VBL:<H++$#;\-$%3H4__]^?7*HQ%8)F"4 'J
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MXO((*Z.?A8J_R;0N!T$]7E>-SQ65K@!G>CKQ:%U7D,ZA:'Q>U6 $K\Z6EY8
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M&-_FYUP$;93)#E^!.(\:Y8U_Q+' G!"'@XYK&VP.E;?*4.L2>);"3UL"SW,
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M?&"&E";3BY.*R=-,-$6C&8_(@WF$.$D*@65+D E2*N:H9;$@%7,(82E]L<M
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MQ/ %Q7"P^"+CQBJF!)<D6>)44D(%CW7 ^A'UIDH,?SX,'S<#,VOWQ 9D>!2
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M)DZY13/;DJQE+LF!.::1<,&\2<0QI927P:A1]:_2Q'D=$V>TXRT]I3!#$L5
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MQFG1G?V3? KBMDWN U(=Q47^:RDPB_YM0M:4"Q.1;A;[A(:#\LV@"RA2"/(
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M(*]1]KG+AQ?A23&_EM.6X#3S_/H;[+<5:+XC ^6#2@_!_@)HZ,DF5YBM.$;
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M^;DJFY8Z4S'-J[DQS98&Y]/@D7EQ]=?/\ZLOOP!*F-W;;R $--UT0EES?:S
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M3.&&J?$63VV'!)N3@JAX@:K:@0$'$VBRP55?9BQT9)MI9JBXCJ(X)O9\?;0
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M,Q5NVM;!^S =9;.$!0HBJ$]DM@-X@]ZP6R/#_GL>B+:@<B]*((-]OFIW3\X
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M)$VKJS3B;4E+_!U] 90X,AS,N5HS/1RGR(S8GCKM%PH9S6[@4:)MBN'!F=R
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M;X@;7E$ETK($/DB]NDO!*RH967VT4J5]M7.7@30?K$BW+)=>H=J8>2?5[A_
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M+9@2VY:I2,!+X?\[^$?D!)K! ]]TF>X8/%0<VW T30^X9MB>Q>QO-MB*E'P
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MCGIPN@REZ,UU"8U&DJ$A%F*.<15Z5;&)R-X-4^7-"TU<O5L!-3>KSP!L<@E
M=2QD'ISC;9K]$!%4BH@?EC^(7*Y 9"L1+Y:W$/TT&Z24Q0,299#B54_I<N1]
MY_Z0[M$4[D3,1"Y\J0*)DPM5,"L"7W@YR1J!8\2),.!9^DIA_([I,43Y%!*
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M6UG'*?UK%(]KD+[$&17VRA)']"^6"!1(9R1>]'3GLRWR0M01WE%?U=]"'98
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M@AOA4:H"CO55=^$H9G'CIGH1.A*)\7'$PS+:!9I'$5"^K!?7^$3;41V^L.R
MILP6'O!]'N/)-O>Z$2JDLE@B1'@"P_81"17^%04=-5DZNN[-=[Y,O=V>NEO5
M8WG3Q2C5;I?I:3N/*2(PC_;3LG3@!.V1;35#=]5FUB9)@WA1!,-@B(F&$YX%
MXB]02"&UF&O07'6I8N;=P(A ^O@]^ #CE,A/5 &G"(R(.B#*8F;J@%7^P H&
M= F<LMCF5$:H=F<>L># C0E7[+EK:H,2%Y_TXL>62) ICJDN#A0U20I%(.YF
M"M]J7.@3@F]L #!(N%I1CY3V^V$AO8M]$[F18C.+$&+A(;DMC)"[& \%_BT'
M@F-Y@YN1//.\UG!B]")+\H[LCS8=<<ET1*--1]SX5-ITQ/5[X81:W$%1CO[Z
MJBS1H"A+1,A+U&XB4'%8I/?5-951A(HOT,<Y+ QL0Q\A!X"";#2H;-.Z,$PA
M^YLBMS2P 6G$B+6"$=Z]PY!<$8U#-[20V>63.$J"OB:JQX"94^0C1GNDNH!9
MA%["$<:69E+:>Q%0_(P.*8IJB;+0<T#,7!U361S76%0Z(:R&9C(Z&7Q>7>"K
MMJ]X6Q,&"C=9/CEGBH1F=/\M27'$XM(?.MFRH,2V0$!<8#RQBS7.K+>H*#D
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M)I:W .@5,\Q\!6J(89CB?,MRG45%$#KZJOX(;2J&*!]!ZGG]ID44WGG,^'
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M^6S?.&AV.LWF/O16_FPTB+<:^R1U=<.HF\X$)F<9I<5P(7[)DB9"#7]C=L!
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M%YZUFO7TL];^T#&7\&?BSZ;=_P-02P,$%     @ $(JC5 \BB"L9$0  NKD
M !$   !S9W)Y+3(P,C(P,S,Q+GAS9.U=ZW/B.!+_OG^%+U]NK^J88'!>4SMS
MQ1 R25T2<L#L[GW:$K9,?&,L1K*3L'_]=<LV&(SE!S#C.ZC:F@VV^J'^M5JM
MAZ5?_O$V=;47RH7#O \G^KOFB48]DUF.-_EP\F5TT[@\^<?'GW[ZY2^-QN^?
M!O?:-3.#*?5\K<LI\:FEO3K^L_:;1<57S>9LJOW&^%?GA30:'R51E\WFW)D\
M^UJKV6JMO^7OQX9%QO3<;EQ>6N.&89NMQOC\?-S0VU>F3EJV3BY:?Y^\IY<M
MTC;:EPV;G%TUC':;-B[/STF#GAN689U=7#1;8\GT3;P7YC.=$@TJYHGW;^+#
MR;/OS]Z?GKZ^OKY[;;]C?'+::C;UT]\?[H>RZ$E4UG6\KRNEW\;<C<NW3_'U
MF @:%Q<3/E\I+@(^H7P^(]SWP*+O3#8]Q5HWVVT])D*6CD*(XPF?>.9"B.7S
MAC^?4;&9!EZ?XFN4TVPT]48+)!'?Y\XX\.D-X]-K:I/ ]3^<!-ZW@+B.[5 +
M,'8IHKA2(/':)U 3_Y%,J9@1DQ:OY<>?- TQ<*8SQGW-2W&PB1A+S07WD4Q'
MI=$\(6KWS"2^=$4L+X! 5C5%=4I=7^"OQI+'NS=AG9P6UR 0C0DALPI:)"E#
M3:(GY;5).*5^=75U^H9>MEF/C?XBRS?PSX;>*B<VR_&*RX9?C9AN%SHL6U@Y
M'6*Z+778V)BR/"*/4OX6!=60C 0UWTW8RZE%'>E9WXP<?TP3X)^-\,]5R<3S
MF"]YX)/HV6SF>#8+'\ CM.+[V)0#:L<1*Q46-_BK_-][PDW.W!SG/IUQ-J/<
M=ZA(AE3)X)E3^\,)!M9&'%+^<,GX'6@2%TD)6/4'?'T*)-2]7]8DID5(@#W
MX-+0-G6N^(S3LA4'$@%A70+]/U]_D[AEZP\D9N#^?U3?HG;9Z@.)XSD5:H_4
M(WBO.=:'DRZ#?/!$PV=?!G>Y?;^4'-+$3&.V2WT^-B'C@O^TQC*#;&B2ZI?3
M];)K7 )!K;[W4?Z][N 1<51$0;CF&87I5DVZD2QZ&-M09=G^XW7O<=B[AC^&
M_?N[Z\ZH=_VI<]]Y[/:&M[W>:%C6[/D,%9CH$I,6 #$$B](8E)BGEF2J15RU
MD.T1M(2-GPB'ZCU3WP&%=X[@*G<UG!@*JL"I_;PBY6^'#N]P!/\^]!Y'P_Y-
M_ZDWZ(SNX.TNH,W@K(:UW6P:Q6!=LM?Z-]I2P!'0I=F[_8>G0>\6RMS]VKM[
MA)^]^_YPY^AFB5%#;32;9U6@7I&FA>*TGU'@L3$G0!F.^MU_WO;OKWN#8>]?
M7^Y&_]XU[!LDJ!$_:S;/JR">%/17+11UA#K1_CK#VYO[_F^[;]@+QFI@SYO-
MBTI-&?AK4L !P=GG$^(Y?THMB&<-@^F4\#FS.Z;) L]WO,D3<QT3!D\EX2S!
M6 %G2V_J>CA\<83I,A!'X4>2N0;<M8B]QFQM*4"+)1SQW&#VO>-:"%\Y[-X6
M7TBCH[\.J=,MCL2(C-T] AVQ5\'<;K;;.X YE'0$>1,*R9+7U">.NS_$-\E2
MP6\T#6-[^-<H?HXD']UA$T3=SJ W['1'^W:%=3EJ-S@SY+S7EFX@96H@].@#
M2FQ^)=S!B'GG^12J[/?@+<Z#[]LG\N2J?>3<D)-I6_I(K(,6*Z'%6AR=1MV@
M">=S^-V9X@LH>T,<_BMQ \KL>^9-1A3W+HS]O0>6DGJHG>K"D%-YVP:>2"<M
M5$H2H5J:U OI4+,&JJ:A;D=74T*,VX"LP 5 !_2%>@$5X_F0\A?'E-SV[6$%
MQ:L=Z]*0$X=;.E:L"I:(E='&<RU21Y/&/3I3:319P,W]]W<%1*N=Z,J0<Y'[
M<J)0E:/_*$$<,->U&7\EW&+V9\:L5\=U]^TY2J%*G]&;AISFW-)G$@I@H5B%
MHZ\4;/"/S.LRSP<^P&\2YYIB0"U*IYA_?K_84U@5M5_IT*?M-A:!8HV$9HN,
M7/K?0KNCRREQOO/ .>B(O.V_.]L@2NTRV(-M[S*A6$W*/4AGZ)C? D=(;@(L
M!N:<,4%* YW)1KG.HK?U]-1,DI4$<<'L"$NU6?4<9LHY=-UHEX'H$*?+L\R;
M?%XM?);AK(Z69Y"[E4!Q[>4Q,"YM'W4INP5TC:D:RW/(ETIA&?>"1QB7%E_\
M@0^I"6\A*;#('AIK$4EJP"\@VRD%^/)O^69-Z$'Z07+VMB2P*Z3J?.923R\C
MK,[.'JC)*^4M&QBH<Y6K=I[Y#S$_29IQJ]Y+P4@9P%I-0\_#Y;![J6S+_J'O
M#*0_]"-,NX/ID7 .ZKQ4G&Q3LE+#I!MZ:EDQ!=."YV$"18DHW]V$1,H>OM72
MTVNZ(>'!F;=:GYXD5?;FK78[R]0'V8O+FG?9=,8\J(5@]@"/VF!V(#I"4!^'
M%_<.&3NNW' RH"X>V>&SD*YBD-J)3'4T,PP]M98=H8P?C<:BY?HB"F\PNQ$(
M+90OQS<)#;1(!<UG"U<YV/"W;0^UF8D:S3-#3RTJ+] \]DE4R'][;S/J"0K.
MVR7B^<9EKW>>S?ATBWVT9;FK83PW]-0Z[P)&^8<629$M$.5H*$A+2#I(D*\I
M=UZDCV-LO*76!'>3F?! QJ>2H.9Q4Z<J%WIZEU""HT0NXJDMF1[!BBU1*;\I
MQE.=^%RVJP!WB$E1CK6W[ '+<E?'U"M#3^UQ*(#JH7>;.2#$^SH&D/8-7\D,
M"R6?=>%1/_#QW"H\YVXOCE!1!Z6[P-A'3^UO*.0NB[WG*%J3^LC"J\]1)RVA
MU-&WTK@F7F\:[NS%EPK*5/N.;K12J[V%?"=9*&.$=?23%&9/'$SRUK-M:L+8
M.%&8>9U^]PXW/L7?A3.[/Z-\FV7&_>JB]BN<?*SD5Z!5 ]320KUP+)\D@[$"
MZA;NV%I\00^%EOH=I-OU"/? E.*)\N$SX;2DIZ3(E<.%=EM/[P>/66C 0Y-,
M#MC\E<8#&4R4 X V]/X%H#C$A'_=G%NM9^8P4\?",Z.5VI2Q :/#7C#K^\^4
M=P..YXTEDHBRNX@SN*CCV;F^X5L%Y*1%K))IS1&3:N<U*'FI@]Q%NP0^AQCK
M,HR[5<@KQE,=^2Z-5OI;Z4S@#CL =METZOB8SV*VCA^D0/] O0IGX*@XJ0/A
ME9[^N";!+9S!3_([XF-6'MX78*AL74;3:*56O95H'62[&M()FF- \9!U,$5)
ME%+DRA9DZ'KZ6Z.(A;;@<<#6KY0[9#!1)@W0\Z1C60J)0TP6UJT9?XL-X2*:
M1<'/,_%CM_$\+(0FBJBJA;J=B%0'0P \M1*6AKNQ_/(<H^-">/QUWWBN+>4O
MZ(]ATYLLIIAQ!?\IX.8SKO$S^RD\OGX.;WK? F>&1./YPK [=9O=Z*#V(\-H
MI294-OE18LY;[FE8J(.SD;%"\O5")?2NI<<=M',%8T&_!5"!W@NF*F7]8IU<
MW2>?Z>DOVI8LM)#' 5N_8N/,X*)N7N=&*S643V'Q_]XF?CE=O6<G_+UR%P_>
MQ!/=QB4QPTM _N@RUR5C%B[QC\A;9\*I+))<0OY$A".&8 MB,2\^9@Q?G&AD
M+'Q.3/_#B4U<O&8$KQS"D<UV;#T'Z?$>$I\'>'D)7F;V'@*=PZR1O%[$"L+%
MF1-- -:^XP?XZS-GP>S#25C<\>GT1 MO(UG<;H9,3%0$7B*GY<U%*=L\R44B
M>N>!4^'%4P]T.L;[2I9U#I4+JYQ5>H]5L=B4.%Z!FL3&[7C6\!GZ&]RK+S?2
M=9GP,T',H2I3L?#=F+AH&7A!QXY?L+KADRGSH/WR>8'*+@_8>&20@J7.!X&\
MC&,MKFGX_QO.ID@SG<G%OCZ/^]V^O3BW(]-&^Q&VA6E!C+4_VPXA=..]'3?$
MC*;8U(TBNWP=FD4>> /X>1,>%915P5(L=E[G\ GHA1+SZWOC>.@D^2T_7;"N
MC3W^V%AR['LY,3JK=!V<<4@]A_$OGJ FY##6(_.IN YHJ]FZR&EC^83UJ)]K
M/Y%Y-%C.J]*FLG6HQ<:#7N>/ 6K8MY=A+K=3S6>07]WP1LQR;<L!N9!];^60
M9U4=\JQ.4*;[IMZ;(W @_4#X5QB)E^W:,LCK4-=.JZE?A+@,0U2Z,D^(E)^K
MJUJ4N@XUA;!QX[Q1"[>>#IVWG)Q]<^$ZU"/^>N:>"D%I)U(_JR)9I7]TQB$S
MB'A!=IX9%->+E0A]WS7]3?I+;K*14;@.SC5ZAN'X@)H41N=2Q]0F<G75BM/7
MH;:? N%XT#"Z;#J&Q!;9@^YLXCE_@N86E'7L<* K)V#EX3;@1IV5O<_P+IC2
MY=I"0<_^+K+_%YJ+=)GB#6:E>!V<*,[0,LX<O?/NO&M(5UTV"Q<&'MD+2Z<(
M,;Z9_K)K,7OJ (IGD1+(&-DJ82:7M@[>$;7>E58;]L5R,7A$W_Q/+C._9N)>
MG,$>J^O'4@K-G2RCOVRPKTP-IH*@#@C*40KX6CSA&>:Y]XQX.4Y:@+ .]>LR
MSCSRXO! =!QK0%V'VKBX:3*/31U3J@V=2<?TP_MM3/\SWIGM(9?/G."2J<3/
MZI@F,.=XT '4>AJNM64N ^Q3:&UG2=<^O\MM&MGEZ^ Y>5.<\D#C>7Z(*\VG
M)I%N#9W<O#^[?!W07$FR\APSHW =ZO$ UN4.<=WY ^,P%L$A*7[TE0-.+ED=
MZA9_R?&)VJ!D[$_1\>0S3DU'*@"]36>*NT?^C/3):'A5V=4VON8FR?M(O&N=
M9<L=\-'5.3GYRL:B=?#Z#4-E-/^$1Z-F>;82KD9AFOQ <0^)_%5F[%V085U7
MNU"]<,=88I@0??>@2,)41'6=.UA,=@ VR>7(Z.2?S-KFTM456]DNGT P/(V:
M9[3^%=UF5*!9%R&O0U._I<3UGTW":?+2C%7MU=4MPZ$.-7[BS*34$KC_8SG&
M@5&_@XW+S/;G?,*Z.G2BHYR.<2\<X_-AN/6O2[%?S?'HXO1U 'A]H\^=EXP^
M^1/%A>GK"O<#] ;8'C<,U3MX]KQ-H<>QEBZ,NS"@6\GMOK;F6]<>+F\\G-PR
M=NW@0&4L-1 CMIG@EKD6M(K* _#J NOJDZDYQ_Q%""5)'0+-Y@%*\D:&3N+^
MA\2VPEOJ6I_FF\DC)!]I=CO<N]S:#S?3(\#^JT>M!_(?AK.8<9URAYB%^?SH
M'4"0>UB!*>-L/&"\AQ$54HK,*2,ES8_>C[!F^GFQ(7,>51W"PLK6QFQ/DVT0
MXSJU.@+;)!'/\$PX%N7J6:3="?CALR7KVUOUO.TU"H(?[=%+R\=8W#(Q<R -
M*IQ>9Q+6PJ^C!*\WG;ELCKM.Y+1-B?F/$ASJFBKF]!Q5>YP:]#")!8:;W,G[
MK-)U\%.Y1U)^(<.(]T#\ -MOJ]DR"FRM5)'5H6[Q'<F_07KB4Z]OVU$;&K$A
M<6G?CF=:OWB.WTE=-);IGEOSK6W*^!D,>\^$Z'MAMRD3Y+Z]V.51V$)E^=36
M(GO9""?O9.C;7T1$]7VWX:6E5^\_]ON1S.*XR\4\TB-#$<3M3/%>XC"_@2HM
MKKQ0]*85>-6V7V5^Q77D(I1U"-WI:<757:2%6U!Y1K4-1>JIUBTLHF936WM$
M.ZWD8E%V3[12J+9UP8E*&'$F/K]ETWCM+V=V2TU7VQJGW;#JC'D)3Z\NHJY3
MQ9NV*G:J;%4<T%F5;9%;RZJK86-G")O4B+PE,BIH67T;#^[ Q"%W %^ 0UT3
MC?55A=Q-A J".J05F[HX]===J<(US97!O4+;R]% ?&S)(M?-FVPJ2EY71]TZ
M-(FXM6Z[3WR'4NMK[(Q3<IXX^P\U<2*$O W!+MY$X!Q1^>-V,AGM:=HZ)MI^
M3K.[F->H/K^YRJ-6<YTLX"7F.A.EZQ#]XUFIY96;8/.)%#JDOA\6A_8K]Z0M
MWZEW:V['M+;I><<S435><*DQL_AWQ5V>'B;,9SHE'W_Z+U!+ P04    "  0
MBJ-4]S>SU+\?  !F-0$ %0   '-G<GDM,C R,C S,S%?8V%L+GAM;-U=67-;
MN;%^SZ_P=5XOQMB7J22W-%XFON49N6Q/DC<6EH;,"D7J\E!>\NMOXY#4OE D
M0!VY:DICD13/U^@/C>Y&H_&7__EV/'GV!>;=>#;]ZW/V$WW^#*9QEL;3H[\^
M_^/3&V*?_\_?_O2GO_P7(?_ZY<.[9Z]F\?08IHMG+^?@%Y">?1TO/C_[9X+N
MW\_R?';\[)^S^;_'7SPA?^O_Z.7LY/M\?/1Y\8Q3SJ^^._\YR.0#Z$RL38'(
M'#D)6@?"A(O,\\R\X?]]]#-8[H44EF2O')%" +%:>P):)IF4,92'_DLGX^F_
M?RX_@N_@&0HW[?I?__K\\V)Q\O.+%U^_?OWI6YA/?IK-CUYP2L6+]:>?KS[^
M[=KGOXK^T\PY]Z)_]^RCW?BF#^+7LA?_^NW=Q_@9CCT93[N%G\;R@&[\<]>_
M^&X6_:(?\WMQ/;OU$^4WLOX8*2\1QHE@/WWKTO.__>G9L^5PS&<3^ #Y6?G_
M'Q_>7GID=SH_@OGW$S]?3)$%/\79\8ORN1<O#W]_]?KWCZ]?X3\^'KY[^^K@
MT^M7OQR\._C]Y>N/?W_]^M-'%*?_^L7W$_CK\VY\?#*!]6N?YY#QM:/Y=U+T
M3L42U)\W^-87Y\"CG\3323].[_#WU7<7>&UD@&\+F"98CMT:Q&06+WUH4C0W
MFZ__<H+TG?2OCDX[<N3]R>C=V(?Q9+P80_?R=#['V3*2$+Q@X(D!DPO-);'1
M21(DY<)IPT#RRV-7Y.M0P%[CV7>A5_OJ$:A^SE[ 9-&M7RG#S AE*^W_^78L
MRP'>7KJ#&&>GTT7WWG_W80)K":W3(7GJB9,T$FD4_@NH)IX%+RFU)DC=1,*;
M\5R6\@*1#N;QV6R>8([6[OFSKU!LT\KP+<'Y>;S&L,O3;O6)%]WI\7'_G62\
M@./UWQ<K6)4/BUEU!2QUC7+L2H;7..EGWP'-RZ2L!C=(&F@(+DE&P!E/).>.
M6)DR$0Z232HR9ED37MP+;1.*\*=)D;IJV9DM91T8_09I'/T<D+XP@7G!A0PN
MOD1W,$VO( ,B2[_.T!F9EE?]Y->YQS?7B#6E/&F#2URBADBM<#RXEL1PZIVU
M%!\7[UM^:@#9A#;B:=%F[_JI9G\.%Y]A?L,H^(1&T*%1,%(B&!D8<319XI2V
M,:/GF)QL8G5N ;0):>33(DU-%53CP[O9].@3S(]?05@@:U_ZDS$2]1V@?WP8
M)N.C?GS.(%K+1)88?$BJ8Q&;$2N4PL4SYY@I**MS&Z_L(3 WX8YZFMQIIZYZ
MC#J7&!%^7,SBOS_/)CCHW>O_.QTOOH^$E,QZ0$.7!4:PQCGBJ:$D!8T&D4-D
M.;9V[6]$5E'RM08@6I:\L00LQ3#<(BB7$_YPVKK,4@Z,MI9UV [^[ARY-D=V
M4\.>3>N(*RF3ADAPN<>IF:&8 W0#O%2)FRC Q/"(-G6@3G\#VM175SVO[:3X
ME^/I40]G/0S??Y]-XWI1"0ID3(G@$B(P/!&9^(0_C#'<*.0_4&CCO]T';:#N
M?WT"U552,X__ IX48U;2&**@F$6,.H@7,I"4 EK%F+)O9'INQS10O[\!6^JH
MI1I-/D "."[YL8)D-EW@4.%GC]Y.%S"';K$4^:6?S[_CJP?'):,VHAP-( N4
MN(1*ED8JXC0ZF(Q&HZ2.T<4V\< V: <:%M2G5G-55B/==<'?3N/DM&RFO9_-
M>]TL%O-Q.%T4:3[-;I9GQ T--'@@8)@E$B<)\0")6&>=YH +=11-:%@'_R;$
MU#\",1]!W0VI.LH9M"K$R(FC*^BE((X#+NQ6.9Q-.!;>[XEVNTKW?KY*5_9?
M_0\_.8614$:"-YHX9<HRA/\*1@DBK$4G. ACO&HBW@U@AA2\[LB$JY-BUZ&O
MQO"7L^/CV?0<Q>'IHFS#E]DY,K@4&%XRDA[GG0S4DB!H(L))S2VS(AO;A MW
M@!I29%J9$[5448T;!RF-RS#XR7L_3F^GJ^AX1*U&8\L]49*5,I-"6:IQ2> F
M1PR(I1!M>'$+H"$%FY4Y44,%]?@0X^GQ:;]7V@<R2-B3.7R&:3?^ KBHSX[A
MW:SK?H?%8?[DOXUB#,F#323'A.(JPXA-0A,C4N19:T@QM2IV> C0(86?M?G3
M4&45H]"%'T\AO?;S*1J[[@+H5Y#'<8S>GZ 8BDC4-/4X!@D<6D*-" /&Q4XX
M$5T;M^1^;$.*,"NSI[)BZAFBKH-%-XH\>A<L4M3&C$\LF;6(RZ.RG%'NC>6Q
M3=',\OEUI%CO5K!HC I.$Y^%1^T$7.%#,!C?> 94TR!TFUSN)1A#<KFWT/(U
M\[?U$%?CZOOY[ 3FB^_O)WY:MAC*M#PIE2'X[S?C::EX[5/''\J('N8_.NA!
M'V2,>R_--[3;<;S4Q30=')?0^3_]KZ-@@3F?5)G3N83&">7BFO!DN9/,9QO:
ME'&TEVU([GX%/@Z,#-5(_G:*@<K1.$R6>(L_<9;D^74V2U_'D\DHT.0H&$YL
MG^&V3A'7YW*B#R*PZ#AMD[#;!-V08H@*1*NND(I4^0+=HB^8>SL]R'D\01Y#
M]_$T=.,T]O.2@^RZ6>Q?17+_[VP\7?P#/WXZAVZDK$V1.5ER).ADT @D<&70
M/S4F"W#9LS;UTSO!'E* 485<^U)AH[WT*^9UE!P&S3PD LQ((IF0Q%)C2<I2
M*4MC%-GM81_]"JPA!1856%-/!=58L2[770;"&/^>&<M1XL9P*2A!"PD8",=(
M/,<PAZ.!= F2YKQ-O=KMF(:T8U2!#Y4&OV[)Q K#^;8\,S0IFR0)KE@K[2FQ
M!@P!2$D!Y)R@8;7$53B;4, \'0KL/N1#VY1FW()VB9/@&8:8@+;,!XM2B&0T
M)&<#;9.2:+$I766_U)F$=KVDIF4I1]:*D6"S)M;G))6W.)?;%,/>MU\ZM/W$
MYGR[?V/^0<JJ-O5^&T]G\WX UD(%E<N*CRZAQVB$Y4AL4II0ZP.5R2EOVDRB
MJTB&E'T8 &%V4E3EY._9N8KD2YFW):(<=)?")N)*=H]ZR5 FRY5JD_NZ(VVZ
MQ2Z\[S[WY<?=YZ+;+W[2'RA;K,NUE@4"C 4&4@JBT2_"R(D'$D1$!7*PW/HH
M1*/]M(W@#<FZ;L^1:YORU353<SNV/^'\ 2(@L%+Y!XNUS$9P:YG6B ,23DWG
M2* B$K ,S;H3S&;3:N_U5E1#LJ?U*%)-#U5S;%/\R/<23$&4:*)I(,E1C*QC
M#J5WB"(\HVR*1J%2F]7T(HKAI5=K:'[K<:ZXNP0G?IQ>?SN!:0?GATHQ]%*E
MCI>5ZA T3<19C@$5VB$*'%@(;7SN&^$,+_M90_>[CWR+S,79,7/!M:0I$!LB
MFAVC&7&ESMNHZ'PPZ-B'-C7ZU[$,+XU90_T[COD5W?_EQ=7!>8>_M^A-]/$3
M_OSM]>^?/AZ^.7S_^L/!I[?X[F58.S0INN7K6W<KVD2J2FV+SHNFWB"]7F*(
M-9Z>HB.X2F_/IMTOD&=S.$MK0O<*_]$MQG'$A*;@RMFOD)!P(5)<(L 0BC:C
M. D>H$WM^ Z@*VP-]\'B\JM7YA*#T]EZ.Z!?.ZWA,OJ(\R_(4D7D23!<$&"^
MU/:+&'(K'^5^=$,*;/;%OAOVD^MJL?[.WOG0C"@PIE :M+^B6&+JB"O^6&8I
MY:059ZQ-I<$-8(84\SP6>W;545.R@,B0,SZ>.QG0;V>&. >9*/0!,&PWVM,V
M3>?N)<LVE;08D)S"6KMS'Q?_'"\^OSSM%OB$^5G&L#@N^%\J);]!)9DE2NUS
M*1!5+!)+&<H?9+(F:Y,;E>5L 79(IGA7+ETOMFVKN_J3:+4,=*.(4B<1+7&R
M.-)4HR,-UA%M U=>F6QSF\3D-2@/M+;D23%DMX&OIO]E+=E:(!\-H+$&(F7Y
MX74DP=-,6+!(QQBS86UT?PE&A2K=/%[T D4<N&2H)BP;3B3@PWU +R9':9B6
MS.I&Z\$YAB&9N>VU?4/QZS9CW(:W&VV66?"&>9<(QNX6IY=7Q&KNB07!3$Q@
M<FIST.W!4 =E]^I1IJW*:M;XKYFM0M+!H8S9>X'VO=2QA92)U$P)FXT1L=7Y
MZ9NMQWXS',(PIDL2')>W4L:77&EOJ4@2N,!YBOZ^:5,V5RW#\;C6=DLF70_7
M]Z/"BCM6*R KU^87F$(NQ\L\2)>S(]%;C!)%.?=L,$KD,O;=W9)D;2IS;P$T
M*#M;E2R[C7W]X.+EK.M;ZI[YNLGXZ'#Y(#Q"*33DDG@PANBR\\Z\52*V,2VW
M0MJY5Z /LSE^WZK_].IK1UYP;H.SA#.,YV0PFG@1/ '/2G%6Z772YHS#S7B&
M9![KL.-:$\#=]5"O#O7TY&0RAFX-HMSN@;$=(YH[!,%]1G\F1 (Q,?SK($-L
M$XU< 3*D-&8;%NPR\E4]2>BZON/#&T")J$!Q3.!$)8V1DDJ)> SV^]/<&IA.
MN"0W\R<O(AE2!4<; NPT]G6Z_Y\)=N4\Z)J34,(8"+9$R^4^@F"(\])A!%T<
MLZRI-U=.(]S2W?^>!PVI9*.NLJL/<]TJCB+CN8AG.$?"BH0D9$3)TH!-ZT0"
MATBX=58XRT"I1IU>[T UI,J.-B:AFDX:)M^SY8'%:(C7?>UIYB24XY4^QX#(
MF+"\T24.=R??:_K^D7'!(I4$1>7E'I9$G 2*-MEQ"I*GG!K+>+?O/Q"O>"M.
MW+K+L),6JA'^5XQ&YWY2VARDX_%TW"T*NB]GMEI9XP05F0BA6=D"$\0%]-)I
M$B!" (E3M DU[@$V2(>Y"D%J:J3B4=[SEACX[PG<U!N#9N\31P)35ZY1%(Z2
MX(IR469\ W_:-GM5FZ ;I(-=A3#5=5,Y[;C.DRZ/5?T&B\^S=*''P8@:Y4%S
M@Z&?*9$@16@B.V+*SJU#NIM&VT ;P7N@K[ZG+>\JQ*FOGCIAVJ]^/"VH#J>O
MQMW)K.M;-![F93EP?PU8G$V[V62<5MP6D@L?*4G4%6XG(#X*2ZAUC.HH2VBY
M4=CVP <_T$%_"M1H/O[5;,LOI]UX"EWW<G8<,,8L0,HNY=%R V:5:^Q]K)'D
M3MO@,\D444E#,W$9!R+WF7:)?I=L4Q>\.<8A-9^H:V0:Z:F2I2F7!ZXJPT8>
MV:MUWZJ)Q[*W+8E-'$C.07(%TK.K>\NWF9$+W_K EA)/QT9L.W+U(I>5E5I1
MZ-/L'=JIY8U"'V&QF,!Q?T 0'RYHC$0IA]ZRZ/MS.F172-*;Y S7;1J,; 1O
M$W;8I\6.=NJIFPK\?39%K_ET/C\K(#S;F3 !8^U2V6+1%DE;3AHZT(0IZW2F
M)K7:$[H;UR9<<4]RB:BHCT;5;%_\>+*LB[K017[5+>(7WXWCJ-SE4G*21-M2
M*BP$D! =$.9!>6N4CK3-B< ' JU;G<HCUZ#!DVP2)3*6BTNR"42CQR>-#-JY
M-L?@[ZA.'5 ]9V7>W%F^]R!=5)LF?TQ325"5NL'S/M:]Z)/^CXOA?^_GBW$<
MG_0&XV.9X_U5.$OYM9(\6JF)@2*_YARG.;H.S 4?I"JW,+0I.]D5^:!*E?;)
MNKVJ?! '>5\>_O;^P^N_XV?>_N/UV]_QU]?O#C^V.=5[V[/V><1W(WDKG?>]
MX<:$]6T)6S5@"A3#1HW3W=/HB90979"(1$]@.#J3(OO49B>WLB 5:Z:YCS(;
MG.*,48Z3O9P@Y481T-3@^(#SKDU^=9@G+AZ3<7><V7B(EFH71=QX:4GIR?1F
M,OOZ=TA'L([F^E;I'R!.?->-\SCZU5Y#.2U'@1F&\3Y!-Z0L*BF4*S83,3PE
M:HRRRC6J(*THQ9#V%8?$U$=C2LVKV&X;S5%FA@L%&%BRDGE,*I)@E274499U
M0%"-KGBX U1#>;=BCQ',Y])[)PI6;KIAEEBE1;G>PVAF8@;;IFZZZ<HZV+7H
M09R\X:Z[1]/]/B;LAN8.5,PR$U9NW))991)*$\%@I('@I;6IS;;/CL '%5D^
M D.K*W<80>3!Q[^_>7?XST9AX]FW[S50O%FF6J$ANA57&H-^@))YB&7'<-DX
M]/(+%S[Y'N;C4L<0YZ7R^!4L_W]F_%Y_BY_]] @^^ 6\SAGB8F1I0O*@>0,J
MRIV/PA.7K"5>>ZL9B$0;7;NY7SDK)( +!(Q<OHQ1Q[]\_Z,KEPPLZ[Q+S7=<
MC+_TV9Y18A"4= *=.XUS5%FT#S%:$@VE,M+BB[;Q&#;'."AG8+A\OR'SW(($
M-7=O;L*W+&NZC$_[J PX3EC?9#M90X)2G*BH0E+,1I.;;=QLB'%0,>F3)^FN
M)&A-TO/3,^?X> Q99(4<4F"(Y$D26ZX:38Q+R<J!F=2FB=3F&(=47_OT2;HK
M"1[#DH)/C@80A%(KB:0AE!$(A(J(88%F3,=F[5RVLJ1;9-7]][XH]M/L(")C
MYG#KC9,CC(HQ1N$8*(-WY;Y>3FS&4(4Q9[6%%%BCK?'-,3[0^6F^A=F":-<R
M[FTT6.^$\E5\Z_I)6-XBWENOY3MI!"$&;:DG'M>O4C-EB3-&D:Q=\HPFD(U2
M<@]!.:ATQF.QK)86:YZ$CP"IK_S_B O?8<97TFD1?W6GZ8CBDN:\\23W59V<
M41(X^D@\"A8# &]FP>[%-B1G8U^4JJNPZ@;KS6Q^$6*_7W2CJ\U"]@;U[D(L
M_8]L($XE2AQ7WE&,!Q5MU''A84 '=>YGSV:KA2X;6J[;3BY)*F5.Z)?K1&VY
MYY(2ZP!(=H%*I[07IDUHOS'$(1WQ?S0[5D-]K>.=FS);E'G-2@<;Z@5%<UON
M]?/H*0(U.7%-!8UMFJ=MF]Y\^&A\@).523C,[V;3HT\P/WX%83&B'B<WRYK0
M%!G.?*51-SH1GS.ZS#YX:)0UNPW14XAE=B71]9;6%;13W1$XS 7#VZX[+8U?
MEB>[$M/):,'1N_5H,*P -!C%V05/E:!<ID:79-T!ZBG$);494TM'#4C3%RE?
M1A2,,@#HQ3(NR\&/D(@U*1$!423.H]2Y4;/7.U ],/3XP6BSHY::.(%K.!A6
MGY>[CR1S622,JA&00^\A1!*"-42H%(T4FJO8IOKC7FA#ZOZU+P)555=C%EU>
M2JGBLK3,H$$7J6W&I90+PGQ("-@FVBI<O1?;$P@>]L.CK176PO<9EP&8IN[:
M;<Z2>^.C022Q[!(Y*H@#*4G9'_>61:I"F^XX&X![8/N!'VQ1JZ.SEF1ZCWR
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MYLRSRU B_Z/QU<=%0.D%%"-W%?!U.0?A$9\ C4>D1!L73TTT=!-7\\B/;FA
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MI4$U G56%-L*8KF<SQ$GC$<;-PB!JP]6UKGL]%0;5+NT0_97187;,+:W-#;
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M[9R[&*3DD9?9/]3QS%2RRG*[L=BUR8,/.P/>#''U\''JIW.S];D?E''Y'[\
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M!/B=OUSE )K KII)W1/X<?*KI\BEQZ(>E8EP0CQV!H]GIBUA$K<N&44BP8A
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MJ.]:O16D6:,3Y8XA.S^TM-;4&AH)9]D3F1C@H>5D&9]E0X@J2NC""SPG\_Y
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M$*Q.G?EN.(^]4>W'EWN!Y'JZJ1!NO(VV9X"63*O!31-W3MR>/7%) U$RRR3
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M"E[%9GR&2J-=)*PT?4MA/0DN"V)\9C)[Q6RJ<X%:MY38XFEVRH@=)%XE]K
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M%$R+1+UGB5!C$I$B.6(Y&G(^4V,=XX&[.O[>:<]>VTE3#6:O[2+F*G[_]L&
MP3"@C!G"@LYE,* M40E+.(]>X9D(UOV8SW@8,]I60X4]XKD?H*\''[\ 3-^.
MXLV&:'707J.E!+I<1&>37XRMCU1%;[CTGM=QFC8A>GJF9RNZJ>"-/X1K^;8T
M05;5_-R,[3@&:#LZ;$", Q30T;:R1*B98MR (4FFL.B)#RJSD@Y-VD "J#07
MN&MJ;#%$NV;&+G*OP(CY-HFF4IR-QWCZ+;*6JS,0E CE]MQ,%4+S#K?+4&YL
M-AJAX;E;ZUZB1T!U;X*TI;M1'<%7,%/7H-U*8"_QT1"\<D839@7'5X$BOAP3
MGI[&61E9!%DG4;P-V;FRXS 55&UV?.CZ-NE"=J5+@$=+),<],S@ HCR3H!+W
M)M2Y=^#\.JL/L5-;TU&%2=./W^38 -N/SNH]=;G3E9I[**+KSFKN3,+_62+F
M(9W(/7',*D)I=#H%$U.S49;? 4D.NE*S%D=VD7\%;FRXX='B"D52!M>7!"Z7
M)>*HYX1&A,5HS,!"%59\%U=J[J2S9E=J[B+P"B;KPW<\\DQU+MWAF256>D_+
M#6]H1X-)"JUH*>)ZC\H3NE*S+1+L)^Z-6\$1*JC?CV'J_WR5,\3I*-_Z9=3-
MQ8LW^$\^3G&A93\=Y0NT_>:&7,7*Z@,!=59QW:;@UBNQT85),H./P4B?J%6!
M!9Z=,DYY2'9;)?:!T$ZT0AL]/F8B> *4XRFN\ ^G62#:<Y$I.GVI4I#N5"NT
M-TY,&TTF+_SDR^O!Z(_"#?@[;GGEF^L+>0YY-$9GZ\\> ZTBE8JP^0E&T=^R
M661TJS-3- >C19V9F^VMX8S**'=A^H/!D^Y)42L2M\M*%LCO:668RF*TERGX
MS/&<!T,D2$%",I$DQ93(GH(0%<-V;2WC!\F/3(U:68@FBUF'_WHT?MF?E-K/
M_G!6 K$WKRZUGND<',G.EH;-9(AGH(A5QG(;#76RSD7*%1;S@_,G09.3*Z%'
MUSHRA])+5 *11NIRFT4@5'&FLG#)5DK$/.T2^D,XW)W"3[R$WE M<BP3KUER
M^.)I2X(M<TT$PT6@..-ZX_J/$OK#^-"LA'X7O719)]T$UX\2^IVTU[1@>A_1
M=UI"KW3*+)2I*^5NKXQ>6DBI]#5Y3Z/P5#6[DO#$*;%?"7T51NPB\8Y*Z%D4
M"G=#0V ^%#9%3P*GDD1N,V/:@HUU6K).O(1^%TTU**'?1<Q'*J$O1!<^:L(2
MUT0&[HB=U^'P'!7EV=A<)_GWG970'\",MM50)3-<S*3K*/^=6D[(EON(JQ9\
MW@-K)0E41,)YP/V0>T%9G3CZ(Z">G@':EH8JN.4;H*U:"AN JVJ*/@KO./9H
M:\IL1I(#--'=7K.:5Z:!@K8,]T"-?]CY>%W\TC 914S9!U.K&*5SFFRQ48_#
MDET44"NZO4"XJI;A$ S+CC@ N[CGPDL32;0VR)"-"C5CT[>A=&^/M*BJA\+#
M>\NY8E72JS^_XONQ L4TM> @$4.MP2,S4((&F,8OE3:IW..EZRC_03CG1(##
MY=UI6=(K/QZBX3QY#^./7_P8/LXN+_WXZH"ZHBV?V%YAT"[0URI[C#+4>&6=
M21F5D0.^ATPY2QU0'WGL;?GLPU[)]0]_[B?]>!/9-T([QG(@D8$@4@M*@M5
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M:GU/BNVNLN[X];(_*$?Z/<R][!V#0!6A+J-@A$:90,)M7>CD:;+*QSI.V(Y
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MYC_O*6<T56AJ<5TLKVPC\;84W]-8CFP$K^MLU4T1?N?<JJJ0&E&-NXM?Q'"
M6V>]-P1M0D,D=[&(@!/F$T(%E6QNE!\]]#SO-N%>@P8'B_?86?1-"\%_MKB#
MS"GM.)ZNW'&-]'6!.(UKL7C^Y!QEC*).\'P#H*.%2@]6]!;F["/P&D&P^[!6
M%PXV %8W(KH)VI&BHVTH<#LI#I!^I_2@'F)&2"1IM(TD]92X%#0147 %-F<&
MXAQHL2UVVBDK=A%Z?3;<)((=:&%(*?E&_\Q98A4P8C18$$;1'.M,V7L0SM'M
MS7W5]3@)]I!UA:3[:]\?_Y<?S.#YU;S0^<7 3Q99 BE5I,AYDED9VJN"*M4
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M6K7AY)UZ-U_2)9_3Q2:OM-S(_V4D1@0K DFFC&HC,3\E)N<3AX&(,1(A=4J
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M;O)3,\@XBV!$TD0$5-* (Q=./3/.U.ARL\[:7U&Y=R0YAZO;.O4*M,9:D#H
MU7O9>0:&0=:7AV.]R$+RC,/G5HSG/MZ/$NK [K_F0KY?JKQXJE:BG^57N5Q7
M9UYOO^LG<4D7K]?E*G^2Q0=MP_N5?"IG$4^%7C'&, V#S*CX*).CJ& H(Y%2
MO9A,E-."L;<E4Z.5QN;ZS+FU&K1F@]^-X:"RW)%F^L^5'1&-,@,#4Y4/\)VI
MZVK@O));?VM&I;^K03LDR.MOV.=HKFKDHD<LUP75?C=G)U&("=4L"#DW$F<1
MYI!)$D(B)8D9%C3B5M*#'6-,C?8:*\&\-=/E .HTBC8'=%=C,_0)70/+QL)>
M!W2G\7$YH;L:I[&.Z-SQ<CRCZT2B^Y#N]*4CGM)UVKY_3-?]T7[18MV[8=L)
MCR[,K>\?I305-;="5&$I79@.FHM<CRS+7W[H?SSG)5W\N<C7S^5&P+KJLJDI
M6[.SJ#<636)5W1LS#1C5T$,B0@E1PA7$D6;/E!,5BH1'B7#:XQO'[*D1<NL
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MYISUL&/<K+3^0!WEK5UQJ^MUPSX5.I2;/]/%)_JCBN-GL8IT0!PE,!21@"A
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MOR*F(";+8I8&%$%%4*9#/84A)5C_E'"4$AK$01"Y,(?;\%.CD]NO=+YH"AU
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MS71")I F7)D$9I2D>BF6DNL$>X^&M'K@7E:O5VB;P;Q5G;U*K?<8<3L6NQ;
M\;5ZC9TC2/6>A6,@I=[C\5Y(J/>LX^=U>L]?TKO!EUCSU;GJYI0AE62IU+%2
M*B#2T$(2\1B2!(<!BE HB-,RJGNXJ05)K9#"?75'Y_997<!:4H8WN(9FC=K0
M<8K&[5#QW3:J:\BQ^SY9N'^B<9/-5;VE;JH-SC\7^?KY]8*6Y5S->=WBR73'
M0()0D;$8"FX:S6:(0D98"/4JC%(<QA0KIP.E"^--C4=:<T%E+]@WN%\OD@N
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M\0KU3)L[U@%KW@VH#*PK76H;06.DJZD'I9GNIQNPM124IH+&5G>?QMHW7N(
MC_B-EWH@7_HMESS,(^]Q/5I]^3[D#A<%](C:7OS0IYQND<<7O79CKKXN%S^G
M2JOWK[^OW$YLW3%SMV'$K5BMEURN)VFB#7?O<<,H@3@A":1:%I#QG!5%)A3+
M54@@$J["V%[7Y9@W,UO\6?55 :91?:>+S7^$Q20=UL4O1.D7[9Y?O5;Y:J9>
MHSX0K^"=LP!,Y[^ C1$[C6S 'XT=$<.8[B!&C6HZJ#%HD-,=IL.8YXH[!89
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M^NTQ"Y^5!RVK22XE13+-88XP@EB3#'*#&*2,Y#J7)I4%]<Y9B*?7V![WQ@[
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MZ]32A>:N21N"@N<67#=PBW FM?0.'UHEC8XTJN(T=XJYKRZH] TMWCL'\.6
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M^4"Y8_:;&\6WC;4;U;L=L?HN1:A[' W@ =WA*["]PNGU0JHG)[==]ALYM5Z
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M O-40YHCR[\&95#DQL#")*ET8RXU#6J<VT&'L=%R]0Z$HDRXESN*@G=5 \O
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M8YN=>+)I=_]Z8UVKR@K 2S-N@&D,<=GJE24!U4Y=%JJ=H8: ?[A(_O,6^<8
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M,9KPG"N(9))!+.Q_:)(S:&/B7&N<\#0-ZC/9*FWLKS;0J-OQ$+$=ZDYOC.X
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MA=A@5Q>2"IA1K5&62"(SK[K2LQ+&20W34L,;,-?GO]^>" ;PP$@;O5>0U"=
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M-VE8_NAI,6-CI@<^X\MRL(%]VPL]UV8://[V-)Y^]',]2CU33:E@B4ZM8M/
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ME#\VIJAZ>)E&4< WF@:GMP0M@Q^=] ANST33: [<(P/>-<H#LUC^4C=.VQ@
M;B^#WB4GI@MTL1-G@G08.KNF"T G4G ZW:9#-^__U'SV_U?WK;UQXUC:W_=7
M$'@7^W8#YD(72J)F@04<)^D-T!,'27H&[]L?"KS:FJY('JGL3O;7+ZE;W56D
MBI*U TS'=DGB.0]+#V_G/&?SR$@I[LL'DF?_7:\B/S62/U]$^9*QKCPZXUY
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MN>>59?*Y+?B!E S3-(!!'#.UM(T]F'I^ G$0"E\0]9GP[&0!)X1_GE#$S@%
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MBFJS\D(4^)&'8$A]-4GTA:([-7.'?DAIB,.42<)-YO GG[ZT6?E7W4:;(B[
M6IL)F++3)IOO"$$#KKL&EXE)KC4-U+;= &W=-6!8<-HUH,Q$9C;@V)'8.><'
MV>OHIOEHZYR]>WQU]J+K,M@4#6H5N59L8T4E0YXN$4I(&$$4(P^F7"10^ %3
MRUTAL!R5L[;?S-*F:'VZSU-CYK@TJ0,H39>@UP(T^>JRQ::UL!?%<9_W=!J#
M23*=#IIZE=RFT^Z>RV8Z<_7HB.<']=AO;P7=?%6/N/V>52LO#@GWD0]EQ'R(
M4"!A&GHQ5#,5@G5ZDV^7!'&JD:6]^=I&J(T$VLH;H.T$OVM+;;.:3B%J1@'7
MXC0Q 8R!:$S \ED,7,<G'S<T=SCR65=/1!^?OW9DL+%ZU%;R7=?YK;X\E8+P
M^_QOI,PTQ^CH9G\5L20@+(UAG&B!]H#',%4L !G'^L#<TYE15C''A@TOC2*T
MW2#K#;\!5)L.JMIV4.3@I;7^JMJ\QMUBQBE3@#TQS]0X?]C!N;8:?.EQ[@RO
MDR<<ABA;0N4V4MFT\7D#EBTA.8I;MKU_')7M+HD^ZW/=>_E;)6KUP!U)T59=
MBZP_%56FE[3OOF^TK*@RXM=,K:I#*KR0H!B*$ =:IB-0TYZ8P$CZ<1HH"@R0
M5?*V$ZN61H('B_7:+UA(J#P#M6LW8$^CMW</=/Z!W[<> NVBY03+36>;L>?L
M73CO/M2UO?<N5^]U<WSD< KH%'2G).W&LED9W"F8A_3N]N$CN9]D95T@Y,V/
MORH[GDO1#S7UTBNB3 2)1R FB.@RE0)2M7Z% >=<HH!XOF>UD76AO:7Q]8Z-
M[3QJS*+V$LB&;.H.NHEYTAHU>Y(SP\(M?5UH<UYB,@/@B'(,;QL3JU 6_)EM
MJMN<MQ)QU:]9+CXH'JM6H?H?"D,!H]C7 JG8@SBD"'+?H\SGH?"146CXQ9:6
M1B"=K4 9VRD:JM=!VPMJ@ZT.Z8<@-CCB<P7<Q/0Q'V8VT0V.L)LKQ&$\AI:1
M#@:X#(<[##U@QI@' S_V Q],;KAR4K8S^]LI+]ED^:Q(@D-).(<H)A(B225,
M48I@Q%*2L( BWQ>CIF9#K2Z-7[71;5'"O077CN$CYVJ#V%O.V%PA.O7Z]C*8
M\V@X60$WS21OL.77F>J9@'%VPF=T\]7ESW1M[_?KXL^M+J$,?!E1$4 6> @B
M(K2.K\Y0DY&?$A3*T++L]D!C2R.G_7);REI0F^NBG-DQT&:4Y J^B9GH"N2N
M*4]V%I*I:I$=-_A:A<?.NCY09>S\/2.+"[4%/;X6M^R?SUDIWJG_;M1*=?-8
M\ _YBZ@V]><KBH0($A1"3/P HLCWF@**!"<^]Y'P96J5:6S:\-((IJ]SLRD
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MJ_KI/_^E^XOZ#R65^,]_^1]02P,$%     @ $(JC5#V=-:V@A0  ( L& !4
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M8L)&@5&9<D38<N-2>5?*D#AQ(J2,#KER\JE[K/LBYPXY_0)H'_T^")5]A-T
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MN)PW.?&&@7*:"(E!BTQHLQTM]=\Z:,ECR-X_U2.V.Y=_2X0=PNNOB+!N%-(
MM#Y# CA?W%!"'B;C.7X^OO=LT0P59O.ET-;7X8[.2Y9P$)T"Q14G>M$Q@GKT
M.SQZFI$J+T$[S6*=(\A=J&TF**@'Q^I*; "H]T5W53GYJ=3FHCKG\^DP7,R+
M'$XG#TOB6MS<*YL<$!=91G&'4MR.#@C5U!KJ\,N3?8;V:6?0)1_-Q"?UP-VC
MXAN _:?U<Q=B6%Y'CCXSX+Z,-8IZ6>ED&?<D6F#"9(&KNDZEX@/$]-VCHC]L
MW+^4MY>B&L#:C4:4"_IO]J%$SYA3[7"W\#X1Z<J$/J$4T9(:K50"2NO8RR>(
MZKN"I!GL=:6X!C!XE-*B!L>//OEA>C]>90P&@9M24ZX)-2(2F7,F3B1%H@]E
M[%_,R$B=(H"'">HWC&X(>UTHK 7<75_]6@1WI7'S%+[">#;\#LMJXP^362DT
M/LFG_L? 9B^$Q<5$&4>W)B8@ :@CF6D'E"GTH.O<5=Z2T'Z#\99P6E'!#>#W
M,\S]< SIG9^.472S6U<9\S .YP-!@<K%]1Q:*EU-]B0$04D$X7&3$.!#K:C]
M.=KZC=$;0FG':FP F/>%.[!E)J=1@L10KHVIQ)"#((F3%J31(%.E@K[[M/0;
M/S<$O#W5U,"9X._#\62Z'N.$8ADHZ2)&69E8%:$,Z_'$!G1(T 6F @$2N:D3
M)M^EI-]K- V!;"\5-6G+=A'E0%%05.9$E'<611AYJ3:CA?5(B\_,*Q73=$-_
MOS> &H)S#W!HP,X^E_0=2&^U3A((C;;L&TH1IS0E1O$ +O"4>:6JBV<HZ]<.
M'_HRR/[*Z0QL?;7\_K10S%>8#Z,?W>:JJ_[?MQ]QV&;@3[!WR,[@3C'+$K5$
MV7+.+;@@'A(G200G@=H8>)T2A$-T!M^UG=!FG80L9[B\E29!*S3]&@)^QRC)
M.D85(B@1GQJ.=/B&4MWUDNJW;_DVF.VJPU3WD&C );Y][(46Z62Z4$!:'$1\
M@NEBI-E 9TNE<^CHYU":,TA7KMH'HKDK<S(%4[Y.[FDS^OH^2:J.V,Z5U!ST
MEJ/SCB[F7S'$_$](@XS[N([<$91-*<1*N)!,0/F)P'W&N!-D+=OZ%%U]'QP=
M%&I[*:51B+V?S2Z0$]":"VL$L5XSM--4D1*N$:U]S)+1I&B="M_':>K[K*<'
M:.V@C$9A=?/,GF?MP4A-N#*L9 2 >,> ).,%RU)B?'*(W7*W@:L5CVEZ -BN
M:FD 93>J0A[=\@,UTFC!"$0HZ:^RA(),),A2'Y(86N4Z-T8W(*[OLYG*:.M:
M/6TA[M[.+WB95>PM*3U,2U]J05QFC"3' EIGRJ2L7D"VDR]6\6#F< C;2QTM
M(FNU\7NP7(:42(E<T)_D&#<'8,2'H"-^"9D="%5;N& 5ST8.C:@=U- BFF[N
M\N"CC=D!D5PJ]"6C)M;H1*C6F>5(%:\T_&_O4?>=SQWM#U>[*N0E3BG]<HI?
M?W_W\?3+R2\GG]Y]/CI]C[_M[+CBD8^O?E2Q"5L='5,LR_>N4'H%21YU]@"1
M\"QL@:0BGDM<>S(R1)50ME(*Z!&"]B_R^P[C"_@%%^AQ.4C&C_S'</[U^&(V
MQ\=-KTZ?2[X9_TNECC$ +@\G>&FK)(D$I-=Z7$PZ:2^22(Q5ZD:\ [']'AQT
M@:+[]7QU-=; 9GIUVWHUC^JZ.VMB@F9'/0FT5/?H2$E@5!-08&BDWK-*4\ >
M):G?/'\-@'4C_09@A!\RF1Z-TZI5W(J=@6'><6HMT9[S<HU (C\Y$7 )16:U
M#97F0SQ,3[\6JB-EWZT9V5_R#>#GR\6W;Z,AS-;D9RVCU4Z1C,XG+JJ P8E,
MAE"NC.")1>WJ7!BZ0TB_)J<.8O:1=0-0^32=9-QM%Y>6?@&8#2"9Z#4(DGAI
MIL3+](D4+7%2^*"# Y_K^$AW*>GW<+ .6/:2=M\M/Z]$<J>V8XU\ =K84)RS
M0$N/#U2Q3[AURVAR$)1#SG=. 1]IZ?G,@_H]VNL6&)T+M@&3LKI2-EO4 RU9
MN.)PH)QP&10E(C"!#CT$XI+0:!ZULXIGFF6=ONA/4=7O65X=4].9%EI U)KP
MPL_LFJ'9P"?F7"D.H[HD6QWW&"X$2FA21AH5,X@Z]=6/DM3O25TE+'4B_P;J
M]7^%,7(R*G6&Z7PX'A;9S(??KRPMQVW7H,:)L"J5 2AE9)(7)-(4G+69B5#G
M)O,SA/5[.%<'5%WJH@$;=;..%;\?P4,%K3I:*H4R1($(N%S28L .1T DG8ST
MSJ8ZYRF;4-?O>5T=D'6NE0:0]N9B-AQC%'$\.0_H+186ROVIL^GBVU7F8F&I
M!TY)B_88-_84+)%28G@12H<S%I1R67C+ZA1/;4YCOZ=Y=5!724-]!X"+.0&K
M+/[ &2,C6FCBHU9$*G#$VD2)TEYR!9Q'?^?BYB/1WLU/W2RE2%\&&O:3V?;*
M=DMEC^&LP.NT(YW[X;CT CD9OQW.OJW.N4_R:O9<F2<1)^/99#1,2UOJ@N0<
M3")@'>[:P98J+>H(XSJ:P*)-&R8!MGSP9LAY(=GHZI+?%UR=[&/7C6;*D>#R
M3N;O,/\Z23<F,0]X$A$4&DB5G,3-64?B1*8D>66!<B=UKN.2;T3>9K![82GM
M[A73OS&[BCI6JVJU"9]./N"Z6K9>_P+S^6AQ&CD(D"24M>2%+K=_P);1N;BT
M9.GZX4STJLZ!R4;D;0:Z%Y8:[UXQ[8!ND8O[.!EC*'(QG2[Z'905MHYT:9#&
M<,](3#2CV#@*4&A-HA=11)^S-G5Z8#Q-UV8P>R&)]@JJ:" 4O">C@8CH8F;I
M2 JY=$WPF3C)!8F*I2 4A5BIM/P>*9O!YZ5EU?<2> ,9T"L&KC?Y@8S6.F5"
M::U!,?),K$R *$-^8_9*&"-LG=+ !XCI]]2W:E72CA)O #3K]CRW;"4:T<F:
MM8\P1],9N$[*$,NS*84/R)U(^&.PZ!<JYV.EUA>;4-?OF7$-6'6NDP:VL]N!
M1RD2'8XOD)75$L)P]PWDR735HO34_X#96_QF-A_&05#.Y0R::&O+Q#=T"KVC
MEG!N07.."ZK2584]B.[WW+D.*@^CP2:,XHJ%U=I[ V/(0W0OC#;*245R#@(=
M@E*\S%*YHF&=E%8QY*4B$.\1U.^!=#V0[2?Y=H+#4A,VG"_<@@2>H0-)"=?4
M$6E+,TB-0C$>HF$ R015!3K7-/1[TEP#+3O*MP$+@SOXM3W=J'VBY!)YR(J4
M\:;E)-,0QZ)&?C$2"12L377:O&Y-:K^'S35P5E=;[=BK6WP. @-NLL U%#(N
M*0:+U!Q*+#FJ(JXNQ^MD2F^1T>\A<G4T;27E!@S7'^-4RGG* KANW[Y8%J/%
M'Y?T[B<_1:=O^&T1JWPIV;A%I\XW?H:N(/,J11X]2<'X$K=87!D*B,B..YTS
M=[%.1G1?RGL^P*Z!Q(,JLXF#R=N6_+L?CI9F_,;-[%4CV16#/ FN;1ETKS!P
ML>A;6* *,>9Q86:=!-2ILMF2T)[/R.MONMVJJ@%#NEYNZR8X"R;*V?]P5%;C
ME0BU8DYX38EFIO"6.7&@,X&L+4]&>1OK7-K9D,">C\EK(*^&:AI(P3W(UH"B
ME8Z>9Y(@H*<*Z+,&9PQAL=Q2*KX)@\/AJ]^+IU44OPFXMM)"@U!:"6B@+576
M6TZ8*>=O% +QVF7BN/$^Z1@#K;-=/D)0O[=2^X#3+IIH %#_@-)%&F7R':;^
M##Y>G >8GN1[77)6[+T=SN)H,KN8PGNT^]?GOU$G9F4&%)TO:4(')#"9B0S1
M"FF%!UEGL^R&_IZK?VKLI3TH]@7!>6G\@^(\,U\ZNI:&F]9P8F-F!(*0($RP
M$.MLP5N1V>_6W >.=H3R]DIM%[$K<=[O5A9S3"Y%C+&,+=U[!"T7:P))291>
MQ$8K.*BE?8S0?CV =E';B6)?>ANZXY/?/WU^]QN^Y_W?W[W_B#^^^W#RI4Y/
MNL>>== &=1LQW/U0G:5C@9[O ]-HKT#.'.3 -1 5O2-2.DVL DXXYZ!5$#3X
M.KO@EH1V>"AL?**,8=1GA$"6T9\B(8$B,NN<\3<AFEK-];<Z%#[$$)O.,?+$
M8?$V<M_9QJ&]#9-N^VX\.<H9(\!AN<81IZ7!R%M8_GLENARE\"IA:,D\[AS2
M*.)B2"2 %*"CXC'6*:+:G_9FQM94Q^B!]=R W_D4Q\=^]O67T>3/WR"=P?H2
MR5'&AW^&./*SV3 /XWJZ5&DIJ1,P#283YAWZ2=X&%'TP1#E7VO,JZFR=.M4N
MN>BY]]Z!$;C% J@*AP:6P@-LKR6^T\#5I'E6#)GF(7,B8^D]Q@(CEC/*HA(I
M5KI>V3$CS8R2JF[^^T1  T>B3["_$;LA*<V]U$1Y9M"MBT"<MIG8X#,$;H2N
M5"*W)^'-#+3J$^"=:[B=LKHGN!Y *#W_O2&@7"ZE"YP$7^9* &5&<9%PTSPT
M9IN9?]4G'K?2S$L<(7TS+_3E].3XO_]V\N'MN\]?WOV//]Z?_J\J.; ''G/0
M]-=S;':?^7IB_CEPJBWW:,%*)S3I(N[+&AA![]AGC]^%6*?E]T;D[=VG>OV0
MTV+0!V ]TU(K$DVY ,1"+K?5!(F OKAQ,F&L4)?9!1W-9+LZPL6]CM6[2[V!
M .B*^J5$BG&>C$M#DJ,?P]G I1A+L32A.:,]=CD09Q@:98PVI0$?(JUS_?U)
MLAI!U [Z?@PZ>PN_ 23=X>'MY-P/QX,<*36<9H)N 45/@2MBF3&H;YZ!I>RH
MJ!,0/TA.(\C97]UW*Y+VEGT# +I19/P[E!/3@?. H0=/Q$:KRKU^(-;21"CU
MPBCC4[#5YZ4M2>FY1G)_]3X^%6T'63< EJ.4%AW<_.B3'Z;WXV/_;8AN_8J9
M8,!)I0.1QFK\DA-Q%@PQVFJI H8OM,ZEX2?)ZKDRLG,0=:>#%@ 5X\7YQ:)9
MUF,)\15CQ4Z;4BV<E>7EVJLEWE-7#'7D@4HO*@T&W9C$?K.W%8!613<-@.XS
MS%$VU_? 5ESH*$I'$4.R*8<H.01BD]+X(R@G?7:A4DGMP_3TFROM'DX=2+T!
M[#R<KEWQ8K+1VG-#G+"N3#:))'B0A"<7'4B!EKF.Y_045?WF.+O'46<:: !-
M5[')!UP9BTK(@0Q1@5>*^)0,VE*!OF&2B1B77=0Z.\GJM,^X3TLCU2@=1OR[
MB;D!H-PM07@_OI]7^XPKXI?)]$\_38.@(HI+&]R"RW7E4DSK@XN$<</+W5$G
M7+7^/=L0VDAJ8$=<W&_I4TU)#6#P^*F9WD;EJ$H;&@B*E>8.0(+CFE 3,/Y
M:PRACO/T%%6]CQ^N!X=MYJUOHYN=<?9M42J%*VHZ[VAKO"NKG0I#N..6)0R
M/2V]EC% (<[02)0V6M"4N'>U<NE=T-_[?..#(;@'?3>#]5L-()YE&ZD$."\_
M/B(#);R7)G"20YEGAKXT\1(CK/*J,9I9D>LTGNF6C]Z[Z!X,^SWJOP&_8B'7
M][/9!:2W%Z6;^;+J=KF/K:^3PZ(R!L:SY9P02ID2E 52=K RA"8@=RH0QYR)
MB9<Y-+5*"K8FMO>VO8>UX14UV2Y8_^Y'%_ (AY9)8Y-FQ,I8SGB<(9:Z,EXR
M29UUD-;6F1:[/:V]]_+M&ZI=Z;$!I!ZE_W.Q&G-S.GGDT.CM\/LPP3CAIO/N
M1X39["3?3=,.),W&XM9!K%":2&<D+E4JRK@!JEBRR57RH#MBH/?6P0?#=!\:
M;Z?V^,G-YR/\N?C5;, B."[*L%_+2S?Y:(@KYPU,9.X3+F-?Z91G,_IZ;UW<
MMP7>1U]-W&!]:F>Y9LOZH!7/DF2=<3-)D(BU( DH7"%2IZA<G1L<&Y'7>V/C
MOE&XA[:: &&GMPM%8"E$!NB8<Y2O+:.%@6IB> PZ6I-!U\'JP2^;UNRN?#!(
M]Z;[7I&_&#?Z<3(^OI\0.8HHW^7HT<7,T<4D4C^:E6LWRW?,?H-1>G/Y\)__
MME12&4435#"A7/,-N=S $9$2"[FTGLO44"FTL<_>'3D$H?UW<*Z.]N;TW4#(
M]_MP/)DN,N=+3M;R+V-LWJ[[7Q>I/)8^7[$^T#K&Q*DD,?"2E)&V%%0H DP&
M$5+D('05B]\5!_UWB3Z8N>]%Z>V$?4^>?#JCE*8ZDV2T(%(&B?N8X$2[F(7@
M*=:Z>;;_J?2K.-3K3#E['M6]&W?35+^C0\J2\*8Z<0)1!B(9+K(0;";**P ?
MDXRB8@[B,(?259NWOK13Z6T4WBG4^VHW>/3EMU\^G/RC4H/!JT\_;$O!AYGJ
M_BKU.DB[;HL)RFCIT$ BB"B1(6OT0UDDV2?II%2>T^H= ^]1U4'50_G,3]-)
M24FC._['#-+[\=6HV:,X'WY?C&"YD@.N&<J%B(12RXA,94ZQ2)X$;E6@3,D,
MU08U;4EK(Y6-^Z+I@5*%FDIK((BZT3U1"N4%4X[06!IC+'IB4/P1@S\;I(N>
MFSJ)KU:Z5M;6]N.-*[<1?1,9UQN';\4)0*DM"HI/)Y\!/8(X',&M*I_3R;:"
M]0PT5<(2)DMEFY2<A)P#4>!\,EYY8'5B\MJ<]5OC>&"(-P63!JSM6\ GQ^%"
MW?C]"%:YYZ/SXE[_YZKR(OI@?,BE@2U'@2=!'(V&I!R!<JI1%W7N56U"7;\6
MNBT\32HKMXD3AH60'QQ<#_-!9M90KLO18/:EGT0BG@G$%LW>!">],O&Y &B3
M!_5K-)M$7>?Z:2?)^4A%6G04#%>9&!T2D:R,4Z*9H:AL0D!)IV2=(51[5 ]6
M2PLUB<D.%=CC9KU86>O3XI/Q\D!M<;YVDH]F,Y@OCMF*F&>3T3 M>7,Q,K N
MDN02&G>5%'$<-.$<**4A1:O41I9PRP?W6V[=) JKZZ\=2_EV]?2EB$_]CY7M
M?P-CP-AR8$+FS#H@5AE+4(24N.Q4R0TC[&B %.J<"#U#6+^5UTVBMH9*&XAX
MKL583FB7APJ_P_QKZ3/_'=9:*+U9KVIU3Z:W#G('S#@1D[,E+U*^9$F<P5W$
M)\LD=YFY2M-4]J>]WVKLIG%^8&"T8[.O!/JA'.>M5O= 2K!!"HV!8,D ,I1B
MD)$3A8Z[YE(*J#1W[4%R^JW+;AJW^ZNO#:M\YU#YBJW5S8DK624?0V 8/5)A
M<DE8.&(="@P7FE%"(^.F3B)V<QK[K=]N&JV5%-TDA(]BG%R@%E#N,/R^:*-C
M5:0\@27>EOZ -**?Q+@F63KF\3^C*K47VH2ZUOIU=(.,9P&XIYKZW\@7\>5]
MOGZ'-(PH>N0/1D62D#[YRX5=6,2;2U)_G7R'Z;B\ZD>_3CW^<N"UBCH:2J)D
MG$A 9]X)&0A8G51BPGA[Y]SUD=1!=S2UUHBC4VCVJ;\F#>?B"L5=$9?TL= J
M4TDSB3$@9]EHXLHI->Y!H),WH,RA^FH]1F-K;3,.9$0[45G_IG3[8^F!\#I(
MQ6B9]B8QZ*.<>)4LND3!.26#\[Z./[HYC?UB\L!'_)54U\#8LD<X6Z8G'A8D
M-T'++(%02]&1"1@0!N\M,9%S@")87J=R<7M:&VEW>:"*O:Z4UL#^O79*3B>+
MFU]30%YQL<TO/XW0'4%7I>32OI6W#*(!K4O;4 K2+/><D"(EN,YBE#;2X.ND
M_S>GL<F*O\[0<K?BKX[JVMG'[S'XYF(V',-L!LM4;A'VZC=I$( : =(3!B$0
MR4L+=?"<4&.016=%E ="YQ-4-EFN=S!\=J6^AA ZG42 M#AT^.)'<)+QE711
MY C+P^&!3TY9@<X)0VFA"PV9H'_D260Y:!54.0NN50?]#&U->I;5T-BMJEK8
MNN]Q],BYUX"RY%W.CJ22%I,\91+*H(F4(F0,%RTS=2:>;TQBOX4GO4.Q"\6U
M@,B5Q?]E,KW)XR*]\( P!P:2$%P9 I9&(BVW&,))2BR/2AN,[Y*K$^!L26B_
M!28];=LUE-C.SKVY4 >*95DF:A+NG2_%7*DD&HH;G:.W3N3,ZO2@W)S&?BM#
M#@S02JIK-T?TRW#LQ_%A05*IE$PQDBB8+3Y+Z3?(!$D\ZRRSYD8?]%;G$[3V
MZVX>.D?4E=(:V-8_P[?5GG"2/TS&9VB%S]]"F \TC>B!)$'022G]!;5'L9F
MIC_S**1C.=?9OQ^CJ,G\3V=(N#<4K .UM+,CWW0V2NM E!G<82Q&%VQ &0FJ
M<=<HG2T];B#('>?41DIYJE/6]CQM369V:B&O8U4U8.(^7:VD0OV:I^/)#(.P
M2!U8;12QLK3Q4P@/GQ@GS.MDM0N1T3K^WQ-$-9FZJ0:WCI33NJV[T?%I@-3G
MF#W*"V-](J7WI8ODXN0]1'106*WK:<^2UF2JYK"6;E=%-67HKKKW7B\FK0*8
M&!(Q0J.D*'/$:FI)U,)K%@./L5*N^@FJFDR^U#=U>ZJG(5MW;;W75R\^K2E:
M,'DT3LL7 #E=+BJP'FQVC#!P4*:N83PFN"#2<18XS<R;2H[>]L0VF7LYP%9<
M19E-P_9NM]"!!4V]MI%8*D(9>%G2!E$1FE/T26E&0YWDRP;$]7OIIG]8[J6L
M]F!X.EDSM+@.OVJK.'!4*"IL(CRJ,CT^4.*1%9*H9EPGY _JC*M[FJY^[]#T
M!+X.5-00[FXXO@^R9117S,E$6/!Z6;#A%"XLD[R24:H4:;7^;D]2UN^P@A[C
MD[W5U$)X<H.?&P>1B\/'!V0XR)D["U01='\IRHY)8KGUQ#IJI114"%WG-O>6
MA/8\5*!'5':MQ09 NKDT!U$HZR 80J7#Y<=H)-Z!(4KKS#4N1Y'K1-2;T]AS
MN_\#0[.2[AHX/"YLE?^76J+O?@2+2Y&EP4%$QV!1:SE.MU^X\<[EY*;[-X-6
M_;K?_8A?_?@,/J.3\2YG*$>FTM&TN-L1DR-262!.>(HZ44 350)8G=&&A^6S
MWVQGM4/KAL'RTI?20 0+(2B'#C\KQZ^6DQ 8D!B4B=%+RU*=CIM[D=UOFK5-
MH&^ERCUG#Z $IO,&T)NI<S'*C" K2]4:38*FG( 0,63*K=4O%;W5DK"-HG<;
M5;Z R1DGTS,_7G6^]>/TY>+\W$\O)WG5 F(Q5F0TC,6EO<749I,SMOCT+B=G
M[,I41Y,S;C[^^&8+PV4>_XJWD[SRD/WH"NPW("ZHYLXY8J60:":-)8X[(#Y:
MIX$%;F0=7[ 3\O>UMV_\;#@KUTEN&!W4Y/!LO!@(.9[?U^4IJN_-J!R.>'2&
MZ&)\DZ"X1@.@U*S!O090N1CCB,CJF-M]J.ZWS.[PF+UKE@^F\<Z2'7U;Y,-8
MYIXM] NPU)9EZGD,)!D7B60)G1%&-<E&9,2>SM[6.2]JR5+?T=SE\NOU"C6Q
M#$87G%!7&EA0]*"\#IF@O3 T*AVBJ5/PMQE]K\'Z;H/#1ZQOEUIL(*E\2Y9W
M>?$1(]% @60PBDBM&+'4"6(]U5I&R*92">I35/5;\MP_#CO36 /H^V-6;J'.
MYL-S%%&9($55 NL(!8]K!T0B@7E.A#$J"AI]8G4.=V_3T6^5<_\(VT,K#6#J
MELS^[J?#TIUQ78[S#BWW?&6S!S0K+\%'(J2TY<)*( %,(LF9Q+.R24"=4]R-
M2>SW&*!_)-;190,@_<4/IW_WHPNX(;OW8Y38Q4)X*Z:<#3E'KDBRI7"1:D,\
M31BX:0,@C,_:USG&W8B\?E/W_8.S>QTV ,S/\!W&%XM)],=E*C(*Z1_#^=?C
MB]E\<@[3>_Y&8HXGCSPAD^6^E2J#'"3)W(4@G%6TTG37[>CL-T_?/U0K:K4!
MS*Y.))X[L;A[G+Q<G[PT<P1DSH02KX6$\1J&;L79R1'C.)ZSK.,$[$%UOU76
M_>/Y8!IO -W7+<9G=]<IUP'='94)50;W%F"6!.T0:>6VM6)1BE#'/WB<IGY+
ML/M'9D?::@!WOTXFZ<_A:(2B0X_;C\^&R-2R9=GZ5^L%Q52V9;9#=HP2&0WZ
MWA$BH59G$)1*+>MTV-Z8Q'Z+L_M'91U=-@#2MS#%U5::Z=U;;A2"I"R$<NL+
MY95M:06-?K@ 84%K9FIU"7F<II[+L?O'84?JZGNNYF=( .?%R)=A.<6AGHSP
MC6?KS,1=WF1V6>6HB7#1XZ)2 ?UIDTDIY5))"V!WBU8?&8ZQY8-[KK'N#V_5
MM=2 Z;N:K7B/#R>4-AD(FFI-I$V)!$]Q.45)E4I.JTJM7Q^C:#,8ON(CFTY4
M]6J*,DX7WG'=DHS5,_HIR'B(P;;*,80'ZHTAWI7:4$$E<5%A!!PD"UYI!;Q.
MEY<FRC&^Q*^0+DK_VV,_G5ZBXA99W#(@:7WHE:YRN^ON/]=YW85VKY=PEA 9
MI9D8Z4I=52B=@( 3K9.6 ;B3K$[^J%,V7D5QQQ:HOC?LO3=,-.!)K)F?E19#
MXP@E0;P4]^?A[)]O+LO77U#"D^DUBRIXH3A(LNA<+CGNA,'%3+0WT0;PP5<:
M];H#L:^B8J0#<-?2;T,0/LGK?,8U*X%&%HV@Q%%=5F.DQ$H;B6$2_389=%)U
MJDJ>(.I5E)AT8F_WTU<#T'LNS+RS-^@@K.2Q-)Y6&&4F3HGG&:/,,B%4BL1T
MJ#,P9CLZ7T7ER1X K:C55Q/(W7SG6YC[X:AR5/?0 _L)\9YEO:EX+W(6-"1%
MN)&X$+@UQ+EDB4E94VX8-Z9.1JB)>.]H.,5?P6KN3G'IO\#T^S"N O4!E]G9
M$"3)O@PU+?Y.T$Z@L)Q.+$*(E6I8GB'L-<1DVR#OK@GN4F]]GAA,YX,5#R?3
M%0='/X:S 2T7!3(S!&@T1&8=B*<B$4 _.WL='6P60N$#;F .?[J+M\<HZ!=@
MG:IWTJ&LV\#*38&\G9S[X7@@K)/@O2(6W0DBO?;$91H)]=Z%J#VG>:/[KML
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MS>477T8!SQ]>K2O;3[6P22A<KDXAKX !L]?4$4JMU9"T,)6F;NU#=;/@W 5
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M;&_\OC]8B>>W3'%9)6.#H4C"DBI%C1"1W,)$ZMHKTMC>[->Y<NLKNO*QC\'
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M.-]+-3S]_*Z*?(_6"0/PK@-E\# V_QA^UF+WQ86B8#QX82&Z;.I-.X>@C8.
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M5K<L!/ JDGHCJ,N2+!:QGYG8]H:.:^2.1L0@W.P,$O?T7#16"". HTJT""O
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MLV8=UOIFV:/R"T[3D3=VNQXWY+G1WF0/=%IT[WVO-M[W!.9"5)%+)H!9YVN
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MOE<3\QZO:@?C15KVL>/H->=9@Y/"DR/B-40F-:AH#98<N=ML7[9%I>W]RKT
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M-I,W$]]?(S$.;\I/EO4!OR!1E-9U4=/\ZEME\?]=?GF!R0BR YHBUV4?(9;
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M=#$P,2YH=&U02P$"% ,4    "  0BJ-4+A#=VR!(  ![G $ %0
M    @ '22   83(P,C)Q,65X:&EB:70Q,#(N:'1M4$L! A0#%     @ $(JC
M5$+S3MZ81P  59H! !4              ( !)9$  &$R,#(R<3%E>&AI8FET
M,3 S+FAT;5!+ 0(4 Q0    ( !"*HU0^H$L?\@<  'LC   5
M  "  ?#8  !A,C R,G$Q97AH:6)I=#,Q,2YH=&U02P$"% ,4    "  0BJ-4
M;UP4<PH(  !5(P  %0              @ $5X0  83(P,C)Q,65X:&EB:70S
M,3(N:'1M4$L! A0#%     @ $(JC5-!;1!X*!0  ]1<  !4
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G+3(P,C(P,S,Q7W!R92YX;6Q02P4&      P #  < P  CGT$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
